https://dermsquared.com/videos/wch-2024-conference-highlights/wch24-welcome-reception 2024-01-26T15:25:16.519Z https://image.mux.com/8O2Kab2EE025KTLhG0100BYBl7q84HxIxIbyt4xn6dghDs/thumbnail.jpg WCH24 Welcome Reception Join our esteemed Winter Clinical attendees and gain insights from the distinguished Nicholas Brownstone, MD, and Danny Zakria, MD, as they share their expertise during our captivating Welcome Reception! https://dermsquared.com/videos/wch-2024-conference-highlights/wch24-welcome-reception 182 2024-01-26T15:25:16.514Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-with-pdt-therapy 2024-01-26T15:24:46.952Z https://image.mux.com/isI4OqC5OcBSxpmC9bhAlBhKtVBLTZjhBSkcACfzN2w/thumbnail.jpg What's New and Hot with PDT Therapy Roger Ceilley, MD took us through a riveting review of the innovations in photodynamic therapy but not before completing an overview of its mechanism of action and some industry updates for clinical practice. Notably, a new red light laser (635nm) has garnered FDA approval with a flexible multipanel lamp for full face coverage, and CPT codes strictly dictate clinician involvement in PDT procedure: 96567 for no direct participation, 96573 for clinicians applying photosensitizer and initiating light illumination, and 96574 for the performance of curettage or debridement prior to PDT. He emphasized the importance of setting expectations, especially surrounding one of the major disadvantages of PDT which is the discomfort and erythema that remains post-procedure. While compliance with PDT remains much higher than that for topicals in the treatment of actinic keratoses, Dr. Ceilley proposed multiple methods to mediate patient discomfort. One split-face study that compared blue light PDT with two photosensitizers, 10% ALA-gel and 20% ALA solution, demonstrated that the gel formulation was associated with significantly less local skin reactions. Other options to mitigate pain include fans, cold compresses, antihistamines, and topical or local anesthesia, though modifications to the actual treatment regimen, i.e. shorter incubation times or lower irradiance, may be the most effective. Even immediate irradiance, “simultaneous PDT”, for 30 – 60 minutes after application of ALA could be a promising option to dramatically lower pain scores while maintaining almost identical clearance rates to conventional PDT in another, albeit small (n=23), split-face study. Moving on to treating the extremities and trunk, Dr. Ceilley showed that efficacy can be increased with the addition of occlusion dressing during the incubation period or with pretreatment of adapalene for 7 days in two RCT trials. Microneedling prior to treatment with ALA appeared to have less dramatic results, with improved AK clearance after 20-minute incubation but not for 10-minute incubation. While simultaneous PDT may be effective for the face, he recommended sticking to an incubation time of at least 2-3 hours for the extremities. Other tricks to increase efficacy of PDT include adding cryotherapy before incubation and warming the extremities before irradiance, called “thermal” PDT. New frontiers include the use of PDT for alternative conditions like photodamage, which has already shown promising results, inflammatory conditions like acne and psoriasis, and cutaneous T-cell lymphoma. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-with-pdt-therapy 57 2024-01-26T15:24:46.942Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-office-practice-coding-tips 2024-06-26T14:42:55.619Z https://image.mux.com/uPFxlyyVEoc2Q23zCK3IuX830162GBNL6xsSdSLo0062Y/thumbnail.jpg Office Practice & Coding Tips You May Not Be Aware Of It is essential to understand billing and coding to run a successful practice, and Mark Kauffman, MD delivered a rigorous session to get us up to speed on coding strategies and the current fiscal physician landscape. He informed us of the dramatic decrease in physician reimbursement throughout the 2000s. While lobbying, legislation, and larger bureaucratic changes are required to truly fight inflation’s impact on physician salary, there are some small steps to take in your practice right now. He warned us to be aware of E/M leveling as payers begin to lump diagnoses into specific complexity levels robbing clinicians of the ability to make appropriate claims. These leveled claims should be appealed if necessary. Perhaps one of the most actionable tips Dr. Kauffman gave us is that suture removals can now be billed to capture clinic supplies required for these minor procedures. Explicitly, 15853 should be used for removing sutures or staples, whereas 15854 should be used for sutures and staples. However, both of these codes are for 0-global day procedures or can be used when outside of a global period when an E/M service is performed in the office setting, such as reviewing pathology results. They can never be reported during a global period of any procedure. A few notable changes to the 2024 Current Procedural Terminology book: 96920-96922 for the treatment of psoriasis with excimer laser now requires both a specific diagnosis and specific laser for billing. Dr. Kauffman ended this session by reminding us to use the entire fee schedule including facility fees or J codes when a drug requires an infusion or injection. In practices with multiple subtypes of dermatologists, such as pediatric, procedural, and dermatopathologic, each physician can bill and be paid without regard to their membership in the same group. Important dermatologic taxonomies are as follows: Dermatology 207N00000X, Mohs Surgery 207ND0101X, Clinical and Lab Derm Immunology 207NI0002X, Pediatric Dermatology 207NP0225X, Procedural Derm 20NSO135X, and Dermatopathology 207ND0900X. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-office-practice-coding-tips 33 2024-01-26T15:24:37.095Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-hs 2024-01-26T15:20:26.744Z https://image.mux.com/Ov01b7026pmzDP601EOH3ZfOyybf8fi9nC01Z6pyLc8pj9k/thumbnail.jpg What's New and Hot in HS Hidradenitis suppurativa is a life-altering diagnosis that impacts all aspects of a patient’s life from professional to psychosocial. In this presentation delivered by Joslyn Kirby, MD, the acting president of the Hidradenitis Suppurativa Foundation, emerging therapies that may change the landscape of this difficult-to-treat disease were covered along with clinical practice tips to assess treatment response. She recommended seeing patients every 4 to 6 months to assess for migratory lesions, which may indicate the need to switch treatment regimens, or persistent lesions, an indicator that procedures might be the next step. Beyond adalimumab and infliximab, secukinumab, an IL-17A inhibitor, 300 mg weekly for 5 weeks followed by a bimonthly dosing regimen, achieved 50% reduction in inflammatory lesion count by 16 weeks. Bimekizumab, which has high affinity for both IL-17A and IL-17F, also has demonstrated promising results. JAK inhibitors are another encouraging treatment path for this disease, though we still await results of ongoing clinical trials. Besides new biologic medications, other innovations in the field of HS include smartphone photos to harness artificial intelligence to aid in the diagnosis HS. Given the plethora of antimicrobials sometimes erroneously recommended to these patients, this technology could be useful for medical providers. Early prototypes detected moderate to severe HS with 79% sensitivity and 77% specificity. Dr Kirby also detailed up-to-date bench research on the genetics involved in HS, which may provide insight into its complex pathogenesis and potential therapeutic targets. Some things to be on the lookout for are the use of topical ruxolitinib cream and topical aryl hydrocarbon modulators for more mild disease, both of which are currently undergoing trials. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-hs 96 2024-01-26T15:20:26.738Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-in-60-minutes-day-3 2024-01-26T15:23:36.967Z https://image.mux.com/BhTcFcObO3dVmWzcVioyE2x9wLpy6FBl501uXDnUMLR00/thumbnail.jpg 60 Tips in 60 Minutes - Day 3: Acne, Psoriasis, Eczema, Urticaria, Skin Cancer and Office Management For the final round of 60 tips in 60 minutes, inflammatory skin diseases, rare infectious diseases, and with a few general life pearls were delivered. Mark Lebwohl, MD reviewed a few highly recalcitrant disease treatments including penicillin to decrease recurrence of cellulitis and timolol gel for chronic venous leg ulcers. Timolol ophthalmic solution (0.5%) applied topically can also be used for hypergranulation seen in hidradenitis suppurativa, Dr. Kirby told us. Other tips in the management of HS include utilizing the HS foundation website which has prior authorization templates for a variety of systemic drugs and laser hair removal. Dr. Stein Gold covered two RCTs for topical atopic dermatitis medications: roflumilast and tapinarof. She also reviewed promising long-term results from the 1726nm laser for acne in 104 subjects followed for 12 months. Lesion clearance and IGA were improved at the 12 month mark post treatment even compared to 3 months after completion of the regimen. A few new infectious etiologies were brought to our attention by Dr. Tomecki, including Orf virus, a pox virus, which leads to contagious ecthyma contracted from sheep, goats, oxen, and reindeer, as well as talaromycosis, a soil-dwelling fungus. Our hair loss pearls in this session were delivered by Dr. Leavitt who covered dutasteride in depth. He started by reviewing a series of patients with frontal fibrosing alopecia (n=224) who were followed for at least 12 months while on dutasteride or another systemic therapy, such as hydroxychloroquine, doxycycline, and isotretinoin. Those on dutasteride had higher stabilization rates than the other groups, around 60% in all scalp regions. Dutasteride for androgenic alopecia was also deemed superior to finasteride and minoxidil, but he recommended combination therapy for maximal benefit. Dr. Siegel gave us a helpful clinical pearl to scrape rather than clip nails for a KOH prep. Leaving us with a few real life warnings, he recommended backing up our documents and photos often and taking steps, like ultra-wideband technologies in tags and cards, to prevent us from losing our electronic devices for those of us who seem to misplace things all too often. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-in-60-minutes-day-3 94 2024-01-26T15:23:36.957Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-clinical-and-therapeutic-pearls-psoriasis 2024-01-26T15:21:08.638Z https://image.mux.com/0201QQ202gqZARwB500sIE01cQO4EolxVkDUzxEW700Kulco8/thumbnail.jpg Clinical and Therapeutic Pearls in Psoriasis In this multispeaker session, psoriasis, its subtypes and its treatments, were reviewed. The clinical treatment of palmoplantar psoriasis, which should be considered separately from plaque psoriasis with palmar involvement, was covered by E. James Song, MD, who laid out his algorithm for management, starting with cyclosporine often combined with phototherapy, topicals, retinoids, and biologics before switching to methotrexate to maintain response. To mitigate adverse reactions with methotrexate, Dr. Song recommended increasing folic acid, splitting the daily dose, or adding ondansetron for GI intolerance, while nonspecific complaints may be helped by adding dextromethorphan on dosing days. He emphasized that treatment can’t be expected to mimic psoriasis vulgaris, and that monotherapy is often inadequate. JAK-inhibitors may be a promising new treatment for refractory disease as shown in a case series of 7 patients on tofacitinib.Next a thought-provoking case series on patients with psoriasis developing spongiotic dermatitis following IL-17 inhibitor treatment was presented by Alice Gottlieb, MD. One patient discussed in particular failed subsequent anti-IL-23 treatment and, in the end, responded to upadacitinib, which also improved their psoriatic arthritis. Conversely, Dr. Gottlieb presented data on a small subset of patients with AD treated with dupilumab who developed enthesitis, arthritis and/or tenosynovitis suggestive of psoriatic arthritis (26 of 470). Symptoms ranged from mild, which could be treated with temporary discontinuation, dose reduction, or NSAIDs, to moderate-to-severe, which persisted for months despite reduction or discontinuation of dupilumab. Mark Lebwohl, MD gave us some actionable tips to prescribe oral PDE4 inhibitors for our patients and managing associated side effects. In a pooled analysis of patients with psoriasis (ESTEEM 1&2 trials) and psoriatic arthritis (PALACE 1 trial), treatment-associated diarrhea more commonly began within 1 week of starting apremilast and lasted for 1 to 2 weeks, compared to placebo-reported diarrhea. Taking apremilast with food and avoiding caffeine may be enough to ameliorate GI symptoms, but loperamide and fiber supplements are options for persistent or severe symptoms. His next tip focused on clinical administration of spesolimab for GPP, reminding us to assess for active infection, including WBC counts and/or CRP, if clinically indicated, prior to initiation in addition to tuberculosis testing. Dr. Lebwohl’s last pearl shed light onto psychiatric concerns with brodalumab for psoriasis patients with a history of depression. While vigilance is always recommended, detailed analysis of RCTs did not incur a causal relationship between completed suicides and brodalumab and in fact demonstrated improvements in Hospital Anxiety and Depression Scales with treatment. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-clinical-and-therapeutic-pearls-psoriasis 72 2024-01-26T15:21:08.630Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-jak-of-all-trades-focus-jak-inhibitors-different-dermatoses 2024-01-26T15:20:35.640Z https://image.mux.com/6702xLFm5ykaYxNsj6Gw00E7soP7eSQs89SvbQ4ijJWZo/thumbnail.jpg JAK of All Trades: A Focus on JAK Inhibitors for Different Dermatoses JAK inhibitors have flooded the dermatopharmacologic market with indications for many inflammatory dermatoses. Drs Golant and Del Rosso covered the physiology of this medication class along with important trials and safety data. As a quick reminder of the JAK STAT pathway, extracellular binding leads to JAK-receptor dimerization and phosphorylation of STAT proteins. Dimerized and phosphorylated STAT proteins translocate into the nucleus to activate target gene transcription. The dimerization of the JAK receptor is of particular importance as it is selective for a variety of interleukins and cytokines. While at high concentrations, JAK inhibitors likely would block all JAK receptors, they have selectivity: baricitinib is preferential for both JAK1 and JAK2, while abrocitinib and upadacitinib primarily inhibit JAK1 and secondarily JAK2.They moved on to review important trials on JAK inhibitors, like the MEASURE UP and JADE MONO trials, and the comparisons against dupilumab. Both doses of upadacitinib were effective in reducing EASI scores and, impressively, pruritus scores within 2 days of treatment in patients with atopic dermatitis. At 16 weeks, more than 60% of patients on upadacitinib 30 mg obtained an EASI 90 compared to <40% of those on dupilumab monotherapy. In JADE COMPARE, which compared abrocitinib and dupilumab while patients were utilizing topical steroids, efficacy between dupilumab and high- and low-dose abrocitinib was similar. JAK inhibitors have been able to achieve more stringent endpoints for atopic dermatitis compared to dupilumab, which may alter our patients’ expectations of treatment response. Safety is an extremely important topic when discussing JAK inhibitors with patients considering the class-wide black box warning for mortality and major cardiac events. This resulted from a post-marketing study in tofacitinib use for rheumatoid arthritis patients. In atopic dermatitis, acne, headache, and nasopharyngitis are the main adverse events related to treatments. For older patients, there is an increased incidence of herpes zoster, and age-appropriate vaccination should be encouraged. Recommended labs include CBC, CMP, and fasting lipid panel, along with pregnancy, hepatitis, and tuberculosis screening at baseline. CBC, CMP, lipids and CPK should be rechecked every few months. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-jak-of-all-trades-focus-jak-inhibitors-different-dermatoses 186 2024-01-26T15:20:35.635Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-jama-derm 2024-01-26T15:24:25.962Z https://image.mux.com/A01bsJocYrZ02VslO4jgsg00rhsRqGPElAYpd01uhS6gZ6U/thumbnail.jpg What's New in JAMA Derm April Armstrong, MD filled this jam-packed session with treatments and techniques to use in difficult dermatoses. She started by detailing a multi-sectioned retrograde injection of certolizumab (total 60mg in 0.3mL) every 4 weeks for 3 months for refractory lupus pernio, and then moved on to another resistant disease, palmoplantar pustulosis. Guselkumab, risankizumab, and brodalumab are all approved for palmoplantar pustulosis internationally, though topical steroids remain the most commonly prescribed treatment in a review of almost 200 patients. In a case report, tocilizumab, an IL-6 receptor inhibitor, was used for corticosteroid-refractory immune checkpoint inhibitor-induced generalized morphea. Botulinum toxin A was used to treat primary palmar hyperhidrosis but effectively cleared concomitant yellow nail syndrome in another case report. Another few case reports showed promising results of JAK-inhibitors for novel indications. Netherton syndrome, a rare autosomal recessive skin disease characterized by hair shaft defects and ichthyosis, was treated successfully with abrocitinib, while a patient with epidermolysis bullosa acquisita who failed high dose prednisolone and methotrexate was treated successfully with tofacitinib, allowing him to taper prednisolone to 5mg at 20 months. Severe lupus miliaris disseminatus, a facial granulomatous skin disease, that was unresponsive to oral doxycycline and topical ivermectin, responded to topical ruxolitinib 1.5% cream. Moving on to more common clinical syndromes, Dr. Armstrong detailed a needle-free injection technique of 5-flurouracil for verruca vulgaris which involves paring with a scalpel without reaching bleeding point and then using a spring loaded mixture of 5-FU and lidocaine into each wart. Two treatments led to complete resolution without hyperpigmentation. She also covered the hot topic of venous thromboembolism in atopic dermatitis patients on JAK-inhibitors. In a meta-analysis of 466,993 patients of patients with AD, 3 of 5722 (0.05%) on JAK inhibitors experienced VTE compared with 1 of 3065 (0.03%) receiving placebo or dupilumab, indicating no increased risk of VTE in AD patients. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-jama-derm 165 2024-01-26T15:24:25.953Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-networking-reception-dinner-hawaiian-luau 2024-01-26T15:20:42.506Z https://image.mux.com/vcRfYcDbhSCK4WT4r02QuEbjd5OBXGHe5zSgyLvVbZOQ/thumbnail.jpg Networking Reception and Dinner - Hawaiian Lu'au Networking Reception and Dinner - Hawaiian Lu'au https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-networking-reception-dinner-hawaiian-luau 118 2024-01-26T15:20:42.501Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-alopecia-areata-and-other-hair-disorders 2024-01-26T15:18:56.824Z https://image.mux.com/hYM01mGIpnIfpXvytVpti5KUoFVWoSIx9xVghOwjMgy00/thumbnail.jpg What's New in Alopecia Areata and Other Hair Disorders In our first full day of lectures, Amy McMichael, MD, kicked off this update on alopecia areata with an examination of alopecia areata (AA) epidemiology. The disease is most prevalent in non-White females, including Asian, Black, and Hispanic women, and this trend carries through from the pediatric to adult population. Prevalence increases in patients with other atopic conditions, but AA also is associated with diabetes, thyroid disorders, hypertension, obesity, and depression. On dermoscopy, this condition is characterized by exclamation point hairs, which should be differentiated from pigtail hairs in tinea capitus, and yellow dots within the follicular ostium. She shifted gears to review treatments for alopecia areata, some decades old and some new to the marketplace in 2023. For refractory alopecia areata, contact immunotherapy such as topical squaric acid dibutyl ester has been used despite risk of cutaneous side effects, which can range from mild to severe. Like all treatments for alopecia areata, maintenance is required to reduce incidence of relapse. Dr McMichael showed 2 trials that used oral minoxidil. While on its own this hypertensive drug rarely led to significant hair growth in patients with AA, it may boost efficacy of other systemic agents, as one patient only responded to tofacitinib after its addition into the treatment regimen after a year of solo therapy. Another combination treatment that has been studied is methotrexate with low-dose prednisone, which allowed for complete regrowth in 7 of 35 patients with either alopecia totalis or universalis, despite many of the responders obtaining <25% hair regrowth with 6 months of methotrexate alone. There are some new prominent players in the treatment of alopecia areata, which is now understood to be a complex inflammatory condition. While topical ruxolitinib was not demonstrated to be effective, oral JAK inhibitors are nothing short of a monumental breakthrough for AA with the approval of barcitinib for adults, ritlecitinib for ages 12+, and deuruxolitinib currently in a long-term extension study. Dr McMichael recommended uptitrating to 4 mg in patients who do not respond to the 2-mg dose of baricitinib. Some emerging treatments to be on the lookout for include bempikibart (an IL-7 receptor inhibitor), ustekinumab, other JAK inhibitors, and dupilumab. Platelet-rich plasma and microneedling may also be powerful adjunct therapies. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-alopecia-areata-and-other-hair-disorders 153 2024-01-26T15:18:56.818Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-the-medicine-chest 2024-01-26T15:23:27.846Z https://image.mux.com/Vr4AIhhOCNxQgV02waDkwvksWp1N5IGPN015uBFomQbgc/thumbnail.jpg What's New in the Medicine Chest? Acne, Rosacea, Actinic Keratoses, Psoriasis, Urticaria and Other Common Dermatoses Dr. Del Rosso led an engaging and data-driven session on new therapeutics and updated guidelines, though he did remind us that while new medications are constantly in development, many tried-and-true formulations remain the anchored in treatment algorithms. The art of medicine is determining when dupilumab, for example, remains an excellent choice, where topical corticosteroids fit into a regimen, and which patient needs something more nuanced. He started his presentation by reviewing topical medications for itchy and inflammatory conditions, such as topical ruxolitinib which shows significant impact on patient report of itch in AD in even 2 days. Topical tapinarof, an acrylic hydrocarbon receptor modulator, works by regulating Th2 cell differentiation as well as reducing resident memory T-cell generation. In 2023, an 8 week RCT in >= 2 year olds showed significant impact on IGA, EASI, and Itch scores in AD though follicular events are a pertinent side effect that can be minimized by avoiding normal skin and applying a thin layer of the ointment. Further, as a steroid sparing agent, tapinarof’s usage in intertriginous psoriasis in a phase 4 trial showing iPGA of 0 at week 12 in 65% of patients is particularly vital. Topical PDE4 inhibitors, which interrupt the inflammatory cAMP pathway, are another steroid-sparing agent, and roflumilast has shown efficacy in seborrheic dermatitis, psoriasis, and atopic dermatitis. A long-term open label extension study using roflumilast 0.15% twice weekly maintained efficacy in about 50% of patients, defined as an IGA of 0 or 1, with AD. For psoriasis, the cream at 0.3% achieved PASI 75 in 40.3% and a PASI-HD-75 in almost 60%, a more precise assessment of severity when BSA<10%. Roflumilast 0.3% foam was also used effectively for skin and scalp seborrheic dermatitis. No relation to diarrhea has been seen with the topical formulations.Systemic players are nemolizumab, the IL-31 inhibitor, which interrupts the itch cycle at the immune and nervous system level, lebrikizumab, the IL-13 inhibitor that is a promising new injection for atopic dermatitis, and bimekizumab, the IL-17A and IL-17F inhibitor that shows dramatic clinical efficacy rapidly in plaque psoriasis, with 90% of patients achieving PASI 90 by week 16. While medications for inflammatory conditions can lessen symptoms and signs, many patients, after achieving control, wonder if treatment can be stopped and remain in remission. Dr. Del Rosso addressed this question starting with dupilumab, which has data to support prolonging dosing to every 4 weeks if atopic dermatitis is well controlled. However, new systemic medications may be able to target memory T cells which perpetuate eczema flares in atopic, but normal appearing, skin. Rocatinlimab, the OX-40 inhibitor, is one of these potentially disease-modifying drugs, as the OX40 pathway promotes differentiation of activated effector T cells into memory cells. Amlitelimab, the OX-40L inhibitor, is another such medication currently under study with 40% and 60% of patients achieving an EASI 75 at Week 16 and Week 24 respectively. These pathways may not be as rapid as JAK inhibitors, but more data is required to assess if they can truly lead to a period of disease-free remission after dosing. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-the-medicine-chest 138 2024-01-26T15:23:27.819Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-60-minutes-day-1 2024-01-26T15:21:26.407Z https://image.mux.com/00Sn6Qzvm5owIoOjVTbMxbuVoBvYYW3MHlP6HjoymeaU/thumbnail.jpg 60 Tips in 60 Minutes - Day 1: Acne, Psoriasis, Eczema, Urticaria, Skin Cancer and Office Management Our first full day in Hawaii commenced with this favorite multispeaker session covering clinical pearls, novel treatments, and medication side effects. Clay Cockerell, MD, educated us on dermatoses with atypical histologic findings such as photodermatitis with minimal inflammatory infiltrate or a subepidermal blistering disorder in older patients with DIF-negative and cell poor findings often in relation to NSAID usage. He also detailed the shift to grade dysplastic nevi as low- or high-grade, the latter requiring excision and reevaluation. On all things hair loss, Dr Leavitt reviewed trichoscopy findings of androgenetic alopecia, lichen planopilaris, and CCCA. He recommended trialing minoxidil for at least 6 months for multiple subtypes of alopecia. One small trial (n=89) did not show significant impact on blood pressure. Joslyn Kirby, MD, recommended trialing adapalene 0.1% for acanthosis nigricans and gave us an easy tip for picking patients, including children with atopic dermatitis and adults with acne: hydrocolloid patches. N-acetyl cysteine, though it can cause GI upset, can also be used for picking patients dosed at 600 mg to 2400 mg daily. Dr Green gave us some tips on prescribing antibiotics for acne, including adding a probiotic after dosing, preferably the liquid formulations, and to minimize treatment to 3 months. Spironolactone may also be a viable antibiotic-sparing treatment even for nonhormonal acne. Dr Lebwohl showed us 2 multicenter RCTs using cantharidin in molluscum contagiosum with superior clearance response in the head/neck and groin regions. He also covered a review of laboratory tests in chronic urticaria and angioedema, which very rarely impact management. All doses of omalizumab significantly improved itch severity score in patients with antihistamine-refractory chronic urticaria and spontaneous urticaria, and the risk of anaphylaxis with this medication is estimated to be 0.2% from reports of about 57000 patients. For those with uremic pruritus or notalgia paresthetica, a new medication, difelikefalin, has dramatically impacted itch scores as soon as one week in multiple RCTs and may be useful in patients with refractory itch in atopic dermatitis. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-60-minutes-day-1 365 2024-01-26T15:21:26.400Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-with-botulinum-toxin 2024-01-26T15:24:56.108Z https://image.mux.com/00UsqnK70000LWPz1y02hhocWZ4R9Aj4xGGoXrJWWmTSF5c/thumbnail.jpg What's New with Botulinum Toxin This has been a big year for botulinum toxin, with the approval of the touted longer-lasting daxibotulinum toxin A. Dr. Goldberg presented a summary of the updates in this principal dermatologic class. He started off by reviewing unit equivalence when diluted with 0.9% sodium chloride: 1U ONA: 1.5U INCA: 1.5U PRA: 2.5U ABO. Addressing a long-standing question on toxin use, he reviewed an open-label clinical trial using high dose (120U) of abobotulinum toxin for glabellar lines to assess impact on duration of effect. Patients were followed monthly for up to 11 months, and the >75% of subjects had a duration of >120 days of at least 1 point improvement on investigator IGA, long over what is considered its typical dose-duration. Enter daxibotulinum toxin, which has been approved by the FDA with a median duration of effect of 6 months. High dose and novel formulations of botulinum toxin will impact clinical care and potentially consistent results until they are adequately tested. In the second half of this presentation, Dr. Goldenberg focused on injection techniques discussing lateral brow lift via the orbicularis oculi and the medial frontalis, lip lift via the depressor anguli oris, and “gummy smile” via the levator labii superioris. Perhaps more importantly, he also reviewed danger zones that are rife with poor outcomes. Lastly, in a world where patients can increasingly obtain botulinum injections from outside a physician’s office, Dr. Goldenberg stressed the importance of marketing. Start with the cosmetic consultation, and your connection to the patient already in your office. After this, emailing prior patients with promotions and educational content is a good way to keep them coming back, while social media should present your “brand” consistently to newcomers. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-with-botulinum-toxin 67 2024-01-26T15:24:56.103Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-cosmeceuticals 2024-01-26T15:23:46.329Z https://image.mux.com/z8TFqXYWOLpsoM9wzf8QoybjljG01Z01LPzxY6Zvbl3Yc/thumbnail.jpg What's New and Hot in Cosmeceuticals Keeping up with cosmeceuticals can feel like a full time job as the field has grown to include everything from botanicals to exosomes. To make things more challenging, our patients increasingly desire clarification on postulates consumed on social media regarding myriad products and techniques. Emmy Graber, MD walked us through the data to ensure we have all the information to answer our patients’ questions and contextualize the newest skincare trends. The current on-trend ingredient list she covered includes niacinamide, snail mucin, alternative retinoids, which differ from their prescribed counterparts as they do not bind directly to nuclear retinoid receptors, and mushrooms. Niacinamide has shown substantial growth in the past few years for its seemingly innumerable benefits by inhibiting sebum production and inflammatory cytokines, increasing production of collagen and skin barrier lipids thereby reducing transepidermal water loss, and decreasing melanosome transfer to keratinocytes. One placebo-controlled split-face trial (n=50) showed decreased fine lines, hyperpigmentation spots, and redness with the use of niacinamide 5% in middle-aged women in 12 weeks. Another split-face trial (n=50) in patients with rosacea also demonstrated improvement in a variety of features including inflammatory lesions and erythema by week 4. Snail mucin, another hot topic in the cosmeceutical industry, contains secretions from cryptomphalus aspersa which, in a 14 week split-face RCT, demonstrated significant improvement in periocular rhytides that persisted 2 weeks after discontinuation of this anti-photoaging product. Alternative retinols, or “bio-retinols”, such as bakuchiol have been touted to be less irritating, and this was supported by a RCT in which patients applied either bakuchiol 0.5% cream twice daily or retinol 0.5% cream daily. Bakuchiol users did report less skin scaling and stinging without significant impact to grading of rhytides. The last popular ingredient Dr. Graber discussed was mushrooms, which may be referred to as “adaptogens”. One study on veratric acid, which can be derived from medicinal mushrooms, reported significant impact on rhytides by modulating matrix metalloproteinases and epidermal layer integrity. More studies are required to ascertain efficacy against alternative options. She concluded by addressing an emerging concern of visible light in photoaging by inducing reactive oxygen species. An adequate method to mitigate this is opting for a sunscreen product with antioxidants. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-cosmeceuticals 110 2024-01-26T15:23:46.322Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-60-minutes-day-2 2024-01-26T15:21:17.242Z https://image.mux.com/VxWvKZchXlhG00qjdnwJis2GPgLBrOCaMhQiir8eIUzY/thumbnail.jpg 60 Tips in 60 Minutes - Day 2: Acne, Psoriasis, Eczema, Urticaria, Skin Cancer and Office Management While blood work is often unnecessary to diagnose most alopecia subtypes, Dr. Leavitt did explore the association between vitamin D deficiency and insufficiency in CCCA which could be an easy target for supplementation if studies examine the impact on this progressive disease course. Linda F. Stein Gold, MD went through some clinical pearls on atopic dermatitis, reporting that patients often can complain of itch even after skin lesions resolve and that failing one biologic doesn’t necessarily preclude success with another. Shifting to skin and soft tissue infections, Dr. Tomecki recommended against antibiotics unless in a high-risk patient, severe or system, or otherwise complicated, preferring incision and drainage as first-line treatment. Further, compression stockings may prevent recurrent cellulitis.Some new medications covered in this section were sonidegib, a hedgehog pathway inhibitor, for advanced basal cell carcinoma, nemolizumab for prurigo nodularis, and dupilumab for chronic pruritus of unknown origin all presented by Dr. Lebwohl. Aphthous stomatitis was effectively treated with vitamin B12 and apremilast in two RCTs. Dr. Green also gave us some surgical tips like using intradermal sutures for closures on the back to improve closures and when, why, and how to document appropriate undermining. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-60-tips-60-minutes-day-2 124 2024-01-26T15:21:17.237Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-navigating-approval-process-systemic-medications 2024-06-20T17:46:39.471Z https://image.mux.com/iy91juSr3BxXEPjmoCtghj5ErpAoKnsNPULfU75P1rU/thumbnail.jpg Navigating the Approval Process for Systemic Medications While assessing and diagnosing a problem, educating the patient, and picking an appropriate treatment are essential pieces of almost every new patient encounter, ensuring the patient actually acquires this treatment can be an entirely separate battle. G. Michael Lewitt, MD, took us to the front lines to highlight key challenges in obtaining biologic medications for both our patients and our offices. Dermatologists are often hindered by a lack of knowledge and significant time required, which may be compounded if the practice lacks a “biologic coordinator”. Dr. Lewitt’s first tip is to find a biologic mentor who can recommend a good specialty pharmacy, provide examples of prior authorization letters, and support when denials inevitably return. Patients can be discouraged by the prior authorization process as well because it requires adequate medical literacy to negotiate insurance claims, seek a provider who is willing to prescribe treatment, and switch pharmacies. Despite these hurdles, Dr. Lewitt encouraged us to stick with the process not only because there is significant demand and a paucity of providers, but because patient improvement can be dramatic. Consider that before biologics, most generic medications for inflammatory conditions consisted of topical steroids. For patients with severe disease, the amount they can progress with a shift from topicals to biologics is life-changing. While biologics may make up only ~10% of prior authorizations, in a study from a single academic center, they take up almost 25% of staff time. Some options that exist to assist patients in obtaining needed medications are copay cards and assistance programs. Copay cards are used to place payment ceilings on drugs for commercially-insured patients, and is set nationally, whereas patient assistance programs (PAPs) are unique to each pharmaceutical company. PAPs may be a good option for low-income individuals who are uninsured or insured but denied coverage; they can also assist Medicare Part D enrollees by operating outside of the Part D benefit. Lastly, bridge programs are generally short-lived programs during coverage caps or delays for newer medications. Dr. Lewitt also reviewed some important terminology in the approval process: accumulators, maximizers, and step therapy. Accumulator programs apply only to medications without biosimilars or generic alternatives and work to exclude a patient’s copay cards or any manufacturer support in their contribution to their deductible or out-of-pocket maximum as a way to control drug spending. However, an important lawsuit in September 2023 may lead to the appeal of this rule which could have far-reaching impact on patients and manufacturers alike. Maximizers set an individual’s cost-sharing amount as the maximum manufacturer copay assistance either broken into even monthly intervals or frontloaded into the early months, after which the maximizer would cover the full cost of the drug. The last definition he reviewed was step therapy which is implemented by insurance companies to start patients on the most cost-saving drug options, however he emphasized that documentation is the best offense in this situation. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-navigating-approval-process-systemic-medications 67 2024-01-26T15:24:06.269Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-clinical-and-therapeutic-pearls-medical-dermatology 2024-01-26T15:23:57.830Z https://image.mux.com/svRaFmxo4H7fHKRp3VuKxPKn7FWdgBvNM01CsvZrCano/thumbnail.jpg Clinical and Therapeutic Pearls in Medical Dermatology This is always a favorite multispeaker session that provides useful pearls on a wide range of dermatologic diagnoses and therapeutics. Boni Elewski, MD kicked off this session by discussing a popular option for alopecia, minoxidil, which in a combined review of 17 studies and over 630 patients showed efficacy in androgenic alopecia, telogen effluvium, lichen planoilaris/frontal fibrosing alopecia, alopecia areata, and chemotherapy induced hair loss. A larger review (n=1404) of adverse events with low-dose minoxidil highlighted hypertrichosis and effects related to the drugs impact on blood pressure like light-headedness, tachycardia, and fluid retention (all <2%), the latter of which Dr. Elewski recommended could be ameliorated with the addition of spironolactone. Rarely, the drug has been linked to generalized anasarca including pericardial and pleural effusion. The next pearls focused on treatment of actinic keratoses and the efficacy of PDT, imiquimod, 5-FU, and other treatments. Dr. Pariser delved into the reasons behind different reported reduction rates between trials including patient adherence, the addition of curettage before PDT, and the grades of AKs studied. Other PDT pearls to enhance efficacy are to use heat, “thermal PDT”, prior to treatment and occlusion on the extremities. He also covered a novel phase 3 trial that used PDT for superficial BCC successfully.Giving answer to an pertinent clinical question, Dawn Merritt, DO presented data from a prospective multicenter study examining patch test results before and during dupilumab treatment (n=36); results were 83% congruent with 3.6% turning negative i.e. patch tests maintain reproducibility. She also covered chronic urticaria and reported that omalizumab can be uptitrated to 600mg or dosed every 2 weeks for uncontrolled patients. For patients with 6-9 months without attacks, she recommended decreasing dosage by 150mg monthly until the patient is on 150mg monthly at which point the interval can be widened to 6 weeks before stopping entirely. After discontinuation, if the patient does flare, luckily there is a strong recapture rate at normal dosing levels. For the clinician, tips for practice were to use a scribe both to minimize charting time and maximize patient volume, and to try placing steri-strips parallel to incisions to help brace external sutures in thin and friable tissue. Though research on biotin supplements is conflicting, many patients take these vitamins, sometimes in high doses which can impact various laboratory results. Dr. Elewski explained that high doses of biotin can lead to the misdiagnosis of hyperthyroidism by impacting streptavidin-biotin based immunoassays and cause both falsely low and high troponin levels, depending on the test used. Patients should halt supplements at least 72 hours prior to scheduled testing when possible. Dr. Nguyen covered a few unique treatment indications including dupilumab for bullous pemphigoid at standard AD dosing, apremilast for generalized granuloma annulare, and topical ruxolitinib for connective tissue diseases like CLE and dermatomyositis. He also proposed a few atypical medication formulations such as topical cyclosporine, 100mg capsules of which can be compounded with 100% vitamin E oil, for PG which improved both ulcers and patient symptoms in 6 of 7 patients in a case series. Another case series he presented treated toxic erythema of chemotherapy and radiation dermatitis with very high doses of vitamin D (50,000-100,000IU). https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-clinical-and-therapeutic-pearls-medical-dermatology 245 2024-01-26T15:23:57.822Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-late-breakers-in-psoriasis 2024-01-26T15:21:38.635Z https://image.mux.com/KhTDZm02KJr8V9VAR027jm4VgrGlIGSPcl00klKoy01hOzM/thumbnail.jpg Late Breakers in Psoriasis Mark Lebwohl, MD kicked off a summary of the newest developments in the world of psoriasis with a review of two newly approved therapeutics: bimekizumab and spesolimab. In the BE VIVID trial (n=567), bimekizumab, the IL-17A and IL-17F inhibitor, was superior to both placebo and ustekinumab with 85% of patients achieving PASI 90 at Week 16, compared to 5% and 50%, respectively. Even more remarkable is that almost 60% of patients on bimekizumab achieved a PASI 100 at Week 16. In the BE ACTIVE trial, all bimekizumab dosing arms achieved significant improvements in ARC scores, a marker of psoriatic arthritis, as early as week 12. Spesolimab, the newest biologic on the market for generalized pustular psoriasis, is an IL-36 receptor inhibitor that demonstrated rapid pustular clearance at one week in 54% of patients, compared to 6% treated with placebo. Further, research has demonstrated that high-dose spesolimab may be the key to preventing flares of this recalcitrant disease in a 48 week study. Dr. Lebwohl encouraged us to keep on the lookout for data from another IL-36 receptor inhibitor, imsidolimab, which was also recently trialed for use in GPP. The next part of his presentation covered exciting updates on more established biologic therapies for psoriasis: anti IL-23, anti IL-17, and anti-TNF molecules. Oral formulations of these inhibitors are now in trials, such as an oral IL-23 receptor antagonist that demonstrated significant efficacy in a phase 2 dose-ranging trial, FRONTIER 1. An oral IL-17A inhibitor is also on the horizon, with the higher 800mg BID dose causing a 40% improvement in PASI within one month in a small phase 1c trial for mild-to-moderate psoriasis. Lastly, an oral anti-TNF that inhibits only the TNFR1 signal by binding soluble TNFα, which is more involved in inflammation, demonstrated PASI improvements by week 2. Ending with other oral options for your psoriasis patients, Dr. Lebwohl reviewed new data on the TYK-2 inhibitor, deucravacitinib, and the PDE4 inhibitors, apremilast, roflumilast, and orismilast. Extension trials on deucravacitinib show maintenance of PASI and sPGA in week 16 PASI 75 responders over a 3 year observation period without notable laboratory trends, serious infections, or herpes zoster activation compared to placebo. Apremilast was also shown to be as safe as placebo in a large pooled analysis of patients with psoriasis, psoriatic arthritis, and Behcet’s syndrome in addition to being efficacious in a 16 week pediatric psoriasis trial. Lastly, Dr. Lebwohl covered cardiovascular implications in psoriasis, in particular data from a trial with roflumilast that showed a significant decrease in cardiometabolic parameters, including BMI, by week 12. This may provide an important added benefit for obese patients struggling with weight loss and psoriatic disease control. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-late-breakers-in-psoriasis 98 2024-01-26T15:21:38.630Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-acne-and-rosacea 2024-01-26T15:21:49.926Z https://image.mux.com/zj3LQACn3AUhlf018RPJ9DEBSmP3VEvJ01FE25XfljufQ/thumbnail.jpg What's New and Hot in Acne and Rosacea Major developments in the treatment of acne and rosacea in the past year have changed the face of these two common clinical conditions. In this relevant update, Hilary Baldwin, MD started by refreshing us on a consensus shift in literature to phenotypes of rosacea rather than distinct subtypes, all of which maintain centrofacial erythema as the key diagnostic feature. Other features of rosacea such as telangectasias, flushing, papules, and ocular manifestations are not diagnostic in and of themselves but useful to assess severity when considered all together. The shift from subtypes to phenotypes is particularly important, Dr. Baldwin assured us, when considering treatment options and algorithms. Specifically, for papules and pustules, treatments remain focused on topical antimicrobials including ivermectin 1% cream, minocycline 1.5% foam, and microencapsulated benzoyl peroxide 5% with or without the addition of an oral tetracycline or isotretinoin. Oral options include sarecycline, which has narrower antimicrobial activity compared to other tetracyclines, and low-dose extended-release minocycline which showed superiority at all timepoints to the customary 40mg doxycycline. For persistent facial erythema, Dr. Baldwin recommended alpha agonists like brimonidine and oxymetazoline, beta blockers for flushing, and vascular lasers for telangiectasias. While the potent vasoconstriction by alpha agonists makes them a clear choice for any erythema acutely, a more recent study showed that the efficacy of oxymetazoline cream increased overtime as patients had improvement in even pre-application erythema severity scores at 52 weeks with consistent application. One clinical pearl is to target perilesional erythema by treating papules and pustules rather than targeting the erythema itself. She concluded the rosacea portion by reviewing some atypical treatments such as mast cell stabilizers and botulinum toxin, which also inhibits mast cell degranulation as well as decreasing substance P release and calcitonin gene-related peptide to decrease erythema. Acne, one of the most common conditions seen in the clinic, affects a wide range of ages and Fitzpatrick skin types. Dr. Baldwin reviewed some accessible topicals that have emerged for acne including microencapsulated benzoyl peroxide 3%/tretinoin 0.1%, which was more efficacious than either component alone without an increase in adverse events, and clascoterone 1% cream, a promising new androgen receptor inhibitor. Due to rapid metabolism in the skin into cortexelone, which has no anti-androgenic activity, it is considered safe for men, and results from a RCT demonstrated significant efficacy with about 20% of patients achieving an IGA score of 0 or 1 by week 12. Perhaps the most exciting novel treatment for acne vulgaris is the 1726nm Nd:YAG laser which destroys sebocytes and is safe for use in darker skin types. Dr. Baldwin concluded by presenting data in over 100 subjects with mostly moderate acne vulgaris who were treated with 3 total 30 minute monthly laser treatments. 80% of patients obtained a greater than 50% reduction in inflammatory lesion count 3 months after their final treatment. Overall, this session reviewed some practice-changing therapeutics for rosacea and acne vulgaris, which have taken center-stage of innovation in inflammatory skin disease. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-and-hot-in-acne-and-rosacea 210 2024-01-26T15:21:49.921Z yes https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-derm-surgery 2024-01-26T15:24:14.660Z https://image.mux.com/FR0101kc3eJPEyuz1y4tjXLnhZ7drsXkWbAGBzy02aJlhI/thumbnail.jpg What's New in Derm Surgery In an exhilarating review of what is new in dermatologic surgery, Brett Coldiron, MD took us through topics that he found to be noteworthy in 2023. He started by reviewing treatments for basal cell carcinoma, including a small study from Sweden demonstrating efficacy of Mohs surgery as an initial treatment and another that compared curettage and cryosurgery. Out of 228 superficial basal cells in 97 patients, those who received cryosurgery had no recurrence at 1 year while 5 of 115 that were treated with curettage demonstrated histopathologically verified recurrence. While superficial basal cells do well with a variety of treatments, squamous cell carcinoma has numerous reports of bone invasion mostly on the skull emphasizing the importance of completely clear margins. Rounding out the discussion of skin cancers with melanoma, Dr. Coldiron reviewed a large cohort study that examined the impact of time between diagnostic excision biopsy and sentinel lymph node biopsy. In short, out of over 10,000 patients, no significant association was seen in overall survival and time until SN biopsy or SN positivity. With the advent of PD-1 inhibitors, treatment algorithms for primary melanoma may be changing. One study from JAMA Dermatology on stage-specific risk of melanoma highlighted the inaccuracy of TMN staging on predicting overall survival and pushed for an increase in PET scans for thicker lesions or immunotherapy with resultant high risk gene analysis. In the second half of this presentation, he covered a few rare cancers and distinguished pearls. Cutaneous leiomyosarcoma may have more clinical variability due to different muscular origins. More aggressive varieties are TP53 +, RB1 +, and MYOCD amplification. Recurrence should be minimized by wider margins and potentially Mohs. One study published in JAAD showed a significant risk of recurrence and disease-specific death when postoperative radiation was delayed more than 8 weeks for Merkel cell carcinoma. Dr. Coldiron also presented some odd factoids to be aware of such as a 10% increased skin cancer risk in patients taking statin medications and a lack of bleeding complications with patients on novel oral anticoagulants during Mohs micrographic surgery, especially compared to aspirin. Other insights included the environmental burden of procedures occurring in hospital operating rooms which may make an argument to move them to the office setting when appropriate and the increasing use of AI in all aspects of dermatology, specifically as a tool for detecting skin cancer. https://dermsquared.com/videos/wch-2024-conference-highlights/WCH24-whats-new-in-derm-surgery 112 2024-01-26T15:24:14.649Z yes https://dermsquared.com/videos/business-unblemished/employee-engagement-success-part-1 2026-01-08T18:07:29.257Z https://image.mux.com/3BWLPzY32q6CpkCrVs57vXMvkIQIoQ02NF7bvqI00RuJ4/thumbnail.jpg Employee Engagement as a Strategy for Success in Large or Small Practices (Part 1) In this episode of Business Unblemished, Dr Stephen Lewellis, founder of Above & Beyond Dermatology, interviews Jamie Danley, Chief Human Resources Officer at Advanced Dermatology and Cosmetic Surgery, on how best to translate practice principles between small and large dermatology practices.Part one of this two-part episode, Dr Lewellis and Jamie discuss how to achieve employee engagement and establish culture across practice sizes, including the importance of defining culture and its role in creating a thriving practice. https://dermsquared.com/videos/business-unblemished/employee-engagement-success-part-1 735 2025-04-03T14:55:29.379Z yes https://dermsquared.com/videos/business-unblemished/new-year-deductibles-and-reimbursements 2026-01-08T18:07:03.964Z https://image.mux.com/onU1yJdMUsDTbrSNEK2w00nbSOEHwBV935xCKVMBprms/thumbnail.jpg New Year Deductibles and Reimbursements Welcome to Business Unblemished, a video series that explores the business side of dermatology. Each episode will feature practice owners, managers, business leaders, and other experts sharing best practices to streamline operations, improve patient care, and navigate daily challenges.In this episode, Erik Domingues, MD, (Founder & CEO, Modern Dermatology) and Leslie Lucas, MBA, (COO, Oakview Dermatology) break down essential updates for 2025, including insurance benefits and changes impacting patients, updates to patient assistance programs, and the Inflation Reduction Act and its effects on dermatology practices.Insurance changes: starting the year proactivelyWith each new year, insurance benefits reset, and dermatology practices need to be proactive. Leslie Lucas emphasizes the importance of treating every patient as if something has changed, whether it's a job change, aging into Medicare, or new coverage details. Practices should:Request updated insurance information at every check-inVerify deductibles and out-of-pocket costs, particularly for surgical and biologic patientsTrain front-desk staff to confidently collect copays and discuss financial policies with patientsDr Domingues shares that his practice requires annual patient sign-off on financial policies, ensuring transparency and clear expectations. Lucas adds that thorough staff training, including scripting for financial conversations and understanding how insurance impacts billing, can improve workflow and reduce claim issues.Medicare Part D reforms: expanding access to biologicsThe Inflation Reduction Act introduces major Medicare Part D changes in 2025, significantly improving access to costly dermatologic treatments. Lucas outlines 3 key updates:Annual deductible remains at $257Out-of-pocket maximum drops to $2000 (down from $3300)Elimination of the "donut hole"—patients reaching the out-of-pocket limit no longer have additional costs for the yearFor dermatology patients, these changes may increase affordability for biologics. Patients previously limited to topicals or traditional immunosuppressants may now be able to more easily access safer, more effective injectable and oral therapies.Additionally, early financial planning can help patients manage biologic costs, as patients who enroll early can spread medication payments throughout the year, improving adherence and long-term outcomes.Patient assistance programs: reapplications and eligibility changesPatient assistance programs remain a critical resource, but eligibility thresholds are shifting in 2025. Dr Domingues and Lucas recommend reapplying for every patient, even if they were ineligible before.Key updates include:Novartis, AbbVie, and Regeneron programs have adjusted eligibility criteriaBoth Medicare and commercially insured patients may see changesLucas highlights the importance of staff education so teams can effectively communicate financial assistance options to patients.Planning for insurance and policy changes in your practiceBoth experts stress proactive planning as the key to navigating insurance updates:Review and update processes for insurance verificationEducate staff on policy changes so they can confidently assist patientsDevelop handouts and resources to help patients understand coverage updatesPrioritize shared decision-making, balancing medical need with insurance realitiesDr Domingues underscores that the most important goal is ensuring patients receive the best possible treatment with minimal financial barriers. By staying informed and prepared, dermatology practices can streamline access to care and optimize patient outcomes.Key takeaways:Verify insurance at every visit—patients’ benefits may have changedMedicare Part D reforms may expand access to biologics, lowering costs for patientsReapply patients for patient assistance programs, as eligibility requirements are shiftingEducate staff on financial processes to improve workflow and patient experienceProactive planning ensures smoother insurance navigation and better patient outcomes https://dermsquared.com/videos/business-unblemished/new-year-deductibles-and-reimbursements 923 2025-02-11T20:15:00.762Z yes https://dermsquared.com/videos/business-unblemished/implementing-pdt-ak-dermatology-practices 2026-01-08T18:07:14.550Z https://image.mux.com/Oc01PNsxJlMJGQwyACguNw3k9oKq00BeiziE7CIx8sbS4/thumbnail.jpg Efficiently Implementing Photodynamic Therapy (PDT) for Actinic Keratosis (AK) in Dermatology Practices In this episode of Business Unblemished, Dr Dawn Merritt and Dr Aaron Farberg discuss how to efficiently implement photodynamic therapy (PDT) for actinic keratosis (AK) in dermatology practices. They address common misconceptions about PDT’s cost, logistical challenges, and practical strategies to maximize both its clinical and financial value.Why use PDT for actinic keratosis?PDT is an effective field therapy for actinic keratosis. While individual lesions can be treated with cryotherapy, many patients require broader treatment, making PDT an excellent in-office option.Dr Merritt, an early adopter of PDT, has integrated the treatment into all 10 of her practice locations, where it is performed daily. Dr Farberg strongly believes every dermatology practice should offer PDT, noting that dermatologists are likely to see multiple patients every day who could benefit from it. While topical therapies remain a viable and effective option, PDT offers greater control over treatment application and adherence, ensuring patients receive consistent and effective care.Optimizing workflow and staffingDr Merritt emphasizes that proper scheduling is key to ensuring PDT does not disrupt clinic flow. Instead of scheduling PDT as a physician-led appointment, she recommends setting it up as a nurse visit:Medical assistants (MAs) handle the setup and patient preparationThe physician only needs to be present for consent, curettage, and product application, allowing them to continue seeing other patients while the PDT session runs in the backgroundDr Farberg adds that while MAs can manage most of the process, physicians should personally apply and initiate PDT for optimal reimbursement and quality of care. A simple way to improve efficiency is to provide patients with a bell to call for assistance while MAs manage other tasks such as prior authorizations or patient paperwork.Space considerations for PDT implementationOne common concern among dermatologists considering PDT is space requirements. However, PDT does not require a dedicated room:Dr Merritt recommends using a nurse visit room or an overflow exam room to allow smooth patient flowDr Farberg has successfully implemented PDT in small rooms, demonstrating that space limitations should not deter practices from considering the serviceAddressing cost concerns and maximizing revenueFor newer or smaller practices, the upfront cost of PDT equipment may feel like a barrier. However, both doctors emphasize that PDT is a long-term revenue generator:Established practices can confidently invest, knowing they will recoup costs over timeNew practices with tighter budgets can explore equipment rental options, which allow them to offer PDT without large upfront costsDr Merritt routinely budgets for PDT when opening a new office because she knows its profitability and value to patients.Educating patients about PDTDr Merritt emphasizes that patient education is crucial for successful PDT integration. She advises new practices to:Create a simple handout explaining what patients can expectAlways schedule 2 PDT treatments upfront, with a third follow-up visit 8 weeks later for evaluation.Dr Farberg finds that offering multiple field therapy options allows patients to choose what works best for them, though many prefer PDT due to its ease of use and convenience.Training staff to promote PDTDr Merritt utilizes rolling screen advertisements in her offices to inform patients about PDT before their appointment. Additionally, she has trained her MAs with instructional videos that cover:PDT setup and applicationHow to explain the procedure to patientsWhen to involve the physician during treatmentThis structured approach ensures the entire team is aligned and helps patients feel more comfortable with the procedure.Identifying ideal candidates for PDTDr Merritt has a simple rule of thumb for determining when to recommend PDT:If she has to freeze more than what fits on one hand, the patient needs field therapy—and PDT is her first choiceDr Farberg also sees PDT as a built-in marketing tool; patients who receive it often remark that they have never had it offered at other dermatology offices. These patients share their positive experiences with friends, bringing in new patients and strengthening practice growth.PDT remains one of the most effective and well-established treatments for AK field therapy. While some dermatologists hesitate due to logistical concerns, both Dr Merritt and Dr Farberg emphasize that with proper implementation, PDT can enhance patient care while becoming a valuable revenue stream.Key takeawaysPDT offers precise, in-office field therapy for patients with AKWith efficient scheduling, PDT can be integrated seamlessly into any practice workflowSpace constraints should not deter practices from offering PDTThe cost of PDT equipment is quickly recouped, and rental options are availableA well-trained team and patient education help maximize PDT’s impact https://dermsquared.com/videos/business-unblemished/implementing-pdt-ak-dermatology-practices 859 2025-02-24T20:07:14.667Z yes https://dermsquared.com/videos/business-unblemished/employee-engagement-success-part-2 2026-01-08T18:07:40.430Z https://image.mux.com/UkWOy2m8jpYUhOtBFGFoWavUd102zWMMP01s5C85SOduo/thumbnail.jpg Employee Engagement as a Strategy for Success in Large or Small Practices (Part 2) In part two of this episode of Business Unblemished, Dr Stephen Lewellis and Jamie Danley continue their conversation about growing and evolving a small practice into a larger practice. They discuss ways of achieving buy-in from employees, empowering team members, and establishing culture based on a firm conviction in a practice's core values. https://dermsquared.com/videos/business-unblemished/employee-engagement-success-part-2 736 2025-04-03T14:49:58.853Z yes https://dermsquared.com/videos/business-unblemished/underused-revenue-streams-cpt-codes 2026-01-08T18:08:03.505Z https://image.mux.com/PQiW02MF3GR02FbQ8APMCBUjeanuWSY01ibEw9RJOluI24/thumbnail.jpg Underused Revenue Streams and CPT Codes: Maximizing Reimbursement to Support Patient-Centered Care In this episode of Business Unblemished, Erik Domingues, MD, sits down with Mark Kaufmann, MD, to unpack the coding strategies, buy-and-bill models, and overlooked CPT opportunities that can help dermatology practices stay afloat in the face of shrinking reimbursements and rising costs.They discuss how to:Use underutilized codes like G2211 to capture the full scope of careDetermine when buy-and-bill strategies are worth the riskAvoid common pitfalls that lead to lost revenueRecognize how accurate, complete coding can safeguard independent practiceAs Dr Kaufmann puts it: inflation is squeezing physicians, but smarter billing may be the key to better survival. https://dermsquared.com/videos/business-unblemished/underused-revenue-streams-cpt-codes 1064 2025-05-12T14:29:23.762Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/nonsurgical-treatment-of-hair-loss-in-2024 2024-02-22T18:00:34.450Z https://image.mux.com/01CEJGU1PMB01D3ysVh8mOfYvvy4r98R00SoN01jJ00MhX01M/thumbnail.jpg Nonsurgical Treatment of Hair Loss in 2024 Gary Goldenberg, MD, focused on regenerative techniques in this up-to-date lecture on nonsurgical treatment of hair loss. He started with platelet-rich plasma (PRP), which harnesses the power of platelet products including growth factors, chemokines, and cytokines to promote cell differentiation and proliferation. Specifically, platelet-derived, vascular endothelial, fibroblast, epidermal, insulin-like, and connective tissue growth factors are responsible for these benefits, which explain this treatment’s usefulness in the treatment of androgenetic alopecia. PRP promotes anagen-associated angiogenesis and neovascularization, dermal papilla cell proliferation, and anti-apoptotic effects. The anagen phase of the hair cycle is extended as dermal papilla cells are protected from premature breakdown. Both dosing at 3 monthly sessions with subsequent injections 3 months later or 2 sessions every 3 months lead to statistically significant increases in hair count, though another trial sponsored by a PRP system manufacturer did show increased hair density with monthly injections compared to quarterly. Further, PRP can be effectively used as an adjunct treatment to many other treatments including microneedling and minoxidil. He moved on to discuss exosomes which are vesicles for intercellular communication, and beyond growth factors, enzymes, and chemokines, also contain mRNA and miRNA. In and of themselves, exosomes could be good or bad, but those used in dermatology are often derived from mesenchymal stem cells, conveying messages to develop into various connective tissues supporting regenerative functions. In hair loss, in addition to the benefits from growth factors and chemokines given by PRP, exosomes also promote hair matrix cell proliferation to revitalize degenerative follicles. Other examples of multipotent stem cells sources are umbilical cord blood and adipose tissue. However, the number of multipotent stem cells present in adipose tissue depends on host factors such as age and general health. Harnessing these cells for hair loss could be in the form of inducing the generation of CK19 positive cells and hairlike structures from mesenchymal stem cells. There are a few small trials that have used adipose-derived stem cells for alopecia, but larger randomized controlled trials are needed. https://dermsquared.com/videos/wcm-2024-conference-highlights/nonsurgical-treatment-of-hair-loss-in-2024 70 2024-02-22T18:00:34.444Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/the-science-of-botulinum-toxin 2024-02-22T18:00:38.567Z https://image.mux.com/Lglj8OA02gtAAl8AP8uclCu01S01K3kxZY9xUxyjIjI59g/thumbnail.jpg The Science of Botulinum Toxin Mark Nestor, MD, PhD, took us through a rigorous review of key clinical postulates of botulinum toxin type A to optimize results for our patients and assess properties to discern differences between commercially available products. His first postulate states that all the type A toxins have the same mechanism of action: the heavy chain of the 150kDa active molecule irreversibly binds SV2 receptors on presynaptic cholinergic neurons, leading to cellular uptake, disulfphide bond breakage, and cleavage of the SNAP 25 protein by the light chain to prevent acetylcholine vesicles from fusing with the cell membrane. The rate-limiting step of this cascade of events is the first, SV2 receptor binding. Potency, therefore, is defined by the amount, activity, and affinity of toxin to bind to this SV2 receptor. This is not directly proportional to manufacture units, as lyophilized toxins may vary by 20% within each vial, and daxibotulinumtoxin peptide may prevent aggregation thereby increasing affinity. It follows that increasing the potency may be possible by increasing the number of SV2 receptors, and there is technology looking at additive enhancer toxins for this purpose. The light chain remains active in the cytoplasm for up to 10 months, but the recovery of response leaves many investigators with questions. While muscle mass and age may play a role in differences seen among patients, acetylcholine receptor gene upregulation, proliferation of neuronal axon sprouts, and myogenesis are the least understood parts of toxin response and lifecycle. These myriad factors that influence clinical efficacy are addressed by Postulate II and III, while also bringing in more clinical variables like the distribution of toxin. The efficacy and duration of the effect of botulinum toxin is proportional to the degree of molecular saturation of molecules bound at neuromuscular junctions as well as the time to recovery, but this is difficult to ascertain objectively for commercial products. While each manufacturer uses its own methodology to tout potency results, Dr Nestor recommended comparing independent trial data or results in an individual split-face study. For example, noninferiority trials looking at glabellar lines and the frontalis muscle compare different toxins on contralateral sides of the face. Abobotulinum toxin demonstrated a faster result than onabotulinum toxin for the frontalis, while there was a slight but insignificant preference for prabotulinum toxin compared to onabotulinum toxin for glabellar lines. Postulate V states that increased molecular potency will decrease the time to onset and increase the duration of effect, up until a certain point that is. Diffusion, a passive process that is the same for all toxins, and spread, based on anatomy, technique, and reconstitution, should also be considered when administering toxin. The later postulates consider the impact of diffusion and spread on clinical effect, and while increasing injection sites may allow for optimal spread, the technique comes with more risk of bruising and consumes more time. Looking into 2024, Dr Nestor also mentioned 2 new toxins in the process of garnering FDA approval, letibotulinumtoxin A and relabotulinumtoxin A, the latter of which is derived from clostridium botulinum. Overall, this was a thorough evaluation of one of the most commonly administered injections in the aesthetic domain. https://dermsquared.com/videos/wcm-2024-conference-highlights/the-science-of-botulinum-toxin 75 2024-02-22T18:00:38.561Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/30-innovations-30-minutes-aesthetics-and-regenerative 2024-02-22T17:58:05.018Z https://image.mux.com/AUUui9K6p00i9TLsb111HZ00QstbWfdgSWxBICMNbtMdw/thumbnail.jpg 30 Innovations in 30 Minutes: Aesthetics and Regenerative Rounding out our first day in Miami was a favorite multispeaker session on the newest technologies in aesthetics and regenerative dermatology. Mark Nestor, MD, PhD, started this session with an overview of how he runs a successful dermatology practice by bridging clinical patients into aesthetic referrals and retaining patients. Dr Glaser also encouraged us to use complications from outside providers as opportunities to retain new patients and demonstrate a collaborative clinical manner. She later covered a trending area for cosmetic products and procedures, the neck, which can have a higher risk of complications with energy-based devices. She recommended hyaluronic acid diluted with 0.4 cc of 1% lidocaine for horizontal lines, though bruising can occur, and high-intensity focused ultrasound, which has no downtime. Dr Weinkle demonstrated an injection technique using a cannula for this area as well as the central face. Dr Goldenberg encouraged us to use devices to their fullest potential in our clinical practice, including for diverse indications like acne. Dr Katz also emphasized the importance of reviewing data on devices before incorporating them into clinical practice. His go-to devices are fractional CO2 and erbium lasers, pulsed dye lasers, radiofrequency microneedling, and picosecond lasers. Dr Goldenberg underscored the importance of anxiolytics and cooling devices or NSAIDs in a device-heavy practice to help retain patients. New aesthetic treatments reviewed included a new injectable polypeptide nanoparticle that delivers siRNA to target TGF-B1 and COX-2, leading to apoptosis of adipocytes in novel fat remodeling technology which is now in Phase 1 trials. Dr Katz also showed the mechanism of the new microcoring energy-based device for skin laxity. Another novel device is a bilayer patch with alkali metals to reduce sweat and inhibitor bacteria in the axilla by generating heat when in contact with sweat, thereby inactivating the sweat gland. Dr Glaser showed us how this novel process of alkali thermolysis works with application of under 3 minutes and a peak temperature equivalent to that of a hot tub. Diosmin, a medical food, is a flavonoid covered by Dr Nestor that may be able to improve progressive pigmentary dermatosis, or Schamberg disease, senile purpura, and rosacea by impacting capillaries and vascular wall permeability. Curcumin, a derivative of turmeric that requires specific complexes and processing to become bioavailable, may also help with pigmentation, premature aging, and dark circles by suppressing melanogenesis and tyrosinase activity. Another medical food covered was genistein, which works at the estrogen-beta receptor and is cancer protective, unlike its alpha-type counterpart. It may play a role in improving skin hydration, increasing collagen synthesis, and decreasing bruising and has a small (n=26) RCT that indicated significant improvement in fine wrinkles and elasticity. Lastly, Dr Weinkle covered some practical injection tips like dropping injections of the procerus to be in line with the medial canthus and similarly lowering corrugator injections to avoid frontalis fibers. She cautioned us to avoid zygomaticus major, levator labii alaeque nasi, and the depressor labii inferioris when injecting the masseter, platysma, or orbicularis oris to avoid impacting facial expression. https://dermsquared.com/videos/wcm-2024-conference-highlights/30-innovations-30-minutes-aesthetics-and-regenerative 112 2024-02-22T17:58:05.011Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/newest-in-dermatology-acne-atopic-dermatitis-actinic-keratoses-psoriasis-skin-cancer-and-more 2024-02-22T18:00:26.744Z https://image.mux.com/02uA56StcXNur3LG3Xd1tjp5YuDSSE022pGRH02ddiWa7Q/thumbnail.jpg The Newest in Dermatology: Acne, Atopic Dermatitis, Actinic Keratoses, Psoriasis, Skin Cancer, and More A much-anticipated session with Drs Del Rosso, Lebwohl, and Zeichner reviewed the hottest new trends and therapeutics for multiple common dermatoses. Starting with acne, results from a clinical trial with the triple-combination gel with clindamycin, adapalene, and benzoyl peroxide were shown, touting a dramatic reduction in inflammatory and noninflammatory lesions by week 4. For psoriasis, 3-year safety data has been published on bimekizumab, noting 18.5 events per 100 person years in the first year on the IL-17A and F inhibitor. Spesolimab has been shown to decrease flares in generalized pustular psoriasis with those who were started on high-dose spesolimab with a GPPGA score of 0 or 1 remaining flare-free for 48 weeks after week 4 of dosing. Deucravacitinib also has long-term efficacy data from clinical trials, with patients who achieved a PASI75 and PASI90 generally maintaining response for 3 years. The speakers moved on to discuss updates in atopic dermatitis including delgocitinib cream for chronic hand eczema, which tripled those obtaining IGA treatment success by week 8 when compared to placebo. For standard atopic dermatitis, response to abrocitinib may be predicted by week 4, and, for those who don’t achieve an EASI-50 reduction by this time point, dose-escalation to 200 mg should be considered. Tapinarof 1% cream has significant efficacy in children 2 years and up all the way to adults in atopic dermatitis. In a review of novel medications for a few other conditions, the efficacy of roflumilast foam for seborrheic dermatitis, which allowed 79% to obtain IGA success by week 8 compared to 48% using vehicle alone, was covered, along with the improvements of eyelash and eyebrow growth in patients with severe alopecia areata on baricitinib. Deuruxolitinib is another JAK inhibitor undergoing clinical trials for this condition. For chronic spontaneous urticaria, dupilumab improves itch and omalizumab improves sleep. Other advances in dermatology that were covered in this presentation centered around the improvements in gene expression tests. This may lead to advances in difficult-to-diagnose conditions like mycosis fungoides. The 2-GEP assay has a negative predictive value of 99.7%, indicating it can be used to rule out melanoma. https://dermsquared.com/videos/wcm-2024-conference-highlights/newest-in-dermatology-acne-atopic-dermatitis-actinic-keratoses-psoriasis-skin-cancer-and-more 113 2024-02-22T18:00:26.729Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/melanoma-update-what-s-new-in-2024 2024-02-22T17:58:08.422Z https://image.mux.com/d02sXd3Q00pE5g8Figky3gkaUJSLgUVuVNfDbq3cuqYr4/thumbnail.jpg Melanoma Update – What’s New in 2024 The incidence of invasive melanoma is rising, and Dr Darrell Rigel gave us the data we need to contextualize risk for our patients and ensure they receive the most up-to-date treatments. Importantly, in a pooled analysis with data from 2013-2019, 5-year survival rates were significantly worse for African-American patients with localized, regional, and distant melanoma diagnoses giving melanoma the largest racial disparity in survival difference. This trend is reflected in racial and ethnic minorities across other skin cancers and deserves clinical attention. However, the past decade has also seen advances in targeted therapies and immune checkpoint inhibitors, which likely account for demonstrated improvement in malignant melanoma survival in Italy between 2003 and 2017. Dr Rigel covered who is at risk, especially those subjected to childhood sunburns and frequent sunburns. A less obvious connection was found between those with a family history of melanoma and Parkinson’s disease after following 131,342 patients for many decades. Alcohol consumption also may be a risk factor. While risk factors may provide clinical indication that more information about a lesion is required, the diagnosis of malignant melanoma is not always straightforward and has been quoted to be as low as 65% accurate. Genomics has become an increasingly important tool alongside pathologic findings as atypical genomic data in markers such as PRAME and TERT reflect cellular atypia. Genomic data can further be harnessed to identify patients who are at a higher risk for developing metastatic disease and would benefit from sentinel lymph node biopsies. Dr Rigel walked us through how to understand results from DecisionDx and emphasized the importance of using genomics to optimize clinical care. The last portion of the presentation focused on what happens after diagnosis. In one study, over 3500 patients with sentinel lymph node metastases were randomized to get either immediate dissection or nodal observation with ultrasonography, and melanoma-specific survival at 3 years was similar between groups. Histopathologic regression in patients with metastatic melanoma getting sentinel lymph node biopsies or with metastases on immune checkpoint inhibitors was associated with better survival as was treatment with 2 complimentary immune checkpoint inhibitors, specifically adding relatlimab, a lymphocyte-activation gene 3 inhibitor, to nivolumab, the PD-1 inhibitor. One RCT comparing neoadjuvant-adjuvant and adjuvant-only pembrolizumab in advanced-stage metastatic melanoma demonstrated significantly longer overall survival in those who were treated with the PD1 inhibitor before and after surgery. Other factors that may impact survival are beta-blocker use, statin use, and estrogen levels. He concluded by discussing some exciting innovations like an mRNA vaccine for melanoma for those at high risk of recurrence, which was studied in a Phase 2b trial. https://dermsquared.com/videos/wcm-2024-conference-highlights/melanoma-update-what-s-new-in-2024 68 2024-02-22T17:58:08.417Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/alopecia-areata-update 2024-02-22T17:58:11.895Z https://image.mux.com/C4WyGJmuQg029XVedidMEhaplq83eDRhoVNN01Xx11Z004/thumbnail.jpg Alopecia Areata Update Dermatology is entering what may be considered a golden age for alopecia areata (AA) with many new treatments available for adolescents and adults alike. While both genders are equally impacted by the condition, it appears that non-White individuals have a higher odds of developing the condition. The prevalence of AA has been increasing for the past 2 decades, and, while genetic predisposition cannot be discounted, Dr Mesinkovska indicated various triggers play a role in the initial loss of immune privilege of the hair follicle leading to destruction by cytotoxic T cells. She launched into the proliferation of treatments for AA, starting with JAK inhibitors bariticinib and ritlecitinib, both of which are approved for the condition. After a review of the JAK/STAT pathway, she covered the real-world application of JAK inhibitors in her practice, indicating the goal is 80% regrowth or a SALT20 in patients who started with complete loss. On baricitinib 4 mg daily, 1 in 3 patients achieve this goal by 36 weeks. Ritlecitinib targets JAK3, which has been shown to be present in skin and lymphoid organs and the TEC kinase family, which consists of 5 members that are involved in intracellular signaling downstream of surface receptors. Regardless, ritlecitinib shows similar results with 43% of patients achieving SALT20 by week 48. Eyebrow and eyelash growth, which for some patients can be more anticipated than scalp hair growth, is slightly higher in ritlecitinib than baricitinib between 40% to 44% compared to 31% to 34%, respectively. The last JAK inhibitor to be aware of is deuruxolitinib which has not yet achieved FDA approval. When discussing JAK inhibitors with her patients, Dr Mesinkovska does not hide the fact that treatment will need to be continued once hair growth is obtained, as stopping or skipping medication can lead to relapse of disease. Those with a disease duration of less than 4 years have the best chance of responding to treatment. The boxed warning for infections, mostly URIs, HSV, and VZV, as well as malignancy and cardiac events, though seen initially in an alternate population using tofacitinib, should be discussed. The hazard ratio for thrombosis is small but should be evaluated in patients with risk factors or those taking OCPs. Other medications to be on the lookout for are probenecid, or other OAT3 transporters, with baricitinib, and CYP1A2/CYP3A inhibitors with ritlecitinib. Isotretinoin and doxycycline can be administered concurrently, especially for those suffering from JAK-inhibitor-induced acne, which is fairly common. She concluded her presentation by presenting a few medication alternatives, including antihistamines, especially in those with atopic background, dupilumab for children or those who are JAK reluctant, and minoxidil in almost all patients to bolster results. https://dermsquared.com/videos/wcm-2024-conference-highlights/alopecia-areata-update 45 2024-02-22T17:58:11.890Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/how-should-i-use-jak-inhibitors-in-my-practice 2024-02-22T17:57:53.559Z https://image.mux.com/JGUIWDJARspbP02tjHamQzJsbDCcWiRfCD4494ulNhb4/thumbnail.jpg How Should I Use JAK Inhibitors in My Practice JAK inhibitors have exploded in the dermatopharmacologic market over the past few years, with myriad disease indications and formulations available. Raj Chovatiya, MD, PhD, started this vigorous session with multiple cases including atopic dermatitis, alopecia areata, and vitiligo, all well suited to treatment with JAK inhibitors. He postulated that the JAK inhibitors work well for numerous dermatologic conditions as, though they themselves are very targeted, the JAK family of proteins impacts many different downstream cytokines. For example, in alopecia areata, MHC Class I expression is increased through JAK 1 and JAK 2, and the activated CD8+ NKG2D+ cells release IFN-gamma, which binds on follicular epithelial cells leading to transition into the catagen phase. JAK inhibitors are perfectly targeted to interfere with the feedback loop that is perpetuated in this disorder. In addition, because they are small-molecule-based treatments, they do not develop immunologic memory like other biologics or theoretical tachyphylaxis. First-generation JAK inhibitors are ATP competitive, meaning they are less inherently selective and have a higher risk of adverse events while they target the highly conserved JAK H1 domain. First-generation JAK inhibitors include tofacitinib, baricitinib, ruxolitinib, and oclacitinib. Second-generation JAK inhibitors are also ATP competitive but are more selective. Conserved adverse effects include cytopenias, hyperlipidemia, and infections. The shared box warning for this class of medications was derived from a 10-year oral surveillance study of patients with rheumatoid arthritis on tofacitinib compared to those on TNF-alpha inhibitors. All of the patients were on methotrexate and many were over 50 years old with more than one cardiovascular risk factor. There was an increased incidence in opportunistic infections, major cardiac events, and malignancy. While this highly conserved evolutionary pathway is important in many pathways, including many that are not related to dermatology, adverse event rates seem to reflect underlying risk factors of the treated population. Dr Chovatiya emphasized the importance of knowing where the warning comes from and how to educate your patients on their own risk to decide if JAK inhibitors are an appropriate treatment.He finalized his talk by driving home the uses of the various FDA-approved JAK inhibitors. Ruxolitinib 1.5% cream is excellent for atopic dermatitis, simplifying complicated treatment routines, and vitiligo, especially in combination with NB-UVB. Abrocitinib and upadacitinib are approved for atopic dermatitis, while the latter has many clinical trials underway for other indications. Both of these JAK1 selective inhibitors demonstrated remarkable responses within 12 weeks of treatment. Baricitinib, a JAK1 and 2 selective inhibitor, was the first JAK inhibitor approved for alopecia areata in the US and is in studies for juvenile idiopathic arthritis. Ritlecitinib shortly followed baricitinib for alopecia areata. Lastly, deucravacitinib, the TYK-2 inhibitor, may be the superior oral option for patients with psoriasis. https://dermsquared.com/videos/wcm-2024-conference-highlights/how-should-i-use-jak-inhibitors-in-my-practice 89 2024-02-22T17:57:53.554Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/new-treatments-for-your-psoriasis-patients 2024-02-22T18:00:49.299Z https://image.mux.com/ZRkrMkanTJv5vkxQweFn01scqtqfg4fNtc3A5A2ywobU/thumbnail.jpg New Treatments for Your Psoriasis Patients While many medications exist for the treatment of psoriasis, Dr Armstrong focused this lecture on the new and emerging therapies for this condition. She started with newly approved nonsteroidal topical medications, tapinarof and roflumilast. Interestingly, the former is derived from a species of bacteria within a roundworm with prominent anti-inflammatory properties, and patients treated with the cream demonstrated marked response that was even maintained for 24 weeks after stopping application. Dr Armstrong next reviewed the mechanism of action of deucravacitinib, the TYK2 inhibitor, which modulates the IL-23/IL-17 axis by binding to the more unique regulatory domain of the TYK2 molecule. Patients who obtained PASI75 or PASI90 by week 52 maintained response through an extension study of 3 years, and patients don’t require laboratory monitoring unless they have known liver or lipid disease. Novel IL-23 and IL-17 inhibitors are also under investigation. Bimekizumab is the newest approved biologic for psoriasis and has demonstrated fast onset and high efficacy with almost 70% of patients achieving a PASI100 by week 16 with noted improvement by week 4. Oral candidiasis is a known adverse event to be prepared for in patients on bimekizumab. She concluded by reviewing generalized pustular psoriasis, which has its first approved treatment with spesolimab. However, another important discussion launched by Dr Armstrong in the discussion of biologic medications is the clarification of biosimilars. They are defined as having identical therapeutic amino acid sequences relative to the reference product and must demonstrate biosimilarity in 3 features: pharmacokinetics, pharmacodynamics, and immunogenicity. She noted, however, that creating consistent identical copies of a biologic is nearly impossible, and dissimilarities exist even from batch to batch within the same manufacturer. Differences in biosimilars may be accounted for in delivery device, product concentration, or citrate content. https://dermsquared.com/videos/wcm-2024-conference-highlights/new-treatments-for-your-psoriasis-patients 91 2024-02-22T18:00:49.294Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/use-of-otc-products-in-your-practice 2024-02-22T18:00:56.785Z https://image.mux.com/XVK1kO4jATLpJfaFROI7RuOgSxOcJQ00T02fdisdt6LQ00/thumbnail.jpg Use of OTC Products in Your Practice Joslyn Kirby, MD, walked us through how to manage patient expectations and social perceptions when “prescribing” over-the-counter products in practice. She started with evidence-based treatments for itch, specifically the use of second-generation antihistamines for chronic spontaneous urticaria. While hydroxyzine and lorazepam require prescriptions prior to procedures, diphenhydramine can be kept in the office and used 30 minutes prior at 25-mg to 50-mg dosages for anxiety. She also gave us the recipe for orange juice mixed with 10 x 50 mg naltrexone tablets, which can be dosed in 1-tsp (5-mL) quantities for various pruritus-inducing dermatoses, though patients should be counseled on vivid dreams and headaches. Dr Kirby had even more hacks for our patients as she presented a study from JAAD that demonstrated that salicylic acid improves the penetration of topical steroids. N-acetyl cysteine functions as a glutamate modulator and antioxidant but has demonstrated efficacy for treatment of picking disorders at 600 mg to 2400 mg daily. If picking becomes pimples, an alternative to antibiotics is zinc gluconate at 90 mg daily for more conservative patients with acne. Pimple patches are also remarkable at keeping hands away from these lesions. Her last pearls are to try out adapalene for acanthosis nigricans, which has more evidence than calcipotriol, and don’t forget to recommend compression stockings, which can be layered at lower strengths for ease of application. https://dermsquared.com/videos/wcm-2024-conference-highlights/use-of-otc-products-in-your-practice 112 2024-02-22T18:00:56.779Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/state-of-photoprotection-in-2024 2024-02-22T17:58:01.157Z https://image.mux.com/02rM29mqYNJgrImgxoXYjT7AaezVnBkwFh6yMt7E5vP8/thumbnail.jpg State of Photoprotection in 2024 Sunscreen is a product almost all dermatologists recommend on a daily basis in clinic, and Roger Ceilley, MD, presented what’s going on behind the scenes in this industry as the United States lags behind other countries in available protective UV filters. Currently, the FDA is requiring additional data on a dozen different chemicals to prove them generally safe and effective. More studies are required to determine the quantity of detectable filters in the blood after application before the FDA will give the official approval on many ingredients already approved in Europe, though companies are not required to remove products from the market until the FDA has given their final word on the ingredients within. Of the 17 filters currently approved in the US, 5 are not commonly used, leaving us with 12 compared to almost 30 in the EU. A primary difference between the chemicals available in the US compared to the EU is that we have fewer ingredients that provide protection against UVA1 (340-400 nm), which plays a large role in photoaging, and these include zinc oxide, titanium dioxide, and avobenzone, the last of which still awaits the FDA’s final verdict. It is not uncommon for patients to look for sunscreen abroad where they have access to more filters such as Mexoryl SL/XL/400, Tinosorb S/M, and TriAsorB. However, Dr Ceilley assured us that new filters in the US are on the way, such as bemotrizinol (BEMT), which is currently undergoing FDA approval and would be the first in over 2 decades. He also presented absorption graphs for TriAsorB, Mexoryl 400, and another novel filter for the EU, BDBP. Moving on to more clinical implications of the sunscreen industry, Dr Ceilley discussed melasma and the importance of photoprotection beyond just sunscreen like photoprotective clothing. The photobiologic impact of visible light has also been a hot topic within the past year, and it, along with UVA1, may aggravate conditions driven by sun exposure like melasma and postinflammatory hyperpigmentation. Tinted sunscreens and oral agents are the best tools against these longer light wavelengths, especially before new filters come to the market. However, tinted sunscreens aren’t as inclusive for all skin types as they should be, especially since Fitzpatrick types IV-VI may benefit more from protection against UVA and visible light, compared to Fitzpatrick types I-III which require UVB protection as well, broadly speaking. An extract from a fern plant native to Central America, Polypodium leucotomos, has been shown to downregulate visible light and UVA1-induced pigmentation and can be recommended as an important adjunct treatment. https://dermsquared.com/videos/wcm-2024-conference-highlights/state-of-photoprotection-in-2024 51 2024-02-22T17:58:01.152Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/rare-diseases-update 2024-02-22T17:57:49.650Z https://image.mux.com/oafzDmVvCIOwEyE7Zai4gxCwk4pj1vB00ywcoAqzFf4w/thumbnail.jpg Rare Diseases Update Ruth Ann Vleugels, MD, took us through a review of rarer dermatologic conditions and new therapeutics to be aware of when treating these patients. Starting with DLE, Dr Vleugels reviewed 2 cases that had exhausted the typical treatment ladder from photoprotection through antimalarials and oral steroids and finally to IVIG or rituximab. She presented a promising new drug, anifrolumab, an anti-type I IFN receptor monoclonal antibody, which has recently garnered approval for SLE. However, in the TULIP-2 trial, it showed promising results for CLE as well in patients who had tried and failed many other systemic medications, indicating this may play a role earlier in the treatment algorithm than systemics with more side effects like rituximab. Not only did mucocutaneous lesions show vast improvement, but almost half of patients had more than a 50% reduction in CLASI score, a measurement of cutaneous lupus activity, compared to 25% on placebo (total n=89). Dosing is 300-mg IV every 4 weeks, which has also been successfully used in adolescent studies. She then moved on to reviewing a few different options for dermatomyositis, including IVIG, which demonstrates superiority from placebo within 4 weeks and is now FDA approved for the condition, and tofacitinib, a JAK inhibitor. Larger randomized controlled trials are required to demonstrate efficacy of JAK inhibitors for dermatomyositis, but open-label pilot studies and retrospective studies have shown promising results. Given the strong type 1 interferon signature in dermatomyositis, JAK inhibitors may be a viable option to interrupt this pathway. Dazukibart, a monoclonal antibody directed against IFN-beta, is currently undergoing phase 3 trials for dermatomyositis. Anifrolumab also demonstrates evidence in the treatment of this disease. Lastly, Dr Vleugels reviewed the use of tofacitinib for cutaneous sarcoidosis. JAK inhibitors may be especially useful in treating overlapping autoimmune conditions. https://dermsquared.com/videos/wcm-2024-conference-highlights/rare-diseases-update 83 2024-02-22T17:57:49.644Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/how-i-choose-the-right-biologic-for-my-psoriasis-patients 2024-02-22T17:58:16.440Z https://image.mux.com/faaGizrUo7OQbeIfnpcq00Uf01OUVm1sxIW67KcjBrPU00/thumbnail.jpg How I Choose the Right Biologic for My Psoriasis Patients Dr Lebwohl expounded upon a common clinical question: how to choose a treatment regimen for patients with psoriasis in a world with dozens of biologics and small-molecule inhibitors. In addition to considering pertinent medical history like inflammatory bowel disease or concomitant autoimmune disorders, Dr Lebwohl looks for biologic medications with evidence to mitigate or prevent psoriatic arthritis. He presented data from numerous randomized trials that showed promising results from various TNF-alpha inhibitors and biologics alike. Etanercept inhibited structural damage of joints compared to placebo based on no change from baseline of the Sharp, or van der Heijde, score in one trial, and 45% to 58% of those on secukinumab demonstrated a 20% improvement in ACR, depending on previous TNF-inhibitor exposure, compared to 15% who were on placebo. Ustekinumab, ixekizumab, and bimekizumab demonstrated similar, if not superior, responses, suggesting that IL-17, IL-23, and IL-12/23 inhibitors share this effect. Bimekizumab in particular achieved an ACR20 in 62% of people compared to 68% on adalimumab at week 24. Guselkumab dosed every 4 weeks demonstrated significant improvement in Sharp, or van der Heijde, score, though every 8 weeks did not reach significance. Dr Lebwohl then examined multiple trials looking at the other small-molecule inhibitors’ impact on psoriatic arthritis. He started with apremilast, the oral PDE4-inhibitor, which also showed moderate improvement in ACR scores at both doses at week 16. Known for their quick onset of action, the JAK inhibitor class also has shown benefit for psoriatic arthritis with 70% of upadacitinib users achieving ACR20 at week 12. Deucravacitinib, the TYK2 inhibitor, similarly decreased ACR scores in multiple RCTs. On the other hand, methotrexate has not been shown to prevent joint damage on x-ray. Dr Lebwohl also reported cyclosporine and acitretin as not effective in preventing joint disease. Another variable to consider in some patients, Dr Lebwohl showed us, is weight in obese patients who haven’t achieved adequate response to medications. One trial showed that response to ixekizumab was modified by weight with 75% of those <80 kg achieving a PASI90 compared to 61% of those >100 kg achieving the same response. The difference was even greater for those receiving every-4-week dosing. Response to adalimumab can also be stratified by body weight, interestingly including the placebo group in the CHAMPION trial. For both ixekizumab and secukinumab, the higher doses were more efficacious for patients >90 kg. It appears that almost all of the biologics have evidence for weight-stratified responses. More evidence is required to determine if the same is true for the JAK inhibitor class. https://dermsquared.com/videos/wcm-2024-conference-highlights/how-i-choose-the-right-biologic-for-my-psoriasis-patients 63 2024-02-22T17:58:16.428Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/treating-your-challenging-psoriasis-cases 2024-02-22T17:57:57.270Z https://image.mux.com/7Yn01GZCxWc31eJSv02tU5V2U01PaUydFOL6mF531Zk8mw/thumbnail.jpg Treating Your Challenging Psoriasis Cases Kicking off our first day of lectures in Miami, Dr Brad Glick reviewed his tips and tricks for treating challenging psoriasis, including when psoriasis ends up being something else entirely. In this case-based presentation, he reviewed therapies for unresponsive palmoplantar psoriasis, comorbidities that may impact treatment of plaque psoriasis and psoriatic arthritis, and a psoriasis look-a-like presenting as exfoliative dermatitis. In the first case, a 74-yo female with palmoplantar psoriatic disease who failed many biologic therapies including secukinumab, ustekinumab, and risankizumab was started on deucravacitinib with remarkable improvement in palms, soles, and scalp psoriasiform lesions. This novel TYK-2 inhibitor can be considered as an “add-on” therapy due to its complimentary mechanism of action to many other biologics and is a reminder that more challenging cases may require compound treatment regimens. In the second case, a former smoker with severe psoriasis, psoriatic arthritis, and a pertinent medical history of valvular heart disease, cerebral aneurysm, and obesity was walked through a variety of treatments with gradually improving responses. While more targeted therapies may have been partially contributing to this patient’s dramatic reduction in IGA, Dr Glick also proposed the importance of weight loss for obese patients with only moderate responses to treatment. Two articles that were cited examine the impact of bariatric surgery and weight loss in general on psoriatic disease. Another pearl in this case is to consider repeating positive QuantiFERON-TB Gold tests before removing patients from successful treatment regimens, as they may be false positives or laboratory errors. He ended with a case of severe exfoliative dermatitis unresponsive to many different therapies that, after review of an initial biopsy report by a second pathologist, was more consistent with pityriasis rubra pilaris. Islands of sparing were evident in clinical photos, and the patient responded to risankizumab and acitretin. In patients with exfoliative dermatitis, always test for scabies and take a detailed exposure history. https://dermsquared.com/videos/wcm-2024-conference-highlights/treating-your-challenging-psoriasis-cases 153 2024-02-22T17:57:57.260Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/prp-and-exosomes-hair-and-aesthetics 2024-02-22T18:00:42.216Z https://image.mux.com/3sDeZzS2OvBEuRv5V3E7Hi34asUPNE8ZijV24mtGP02M/thumbnail.jpg PRP and Exosomes Hair and Aesthetics Dr Glynis Ablon kicked off our last full day in Miami with an in-depth discussion of 2 popular treatments in hair aesthetics: platelet-rich plasma (PRP) and exosomes. Both PRP and exosomes can act as adjunct treatments to other procedures including with each other. Differentiating between the 2, PRP is an autologous blood component that harnesses the secretory prowess of activated platelets, specifically the alpha-granules they release, which contain growth factors and various other cytokines involved in angiogenesis, remodeling, coagulation, and inflammation. After extraction, PRP remains stable for about 4 hours. Notably, the FDA does not classify PRP as a human cellular/tissue product, and all systems require a 510(k) clearance to be sold. Exosomes, on the other hand, are endogenous nanoparticles released by stem cells to create phenotypic change via growth factors to enhance healing and collagen synthesis, miRNA to regulate gene expression, and cytokine to invigorate cells. Since they include mRNA and miRNA, they have effects long after that of cytokines and growth factors alone. Exosomes can come purified, which are frozen and contain intact active exosomes, as well as lyophilized in a powder that requires reconstitution, or suspended in a cream. We await studies to demonstrate the integrity of lyophilized exosomes, but they are appealing to consumers in a variety of skin care products. Exosomes also are present in small numbers in PRP and in some plants, though plant-derived exosomes will not bind to human-derived cell receptors and thus efficacy may be limited. Other concerns regarding exosomes include the limited quality control measures, stem-cell sourcing, and the scalability of the extensive and expensive purification process. There also isn’t a set standard for treatment frequency. Unfortunately, as of now, there are few clinical trials involving exosomes related to dermatology, but that may change in 2024. https://dermsquared.com/videos/wcm-2024-conference-highlights/prp-and-exosomes-hair-and-aesthetics 75 2024-02-22T18:00:42.211Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/treatment-of-hidradenitis-suppurativa-in-2024 2024-02-22T18:00:45.865Z https://image.mux.com/i2l011YqyPHZUpoQOEXsdBKY7E3VPzEr01eftgci00uWks/thumbnail.jpg Treatment of Hidradenitis Suppurativa in 2024 Hidradenitis suppurativa is one of the toughest inflammatory conditions dermatologists treat as it impacts social, psychological, and professional aspects of a patient’s life. Andrea Murina, MD, reviewed oral antibiotics, injectable biologics, and procedures and how to combine them for HS. For long-term maintenance, she recommended spironolactone, metformin, and dapsone. Isotretinoin 20 mg to 60 mg daily is well-suited for patients with evidence of comedones or follicular occlusion phenotypes, while acitretin is good for men and postmenopausal women. Useful additions are zinc 90 mg daily or niacinamide 30 mg daily. Short flares should be managed with oral antibiotics, intralesional steroids, and prednisone if needed. Pain management in HS is another important topic for your patients, and there are a variety of treatment modalities to deploy in treatment. Appropriate wound care, NSAIDs, duloxetine, topical lidocaine, abscess drainage, physical therapy, and even opioids for breakthrough pain may be utilized. Procedural treatments should be considered for both focal and widespread disease in good candidates. Focal disease can be treated with deroofing procedures, Nd:YAG laser, or wide excision, while widespread involvement may benefit from targeting selective areas for excisional surgery in combination with a biologic. Established biologics include adalimumab and secukinumab, which are both FDA approved for HS, and infliximab off-label at 7.5 mg/10 mg per kg every 4 weeks. In 2 RCTs, over 40% of patients on secukinumab achieved at least a 50% reduction in total inflammatory and abscess count by week 16, and over 75% of these patients maintained their response until week 52. However, a few new biologics are on the way including bimekizumab, an IL-17 inhibitor, spesolimab, an IL-36 inhibitor, and various JAK inhibitors. Bimekizumab demonstrated remarkable efficacy with over 50% of patients achieving HiSCR response at week 16 in BE HEARD II at both 2- and 4-week dosing intervals. Draining tunnels improved at week 12 in patients treated with speoslimab, though significant differences were not seen in abscess and inflammatory nodule count. Dr Murina ended her talk with a warning that rising temperatures may increase HS flares. https://dermsquared.com/videos/wcm-2024-conference-highlights/treatment-of-hidradenitis-suppurativa-in-2024 57 2024-02-22T18:00:45.859Z yes https://dermsquared.com/videos/wcm-2024-conference-highlights/clinicians-guide-to-managing-hidradenitis-suppurativa 2024-02-22T17:58:20.464Z https://image.mux.com/d01bz3ki02yJ98iTH5WN01sWLaXD0125M2l49R0221jfH6RM/thumbnail.jpg A Clinician's Guide to Managing Hidradenitis Suppurativa A Clinician's Guide to Managing Hidradenitis Suppurativa https://dermsquared.com/videos/wcm-2024-conference-highlights/clinicians-guide-to-managing-hidradenitis-suppurativa 23 2024-02-22T17:58:20.459Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/psoriasis-tips 2025-01-22T16:35:40.807Z https://image.mux.com/KEe6H3d43DeQhBPHAe1Qwv9hBdJeylab8pN900TopBKU/thumbnail.jpg Psoriasis Tips Mark Lebwohl, MD, addressed a common clinical dilemma: selecting appropriate treatment regimens for patients with psoriasis amidst an expanding array of biologics and small-molecule inhibitors. His presentation emphasized the integration of therapeutic strategies tailored to disease severity, comorbidities, and patient preferences. He discussed vaccine management for patients on systemic therapies, perioperative considerations for immunomodulators, and obesity interventions using GLP-1 receptor agonists, which not only support weight loss but also improve psoriasis outcomes. Short-term biologics were highlighted as effective options for guttate psoriasis, while rapid interventions for generalized pustular psoriasis, including IL-36 inhibitors, were underscored as critical to mitigating severe disease progression.A key focus was the utility of emerging therapies, such as risankizumab and bimekizumab, in achieving high clearance rates even in challenging cases like scalp and nail psoriasis. Dr Lebwohl also explored the management of refractory “mild” psoriasis, advocating for an individualized approach to care that improves patient-reported outcomes, including quality of life. His comprehensive discussion provided actionable insights into optimizing treatment plans to address both common and complex scenarios in psoriasis care. https://dermsquared.com/videos/wcm-2025-conference-highlights/psoriasis-tips 183 2025-01-22T16:35:40.774Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-table-in-2024-impacts-2025-part-2 2025-01-22T16:36:38.396Z https://image.mux.com/FCfF7kPl9YXEto5Sww5e2NAVUPU00cMudtLKj9JxdRtk/thumbnail.jpg What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 2 In Part 2 of “What Did Dermatology Bring to the Table in 2024 that Impact Patient Care in 2025” series, Seemal Desai, MD, Mark Lebwohl, MD, Dawn Merritt, DO, Joshua Zeichner, MD presented new data on several key dermatological conditions from vitiligo to acne.Seemal Desai, MD presented exciting advancements in vitiligo treatment, starting with topical ruxolitinib, which showed significant efficacy, including 95% improvement in F-VASI by week 80, with 66% achieving 75% improvement and 33.9% reaching 90% by week 104. He highlighted promising oral therapies, such as upadacitinib and povorcitinib, for recalcitrant cases, along with phase 2b trial data on ritlecitinib for nonsegmental vitiligo. Dr. Desai also discussed innovative approaches like autologous skin cell suspension grafting for repigmentation and introduced thiamidol, a tyrosinase inhibitor that offers a targeted option for lightening hyperpigmented areas.Dr Lebwohl presented updates on treatments for psoriasis, psoriatic arthritis, hidradenitis suppurativa (HS), atopic dermatitis (AD), and bullous pemphigoid (BP). In psoriasis, the FRONTIER 2 trial showed icotrokinra achieved PASI75 and PASI90 in 76.2% and 64.3% of patients by week 51, while TAK-279 (zasocitinib) reached PASI75 in 67.5% by week 12, and bimekizumab maintained PASI90 and PASI100 in 87.5% and 62.7% by week 16. For HS, the BE HEARD trials confirmed bimekizumab’s efficacy. In AD, lebrikizumab achieved EASI75 and EASI90 in 81.9% and 61.4% of patients by week 52, with upadacitinib outperforming dupilumab in EASI90 and EASI100 rates at 16 weeks. The JADE COMPARE trial found abrocitinib achieved higher EASI75 rates than dupilumab, while roflumilast maintained disease control in 57% of patients through week 56. Dupilumab showed significant efficacy in BP and CSU, reducing itch and hives regardless of baseline IgE levels. Lastly, a JAMA study examined short-term cardiovascular risks with JAK-STAT inhibitors.Up next, Dr Merritt highlighted advances in the treatment of chronic spontaneous urticaria (CSU). Despite the historically low usage of omalizumab among dermatologists, there is renewed interest and promising developments in CSU therapies. Notable innovations include dupilumab, which has demonstrated significant improvement in itch and hive reduction during phase 3 trials, and remibrutinib, an oral medication showing remarkable efficacy in biologic-naïve patients. Additionally, barzolvolimab, a humanized monoclonal antibody targeting KIT, exhibits profound mast cell suppression and promising results from phase 2 trials. These emerging treatments, coupled with ongoing research and upcoming FDA submissions, signify a transformative period for managing CSU and enhancing patient outcomes.Dr Zeichner explored the controversy surrounding benzene contamination in benzoyl peroxide (BPO) acne treatments. Testing revealed benzene levels above FDA safety thresholds in 34% of over-the-counter BPO products, raising concerns due to benzene’s carcinogenic potential. However, studies using data from NHANES and a retrospective cohort of over 50,000 individuals found no evidence linking BPO use to increased benzene blood levels or long-term cancer risk, including leukemia and lymphoma. He emphasized balancing risks and benefits, with practical tips like proper storage and application to minimize exposure. The findings reassure that BPO remains a safe and effective acne treatment when used appropriately. https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-table-in-2024-impacts-2025-part-2 220 2025-01-22T16:36:38.388Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/whats-new-pediatric-infections 2025-01-22T16:35:04.693Z https://image.mux.com/N3p7BSo8pcC100tv6cdNQaVBMYfNdy1DlLbmubhRYgNI/thumbnail.jpg What's New Pediatric Infections Rounding out the first day, Elizabeth Swanson, MD, presented an engaging review of emerging trends and treatments in pediatric infections, offering updates across various dermatologic conditions. She began with herpes zoster, noting an increase in cases among children due to waning immunity from chickenpox vaccination and emphasized the importance of antiviral treatments like acyclovir and valacyclovir, along with precautions for unvaccinated individuals and pregnant women. Dr Swanson also highlighted the efficacy of intralesional HPV vaccines for recalcitrant warts, outperforming intramuscular approaches. For molluscum contagiosum, she discussed the recently FDA-approved cantharidin and other treatment options like topical retinoids and Candida antigen injections, introducing pseudofurunculoid molluscum as a marker of resolution and cautioning against drainage. She also reviewed Gianotti-Crosti syndrome, emphasizing its viral triggers, self-limiting nature, and the use of topical steroids for symptomatic relief.Dr Swanson continued with practical insights on distinguishing impetigo from HSV through bacterial cultures and PCR testing, addressing recurrent cases by identifying nasal carriers. She explored severe cases of hand, foot, and mouth disease, particularly eczema coxsackium caused by coxsackie A6, which requires targeted eczema management and supportive care. Updates on fungal infections included strategies for managing resistant strains like Trichophyton indotineae and pediatric-friendly treatments for onychomycosis. Concluding her session, Dr Swanson provided practical clinical pearls, offering actionable insights and highlighting the importance of evolving, patient-specific therapies in managing pediatric infections. https://dermsquared.com/videos/wcm-2025-conference-highlights/whats-new-pediatric-infections 42 2025-01-22T16:35:04.687Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/botulinum-toxin-update 2025-01-22T16:43:21.357Z https://image.mux.com/B5kk02ilfvtv1ddVTMS01YUE00ahbPGoa6Hjn2c38FZyyE/thumbnail.jpg Botulinum Toxin Update Mark Nestor, MD, PhD, provided an in-depth update on the science of botulinum toxin type A (BoNT-A), focusing on how to select the right toxin and optimize clinical results. Dr Nestor astutely points out that understanding the clinical science of BoNT-A) injections allows providers to more accurately assess properties and differences between commercially available products. Going through the mechanism of BoNT-A, he demonstrates how molecular potency (MP), receptor binding and the role of patient-specific factors like age, muscle mass, and genetics influence toxin efficacy, onset, and duration.Dr Nestor discussed the concept of the "Area of Clinical Effect (ACE)," which is defined by the spread of the toxin suspension multiplied by MP. He discussed how optimal injection techniques, reconstitution volumes, and the number of injection sites can maximize results while minimizing adverse effects. He concluded by emphasizing that while all type A toxins share a similar mechanism, efficacy of the BoNT-A injection depends on a range of factors that include patient attributes, MP, technique, toxin spread, optimal reconstitution, and number of injections. https://dermsquared.com/videos/wcm-2025-conference-highlights/botulinum-toxin-update 83 2025-01-22T16:36:13.750Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/contact-dermatitis-update-for-2025 2025-01-22T16:34:28.778Z https://image.mux.com/2BqPPvaGmBjkJmXFq02xy6c602lx1k00J027NJaNf01R011HM/thumbnail.jpg Contact Dermatitis Update for 2025 Kicking off the first day of lectures in Miami, David Cohen, MD, MPH, provided an insightful overview of contact dermatitis, focusing on allergens dermatologists should monitor in 2025. He highlighted shifting trends, noting that while nickel and methylisothiazolinone (MI) remained the top 2 allergens, fragrance mix components like hydroperoxides of linalool and benzisothiazolinone (BIT) moved up the rankings. Through patient case studies, Dr Cohen explored common offenders such as MI, lanolin, and fragrance, emphasizing the rising prevalence of MI sensitization, which increased from 2.5% in 2010 to 13.8% in 2023. Despite being a common test allergen, MI testing may miss up to 60% of BIT sensitizations, prompting the need for broader testing strategies. Lanolin, designated as the 2023 allergen-of-the-year and commonly manifesting as contact dermatitis on the lips or genitals, was noted to be more likely seen in patients with concurrent atopic dermatitis. Fragrance sensitivity was also prevalent, with nearly 1 in 4 patients with contact dermatitis reacting to allergens like hydroperoxides of linalool and limonene, which require specific inclusion in patch test panels.Dr Cohen also addressed systemic contact dermatitis, a condition triggered by systemic exposure to allergens and often misdiagnosed due to its varied presentations, such as baboon syndrome or dyshidrotic hand eczema. He concluded with a focus on sulfites, the 2024 allergen-of-the-year, found in cosmetics, food, beverages, and pharmaceuticals, including topical antifungals and local anesthetics. By emphasizing the importance of recognizing new trends, refining diagnostic tools, and expanding patch test panels, Dr Cohen underscored the evolving landscape of allergen detection and management in dermatology. https://dermsquared.com/videos/wcm-2025-conference-highlights/contact-dermatitis-update-for-2025 160 2025-01-22T16:34:28.765Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/clinical-pearls-panel 2025-01-22T16:41:03.470Z https://image.mux.com/ckscRG02lIwcZyxoDP37ngAd8EluOBhKzyWNT4sQto2g/thumbnail.jpg Clinical Pearls Panel Rounding out the second day was a multispeaker session on clinical pearls by Gary Goldenberg, MD, Brad Glick, DO, Edward (Ted) Lain, MD, MBA, Elizabeth (Lisa) Swanson, MD, and Joshua Zeichner, MD. Dr Goldenberg opened the session with 5 practical clinical pearls to address common challenges in practice. He emphasized the importance of going beyond simply prescribing medications, urging providers to incorporate advanced tools like platelet-rich plasma for hair loss into their treatment strategies. Dr Goldenberg also posed a thought-provoking question about the future of regenerative medicine, highlighting how regulatory and practical challenges may hinder its progress. Additionally, he stressed the importance of managing patient anxiety and pain during procedures to optimize outcomes. He concluded by encouraging providers to discuss dietary habits with their patients to combat photoaging and manage common skin conditions effectively.Dr Glick emphasized the importance and criticality of early detection and diagnosis of psoriatic arthritis (PsA). Studies have shown that there is an average delay of 5 years in PsA diagnosis, but even a 6-month delay in diagnosis can have detrimental effects including irreversible joint damage, worse long-term physical function, and decreased quality of life (QoL). There are several QoL measures in PsA, one of which is designated as minimal disease activity (MDA), which consists of 7 criteria—5 of which need to be met to achieve MDA. While MDA primarily assesses clinical disease activity, studies have shown that achieving MDA is strongly associated with slowed or halted radiographic progression of joint damage. Because early detection and diagnosis is critical to patients with PsA, it is important to know that patients with plaque and scalp psoriasis have a 50% or greater chance of having PsA. The 5 major risk factors for development of PsA in association with psoriasis additionally include higher BSA involvement, obesity, intergluteal or perianal lesions, and nail dystrophy. Dr Lain continued the discussion by addressing the management of rosacea, focusing on strategies for handling flares in previously controlled cases. He emphasized using low-dose isotretinoin (20–30 mg every other day) as an option for recalcitrant rosacea. For patients experiencing a flare after being well-controlled, Dr Lain suggested evaluating for small intestinal bacterial overgrowth and considering treatment with rifaximin 550 mg twice daily for 10 days. He also highlighted the potential role of probiotics in rosacea management. Additionally, Dr Lain recommended the use of minocycline rather than doxycycline for addressing rosacea-related papules and pustules.Dr Swanson followed with clinical pearls for pediatric dermatology, sharing practical and innovative approaches to common challenges in this patient population. She highlighted the Aron Regimen as an effective compounded treatment for severe atopic dermatitis, especially in infants and toddlers. Dr Swanson also discussed eclipse nevi, commonly found on children's scalps, emphasizing that these lesions are benign and typically do not require biopsy. For pyogenic granulomas, she discussed the treatment option of topical timolol. She also provided insights into managing warts, advocating for an approach using salicylic acid and 5-fluorouracil, which has shown to be highly effective with minimal pain. Finally, she shared a lighthearted but meaningful tip to always provide a snack to teenage boys after a biopsy, ensuring a positive experience for young patients.Lastly, Dr Zeichner presented clinical pearls for acne management. Key takeaways included starting with combination therapy such as IDP-126, a fixed-dose triple-combination topical consisting of clindamycin, adapalene, and benzoyl peroxide. Simplifying regimens was highlighted as a way to improve adherence, with once-daily treatments showing higher compliance compared to more complex regimens. Dr Zeichner also underscored the importance of considering acne a chronic condition and continuing treatment beyond 12 weeks, involving patients in shared decision-making to enhance engagement and adjusting isotretinoin doses based on clinical evaluations to ensure effective absorption. https://dermsquared.com/videos/wcm-2025-conference-highlights/clinical-pearls-panel 567 2025-01-22T16:36:06.104Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/say-no-to-spontaneity-treating-chronic-spontaneous-urticaria 2025-01-22T16:41:40.577Z https://image.mux.com/6uKG02BkIGOAddQDm2uxry9NQm1ptLSKxyUstFF4uYEo/thumbnail.jpg Say ‘No’ to Spontaneity: Treating Chronic Spontaneous Urticaria Chronic spontaneous urticaria (CSU) is defined by recurring hives, swelling, or both, and lasting 6 weeks or more, without identifiable triggers such as allergies or external stimuli. Dawn Merritt, DO, Mark Lebwohl, MD, and Marc Serota, MD, examined the challenges of second-line antihistamine treatments, explored new therapies, and emphasized personalized treatment strategies for CSU. Current guidelines have not yet integrated emerging therapies like omalizumab, remibrutinib, and dupilumab. Omalizumab, the only biologic currently approved for CSU, has demonstrated strong efficacy, achieving good control in 51.9% of patients and complete control in 35.8% of patients at the highest dose (300 mg). However, concerns over its black box warning for anaphylaxis have contributed to underutilization, even though the risk is rare (0.09%-0.2%) and mostly occurs within 2 hours of initial injections in patients with prior anaphylaxis history.New treatments like remibrutinib, rilzabrutinib, and dupilumab offer hope for improved CSU management. In the REMIX-1 and -2 trials, remibrutinib achieved UAS7 scores of 6 or less in 11.9% more patients than placebo, demonstrating rapid onset and sustained response over 52 weeks, with additional improvements in sleep and weekly itch severity (AIS7). Its safety profile includes mild adverse events like nasopharyngitis (6.6%), headache (6.1%), and petechiae (3.8%). Dupilumab, evaluated in the phase 3 Liberty-CUPID Study C, showed significant benefits over placebo, including greater reductions in itch severity, UAS7 scores, and improved disease control, with 30% achieving complete response. Dupilumab's adverse events were primarily skin-related. These advancements, including ongoing FDA reviews, signal a new era in CSU therapy, with the potential for better disease control and enhanced quality of life for patients. https://dermsquared.com/videos/wcm-2025-conference-highlights/say-no-to-spontaneity-treating-chronic-spontaneous-urticaria 239 2025-01-22T16:41:40.565Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/therapeutic-update 2025-10-20T22:30:07.843Z https://image.mux.com/hCm9Obm1iedwLbvqX01jJEtrpPoNv27KDWbctrxcUUig/thumbnail.jpg Therapeutic Update Gary Goldenberg, MD, opened day 2 with an extensive review of the latest research on a broad range of dermatologic conditions, including acne vulgaris, psoriasis, atopic dermatitis (AD), alopecia areata, vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), seborrheic dermatitis, actinic keratosis (AK), chronic spontaneous urticaria (CSU), melanoma, onychomycosis, and cosmetic treatments. He began with acne vulgaris, highlighting innovative treatments such as clindamycin phosphate 1.2%, adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB gel), clascoterone, sarecycline, trifarotene cream, and 1726 nm laser. CAB gel, shown to outperform dual combinations and vehicle gel in Phase 2 and 3 trials, and clascoterone, which demonstrated improvement in acne lesions, pore size, and shine by week 12, were particularly noteworthy. Sarecycline, a new antimicrobial with better gut microbiome preservation, also stood out. Dr Goldenberg then transitioned to psoriasis, discussing biologic advancements such as risankizumab, guselkumab, and bimekizumab, as well as alternatives like the 308 nm excimer laser. He reviewed AD therapies, including roflumilast, dupilumab, and lebrikizumab, before covering alopecia areata treatments like ritlecitinib and baricitinib. For vitiligo, he presented promising data on ruxolitinib and upadacitinib, alongside preclinical studies of VY201. HS therapies featured novel agents such as MC2-32, while PN, seborrheic dermatitis, and AK saw advancements in dupilumab, roflumilast foam, and tirribanibulin ointment, respectively. He concluded with updates on CSU, melanoma diagnostics, and cosmetic innovations, showcasing the latest in cutting-edge dermatology research. https://dermsquared.com/videos/wcm-2025-conference-highlights/therapeutic-update 82 2025-01-22T16:35:29.832Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/choosing-the-right-systemic-treatment-for-your-patients-with-atopic-dermatitis 2025-01-22T16:36:20.094Z https://image.mux.com/qw3H7Rk82VJuD02wQppH69nBzAzR01LwdbxEPq01uGuFD00/thumbnail.jpg Choosing the Right Systemic Treatment for Your Patients with Atopic Dermatitis While many systemic treatments are available for atopic dermatitis (AD), Dr Alexandra Golant focused her lecture on the latest advancements and evidence-based strategies for choosing the right therapy. She began with a series of cases and clinical images emphasizing the range of presentations that AD can take, which can create discrete endotypes within the AD population. Fortunately, scientific discoveries on the pathogenesis of AD and treatment targeting now mirror the range of clinical presentations, allowing for an individualized approach to selecting a systemic therapy. Dr Golant reviewed when to reach for systemic therapy guidelines but also emphasized the importance of documenting disease severity, quality-of-life impacts, and treatment targets. She presented data on key therapies, including dupilumab, which showed sustained efficacy over 2 years, and tralokinumab, which demonstrated effectiveness in patients with head and neck involvement. Emerging options like nemolizumab and lebrikizumab were discussed, showcasing their promising results in clinical trials for moderate-to-severe AD. Dr Golant concluded by stressing the importance of achieving optimal treatment targets within 3 to 6 months and tailoring therapy to each patient’s needs and disease characteristics to improve outcomes and quality of life. https://dermsquared.com/videos/wcm-2025-conference-highlights/choosing-the-right-systemic-treatment-for-your-patients-with-atopic-dermatitis 68 2025-01-22T16:36:20.088Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/whats-new-in-the-treatment-non-scarring-alopecia 2025-01-22T16:34:52.666Z https://image.mux.com/R25gFPaAdipYORfs5bWSrKYrjM7wr7100uP1PvOnC3YI/thumbnail.jpg What's New in the Treatment of Non-Scarring Alopecia In this presentation, Amy McMichael MD, discussed the latest updates in the treatment of common types of non-scarring alopecia, including pattern hair loss and alopecia areata (AA). She began by highlighting FDA-approved treatments for pattern hair loss, such as topical and oral minoxidil, finasteride, and low-level laser therapy, while also addressing emerging therapies like bicalutamide, sublingual minoxidil, and mesotherapy. The presentation emphasized the superior efficacy of oral dutasteride for male pattern hair loss compared to other therapies.For AA, updates included the disproportionate prevalence in patients of color and the efficacy of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib, which are approved for severe AA in different age groups. A new tool, the Alopecia Areata Scale (AASc), was introduced to standardize the evaluation of AA severity and guide treatment decisions. The presentation also discussed combination treatments, side effects, and long-term safety data for JAK inhibitors. https://dermsquared.com/videos/wcm-2025-conference-highlights/whats-new-in-the-treatment-non-scarring-alopecia 116 2025-01-22T16:34:52.661Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/alopecia-areata-update-wcm25 2025-01-22T16:40:11.446Z https://image.mux.com/n1DainOT02kSXBlwHoDBllStyv0001llrUg2zyDIIzHCVg/thumbnail.jpg Alopecia Areata Update at WCM25 Alopecia areata is a complex autoimmune condition with profound physical and emotional impacts on patients. Natasha Mesinkovska, MD, PhD, opened her presentation with a fascinating discussion on mortality rates in patients with alopecia areata and vitiligo, noting that these rates are lower than in the general population. She then delved into factors beyond autoimmunity that may contribute to alopecia areata, including stress, reduced antioxidant activity, low levels of vitamin D and zinc, associated celiac disease, and imbalances in serum Th1, Th2, and Th17 levels.Dr Mesinkovska provided updates on treatment innovations, particularly the expanding role of JAK inhibitors such as baricitinib, ritlecitinib, and deuruxolitinib, which have demonstrated significant efficacy in clinical trials. She highlighted the need for sustained, long-term treatment to maintain hair regrowth and emphasized the importance of weighing safety and side effect considerations. Additionally, she addressed challenges regarding the use of JAK inhibitors in pediatric patients and during pregnancy, as most JAK inhibitors cross the placental barrier (with deucravacitinib being a notable exception). Despite these challenges, she advocated for maintaining JAK inhibitors as an option for patients of reproductive age.The presentation also explored the strong association between alopecia areata and atopic dermatitis, the most common comorbidity in these patients. She reviewed treatment approaches for concurrent conditions, including dupilumab, tralokinumab, and lebrikizumab, each showing varying levels of success. Dr Mesinkovska concluded with an exciting potential treatment: localized injections of baricitinib-loaded mesenchymal stem cell exosomes, which may represent a novel approach for managing alopecia areata. https://dermsquared.com/videos/wcm-2025-conference-highlights/alopecia-areata-update-wcm25 92 2025-01-22T16:36:26.739Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-table-2024-impacts-2025-part-3 2025-01-22T16:36:46.403Z https://image.mux.com/58fhKaWN8Ajish3TbfWMbQ5NUWkSyoOdyg00iUY86UTk/thumbnail.jpg What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 3 In this presentation, Gary Goldenberg, MD and Mark Nestor, MD, PhD, provided valuable insights into botulinum toxin (Botox) injections, collagen biostimulators, androgenetic alopecia (AGA) treatments, and innovative aesthetic devices for 2025. They began by discussing Botox injections, emphasizing that while all Type A toxins share the same mechanism of action, variations in results arise from differences in molecular potency, dosage, patient-specific factors (such as age, gender, and muscle mass), genetics, and injection technique. Using detailed diagrams, they highlighted optimal injection sites to achieve desired outcomes and noted how targeting the correct muscles not only influences facial aesthetics but may also impact mood through facial feedback.The discussion then moved to collagen biostimulators, including poly-L-lactic acid (PLLA), calcium hydroxyapatite (CaHA), and cross-linked hyaluronic acid (HA). The presenters reviewed clinical studies, case results, potential mechanisms, and possible side effects of these biostimulators. For AGA, a variety of treatment options were explored, ranging from platelet-rich plasma and stem cells/exosomes (often paired with microneedling) to red light therapy, topical medications, vitamins, and low-dose oral minoxidil.Lastly, the presentation introduced two cutting-edge aesthetic devices. RF microneedling was highlighted for its versatility in skin tightening and fat reduction, particularly in the infraorbital and submental regions. The Thulium 1928 nm laser was showcased as a promising tool for effectively treating pigmentary disorders, demonstrating excellent clinical results. https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-table-2024-impacts-2025-part-3 228 2025-01-22T16:36:46.397Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/topical-and-systemic-antibiotic-therapy 2025-01-22T16:34:38.721Z https://image.mux.com/01PYtqluWfQHJc42G02y7Gi2YhD73JoCJH4w6j6yJUeAQ/thumbnail.jpg Topical & Systemic Antibiotic Therapy Antimicrobial resistance (AMR) has become one of the most urgent global health crises, as highlighted by Theodore Rosen, MD, in his impactful session, "Topical and Systemic Antibiotic Therapy." Dr Rosen opened with a case of a Serratia marcescens infection following a cat bite, which ultimately led to a finger amputation despite aggressive antibiotic treatment, showcasing the severe consequences of resistant pathogens. He stressed that AMR is a present and growing challenge, driven by the overuse and misuse of antibiotics, the adaptability of microbes, and a stalled pipeline for new drug development. With 1.3 million deaths attributed to AMR in 2019 and projections reaching 2 million annually by 2050, the presentation shed light on resistance mechanisms, such as efflux pumps and enzymatic degradation, and the diminishing arsenal of effective therapies.Dr Rosen emphasized the necessity of antibiotic stewardship, urging clinicians to ensure accurate diagnoses, select appropriate therapies, and minimize treatment durations. He also explored innovative solutions to combat AMR, including bacteriophages, antimicrobial antibodies, AI-driven drug discovery, and vaccine development. Expanding beyond bacterial resistance, Dr Rosen highlighted the growing threats from resistant viruses, fungi, and parasites, such as acyclovir-resistant HSV and terbinafine-resistant dermatophytes. Concluding with a call to action, he underscored the need for global collaboration, innovation, and vigilance to avoid a post-antibiotic era where even routine infections could become life-threatening. This session served as a critical reminder of the pressing need to address AMR through multidisciplinary efforts and cutting-edge research. https://dermsquared.com/videos/wcm-2025-conference-highlights/topical-and-systemic-antibiotic-therapy 137 2025-01-22T16:34:38.715Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/winter-clinical-miami-2025-opening-reception 2025-01-28T16:41:35.245Z https://image.mux.com/I00XxAZyvhtE9Vg7Kwb02PATt00MtEaTzDMk9Gzz00CgQEo/thumbnail.jpg Winter Clinical Miami 2025 Opening Reception Watch highlights from the Winter Clinical Miami 2025 Opening Reception in Miami, Florida! https://dermsquared.com/videos/wcm-2025-conference-highlights/winter-clinical-miami-2025-opening-reception 290 2025-01-28T16:34:49.576Z yes https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-to-table-2024-impacts-2025-part-1 2025-10-20T22:29:32.112Z https://image.mux.com/A00K6J6s3OOcTF9r2pEFGSYyB323sePeowaNT26BcdJM/thumbnail.jpg What Did Dermatology Bring to the Table in 2024 That Impacts Patient Care in 2025 - Part 1 Darrell S. Rigel, MD, MS started this multi-part discussion highlighting significant advancements in dermatologic oncology. Key updates include the efficacy of tirbanibulin 1% for treating actinic keratosis (AK) over larger treatment fields, supporting its expanded FDA approval. In invasive squamous cell carcinoma (SCC), watchful waiting was found reasonable for clinically resolved low-risk lesions, although immunocompromised patients face higher recurrence risks. For basal cell carcinoma (BCC), consensus guidelines favor hedgehog inhibitors for advanced cases, with strategies to mitigate side effects enhancing compliance. Advances in gene expression profiling (GEP) aid risk stratification and treatment decisions for melanoma and SCC, improving outcomes with early detection and targeted interventions. Additionally, neoadjuvant therapies, including nivolumab and ipilimumab, show promise in stage III melanoma, emphasizing personalized care in skin cancer management.Brian Berman, MD, PhD followed with a review of key advancements in actinic keratosis (AK) and basal cell carcinoma (BCC) treatments, along with innovative technologies in dermatology. Highlights included FDA approval for expanded use of tirbanibulin 1% for larger AK treatment areas and its correlation with high patient satisfaction. Intralesional therapies like STP705 siRNA and AIV001 showed promise in achieving high histological clearance rates for BCC with minimal adverse effects. Additionally, augmented reality-guided facial injections and surgeries emerged as cutting-edge technologies, offering enhanced safety by visualizing anatomical structures in real-time. These developments underscore significant strides in dermatologic treatments and procedural safety.David Cohen, MD, MPH, concluded Part 1 with an insightful discussion on the latest data regarding contact dermatitis. He highlighted the significant overlap between the pathways of allergic contact dermatitis (ACD) and those driving atopic dermatitis (AD). These shared mechanisms involve a diverse range of helper T-cell pathways, including Th2, Th17, and Th22, as well as various interleukins. Given this overlap, he noted that dupilumab, a treatment for AD, has been shown to alter clinical outcomes and impact patch test reliability. This can complicate the interpretation of patch test results, as dupilumab has been associated with an increased false-negative rate. https://dermsquared.com/videos/wcm-2025-conference-highlights/what-dermatology-bring-to-table-2024-impacts-2025-part-1 399 2025-01-22T16:36:32.722Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/derm-atopic-derm-what-else 2025-10-31T20:03:14.366Z https://image.mux.com/UrcdIgEBGugkp3t01U36yat75Kwi8vqH9AmAzMnQYHrs/thumbnail.jpg What’s Itching You Today? Contact Derm? Atopic Derm? What Else? Shawn G. Kwatra, MD, presented a compelling session on the evaluation and management of chronic itch, underscoring its profound impact on patient quality of life. Chronic pruritus, he noted, impairs quality of life to a degree comparable to that of stroke and more than conditions such as heart failure with an implantable defibrillator or patients on hemodialysis. Despite being one of the most common symptoms in dermatology, pruritus often remains diagnostically elusive and therapeutically challenging. Through a series of illustrative cases, Dr Kwatra emphasized that chronic itch can be the first sign of systemic disease and requires careful evaluation beyond the skin. Dr Kwatra discussed emerging insights into the genetic and immunologic underpinnings of chronic itch, including a potential polygenic risk association in prurigo nodularis. He reviewed targeted treatments such as dupilumab, which has shown efficacy for chronic itch of various etiologies, and low-dose naltrexone, which modulates μ-opioid signaling and inflammatory mediators to relieve refractory scalp pruritus and symptoms in conditions such as epidermolysis bullosa. Additionally, he provided a practical framework for laboratory and clinical evaluation, including eosinophil counts and screening for systemic causes when the origin of itch is unclear. Concluding with complex cases of widespread pruritic dermatoses, Dr Kwatra illustrated how integrating immune profiling and genomic analysis can identify dominant cytokine pathways (IL-13, IL-17) and guide rational biologic therapy selection. https://dermsquared.com/videos/fc-2025-conference-highlights/derm-atopic-derm-what-else 87 2025-10-31T20:03:14.358Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/management-for-chronic-hand-eczema 2025-10-31T20:04:17.326Z https://image.mux.com/7Tv01EuKP02juMPT798eZdcrtBOnQywljdEji00qPTu2cw/thumbnail.jpg Seminar-in-Depth: On the Verge of Better Management for Chronic Hand Eczema Benjamin Ehst, MD, PhD, and Alexandra Golant, MD, presented an insightful session focused on the complex diagnosis and evolving treatment landscape of chronic hand eczema (CHE), a condition characterized by persistent inflammation, multifactorial triggers, and limited long-term therapeutic success.Dr Ehst began by emphasizing that CHE, defined as hand eczema lasting more than three months or recurring twice or more within a year, is rarely caused by a single factor. He described how atopic dermatitis, allergic contact dermatitis, and irritant exposures often overlap, complicating management. Through a case example of a 64-year-old manufacturing employee with recurrent fissuring and scaling, Dr Ehst demonstrated the importance of comprehensive history-taking and patch testing to identify occupational allergens. He highlighted that the pathophysiology of CHE involves cytokine-mediated inflammation via the JAK-STAT pathway, providing a rationale for the recent wave of targeted therapies. Dr Golant echoed the need to individualize care, noting that traditional approaches, such as topical corticosteroids, calcineurin inhibitors, and systemic immunosuppressants, often fail to maintain remission once treatment is stopped.The discussion then turned to emerging therapies offering renewed hope for this burdensome condition. Dr Golant reviewed pivotal phase 3 data from the DELTA 1 and 2 trials showing that delgocitinib cream, a topical pan-JAK inhibitor, achieved significant Investigator’s Global Assessment (IGA-CHE) responses by week 24, with nearly one-third of patients attaining clear or almost-clear skin in the long-term DELTA 3 extension. Dr Ehst highlighted similar promise from ruxolitinib cream, which produced rapid reductions in itch and eczema severity by day 7 in phase 2 studies. Additional data from the LIBERTY AD-HAFT trial demonstrated that dupilumab significantly improved hand and foot eczema outcomes, while interim tralokinumab results suggested parallel benefit without new safety concerns. Both speakers underscored the favorable tolerability profiles of these agents, marking a major shift from chronic steroid reliance toward precision-driven. https://dermsquared.com/videos/fc-2025-conference-highlights/management-for-chronic-hand-eczema 165 2025-10-31T20:04:17.318Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/fall-clinical-2025-highlights 2025-11-13T20:57:47.464Z https://image.mux.com/2dbavpDUbhjyJfi02rxf2Zms6DMOf7pS7007xFirToYA4/thumbnail.jpg Fall Clinical 2025 Highlights Take a peek at the atmosphere and buzz in the conference rooms, exhibit hall, and receptions from Fall Clinical 2025 in Las Vegas! https://dermsquared.com/videos/fc-2025-conference-highlights/fall-clinical-2025-highlights 38 2025-11-13T20:55:56.061Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/management-of-atopic-dermatitis 2025-10-31T20:03:23.641Z https://image.mux.com/3RM5N2rl7zBoAQhP21bN00yKs00cPkVdPFqKfwAZ2wpmM/thumbnail.jpg CME Satellite Symposium: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic Dermatitis Alexandra Golant, MD, Mona Shahriari, MD, and G. Michael Lewitt, MD, presented a session focused on the evolving role of interleukin-13 (IL-13) inhibition in atopic dermatitis, sharing new insights, case experiences, and strategies for optimizing treatment in clinical practice.Dr Golant opened by underscoring the central role of IL-13 in atopic dermatitis pathophysiology. Elevated across age groups and skin tones in patients with atopic dermatitis, IL-13 drives barrier disruption, decreases filaggrin expression, and fuels pruritus and lichenification. She reviewed case examples, including an adolescent with long-standing disease who achieved rapid and sustained improvement on lebrikizumab. Dr Golant emphasized how patient-defined goals such as comfort at school, confidence in social settings, and reduced topical burden align with the responses seen in trials. Early and aggressive targeting of IL-13 was presented as a way to meet both clinical and quality-of-life outcomes.Dr Shahriari expanded on the comparative efficacy of IL-13 biologics, highlighting pivotal data from SOLO, ADvocate, ECZTRA, and long-term extension studies. Both lebrikizumab and tralokinumab demonstrated durable control, with maintenance of EASI90 and pruritus relief extending beyond 2 years. She also addressed switching strategies, noting that patients discontinuing dupilumab for adverse events often achieved better outcomes on lebrikizumab compared with those stopping for inadequate response. Dr Shahriari presented cases of patients with dupilumab-associated ocular surface disease whose symptoms resolved when transitioned to tralokinumab or Janus kinase inhibitors, underscoring the importance of individualized sequencing.Dr Lewitt concluded with a practical perspective on integrating IL-13 inhibitors into daily practice. He illustrated this with a young adult patient who prioritized clearance of hand and facial dermatitis with minimal treatment burden. After 16 weeks of lebrikizumab, both skin clearance and pruritus improved markedly, restoring confidence and function. Dr Lewitt highlighted safety profiles across the IL-13 inhibitor class, emphasizing that adverse events are generally manageable and that selective inhibition may be particularly appealing when patients prefer targeted therapy without systemic immunosuppression. Looking forward, the faculty noted that biologics with extended half-lives, bispecific antibodies, and oral agents may further expand long-term disease control options. https://dermsquared.com/videos/fc-2025-conference-highlights/management-of-atopic-dermatitis 170 2025-10-31T20:03:23.595Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/who-has-better-pearls 2025-10-31T20:04:29.283Z https://image.mux.com/BI027BorIOM8VU7STLoEoGIESdAsDFWNFyMpSEOQrPgY/thumbnail.jpg Pediatric Dermatology – Who Has Better Pearls? Lawrence F. Eichenfield, MD, started the session, delivering a highly informative lecture centered on practical pediatric dermatology pearls that enhance both diagnostic accuracy and patient care. Dr Eichenfield began by sharing a simple but effective clinical tip: using an otoscope to differentiate pilomatricomas from epidermal inclusion cysts or dermatofibromas. The illumination helps highlight the calcium deposits characteristic of pilomatricomas, allowing for a more confident bedside diagnosis without the need for advanced imaging.He continued with guidance on managing localized eyebrow alopecia, recommending a tiered tapering approach using clobetasol for seven days, followed by consideration of topical minoxidil or ruxolitinib as adjunctive therapies. Dr Eichenfield also provided practical strategies for improving pediatric procedures, including employing “iPhone hypnosis” for distraction and using a “spreadsheet method” to ensure efficiency and consistency during clinical interventions. To address parental hesitation toward treatment, he introduced the “unpack the backpack” method: an empathetic communication approach encouraging providers to explore and understand parental concerns before offering reassurance and education. The session concluded with an evidence-based review of pediatric hemangioma management, supported by clinical imagery that underscored treatment effectiveness and expected outcomes.Elizabeth (Lisa) A. Swanson, MD, then shared her top pearls—equal parts humor, empathy, and practical wisdom. She began with management strategies for atopic dermatitis (AD), emphasizing the growing array of new topical nonsteroidals such as tapinarof 1% cream (approved for ages 2+), roflumilast 0.15% cream (6+), and ruxolitinib 1.5% cream (2+). Dr Swanson highlighted how these agents offer steroid-sparing options that resonate with parents increasingly wary of topical corticosteroids due to misinformation circulating on social media.She also championed the value of compounded formulations for challenging pediatric cases. Two standouts included the Aron Regimen, a gentle yet highly effective combination of betamethasone valerate, mupirocin, and vanicream for severe facial AD in infants and toddlers, and a salicylic acid + 5-fluorouracil compound for recalcitrant warts, applied under occlusion for rapid clearance.Transitioning to communication pearls, Dr Swanson discussed the power of language in pediatric encounters. She reminded clinicians that words matter, urging them to avoid alarming or judgmental phrases (“shot,” “mutation,” “herpes”) and instead foster trust through reassurance (“I can help you,” “You came to the right place,” “I’m on your team”). She underscored that framing matters as much as pharmacology in building lasting therapeutic relationships. https://dermsquared.com/videos/fc-2025-conference-highlights/who-has-better-pearls 201 2025-10-31T20:04:29.274Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/alopecia-areata-and-beyond 2025-10-31T20:05:18.623Z https://image.mux.com/Gtb34CghCLQ6RFRsyPoqFOJcf7E02nu01xkh4Df017vKtE/thumbnail.jpg Answers to Hair Questions: Alopecia Areata and Beyond Natasha Atanaskova-Mesinkovska, MD, PhD, presented an engaging overview of both established and emerging treatments for hair loss. She began with a classic focus on minoxidil, highlighting dosing differences across men, women, and children. In addition to its well-known vasodilatory mechanism, Dr Mesinkovska emphasized that minoxidil also has anti-androgenic and anti-inflammatory properties, giving it therapeutic potential across several forms of hair loss. She addressed common concerns about blood pressure effects and rare complications such as pericardial effusion, presenting data and practical strategies to help clinicians manage these issues confidently.She then discussed JAK inhibitors, reviewing their efficacy, mechanisms, and safety in conditions such as alopecia areata, frontal fibrosing alopecia, lichen planopilaris, and central centrifugal cicatricial alopecia. Dr Mesinkovska recommended a treatment trial of six to nine months before assessing hair regrowth outcomes.Next, she addressed the connection between allergy and hair loss, encouraging clinicians to consider atopy in all patients with hair loss. She reviewed possibilities of allergic contact dermatitis and the role of patch testing in patients with unexplained alopecia. Her research suggests that environmental allergens, such as dust mites, may influence immune responses in alopecia areata and contribute to earlier onset and greater severity, particularly among patients of Chinese ancestry. Reflecting this allergic-immune link, she noted reports of hair regrowth with dupilumab in pediatric alopecia areata and with tralokinumab in adults who have both atopic dermatitis and alopecia areata.Finally, Dr Mesinkovska highlighted several innovative therapies, including PP405, a topical small molecule in development, and exosome-based approaches. Exosomes are extracellular vesicles that carry bioactive molecules and act as natural biological messengers. They show promise for regenerative, anti-inflammatory, and hair-restorative applications in future dermatologic care. https://dermsquared.com/videos/fc-2025-conference-highlights/alopecia-areata-and-beyond 70 2025-10-31T20:05:18.615Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/managing-inflammatory-skin-diseases 2025-10-31T20:05:29.790Z https://image.mux.com/02P7sKMQh9mGd3qoWTlp9JgL01luke2Eqz9D00ZUugJ6rw/thumbnail.jpg Pearls in Managing Inflammatory Skin Diseases Brett King, MD, PhD, and E. James Song, MD, delivered a comprehensive and practical session on inflammatory skin diseases, focusing on the evolving role of JAK inhibitors (JAKis) across multiple dermatologic conditions.Dr King began by outlining strategies for differentiating types of alopecia and optimizing therapy for alopecia areata (AA). He emphasized that patients may respond differently to various JAK inhibitors and that lack of efficacy with one agent does not preclude success with another. For AA, he recommended combining baricitinib with oral minoxidil and advised switching to a different JAKi if there is no regrowth after six to nine months at maximal dosing. He also reviewed data supporting the use of abrocitinib and tofacitinib for generalized granuloma annulare, drawing from open-label clinical trial results. In atopic dermatitis (AD), Dr King highlighted similar therapeutic nuances, noting that patients unresponsive to one JAKi may respond to another.Dr Song expanded on this discussion, focusing on managing partial responses to JAKis and strategies such as adding corticosteroids or dupilumab. He reinforced that nonresponse to one JAKi does not predict universal failure across the class. For AA, Dr Song discussed considering dupilumab as an alternative in patients with a strong atopic history or elevated IgE (≥200 IU/mL). Shifting to AD, he reviewed the latest insights on nemolizumab, approved for pruritus associated with AD, including emerging reports of dermatitis-type adverse events and recommendations for clinical use. He also discussed predictors of dupilumab responders and concluded with a look at tofacitinib’s potential role in unstable vitiligo, underscoring the expanding therapeutic landscape of JAK inhibitors across inflammatory dermatology. https://dermsquared.com/videos/fc-2025-conference-highlights/managing-inflammatory-skin-diseases 150 2025-10-31T20:05:29.782Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/fall-clinical-25th-anniversary 2025-09-05T01:40:05.858Z https://image.mux.com/IrT2KdyfGXMznTReBc02dl9en00Foi3Qa02xqQu01zLBz3U/thumbnail.jpg Fall Clinical 25th Anniversary To learn more and register, click below! Learn more! https://dermsquared.com/videos/fc-2025-conference-highlights/fall-clinical-25th-anniversary 71 2025-09-02T15:26:30.184Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/other-hyperpigmentation-disorders 2025-10-31T20:04:59.994Z https://image.mux.com/9lOKYu6C02D9UwxNcGdGGtEsJkqoMSH4kdg2dMLvp9JQ/thumbnail.jpg Melasma and Other Hyperpigmentation Disorders Andrew F. Alexis, MD, MPH, began by reviewing the multifactorial pathophysiology of melasma, which involves ultraviolet (UV) and visible light exposure, hormonal triggers, vascular changes, and inflammatory signaling. He highlighted recent evidence underscoring the central role of oxidative stress and the JAK–STAT pathway in melanogenesis. Topical therapies remain first-line, with hydroquinone continuing to serve as the gold standard despite limitations such as irritant dermatitis and risk of exogenous ochronosis. Dr Alexis discussed novel non-hydroquinone agents, including cysteamine, thiamidol (a potent human tyrosinase inhibitor), and multitarget cosmeceutical combinations like MB3 (2-MNG, niacinamide, cystoseira extract, and lipohydroxy acid), all of which have shown significant mMASI score reductions comparable to or exceeding hydroquinone-based regimens in clinical studies. Dr Alexis then focused on systemic and procedural advances. He reviewed data demonstrating that oral tranexamic acid (TXA), given at 250–325 mg twice daily for three months, can reduce mMASI scores by nearly 50%, with no thromboembolic events reported in large retrospective safety analyses. Adjunctive use of oral antioxidants such as Polypodium leucotomos and combination regimens integrating TXA with topical hydroquinone, retinoids, and kojic acid further improve pigment clearance. Procedural therapies, including glycolic acid peels, microneedling, and fractional 1927 nm thulium laser, enhance epidermal turnover and melanin removal, with best outcomes achieved when paired with maintenance topicals and strict photoprotection using mineral- and iron oxide–based sunscreens. Dr Alexis also highlighted that disorders like lichen planus pigmentosus and acquired dermal macular hyperpigmentation can mimic melasma and may respond to oral isotretinoin and low-energy fractional laser therapy. His concluding message stressed that successful pigment management hinges on personalized, multimodal regimens that address both melanocyte hyperactivity and skin barrier dysfunction. https://dermsquared.com/videos/fc-2025-conference-highlights/other-hyperpigmentation-disorders 114 2025-10-31T20:04:59.987Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/chronic-spontaneous-urticaria-care 2025-10-31T20:03:57.336Z https://image.mux.com/QgCnXPbeYY89oFtPQv6f9YkbWhjAnF9PFrj28QCwRJI/thumbnail.jpg CME Satellite Symposium: Tips and Tricks to Advancing Chronic Spontaneous Urticaria Care Marc Serota, MD, and Michelle Tarbox, MD, led an in-depth session on the evolving management of chronic spontaneous urticaria (CSU), emphasizing diagnostic precision, disease activity assessment, and the integration of novel biologic and small-molecule therapies into clinical practice.The duo began by outlining the classification of urticaria based on duration and cauases, differentiating between inducible and spontaneous forms, and underscoring that nearly 80% of chronic cases are spontaneous. They discussed current international guidelines recommending a stepwise approach: beginning with avoidance of triggers and second-generation H1 antihistamines, escalating doses up to fourfold if needed, and advancing to omalizumab or cyclosporine in refractory cases. The speakers emphasized disease monitoring using the Urticaria Activity Score (UAS7) and the Urticaria Control Test (UCT), where a UAS7 ≤6 or UCT ≥12 indicates well-controlled disease, reinforcing the shift toward objective, quantifiable disease assessment to step-up or step-down management. The session transitioned to therapeutic developments poised to transform CSU care. The team reviewed recent evidence supporting omalizumab, citing meta-analyses of 67 real-world studies confirming its strong efficacy and safety. Next, they presented emerging phase 3 data from the LIBERTY-CSU CUPID trials demonstrating significant reductions in itch severity and urticaria activity with dupilumab compared to placebo, achieving complete response rates in up to 30% of patients. They also highlighted the REMIX-1 and REMIX-2 studies evaluating the BTK inhibitor remibrutinib, which achieved meaningful UAS7 improvements by week 24 with comparable safety to placebo. The discussion concluded with an outlook on integrating these biologic and targeted therapies into personalized treatment algorithms, aiming to achieve faster disease control and improved quality of life for patients with CSU. https://dermsquared.com/videos/fc-2025-conference-highlights/chronic-spontaneous-urticaria-care 173 2025-10-31T20:03:57.327Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/landscape-of-topical-therapies 2025-10-31T20:03:40.413Z https://image.mux.com/Ng9J6Y3P9WQnbQbnrxHE00W1j01jB2kDS2WEracVy02FhE/thumbnail.jpg The Changing Landscape of Topical Therapies Linda Stein Gold, MD, MS, Cheri Frey, MD, FAAD, Peter Lio, MD, FAAD, and Bruce Strober, MD, PhD, led an expert discussion highlighting cutting-edge advances in topical dermatologic therapy that are transforming treatment safety, efficacy, and patient outcomes across acne, rosacea, atopic dermatitis, and psoriasis.Dr Stein Gold opened with an evidence-based review addressing concerns regarding benzoyl peroxide (BPO) and potential benzene contamination. She summarized recent multicenter studies from 2024–2025 confirming that BPO use does not increase the risk of benzene-related malignancies, emphasizing that product stability depends on formulation chemistry and appropriate storage, specifically refrigeration, avoiding heat, and renewing products every few months. Dr Stein Gold also discussed the FDA approval of low-dose extended-release minocycline (DFD-29, 40 mg) for rosacea, presenting phase 3 data demonstrating strong efficacy, a favorable safety profile, and minimal microbiome disruption, supporting its role as a next-generation oral option for long-term rosacea management.Dr Frey followed with an overview of advances in cosmeceutical science, focusing on novel retinoid analogues, peptides, and regenerative skincare. She explained how new retinoid derivatives such as retinyl retinoate and hydroxypinacolone retinoate enhance collagen and hyaluronic acid production while reducing irritation compared to traditional formulations. Dr Frey also described the therapeutic potential of bioactive peptides, palmitoyl tetrapeptide-7, oligopeptide-68, acetyl hexapeptide-3, and copper tripeptide-1 (GHK-Cu), in promoting skin repair, modulating pigmentation, and attenuating inflammation, though she noted that delivery optimization remains a clinical challenge. She concluded with an introduction to exosome-based regenerative skincare, which can promote wound healing and dermal rejuvenation through the Wnt/β-catenin and VEGF pathways, while underscoring the importance of regulatory oversight and controlled clinical validation.Dr Lio then presented an update on the evolving therapeutic landscape for atopic dermatitis (AD), structuring his discussion around the practical goals of “Get Clear, Keep Clear, Keep It Up.” He reviewed new guideline-supported treatment algorithms incorporating topical corticosteroids, calcineurin inhibitors, and an expanding array of nonsteroidal options such as ruxolitinib, roflumilast, delgocitinib, and tapinarof. Comparative data demonstrated superior patient-reported outcomes with tacrolimus 0.03% versus crisaborole, while ruxolitinib and tapinarof provided durable disease control and favorable safety. Dr Lio emphasized the need for long-term maintenance strategies and barrier repair to sustain remission and improve quality of life.Dr Strober concluded with a discussion of topical innovation in psoriasis and seborrheic dermatitis. He reviewed pivotal trial data showing that roflumilast 0.3% and tapinarof 1% achieve high rates of clearance, durable remission, and excellent tolerability, even in intertriginous and facial regions. Dr Strober highlighted the DERMIS and PSOARING programs, noting the remittive effects of tapinarof and the consistent tolerability of roflumilast across age groups. He positioned both agents as first- and second-line nonsteroidal options that deliver biologic-level efficacy through topical mechanisms. Collectively, the speakers illustrated how formulation science, molecular innovation, and patient-centered design are converging to usher in a new era of precision-driven topical therapy in dermatology. https://dermsquared.com/videos/fc-2025-conference-highlights/landscape-of-topical-therapies 320 2025-10-31T20:03:40.364Z yes https://dermsquared.com/videos/fc-2025-conference-highlights/15-tips-in-15-minutes 2025-10-31T20:04:43.940Z https://image.mux.com/sYvvLqcyKQVzGPUHnaPjbpAuOxr4VRbvthXv01lQ02emE/thumbnail.jpg 15 Tips in 15 Minutes Mark Lebwohl, MD, opened with updates on ritlecitinib, highlighting sustained scalp and brow regrowth in patients with alopecia areata over 24 to 48 weeks, and described a five-year follow-up case showing the need for ongoing intralesional triamcinolone for brow maintenance. Adelaide A. Hebert, MD, shared emerging evidence on topical ruxolitinib’s benefit in lichen planus and presented data on high-dose oral vitamin D rapidly attenuating inflammatory responses in sunburn and radiation dermatitis. David M. Pariser, MD, emphasized the practical role of medical scribes—whether in-person, virtual, or “on a stick”—in improving workflow, patient interaction, and the “Dermatologist Life Quality Index,” noting that the financial return often outweighs the cost. Neal D. Bhatia, MD, cautioned clinicians about the increasing ease with which patients file medical board complaints, urging vigilance in documentation, communication, and early legal consultation to mitigate risk.Later segments covered innovations in disease management and procedural dermatology. Dr Bhatia spotlighted SGX301 (topical hypericin photodynamic therapy) as an effective, non-mutagenic treatment for early-stage mycosis fungoides, achieving lesion responses up to 49% by week 24 with minimal local adverse effects. Dr Pariser discussed glycopyrronium cloth and sofpironium bromide gel as promising topical options for hyperhidrosis, while Dr Hebert highlighted updates in birth control pill use under the isotretinoin REMS program. Dr Lebwohl added that zoster and influenza vaccination may reduce dementia risk, underscoring the broader systemic value of preventive care. The panel concluded by encouraging clinicians to stay alert to emerging intralesional options—such as methotrexate, 5-FU, and cemiplimab—for keratinocyte carcinomas, reminding attendees that innovation continues across every corner of dermatology practice. https://dermsquared.com/videos/fc-2025-conference-highlights/15-tips-in-15-minutes 212 2025-10-31T20:04:43.933Z yes https://dermsquared.com/videos/panp-360/how-to-administer-the-pest-exam 2026-01-23T21:21:13.054Z https://image.mux.com/2JneUd8XXAYlRydJCjZDofnVL8vDdHIIn2NICv3oRos/thumbnail.jpg How to Administer the PEST Exam Download the Psoriasis Epidemiology Screening Tool (PEST) to use in your practice:A Practical Screening Tool for Psoriatic Arthritis Psoriatic arthritis is common, disabling, and still widely underdiagnosed. For patients with psoriasis, missing it can mean irreversible joint damage and loss of function. For PAs and NPs, it represents both a challenge and a unique opportunity. In this video, Henry Yu, PA-C walks through how he uses the Psoriasis Epidemiology Screening Tool (PEST) as part of routine psoriasis care. Not as a rheumatology workup, but as a focused, efficient screening approach that fits seamlessly into busy days in the clinic. Simple by design, the PEST exam is a brief five-question questionnaire paired with a targeted physical exam. But when used intentionally, and documented clearly, it becomes a powerful bridge from observation to strategic action. (Henry Yu likes to use the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) app to administer the PEST exam) Why the PEST Exam Matters As Yu explains, managing psoriasis without understanding a patient’s PsA status is incomplete care. Psoriatic arthritis can be present regardless of skin severity, and many patients see their dermatology provider more consistently than any other clinician. Used correctly, the PEST exam helps clinicians: Identify patients at higher risk for PsA earlierDistinguish inflammatory joint symptoms from common misdiagnoses like plantar fasciitisPrompt timely referral or treatment escalationInitiate therapies that protect both skin and joints before permanent damage occurs What the Exam Includes Five yes/no questions that address joint swelling, arthritis history, nail changes, heel pain, and dactylitis. A score of three or more signals the need to move forward with further evaluation.A focused, systematic physical assessment of:MCP, PIP, and DIP jointsFingernails (pitting, onycholysis)Toes and signs of dactylitisAchilles insertion points and plantar fascia He emphasizes specific documentation not just for accuracy, but because clear documentation forces a treatment decision and supports a shift toward dual-action systemic therapy when indicated. The full PEST exam takes less than five minutes. But, as Yu notes, it can change the entire trajectory of a patient’s life, allowing dermatology clinicians to intercept psoriatic arthritis years earlier than might otherwise occur. Editorial note: A substantial proportion of patients with psoriasis have undiagnosed psoriatic arthritis; meta-analysis suggests approximately 15% of psoriasis patients may have unrecognized PsA, with reported prevalence across studies ranging widely and, in some cohorts, approaching 30% or higher, depending on diagnostic criteria and screening methods.¹,² Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242-248.Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-265.e19. https://dermsquared.com/videos/panp-360/how-to-administer-the-pest-exam 306 2026-01-21T17:17:41.485Z yes https://dermsquared.com/videos/panp-360/nail-conditions-101-part-1 2026-03-02T19:37:05.415Z https://image.mux.com/VBdNo7b8U5PGp5e53XjbVglKfIaJLKeX9iu1jX02OVTs/thumbnail.jpg PANP360 Nail Conditions 101 - Part 1 PANP360 Nail Conditions 101 - Part 1 https://dermsquared.com/videos/panp-360/nail-conditions-101-part-1 503 2026-03-02T19:37:05.408Z yes https://dermsquared.com/videos/panp-360/hair-loss-exams-look-before-diagnose 2026-06-09T20:45:43.134Z https://image.mux.com/yuff5Rk2wFihxaLt4vCFq01gYs6HFHiz300NQ901LvEdiw/thumbnail.jpg Hair Loss Exams: What to Look For Before You Diagnose Hair loss can’t be evaluated well from the scalp alone. In this hair and scalp exam video, Garland James, PA-C, walks through a practical approach to evaluating hair loss in clinic, from taking a focused history and asking about styling practices to looking for signs of inflammatory and noninflammatory alopecia. She also emphasizes the parts of the exam that can easily be missed: asking permission before touching the hair, photographing the scalp for comparison, recognizing when biopsy may be needed, and building a treatment plan with the patient instead of around them. Use the accompanying Hair and Scalp Exam: A Practical Clinical Guide for PAs and NPs as a quick reference for assessing hair practices, tension patterns, density and distribution, dermoscopic clues, and care considerations in textured hair. Question: In the video, James emphasizes that the clinical history can help guide the hair loss exam. Which of the following is most relevant to ask before examining the scalp? Whether the patient prefers prescription or over-the-counter treatment Current and recent hair care practices, including protective styles and duration of wear Whether the patient has used cosmetic hair coloring in the past 10 years Whether the patient is willing to stop all styling during treatment Rationale: Rationale: Hair practices can help explain the pattern of hair loss and should be discussed before the exam. The accompanying guide also notes that hair practices often explain the pattern and recommends asking about recent styling changes, current routine, symptoms, and prior treatments. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } Question: During the exam, which finding would most strongly support considering biopsy for possible inflammatory or scarring alopecia? Diffuse shedding without scalp symptoms Mixed hair shaft diameters consistent with miniaturization Perifollicular erythema or scaling with concern for scarring disease Mild dandruff without tenderness or visible inflammation Rationale: In the video, James notes that if the exam raises concern for an inflammatory component that could lead to scarring, biopsy should be strongly considered. She also cautions that biopsy location matters; avoid areas that are already fully scarred and sample near active inflammation when possible. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } https://dermsquared.com/videos/panp-360/hair-loss-exams-look-before-diagnose 714 2026-06-09T20:36:46.098Z yes https://dermsquared.com/videos/panp-360/reading-the-nails-clues-you-cant-skip 2025-12-18T16:12:05.518Z https://image.mux.com/dTwHI4uVhag8BBORdvSqBoNgqvIg7SNKw00Zjwkr4dhs/thumbnail.jpg Reading the Nails: Clues You Can’t Skip Nail disease isn’t cosmetic; it’s a clinical signal. NP Nasslynne Lenz discusses how standardized nail scoring can improve consistency in documentation and communication, and how certain nail findings may serve as early clues of psoriatic arthritis. She also highlights how nail assessment can support when to consider PEST screening or rheumatology collaboration. Watch for a briefing on what to look for during nail checks, and why nail evaluation belongs in every psoriasis visit. Question: When evaluating nail involvement in a patient with psoriasis, which of the following best explains why using a standardized nail scoring tool (such as N-NAIL) can meaningfully influence clinical decision-making? It allows clinicians to automatically determine whether the patient meets diagnostic criteria for psoriatic arthritis. It ensures insurance approval for systemic therapies in patients with mild psoriasis. It replaces the need for clinical examination by providing a numeric score that can be tracked over time. It creates a consistent and validated way to capture the extent of nail disease, which may help identify patients at higher risk for psoriatic arthritis and guide when to escalate evaluation or collaborate with rheumatology. Rationale: Nasslynne notes that standardized nail tools bring consistency and clarity to how nail disease is documented, improving communication across clinicians and helping surface clues that may indicate underlying or emerging psoriatic arthritis, even before joint symptoms are obvious. The scoring does not diagnose PsA on its own, but it does support earlier recognition and informed referral or co-management. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } https://dermsquared.com/videos/panp-360/reading-the-nails-clues-you-cant-skip 240 2025-12-10T20:47:40.027Z yes https://dermsquared.com/videos/panp-360/decoding-the-alphabet-soup-when-psoriasis-meets-psoriatic-arthritis 2025-12-10T20:49:07.272Z https://image.mux.com/TP62yVvzV1118h7EpVD2ya3gxjS81vouxPjcv6zxXio/thumbnail.jpg Decoding the Alphabet Soup: When Psoriasis Meets Psoriatic Arthritis If you’ve ever felt buried in acronyms (PASI, DLQI, ACR… and now PEST?), you’re not alone. In this teaser, Henry Yu, PA-C, reflects on the quiet clues we sometimes overlook and why speaking a shared language across specialties matters. This is the start of a full-circle look at psoriasis, psoriatic arthritis, and the tools that help us catch what’s easy to miss https://dermsquared.com/videos/panp-360/decoding-the-alphabet-soup-when-psoriasis-meets-psoriatic-arthritis 106 2025-12-10T20:49:07.265Z yes https://dermsquared.com/videos/panp-360/nail-conditions-101-part-2 2026-03-02T19:37:10.233Z https://image.mux.com/XU4GN8buoOrMHBXXaiyda3D12R4rmXqos201dTZTEmtY/thumbnail.jpg PANP360 Nail Conditions 101 - Part 2 PANP360 Nail Conditions 101 - Part 2 https://dermsquared.com/videos/panp-360/nail-conditions-101-part-2 670 2026-03-02T19:37:10.228Z yes https://dermsquared.com/videos/panp-360/nail-conditions-101-part-4 2026-03-02T19:37:33.878Z https://image.mux.com/RpHLfs6ohSv00eMvGxN1qlUAW02Z8mvjTyj7hX5BlrwLQ/thumbnail.jpg PANP360 Nail Conditions 101 - Part 4 PANP360 Nail Conditions 101 - Part 4 https://dermsquared.com/videos/panp-360/nail-conditions-101-part-4 555 2026-03-02T19:37:33.869Z yes https://dermsquared.com/videos/panp-360/nail-conditions-101-part-5 2026-03-02T19:37:41.819Z https://image.mux.com/MsPzjbjhMbNQc01vC00DqehzTqJwWGa9JJOl2h88Aas2U/thumbnail.jpg PANP360 Nail Conditions 101 - Part 5 PANP360 Nail Conditions 101 - Part 5 https://dermsquared.com/videos/panp-360/nail-conditions-101-part-5 533 2026-03-02T19:37:41.813Z yes https://dermsquared.com/videos/panp-360/nail-conditions-101-part-3 2026-03-02T19:37:17.229Z https://image.mux.com/jdUTvjepMx6gquCDHxhtl7O02T02M01AoQfiQ7SV5f5pzA/thumbnail.jpg PANP360 Nail Conditions 101 - Part 3 PANP360 Nail Conditions 101 - Part 3 https://dermsquared.com/videos/panp-360/nail-conditions-101-part-3 696 2026-03-02T19:37:17.097Z yes https://dermsquared.com/videos/panp-360/how-scoring-tools-help-shape-patient-care 2025-12-11T14:56:39.595Z https://image.mux.com/uPVmJqc302zLIIFmI8S9YpmTHD00azpDA2cw00NdEv5vI4/thumbnail.jpg How Scoring Tools Help Shape Patient Care What do PASI, EASI, SALT, and ACR actually do for us in everyday practice? Here, Jill Cowan, NP, breaks down the role of validated scoring tools—not as numbers to memorize but as frameworks that help us communicate treatment expectations, evaluate response, and bring clinical trial results into meaningful patient discussions. This teaser leads into our upcoming full breakdown on applying scoring tools at the point of care. Question: Which of the following best describes the purpose of using validated clinical trial scales such as SALT, PASI, EASI, or ACR in dermatology practice? They are primarily designed to simplify documentation for insurance paperwork. They standardize how disease severity and treatment response are measured, enabling consistent, objective interpretation of clinical and research findings. They eliminate the need for clinical assessment by replacing it with numerical scoring. They are only useful in clinical trials and should not inform patient counseling in practice. Rationale: Jill explains that validated scoring tools provide standardized, reliable, and responsive measures of disease severity and treatment response, enabling reproducible evaluation and helping clinicians translate trial results into clear, meaningful expectations for patients. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } https://dermsquared.com/videos/panp-360/how-scoring-tools-help-shape-patient-care 223 2025-12-10T20:46:09.856Z yes https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-epidermolysis-bullosa 2024-02-29T16:26:13.463Z https://image.mux.com/IPEmPZ6qQBbZSPyd5yUb9vkK01ImsZ4PhW2tGu4Jq01Ok/thumbnail.jpg Rare Diseases in Dermatology: Epidermolysis Bullosa For Rare Disease Day on February 29, Topical Conversations will be exploring some of the rare diseases seen in dermatology. In this installment, Charlie Dunn, MD, speaks with Brett Kopelan, Executive Director of debra of America, a nonprofit organization dedicated to improving the lives of those impacted by epidermolysis bullosa (EB) and supporting the clinicians who treat this condition. Watch Part 1 to hear Dr Todd Schlesinger discuss SCLE and dermatomyositis.Watch Part 2 to hear Dr Naiem Issa discuss tuberous sclerosis complex and a helpful treatment tip.Watch Part 3 to hear Dr James Del Rosso discuss new and emerging therapies for congenital ichthyoses, EB, and facial angiofibromas.About debra of America Founded in 1980, debra of America emerged from the dire need for institutional and public knowledge about EB. debra, which now comprises over 52 autonomous branches worldwide, works to improve the quality of life for all patients, families, caregivers, and clinicians who manage EB through programs and services, educational resources, and research funding. Resources for patients and clinicians debra of America's mission is to enhance the lives of those living with EB through patient services, industry partnerships, and support for clinicians and researchers engaged in innovative research. Recognizing the challenges faced by medical professionals unfamiliar with treating rare diseases, debra offers programs such as the EN Nurse Educator Program. The EB Nurse Educator serves as a trusted source of accurate information for those living with EB, their families, and the medical community. debra estimates that 20% of the calls the EB Nurse Educator receives come from medical professionals seeking guidance on how to care for patients with EB and resources to support them. The debra website also boasts a robust How To section, which provides resources to guide patients and caregivers in making informed decisions surrounding proper EB care. These guides cover topics such as caring for wounds and blisters, caring for newborns, preparing baths, recognizing infection, choosing products, and more. Physician resources and multidisciplinary approaches In addition to patient-focused resources, debra also collaborates with health care professionals to cowrite clinical best practice guidelines that address anesthesia, pain management, GI issues, social and emotional well-being, and more. The complex nature of EB often necessitates a multidisciplinary approach to care, involving dermatology, gastroenterology, physical therapy, occupational therapy, pain management, psychology, and cardiology, and debra curates services for all aspects of care. Emerging therapeutics Exciting developments in EB therapeutics include the recent approval of the first redosable gene therapy and a topical wound healing agent. Anticipated approval for a second gene therapy, an ex-vivo approach, in May 2024 adds to the optimism. debra of America plays a crucial role in bringing the patient voice into drug development for EB, potentially easing the regulatory pathway and reducing the time it takes for new therapies to get to market. An appeal to the dermatology community EB is traditionally thought of as a pediatric condition within the dermatology community. As emerging therapies extend the lifespan of patients with EB, debra urges dermatology professionals to pay increased attention to adult care and treatment. With only one adult multidisciplinary center in the country, there is a need for the dermatology community to embrace the challenges associated with transitioning from pediatric to adult EB care. Interested in getting involved with debra? Check out opportunities here. Download How To guides for patients and clinicians here.Read about the EB Nurse Educator Program here. Download the Skin and Wound Care in Epidermolysis Bullosa Best Practice Guidelines here. https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-epidermolysis-bullosa 753 2024-02-29T16:17:21.999Z yes https://dermsquared.com/videos/topical-conversations/on-the-horizon 2026-05-19T18:01:59.642Z https://image.mux.com/vMbc6V3p2yGcD8WL02AcKT5nIbNcVhQsXYv01Z02kf1h00U/thumbnail.jpg Cutaneous Lupus: Identification, Systemic Screening, and What’s on the Horizon In this episode of Topical Conversations, Joseph Merola, MD, and Scott Elman, MD, examine the evolving understanding of cutaneous lupus erythematosus (CLE) and its place within the broader spectrum of connective tissue disease. Their discussion highlights the dermatologist’s central role, not only in recognizing and treating skin manifestations, but also in screening for systemic involvement and coordinating care when needed. A disease state in transitionAdvances in understanding the pathophysiology of cutaneous lupus are beginning to translate into therapeutic momentum. What was once a space with limited targeted options is now seeing the emergence of multiple investigational therapies, reflecting a shift toward more mechanism-driven treatment approaches. Clinical identification: recognizing key subtypesCutaneous lupus is often categorized into several major subtypes, each with distinct clinical features:Acute cutaneous lupus: Classically presents with a malar rash that spares the nasolabial folds Subacute cutaneous lupus: Typically papulosquamous or annular, often in sun-exposed areas such as the shoulders and arms; may be drug-induced Chronic cutaneous lupus: The largest category, with discoid lupus as the most familiar subtype; characterized by scarring plaques that can lead to permanent hair loss and disfigurement Recognizing these patterns remains foundational to diagnosis and helps guide both evaluation and management. Screening for systemic disease: a core responsibilityA key theme emphasized in this discussion is the importance of routinely assessing for systemic lupus erythematosus (SLE) in patients with cutaneous disease.Practical screening approaches may include:Laboratory evaluation: ANA testing as an initial screen, along with CBC, CMP, and urinalysis Clinical review of systems: Assessing for joint pain, mucosal involvement, and other systemic symptoms Ongoing surveillance: Repeating assessments every 3 to 6 months, rather than relying on a single evaluation Importantly, a negative initial workup does not exclude future systemic involvement. Dermatologists play a critical role in maintaining longitudinal awareness and determining when to involve rheumatology colleagues. Patient burden: beyond skin findingsThe impact of cutaneous lupus extends well beyond visible disease. Quality-of-life studies suggest that the burden experienced by patients may be comparable to chronic conditions such as hypertension, type 2 diabetes, congestive heart failure, and recent myocardial infarction.This burden reflects both active symptoms and long-term consequences, including scarring and disfigurement Early recognition and appropriate treatment are essential to mitigate these outcomes. Emerging therapies: expanding possibilitiesAfter decades of limited progress, the treatment landscape for lupus is beginning to broaden, with several agents under investigation for cutaneous and systemic disease:Anifrolumab: Approved for SLE, with ongoing phase 3 evaluation in CLELitifilimab: Targets plasmacytoid dendritic cells, with downstream effects on type I interferon and other cytokines Deucravacitinib: Approved for psoriasis, currently under investigation in lupus with early signals in CLE Enpatoran: Early data suggest potential activity in CLE These developments reflect a growing focus on targeted immunologic pathways relevant to both skin and systemic manifestations. Comanagement: aligning dermatology and rheumatologyFor patients with overlapping cutaneous and systemic disease, coordination of care is essential. Thoughtful selection of therapies may allow for alignment across organ systems, with the goal of controlling disease activity while minimizing progression and long-term damage.Dermatologists play a key role in initiating and optimizing treatment for skin disease, monitoring for systemic involvement, and collaborating with rheumatology when indicated As familiarity with these therapies grows, opportunities to refine treatment strategies across specialties are likely to expand. Key takeawaysCutaneous lupus encompasses multiple clinical subtypes, each with distinct presentation and implications for management Dermatologists are central to both diagnosis and ongoing screening for systemic lupus involvement Systemic evaluation should include labs, review of systems, and periodic reassessment over time The burden of disease extends beyond visible lesions, with significant quality-of-life impact and risk of permanent damage A growing pipeline of targeted therapies is beginning to reshape treatment considerations in both CLE and SLE Comanagement with rheumatology is critical for patients with systemic involvement https://dermsquared.com/videos/topical-conversations/on-the-horizon 529 2026-05-19T18:01:59.629Z yes https://dermsquared.com/videos/topical-conversations/safety-alert-essential-guidance-for-dermatologists-on-counterfeit-botox 2024-04-22T14:59:59.423Z https://image.mux.com/DipwSJ1ZkAuACm522tri01xCZ1aEHEmvI7UP6d7B3jcY/thumbnail.jpg Safety Alert: Essential Guidance for Dermatologists on Counterfeit Botox In this installment of Topical Conversations, Cheri Frey, MD, an assistant professor of dermatology at Howard University, comments on the concerning issue of counterfeit Botox recently highlighted by an FDA notice. A critical safety notice The FDA has issued a safety notice to health care practitioners and the public regarding the presence of a counterfeit version of Botox found in the United States, which may have been sold to doctors’ offices and medical clinics nationwide. This counterfeit product, distributed by an unlicensed supplier unauthorized to distribute drug products in the US, poses a significant risk to public health. Recognizing the symptoms Dr Frey details some of the severe health complications seen in patients who received counterfeit Botox products, including difficulty swallowing, difficulty breathing, and blurry vision; in some cases, patients required hospitalization and treatment with an antitoxin. Importance of counseling patients She emphasizes the critical need for dermatologists to disseminate this information not only among their peers but also to patients and their networks. She stresses the importance of counseling individuals seeking botulinum injections to visit licensed providers, whose qualifications vary by state. Ensuring patient safety Dr Frey underscores the significance of dermatologists being vigilant about recognizing the signs and symptoms of counterfeit botulinum toxin complications. Additionally, she stresses the importance of counseling patients who may be affected to seek immediate emergency care at the first indication of trouble. https://dermsquared.com/videos/topical-conversations/safety-alert-essential-guidance-for-dermatologists-on-counterfeit-botox 73 2024-04-22T14:59:59.417Z yes https://dermsquared.com/videos/topical-conversations/moderate-ad-considerations-approaches 2024-09-13T15:43:35.081Z https://image.mux.com/HtHKqv2EcgV65YiRY7yfXsGvW4U4COPieEDtvpa3lGw/thumbnail.jpg Moderate Atopic Dermatitis: Treatment Considerations and Approaches In this episode of Topical Conversations, Kristine Kucera, PA-C, and Aaron Farberg, MD, discuss the challenges of managing moderate atopic dermatitis (AD). This segment offers insights into how clinicians define moderate AD, set treatment goals, and decide when to move beyond topical therapies to systemic treatments. Defining moderate atopic dermatitis Dr Farberg highlights that defining the moderate AD patient can vary depending on the context. In clinical trials or insurance approvals, moderate to severe AD is often based on scoring systems like the EASI score. However, in practice, the definition relies on a more personal approach—talking to the patient and assessing the impact of the disease on their daily life. For clinicians, body surface area (BSA) is often used to classify AD severity, but Dr Farberg emphasizes that the location of eczema can sometimes be more telling than the extent of coverage. For example, AD affecting sensitive areas like the scalp or groin may have a significant impact on quality of life even if it doesn’t affect a large area of skin. He suggests that the key is understanding how AD affects the patient, which helps determine whether a patient should remain on topical treatments or transition to more systemic options. Treatment goals for moderate atopic dermatitis According to Kristine Kucera, setting clear treatment goals is critical, starting with patient education. Patients need to understand their condition and the rationale behind the treatment approach. Kucera advocates for shared decision-making to establish patient-specific treatment goals, ensuring both the clinician and patient are aligned on expectations. Patients may not always realize what is achievable with appropriate treatment. Kucera emphasizes that even if patients feel they are "doing okay," clinicians should probe deeper to assess if lingering flares or other symptoms remain. Better control of symptoms can significantly improve a patient’s quality of life, and patients often don’t realize how much improvement is possible. Dr Farberg highlights the importance of aiming for near-complete clearance. Studies in related conditions like psoriasis have shown that getting a patient from 75% to 90% or more clearance can lead to meaningful improvements in quality of life. This goal should be communicated clearly to patients, ensuring they understand that optimal control can be within reach. Skin care and basic advice for moderate AD patients Both Dr Farberg and Kucera stress the importance of providing patients with advice on basic skin care routines. Clinicians should not overlook recommending gentle skin care practices, including using gentle cleansers, moisturizing frequently, trimming nails to prevent scratching, and using a humidifier. These foundational steps can complement medical treatments, helping patients maintain better control over their symptoms. Transitioning to systemic treatments: when and why The decision to move from topical treatments to systemic therapies is pivotal in managing moderate AD. According to Dr Farberg, the conversation about systemic treatments should happen early, even during the first visit. Discussing options like JAK inhibitors and cytokine inhibitors, such as dupilumab (Dupixent), helps patients understand their choices upfront, reducing the likelihood of patients questioning why certain treatments weren’t offered sooner. For moderate AD, Dr Farberg emphasizes the importance of treating the disease as systemic from the outset. While topical therapies are useful, many patients require a systemic approach to achieve meaningful control. Dupilumab: a go-to treatment option When it comes to systemic therapies, dupilumab has emerged as a strong option in the treatment of moderate atopic dermatitis. Dr Farberg explains that dupilumab is well-tolerated, with a safety profile supported by years of use across various conditions. Patients are increasingly open to the idea of injections, particularly with the rising familiarity of injectables like GLP-1 inhibitors for other health conditions. Dupilumab’s every-two-week injection schedule, with the possibility of extending to once a month in certain cases, appeals to many patients who prefer fewer interventions compared to daily oral medications. Personalized care for moderate AD patients Both Kucera and Dr Farberg highlight the importance of personalized treatment approaches for moderate AD. Every patient is different, and clinicians need to be flexible in tailoring treatments to individual needs. With an array of available options, from topicals to systemics like dupilumab and JAK inhibitors, the goal is to find the right combination that maximizes each patient’s comfort and quality of life. By engaging in open discussions with patients, setting realistic treatment goals, and considering early transitions to systemic therapies, clinicians can help patients achieve better disease control and improve their daily lives. https://dermsquared.com/videos/topical-conversations/moderate-ad-considerations-approaches 756 2024-09-13T15:43:35.073Z yes https://dermsquared.com/videos/topical-conversations/systemic-therapies-moderate-ad 2024-10-09T16:14:07.627Z https://image.mux.com/peGgQh2d02zXOpucb2sPmtdg8QOd02MQmARl2TtAlZ00iw/thumbnail.jpg Approaching Systemic Therapies for Moderate Atopic Dermatitis In this episode of Topical Conversations, Heather Gates, PA-C, and Marc Serota, MD, explore the challenges and treatment strategies for patients with moderate atopic dermatitis (AD). They emphasize the importance of assessing patients accurately and highlight the evolving role of systemic therapies. Understanding moderate atopic dermatitis: assessing the patient Patients with moderate AD often present with fluctuating symptoms. They may appear well on the day of their visit but experience significant discomfort during flare-ups. According to Dr Serota, dermatologists must go beyond the snapshot of what they see in the office and dig deeper into the patient’s daily experience with the disease. Important factors to assess include: Body surface area (BSA): Evaluate the extent of the skin involvement over time, not just at the visit. Itch intensity: Gauge how severe the itch typically is, on a scale from 1 to 10. Impact on daily life: Ask about the emotional and social effects, especially in pediatric patients who may experience itch during activities like sports or in school settings. These considerations often reveal that even if a patient seems to have mild symptoms in the office, their overall burden of disease is much more significant. Transitioning from topicals to systemic therapies Deciding when to transition from topical treatments to systemic options is crucial in AD management. As Heather Gates and Dr Serota explain, the availability of newer, safer systemic therapies has shifted the conversation. Both Gates and Serota agree that every patient with AD should have a topical treatment available, particularly nonsteroidal options. This remains a staple of treatment regardless of whether the patient is on systemic therapy. Historically, systemic treatments like methotrexate were avoided early in treatment plans, especially in pediatric cases. However, with the introduction of safer alternatives such as dupilumab, Dr Serota now initiates the conversation about systemic options early, even during the first visit for patients with moderate AD, noting that these patients deserve to be informed of all treatment options, and the decision on whether to start systemic therapy can be made collaboratively. Choosing a systemic therapy Selecting the right systemic therapy for moderate to severe AD depends on several factors, including the patient’s age, comorbid conditions, and the severity of their symptoms. Newer systemic therapies have provided safer alternatives to traditional treatments like methotrexate and cyclosporine, which were often associated with significant side effects. Dr Serota highlights the utility of dupilumab for patients with comorbid conditions, noting that with its indications for associated atopic conditions, it can address skin symptoms as well as target related conditions such as asthma, making it a holistic treatment option for patients with multiple atopic diseases. Communicating systemic treatment options to patients and parents When discussing the possibility of systemic treatments, setting realistic expectations is critical. Gates and Serota emphasize the importance of framing the conversation in a way that is clear, reassuring, and rooted in long-term management. Gates advises underselling the benefits and overdelivering. She stresses to parents that AD is a chronic disease, and the child will likely need long-term therapy. This helps prevent disappointment and encourages adherence. Dr Serota uses simple analogies to help explain systemic treatments. For example, he compares dupilumab to a radio signal blocker that specifically targets allergic cells, avoiding broad immunosuppression. He also compares the injection schedule to that of diabetes treatments, explaining that the infrequent administration (every two weeks or once a month) is manageable compared to daily insulin injections. Systemic therapy for moderate AD: a shift in treatment paradigms With advances in systemic therapies, the approach to treating moderate atopic dermatitis has shifted dramatically. Dermatologists are now empowered to initiate conversations about systemic treatments earlier in the disease course, offering patients the chance to live with less itch, better sleep, and improved quality of life. Even if patients choose not to proceed with systemic therapy, ensuring that they are aware of the benefits, risks, and availability of these treatments is essential for shared decision-making and better long-term outcomes. https://dermsquared.com/videos/topical-conversations/systemic-therapies-moderate-ad 868 2024-10-09T16:14:07.574Z yes https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-expert-strategies-skin-health-middle-aged-adults 2024-11-26T18:16:30.374Z https://image.mux.com/XS6rorf01Pgg00GQ00NhlaocckLNcue2gKwWDO3CY017zdQ/thumbnail.jpg National Healthy Skin Month: Expert Strategies for Optimizing Skin Health in Middle-Aged Adults For National Healthy Skin Month, we’re spotlighting skin health practices across all stages of life. In this segment, board-certified dermatologist Dr Gabriela Maloney shares evidence-based strategies for managing skin health in adults and middle-aged patients. Highlighting preventative, therapeutic, and cosmetic interventions, Dr Maloney provides practical pearls for dermatologists to enhance outcomes and improve quality of life for their patients. Sun protection: the cornerstone of skin health Dr Maloney emphasizes that broad-spectrum sunscreen with an SPF of 30 or higher is essential for preventing photoaging and reducing the risk of nonmelanoma skin cancers. Evidence has demonstrated significant benefits, including a 40% reduction in the incidence of invasive squamous cell carcinoma and a 24% decrease in actinic keratoses over 4 years with daily SPF 30 use compared to SPFs of lower formulations. Educating patients on proper application techniques and the importance of reapplying every 2 hours, especially during outdoor activities, is critical. The "magic trifecta" for anti-aging Counseling this patient group on anti-aging, Dr Maloney recommends a simple yet effective regimen: sunscreen, vitamin C, and retinoids. She advises patients that vitamin C, known for its ability to neutralize free radicals, brighten skin, and boost collagen synthesis, is particularly effective when paired with sunscreen. Retinoids, including prescription tretinoin and over-the-counter retinols, promote epidermal turnover and dermal remodeling, reducing fine lines, hyperpigmentation, and acne. Counseling patients to start with low concentrations and gradually increase use minimizes irritation and ensures a positive experience. Expanding the toolbox with additional ingredients For patients seeking advanced options, Dr Maloney advises patients that they may benefit from ingredients like azelaic acid and glycolic acid. Azelaic acid offers anti-inflammatory, antimicrobial, and depigmenting properties, making it ideal for rosacea, melasma, and acne. Glycolic acid facilitates exfoliation, improves collagen production, and enhances skin tone and texture, providing versatile benefits. Chemoprevention and skin cancer surveillance In high-risk populations, Dr Maloney recommends proactive interventions such as nicotinamide supplementation, with evidence suggesting that 500 mg twice daily may help significantly reduce the incidence of new actinic keratoses and cutaneous squamous cell carcinoma. Regular full-body skin examinations and patient education on self-surveillance are essential for early detection of skin cancers, improving outcomes and survival rates. Integrating preventative, therapeutic, and aesthetic care Dr Maloney highlights the importance of combining evidence-based recommendations with personalized care to optimize patient outcomes. By integrating preventative measures, therapeutic treatments, and cosmetic enhancements, dermatologists can elevate patient satisfaction and quality of life. Key takeaways for dermatologists Prioritize sun protection: Educate patients on proper application and the importance of reapplication Simplify anti-aging regimens: Recommend the "magic trifecta" of sunscreen, vitamin C, and retinoids for effective and evidence-based anti-aging benefits Proactive interventions: Utilize nicotinamide supplementation for high-risk populations and ensure regular skin cancer screenings paired with patient education on self-surveillance Integrate care approaches: Combine preventative, therapeutic, and aesthetic strategies to provide personalized, evidence-based care that enhances patient outcomes and quality of life Check out Part 1 here for expert insights on caring for the skin of dermatology's youngest patients, Part 2 for tips on managing adolescent and young adult patients, and Part 4 for guidance on caring for the older adult patient population—all for National Healthy Skin Month! https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-expert-strategies-skin-health-middle-aged-adults 235 2024-11-22T18:48:32.941Z yes https://dermsquared.com/videos/topical-conversations/safety-first-addressing-sharps-injuries-mohs-surgery 2024-05-20T19:58:43.280Z https://image.mux.com/oMtK771h01fbOfVQqqTYBl3k00KPPzulv1HWgU9vR602Nw/thumbnail.jpg Safety First: Addressing Sharps Injuries in Mohs Surgery In this quick-hitting installment of Topical Conversations, Aaron Farberg, MD, gives a concise and effective tip for preventing sharps injuries among Mohs surgeons and staff.Prevalence and underreporting A recent survey of Mohs surgeons with membership in the American College of Mohs Surgery found that 56.7% have reported at least one sharps injury in the past year, mostly self-inflicted, of which 14.7% resulted in bloodborne pathogen exposure. Compounding this issue is the tendency to underreport, with 44.1% of the injured surgeons stating that they did not report their injuries.1 Another study that surveyed Micrographic Surgery and Dermatologic Oncology fellows about sharps injuries concluded that the most common reason for not reporting was a perceived low risk of infection.2 However, the risk of viral transmission following a sharps injury, while generally low, varies based on factors such as transmission mode and patient source risk factors.3 A succinct strategy for reducing injuries As a practicing Mohs surgeon, Dr Farberg recognizes the critical role of practice in preventing such incidents, advocating for a culture of perfect practice within his clinic. He emphasizes the importance of ensuring that every member of the surgical team is well-versed in their respective roles and responsibilities to minimize the likelihood of errors. Developing and disseminating a standardized sharps handling protocol can also help mitigate the risk of injury among dermatologic surgeons and their staff.1 The prevalence of sharps injuries among Mohs surgeons, coupled with the tendency to underreport these injuries, underscores the need for proactive measures to enhance workplace safety. By implementing proper training and standardized protocols, clinics can mitigate the risk of sharps injuries and safeguard the well-being of both surgeons and their staff. References Talebi-Liasi F, Lewin JM. A cross-sectional analysis of sharps injuries among dermatologic surgeons: a survey of American College of Mohs Surgery members. Dermatol Surg. 2023;49(11):985-988. doi:10.1097/DSS.0000000000003907 Santillan MR, Salian P, Weiss J. Sharps injuries during micrographic surgery and dermatologic oncology fellowship training. Dermatol Online J. 2022;28(6):17. Brewer JD, Elston DM, Vidimos AT, Rizza SA, Miller SJ. Managing sharps injuries and other occupational exposures to HIV, HBV, and HCV in the dermatology office. J Am Acad Dermatol. 2017;77(5):946-951.e6. doi:10.1016/j.jaad.2017.06.040 https://dermsquared.com/videos/topical-conversations/safety-first-addressing-sharps-injuries-mohs-surgery 19 2024-05-20T19:58:43.273Z yes https://dermsquared.com/videos/topical-conversations/the-role-of-oxidants-and-antioxidants-in-vitiligo 2023-12-12T02:02:18.524Z https://image.mux.com/SpsjA5WZ82xvhLf012cEkedM1mpA5diEEj00ICeJtn4Ak/thumbnail.jpg The Role of Oxidants and Antioxidants in Vitiligo In this installment of Topical Conversations, Naiem Issa, MD, PhD, FAAD, discusses oxidants and antioxidants and their role in the development and resolution of vitiligo. Why do oxidants and antioxidants matter in vitiligo? Vitiligo starts with an insult that can come in many forms, including sun damage, major stress, traumatic incidents, medications, and other autoimmune disorders that cause inflammatory destruction. This kind of stress manifests in a reduction in the immune privilege of the melanocytes in the skin. Melanocytes are typically immune privileged, meaning that the immune system does not recognize the antigens on the melanocytes and do not attack them. The stress initiates a reduction in the immune privilege of the melanocytes, which triggers production of CD8+ T cells that cause destruction of the melanocytes, leading to vitiligo. This mechanism is similar to that seen in alopecia areata, in which hair follicle immune privilege becomes decomposed. During this destructive stress, there is an increase in oxidants, which causes the formation of reactive oxygen species that affect the cell membrane of melanocytes and the organelles of the cell and cause overall oxidative destruction. This destruction, in turn, causes apoptosis and increased expression of antigens by the dying melanocyte that the immune system recognizes. As a compensatory response, antioxidants such as catalase or superoxide dismutase try to act, but with malfunctioning machinery, there is a reduction in the utility of those antioxidants. Catalase expression in vitiligo A paper by Kassab et al published in the Journal of Clinical Medicine looked specifically at the antioxidant enzyme catalase. The study found that in vitiliginous lesions, when compared to normal lesions, there was a reduction in the catalase expression in the serum of these patients and more so in unstable vitiligo, which showed even less catalase than in stable vitiligo. This demonstrates there is an effect on reducing the amount of antioxidants in the system to allow for compensation. However, the study also showed a paradoxical increase in those patients in superoxide dismutase, also known as the anti-aging protein. This could be a compensatory methodology to make up for the lack of catalase and for the increase in the oxidative molecules, representing the interplay present between oxidants and antioxidants to try to prevent the destruction of the melanocyte, thus the antigen presentation. The future of antioxidants in vitiligo research While the data in this area is still premature, there are studies currently looking into the use of antioxidants like n-acetylcystein and other types of supplements to mop up oxidants and prevent the formation and progression of vitiligo. Current knowledge does support that the progression of oxidants leads to the development of vitiligo, and future research is warranted to determine if the use of antioxidants can prevent it. https://dermsquared.com/videos/topical-conversations/the-role-of-oxidants-and-antioxidants-in-vitiligo 254 2023-12-11T19:34:54.436Z yes https://dermsquared.com/videos/topical-conversations/atopic-dermatitis-jak-inhibitors 2025-09-10T20:22:05.495Z https://image.mux.com/DJYq3rVJw02BDgA3Y02U3PvnLj42L96smHxp2uWF5001RI/thumbnail.jpg Personalizing Atopic Dermatitis Care with JAK Inhibitors: Clinical Pearls for Real-World Practice In this episode of Topical Conversations, Graham Litchman, DO, MS, and Naiem Issa, MD, discuss the role of Janus kinase (JAK) inhibitors in atopic dermatitis (AD). These agents are increasingly valued for their efficacy and safety in clinical practice. A key advantage is the ability to individualize therapy through dose escalation, allowing JAK inhibitors to support a more personalized approach to managing this heterogeneous condition.Safety considerationsDr Litchman and Dr Issa review the safety profile of JAK inhibitors, noting that these medications are widely used and generally well tolerated. Large-scale studies of abrocitinib and upadacitinib, encompassing thousands of patients across multiple countries, support their safety and efficacy.Dr Issa emphasizes the importance of proactively addressing the boxed warning during patient discussions. Many patients will review the package insert and raise concerns, so he begins the conversation by explaining the history and context behind the warning. The boxed warning stems from the ORAL Surveillance study of tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis aged 50 and older with cardiovascular comorbidities; many of these patients were on concomitant methotrexate and often corticosteroids. This population differs significantly from typical patients with AD.The “big 5” risks listed in the boxed warning (infection, major adverse cardiovascular events, thrombosis, sudden death, and malignancy) are framed as “reports” associated with JAK inhibitors, not as placebo-controlled findings. Dr Issa notes that clarifying this nuance helps patients understand the data in context and alleviates concerns. Dr Litchman adds that while these conversations can be complex, the majority of AD patients are not the same as the population studied in ORAL Surveillance, and most tolerate JAK inhibitors well in practice.Personalized treatment and dosing strategiesBoth experts highlight the role of JAK inhibitors in moving toward personalized medicine for AD, a heterogeneous and fluctuating disease. Treatment plans can be tailored based on individual patient needs, with the ability to adjust dosing when necessary.Data from studies such as the JADE and LEVEL UP trials support flexible dosing. For example, abrocitinib can be initiated at 100 mg daily, with evidence supporting escalation to 200 mg if additional efficacy is needed. Upadacitinib has a similar dose-response profile, with starting doses of 15 mg and higher efficacy seen with 30 mg. Importantly, long-term safety data have not shown an increased risk of adverse events of special interest when escalating to higher doses.In practice, Dr Issa often re-evaluates patients within 2 weeks, especially those with itch-dominant disease, and escalates dosing earlier if needed, supported by lab monitoring. Biological and mechanistic insightsBeyond clinical outcomes, Dr Litchman highlights emerging data on gene expression changes with JAK inhibitors. Studies suggest that these therapies, like biologics, may help normalize core gene sets associated with AD, particularly those related to itch pathways and skin barrier function. Observing both clinical improvements in itch and skin clearance, alongside genomic changes, reinforces confidence in the biological rationale for JAK inhibitor therapy.Key takeawaysSafety in context: Boxed warnings stem from rheumatoid arthritis data; most patients with AD tolerate JAK inhibitors wellFlexible dosing: Clinical trials support dose escalation (eg, increasing abrocitinib dosage from 100 mg to 200 mg or upadacitinib from 15 mg to 30 mg) without added long-term safety signalsBiologic rationale: Emerging gene expression data support the mechanistic role of JAK inhibitors in normalizing AD pathwaysFor a closer look at how dose escalation can influence outcomes in practice, explore a case report authored by Graham Litchman, DO, MS. It details a 25-year-old patient with longstanding, refractory atopic dermatitis who achieved complete clearance on abrocitinib following dose adjustment, with before-and-after photos documenting the clinical response. https://dermsquared.com/videos/topical-conversations/atopic-dermatitis-jak-inhibitors 818 2025-09-09T14:58:29.876Z yes https://dermsquared.com/videos/topical-conversations/examining-role-optical-coherence-tomography-recurrent-basal-cell-carcinoma 2024-01-11T15:47:16.977Z https://image.mux.com/B93IuiVliRWBDQ8VzNSOEwumyRWRRD00jQc3BRmSb2bE/thumbnail.jpg Examining the Role of Optical Coherence Tomography in Diagnosing Recurrent Basal Cell Carcinoma In this installment of Topical Conversations, Todd Schlesinger, MD, discusses an article published in the Journal of the American Academy of Dermatology by Wolswijk et al, titled “Optical coherence tomography for diagnosing recurrent or residual basal cell carcinoma after topical treatment: A diagnostic cohort study.” This study evaluated the use of optical coherence tomography (OCT) to diagnose recurrent or residual basal cell carcinoma (BCC) after topical treatment. Study background The small diagnostic cohort study involved 100 patients and aimed to determine if OCT could improve the accuracy of detecting superficial recurrent BCC after treatment with topical therapy (specifically imiquimod, 5-fluorouracil, and photodynamic therapy) compared to clinical and dermoscopic evaluation. Study outcomes on sensitivity and specificity The results showed that OCT improved the sensitivity and specificity of diagnosing recurrent superficial basal cell carcinoma after topical treatment. Patients were evaluated on whether there was a low or high suspicion of recurrence; patients with a high suspicion of recurrence underwent a punch biopsy, while patients with a low suspicion of recurrence underwent a control biopsy. The sensitivity for detection of recurrent or residual BCC was 60% with clinical and dermoscopic evaluation compared to 100% with OCT, suggesting that combining dermoscopy and clinical exam with OCT may significantly improve sensitivity. The specificity was over 95% for both methods. Limitations to the use of OCT in BCC diagnosis Dr Schlesinger notes that there are some limitations to the use of OCT in detecting recurrent BCC. Since OCT has a steep learning curve, the experience of the person interpreting the OCT images is crucial. He also notes that access to OCT may be limited due to its cost. The prospective role of OCT in BCC care The study suggests that incorporating OCT into practice can enhance diagnostic accuracy and potentially reduce the need for biopsies in recurrent BCC after topical therapy. Overall, the article highlights the potential benefits of using OCT for follow-up and detecting recurrence in patients with basal cell carcinoma. Key points A diagnostic cohort study aimed to determine if OCT, in conjunction with clinical exam and dermoscopy, can improve detection of superficial recurrent BCC after topical therapy Use of OCT improved sensitivity and specificity of diagnosing recurrent superficial BCC Limitations include the experience level of the person interpreting the OCT images and cost-related access challenges Incorporating OCT into practice may enhance diagnostic accuracy and potentially reduce need for biopsies in recurrent OCT after topical therapy https://dermsquared.com/videos/topical-conversations/examining-role-optical-coherence-tomography-recurrent-basal-cell-carcinoma 223 2024-01-11T15:47:16.971Z yes https://dermsquared.com/videos/topical-conversations/advances-acne-treatment-2024-highlights-what-to-watch-2025 2025-01-16T14:47:59.636Z https://image.mux.com/XCx459cmU3LD019QvWhVtEkqw6bv7RReJJoGNhOKYeLs/thumbnail.jpg Advances in Acne Treatment: 2024 Highlights and What to Watch for in 2025 In this episode of Topical Conversations, Dr John Barbieri of Brigham and Women’s Hospital in Boston provides an overview of the exciting developments in acne treatment in 2024 and shares key innovations to look forward to in 2025. 2024: a year of breakthroughs in acne care Fixed-dose combination therapy One of the standout advancements of 2024 was the introduction of a fixed-dose combination therapy comprising clindamycin, adapalene, and benzoyl peroxide. Dr. Barbieri highlights this as the most efficacious single-agent topical treatment currently available for acne. Optimized vehicle: Unlike other products, this combination utilizes an advanced formulation to minimize irritation and improve patient comfort. Enhanced adherence and outcomes: Studies comparing fixed-dose combinations to separately used components have demonstrated improved adherence rates and superior clinical outcomes. Comprehensive mechanism of action: Pairing this fixed-dose therapy with another agent, such as clascoterone, addresses all major acne pathways, offering a robust, well-tolerated treatment option. 1726 nm lasers: targeted sebaceous gland therapy Another significant development in 2024 is the emergence of 1726 nanometer lasers, including devices like AviClear and Accure. Precision treatment: These lasers directly target sebaceous glands, providing a focused alternative to systemic therapies like isotretinoin, which often carry off-target side effects such as eye dryness and systemic impacts. Clinical efficacy: Clinical trials show promising results: Around 40% of patients with moderate to severe acne achieve clear or almost clear skin for up to 6 months post-treatment. Eighty to 90% of patients experience at least a 50% reduction in inflammatory lesions. Well-tolerated option: While transient acne worsening can occur, the overall side effect profile is favorable, offering a new avenue for patients who cannot or prefer not to use systemic treatments. Looking ahead: innovations in 2025 and beyond Spongilla lacustris extract mask A topical treatment derived from Spongilla lacustris extract is under development as a once-weekly mask with dual anti-inflammatory and antimicrobial properties. Phase 2 success: Early trials have shown promise, paving the way for this novel therapy to become an accessible option for patients with acne N-acetyl-GED Another exciting candidate is a topical treatment targeting the sebaceous glands. Direct Action on Sebaceous Glands: This innovation offers a rare mechanism of action for topical therapies, focusing on reducing sebum production, oiliness, and acne-promoting factors like C. acnes bacteria Potential for Impact: With few existing treatments addressing sebaceous gland activity directly, this agent holds potential to reshape acne management The Road Ahead in Acne Treatment As we look ahead to 2025, the landscape of acne treatment is set to evolve with a mix of innovative therapies and technologies. Fixed-dose combination topicals, advanced laser technologies, and novel agents in development offer new options to address the complex mechanisms of acne. These advancements provide dermatologists with more tools to tailor treatments to individual patient needs. By staying informed and incorporating these developments into practice, dermatologists can continue to refine their approach to managing acne and improve overall outcomes. https://dermsquared.com/videos/topical-conversations/advances-acne-treatment-2024-highlights-what-to-watch-2025 210 2025-01-16T14:47:59.628Z yes https://dermsquared.com/videos/topical-conversations/tackling-comorbidities-atopic-dermatitis 2025-05-05T22:37:41.101Z https://image.mux.com/nfqXSuLlxleC5jp741FLuRwdm018KkBQ00AKiIn9IlF9Y/thumbnail.jpg More Than Skin Deep: Tackling Comorbidities in Atopic Dermatitis Atopic Dermatitis: A Systemic Disease In this episode of Topical Conversations, Michael Lewitt, MD, and James Song, MD, explore the systemic nature of atopic dermatitis (AD) and its far-reaching effects beyond the skin. Drawing comparisons to psoriasis, they discuss how inflammation in AD is not confined to lesional areas, but extends to non-lesional skin, the bloodstream, and other organ systems—making the need for early recognition and intervention increasingly urgent. Comorbidities: Atopic and Beyond Drs Lewitt and Song break down the diverse comorbidities associated with AD. Atopic conditions such as asthma, allergic rhinitis, eosinophilic esophagitis, and allergic conjunctivitis are common, but so are non-atopic burdens like sleep disturbance, reduced school and work productivity, and complications from systemic steroid use. They highlight the importance of recognizing both types of comorbidities to guide management strategies. Prioritizing Conversations in a Short Visit Given the time constraints of typical dermatology visits, both physicians emphasize using a "high-yield" mental checklist to screen for potential comorbidities. Asking simple questions about breathing, swallowing, nasal symptoms, and eye dryness can help uncover issues early. Dr Song underscores that while dermatologists cannot manage every comorbidity, timely recognition and referral are key. The Role of Early Intervention Early treatment of AD may do more than control current symptoms—it could potentially prevent the development of future comorbidities. They discuss how therapies targeting key cytokines like IL-4 and IL-13 might reduce barrier dysfunction and immune activation, ultimately altering the long-term trajectory of the disease. For pediatric patients especially, intervening early could disrupt the "atopic march" toward additional allergic diseases. Collaborating Across Specialties Both doctors advocate for strong collaboration with allergists, pulmonologists, gastroenterologists, and mental health providers when managing complex cases. Dr Lewitt likens it to having multiple cooks in the kitchen making the same dish—working together toward shared patient goals. Dermatologists, they agree, are often in the ideal position to recognize systemic signs first and initiate appropriate care pathways. Key TakeawaysAtopic dermatitis is a systemic inflammatory disease that extends beyond the skin. Common comorbidities include both atopic (asthma, allergic rhinitis) and non-atopic (sleep disturbances, productivity loss) conditions. Early screening for comorbidities during dermatology visits can improve patient outcomes. Early intervention with targeted systemic therapies may help prevent the progression of the atopic march. Collaboration with other specialists is critical for comprehensive patient care. https://dermsquared.com/videos/topical-conversations/tackling-comorbidities-atopic-dermatitis 571 2025-05-05T22:37:41.094Z yes https://dermsquared.com/videos/topical-conversations/oral-therapy-deucravacitinib-vs-apremilast 2025-07-15T03:10:28.228Z https://image.mux.com/8YLjhr46CsmCHgpp01xAdPFz4JLkp6ZB01iJ8501C019Hss/thumbnail.jpg Choosing an Oral Therapy: Deucravacitinib vs Apremilast Defining the oral advantage in psoriasis treatment In this episode of Topical Conversations, Dr Shahriari and Dr Bunick explore the evolving oral treatment landscape for plaque psoriasis, focusing on head-to-head comparisons between apremilast, a phosphodiesterase 4 (PDE4) inhibitor, and deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor. The discussion provides practical guidance for clinicians navigating therapeutic choices based on long-term efficacy, tolerability, and patient preference.Efficacy and tolerability Deucravacitinib demonstrated superior efficacy compared with apremilast in 2 phase 3 trials (POETYK PSO-1 and PSO-2). At week 16, Psoriasis Area and Severity Index (PASI) 90 response rates were 36% vs 20% in PSO-1 and 27% vs 18% in PSO-2, respectively. At week 52, 19% of patients receiving deucravacitinib achieved PASI 100.Regarding tolerability, common adverse events associated with apremilast (eg, nausea, diarrhea, headache) remain frequent. In contrast, deucravacitinib’s adverse event profile was comparable to or lower than placebo across clinical trials.Molecular mechanisms: explaining the difference Dr Bunick explains how apremilast’s chemical structure limits its mimicry of cyclic adenosine monophosphate (cAMP), potentially reducing potency. Deucravacitinib, by contrast, exerts selective allosteric inhibition of TYK2. Dr Bunick references his recent laboratory findings, which show TYK2 contains more phosphotyrosine sites than other Janus kinase (JAK) family members, enabling high STAT phosphorylation activity and robust cytokine suppression.Oral vs injectable Although biologic agents remain widely used, oral therapies play a growing role in psoriasis management, particularly for patients seeking noninjectable options or those already managing multiple conditions with injectable drugs. Dr Shahriari and Dr Bunick stress the importance of shared decision-making in determining patient preference.Sustained effects after discontinuation A notable finding: following discontinuation of deucravacitinib, patients maintained a PASI 75 response for a median of 12 weeks. This contrasts with JAK inhibitors used in atopic dermatitis, where symptom recurrence often occurs within 1 week of withdrawal. The speakers attribute this durability to TYK2’s upstream modulation of the Th17 axis and inflammatory cytokines.Key takeawaysDeucravacitinib demonstrated superior efficacy over apremilast in PASI 90 rates at week 16, with 19% of patients on deucravacitinib achieving PASI 100 by week 52Deucravacitinib is well tolerated, with adverse event rates similar to placeboSome patients prefer oral therapy due to convenience, control, or injection fatigueDiscontinuation of deucravacitinib does not lead to immediate loss of efficacy, supporting its role in long-term disease control https://dermsquared.com/videos/topical-conversations/oral-therapy-deucravacitinib-vs-apremilast 831 2025-07-15T03:02:35.233Z yes https://dermsquared.com/videos/topical-conversations/beyond-short-term-response 2026-05-20T16:45:44.926Z https://image.mux.com/EFqkEHQLdJSIvl00wxrCb5RcOTQ2sQqJW00qhagCr13as/thumbnail.jpg Durability Matters in Atopic Dermatitis: Thinking Beyond Short-Term Response In this episode of Topical Conversations, Dawn Merritt, DO, sits down with Naiem Issa, MD, to explore how dermatologists think about managing atopic dermatitis (AD) over years, not weeks. Their discussion centers on durability, consistency, and the patient experience, and how those factors shape treatment decisions in real-world practice. Using therapies such as tralokinumab as reference points, they examine what sustainable disease control truly looks like for chronic inflammatory disease.Thinking beyond short-term endpointsWhen asked what matters most when choosing a therapy for AD, Dr Issa reflects on the tension between modern expectations for rapid improvement and the long-term nature of chronic inflammatory disease. While regulatory pathways emphasize short-term endpoints to determine whether a drug moves forward, the clinical reality is that patients often require treatment over the long haul.Early improvement is important, but Dr Issa emphasizes that lack of immediate response does not necessarily signal failure. Given the chronicity and complexity of AD, there are situations where allowing more time on therapy is appropriate, particularly when the treatment is well tolerated.Setting expectations for a chronic diseaseDr Merritt highlights the importance of patient education and expectation-setting, particularly for individuals who have previously relied on fast-acting but unsustainable options such as steroids. Both clinicians stress the need to reframe the conversation. AD is not curable; it must be managed. The goal is to identify therapies that are safe and effective over time, rather than those that simply offer rapid but temporary relief.Explaining the biology to support patienceDr Issa notes that bringing biology into the conversation can help patients understand why durability matters. Rather than “setting off an atomic bomb” on the immune system, modern systemic therapies aim to target specific pathways involved in disease pathophysiology.Helping patients understand that targeted immunomodulation works differentlyand can make waiting feel like a purposeful investment rather than a setback.Why IL-13 inhibition may matter for long-term controlThe conversation then turns to treatment selection, with a focus on IL-13 inhibition. Dr Issa explains that while IL-4 has long been recognized as part of AD pathophysiology, growing evidence suggests IL-13 plays a central role in driving disease.With direct IL-13 blockade, clinicians may avoid some of the effects observed with therapies that inhibit both IL-4 and IL-13. Dr Issa references clinical experience and published cases in which patients switching from IL-4 blockade to tralokinumab experienced resolution of arthralgias. He also discusses head and neck dermatitis, including instances of de novo head and neck involvement reported with certain therapies, which can influence treatment choice when considering holistic patient care.Avoiding unnecessary treatment switchingDr Merritt notes that clinicians can sometimes be too quick to switch therapies in response to flares or adverse events. Frequent switching may introduce additional risk and uncertainty without improving long-term outcomes.Dr Issa describes his approach as selecting therapies early that are designed for sustainability. The goal is to reduce risk while optimizing results in a single, cohesive strategy. In his clinical experience, tralokinumab has the potential to support this approach, including for patients who require a switch from another biologic.The role of dosing flexibility in long-term adherenceDrawing from her own practice, Dr Merritt shares that patients who remain on tralokinumab through the initial 16 weeks may transition to once-monthly dosing. While the concept of long-term therapy can initially be difficult for patients to accept, the possibility of reduced dosing frequency can help ease concerns and improve adherence.Dr Issa reinforces this point with clinical trial data, noting that patients who transitioned from every-2-week dosing to every-4-week dosing after 16 weeks maintained similar efficacy. He further highlights data showing that a subset of patients who discontinued therapy maintained clear or almost clear skin, or achieved EASI-75, for the remainder of the year.He frames this as a practical question for patients: if there were a 1-in-4 chance of maintaining control after stopping therapy, would that be worth it? Dr Merritt notes that, in her experience, most patients would accept those odds.Building a plan for the long termThe discussion concludes with a shared emphasis on early selection of therapies that balance efficacy, tolerability, and durability. Lowering the risk of adverse events, minimizing unnecessary switching, and giving patients a realistic path toward long-term control, including the possibility of dose reduction or sustained remission, are central to this approach.The clinicians end by emphasizing that durability is not just a clinical endpoint; it is a strategy that supports better outcomes, better patient relationships, and more sustainable management of chronic inflammatory disease.Key takeawaysAtopic dermatitis requires long-term management, not short-term thinkingEarly efficacy matters, but durability and tolerability often matter more over timeSetting realistic expectations helps patients stay engaged with chronic disease therapyAvoiding unnecessary treatment switching can reduce risk and improve continuity of careDosing flexibility and the potential for sustained control can improve patient acceptance and adherence https://dermsquared.com/videos/topical-conversations/beyond-short-term-response 460 2026-02-05T15:23:03.905Z yes https://dermsquared.com/videos/topical-conversations/relief-cant-wait-in-atopic-dermatitis 2025-10-21T13:01:15.092Z https://image.mux.com/00sLz7HqVgzDnrkmJ00RxMze01Atohga5JMNWsWMvAGl1c/thumbnail.jpg The Itch Factor: Why Relief Can’t Wait in Atopic Dermatitis In this episode of Topical Conversations, Matthew Zirwas, MD, and Raj Chovatiya, MD, discuss one of the most important, and sometimes underappreciated, aspects of atopic dermatitis (AD) management: rapid itch relief. Despite the progress made with targeted therapies, many dermatologists may still overlook how profoundly itch drives disease burden, adherence, and patient trust. Drs Zirwas and Chovatiya share practical approaches for evaluating itch severity, setting realistic expectations, and understanding how new-generation therapies are impacting the conversation around early symptom improvement.Why itch still warrants more attention in ADDespite the numerous treatment options for AD, Drs Zirwas and Chovatiya agree that itch remains an under-discussed symptom during dermatology visits. Dr Chovatiya points out that while dermatologists often assume they’re addressing itch adequately, in practice, they may not be asking the right questions about itch severity or fully exploring its impact on quality of life.Dr Zirwas adds that while the Numeric Rating Scale (NRS) for itch is useful in research, it’s less practical in routine clinical settings where patients are seen only every few months. Instead, he recommends a more straightforward, contextual approach: asking patients whether their itch is none, mild, moderate, or severe. He likens mild itch to a single mosquito bite, moderate to 20 mosquito bites or some poison ivy, and severe to widespread poison ivy or hundreds of bites. Framing the question this way, he explains, helps patients describe their experience more accurately and meaningfully.The broader impact: itch as a holistic problemDr Chovatiya emphasizes that itch is not a surface-level symptom, but rather drives a cascade of issues including sleep disturbance, fatigue, mood changes, anxiety, and depression. Persistent itch can also erode trust between patients and providers when relief isn’t achieved quickly enough, leading to frustration with otherwise effective treatment plans.Both dermatologists stress that understanding itch’s impact on quality of life is essential not only for patient empathy but also for maintaining long-term treatment adherence.A new era of therapies and a shift in expectationsThe landscape of AD therapy has evolved dramatically, introducing multiple biologic and small-molecule options that challenge old assumptions about speed and safety. Dr Chovatiya notes that dermatologists historically viewed biologics as “safe but slow,” but that perception no longer holds true. Today’s therapeutic arsenal includes IL-4/IL-13 inhibitors, IL-13 inhibitors, IL-31 inhibitors, and potentially soon, OX40 inhibitors, which are all capable of rapid and meaningful itch improvement.When discussing the pace of itch relief, both agree that while oral JAK inhibitors may deliver the fastest onset, biologics now demonstrate impressive early itch improvement as well. Dr Chovatiya points to real-world data showing that many patients experience noticeable relief early in their biologic therapy, not just lesion improvement.Tralokinumab and rapid itch reliefDr Zirwas highlights that among available biologics, tralokinumab provides balanced performance across efficacy, safety, and speed. He notes that data from the ECZTRA trials demonstrated separation from placebo within the first few doses, confirming that tralokinumab delivers meaningful early itch relief while maintaining long-term control and a favorable safety profile.While tralokinumab has sometimes been perceived as slow-acting, both dermatologists emphasize that this perception is not supported by clinical or real-world evidence. In practice, all approved biologics, including tralokinumab, can provide rapid and sustained itch improvement.Early itch relief is foundational to effective careDrs Zirwas and Chovatiya conclude that early itch relief is not just about comfort; it’s a cornerstone of patient satisfaction, adherence, and confidence in treatment. For patients with moderate to severe AD, agents like tralokinumab demonstrate that it’s possible to achieve rapid itch relief, visible skin improvement, and long-term disease control, all while maintaining a strong safety profile.Key takeawaysItch assessment deserves more attention: Despite being the hallmark symptom of AD, many dermatologists don’t ask enough about itch severity or its daily impact on quality of lifeQualitative scales may be more practical than numeric ones: Replacing the Numeric Rating Scale with simple categories paired with real-life comparisons helps patients describe their itch more accuratelyItch affects more than the skin: Persistent itch contributes to sleep loss, mood changes, and diminished confidence in treatment, highlighting the need for early and meaningful reliefModern therapies deliver faster relief than once believed: Biologics such as tralokinumab have shown clinically relevant itch improvement within the first few dosesBalance matters: Choosing treatments that address itch, skin clearance, safety, and adherence supports both short-term comfort and long-term control in patients with moderate-to-severe AD https://dermsquared.com/videos/topical-conversations/relief-cant-wait-in-atopic-dermatitis 765 2025-10-21T13:00:17.595Z yes https://dermsquared.com/videos/topical-conversations/approach-for-dermatologists 2026-05-20T16:45:25.696Z https://image.mux.com/hpAEB7HT01jASg4fRmZ5XcDGzwA4tDqru30202bKtHghFQ/thumbnail.jpg When cSCC Gets Complex: A Multidisciplinary Approach for Dermatologists This video is sponsored by Sun Pharma. Its content is editorially independent of the sponsor. In this episode of Topical Conversations, Vishal Patel, MD, and David Miller, MD, PhD, examine how the management of cutaneous squamous cell carcinoma (cSCC) has shifted from a specialty-specific approach to a truly multidisciplinary model. Their discussion centers on how dermatologists partner with surgeons, radiation oncologists, and medical oncologists to manage increasing disease complexity, while remaining actively involved from diagnosis through long-term surveillance.cSCC as a team-based diseasecSCC is no longer solely a dermatologic or surgical problem. While many tumors remain straightforward to manage, more advanced cases increasingly require coordination across multiple specialties. Drs Patel and Miller emphasize that optimal outcomes, particularly in high-risk or advanced disease, depend on early collaboration and thoughtful sequencing of surgery, radiation, and systemic therapy.A wide and heterogeneous clinical spectrumThey reinforce the broad clinical range of cSCC, spanning low-risk tumors to locally advanced disease, perineural invasion, recurrent tumors, nodal involvement, and metastatic spread. Dermatologists are often the point of entry, responsible for diagnosis, initial risk stratification, and determining when escalation is needed. However, Dr Miller notes that no single specialty holds all the answers and that successful management hinges on assembling the right combination of modalities for each patient.Recognizing complexity and when to expand the teamA central challenge for dermatologists is identifying when a case is becoming more complex. Dr Patel outlines red flags that should prompt earlier multidisciplinary engagement, including rapid tumor growth, recurrence, deep invasion, perineural symptoms, and tumors in anatomically challenging locations. Dr Miller adds immunosuppression, multiple recurrences, and nodal disease as signals that early collaboration may meaningfully alter the treatment trajectory.Both stress the importance of not waiting until options are limited. Early input from surgery, radiation oncology, and medical oncology allows for better planning around margins, adjuvant therapy, and systemic treatment considerations.The dermatologist’s role beyond referralThe conversation challenges the notion that dermatologists step back once oncology becomes involved. Dr Patel highlights the dermatologist’s ongoing role in managing field cancerization, monitoring for secondary primaries, and providing long-term surveillance. Dr Miller adds that patients often place deep trust in their dermatologists, positioning them to reinforce education, address concerns, and help manage skin-related adverse events even when another specialist is leading systemic therapy.Multidisciplinary decision-making in real-world practiceWhile formal tumor boards are ideal, Dr Patel acknowledges that they are not always feasible. Dr Miller describes practical alternatives, such as informal case discussions via email, phone calls, or brief in-person conversations to align on sequencing, goals of care, and follow-up responsibilities. Both note that time constraints and fragmented care can be mitigated by cultivating a reliable network of colleagues and maintaining proactive communication.Where systemic therapy fitsSystemic therapy has become an integral part of modern cSCC management rather than a last-line option. Dr Miller reiterates that timing and sequencing are critical, whether systemic therapy is used before surgery, after radiation, or as a standalone approach. Patel adds that even when dermatologists are not prescribing these agents, understanding when they are appropriate helps guide referrals and set realistic patient expectations.Cosibelimab in the multidisciplinary frameworkThe discussion turns to PD-1 inhibition, now well established in advanced cSCC. Dr Patel notes that response and tolerability vary, particularly in older patients with comorbidities. Dr Miller points to emerging data suggesting cosibelimab, a PD-L1 inhibitor, may offer a favorable tolerability and safety profile, an important consideration in real-world populations.They emphasize that familiarity with where cosibelimab may fit, whether alongside surgery or radiation, or in unresectable or metastatic disease, allows dermatologists to better guide referrals, support shared decision-making, and manage skin-related adverse events. Even when medical oncologists lead systemic therapy, ongoing dermatologic involvement remains essential as the PD-1 and PD-L1 inhibitor landscapes continues to mature.Communication, coordination, and the patient experienceFrom the patient’s perspective, multidisciplinary care can feel either reassuring or overwhelming. Dr Miller stresses that clear handoffs, consistent messaging, and defined follow-up plans are critical to maintaining trust, particularly in advanced disease, where treatment plans may evolve over time.Common pitfalls and practice pearlsDr Patel cautions that dermatologists may underestimate how quickly cSCC can progress once advanced and how impactful early multidisciplinary input can be. Common pitfalls include delayed referrals, unclear ownership of follow-up, and assumptions that another provider is monitoring the patient.Both physicians highlight simple but effective strategies: clear documentation, direct communication with key colleagues, and staying engaged even after referral. These steps can significantly improve care coordination and outcomes.Key takeawayscSCC management has become increasingly multidisciplinary, particularly for high-risk and advanced diseaseDermatologists play a central role across the continuum, from diagnosis and risk stratification to surveillance and adverse event managementEarly recognition of complexity and timely multidisciplinary engagement can expand treatment options and improve outcomesSystemic therapy is now part of integrated cSCC care, with timing and sequencing determined collaborativelyFamiliarity with agents such as cosibelimab helps dermatologists guide referrals and support patient educationClear communication, defined follow-up responsibilities, and ongoing dermatologic involvement are critical to patient experience and care quality https://dermsquared.com/videos/topical-conversations/approach-for-dermatologists 618 2026-02-06T17:48:09.705Z yes https://dermsquared.com/videos/topical-conversations/advancements-in-treating-vitiligo 2023-06-29T21:04:33.591Z https://image.mux.com/cHA7FlQKE8jTRj4jNUDaVlC6FsVHk8DJBiKGwEb02wwo/thumbnail.jpg Advancements in Treating Vitiligo Advancements in Treating Vitiligo https://dermsquared.com/videos/topical-conversations/advancements-in-treating-vitiligo 70 2023-06-29T19:46:36.050Z yes https://dermsquared.com/videos/topical-conversations/skin-to-joints-dual-targeted-approach 2025-09-09T01:24:26.309Z https://image.mux.com/G00nq6SmU8cRLbniV02SP4xkSIR029pHt7TJVD31xI00ThY/thumbnail.jpg From Skin to Joints: Clinical Impact of a Dual-Targeted Approach From Skin to Joints: Clinical Impact of a Dual-Targeted ApproachIn this episode of Topical Conversations, Erin Boh, MD, and Benjamin Lockshin, MD, discuss the role of bimekizumab (Bimzelx), the first dual IL-17A/F inhibitor, in the management of patients with psoriasis (PsO) and psoriatic arthritis (PsA). The conversation highlights how this mechanism of action has the potential to reshape treatment strategies, particularly for patients with both extensive skin involvement and active joint disease.Treatment considerations in PsO and PsADr Boh explains that her initial considerations include the extent of skin involvement and the presence of comorbidities such as joint disease. These parameters help guide whether therapy should be directed primarily toward skin, joints, or both. She emphasizes a patient-centered approach directed by understanding whether skin or joint symptoms are the main driver of discomfort.For patients with both extensive skin and joint disease, she typically favors IL-17 inhibitors or IL-23 inhibitors over TNF inhibitors, noting that TNFs may struggle to achieve high levels of skin clearance in such cases.Advances with bimekizumabDr Lockshin notes that while treatments over the past 2 decades have been highly effective for skin clearance, progress in joint clearance has been more limited. Bimekizumab introduces a new approach with its dual inhibition of IL-17A and IL-17F, demonstrating robust results in both skin and joints.He highlights that bimekizumab is the first drug to use an American College of Rheumatology criteria for 50% response (ACR50) score as a primary endpoint in PsA trials, providing a more meaningful measure of response compared to ACR20. Clinical trial data showed achievement of ACR20, ACR50, and ACR70 responses in some patients faster than in timelines observed with other agents.Dr Boh agrees, noting that while other IL-17 inhibitors are effective for joint disease, there are subsets of patients who respond incompletely. In her view, bimekizumab represents not only a new drug but a new therapeutic class, with the potential to maximize outcomes in patients who do not achieve adequate improvement with IL-17A inhibition alone.Practical implications and switching therapyBoth Dr Boh and Dr Lockshin emphasize the potential benefit of of switching therapy. Dr Lockshin states he has no reservations about moving patients from a TNF inhibitor to an IL-17, or from an IL-17A inhibitor to dual IL-17A/F blockade with bimekizumab.Dr Boh highlights the potential role of bimekizumab when combination therapy is otherwise limited by access or insurance barriers. For example, if a patient has partial response to an IL-17A, switching to bimekizumab may offer greater improvement without the need for additional agents.Patient-centered decision-makingThe discussion concludes with a reminder from Dr Boh that treatment decisions should be patient-first: the patient comes first, the disease second, and the drug third. With an expanding set of options, including bimekizumab, dermatologists are better positioned to tailor treatment to each patient’s unique presentation, balancing efficacy across both skin and joint disease while considering mechanisms of action and long-term outcomes.Key takeawaysInitial considerations: Treatment decisions in PsO and PsA begin with assessing the extent of skin involvement and the presence of joint diseaseDual inhibition: Bimekizumab targets both IL-17A and IL-17F, offering robust efficacy in skin and joint clearanceClinical trials: In bimekizumab trials for PsA, ACR50 was used as a primary endpoint, a more clinically meaningful measure than ACR20Therapeutic flexibility: Switching from TNF inhibitors or single-pathway IL-17 inhibitors to bimekizumab can maximize outcomes without requiring combination therapyPatient-centered care: The patient’s priorities drive treatment (skin versus joints), with bimekizumab representing an option that addresses both domains effectively https://dermsquared.com/videos/topical-conversations/skin-to-joints-dual-targeted-approach 447 2025-09-08T23:57:09.735Z yes https://dermsquared.com/videos/topical-conversations/bridging-gaps-nail-disorder-management-new-approaches 2024-06-27T17:28:36.167Z https://image.mux.com/G5ULVG7am5Pz9NsjrRVEFEQV6Pqim9t8SEyLBPBXC6s/thumbnail.jpg Bridging the Gaps in Nail Disorder Management: New Approaches for Dermatologists In this episode of Topical Conversations, Dr Jasmine Rana, Clinical Assistant Professor and Director of the Nail Disorders Clinic at Stanford Dermatology, discusses her recent publication, “Nails as Dynamic, Not Static, Entities—Rethinking the Approach to Nail Disorders,” reviewing the practice gaps that exist for nail diseases and offering a few practical takeaways to improve nail disease management. Nail disorders are dynamic Dr Rana emphasizes that nail disorders are not static entities. Instead, they are dynamic, influenced by various coexisting factors that affect nail health. She notes that it is the responsibility of the health care provider to piece these factors together. A key example is diagnosing nail fungus, or onychomycosis. While fungus may be present, it is also crucial to identify other structural influences such as bunions, hammer toes, arthritis, nerve dysfunction, and nail psoriasis, since these factors influence treatment approaches and patient counseling. Recognizing cognitive biases Dr Rana also notes the importance of health care providers recognizing cognitive biases. Many dermatologists are not trained to recognize or treat podiatric disorders; similarly, podiatrists may not be trained to recognize nail psoriasis or conditions like nail lichen planus. Recognizing and addressing these biases can improve diagnosis and treatment. Improving nail disease management Dr Rana emphasizes that nails do not belong neatly to one medical specialty, making interdisciplinary approaches essential for optimal care. She suggests considering interdisciplinary nail clinics staffed by dermatologists, podiatrists, radiologists, vascular doctors, and orthopedic surgeons to provide an opportunity to offer holistic, high-value care. Practical takeaways Acknowledging that establishing interdisciplinary clinics is challenging, Dr Rana proposes a few practical strategies to improve nail disease management: Separate visits for nail concerns: Scheduling separate visits for nail concerns can reduce the stress of addressing multiple issues in one visit, leading to better diagnosis and recognition of nail conditions. Championing nail disease in large practices: In large group practices, identifying a specialist with an interest in nail disease can help champion educational initiatives and facilitate referral pathways, promoting cross-specialty collaboration. By implementing these strategies, health care providers can enhance the diagnosis and treatment of nail disorders, ultimately leading to improved patient outcomes. https://dermsquared.com/videos/topical-conversations/bridging-gaps-nail-disorder-management-new-approaches 199 2024-06-27T17:28:36.162Z yes https://dermsquared.com/videos/topical-conversations/transformative-therapy-for-gpp 2024-05-28T17:26:11.760Z https://image.mux.com/Q00E7Ht43AlaZmpFkzscSZKqZ6T023I8BP5KzzgA013rDY/thumbnail.jpg Transformative Therapy for GPP: From Flares to Maintenance In this installment of Topical Conversations, Mark Lebwohl, MD, and Boni Elewski, MD, discuss spesolimab, the first FDA-approved treatment for generalized pustular psoriasis (GPP). Dr Elewski recounts the case of a patient who experienced a severe GPP flare after receiving systemic steroids and experienced rapid improvement after a single intravenous infusion of spesolimab 900 mg along with triamcinolone 0.1% ointment and hydrocortisone 1% cream. Spesolimab, an IL-36 receptor antagonist, initially approved for the treatment of GPP flares, has now also received an expanded subcutaneous indication for maintenance therapy, recognizing that the chronic nature of GPP requires continuous management beyond just reactive treatment for flares. This expansion was majorly based on results from the Effisayil 2 clinical trial, a 48-week clinical trial that showed that spesolimab significantly reduced the risk of GPP flares by 84%, compared with placebo. In the trial with 123 patients, no flares were observed after week 4 of spesolimab subcutaneous treatment in the high-dose group (n=30). https://dermsquared.com/videos/topical-conversations/transformative-therapy-for-gpp 466 2024-05-28T16:13:52.042Z yes https://dermsquared.com/videos/topical-conversations/examining-role-glp1-inhibitors 2024-12-09T15:31:46.382Z https://image.mux.com/lHLSRl0074EGfuV00ED2oqwGCbQOHK9kfEJffJ0102gnmmQ/thumbnail.jpg Examining the Role of GLP-1 Receptor Agonists in Treating Inflammatory Skin Diseases In this episode of Topical Conversations, Michael Cameron, MD, and James Allred, MD, explore the intersection of GIP and GLP-1 receptor agonists, such as tirzepatide and semaglutide, and inflammatory skin diseases like psoriasis, hidradenitis suppurativa (HS), and atopic dermatitis (AD). They discuss how these medications, originally developed for diabetes and weight management, are emerging as potential tools in dermatology, impacting the way clinicians can approach inflammatory conditions. GLP-1 receptor agonists: a game-changer for inflammation Dr Allred highlights how GLP-1 receptor agonists have shown significant anti-inflammatory effects, even before substantial weight loss occurs. Historically, weight reduction has been associated with improvements in inflammatory skin diseases but achieving it through diet and exercise alone is often challenging for many patients. GLP-1 receptor agonists provide a new avenue, reducing systemic inflammation and complementing existing therapies for psoriasis and other conditions. Dr Cameron adds that anecdotal evidence shows improvements in psoriasis, HS, and AD when these medications are used, often alongside biologics. He emphasizes that GLP-1 receptor agonists are becoming more accessible and commonly prescribed, making it crucial for dermatologists to understand their potential benefits. The role of visceral fat in inflammation Dr Allred explains the pathophysiology of visceral fat and its role in systemic inflammation. Unlike subcutaneous fat, visceral fat is hormonally active, releasing cytokines like IL-6 and TNF-alpha that exacerbate inflammatory diseases. He notes that GLP-1 receptor agonists reduce the inflammatory burden by targeting these fat cells, which are highly metabolically active and prone to cellular damage. Dr Cameron points out that some patients on GLP-1 receptor agonists experience marked improvements in their psoriasis even without concomitant biologics, suggesting the reduction in proinflammatory mediators from fat cells plays a significant role in disease improvement. Practical considerations for dermatologists Understanding the therapy: Dermatologists should familiarize themselves with the prescribing process for GLP-1 receptor agonists, including contraindications such as a history of medullary thyroid cancer or diabetes-related gastroparesis. These medications are relatively easy to initiate, requiring no specific lab monitoring. Holistic patient care: Dr Allred underscores the importance of screening patients with psoriasis for comorbidities such as obesity, lipid abnormalities, and metabolic syndrome. Addressing these factors can improve overall outcomes and complement traditional therapies. Expanding the scope of care: GLP-1 receptor agonists have often been considered the domain of endocrinologists and primary care providers, but Dr Allred advocates for dermatologists to take ownership of treating inflammation as part of managing inflammatory skin diseases. Future directions in research Dr Cameron concludes by previewing ongoing research comparing outcomes for patients on ixekizumab alone versus ixekizumab combined with GLP-1 receptor agonists. Early evidence suggests that this combination may amplify disease improvement in conditions like psoriasis and psoriatic arthritis. Dr Allred believes GLP-1 receptor agonists represent the next major evolution in psoriasis treatment, likening their impact to the revolutionary introduction of biologics. He encourages dermatologists to embrace this innovation to maximize the care they provide for their patients. Takeaways for Dermatologists GIP and GLP-1 receptor agonists like tirzepatide and semaglutide offer promising anti-inflammatory benefits, particularly for overweight patients with psoriasis, HS, and AD Understanding the role of visceral fat in systemic inflammation can help dermatologists appreciate the broader impact of weight management on skin health Dermatologists should consider integrating GLP-1 receptor agonists into treatment plans where appropriate Ongoing research will further elucidate the role of GLP-1 receptor agonists in dermatology, potentially paving the way for new treatment paradigms. https://dermsquared.com/videos/topical-conversations/examining-role-glp1-inhibitors 448 2024-12-09T15:31:46.372Z yes https://dermsquared.com/videos/topical-conversations/navigating-malignancy-risks-atopic-dermatitis-therapeutic-considerations 2024-04-17T18:36:10.863Z https://image.mux.com/wHY4LwMRAYiAGS00qqBIGxEQpRHCl3Dce49z6b02YojHc/thumbnail.jpg Navigating Malignancy Risks in Atopic Dermatitis: Therapeutic Considerations In this installment of Topical Conversations, James Q Del Rosso, DO, discusses the risk of malignancies in patients with atopic dermatitis (AD). He explores the potential correlation between malignancies and specific therapies, particularly considering boxed warnings on Janus kinase (JAK) inhibitors and their associated adverse events. Understanding AD therapies and malignancy risk Dr Del Rosso highlights the importance of scrutinizing the risk of malignancies, which can be categorized into 2 types: nonmelanoma skin cancer and other malignancies. He notes that certain therapies commonly used for AD, such as immunosuppressive agents like methotrexate, cyclosporine, and systemic corticosteroids, may be associated with an increased risk of malignancies. For instance, cyclosporine may raise concerns about lymphoproliferative malignancies, especially considering the medical history of many AD patients. Considering population data However, he also discusses population data suggesting that there is not a significant relationship between AD and an increased risk of malignancy compared to individuals without AD. Despite this encouraging finding, he underscores the importance of vigilance, particularly because patients with AD often undergo various therapeutic regimens. The dermatologists’s role in comprehensive patient care In managing patients with AD, he advocates for a comprehensive approach, emphasizing the necessity of conducting thorough skin examinations, encouraging photoprotection, and maintaining a dermatologist's role in patient management beyond prescribing medications. https://dermsquared.com/videos/topical-conversations/navigating-malignancy-risks-atopic-dermatitis-therapeutic-considerations 156 2024-04-17T18:36:10.858Z yes https://dermsquared.com/videos/topical-conversations/rapid-remission-bimekizumab 2025-08-08T14:12:55.686Z https://image.mux.com/of7ayzet8KSyQe02cFPQS99PPX1RTYsxvhd902PYA6dN8/thumbnail.jpg Rapid Remission of Plaque Psoriasis With Bimekizumab: A Case Discussion In this episode of Topical Conversations, Naiem Issa, MD, and Christopher Bunick, MD, discuss their publication in the Journal of Drugs in Dermatology that highlighted a remarkable case of rapid plaque psoriasis clearance with bimekizumab. They explore the patient case, the mechanism of action driving the rapid response, key clinical insights, and future applications of bimekizumab in psoriatic arthritis (PsA) and hidradenitis suppurativa (HS). Rapid clearance in a treatment-naïve patient Dr Issa describes a male patient in his 30s with over 50% body surface area involvement who had classic plaque psoriasis but had been treatment-naïve for several years after moving to the US. After starting bimekizumab, the patient returned 3 days later, reporting rapid improvement, with plaques melting away and pruritus significantly improved within 24 hours. By 72 hours, 90% of his body had cleared, and within a week, his skin was completely clear, with no residual itching. Dr Issa notes that such rapid improvement is rare with biologic therapies and highlights the potential for bimekizumab to dramatically alter disease progression and patient quality of life. Dr Bunick emphasizes the underrecognized burden of itch in psoriasis, often associated more with atopic dermatitis than psoriasis, reflecting that bimekizumab’s efficacy in reducing both plaques and pruritus so quickly suggests it is a powerful option for improving patient outcomes. Why does bimekizumab work so quickly? Dr Bunick attributes bimekizumab’s rapid and sustained clearance to its unique mechanism of action. Unlike other IL-17 inhibitors, bimekizumab targets both IL-17A and IL-17F. While IL-17A is more potent, IL-17F is more abundant in psoriatic plaques, and inhibiting both cytokines leads to a stronger anti-inflammatory effect. Dr Issa highlights head-to-head trials comparing bimekizumab to adalimumab, ustekinumab, and secukinumab, all of which demonstrated bimekizumab’s superior response rates at 4 weeks. Additionally, IL-17F inhibition has been linked to rapid transcriptional changes in psoriasis plaques, supporting the observed early clearance seen in clinical practice. This challenges the traditional dogma that skin takes time to recover after inflammation subsides. Dr Bunick suggests that some patients may be capable of achieving near-immediate clearance, a paradigm shift in how dermatologists approach biologic response timelines. Addressing safety concerns Mood and suicidal ideation and behavior While bimekizumab’s prescribing information includes a warning for suicidal ideation and behavior, Dr Issa notes that in pivotal trials, Patient Health Questionnaire-9 scores, which assess the degree of depression severity, tended to improve in patients treated with bimekizumab compared to placebo. Dr Bunick compares this to oral isotretinoin, where concerns about depression often contrast with real-world improvements in patient mood and quality of life. As psoriasis improves, sleep, confidence, and social interactions also improve, often leading to better overall mental well-being. Oral and corporal candidiasis Candidiasis is the most common side effect associated with IL-17 inhibitors, but Dr Issa reassures that it is manageable with fluconazole or topical ketoconazole and rarely leads to treatment discontinuation. Dr Bunick explains that oral candidiasis tends to occur once or twice in early treatment but does not persist in most patients. However, if candidiasis is recurrent, alternative treatments may be considered. Expanding beyond psoriasis: bimekizumab in PsA and HS With additional FDA approvals for PsA and HS, bimekizumab is positioned to expand its role in dermatology. Dr Issa highlights that IL-17A and IL-17F levels are significantly elevated in HS, making bimekizumab a logical therapeutic option. For PsA, Dr Bunick emphasizes the importance of dermatologists "owning" psoriatic arthritis—as experts in skin disease, dermatologists should be actively involved in joint disease management as well. Bimekizumab’s efficacy in both psoriasis and PsA provides an opportunity to optimize care for patients with both skin and joint involvement. Positioning bimekizumab in the treatment landscape With IL-23 inhibitors already used for PsA, dermatologists may be wondering how bimekizumab should be positioned within the treatment landscape. Dr Bunick points to the ongoing BE BOLD trial, a direct head-to-head comparison of bimekizumab vs risankizumab in PsA, which will provide valuable insights into IL-17 vs IL-23 inhibition in psoriatic arthritis. Key takeaways In a case study, bimekizumab demonstrated rapid plaque clearance, with a treatment-naïve patient achieving full clearance within a week Its dual inhibition of IL-17A and IL-17F differentiates bimekizumab from other IL-17 inhibitors Safety concerns such as suicidal ideation and behavior and candidiasis are manageable, with mood improvements observed in clinical trials Bimekizumab is now approved for PsA and HS, making it a promising option beyond psoriasis A head-to-head trial with an IL-23 inhibitor (BE BOLD trial) will provide critical insights for PsA management https://dermsquared.com/videos/topical-conversations/rapid-remission-bimekizumab 841 2025-08-08T14:12:55.679Z yes https://dermsquared.com/videos/topical-conversations/overcoming-barriers-systemic-therapy-ad 2025-04-01T13:59:22.235Z https://image.mux.com/Avi4IeYoYGvDydFythNebpemFqKkikd5mh02cFocaMuM/thumbnail.jpg Overcoming Barriers to Systemic Therapy in Atopic Dermatitis In this episode of Topical Conversations, Brad Glick, MD, and James Del Rosso, DO, discuss the delayed initiation of systemic treatments, particularly injectables for atopic dermatitis (AD). They explore the barriers both patients and providers face when considering advanced therapy, how to navigate conversations with patients, and where emerging biologics like lebrikizumab fit into the treatment landscape. Shifting the conversation: helping patients understand systemic therapy Many patients hesitate when the topic of systemic therapy is introduced, sometimes assuming that topicals alone should be sufficient. Dr Glick compares this to the early days of biologic therapy for psoriasis, noting that AD is not just a surface-level condition but rather one driven by internal inflammatory pathways. When discussing treatment escalation with patients, he focuses on educating them about cytokines, explaining that they drive inflammation and itch, which topical treatments cannot fully address. He also reinforces the need for systemic intervention to patients by explaining that AD is often associated with systemic comorbidities, such as asthma, anxiety, depression, and sleep disturbances. Why are so many dermatologists still hesitant? Dr Glick notes that it’s not just patients who hesitate when it comes to systemic treatments, estimating that only 30% of dermatologists routinely prescribe systemic biologics for AD, raising the question: what’s holding back the other 70%? He emphasizes that while biologic options like lebrikizumab (an IL-13 inhibitor) and dupilumab (an IL-4/IL-13 inhibitor) have excellent safety profiles, JAK inhibitors may have contributed to overall hesitation around systemic treatments among some providers. Addressing topicals, Dr Del Rosso reiterates that they have a place in treatment but cannot address the root cause of AD in many patients. He notes that his threshold for initiating systemic therapy has become lower, given that patients with AD often experience significant itch and sleep disruption. Drs Glick and Del Rosso compare AD to psoriasis and acne, questioning why it has been standard practice to wait until disease worsens before initiating advanced therapies. With new insights into the Th2 inflammatory pathways, they stress the need to proactively treat AD earlier with systemic therapies rather than relying on reactive treatment strategies. Lebrikizumab: a unique addition to the ad treatment landscape? With IL-13 inhibition recognized as a key target in AD, Dr Del Rosso asks whether lebrikizumab offers anything new or if it’s just another “me too” biologic. Dr Glick highlights its distinct mechanism of action, explaining that while dupilumab blocks IL-4 and IL-13 via dual receptor inhibition, lebrikizumab selectively inhibits IL-13 by targeting the IL-13 alpha receptor, making it a particularly targeted therapy for AD. Dr Del Rosso also points to long-term data showing that some patients maintain response even after stopping lebrikizumab, noting that this could offer more flexibility for patients who need to pause treatment due to insurance changes or travel without experiencing an immediate relapse. They compare this to oral systemic medications, which require daily dosing and can lead to quick relapse if stopped. Addressing patient fears and misconceptions Despite the strong safety profiles of modern biologics, Dr Glick acknowledges that patients still express fears about systemic treatments, often influenced by direct-to-consumer advertising for older psoriasis biologics with warnings about severe adverse events. He advises his colleagues to differentiate AD biologics from older psoriasis therapies in discussions with patients and reassure them that IL-4, IL-13, and IL-31 inhibitors have well-characterized, predictable safety profiles. Key takeaways Systemic therapy is often delayed in AD, despite evidence that earlier intervention can improve outcomes and prevent progression Patient education is crucial; dermatologists should aim to help them understand that AD is driven by internal inflammation that topicals may not address More dermatologists need to embrace systemic therapy, as current prescribing rates remain low despite the strong safety profiles of modern biologics Lebrikizumab offers a unique approach to IL-13 inhibition, showing significant itch reduction and sustained efficacy even after treatment discontinuation Patient fears about systemic therapy are often based on outdated perceptions, making it essential for dermatologists to address misconceptions head-on https://dermsquared.com/videos/topical-conversations/overcoming-barriers-systemic-therapy-ad 997 2025-04-01T13:59:22.227Z yes https://dermsquared.com/videos/topical-conversations/part-1-value-vitiligo-support-groups-patients-providers 2024-06-20T19:20:34.411Z https://image.mux.com/Ur00UPSHiqOMAOYp6VtzuJPsgeGb3lwzj2oVw00Bl1dJs/thumbnail.jpg Part 1: The Value of Vitiligo Support Groups for Patients and Providers In this Topical Conversations special edition 4-part series, Richard Huggins, MD, dermatologist and member of the board of directors at the Global Vitiligo Foundation, is joined by Amaris Geisler, MD, Katie O’Connell, MS, and Tonja Johnson of the Beautifully Unblemished Vitiligo Support Group, to discuss their publication on the importance of vitiligo patient support groups. In Part 1, they explore how these groups can provide value to both patients and providers and provide some tips on how to start incorporating support groups and related resources into your practice. A window into the patient experience In dermatology, disease and its impact is often measured by morbidity and by patient experience. It is crucial for healthcare providers (HCPs) to make time to listen to patients and create treatment plans that incorporate the social aspects of cutaneous diseases. Support groups offer HCPs an invaluable opportunity to engage more deeply with patients, allowing for extra time to understand their experiences and concerns. One of the most significant benefits HCPs can derive from support groups is the wealth of knowledge gained about patients' lives. For example, consider a patient who neglects other aspects of their health due to the embarrassment associated with a skin condition. Support groups help HCPs recognize that the patient experience extends beyond the visible symptoms. These groups offer HCPs the chance to share experiences with patients, bringing back the emotional connection to medicine that may sometimes be lost over time. Valuable research opportunities for enhanced patient care Support groups also serve as excellent hubs for research. Discussions within these groups can be a basis for qualitative research, and surveys can provide additional valuable data. Participation in support groups gives HCPs profound insights into patients' lives and their experiences, which can enhance patient care. Incorporating support groups and resources into your practice To begin integrating support groups and related resources into your daily practice, consider the following tips: Distribute informational flyers. Provide flyers from organizations such as the Global Vitiligo Foundation or Hope for HS during clinic visits. Handing out these flyers can help patients feel supported, addressing their emotional burden and potentially increasing patient satisfaction. Provide online resources. If you don't have physical flyers, verbally provide website information, write it down for patients, or include it in their discharge notes. This simple gesture can help guide patients towards support. Encourage participation and seek feedback. Encourage patients to participate in support groups and ask for their feedback. Even if HCPs can't attend the groups personally, patient feedback can still offer significant insights into their experiences and needs. For a deeper understanding of how to effectively incorporate vitiligo support groups into your practice, don't miss Part 2, where the discussion explores the critical importance of integrating mental health support within a support group setting. https://dermsquared.com/videos/topical-conversations/part-1-value-vitiligo-support-groups-patients-providers 301 2024-06-20T19:09:03.027Z yes https://dermsquared.com/videos/topical-conversations/hidden-burden-of-atopic-dermatitis 2025-09-19T17:02:26.443Z https://image.mux.com/G7OL3t6U00ZOE8DpGYtRtcBX01CTPtuvT2z9lGhpk02jQA/thumbnail.jpg Beyond the Skin: Addressing the Hidden Burden of Atopic Dermatitis In this episode of Topical Conversations, Nicholas Brownstone, MD, sits down with Dawn Merritt, DO, to discuss the often-overlooked impact of atopic dermatitis (AD). While dermatologists may see a rash that appears mild, for many patients the disease affects far more than the skin, touching sleep, mental health, cognitive function, and overall quality of life across all age groups.Pediatric burdenDr Merritt emphasizes that pediatric patients and their families face a unique set of challenges. Children with AD often require multiple prescriptions per year, and caregivers may spend more than 10 hours weekly managing symptoms. This burden extends beyond the patient, commonly affecting parents’ time, energy, and mental health.The itch burden and mental healthPruritus is central to the disease burden in AD. Studies show patients with itch experience worse quality of life than those with chronic conditions like heart failure or stroke. Sleep disruption from itch can contribute to depression, anxiety, and even suicidal ideation. Dr Merritt notes that over 85% of patients with moderate-to-severe AD report at least itch or sleep disturbance as a symptom.Impact on school performanceChildren with AD may miss school due to rash, infection, or poor sleep. Even when present, they often struggle to concentrate (presenteeism), which can affect academic performance and self-confidence.Asking the right questionsBoth speakers stress the importance of asking beyond “How are you doing?” to uncover a patient’s full burden of AD. Specific questions about sleep, school, itch severity, and mental health allow patients and families to share concerns not visible on exam. Simple tools such as the Atopic Dermatitis Control Test or the PHQ-2 depression screen can help integrate formalized assessments into a busy clinic.Systemic therapies and emerging dataFor patients with significant quality-of-life impairment, Dr Brownstone recommends considering systemic therapy and referral to mental health support. Emerging data highlight that systemic biologics, such as dupilumab, may not only control skin symptoms but may also potentially improve growth outcomes and reduce ADHD medication needs in pediatric patients. A new therapeutic landscape for pediatric patientsSystemic options for AD have been expanding rapidly. Dupilumab is approved for patients as young as 6 months, while biologics such as lebrikizumab, nemolizumab, and tralokinumab are available for patients aged 12 and older. Compared to the limited options of the past, Dr Brownstone describes this as a “golden age” for pediatric AD management.Addressing comorbidities and empowering familiesDrs Brownstone and Merritt conclude their discussion by emphasizing that effective care includes addressing comorbidities such as sleep disturbance and depression. Dr Merritt also uses simple, relatable tools, like asking children to grade their AD with a letter grade, which helps track disease burden across visits. Both recommend connecting families to resources such as the National Eczema Association to provide education and empowerment.Key takeawaysAD can impact far more than the skin, affecting sleep, mental health, school performance, and family well-beingPruritus is a key driver of quality-of-life impairment and may be linked to higher rates of depression and suicidalityAsking specific, pointed questions or using simple screening tools can help clinicians uncover the true burden of disease for their patientsSystemic therapies like dupilumab are transforming pediatric AD care and may offer benefits beyond skin clearanceFor patients with even mild-appearing rashes but severe life impact, systemic agents or mental health referrals should be consideredProviding families with trusted resources, such as the National Eczema Association, can help foster education, empowerment, and adherence https://dermsquared.com/videos/topical-conversations/hidden-burden-of-atopic-dermatitis 931 2025-09-12T22:34:50.791Z yes https://dermsquared.com/videos/topical-conversations/switch-or-combine-treatments 2025-12-04T14:37:54.210Z https://image.mux.com/cC004lbiVHjKIXa8QrBiytG4NFPg5xAc9X4fxanyIrek/thumbnail.jpg Managing Partial Responders in Atopic Dermatitis: When to Optimize, Switch, or Combine Treatments In this episode of Topical Conversations, G. Michael Lewitt, MD, joins David Cotter, MD, to examine a common yet underrecognized challenge in atopic dermatitis (AD) management: how to care for patients who respond to systemic therapy but fall short of full clearance. The discussion focuses on identifying partial responders, optimizing ongoing treatment, determining when to adjust or transition therapies, and navigating conversations about realistic expectations and long-term disease control.Rethinking AD as a systemic diseaseDrs Lewitt and Cotter open the discussion by addressing a foundational challenge in AD care: helping patients understand that it’s not simply a “skin problem,” but a systemic inflammatory disease with diverse clinical expressions. He notes that conversations about systemics flow naturally from an assessment of severity, treatment goals, and disease impact. Patients often voice concerns about “immunosuppression,” and Dr Lewitt suggests reframing this as “immunomodulation” instead, helping patients understand mechanism, safety, and expected outcomes. He also stresses that severity assessment should not rely exclusively on Eczema Area and Severity Index scores or body surface area (BSA) affected; high-impact areas and patient-perceived burden often tip the scale toward systemic therapy.The role of topicals in a systemic eraAlthough systemic therapy is appropriate for many patients, Dr Cotter emphasizes that topical therapy remains central. Tapinarof, ruxolitinib, and other topical options can serve both as initial therapy and as “touch-up paint” during systemic treatment. He routinely checks whether partial responders have tapered or discontinued their topicals, an often-overlooked contributor to perceived loss of efficacy with systemics.Managing partial or nonrespondersThe clinicians then move into the core challenge: patients who respond incompletely or lose response over time.Dr Cotter describes his decision-making framework for adding, subtracting, or switching therapies. When patients improve but plateau (better itch control, reduced BSA, milder disease but persistent burden), he discusses next steps. Options include cycling biologics, switching classes, or transitioning to a small molecule. He highlights available evidence, particularly a head-to-head trial showing that patients with inadequate response to dupilumab were more likely to improve when switched to upadacitinib.Another strategy involves using a JAK inhibitor as a short-term “fire extinguisher” for severe flares or rapid symptom control, followed by a transition back to a biologic for long-term maintenance, a preferred option over prednisone in his practice.When patients want to stop systemic therapyA common scenario is the patient who feels markedly better and asks whether treatment can be discontinued. Dr Cotter frames this as “forever for now,” emphasizing patient autonomy while counseling on likely outcomes.He discusses differences by class:JAK inhibitors typically show loss of benefit within days of discontinuationSome biologics (lebrikizumab, dupilumab, tralokinumab) may allow a significant proportion of responders to maintain stable disease for up to a year off therapyBefore stopping outright, he often also negotiates dose interval extension (eg, dupilumab every 3 weeks instead of every 2; tralokinumab every 4 weeks instead of every 2; lebrikizumab every 4 weeks or even every 8 weeks in selected responders instead of every 2) with his patients.Closing thoughtsDr Cotter closes by highlighting the advantage of today’s toolkit: the flexibility to mix and match systemic and nonsteroidal topical therapies. This allows clinicians to tailor care, maintain long-term control, and address breakthrough disease with precision and safety.Key takeawaysAD must be framed as a systemic inflammatory disease to guide patient acceptance of systemic therapyDisease severity assessment should incorporate quality of life, high-impact areas, and patient-reported burden, not just EASI or BSATopicals remain essential for priming treatment, supporting systemics, and managing breakthrough diseaseFor partial responders, evaluate adherence to topicals before modifying systemic therapySwitching options include biologic-to-biologic transitions, class switching, or moving to small molecules; existing head-to-head data can help guide choicesJAK inhibitors can serve as short-term rescue agents before returning to biologics for long-term maintenanceWhen patients want to stop therapy, consider interval extension before discontinuation and counsel on expected durability of response by therapeutic classCombining systemics with modern, nonsteroidal topicals allows individualized, long-term disease control https://dermsquared.com/videos/topical-conversations/switch-or-combine-treatments 579 2025-12-04T14:37:54.191Z yes https://dermsquared.com/videos/topical-conversations/strategies-to-address-disparities-in-skin-cancer-outcomes 2024-08-27T19:43:21.783Z https://image.mux.com/obM00MQI2QPPuiCLkSDjhuZOjaGA6Wz9xfC3qIWFELDk/thumbnail.jpg Strategies to Address Disparities in Skin Cancer Outcomes Disparities in skin cancer outcomes among different demographic groups remain a pressing issue in dermatology. These disparities are influenced by a variety of factors, including socioeconomic status, access to health care, and differences in the presentation of skin cancer across diverse skin tones. Dermatology professionals are tasked with addressing these inequities to ensure that every patient receives the highest quality care, regardless of their background. In this episode of Topical Conversations, Dr Aaron Farberg shares a quick-hitting tip that dermatologists can employ to combat these disparities. Treating every patient as a VIP Dr Farberg emphasizes a foundational principle that he learned during his residency: treating every patient as a VIP. This approach calls for a consistent standard of care that is applied to all patients, irrespective of their skin color, socioeconomic status, or other demographic factors. This mindset ensures that every patient receives the same level of attention, thoroughness, and care and helps to mitigate the unconscious biases that may influence how care is delivered, ensuring that all patients feel valued and respected. Strategies for dermatologists to address disparities Cultural competency and education: One of the most effective strategies for reducing disparities is improving cultural competency among dermatologists and health care providers. This involves understanding the unique challenges and concerns that patients from different demographic groups may face, particularly when it comes to skin cancer. For instance, skin cancer may present differently on darker skin, leading to potential delays in diagnosis. Continuous education on these differences and how to identify skin cancer across all skin types is crucial. Improving access to care: Disparities in outcomes are often exacerbated by limited access to dermatologic care, particularly in underserved communities. Dermatologists can work to improve access by participating in community outreach programs, offering teledermatology services, and advocating for policies that increase health care accessibility for all demographic groups. Patient education and empowerment: Educating patients about the importance of skin cancer screening and sun protection is vital, especially for those in demographic groups that may not be as aware of their risk. Dermatologists should take the time to educate their patients on self-examination techniques, the importance of regular dermatologic visits, and how to recognize early signs of skin cancer. Collaborative care models: Incorporating a collaborative care model that includes primary care providers, oncologists, and other specialists can help ensure that patients receive comprehensive care. By working together, health care professionals can address the multiple factors that contribute to disparities in skin cancer outcomes and create a more holistic approach to patient care. Reducing disparities in skin cancer outcomes is a multifaceted challenge that requires commitment from both individual dermatologists and the broader health care system. By treating every patient as a VIP and employing strategies to improve cultural competency, access to care, patient education, and collaboration, dermatologists can make significant strides toward equitable care. https://dermsquared.com/videos/topical-conversations/strategies-to-address-disparities-in-skin-cancer-outcomes 31 2024-08-27T19:43:21.774Z yes https://dermsquared.com/videos/topical-conversations/gpp-diverse-presentations 2025-04-01T13:58:21.628Z https://image.mux.com/em79l4TFHm87TRsg02gZ1DJjH1YvruwX9x00YDSHDIHcM/thumbnail.jpg GPP in Every Patient: Understanding Its Diverse Presentations for Better Treatment Outcomes In this episode of Topical Conversations, Ron Vender, MD, and Raj Chovatiya, MD, discuss the varied presentations of generalized pustular psoriasis (GPP) and the importance of early diagnosis and targeted treatment. They explore how GPP appears across different skin tones and levels of disease involvement and share insights for improving patient outcomes. Understanding GPP: beyond plaque psoriasis They begin by explaining that GPP is a distinct clinical entity from plaque psoriasis, presenting with widespread pustules, redness, and scaling rather than thick plaques and induration. While it can occur in patients with a history of psoriasis, it is not merely an extension of plaque disease. Dr. Chovatiya highlights that GPP is often misperceived as an extreme, acute condition, when many patients experience chronic, smoldering symptoms that may be misdiagnosed in nondermatology settings. Recognizing GPP across skin types GPP’s redness and pustules can look different across various skin tones. In lighter skin, erythema often appears bright red, while in darker skin, it may be more purple or brown, and pustules may look duskier rather than yellow-white. According to Drs Chovatiya and Vender, diagnosing GPP requires a careful clinical exam, a detailed patient history, and sometimes biopsy or bacterial swabs to rule out infection, though Dr Vender cautions not to wait for biopsy results to begin treatment. The importance of rapid diagnosis and treatment Drs Vender and Chovatiya emphasize that GPP is a potentially life-threatening condition with risks of sepsis, infection, and organ failure. Delaying treatment can have severe consequences, making early recognition and intervention critical. Spesolimab: a targeted approach to GPP Spesolimab, an IL-36 receptor antagonist, is the first treatment designed specifically for GPP. It is available in 2 formulations: Intravenous (IV) infusion for acute flares to quickly control pustulation Subcutaneous injection for long-term maintenance to help prevent flares Because GPP’s pathophysiology is IL-36 driven, spesolimab is not particularly effective for plaque psoriasis, reinforcing the need for accurate diagnosis and appropriate treatment selection. Dr. Vender emphasizes that educating patients about this targeted therapy can improve adherence and outcomes. By recognizing GPP’s diverse clinical presentations, diagnosing it early, and initiating appropriate treatment, dermatologists can significantly improve patient care and reduce disease burden. Key takeaways GPP is distinct from plaque psoriasis and requires a different diagnostic and treatment approach Smoldering GPP cases may be overlooked; taking a thorough patient history is critical GPP presents differently across skin tones—erythema may appear red, purple, or brown Early diagnosis and treatment are essential due to the risk of sepsis and organ failure Spesolimab is the first targeted therapy for GPP, available as an IV forumulation for acute flares and a subcutaneous formulation for maintenance https://dermsquared.com/videos/topical-conversations/gpp-diverse-presentations 644 2025-04-01T13:58:21.622Z yes https://dermsquared.com/videos/topical-conversations/considerations-for-dermatologists 2026-05-20T16:45:06.981Z https://image.mux.com/LBz00lowR6AYaunLTDdwPgkG500L355ENLIDzVamPM9hA/thumbnail.jpg Coordinating Care in the Transition to Mohs Surgery: Real-World Considerations for Dermatologists This video is sponsored by Sun Pharma. Its content is editorially independent of the sponsor. In this episode of Topical Conversations, Aaron Farberg, MD, joins George Monks, MD, to examine the clinical and logistical realities of transitioning patients from general dermatology to Mohs surgery. Their discussion highlights how evolving treatment options, referral timing, and multidisciplinary coordination influence decision-making, particularly when patients present with complex disease or are already receiving systemic therapy. The patient journey: from suspicion to surgical planningThe conversation begins with a practical overview of the typical pathway to Mohs surgery. After identifying a suspicious lesion, dermatologists confirm the diagnosis via biopsy and then guide patients through treatment options, including Mohs when appropriate.A central theme is expectation setting. Patients diagnosed with skin cancer often anticipate rapid surgical intervention; however, real-world scheduling constraints mean wait times of several weeks are common. In many cases of basal cell carcinoma (BCC), a delay of up to approximately 2 months may be clinically acceptable, while higher-risk tumors, such as certain squamous cell carcinomas or melanomas, require more urgent prioritization.Patients are encouraged to remain engaged during this interval, reporting any changes such as growth, bleeding, or pain. This ongoing communication can help dermatologists reassess urgency and facilitate expedited care when needed. Managing complexity: when and how to engage Mohs surgeonsFor borderline or complex cases, early collaboration with Mohs surgeons is emphasized. Prereferral discussions, which can be supported by clinical images and patient history, can help ensure appropriate patient selection and avoid delays associated with suboptimal referrals.This bidirectional communication is increasingly important as treatment decisions become more nuanced. In some cases, Mohs surgeons may refer patients back to dermatologists for consideration of systemic therapy prior to surgery, reinforcing the importance of shared decision-making across specialties. Expanding the toolbox: the role of systemic therapiesThe growing availability of systemic therapies, including immunotherapies and targeted agents, has broadened management strategies for advanced or high-risk skin cancers.Hedgehog inhibitors (HHIs), for example, have become an important option for advanced BCCs that may not be ideal candidates for immediate surgery or radiation. In select cases, systemic therapy may be used in a neoadjuvant approach to reduce tumor burden and improve surgical feasibility.This approach can also help address practical challenges such as surgical wait times. Initiating systemic therapy during this interval may allow for disease control while optimizing the timing and extent of surgery. However, these decisions require careful coordination and individualized assessment.Importantly, clinicians note that response to HHIs is often evident within the first 1 to 2 months, which can help guide ongoing management. In patients who respond well, continued therapy may be appropriate, while nonresponders may be redirected toward surgical management. Addressing clinical uncertainty: skip lesions and treatment timingThe discussion also addresses concerns around “skip lesions,” particularly in the context of preoperative systemic therapy. While discontinuous tumor spread is a theoretical consideration, both clinicians note that it is not commonly observed in their practices and is not a primary deterrent to systemic use.Greater concern is placed on delays in definitive treatment, which may increase the risk of tumor progression or spread. This reinforces the importance of timely referral and meticulous surgical technique, particularly in cases where tumor margins may be less predictable.Careful clinical assessment, including thorough inspection and adjunctive tools when appropriate, remains essential in these scenarios. Looking ahead: integrating new tools with established standardsWhile Mohs surgery remains a cornerstone of cutaneous oncology, the integration of systemic therapies is reshaping how dermatologists approach complex cases. This discussion highlights the importance of flexibility in treatment planning, balanced with a continued emphasis on evidence-based care and procedural precision.Above all, consistent and proactive communication remains central to optimizing patient outcomes in this evolving landscape. Key takeawaysMohs surgery pathways often involve wait times of several weeks; proactive expectation setting is essential for patient management Ongoing communication during the referral interval allows for reassessment of urgency and potential prioritization Early collaboration with Mohs surgeons can improve patient selection and streamline care in complex or borderline cases Systemic therapies, including HHIs and immunotherapies, are expanding options for advanced disease and may be used in select neoadjuvant scenarios Concerns about skip lesions exist, but appear less clinically significant than ensuring timely and definitive treatment Clear, direct communication among care team members remains a critical component of optimal patient outcomes https://dermsquared.com/videos/topical-conversations/considerations-for-dermatologists 995 2026-04-06T17:11:48.548Z yes https://dermsquared.com/videos/topical-conversations/treating-ad-early-impact-march 2025-01-30T20:55:47.707Z https://image.mux.com/tivezM8czb9XArPPJnimiv02tTDHsuF2jzx02Fkx48IEk/thumbnail.jpg Treating Atopic Dermatitis Early: Can We Impact the Atopic March? In this episode of Topical Conversations, Drs. James Q. Del Rosso and Lisa Swanson explore the concept of the atopic march and the critical importance of early intervention in atopic dermatitis (AD). They discuss strategies for addressing AD in young patients, the potential to prevent progression to other atopic comorbidities, and how to navigate conversations with parents about treatment options. Understanding the atopic march Dr Swanson highlights that atopic dermatitis often marks the starting point of the atopic march, a progression that can lead to other atopic conditions such as food allergies, asthma, and allergic rhinitis. While genetics lay the foundation, environmental factors, the skin and gut microbiomes, and skin barrier dysfunction can trigger the cascade of events that lead to AD and other atopic diseases. Recent studies suggest a connection between AD and food allergies, pointing to how a compromised skin barrier allows aerosolized food particles to interact with the immune system abnormally. The role of skin care in mitigating the atopic march Dr Del Rosso acknowledges that evidence is limited regarding whether early skin care can prevent the atopic march, but he strongly advocates for measures that protect and restore the skin barrier. He emphasizes controlling environmental exposures, reducing the use of fragranced products, and promoting the use of sensitive skin care products. Dr Swanson reinforces the importance of explaining the dual nature of AD to parents: Skin barrier dysfunction: The barrier is compromised, allowing irritants and allergens to penetrate Overactive immune response: The immune system overreacts to normal stimuli, driving inflammation By framing treatment as a 2-pronged approach—nurturing the skin barrier with appropriate products and calming inflammation with medications—Dr Swanson finds parents better understand the importance of adherence to the treatment plan. The potential of systemic therapies to alter the atopic march Both Dr Swanson and Dr Del Rosso discuss the emerging evidence supporting the use of systemic therapies, particularly dupilumab, in young patients with AD. Dupilumab, which targets type 2 inflammation, has demonstrated effectiveness in not only treating AD but potentially reducing the risk of other atopic conditions, including asthma and food allergies. Dr Swanson shares a case of a 6-month-old with moderate AD. After initially treating with topicals, she introduced the idea of dupilumab to the family, citing data suggesting its ability to reduce the impact of atopic comorbidities. While the initial treatment improved symptoms slightly, the family ultimately decided to proceed with dupilumab, with Dr Swanson emphasizing its potential long-term benefits. Dr Del Rosso agrees, referencing data that suggests dupilumab may lessen the severity of asthma or allergic sinusitis if used early. However, he notes the need for more robust long-term studies to confirm these findings. Navigating conversations with parents Introducing systemic treatments such as dupilumab to families can be challenging, particularly when injectables are perceived as more “severe” than topical or oral treatments. Dr Swanson advises a gradual approach: Plant the seed early: Introduce the concept of systemic treatment as a possibility, allowing families time to consider the option Address misconceptions: Explain the significance of treating AD thoroughly and the potential ramifications of delaying care Build trust: Begin with topical treatments where appropriate to establish a connection with the family, then revisit systemic options if necessary Dr Swanson notes her frustration with the minimization of AD’s impact, particularly by primary care providers who may suggest children will "outgrow" the condition. While this may be true in some cases, she emphasizes that appropriate management is critical to improving their quality of life and mitigating future risks. The unanswered question: how early should we intervene? One outstanding question is how early intervention must occur to have a meaningful impact on the atopic march. While some data on dupilumab and early skin care are encouraging, definitive answers have not been established. Dr Del Rosso acknowledges the difficulty in balancing the immediate concerns of parents with the long-term goals of preventing atopic comorbidities, given the lack of long-term studies. However, both he and Dr Swanson agree that early and aggressive management of AD is essential, even if the full extent of its benefits is not yet fully understood. Key takeaways Early intervention is crucial: Treating AD early, particularly in young patients with a family history of atopy, is key to mitigating the atopic march. Skin barrier care matters: Educating parents about the importance of maintaining the skin barrier with appropriate products is foundational. Consider systemic therapies: Dupilumab may reduce the burden of AD and potentially prevent or mitigate other atopic conditions Communication is key: Dermatologists must navigate conversations with parents to address misconceptions, build trust, and emphasize the importance of managing AD thoroughly https://dermsquared.com/videos/topical-conversations/treating-ad-early-impact-march 988 2025-01-30T20:55:47.700Z yes https://dermsquared.com/videos/topical-conversations/understanding-chronic-nature-gpp 2024-05-31T15:54:46.613Z https://image.mux.com/Sh01HLDm4iLjpXDiZCEQkFqnb4Xtkghrx7kVkrLkVUso/thumbnail.jpg Beyond the Flare: Understanding the Chronic Nature of GPP In this episode of Topical Conversations, Raj Chovatiya, MD, PhD, and Laura Ferris, MD, PhD, explore the complexities of generalized pustular psoriasis (GPP), highlighting its chronic nature and the challenges it poses for both patients and providers. They stress the importance of recognizing and treating GPP not just during acute flares but throughout its chronic course. Longitudinal disease activity and the patient-provider disconnect Dr Chovatiya emphasizes that while some patients with GPP may present for the first time in the hospital with severe flares requiring intensive care, many others experience longitudinal activity with symptoms that persist over time. These patients may have less severe manifestations, such as scaly or pustular lesions covering only a small percentage of their body surface area. There exists a disconnect between patients and HCPs, with patients often downplaying their chronic symptoms and HCPs underestimating the severity of the disease unless it presents in its most extreme form. Continuous management and between-flare challenges Dr Ferris echoes the sentiment that GPP is a chronic condition that requires continuous management. She emphasizes 2 key aspects of care: preventing flares and addressing the symptoms that persist between flares. Despite not reaching the severity seen during hospitalization, patients still endure discomfort and impairment in their day-to-day lives. However, historically there has been a lack of effective treatment options for managing these in-between symptoms. A comprehensive approach to GPP management Dr Chovatiya advocates for a comprehensive approach to managing GPP, consisting of 3 steps: treating acute flares, preventing future flares, and providing ongoing control to minimize disease activity over time. By adopting this strategy, the goal is to achieve long-term disease remission or low disease activity. He also suggests that GPP may be more prevalent than commonly thought, emphasizing the need for improved diagnostic accuracy and targeted therapies. Future directions Both physicians acknowledge the current limitations in accurately diagnosing and effectively treating GPP, particularly during periods of low disease activity. They advocate for the development of more targeted therapies that address the underlying mechanisms of the disease to better manage patients' symptoms and improve their quality of life. Ultimately, their discussion underscores the importance of recognizing GPP as a chronic condition that requires continuous monitoring and intervention to minimize its impact on patients. https://dermsquared.com/videos/topical-conversations/understanding-chronic-nature-gpp 211 2024-05-01T13:57:34.301Z yes https://dermsquared.com/videos/topical-conversations/vitiligo-skin-of-color-implications 2023-06-29T19:46:50.174Z https://image.mux.com/402hNDqmObZrIL2IabffTERUkbcxEbDXnmLpaV012qzAQ/thumbnail.jpg Vitiligo and Skin of Color Implications Vitiligo and Skin of Color Implications https://dermsquared.com/videos/topical-conversations/vitiligo-skin-of-color-implications 67 2023-06-29T19:46:50.169Z yes https://dermsquared.com/videos/topical-conversations/new-perspectives-on-chronic-pruritus 2024-07-24T21:06:25.110Z https://image.mux.com/krETOvIb5601WSxwOjZM8K00gisIlfi02ZLMmM1hKnl1Pw/thumbnail.jpg New Perspectives on Chronic Pruritus In this episode of Topical Conversations, Daniel Butler, MD, associate professor of dermatology at the University of Arizona College of Medicine, discusses his recent publication that reshapes the understanding of chronic pruritus.Historical neglect and new understandingThe impact of chronic pruritus has been underappreciated by the medical community. As a ubiquitous symptom that everyone experiences at times, the health care system has struggled to adapt to its more severe, chronic forms, leaving many patients without effective treatments for prolonged periods. Dr Butler reexamines the mechanisms of itch, significantly impacting the perception of chronic pruritus by recognizing the role of both the immune system and the nervous system.Moving beyond a singular entityHistorically, pruritus was viewed as a singular entity—find the right cause, and the symptom can be treated. However, Dr Butler explains that chronic pruritus may be more like a Venn diagram of contributing systems, including barrier dysfunction, immune dysfunction, and neuropathic or nerve dysfunction. This new understanding allows for a more comprehensive approach to treatment. Instead of seeking a singular cause, dermatologists can now consider how to combine treatments to address the various contributing factors. Advances in personalized treatmentsDr Butler explains that some treatments can target multiple systems simultaneously, like biologics that block IL-4 and IL-13 also profoundly impacting neuropathic itch, or tacrolimus, a classic topical treatment, not only controlling the immune response but also affecting neuropathic pathways, making it highly effective for pruritus. The scaffolding and schematic for understanding chronic pruritus are evolving, and by highlighting the unique pathophysiologic mechanisms involved, each with its own treatment targets, this evolution provides dermatologists with a diverse arsenal of treatments, ranging from topical to systemic, and from neuropathic to immune-based therapies.A more effective way to manage patientsDr Butler emphasizes that the most crucial takeaway from his publication is the recognition of chronic pruritus as its own distinct entity. Nearly 1% of all doctor's visits are for chronic pruritus, affecting a wide range of specialties, including primary care, gastroenterology, allergy, and even surgery. By rethinking chronic pruritus not as a singular or secondary disease, but as a complex mix of dysfunctional etiologies and considering various treatment tools that address different aspects of this condition, dermatologists can become more effective in managing these patients with more nuanced and effective strategies. https://dermsquared.com/videos/topical-conversations/new-perspectives-on-chronic-pruritus 373 2024-07-24T21:06:25.104Z yes https://dermsquared.com/videos/topical-conversations/leprosy-unmasked-dermatologic-review-world-leprosy-day 2024-01-29T18:49:43.232Z https://image.mux.com/TYmjftQdT1aqkair1FVKKYB902auppcBxSjWrWaMIwRc/thumbnail.jpg Leprosy Unmasked: A Dermatologic Review for World Leprosy Day In recognition of World Leprosy, join Charlie Dunn, MD, for this episode of Topical Conversations to hear a dermatologist’s overview of leprosy, shedding light on the progress made, emerging insights, and the vital role dermatologists play in recognizing, treating, and caring for patients affected by this rare disease. Reviewing the basics Leprosy, also known as Hansen's disease, is caused by the slow-growing mycobacterium leprae complex, which tends to involve the skin and peripheral nerves. The global health perspective Despite tremendous advancements in recognition and treatment, leprosy remains a significant global health concern. Annually, approximately 200,000 cases are diagnosed worldwide. The United States, while experiencing relatively low case counts, has seen a notable geographical incidence shift, particularly in the southeast. In 2020, more than one-fifth of cases were identified in Florida, with 80% of those cases occurring in eastern Florida. The reasons behind the increase in geographic incidences are not yet identified but may be related to a shift in disease transmission. Disease transmission Due to the slow-growing nature of the bacteria, transmission is not fully understood. Transmission of leprosy is historically linked to genetic susceptibility and prolonged exposure to someone with untreated disease via respiratory droplets. However, there are an increasing number of cases in the US where close contact cannot be established. In these cases, transmission is thought to occur either through prolonged travel within countries with high rates of the disease or through zoonotic exposure. Zoonotic exposure is thought to be key to the increased prevalence of leprosy in the southeastern United States particularly via nine-banded armadillos, which are known reservoirs for mycobacterium leprae strains known to infect humans. Clinical presentation Leprosy manifests in diverse ways, largely depending on the bacteria burden and the infected person’s immune response. Clinical manifestations can be considered across 2 ends of a spectrum. One end is tuberculoid leprosy, where there is a robust immune response to the disease. These patients tend to have a small number of well-demarcated patches or plaques that are lightly pigmented, may be red or rust-colored in the center, and have a degree of sensation abnormalities. Patients may also present with poor hair growth or abnormal sweating. On the other end is lepromatous leprosy, where there is no apparent resistance to mycobacterium leprae. Patients present with poorly demarcated, nodular lesions on all parts of the body. With nerve involvement, patients may present with numbness or tingling of the hands and feet, tender, enlarged peripheral nerves, and lumps or swelling of the earlobes or face. If these nerve findings progress, they can lead to hand and foot weakness, facial paralysis, loss of eyelashes or eyebrows, and leonine facies. Diagnosing leprosy Diagnosis is established via a skin biopsy, ideally from the leading edge of a lesion that demonstrates the bacterial within a cutaneous nerve. In tuberculoid, or paucibacillary, leprosy, this can be challenging; multiple biopsies may be needed, and diagnosis may need to be inferred from clinical or histopathologic clues. One vital aspect of diagnosis to remember is that leprosy is a reportable condition at both the state and federal level. The National Hansen’s Disease Program (NHDP), once notified, provides telemedicine visits and medications for patients and professional consultation for clinicians, all at no cost. Treating leprosyContrary to popular misconceptions, leprosy is highly treatable, with patients becoming noninfectious within days after starting antibiotics. Monthly directly observed therapy (DOT) is recommended by the NHDP, consisting of treatment with rifampin, moxifloxacin or ofloxacin, and minocycline. A key unique component to treating leprosy is screening all patients, at the time of diagnosis, regularly during treatment, and after treatment, for immunologic reactions. These reactions can result in severe nerve injury if not treated promptly. Addressing the stigma Leprosy continues to carry societal stigma. Dermatologists play a crucial role in dispelling misconceptions, advocating against stigma, and promoting awareness at both individual and community levels. Key points Increasing rates of leprosy have presented in the southeast US, particularly Florida, in recent years Transmission is linked to close contact and zoonotic exposure Diagnosis can be made via biopsy or inferred from clinical or histopathologic clues Leprosy must be reported at the state and federal levelsDirectly observed therapy with rifampin, moxifloxacin or ofloxacin, and minocycline is recommended Patients should be screened on an ongoing basis for immunologic reactions Dermatologists play a crucial role in dispelling stigmas around leprosy https://dermsquared.com/videos/topical-conversations/leprosy-unmasked-dermatologic-review-world-leprosy-day 421 2024-01-26T19:51:06.460Z yes https://dermsquared.com/videos/topical-conversations/bright-spots-1 2024-04-01T16:51:56.649Z https://image.mux.com/ePvJHehdwEWFZ01T2b1NN27316epT3x6Ntkqua01iBiOw/thumbnail.jpg Bright Spots: Tapinarof for Plaque Psoriasis of the Head and Neck Welcome to Topical Conversations: Bright Spots, an illuminating 3-part series shedding light on tapinarof, a pioneering nonsteroidal topical treatment for plaque psoriasis. In Part 1, Bright Spots host G. Michael Lewitt, MD, sits down with James Q Del Rosso, DO, to discuss the unique mechanism of action of tapinarof, its remittive effect, and results from the phase 4 open-label trial for treatment in the head and neck region. A unique mechanism of action Tapinarof is the first topical treatment of its kind, a naturally derived aryl hydrocarbon receptor (AhR) agonist. It binds to and activates AhR, which restores the skin barrier function by inducing expression of skin barrier proteins. It downregulates proinflammatory cytokines, including IL-17 and IL-22, with AhR playing an important role in maintaining skin homeostasis in an overzealous disease state like psoriasis. Duration of treatment and a remittive effect For patients on tapinarof, there is evidence that some may experience a remittive effect after stopping treatment. In the PSOARING 3 trial, a 40-week, open-label, long-term extension study, patients (n=73) who entered the trial with clear skin maintained clear or almost clear skin for around 4 months after stopping treatment. Of the patients who entered the trial with a PGA≥2 (n=519), 58.2% achieved PGA=0 or 1 at least once during the study. Head and neck phase 4 results In a phase 4 open-label trial focusing on the head and neck region, tapinarof demonstrated impressive efficacy. At Week 12, 88.5% of patients achieved a target lesion Physician Global Assessment (tPGA) score of 0 or 1 with a ≥2-grade improvement from baseline. Moreover, 80.8% achieved a tPGA score of 0 (clear) for the target plaque psoriasis lesion in the head and neck region, and 96.2% achieved PASI75 of the head and neck region at Week 12. The trial reported no new safety signals, with common adverse reactions being folliculitis, contact dermatitis, sinusitis, and seborrheic keratosis. Versatility and real-world impact A cosmetically elegant and well-tolerated therapeutic option, tapinarof shows promise as a versatile, nonsteroidal therapy for adults with mild, moderate, or severe psoriasis, specifically for the head and neck and intertriginous regions. With about 80% of patients with psoriasis experiencing scalp involvement, the efficacy demonstrated in these challenging areas highlights the significance of tapinarof in clinical practice.Check out Part 2 here to learn more about tapinarof's remittive effect and its impact on real-world clinical practice. https://dermsquared.com/videos/topical-conversations/bright-spots-1 491 2024-03-01T15:36:38.432Z yes https://dermsquared.com/videos/topical-conversations/part-3-value-of-support-groups-vitiligo 2024-06-25T13:36:23.333Z https://image.mux.com/9dc00y3RpqeDXobRKCmEWT7xVXINfHAoT00yg01KrePnag/thumbnail.jpg Part 3: The Value of Support Groups in Vitiligo Care Beyond the Clinic In this Topical Conversations special edition 4-part series, Richard Huggins, MD, dermatologist and member of the board of directors at the Global Vitiligo Foundation, is joined by Amaris Geisler, MD, Katie O’Connell, MS, and Tonja Johnson of the Beautifully Unblemished Vitiligo Support Group, to discuss their publication on the importance of vitiligo patient support groups and how these groups can provide value to both patients and providers. In Part 3, the conversation explores how support groups transform the patient experience and how these groups can support physician education and research needs. Personal rewards and inspirations Dr Huggins shares that participating in support groups has been one of the most rewarding experiences of his life. He acknowledges that patients with vitiligo often face self-consciousness and unwanted attention due to their visible condition, making participation in such groups transformative. Witnessing patients go from discomfort leaving their homes to embracing their condition and leading fulfilling lives can be inspirational both personally and professionally. Educational insights for providers From a physician's perspective, Dr Huggins emphasizes the educational value of support groups. With medical school and residency typically focusing on treatments and medications, support groups offer practical insights into managing vitiligo that are invaluable. For example, learning about cover-up techniques and addressing common misconceptions about vitiligo allows physicians to better care for their patients and provide informed counseling during clinic visits. Participating in support groups can also help physicians learn about and address patient misconceptions directly, such as the belief that vitiligo increases the risk of skin cancer or COVID-19. Support groups as research assets From a research standpoint, support groups are invaluable for providers who participate in clinical trials. They provide a concentrated pool of potential participants and offer insights and ideas that can inform research directions. Support group members play a crucial role in recruiting participants and shaping research priorities.For more on vitiligo support groups, check out Part 1 and Part 2 of this series.For practical guidance on navigating support groups, continue on to Part 4. https://dermsquared.com/videos/topical-conversations/part-3-value-of-support-groups-vitiligo 370 2024-06-24T19:56:04.115Z yes https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-new-and-emerging-therapies 2024-03-06T16:21:22.792Z https://image.mux.com/3qYr02GlFuLqBnpqaVK5mixm7FZRQWkZd59qJYI00apHs/thumbnail.jpg Rare Diseases in Dermatology: New and Emerging Therapies For Rare Disease Day on February 29, Topical Conversations will be exploring some of the rare diseases seen in dermatology. In this installment, James Q Del Rosso, DO, reviews some new and emerging therapies for congenital ichthyoses, epidermolysis bullosa, and facial angiofibromas related to tuberous sclerosis. Watch Part 1 to hear Dr Todd Schlesinger discuss subacute cutaneous lupus erythematosus and dermatomyositis.Watch Part 2 to hear Dr Naiem Issa discuss tuberous sclerosis complex and a breakthrough new treatment.An emerging therapy for congenital ichthyoses Dr Del Rosso begins by reviewing an emerging treatment for congenital ichthyoses, a group of rare genetic keratinization disorders that leads to dry, thickened, and scaling skin and requires lifelong management. The Phase 3 ASCEND study is currently underway and focusing on 2 moderate-to-severe subtypes, lamellar ichthyosis and X-linked ichthyosis, that affect about 80,000 individuals in the United States. The ASCEND study is investigating the efficacy and safety of a topical isotretinoin, TMB-001, in a patented special delivery system. A topical formulation of isotretinoin may help reduce systemic absorption, potentially allowing for chronic use over larger areas of the body and shows promise for those affected by congenital ichthyoses. A new approval for epidermolysis bullosa Dr Del Rosso also lauds a newly approved therapy for epidermolysis bullosa, a topical gel birch triterpenes for the treatment of partial thickness wounds in patients 6 months and older with junctional epidermolysis bullosa and dystrophic epidermolysis bullosa. As the first FDA-approved treatment for wounds associated with junctional epidermolysis bullosa, topical gel birch triterpenes is a promising development for patients facing daily challenges from open wounds, one of the most visible and difficult-to-manage symptoms of epidermolysis bullosa. A topical option for facial angiofibromas Another recent approval making progress for rare diseases in dermatology is a topical sirolimus gel for the treatment of facial angiofibromas associated with tuberous sclerosis. By inhibiting the mTOR pathway that leads to cellular proliferation, this therapy, approved for 6 years of age and older, is a significant step forward in managing cutaneous manifestations of tuberous sclerosis. https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-new-and-emerging-therapies 162 2024-02-28T16:16:18.136Z yes https://dermsquared.com/videos/topical-conversations/advances-atopic-dermatitis-2024-recap-2025-outlook 2024-12-16T21:41:55.617Z https://image.mux.com/DEuPDKXVBtWT8lAh49uROenINvlyVgRA14Hut4MW02yg/thumbnail.jpg Advances in Atopic Dermatitis: A 2024 Recap and 2025 Outlook In this year-end episode of Topical Conversations, Dr Peter Lio provides an insightful overview of the evolving landscape of atopic dermatitis (AD) treatments and trends to watch in 2025. With advancements in AD care beginning to close the gap with psoriasis, Dr Lio shares practical recommendations to help dermatologists prioritize areas for education and optimize patient care. Advancements in atopic dermatitis treatments: catching up with psoriasis Dr Lio notes that AD care is undergoing a significant evolution, with a wave of new treatment options raising the bar for patient outcomes. He explains how the expanding therapeutic toolbox challenges dermatologists to reevaluate whether current treatments are meeting patients' needs—and whether there’s room to do better. The rise of nonsteroidal topicals For decades, corticosteroids were the cornerstone of topical AD therapy. However, the introduction of nonsteroidal options has shifted the paradigm: Tacrolimus and pimecrolimus (approved in 2000–2001): These calcineurin inhibitors offered the first robust nonsteroidal options but are not suitable for everyone due to boxed warnings, stinging, and burning Crisaborole (2016): As the first PDE4 inhibitor approved for dermatologic use, it paved the way for this class but faced challenges with tolerability Topical ruxolitinib (2021): A JAK inhibitor, it is one of the most potent nonsteroidal options. While effective, its boxed warning requires cautious use, limiting application to less than 20% of body surface area and avoiding continuous treatment. Topical roflumilast (2024): Previously approved for psoriasis and expanding into AD in 2024, this once-daily PDE4 inhibitor offers ease of use and no boxed warning, making it ideal for proactive, long-term management Tapinarof (2024): Recently approved for AD, this aryl hydrocarbon receptor agonist shows promise for its potential remittive effect, allowing extended results even after treatment cessation. However, dermatologists must work toward defining remission and its distinction from cure. Biologics and systemic advances Dr Lio also reviews biologic therapies that are revolutionizing moderate-to-severe AD treatment, offering targeted solutions: Lebrikizumab (2024): Targeting IL-13, this biologic binds differently than existing IL-13 inhibitors, demonstrating high affinity and potentially enhancing patient outcomes Nemolizumab (2024): Approved for prurigo nodularis and now AD, it works via a novel pathway, further diversifying systemic options for dermatologists What 2025 holds for atopic dermatitis Dr Lio remarks that with a robust and diverse treatment toolbox, dermatologists are better equipped than ever to manage AD. This new era calls for: Shared decision-making: Engaging patients in treatment planning to align with their goals and preferences Stewardship of medications: Balancing efficacy, safety, cost, and access to deliver patient-centered care Innovative approaches: Exploring new treatment strategies, including acute care, long-term maintenance, and proactive management Dr Lio emphasizes that the wealth of new options allows dermatologists to offer renewed hope to patients who previously felt they had exhausted their choices. By leveraging this expanded toolbox, dermatologists can provide more effective, tailored care in 2025 and beyond, potentially helping patients achieve better outcomes and sustained symptom control. https://dermsquared.com/videos/topical-conversations/advances-atopic-dermatitis-2024-recap-2025-outlook 511 2024-12-16T21:41:55.609Z yes https://dermsquared.com/videos/topical-conversations/evaluating-benzene-concerns-in-benzoyl-peroxide-products 2024-08-02T13:32:23.612Z https://image.mux.com/896dczfr006uDtrqZn6AN7LcjhbwUzzrCxOwqkFFS4Dc/thumbnail.jpg Evaluating Benzene Concerns in Benzoyl Peroxide Products In this episode of Topical Conversations, John Barbieri, MD, MBA, FAAD, shares his updated thoughts on the Valisure report findings from March 2024, which identified potentially harmful levels of benzene in benzoyl peroxide-containing products, particularly those exposed to high temperatures. Call for transparency and FDA input Dr Barbieri expressed the medical community's need for more detailed information from Valisure and guidance from the FDA. He highlighted the importance of updated data to determine whether benzoyl peroxide products remain safe for consumer use. The lack of conclusive data has left health care professionals seeking clarity to make informed decisions for their patients. Approach to patient care In the absence of more comprehensive data from Valisure and definitive input from the FDA, Dr Barbieri shared his approach to managing the potential risks in clinical practice. He referenced 2 recent studies that provide some reassurance regarding the safety of benzoyl peroxide products: One study analyzing blood benzene levels demonstrated that individuals using benzoyl peroxide-containing products do not exhibit elevated benzene levels in their blood compared to nonusers. Another cohort study on cancer risk found no increased risk of leukemia, lymphoma, or other cancers among users of benzoyl peroxide products compared to those who do not use these products. Dr Barbieri found these results reassuring, indicating that routine use of benzoyl peroxide-containing products does not appear to pose the risks of cancer or elevated benzene levels that might be expected. Understanding benzene exposure risks Dr Barbieri explained the general principles of toxicology, noting that "the dose makes the poison." Benzene, a known carcinogen, is not significantly absorbed through the skin, making topical exposure unlikely to cause major risks such as skin cancer. He provided a comparative analysis of benzene exposure, explaining that even the worst-case scenario product tested by Valisure, with 10 parts per million of benzene, would result in about 10 micrograms of exposure from a typical 1-gram application. He compared this to the everyday benzene exposure from a gas stove, which emits about 5 micrograms of benzene per minute. This comparison suggests that the theoretical risk from benzoyl peroxide products is minimal compared to common everyday exposures. Practical advice and continued use in clinical practice Dr Barbieri continues to use benzoyl peroxide products in his practice. He advises patients to store these products properly and emphasizes the importance of considering the supply chain to minimize heat exposure during transit. Awaiting further guidance Dr Barbieri concluded by expressing a need for ongoing input from the FDA to provide clearer guidelines on the safety of benzoyl peroxide products. In the meantime, he believes that with appropriate storage and usage, these products can be used safely, supported by current data and practical considerations. https://dermsquared.com/videos/topical-conversations/evaluating-benzene-concerns-in-benzoyl-peroxide-products 200 2024-08-02T13:32:23.603Z yes https://dermsquared.com/videos/topical-conversations/new-approach-gpp 2025-08-01T14:49:08.902Z https://image.mux.com/N94T8jYx1slkWoCpm5TYdHTr00xH4jj3tgtgZ45gVrKw/thumbnail.jpg Exploring a New Approach to Generalized Pustular Psoriasis In this episode of Topical Conversations, Brad Glick, DO, and Erin Boh, MD, explore the evolving treatment landscape for generalized pustular psoriasis (GPP), with a focus on disease categorization, diagnostic challenges, and the role of spesolimab in managing both acute flares and chronic symptoms. Defining the spectrum of GPP Dr Boh categorizes GPP into 2 distinct clinical phenotypes: acute GPP, which often presents as a dermatologic emergency requiring immediate intervention, and chronic GPP, where patients exhibit persistent, low-grade symptoms punctuated by periodic flares. She emphasizes that understanding this distinction is critical for guiding treatment decisions. Compared to traditional plaque psoriasis, patients with chronic GPP often experience more prolonged flares and persistent systemic symptoms, necessitating tailored therapeutic strategies. Spesolimab: The only FDA-approved therapy for GPP Dr Glick outlines spesolimab’s approval as the first and only FDA-indicated treatment specifically for GPP. The intravenous (IV) formulation is approved for managing acute flares, and more recently, a subcutaneous (SC) formulation has been approved for use in patients between flares to address smoldering, chronic symptoms. Dr Boh explains her evolving approach to managing patients with chronic symptoms. Initially, she investigates potential flare triggers such as systemic steroids, infections, smoking, or other medications, and comorbidities like diabetes or cardiovascular disease for which patients may be receiving treatments from other providers. Historically, she used IV spesolimab for acute flares followed by maintenance with conventional biologics. However, with the SC formulation now available, she considers spesolimab monotherapy as a new maintenance option. Importantly, she stresses the need to distinguish between chronic plaque psoriasis with pustular features and true GPP, as the latter is more likely to benefit from spesolimab-based therapy. Pathophysiologic considerations and precision treatment Dr Boh discusses the evolving understanding of GPP's immunopathology. While IL-36 dysregulation is central, she notes overexpression of other cytokines such as IL-17 and IL-23 as well. This complexity raises questions about how patients may respond to IL-36 blockade alone versus requiring combination or sequential biologic therapy. Looking ahead, she sees potential for more personalized treatment approaches based on cytokine profiling. Chronic symptom burden and the role of maintenance therapy Dr Glick points out that, historically, no agent was specifically indicated for month-to-month stabilization in GPP. He highlights the unpredictable and often burdensome nature of flares compared to plaque psoriasis, making the new SC formulation of spesolimab a valuable addition for long-term control. Dr Boh adds that patients with GPP frequently report ongoing fatigue, pain, and emotional distress even after skin symptoms improve. She incorporates holistic strategies such as nutrition counseling, mindfulness, and therapy referrals into her care plans. She references findings from the Effisayil-2 trial, where continuous spesolimab treatment led to reductions in fatigue, pain, anxiety, and flare frequency, supporting a proactive treatment model over episodic flare-based management. Diagnostic challenges in GPP When patients present outside of a flare, diagnosing GPP can be difficult. Dr Glick asks how clinicians can differentiate GPP from other pustular presentations. Dr Boh explains that in acute settings, clinicians must rule out conditions like AGEP, drug reactions, steroid withdrawal, or infections. For more chronic or mixed presentations, such as plaque psoriasis with intermittent pustules, differentials include secondary infection, candida, vasculitis, or drug-induced eruptions. She distinguishes palmoplantar pustulosis as a separate entity within the pustular psoriasis spectrum. Ultimately, recognizing the degree and pattern of pustulation help guide diagnosis and treatment selection. An evolving practice model Dr Glick concludes by reiterating the clinical value of having both IV and SC formulations of spesolimab. The IV option offers rapid control during acute flares, while the SC formulation supports long-term maintenance. He highlights that in Effisayil-2, nearly half of the patients achieved complete skin clearance. With these new tools, dermatologists can now adopt a more structured and sustained approach to treating GPP, not only improving skin outcomes, but also enhancing overall quality of life for patients navigating this complex disease. Key takeaways Two distinct GPP phenotypes: Acute GPP requires immediate intervention, while chronic GPP involves ongoing low-grade symptoms and periodic flares, each requiring different therapeutic approaches Spesolimab for both acute and chronic GPP: IV spesolimab is approved for acute flares, and the SC formulation offers an option for maintenance therapy between flares Differentiating GPP from plaque psoriasis: Accurate diagnosis is essential, especially when pustular features overlap with other conditions. Misclassification may delay appropriate treatment. Precision medicine potential: While IL-36 plays a central role, other cytokines like IL-17 and IL-23 may also contribute to disease expression, raising the possibility of tailored biologic regimens Evolving treatment strategies: The availability of SC spesolimab has shifted management from flare-based intervention to continuous control, with some patients now managed with spesolimab monotherapy Quality-of-life impact: Chronic GPP symptoms extend beyond the skin. Fatigue, pain, and psychological distress persist even after flares resolve, supporting a holistic, proactive care model https://dermsquared.com/videos/topical-conversations/new-approach-gpp 1147 2025-08-01T14:48:22.034Z yes https://dermsquared.com/videos/topical-conversations/exploring-the-role-of-metformin-in-treating-ccca 2024-09-19T14:53:30.123Z https://image.mux.com/l02QrMXtn5Hy7kotLYgk9tnZpKAmF2TsBs00QLeQt1Fb4/thumbnail.jpg Exploring the Role of Metformin in Treating CCCA In this episode of Topical Conversations, Crystal Aguh, MD, Associate Professor of Dermatology at Johns Hopkins School of Medicine, shares insights from her study investigating the potential benefits of metformin for patients with central centrifugal cicatricial alopecia (CCCA), a scarring alopecia that predominantly affects Black women. Understanding CCCA as a profibrotic disease CCCA is a form of permanent scarring alopecia, and previous research led by Dr Aguh demonstrated that it shares similarities with other fibrotic conditions including idiopathic pulmonary fibrosis, systemic sclerosis, and uterine fibroids. Notably, women with CCCA are 5 times more likely to have uterine fibroids than Black women without the condition. Based on these findings, Dr Aguh and her team aimed to explore potential treatment options that could reverse scarring. Metformin as a potential treatment Metformin, an FDA-approved treatment for diabetes, has been studied for its role in managing other fibrotic conditions. Dr Aguh noted that her initial research on the gene expression landscape of CCCA revealed a decreased expression of PRKAA2, a gene partially encoding adenosine monophosphate kinase (AMPK), which is the primary target of metformin. This discovery prompted the team to investigate whether metformin could impact the progression of CCCA. Case series: topical metformin shows promise In an initial case series, Dr Aguh applied topical metformin to patients with CCCA. Some patients experienced hair regrowth, and building on these findings, Dr Aguh introduced oral metformin into the treatment plan for 12 women with CCCA, administering a low dose of 500 mg once daily. Molecular and clinical impact Among the 12 women studied, 4 provided scalp tissue samples for analysis before and after oral metformin treatment. Bulk RNA sequencing revealed a near-reversal of several profibrotic pathways previously identified as hallmarks of CCCA. Pathways related to fibrosis decreased, while keratin-associated proteins—critical for hair growth—increased significantly. Clinically, 6 of the 12 patients experienced visible hair regrowth after 6 months of oral metformin use. A pilot study with future potential While the results are promising, Dr Aguh emphasizes that this is a pilot study. Larger clinical trials are necessary to quantify the benefits of metformin for CCCA and other scarring alopecias. Metformin is generally considered a safe medication, with common side effects such as weight loss and stomach upset, though stomach upset is less common in the extended-release formulation used in this study. Dr Aguh notes that patients with preexisting kidney disease require monitoring due to the risk of lactic acidosis. To learn more about metformin as a potential novel treatment option for reversing scarring and promoting hair regrowth in CCCA, read Dr Aguh’s full article here. https://dermsquared.com/videos/topical-conversations/exploring-the-role-of-metformin-in-treating-ccca 353 2024-09-19T14:53:30.117Z yes https://dermsquared.com/videos/topical-conversations/empowering-patients-addressing-psychological-impact-vitiligo 2024-06-24T19:36:29.122Z https://image.mux.com/KPd02S1FRQXBSLz7FsrDVz1lYlqXfaCq3p7uijurmUSQ/thumbnail.jpg Empowering Patients: Addressing the Psychological Impact of Vitiligo In this episode of Topical Conversations, Dr Seemal R. Desai emphasizes the importance of addressing the psychological impact of vitiligo on patients during dermatology consultations. He begins by highlighting key questions to ask patients regarding their emotional well-being and social interactions related to their condition. Addressing emotional responses Dr Desai suggests asking patients about their feelings of depression and how vitiligo affects their daily lives, such as social interactions, intimate relationships, and self-image without makeup. These questions not only help in understanding the patient's emotional state but also contribute to building rapport and trust during the consultation. Normalization of the psychological burden He stresses the normalization of psychological burden, stating that there's no shame in feeling depressed or impacted by vitiligo, especially in communities where the condition carries significant stigma, such as communities of color and Southeast Asia. Acknowledging these feelings can empower patients to cope better with their condition. The benefits of support groups Dr Desai encourages patients to join vitiligo patient support groups, both locally and nationally, where they can connect with others facing similar challenges. He highlights the importance of platforms like VITFriends, active on social media and affiliated with the Global Vitiligo Foundation, as spaces for sharing experiences and struggles. World Vitiligo Day Finally, Dr. Desai advocates for World Vitiligo Day, which takes place every June and is organized by the Global Vitiligo Foundation. He encourages dermatologists to mark their calendars for this event, as it brings together patients, educators, researchers, and doctors to raise awareness and advance vitiligo research and support initiatives. https://dermsquared.com/videos/topical-conversations/empowering-patients-addressing-psychological-impact-vitiligo 102 2024-06-24T19:36:29.106Z yes https://dermsquared.com/videos/topical-conversations/updated-aad-guidelines-acne-vulgaris-summary-of-key-points 2024-03-06T16:20:34.275Z https://image.mux.com/c7hfkgl1YeIZpEcNkauE1LXv01IUvM11DRNu3pDvF9aU/thumbnail.jpg Updated AAD Guidelines for Acne Vulgaris: A Summary of Key Points In this episode of Topical Conversations, join John Barbieri, MD, MBA, FAAD as he summarizes some key points from the American Academy of Dermatology’s updated guidelines for the management of acne vulgaris. These evidence-based recommendations were last updated in 2016. Topical treatments Several new treatments have emerged since the prior guidelines were released, including the antiandrogen clascoterone, the first topical treatment that addresses the fundamental hormonal causes of acne. Clascoterone, which is safe for both men and women and approved for patients 12 years and older, received a conditional recommendation for use in the new guidelines. Clascoterone demonstrates a high certainty of benefits over risks; however, a conditional recommendation was issued due to the current high cost of treatment that may impact equitable access. Oral antibiotics Sarecycline Sarecycline, a narrow-spectrum tetracycline, received a conditional recommendation in the updated guidelines. Sarecycline, while effective at treating acne, can have a negative impact on the gut microbiome. As an oral antibiotic, it comes with the limitations and challenges of using antibiotics in the treatment of acne; however, it poses some theoretical advantages to other antibiotics currently in use for acne treatment. The high cost of sarecycline treatment was also a factor in issuing a conditional recommendation for this treatment. Doxycycline and minocycline Notably, doxycycline received a strong recommendation in the updated guidelines while minocycline received a conditional recommendation. The conditional recommendation is supported by the potential for side effects that are unique to minocycline, including severe cutaneous adverse reactions and vestibular dysfunction. Considering this, the guidelines recommend doxycycline over minocycline for the typical patient with acne. This represents a departure from current practice, where both drugs tend to be used equally. Trimethoprim-sulfamethoxazole The guidelines also discuss limiting the use of antibiotics like trimethoprim-sulfamethoxazole, as these can be associated with serious cutaneous adverse reactions and acute respiratory failure. Isotretinoin The guidelines also discuss the use of isotretinoin, one of the most effective treatments currently available for acne. The updated guidelines discuss recommendations for lab monitoring and notable adverse effects like inflammatory bowel disease and neuropsychiatric symptoms. Spironolactone The guidelines also detail recommended lab monitoring for spironolactone. For healthy patients who do not have other risk factors for hyperkalemia, the guidelines advise that routine potassium monitoring is likely a low-value practice. This determination may help clinicians feel more comfortable with patients who would prefer to pursue less lab monitoring while undergoing treatment for acne vulgaris. Key points Clascoterone and sarecycline received conditional recommendations for use in the updated guidelines, with high cost of treatment and potential impact on equitable access contributing to the recommendation Doxycycline received a strong recommendation Minocycline received a conditional recommendation supported by potential for adverse effects unique to minocycline Doxycycline is recommended over minocycline for the typical patient, representing a departure from current practice The guidelines recommend limiting the use of trimethoprim-sulfamethoxazole The guidelines advise that routine potassium monitoring for most patients on spironolactone is likely a low-value practice https://dermsquared.com/videos/topical-conversations/updated-aad-guidelines-acne-vulgaris-summary-of-key-points 202 2024-02-09T16:19:34.911Z yes https://dermsquared.com/videos/topical-conversations/exploring-triple-combination-therapy-acne-management 2024-06-05T21:33:35.196Z https://image.mux.com/EhSxrUNGPYXEg9ZM008SieGCcLsNTBTmp8WjwvLNXLaU/thumbnail.jpg Exploring a Triple-Combination Therapy for Acne Management In this episode of Topical Conversations, John Barbieri, MD, MBA, FAAD, gives an overview of a triple-combination topical therapy for acne comprising clindamycin, adapalene, and benzoyl peroxide, highlighting its efficacy, safety, and tolerability and how this formulation may impact patient adherence. Efficacy In phase 3 clinical trials, the success rates, as measured by the Investigator’s Global Assessment (IGA) of achieving clear or almost clear skin, were 50% for those using the treatment, compared to 20% for those using the vehicle. For context, most single-ingredient topical therapies show a delta of about 10% between the treatment and the vehicle. Fixed-dose combination treatments with 2 ingredients generally show a delta of around 20%. Therefore, the 30% delta observed with clindamycin/adapalene/benzoyl peroxide underscores its potential as a powerful option in acne therapy. Meta-analysis findings A meta-analysis that reviewed over 221 randomized controlled trials found that clindamycin/adapalene/benzoyl peroxide had the highest rates of effectiveness among all acne treatments evaluated. Earlier studies also demonstrated that this triple-combination therapy outperformed any of the dual-ingredient combinations. Tolerability and safety profile In addition to its efficacy, clindamycin/adapalene/benzoyl peroxide demonstrates a favorable tolerability profile. The phase 3 trials reported a discontinuation rate due to adverse effects of just 2.5%. For comparison, phase 3 studies of adapalene-benzoyl peroxide combinations reported discontinuation rates of about 2%, while tretinoin-benzoyl peroxide combinations had a rate of approximately 3.2%. The meta-analysis also indicated that this new treatment is relatively well-tolerated, on par with other topical retinoid or fixed-dose combination treatments. Implications for patient adherence This triple-combination therapy not only shows high efficacy and good tolerability but also has the potential to improve patient adherence. Studies have consistently shown that patients are more likely to adhere to fixed-dose combination products compared to using individual components separately. Improved adherence often leads to better outcomes in acne management, making this therapy a promising option for patients. https://dermsquared.com/videos/topical-conversations/exploring-triple-combination-therapy-acne-management 159 2024-06-05T21:33:35.188Z yes https://dermsquared.com/videos/topical-conversations/combination-therapy-for-vitiligo 2023-06-29T19:46:45.057Z https://image.mux.com/ex7dMd1t00Ss01OJUAX4HMX6DN7k00sHL8ZjO5BDeTj28Q/thumbnail.jpg Combination Therapy for Vitiligo Combination Therapy for Vitiligo https://dermsquared.com/videos/topical-conversations/combination-therapy-for-vitiligo 63 2023-06-29T19:46:45.052Z yes https://dermsquared.com/videos/topical-conversations/risk-not-replace-judgment 2026-06-11T15:07:21.816Z https://image.mux.com/LNPk02DSHkcThJTKrUhPOYKpNWDGJr3A9IpPfDR9t01wA/thumbnail.jpg Rethinking SLNB: Using GEP to Refine Risk, Not Replace Judgment Integrating GEP Testing Into Melanoma Management In this episode of Topical Conversations, Aaron Farberg, MD, and David Cotter, MD, PhD, discuss how gene expression profiling (GEP) is changing the landscape of melanoma management, particularly in guiding sentinel lymph node biopsy (SLNB) decisions. Highlighting new data from a prospective, multicenter study, they explore how the DecisionDx-Melanoma 31-GEP test helps reduce unnecessary SLNB procedures in patients with intermediate-risk melanoma, improving patient care and reducing health care costs. New Data to Guide SLNB Decision-Making Dr Farberg references the prospective analysis showing that integrating the 31-GEP test into clinical decision-making reduced unnecessary SLNBs by approximately 20% in patients with T1 to T2 melanomas. Notably, patients classified as low risk by the test who still underwent SLNB had no positive nodes, reinforcing the test’s reliability. Dr Cotter emphasizes that beyond cost savings, this approach minimizes patient anxiety and reduces the risks associated with unnecessary surgery. Playing the Odds: Balancing Risk and Patient Care Although up to 88% of SLNBs in patients with thin melanomas are negative, both experts stress that forgoing biopsies altogether would leave some patients at risk for undetected metastases. GEP testing provides an objective tool to help dermatologists identify the right patients for SLNB and subsequent imaging. Dr Cotter notes that for node-negative melanoma patients, melanoma-specific survival is approximately 85%, underscoring the need for vigilant follow-up in high-risk cases. Beyond SLNB: GEP for Postbiopsy Management Dr Farberg explains that the utility of GEP testing extends beyond initial biopsy decisions. For node-negative patients, GEP results can guide imaging protocols and ongoing surveillance. He adds that high-risk patients may benefit from additional imaging, such as computed tomography or ultrasound, to monitor for recurrence or metastasis. Augmenting Staging and Improving Specificity Rather than replacing traditional T staging, GEP testing enhances it. Dr Cotter explains that combining GEP results with standard staging maintains high positive and negative predictive values while improving specificity. This approach further reduces unnecessary SLNBs by approximately 20% to 30%. Accessible and Equitable Care Drs Farberg and Cotter also discuss the broader implications of GEP testing in improving access to quality care nationwide. GEP testing, which uses formalin-fixed, paraffin-embedded tissue samples, helps standardize melanoma care in both academic and community settings, including areas where access to SLNB or advanced oncology services may be limited. A Commitment to High-Quality Care In closing, both physicians affirm their commitment to using tools such as DecisionDx-Melanoma to provide the highest standard of care for melanoma patients, focusing on patient outcomes while leaving cost considerations to health care systems and payers. By integrating GEP testing into melanoma care pathways, dermatologists can refine SLNB decisions, personalize postbiopsy management, and reduce health care disparities across diverse patient populations. https://dermsquared.com/videos/topical-conversations/risk-not-replace-judgment 876 2025-03-20T17:51:34.559Z yes https://dermsquared.com/videos/topical-conversations/bright-spots-3 2024-05-01T13:46:28.836Z https://image.mux.com/eVjZEdaObjcrN801E2wsiqmjiZNN5q400UQFqwU5WadH4/thumbnail.jpg Bright Spots: Tapinarof and the Evolving Nonsteroidal Landscape for Psoriasis Welcome to Topical Conversations: Bright Spots, an illuminating 3-part series shedding light on tapinarof, a pioneering nonsteroidal topical treatment for plaque psoriasis. In Part 3, G Michael Lewitt, MD, is joined by Neal Bhatia, MD, to discuss the evolving landscape of psoriasis treatment, particularly the role of nonsteroidal therapies like tapinarof. Paradigm shift: embracing nonsteroidal therapies They begin by highlighting the significant paradigm shift towards nonsteroidal options in psoriasis treatment in recent years. Previously, alternatives to steroids were limited to calcineurin inhibitors. However, with the advent of nonsteroidal molecules, dermatologists now have access to treatments that offer rapid anti-inflammatory action, improved delivery mechanisms, and strong safety profiles. These alternatives provide patients with long-term solutions without the concerns of steroid atrophy or risks associated with facial application, marking them a welcomed advancement in dermatologic care. The continued relevance of topicals Despite the proliferation of small molecules and biologics for psoriatic disease, topicals remain a viable option in many scenarios. Dr Bhatia emphasizes the foundational role of topicals in dermatologic practice, rooted in the principle of working both outside in and inside out. Patients sometimes prefer topicals for their hands-on approach to managing trouble areas, and the trend toward creams and foams reflects a desire for tolerable formulations that offer once-daily application. While topical steroids continue to hold a place for their rapid efficacy, the emergence of new molecules offers a promising alternative for long-term management without the adverse effects associated with prolonged steroid use. The evolving landscape of psoriasis treatment There remains an enduring popularity of topical steroids among prescribers. While these medications continue to play a significant role in dermatologic care, there's a growing recognition of the limitations and potential risks associated with prolonged use. Topical steroids can be rapidly efficacious in extinguishing inflammatory flares, providing a "sprint effect" in managing skin conditions. However, frequent prescription and refill practices can inadvertently contribute to overuse and dependency, leading to adverse effects such as tachyphylaxis and straie. To address these concerns, dermatologists are increasingly exploring alternative treatment options that offer sustained benefits without the drawbacks associated with steroids. New molecules, such as tapinarof cream, are emerging as promising alternatives due to their reliable long-term efficacy, reduced risk of adverse effects, and patient-friendly formulation. Tapinarof: a small molecule topical therapeutic with a patient-friendly formulation Dr Bhatia further discusses tapinarof, an aryl hydrocarbon receptor agonist with a unique vehicle that distinguishes it from traditional formulations. Tapinarof's spreadability and nongreasy texture make it well-suited for application on hair-bearing areas, scalp, and intertriginous regions, addressing patient concerns about discomfort and visibility. Tailored treatment approaches: harnessing tapinarof's versatility Tapinarof's versatility extends to its application in challenging areas such as the scalp and intertriginous regions. Dr Bhatia discusses the transformative impact of tapinarof in these areas, offering patients greater control and efficacy in managing their psoriatic disease. Whether used as monotherapy or in conjunction with biologics, tapinarof presents a valuable addition to the psoriasis treatment armamentarium. Missed Parts 1 and 2? Watch Part 1 to learn about tapinarof's mechanism of action and the phase 4 results from the open-label trial for treatment in the head and neck region. Watch Part 2 to learn more about tapinarof's remittive effect and its impact on real-world clinical practice. https://dermsquared.com/videos/topical-conversations/bright-spots-3 549 2024-05-01T13:46:28.830Z yes https://dermsquared.com/videos/topical-conversations/gpp-plaque-psoriasis-differences 2025-06-02T19:27:38.821Z https://image.mux.com/01AE7AqgYmo48IYIKYdMiHEuZKTWA2IzIKojyNQD019l8/thumbnail.jpg GPP vs Plaque Psoriasis: Recognizing the Differences That Matter Two Psoriasis Variants, Two Very Different Diseases In this episode of Topical Conversations, Jason Hawkes, MD, and Tina Bhutani, MD, discuss how generalized pustular psoriasis (GPP) differs from plaque psoriasis in presentation, immunopathogenesis, and treatment. With the emergence of targeted therapies, distinguishing between these conditions is more important than ever for effective management. Clinical Presentation: Sudden Flares vs Chronic Plaques Plaque psoriasis typically follows a chronic course, with well-demarcated plaques on the scalp, elbows, and knees. GPP, by contrast, is marked by abrupt flares of monomorphic pustules on an erythematous base. These flares may be episodic, severe, and unpredictable—sometimes occurring years apart—and are often mistaken for plaque flares or infections. Dr Bhutani emphasizes the importance of recognizing GPP early, particularly when it coexists with background plaque psoriasis. Immunology and Genetics: IL-23 vs IL-36 Dr Hawkes highlights the distinct immune pathways driving each disease. Plaque psoriasis is driven largely by IL-23 and IL-17 signaling, with T cells playing a central role. GPP, however, is primarily mediated by innate immune mechanisms, including overproduction of IL-36 by keratinocytes. In some patients, mutations in the IL-36 receptor antagonist (IL36RN) gene further amplify this response. These differences in immunology and genetics reinforce the need for tailored therapeutic strategies. Diagnosis and Initial Management Prompt recognition and stabilization are key when managing GPP. Dr Bhutani advises ruling out infection and allergic reactions but stresses that treatment should not be delayed for biopsy results. Dr Hawkes adds that clinical history and physical findings—particularly the presence of sterile pustules and systemic symptoms—can strongly support a diagnosis of GPP. Laboratory tests may assist with assessing organ function or ruling out sepsis, but immediate therapy is often warranted. Targeted Therapy and Clinical Impact In the past, GPP was treated with systemic immunosuppressants like cyclosporine or methotrexate, which carried significant risks. Today, therapies targeting IL-36 offer faster and safer relief. Dr Bhutani underscores the dramatic improvement in outcomes for patients receiving these treatments, noting that they not only control flares but also reduce long-term disease burden and improve quality of life. Improving Quality of Life Through Timely Care GPP’s unpredictability can severely impact patients’ physical, emotional, and social well-being. Both physicians agree that faster diagnosis, patient education, and early use of targeted treatments are essential. For many patients, these interventions can prevent hospitalization and even save lives. Key Takeaways GPP and plaque psoriasis are distinct conditions with different presentations, immune drivers, and treatment needs. GPP is characterized by episodic, severe pustular flares and systemic symptoms, with a risk of organ failure and mortality. IL-36 plays a central role in GPP pathogenesis, and targeted therapies now offer rapid, effective control. Diagnosis should not be delayed for biopsy results; early recognition and stabilization are critical. Treating GPP promptly and appropriately improves both outcomes and patient quality of life. https://dermsquared.com/videos/topical-conversations/gpp-plaque-psoriasis-differences 706 2025-06-02T19:27:38.814Z yes https://dermsquared.com/videos/topical-conversations/predicting-biologic-response 2026-05-20T16:43:15.802Z https://image.mux.com/jWuRp88k5E199MMSpi02jO00CaUJq200DWwve00N433vWus/thumbnail.jpg The Next Step in Psoriasis Care: Predicting Biologic Response In this episode of Topical Conversations, Tina Bhutani, MD, and Adrian Rodriguez, MD, discuss the growing role of precision medicine in psoriasis management and how predictive testing may help guide biologic selection earlier in the treatment journey. With an expanding range of biologic therapies available for psoriasis, clinicians now have more therapeutic flexibility than ever before. However, as Dr Bhutani notes, one of the persistent challenges in practice is determining which patient is most likely to respond to which therapy before treatment is initiated. The discussion centers on Mind.Px, a predictive test that uses a dermal biomarker patch to help identify the likelihood of response to biologic classes including TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Moving toward precision medicine in psoriasisDr Rodriguez frames Mind.Px within the broader evolution of precision medicine across medicine, noting that while other specialties have increasingly incorporated predictive tools into treatment decision-making, dermatology has historically lacked similar guidance for psoriasis biologic selection. He describes the test as a practical tool to help clinicians identify which biologic class may be the best fit for an individual patient, potentially reducing the need for therapeutic switching and minimizing delays associated with insurance approvals and treatment interruptions. They emphasize that this type of approach may be particularly valuable given the growing number of available biologics and the reality that not every therapy will be effective for every patient.Supporting patient confidence and treatment buy-inBeyond biologic selection itself, the conversation highlights how predictive testing may influence patient engagement and confidence in treatment decisions.Dr Bhutani shares that she often finds the test useful in patients who are hesitant to initiate biologic therapy, including individuals with needlephobia or concerns about long-term treatment commitment. Presenting patients with data suggesting a higher likelihood of response may help reinforce confidence in the treatment plan. Dr Rodriguez discusses a patient case involving a needlephobic frequent traveler who was concerned about treatment selection and dosing logistics. In that scenario, the test supported selection of an IL-23 inhibitor, which aligned both with predicted response and the patient’s lifestyle needs due to its dosing schedule. The speakers also note that the report format itself is intentionally straightforward, categorizing biologic classes as likely responder (R) or nonresponder (NR), making interpretation relatively simple for both clinicians and patients. Applications in biologic-experienced patientsThe conversation also explores how predictive testing may be useful in biologic-experienced patients, particularly in situations involving loss of coverage, waning efficacy, or declining patient confidence after prior treatment challenges. Dr Rodriguez notes that the test can help rebuild patient confidence when prior therapeutic choices have not produced satisfactory outcomes. Similarly, Dr Bhutani explains that she often finds the test especially valuable in experienced patients because she wants to avoid another unsuccessful treatment selection that could further reduce patient engagement. Operational and access considerationsThe discussion next shifts to practical considerations surrounding biologic access and office workflow.Dr Rodriguez highlights the administrative burden associated with biologic switching, including repeat prior authorizations, reassessments, and additional staff workload. Selecting the most appropriate therapy earlier in the process may help reduce some of these operational challenges while also potentially lowering costs associated with cycling through multiple biologics. From a workflow standpoint, Dr Rodriguez notes that implementation in clinic has been relatively streamlined. The test involves application of a dermal patch for several minutes, with a kit provided for return shipment and relatively quick turnaround times. Limitations and future directionsThe speakers also discuss several limitations of the current test.One limitation is the binary responder/nonresponder output. If a patient is predicted to respond to multiple biologic classes, the report does not currently rank therapies or indicate which option may provide the strongest response. Dr Rodriguez also notes that current response categorizations were based on PASI75 thresholds, whereas many clinicians now aim for PASI90-level outcomes in practice. He points to ongoing work evaluating PASI90 data as an important future development. Dr Bhutani further explains that earlier studies suggested stronger predictive performance in patients with more severe disease, although ongoing real-world analyses are evaluating performance in patients with lower disease severity. This may become increasingly relevant as dermatologists consider earlier biologic intervention for patients with lower BSA involvement but high-impact disease in special sites such as the scalp, hands, feet, and genital regions. Key takeawaysPredictive testing may help support biologic selection in psoriasis by identifying likely responders and nonresponders across biologic classes Mind.Px uses a dermal biomarker patch and provides a simplified responder/nonresponder report format for TNF, IL-17, and IL-23 inhibitor categories There are potential benefits for both biologic-naïve and biologic-experienced patients, including improved patient confidence and reduced therapeutic switching Practical advantages may include reduced administrative burden associated with repeated prior authorizations and treatment changes Current limitations include lack of ranked therapeutic recommendations and reliance on PASI75-based response thresholds Ongoing research is evaluating predictive performance in lower-severity psoriasis and incorporating PASI90-level outcomes into future analyses https://dermsquared.com/videos/topical-conversations/predicting-biologic-response 847 2026-05-20T16:25:05.880Z yes https://dermsquared.com/videos/topical-conversations/advancements-in-vitiligo-2024-and-beyond 2024-03-13T19:36:19.063Z https://image.mux.com/xXjaNrCjdD4RriIxJko8hHBZnkwGqprDxlpnteUU4o8/thumbnail.jpg Advancements in Vitiligo: 2024 and Beyond Advancements in Vitiligo: 2024 and BeyondVitiligo has long been a challenging condition to manage effectively. However, recent years have seen significant strides in understanding and treating this condition. In this Topical Conversations segment, Seemal Desai, MD, FAAD, shares his excitement about the evolving landscape of vitiligo treatment.Innovations in management and treatment of vitiligoOver the past several years, there have been notable innovations in the management and treatment of vitiligo. One of the most significant milestones was the introduction of the first FDA-approved therapy for repigmenting vitiligo, topical ruxolitinib 1.5% cream. Topical ruxolitinib 1.5% cream is currently the only FDA-approved treatment for nonsegmental vitiligo repigmentation. In the TRuE-V1 and TRuE-V2 trials of ruxolitinib cream 1.5%, nearly 1 in 3 patients achieved at least 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI75) and 24 weeks. Also at 24 weeks, ~15% of patients achieved complete or nearly complete repigmentation in F-VASI (F-VASI90).Emerging research on oral therapeutics for vitiligoLooking ahead to 2024 and beyond, Dr Desai anticipates the emergence of new data on oral JAK inhibitors for vitiligo. While topical treatments have shown promise, oral JAK inhibitors present a new frontier in vitiligo treatment. Among these, oral upadacitinib has shown promising results in recent studies. Additionally, research is underway on oral povorcitinib and other oral therapeutics, offering potential benefits beyond repigmentation.UpadacitinibAt week 24 of a 52-week, Phase 2b multicenter, randomized, double-blind, placebo-controlled study evaluating upadacitinib in adults with nonsegmental vitiligo, upadacitinib met the primary endpoint of percent change from baseline in F-VASI with 11-mg and 22-mg doses versus placebo in adults with nonsegmental vitiligo.At week 52, the percent reduction from baseline in F-VASI was numerically greater than results at week 24 for all upadacitinib doses.The safety profile was consistent with the known safety profile for upadacitinib.PovorcitinibIn a Phase 2b randomized, double-blind, placebo-controlled, dose-ranging clinical trial evaluating the safety and efficacy of povorcitinib, an oral small-molecule JAK1 inhibitor, results showed that treatment for adult patients with extensive nonsegmental vitiligo was associated with substantial total body and facial repigmentation at Week 52.Povorcitinib was well tolerated at all doses and also shows evidence of potential durability of response following treatment discontinuation, with 32 patients who completed the follow-up period through Week 76 maintaining total body and facial repigmentation.Future prospectsThe landscape of vitiligo treatment is rapidly evolving, with exciting developments on the horizon for 2024 and beyond. From the introduction of FDA-approved topical therapies to the emergence of oral JAK inhibitors for vitiligo, dermatology is witnessing unprecedented progress in the management of this challenging condition. https://dermsquared.com/videos/topical-conversations/advancements-in-vitiligo-2024-and-beyond 43 2024-03-13T19:34:30.711Z yes https://dermsquared.com/videos/topical-conversations/guidance-early-career-contracts-career 2024-11-21T22:49:48.067Z https://image.mux.com/rGz1gs8Hy6iYxOj2z01xKpR2rtLMZO2Iz3oaFx01CkDh4/thumbnail.jpg Practical Guidance for Early-Career Dermatologists: Navigating Contracts and Career Choices Thank you to Sun Pharmaceutical Industries Ltd. for sponsorship of this resource.In this episode of Topical Conversations, Brent Bargen, Vice President of Business Development at myDermRecruiter, the leading dermatology recruitment firm in the United States, joins Jaimie Rodger, DO, a dermatologist with extensive experience in diverse practice settings. Having navigated numerous contract negotiations throughout her career, Dr Rodger provides invaluable insights for early-career dermatologists embarking on their job search. As you begin your career in dermatology, there are 4 key factors to consider in your job search: geographic location, practice setting, cultural fit, and contract details. Geographic location Choosing where to live is foundational. Prioritize regions where you have a support system and will be happy outside of work. Being content in your location can directly impact your job satisfaction and career growth. Practice setting Dermatologists have various practice environments to choose from: private practice, hospital systems, multispecialty groups, academic settings, private equity-backed practices, and others. Each comes with its own pros and cons. Reflect on your personality and preferences. For example, those who thrive in large teams may prefer bigger practices with managerial support, while others may enjoy smaller, more independent settings. Cultural fit A high-paying offer may be tempting, but it’s crucial to find a workplace that aligns with your long-term goals and values. Look for an environment that fosters your professional development. Contract details and compensation Contract negotiation is a critical step. Understand compensation structures—particularly regional variations and the impact of collections-based pay models. Make sure to fully grasp benefits such as time-off policies, CME allowances, and tail coverage. Compensation isn’t just about salary; factors like patient population, insurance reimbursement rates, and practice resources also play a role. When evaluating offers, take time to review all clauses, especially around termination and non-compete agreements, to ensure you are protected should anything go awry. Starting early allows ample time for negotiation without feeling pressured into a decision. Final tips Engage with recruiters, network with peers, and use resources like the AAD or online forums to explore job opportunities. Start your search early and keep an open mind across various practice settings to find the best fit for your career. If you are currently looking for your next career move, explore the Dermsquared job board, powered by myDermRecruiter. This platform provides access to top dermatology opportunities nationwide, connecting you with the right positions to fit your professional goals. https://dermsquared.com/videos/topical-conversations/guidance-early-career-contracts-career 772 2024-09-26T17:15:30.568Z yes https://dermsquared.com/videos/topical-conversations/addressing-touch-starvation-strategies-for-improving-patient-well-being 2024-08-14T18:12:47.912Z https://image.mux.com/PPJH02Yv02t52W004kq4v89RFBCA9Y02d60021jiYp00nohiQ/thumbnail.jpg Addressing Touch Starvation: Strategies for Improving Patient Well-Being In this episode of Topical Conversations, dermatologists Nicholas Brownstone, MD, and Alexandra K. Golant, MD, address the critical yet often overlooked issue of touch starvation, particularly affecting patients with inflammatory skin conditions. This discussion highlights how touch starvation impacts patients' overall quality of life and offers practical advice for clinicians on how to address this issue. Understanding touch starvation Touch starvation, in the context of dermatology, is a multifaceted issue with significant implications for patients with inflammatory skin diseases. From a clinical perspective, touch starvation can manifest as patients feeling isolated and less engaged with their health care providers. This reduced interaction may hinder providers from fully assessing the severity of the disease and its impact on the patient’s quality of life. Consequently, patients may suffer silently, experiencing challenges that health care providers may not fully appreciate. Another dimension of touch starvation involves the social and emotional isolation that often accompanies inflammatory skin conditions. This isolation can lead to various negative outcomes, such as mental health issues, social anxiety, and withdrawal from daily activities. Addressing these concerns is crucial for improving the overall well-being of patients and ensuring that clinicians are more attuned to the broader impacts of these conditions. Impact of touch starvation on quality of life Touch starvation significantly affects the quality of life for patients with conditions like psoriasis and atopic dermatitis. Patients may experience a substantial burden, which is often underreported. If clinicians do not actively inquire about quality of life, they may miss crucial insights into how the disease affects the patient's mental health, self-esteem, and interpersonal relationships. Many patients are not proactive in discussing their emotional distress or the extent to which their condition impacts their lives. Therefore, it is essential for health care providers to proactively assess quality of life to better understand the severity of the disease and adjust treatment plans accordingly. Inadequate recognition of touch starvation can lead to undertreatment, leaving patients with a diminished quality of life. Identifying touch starvation in patients To effectively identify touch starvation and its impact on patients, clinicians can adopt several strategies: Frequent follow-ups: It is important to schedule more frequent visits for patients who appear to be struggling or whose condition may be worsening. Shorter follow-ups can help ensure that providers stay updated on the patient’s condition and make timely adjustments to treatment. Intentional dialogue: During clinic visits, take the time to engage in meaningful conversations about the patient’s quality of life. Ask specific questions about how their disease affects their daily activities, sleep, and overall well-being. Open-ended questions, such as “What activities are you unable to do because of your condition?” can provide valuable insights. Holistic care: Regular follow-ups are crucial for identifying mental health strain or comorbidities that may not be immediately apparent. A comprehensive approach to patient care can reveal underlying issues that need to be addressed alongside the primary skin condition. Supporting patients with low self-esteem and poor body image For patients experiencing low self-esteem or poor body image due to their disease, several strategies can help: Access to advanced therapies: The advent of new treatments has provided hope for many patients. Informing patients about advanced therapeutics can offer them a sense of optimism and encourage them to engage more actively in their treatment plan. Support groups: Connecting patients with support groups, either through national organizations like the National Psoriasis Foundation or the National Eczema Association or through local and online communities, can provide valuable social support. These groups offer a space for patients to share experiences and find encouragement from others facing similar challenges. Interdisciplinary team: Leveraging an interdisciplinary approach, including mental health professionals and primary care providers, can address the holistic needs of patients. This team-based care model ensures that patients receive comprehensive support, addressing both their physical and emotional health. Touch starvation is a significant issue for patients with inflammatory skin diseases, impacting their quality of life and overall well-being. By understanding and addressing this issue, clinicians can improve patient care and outcomes. Regular follow-ups, intentional dialogue, and access to advanced treatments and support resources are essential for effectively managing touch starvation and enhancing the quality of life for these patients. For more resources, the National Psoriasis Foundation and the National Eczema Association offer valuable support and information for both patients and providers. https://dermsquared.com/videos/topical-conversations/addressing-touch-starvation-strategies-for-improving-patient-well-being 335 2024-08-14T18:12:47.903Z yes https://dermsquared.com/videos/topical-conversations/expanding-treatment-ak-tirbanibulin 2025-10-20T22:30:29.485Z https://image.mux.com/avqB0202VfR8KfHlYrSxBt6DrD6Andhb2YE5lCkNWBtzI/thumbnail.jpg Expanding Treatment Options for Actinic Keratosis: Tirbanibulin In this episode of Topical Conversations, Neal Bhatia, MD, and Naiem Issa, MD, discuss the use of tirbanibulin (Klisyri) for actinic keratosis (AK), including its expanded indication for broader application areas. The FDA’s expanded approval in June 2024 allows tirbanibulin to be used over surface areas up to 100 cm², offering dermatologists a more versatile approach to treating larger areas on the face or scalp. FDA approval for larger surface area treatment Initially approved in 2020 for application on small areas up to 25 cm², tirbanibulin's expanded indication provides flexibility for dermatologists managing AK. With 2 packaging sizes—a 250-mg dose for up to 25 cm² and a new 350-mg package for up to 100 cm²—clinicians can select the appropriate dose to treat larger surface areas effectively. A practical application technique: the “windshield wiper” approach To maximize coverage and effectiveness, Dr Bhatia recommends a straightforward method he calls the “windshield wiper” approach, instructing patients to apply tirbanibulin from temple to temple, across the forehead, and including the nose and ears. This application technique ensures comprehensive treatment over larger areas, essential for patients with diffuse AK. Mechanism of action: apoptosis vs necrosis One of the unique aspects of tirbanibulin is its apoptotic mechanism, which selectively induces cell death in abnormal cells, sparing surrounding healthy tissue. Unlike traditional AK treatments that cause necrosis and associated discomfort, tirbanibulin’s pathway results in fewer inflammatory skin reactions. This distinction makes it an attractive option for dermatologists looking to offer a gentler but effective alternative to patients with AK, who often experience visible irritation with standard therapies. A sequential approach to AK treatment Dr Bhatia shared his protocol for AK management, combining multiple therapeutic approaches to target both visible lesions and subclinical precursors. His approach involves initially using cryotherapy to address active lesions, followed by a course of tirbanibulin after one to 2 weeks, and potentially incorporating photodynamic therapy (PDT) within a few months. This holistic strategy can help provide comprehensive control over AK, addressing both current lesions and preexisting, yet undetectable, cells. For dermatologists without access to PDT, Dr Issa recommends a segmented approach. He suggests starting with one facial area (eg, temple-to-temple) and then evaluating results after 3 to 4 months. Patients can then treat additional sections over time, minimizing the burden of treating an entire facial area at once. Patient counseling and setting realistic expectations Setting expectations is crucial for successful tirbanibulin treatment. Dr Bhatia encourages dermatologists to advise patients that tirbanibulin’s effects are generally noticeable around days 8 to 15. To help patients understand the process, he likens the experience to a slightly turbulent flight that ultimately results in a smooth landing. Patients often appreciate tirbanibulin’s 5-day treatment protocol, especially when compared to longer regimens required by other AK treatments such as diclofenac or imiquimod. This shorter treatment period increases adherence and may reduce the need for frequent follow-up appointments. Ongoing maintenance: encouraging long-term care for AK Both Dr Issa and Dr Bhatia emphasized the importance of educating patients on the need for periodic AK maintenance. Dr Issa noted that encouraging patients to treat one facial area, then reassessing after several months, fosters a consistent approach to ongoing AK care. Key benefits of tirbanibulin for dermatologists and patients With its unique apoptotic mechanism, flexible dosing options, and shorter treatment duration, tirbanibulin has emerged as a valuable addition to the AK treatment landscape. Dr Bhatia concluded that tirbanibulin’s mild side effect profile, relative safety, and potential for high patient satisfaction make it an underutilized tool with promise for dermatologists. He encouraged documenting patient experiences to support reimbursement, which could enhance accessibility and adherence to tirbanibulin as part of an ongoing AK management plan. https://dermsquared.com/videos/topical-conversations/expanding-treatment-ak-tirbanibulin 456 2024-11-11T18:29:56.228Z yes https://dermsquared.com/videos/topical-conversations/oral-psoriasis-5-year-data 2025-07-02T17:25:01.991Z https://image.mux.com/01Zwc8EV7I9p5DM01Mo4rksWBFDQIhbbtjLte3hH8Btvc/thumbnail.jpg The Oral Psoriasis Evolution: 5-Year Data on TYK2 Inhibition From Newcomer to Cornerstone: The Rise of Deucravacitinib In this episode of Topical Conversations, Dr Shahriari and Dr Bunick examine the long-term safety and efficacy data for deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, in the treatment of plaque psoriasis. Once a novel oral agent, deucravacitinib is now supported by 5-year data that position it as a durable, patient-friendly alternative to injectable therapies. An Oral Option That Holds Its Ground Deucravacitinib has shown sustained efficacy over time, with Psoriasis Area and Severity Index (PASI) 75 response rates nearing 70% at 1 year and remaining above 65% at year 5. PASI 90 scores also held steady or improved modestly over time. More than 50% of patients achieved “clear” or “almost clear” skin by physician global assessment, making deucravacitinib a meaningful option for patients seeking long-term skin clearance with oral therapy. Safety in Focus: Addressing the JAK Association Drs Shahriari and Bunick clarify the distinction between TYK2 inhibition and Janus kinase (JAK) inhibition. Deucravacitinib targets the TYK2 pseudokinase domain selectively, avoiding signal transduction through JAK1, JAK2, and JAK3. This specificity contributes to its favorable safety profile. Over 5000 patient-years of exposure yielded low incidence rates of major adverse cardiovascular events (MACEs), venous thromboembolism (VTE), and malignancy. Understanding the Data: Durability and Rigor The 5-year data are based on modified nonresponder imputation, a conservative analytical method that accounts for dropouts and strengthens the robustness of results. The consistent performance across both safety and efficacy endpoints provides long-term validation for clinicians hesitant to adopt oral therapies without durability data. The Science of Selectivity: Why TYK2 Matters Dr Bunick explains the mechanistic rationale for TYK2 inhibition in psoriasis. By blocking TYK2, deucravacitinib disrupts IL-12, IL-23, and type I interferon signaling—key upstream mediators in the pathogenesis of plaque psoriasis. Genetic studies showing anti-inflammatory effects in individuals with TYK2 inactivation lend further biologic support to this therapeutic strategy. Real-World Practice Considerations The conversation closes with discussion of herpes zoster vaccination, particularly for patients aged ≥50 years initiating therapy. Key Takeaways Deucravacitinib provides sustained PASI 75 and PASI 90 responses, with >50% of patients achieving clear or almost clear skin at 5 yearsLong-term safety data demonstrate low rates of MACEs, VTE, and malignancyDeucravacitinib selectively inhibits TYK2, minimizing off-target effects seen with broader JAK inhibitorsUse of modified nonresponder imputation supports data durability and clinical reliabilityHerpes zoster vaccination is recommended in patients aged ≥50 years prior to therapy initiation https://dermsquared.com/videos/topical-conversations/oral-psoriasis-5-year-data 922 2025-06-24T19:37:24.280Z yes https://dermsquared.com/videos/topical-conversations/tackling-moderate-ad-and-patient-care 2024-08-12T14:05:11.460Z https://image.mux.com/p001ewjahTZlvdT4CKK1UInnyeaNXIin8yTZhJb7zt02Y/thumbnail.jpg Tackling Moderate Atopic Dermatitis: Treatment and Patient Care In this episode of Topical Conversations, Dr Matthew Zirwas and Dr Peter Lio explore the complexities of managing moderate atopic dermatitis (AD), a condition that often poses unique challenges. The discussion highlights the importance of recognizing the distinct characteristics of moderate AD, understanding the common pitfalls in its management, and exploring effective strategies for improving patient outcomes. Identifying the moderate patient Dr Lio describes moderate AD as an especially intriguing category, occupying a middle ground that is neither as severe as the most extreme cases nor as mild as those easily managed with basic care. He explains that moderate AD can be deceptive, with clinical presentations that may appear mild but are often marked by significant symptoms like persistent itching and sleep disturbances. These patients may also show refractory responses to treatments typically effective for mild cases, indicating that they may, in fact, be dealing with moderate AD. A tendency to undertreat Dr Zirwas and Dr Lio discuss the tendency to undertreat patients with moderate AD due to the condition's refractory nature and the waxing-waning course of the disease. They highlight that moderate AD patients often visit the clinic during non-flare periods, leading to an underestimation of their condition. The doctors emphasize that patients may mistakenly believe that small adjustments to their regimen, such as switching topical steroids or skincare products, will suffice. However, this approach rarely brings about complete control of the disease, leaving patients vulnerable to future flares and ongoing discomfort. Patients’ struggle for control Dr Zirwas shares insights into the psychological burden faced by patients with moderate AD, particularly before the advent of effective treatments like dupilumab. He recalls patients who, despite being in a stable phase, would still experience significant anxiety about potential flares, especially during important life events like vacations or job interviews. The discussion reveals that the introduction of effective therapies has been transformative, offering patients a newfound sense of control over their disease. Dr Lio adds that before these treatments, patients often focused heavily on diet as a way to manage symptoms, seeking control through any available means. With the availability of more effective treatments, the emphasis on diet has decreased, as patients now have better options to manage their condition. Evaluating atopic dermatitis treatment results by efficacy Dr Zirwas outlines how he categorizes atopic dermatitis treatments based on their efficacy in clinical practice. He describes achieving a 90% improvement in the Eczema Area and Severity Index (EASI90) as an excellent response, with 75% improvement (EASI75) still being a very good outcome. He notes that patients at the EASI75 level often feel satisfied and resist changing therapies, whereas those at EASI50 might require continued use of steroids. Both doctors agree that dupilumab has been a game-changer, with most patients achieving significant improvements and few needing alternative therapies. Counseling reluctant patients on advanced therapies When it comes to counseling patients who are hesitant to start advanced therapies like dupilumab, Dr Zirwas and Dr Lio emphasize the importance of clear communication and reassurance. Dr Zirwas shares his strategy of explaining to patients that IL-13 blockers like dupilumab can lead to a substantial decrease in skin infections, improving overall immune function rather than suppressing it. He finds that this explanation often encourages hesitant patients to try the treatment. Dr Lio concurs and adds that he uses visual aids, such as a laminated slide showing reduced infection rates, to reinforce the benefits of treatment. He also highlights recent studies showing that dupilumab can normalize the skin microbiome, which he believes is a crucial aspect of managing AD. To further ease patients' concerns, Dr Lio promises that the treatment is not a lifelong commitment and that many patients can eventually stop the therapy and maintain their improvements. This reassurance helps patients feel more comfortable and open to starting the treatment. Addressing the full spectrum of moderate AD In their concluding remarks, Dr Zirwas and Dr Lio stress the importance of not settling for minor tweaks in treatment when managing moderate AD. They emphasize that dermatologists should closely monitor the impact of the disease on patients' sleep and overall quality of life, as these are critical indicators of the need for more aggressive treatment. They also advocate for structured, open conversations with patients about their symptoms, particularly regarding sleep and itchiness. With the availability of effective treatments, it is essential for dermatologists to engage in shared decision-making with their patients to achieve the best possible outcomes. https://dermsquared.com/videos/topical-conversations/tackling-moderate-ad-and-patient-care 763 2024-08-12T14:05:11.454Z yes https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-tuberous-sclerosis-complex 2024-02-28T17:53:31.551Z https://image.mux.com/yEs3NsPq5mibECPdwKn8BZ4u00w8wwM015i2XTrfAD9Ko/thumbnail.jpg Rare Diseases in Dermatology: Tuberous Sclerosis Complex For Rare Disease Day on February 29, Topical Conversations will be exploring some of the rare diseases seen in dermatology. In this installment, Naiem Issa, MD, PhD, gives his perspective on tuberous sclerosis complex (TSC) along with a helpful treatment tip. Watch Part 1 to hear Dr Todd Schlesinger discuss subacute cutaneous lupus erythematosus and dermatomyositis.Understanding tuberous sclerosis complex Tuberous sclerosis complex (TSC) is a rare genetic disorder resulting from mutations in the TSC1 and TSC2 genes. It follows an autosomal dominant pattern and affects approximately 50,000 individuals in the United States. TSC is difficult to treat and requires a multidisciplinary, multimodal treatment paradigm. TSC presents with multiple comorbidities, including central nervous system abnormalities, brain tumors causing seizures or developmental delays, angiomyolipoma and kidney cysts, cardiac rhabdomyelomas, pulmonary cysts, and lymphangioleiomyomatosis. Cutaneous manifestations include periungual fibromas, typically developing around the feet, and facial angiofibromas. Dermatologists play a crucial role in addressing patients' concerns related to facial angiofibromas, one of the most visible manifestations of TSC. Challenges with traditional treatments Facial angiofibromas are often a primary concern for patients with TSC, as they can present with hundreds of lesions. Traditionally, treatment options have been limited to destructive modalities such as curettage, laser therapy, and excisions, all of which come with side effects. Role of mTOR signaling in TSC The pathogenesis of TSC involves the dysregulation of the mammalian target of rapamycin (mTOR) signaling pathway. Inhibition of mTOR has shown promise in addressing both cutaneous and systemic effects of TSC. Oral sirolimus has been a standard therapeutic approach, but recent advancements have introduced a topical sirolimus 0.2% gel approved for ages 6 and above. Topical sirolimus gel for facial angiofibromas The approval of topical sirolimus gel is a significant advancement in TSC treatment. As a nondestructive alternative that inhibits mTOR locally, it provides a targeted treatment that minimizes side effects associated with systemic administration. Dr Issa encourages dermatologists to consider incorporating topical sirolimus gel into their treatment armamentarium for patients with TSC who present with multiple facial angiofibromas. This novel approach not only enhances the management of the cutaneous manifestations of TSC but also aligns with a patient-centered approach by minimizing the impact of side effects associated with traditional therapies. https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-tuberous-sclerosis-complex 112 2024-02-27T16:27:05.122Z yes https://dermsquared.com/videos/topical-conversations/breaking-the-cycle-new-era-ad-care 2025-08-06T21:57:51.139Z https://image.mux.com/FYvSbqHdQNXY6DmjwLs9awMq2WqZADcZtJxYhL00RPiQ/thumbnail.jpg Breaking the Cycle: A New Era in Atopic Dermatitis Care From Environmental Triggers to Emotional Toll In this episode of Topical Conversations, Michelle Tarbox, MD, and Peter Lio, MD, take a comprehensive look at the evolving landscape of atopic dermatitis (AD), a condition that continues to challenge patients, families, and clinicians alike. They explore the multifaceted burden of AD, from environmental triggers and treatment fatigue to the far-reaching impact on patients and their families.Cold Weather, Wildfire Smoke, and the Skin Barrier Dr Lio notes that winter often triggers AD flares due to dryness and disrupted skin barrier function. He highlights emerging research identifying isocyanates—components of wildfire smoke—as potential microbiome disruptors that may directly worsen AD. Dr Tarbox references data linking increased AD clinic visits and hospitalizations to wildfire exposure, reinforcing the importance of climate-related awareness in dermatology. When Topicals Aren’t Enough While mild AD can often be managed with topical therapies and gentle skin care, more severe cases require a different approach. They discuss treatment challenges such as poor adherence in children, fear of stinging medications, and the physical and emotional strain on families. Dr Lio breaks down why topicals sometimes fail and advocates for timely escalation to systemic therapy when appropriate. The Family Burden and the Path Forward The impact of AD extends beyond the skin. Dr Tarbox describes how the condition can dominate daily routines, strain marriages, and even disrupt childhood growth due to chronic inflammation and sleep loss. Both physicians emphasize the importance of moving from the vicious cycle of uncontrolled disease to a virtuous cycle of healing and how newer biologic and oral treatments are making this more achievable than ever before. Biologics and the “Renaissance” in AD Treatment With multiple systemic therapies now available, including biologics for children as young as 6 months, patients and providers are entering a long-awaited “renaissance” in AD care. Dr Tarbox draws comparisons to the revolution seen in psoriasis treatment, noting how gratifying it is to now have effective tools for patients with eczema. Dr Lio adds that some newer therapies may even allow for reduced dosing over time, a hopeful sign for long-term disease control. Shared Decision-Making and Long-Term Trust Treating AD means building relationships. Both physicians advocate for shared decision-making and patience when introducing systemic options, especially in pediatric cases. Dr Lio shares a helpful tool: the Atopic Dermatitis Control Tool (ADCT), which helps patients recognize how deeply AD affects their lives. They close by emphasizing the value of listening, following up, and guiding families toward relief without pressure, but with compassion and clear options. Key Takeaways Environmental triggers like cold weather and wildfire smoke can worsen AD and damage the skin barrierAD affects the entire family and can impact child development, sleep, and quality of lifeTopical therapies are not always enough; systemic options, including biologics, are now available for some casesTimely treatment can prevent disease “hardening” and improve long-term outcomesShared decision-making and regular follow-up help patients feel empowered and supported https://dermsquared.com/videos/topical-conversations/breaking-the-cycle-new-era-ad-care 820 2025-06-05T22:57:02.019Z yes https://dermsquared.com/videos/topical-conversations/integrative-care-atopic-dermatitis 2026-05-20T16:44:20.343Z https://image.mux.com/yxT00XVK01MHuoOyZ01100DZ02vZAM02l01T01yxe4FwWTIaBS4/thumbnail.jpg Integrative Care in Atopic Dermatitis How complementary strategies can support biologic therapy without replacing evidence-based treatmentAtopic dermatitis (AD) care has changed dramatically in the biologic era, but better options have not eliminated the need for thoughtful adjunctive strategies. In this opening conversation, Cynthia Trickett, MPAS, PA-C, and Peter Lio, MD, begin with the clinical reality many dermatology providers know well: even when biologics are appropriate, effective, and well tolerated, patients may still need more support to control itch, inflammation, barrier dysfunction, sleep disruption, and the day-to-day burden of disease. As Dr Lio puts it, integrative care is not about replacing conventional medicine with “something crazy.” It is about “taking the best of both worlds and putting them together in a coordinated way.”Dr Lio outlines what integrative medicine can mean in AD, from mind-body approaches and botanicals to barrier support, microbiome-directed strategies, and other adjunctive tools that may help patients who are already using topical therapies or systemic agents. The conversation also grounds these approaches in the larger biologic landscape, including IL-4/IL-13, IL-13, and IL-31 pathway targeting, while acknowledging that these therapies, however transformative, are not perfect fits for every patient. Part 1 closes where clinical practice often begins—with the need to layer treatment thoughtfully, safely, and with the patient’s goals and comfort in mind. Question: In the conversation, how does Dr Lio distinguish integrative medicine from alternative medicine in the management of AD? Integrative medicine replaces conventional therapies when patients prefer natural approaches Integrative medicine refers only to FDA-approved nonsteroidal therapies Integrative medicine layers selected complementary strategies alongside conventional treatment when appropriate Integrative medicine is primarily used before topical or systemic therapies are considered Rationale: Dr Lio emphasizes that integrative care is not meant to replace conventional therapies. He describes it as an adjunctive or augmentative approach that can be layered with topical steroids, calcineurin inhibitors, biologics, and other established treatments when the patient is interested and the strategy is safe and practical. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } Question: Which set of “pathogenic pillars” does Dr Lio use to frame integrative approaches to atopic dermatitis? Infection, scarring, pigmentation, pain, and systemic inflammation Inflammation, barrier dysfunction, microbiome dysbiosis, itch, and mind-body factors IgE elevation, food allergy, xerosis, sleep disruption, and steroid dependence Pruritus, excoriation, colonization, lichenification, and sleep loss Rationale: Dr Lio breaks AD down into five interrelated pillars: inflammation, barrier dysfunction, microbiome dysbiosis, itch, and the mind-body component. This framework allows clinicians to think more clearly about where adjunctive strategies may fit, including barrier support, probiotics, and habit reversal therapy. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } https://dermsquared.com/videos/topical-conversations/integrative-care-atopic-dermatitis 1042 2026-05-18T19:54:51.571Z yes https://dermsquared.com/videos/topical-conversations/guide-to-winter-skin-care-practical-tips 2024-12-17T21:24:05.017Z https://image.mux.com/N6Q00G00pz1IpG00AEKviMjliMXEwCkU8W8lrxp3fmQPRI/thumbnail.jpg Dermatologist's Guide to Winter Skin Care: Practical Tips to Share With Patients In this episode of Topical Conversations, Charlie Dunn, MD, shares timely and practical tips for dermatologists to counsel their patients through the winter season. With stress, cold weather, indoor heating, and disrupted routines taking a toll on skin health, Dr Dunn outlines his top 3 counseling pearls dermatologists can share with patients to help them proactively manage common seasonal challenges. Proactive treatment for winter flare-ups: Dr Dunn highlights the importance of proactive care for conditions that frequently flare during the winter, such as rosacea, atopic dermatitis (AD), psoriasis, and Raynaud's phenomenon: Rosacea: Since triggers like cold weather, stress, alcohol, and hot drinks may be difficult to avoid for some patients, Dr Dunn recommends augmenting treatment plans with systemic therapies, such as oral doxycycline, to maintain control AD and psoriasis: Preventative topical anti-inflammatory therapies, such as steroids, applied to commonly flared areas—even if they appear clear or in the very early stages of a flare—can help prevent progression. He suggests a Monday-Wednesday-Friday application schedule for ease of adherence. Raynaud’s phenomenon: For patients who are hesitant about oral therapies, Dr Dunn discusses topical options, including 5% sildenafil cream, citing a 2018 JAAD study showing improved blood flow and vessel diameter,1 in addition to practical measures like hand warmers, gloves, and socks for warmth Passive and active skin hydration: To combat winter dryness, Dr Dunn advises dermatologists to provide actionable hydration strategies and provides an easy-to-remember system to share with patients: Passive hydration: Encourage patients to use cool-mist humidifiers, drink more water, reduce indoor thermostat temperatures, and minimize irritants like retinol. Active hydration: Dr Dunn introduces the 4 C’s of moisturization: Cream: Switch from lotions to thicker creams Cover: Use gloves or socks after moisturizing Clean skin: Moisturize after showers and handwashing Chapped lips: Be proactive with lip balm before lips become cracked Don’t neglect sun protection: Dr Dunn reminds dermatologists to emphasize to their patients that UV exposure remains significant in winter, particularly for patients with photosensitive conditions like melasma. Snow can reflect up to 80% of UV rays, far more than sand or sea foam.2 He emphasizes year-round sun protection to his patients, including broad-spectrum sunscreen, protective clothing, sunglasses, and shade-seeking behaviors. These 3 pearls offer dermatologists actionable tools and patient-centered strategies that are easy to implement to help guide patients through the challenges of the winter season. By taking a proactive approach to flare prevention, emphasizing both passive and active skin hydration, and reinforcing year-round sun protection, dermatologists can help patients maintain healthy skin and minimize seasonal exacerbations. https://dermsquared.com/videos/topical-conversations/guide-to-winter-skin-care-practical-tips 314 2024-12-17T20:00:06.165Z yes https://dermsquared.com/videos/topical-conversations/shifting-paradigm-chronic-gpp 2025-02-03T18:42:51.755Z https://image.mux.com/2uiZNlWdpwMwjECeacOKPMZvjKyQygYYirtHtpiFNvw/thumbnail.jpg Shifting the Paradigm: Chronic Management of Generalized Pustular Psoriasis GPP Diagnosis and Treatment: What Every Dermatologist Should KnowIn this episode of Topical Conversations, Dr Aaron Farberg and Dr Neal Bhatia explore the challenges and advancements in diagnosing and treating generalized pustular psoriasis (GPP). emphasizing the need to shift the paradigm in managing GPP from viewing it as an acute, episodic condition to recognizing it as a chronic disease that requires sustained treatment and management. The diagnostic challenge Dr Bhatia identified diagnosis as the foremost challenge in GPP management, noting that many patients present to primary care physicians, urgent care centers, or emergency departments where their condition is misdiagnosed as folliculitis, acute generalized exanthematous pustulosis, or drug eruptions. He explains that misdiagnoses when it comes to GPP are often the result of an awareness gap, as many health care providers are simply not trained to recognize it. Without a timely and accurate diagnosis, patients are frequently prescribed unnecessary antibiotics or steroids in the absence of dermatologic input. Dr Farberg highlighted the importance of collaboration between dermatologists and community physicians, urging primary care providers to involve dermatologists immediately when encountering pustules and rashes. He emphasized the need for dermatologists to make themselves accessible for same-day or next-day appointments to ensure patients receive the appropriate care without delays. Educating dermatologists on rare diseases Both stressed the importance of education on rare dermatologic conditions like GPP. Dr Bhatia noted that medical dermatology topics often receive insufficient attention at conferences due to their perceived rarity. However, he cautioned that dermatologists will likely encounter these conditions during their careers and must be prepared. He encouraged dermatologists not only to remain vigilant for GPP but also to educate their colleagues to bridge the existing knowledge gap. Advancements in GPP treatment Historically, GPP has been difficult to treat, but the FDA-approved therapy spesolimab has transformed the treatment landscape. Drs. Farberg and Bhatia discussed the availability of spesolimab in both intravenous (IV) and subcutaneous formulations, each serving a distinct role in managing the disease. The IV formulation is designed to treat acute flares, providing rapid control of the disease, while the subcutaneous version is intended for long-term maintenance, aiming to prevent flares altogether. Dr Bhatia noted that clinical trials for the subcutaneous formulation enrolled patients in remission to test its ability to maintain disease quiescence. He also highlighted the trial’s rescue component, where patients experiencing flares received IV spesolimab, often achieving prompt symptom relief. Dr Farberg underscored the importance of distinguishing between the 2 formulations, advising against substituting multiple subcutaneous injections for an IV dose during acute flares, as the absorption profiles differ. He reassured dermatologists that the IV option, included in the clinical study design, provides an effective fallback for flare management. Shifting the paradigm Both Drs Farberg and Bhatia emphasized the need to redefine how dermatologists approach GPP, noting that it’s not only an acute condition but a chronic disease that causes a significant quality of life decline for patients. He advocated for transitioning patients on other biologics to spesolimab, which directly targets the IL-36 pathway specific to GPP. Dr Bhatia highlighted the significant improvement in quality of life that spesolimab offers, allowing patients to move from crisis management to a state of controlled disease. Addressing access and coverage Access to spesolimab has been streamlined, with both Dr Farberg and Dr Bhatia commending the support systems in place to facilitate rapid availability of the drug. Dr Farberg noted that he has encountered no significant barriers to obtaining it for his patients, a promising step toward closing both the educational and access gaps in GPP care. A comprehensive approach With spesolimab, dermatologists now have a powerful tool to manage this complex and rare condition effectively. By combining timely diagnosis, interdisciplinary collaboration, education, and advanced therapies, dermatologists can redefine the standard of care for GPP, ensuring patients receive comprehensive treatment. https://dermsquared.com/videos/topical-conversations/shifting-paradigm-chronic-gpp 697 2025-02-03T18:42:51.747Z yes https://dermsquared.com/videos/topical-conversations/role-of-ox40-ox40-ligand-pathway-atopic-dermatitis 2024-10-15T17:37:20.212Z https://image.mux.com/JPi7KpzpDMhYRoa8E3RAtx20201zv01YS4m6DlsSljAqos/thumbnail.jpg The Role of the OX40/OX40 Ligand Pathway in Atopic Dermatitis In this episode of Topical Conversations, James Q. Del Rosso, DO, gives an overview of the emerging role of the OX40/OX40 ligand (OX40/OX40L) pathway in the treatment of atopic dermatitis (AD). As research continues to advance, this pathway has gained attention as a promising therapeutic target that could offer longer-lasting relief for patients with AD by addressing the root causes of inflammation. What is the OX40/OX40 ligand pathway? The OX40/OX40 ligand pathway is a key regulatory mechanism in the immune system, playing a crucial role in the communication between immune cells. Specifically, this pathway is believed to govern type 2 inflammation, which is central to the development of AD, at its source. OX40, found on activated T lymphocytes, and OX40 ligand, present on antigen-presenting cells, act as costimulatory molecules that enhance the activation and proliferation of T cells, particularly Th2 lymphocytes. This T cell activation leads to the chronic inflammation characteristic of AD. Dr Del Rosso explains that when this pathway is activated, it not only contributes to the immediate inflammatory response but also influences immune memory. This means that the pathway helps sustain the immune system's ability to reactivate inflammation during flare-ups and may contribute to the persistence and recurrence of AD over time. Targeting OX40/OX40 ligand in AD treatment Given the critical role of the OX40/OX40L pathway in driving inflammation and disease recurrence, blocking this pathway has become a focus for new AD therapies. Two agents are currently under investigation—amlitemab, which binds to OX40 ligand, and rocatinlimab, which targets OX40. Both therapies aim to inhibit the expansion of T cells that lead to the acute flares seen in AD and block the memory T cells responsible for long-term recurrence. By interfering with this pathway, these treatments have the potential to work on 2 levels: reducing the severity of current flares and preventing future ones. This dual action could represent a significant advancement in AD management, moving beyond symptom control to more durable, long-term disease modification. A paradigm shift in AD treatment As Dr Del Rosso emphasizes, paying attention to the OX40/OX40 ligand pathway is critical as it represents a novel approach to treating AD at its source. By addressing the underlying mechanisms that drive both acute and chronic inflammation, these therapies could transform how dermatologists manage AD, offering patients not only symptomatic relief but also the possibility of long-term remission. For more on this topic, tune in to the Derms and Conditions episode, The OX40/OX40L Pathway: Expanding Our Understanding of Atopic Dermatitis https://dermsquared.com/videos/topical-conversations/role-of-ox40-ox40-ligand-pathway-atopic-dermatitis 123 2024-10-15T17:37:20.195Z yes https://dermsquared.com/videos/topical-conversations/sunscreen-moa-what-dermatologists-and-patients-need-to-know 2024-06-12T22:50:43.878Z https://image.mux.com/xAWIxJ00PPrYRb01i5xlr36UpXZeRx00VSJOz014alAIGXQ/thumbnail.jpg Sunscreen MOAs: What Dermatologists and Patients Need to Know In this episode of Topical Conversations, Dr Ahuva Cices, assistant professor at Icahn School of Medicine at Mount Sinai, introduces why it is crucial for dermatologists and the public to understand the differences between physical and chemical sunscreens and their mechanisms of action (MOA). Common misconceptionsDr Cices addresses a common misconception: that physical sunscreens primarily work by reflecting and scattering UV light. While this was historically true, she clarifies that this is now only a small part of how modern physical sunscreens function.1 Instead, physical sunscreens predominantly absorb UV light, similar to chemical sunscreens. This challenges the outdated understanding that reflection and scatter are the main protective mechanisms of physical sunscreens. Modern mechanism of action With the advent of micronization and nanoparticle technologies, modern physical sunscreens containing zinc oxide and titanium dioxide have shifted their primary mechanism to UV light absorption.2 One study demonstrated that these modern formulations reflect less than 5% of incoming UV light,3 with the majority of protection coming from absorption and subsequent energy dissipation as heat.2,4 Implications for dermatologists and patients Understanding the MOA of modern physical sunscreens is essential for dermatologists when advising patients. While some dermatologists may prefer physical sunscreens due to their perceived safety and simplicity,1 it is important to recognize that both physical and chemical sunscreens now work via similar mechanisms. Therefore, factors like cosmetic elegance and ease of use become more significant when recommending sunscreens to patients. Dr Cices advocates for dermatologists to stay informed about the current MOA of sunscreens. Dispelling myths and prioritizing user-friendly, cosmetically elegant products can help dermatologists guide their patients in choosing effective sun protection, ultimately enhancing compliance and reducing the risk of sun damage. References Zundell M, Wong M, Rubin C, Cices A, Bitterman A. Improving patient communication on sunscreen choice: Updating mechanistic misconceptions. JEADV Clin Pract. 2023;2:963-964. doi:10.1002/jvc2.251 Smijs T, Pavel S. Titanium dioxide and zinc oxide nanoparticles in sunscreens: focus on their safety and effectiveness. Nanotechnol Sci Appl. 2011; 4: 95–112. doi:10.2147/NSA.S19419 Cole C, Shyr T, Ou-Yang H. Metal oxide sunscreens protect skin by absorption, not by reflection or scattering. Photodermatol Photoimmunol Photomed. 2016; 32(1): 5–10. doi:10.1111/phpp.12214 https://dermsquared.com/videos/topical-conversations/sunscreen-moa-what-dermatologists-and-patients-need-to-know 64 2024-06-12T22:46:12.480Z yes https://dermsquared.com/videos/topical-conversations/srt-treatment-modality-nonmelanoma-skin-cancer 2024-05-13T15:20:42.762Z https://image.mux.com/ba62gp6W6Yxn98nKE02Ho37sQ1fWuAAnteXZIpr4Ji4M/thumbnail.jpg Revisiting Superficial Radiation Therapy (SRT) as a Treatment Modality for Nonmelanoma Skin Cancer Nonmelanoma skin cancer (NMSC) remains a significant health concern globally, with various treatment modalities available to address its diverse presentations. In this quick-hitting installment of Topical Conversations, Aaron Farberg, MD, discusses the role of superficial radiation therapy (SRT) for the treatment of NMSC. The NMSC treatment landscape The treatment landscape for NMSC encompasses an array of options, including surgery, cryotherapy, curettage and electrodessication, and radiation therapy (RT). RT includes several techniques such as SRT, photodynamic therapy, brachytherapy, and chemotherapeutic agents. Treatment decisions hinge on several factors, including tumor type, anatomical location, patient characteristics, and physician preference.1 Historical context and resurgence of SRT SRT, one of the oldest modalities for NMSC, witnessed widespread use in dermatology practice until the mid-20th century. However, its utilization dwindled with the emergence of surgical techniques and the unavailability of replacement SRT devices. Moreover, the lack of training opportunities in dermatology residency programs further contributed to its decline.1 However, SRT has begun to experience a renaissance as advocates strive to fill knowledge gaps regarding its use and demonstrate its efficacy with large studies. One study found that using SRT for basal cell carcinoma and squamous cell carcinoma in elderly patients resulted in a 97.4% cure rate.2 Another estimated that 98.8% of NMSCs will not recur after 85 months following SRT.3 Alternative to surgical modalities In instances where tissue-sparing must be considered, SRT may be a favorable alternative to surgery, mitigating undesirable cosmetic and functional consequences. Moreover, certain patient cohorts, particularly those unsuitable for surgery due to advanced age or medical comorbidities, may benefit from SRT's noninvasive approach.1 In conclusion, SRT has reemerged as a viable treatment modality for NMSC, offering comparable efficacy to surgical options with superior cosmesis in select cases. Its historical significance, coupled with recent advancements and favorable outcomes, underscores the need for dermatologists to reevaluate its role in contemporary practice. By leveraging SRT's benefits and tailoring treatment approaches to individual patient needs, dermatologists can optimize outcomes and enhance the quality of care for NMSC patients. References Nestor MS, Berman B, Goldberg D, et al. Consensus guidelines on the use of superficial radiation therapy for treating nonmelanoma skin cancers and keloids. J Clin Aesthet Dermatol. 2019;12(2):12-18. Roth WI, Shelling M, Fishman K. Superficial radiation therapy: a viable nonsurgical option for treating basal and squamous cell carcinoma of the lower extremities.. J Drugs Dermatol. 2019;18(2):130-134. Roth W, Beer RE, Iyengar V, Bender T, Raymond I. Long-term efficacy and safety of superficial radiation therapy in subjects with nonmelanoma skin cancer: a retrospective registry study. J Drugs Dermatol. 2020;19(2):163-168. doi:10.36849/JDD.2020.4647 https://dermsquared.com/videos/topical-conversations/srt-treatment-modality-nonmelanoma-skin-cancer 29 2024-05-13T15:20:42.751Z yes https://dermsquared.com/videos/topical-conversations/a-barrier-repair-formulation-for-radiation-dermatitis 2024-01-26T16:08:46.163Z https://image.mux.com/DZt02XvYNJ6BXZjUMxW9lNSFlQS02l2IVWhzXQ00ESFvfc/thumbnail.jpg A Barrier Repair Formulation for Radiation Dermatitis SummaryIn this video discussion, Dr Jim Del Rosso and Dr Leon Kircik talk about EpiCeram controlled release skin barrier emulsion. They highlight its formulation, which includes ceramides, fatty acids (conjugated linoleic acid [CLA] and palmitic acid), and cholesterol in a 3:1:1 ratio to simulate the intercellular lipid membrane of the skin barrier. They then discuss the indications for EpiCeram, which include treatment of dry skin conditions and managing symptoms associated with various dermatoses like atopic dermatitis, irritant contact dermatitis, and radiation dermatitis. Dr Kircik emphasizes the importance of EpiCeram's unique patented time-release system, which provides 24-hour barrier repair benefits with just one application a day. Dr Del Rosso and Dr Kircik explain the product's 2-sphere system and how the microsphere structure stabilizes the lipids from premature oxidation that can cause malodor in generic versions. Dr Del Rosso highlights the important role of CLA in the formulation of EpiCeram by referencing literature that has shown CLA used post-fractionated laser procedures has demonstrated significant improvement in inflammation, irritation, and swelling.Dr Del Rosso and Dr Kircik then focus their conversation on radiation dermatitis and the ensuing barrier impairment. They emphasize the importance of treating radiation dermatitis early, since while the clinical signs of radiation dermatitis may take up to 3 weeks to appear, the barrier impairment can begin sooner. They conclude by highlighting the importance of maintaining the skin’s pH level to support epidermal barrier function.Key PointsEpiCeram formulation includes ceramides, fatty acids, and cholesterol in a 3:1:1 ratio to simulate the intercellular lipid membrane of the skin barrierEpiCeram has broad indications, including managing symptoms associated with various dermatoses like atopic dermatitis, irritant contact dermatitis, and radiation dermatitisEpiCeram uses a patented time-release system which provides 24-hour barrier repair benefits with one application a dayWhile the product label recommends twice-daily application, data shows that once-daily application provides moisturization over 24 hoursEpiCeram's 2-sphere system prevents malodor by stabilizing lipids from premature oxidationEarly treatment is essential for radiation dermatitis, as barrier impairment can occur before clinical signs appearMaintaining the skin's pH level is crucial for epidermal barrier functionEpiCeram should not be applied within 4 hours before radiation treatment, as recommended in the package insert https://dermsquared.com/videos/topical-conversations/a-barrier-repair-formulation-for-radiation-dermatitis 629 2023-07-27T19:28:20.925Z yes https://dermsquared.com/videos/topical-conversations/ad-skin-color-navigating-therapies 2025-01-31T17:13:42.085Z https://image.mux.com/3ONQn5uBGpcp5cUOMARxViFobdz7t9T900tovnM23dkQ/thumbnail.jpg Atopic Dermatitis Treatment in Skin of Color: Navigating Systemic Therapies and Addressing Unique Challenges In this episode of Topical Conversations, Dr James Del Rosso and Dr Amy McMichael discuss the challenges of identifying candidates for systemic treatment of atopic dermatitis (AD), with a particular focus on patients with skin of color. They explore how AD presents differently in diverse populations, considerations for assessing disease severity, and the role of systemic therapies like lebrikizumab in improving patient outcomes. Challenges in diagnosing atopic dermatitis in skin of color Dr Del Rosso highlights a key challenge in evaluating AD severity in diverse populations—the reliance on erythema as a primary indicator of disease activity. Assessments often include the presence of redness; however, erythema can be subtle or difficult to detect in darker skin tones, making it essential for dermatologists to look beyond color-based cues. Dr McMichael reinforces this by emphasizing tactile and symptomatic assessments. She advises dermatologists to train patients and caregivers not just to treat when skin appears red but also when it feels rough or textured. In some cases, violaceous changes may be more apparent than classic erythema. Additionally, symptoms like itching, irritation, and sleep disturbances can be critical indicators of disease severity, even when visible skin changes seem minimal. Another diagnostic challenge is hidden or underreported disease involvement. Patients may initially present with localized symptoms, but a thorough full-body skin exam can reveal more extensive disease, particularly in skin folds, scalp, or diaper areas for pediatric patients. This is especially important when considering systemic therapy, as true body surface area involvement and diffuse itching patterns can help guide treatment decisions. The impact of hyperpigmentation, hypopigmentation, and lichenification They also discuss discuss postinflammatory pigmentary changes that frequently affect patients with skin of color: Hyperpigmentation, which often resolves over time but can be persistent and distressing for patients; hypopigmentation, which can be more challenging to treat, and if chronic, may not fully recover even after the underlying AD is controlled; and lichenification, which is a common long-term consequence of chronic AD in darker skin tones and can persist despite active treatment. Dr McMichael emphasizes that chronic hypopigmentation resulting from prolonged scratching can cause lasting skin damage. While systemic treatments can control AD, they do not always restore lost pigment, making early and aggressive treatment crucial. Dr Del Rosso adds that hyperpigmentation tends to improve over time, but the contrast in skin tone can make these changes more noticeable and distressing for patients with darker skin. Systemic therapy for atopic dermatitis: when to escalate treatment Dr McMichael follows a stepwise approach when treating AD, usually beginning with topical treatments as the first-line therapy for mild-to-moderate cases. She then moves on to systemic agents for moderate-to-severe cases that are not adequately controlled with topicals. She emphasizes escalating treatment quickly when necessary, particularly when AD affects daily life, including school performance, sports participation, and sleep quality. She highlights the importance of early treatment education, noting that patients and caregivers need to understand that AD is a chronic condition, not a disease with a simple cure. The role of positive reinforcement in patient compliance Dr McMichael stresses the importance of positive feedback in patient care. When patients or caregivers follow treatment plans diligently, acknowledging their efforts reinforces good habits. Encouraging words from a dermatologist can motivate patients to continue treatment, improving long-term outcomes. Key takeaways Diagnosing AD in skin of color requires looking beyond redness, focusing on texture, itching, and pigmentary changes Systemic therapy should be considered when AD significantly impacts daily life, especially when topical treatments are insufficient Hyperpigmentation often improves over time, but hypopigmentation can be permanent, emphasizing the importance of early, aggressive treatment Newer biologics, like lebrikizumab, show promising results in addressing AD Cultural considerations and patient adherence play a major role in treatment success, requiring a simplified, consistent, and collaborative approach https://dermsquared.com/videos/topical-conversations/ad-skin-color-navigating-therapies 1084 2025-01-31T17:13:42.074Z yes https://dermsquared.com/videos/topical-conversations/maximizing-skin-health-for-older-adults 2024-11-26T18:19:19.389Z https://image.mux.com/FuyZKFeTMR8PLVJ4NNDWaT26301RIrhC5joD3kh7o6fM/thumbnail.jpg National Healthy Skin Month: Maximizing Skin Health for Older Adults For National Healthy Skin Month, we’re spotlighting skin health practices across all stages of life. In this segment, Daniel Butler, MD, Associate Professor at the University of Arizona College of Medicine, offers his expert guidance on caring for the skin of older adults. Highlighting the unique needs of this patient population, he provides actionable pearls for both patients and dermatology providers to maximize care and prioritize quality of life (QoL).Addressing skin care for older adultsOlder adults represent a significant portion of dermatology patients, with nearly 50% of all visits involving individuals over the age of 65. Dr Butler emphasizes that their skin requires targeted attention as it undergoes significant changes with aging.For patients, his advice is straightforward but impactful: advise them to moisturize frequently. As skin ages, it loses moisture and its natural barrier weakens, leading to increased dryness and sensitivity. Considerations for providersFor providers, Dr Butler underscores the importance of prioritizing quality of life when treating older patients. Often, there is no one-size-fits-all solution for this population, and treatment decisions frequently exist in a gray area. He encourages dermatologists to have open discussions with their patients about their daily activities and sleep, 2 critical factors for maintaining overall well-being.Additionally, he highlights the importance of encouraging patients to stay active. Citing input from geriatricians, Dr Butler stresses that older adults should not stop exercising or walking, even after surgeries. Key takeaways for dermatologistsDr Butler’s guidance centers on 2 essential points for caring for older adult patients:Encourage patients to moisturize frequently to bolster the skin barrier and combat age-related drynessPrioritize quality of life in treatment decisions, focusing on maintaining sleep, activity levels, and overall well-beingThrough these approaches, dermatologists can provide meaningful care for this important and often underserved patient population. Watch Part 1 here for expert insights on caring for dermatology's youngest patients, Part 2 here for tips on managing adolescent and young adult patients, and Part 3 here for strategies to optimize skin health in adults and middle-aged patients—all for National Healthy Skin Month! https://dermsquared.com/videos/topical-conversations/maximizing-skin-health-for-older-adults 118 2024-11-25T18:26:38.713Z yes https://dermsquared.com/videos/topical-conversations/transforming-alopecia-areata-jaks 2024-08-09T13:59:06.941Z https://image.mux.com/9DE0098IlaUb5Z00clwu1vsF00wBGF0102pJRtCDutA00lFoQ/thumbnail.jpg Transforming Alopecia Areata: The Impact of JAK Inhibitors In this episode of Topical Conversations, Dr E. James Song and Dr Michael Cameron explore the profound burden of alopecia areata (AA) and how JAK inhibitors, particularly baricitinib, have revolutionized treatment. They discuss pivotal trial data and share real-world experiences, highlighting the transformative impact of this therapy on patients' lives. Prevalence of alopecia areata The prevalence of alopecia areata is not well-defined, with epidemiologic data varying widely. Dr Cameron suspects that AA is more common than currently realized; patients with a genetic predisposition to AA can experience hair loss triggered by stress or viral infections, indicating that the condition might be underreported and underdiagnosed. Emotional toll on patients The emotional burden of AA is immense. Both Dr Cameron and Dr Song emphasize that the condition can be emotionally debilitating for patients, noting that dismissive comments patients often hear can minimize the perceived impact of the disease and worsen the emotional burden of AA. Limited options before JAK inhibitors Historically, treatment options for AA were limited and often ineffective. Dr Cameron recounted that earlier methods involved injecting the scalp with Kenalog or using off-label methotrexate and chronic steroids, which were broadly immunosuppressive and had limited efficacy. These treatments were not suitable for long-term use and often provided inadequate results. Revolutionizing treatment The approval of baricitinib in 2022 marked a significant advancement in the treatment of AA. Prior to this, there were no effective treatments for the condition. Dr Song shared that his clinical experience with baricitinib has been remarkable, often exceeding expectations from clinical trial data. Most of his patients have seen meaningful improvements, even if they did not meet the strict responder criteria used in trials. Clinical and real-world effectiveness Both Dr Song and Dr Cameron noted that binary endpoints in clinical trials can be misleading. A patient who improves significantly might still be classified as a nonresponder according to trial definitions. Dr Cameron emphasized that his real-world experience with baricitinib has been excellent, particularly for regrowing eyebrows and eyelashes, which are crucial for many patients' senses of identity. Safety profile and misconceptions around JAK inhibitors Dr Cameron also addresses the misconceptions surrounding JAK inhibitors, particularly in the United States. He points out that dermatologists in Canada and Japan use these treatments more frequently and report positive outcomes. The safety data for baricitinib does not indicate significant risks, and the medication is generally well-tolerated. Initiating conversations and treatment Dr Cameron emphasized the importance of early discussions about baricitinib, even if patients do not meet the clinical trial criteria of 50% scalp baldness. He highlights the functional and cultural significance of beards, eyebrows, and eyelashes for many patients and recommends starting treatment based on individual needs. The approach to treating AA is evolving. Emerging guidelines suggest that factors such as eyebrow and eyelash loss, inadequate response to topicals, severe anxiety or depression, and rapidly progressing hair loss should be considered when determining the severity of AA and initiating treatment. The advent of baricitinib has significantly transformed the treatment landscape for alopecia areata, offering new hope and improved outcomes for patients. Insights from Dr Song and Dr Cameron underscore the importance of early intervention, understanding the emotional impact of AA, and advocating for patient access to effective treatments. As research and guidelines continue to evolve, dermatologists are better equipped to provide compassionate and effective care for individuals affected by this challenging condition. https://dermsquared.com/videos/topical-conversations/transforming-alopecia-areata-jaks 708 2024-08-09T13:59:06.925Z yes https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-supporting-healthy-babies 2024-11-26T18:10:46.647Z https://image.mux.com/VyMzbBqi7cezwe02MLFlr174doOSVdnXtS9AyDxoS5Ws/thumbnail.jpg National Healthy Skin Month: Supporting Healthy Skin in Babies For National Healthy Skin Month, we’re spotlighting skin health practices across all stages of life. In this segment, pediatric dermatologist Dr Lisa Swanson shares her expert insights on caring for the skin of dermatology’s youngest patients—babies. Highlighting the unique needs of infant skin, she offers guidance for parents on how to promote healthy skin from birth, including tips for potentially lowering the risk of atopic dermatitis (AD). Baby skin: unique needs and moisturization benefits Newborn skin has distinct qualities compared to other age groups. Notably, it experiences a higher rate of transepidermal water loss, leaving it vulnerable to dryness and potential skin barrier issues. This increased water loss is thought to be a factor in the later development of atopic dermatitis. "Some studies suggest that the amount of transepidermal water loss in early life may be key in determining which kids develop eczema down the road," Dr Swanson explains. To support skin barrier health, moisturizing a baby’s skin with sensitive skin products early on has been associated with potential benefits, including a reduced risk of AD. Although study results have been mixed—some showing improvement in eczema rates through early moisturization and others showing minimal effect—Dr Swanson notes that she sees no downside to regularly moisturizing baby skin. Encouraging moisturization for infants and toddlers When advising parents, Dr Swanson emphasizes the value of gentle, daily moisturization using high-quality, sensitive skin products. For families of newborns and expectant parents, she provides recommendations for gentle products and accessible, good-quality moisturizers. “I encourage families with a newborn baby to go ahead and moisturize,” she says, noting that applying gentle products poses no risk and could potentially reduce a child’s chances of developing AD. For parents with older children who already show signs of AD, Dr Swanson makes a point to highlight the importance of early skin care for any future children. Shifting skin care recommendations in nurseries and NICUs Many nurseries and NICUs still advise against using products on newborn skin. Dr Swanson hopes to shift these guidelines to encourage regular moisturization for babies as a preventive strategy. Some of the studies exploring moisturization for AD prevention included accessible products, such as Vaseline, and demonstrated a reduction in eczema risk when used consistently during infancy. Dr Swanson’s advice to parents is straightforward: “If we moisturize a baby and turns out it's not a miracle to preventing atopic dermatitis, we've still done no harm.” Key takeaways for dermatologists Dr Swanson encourages dermatologists to discuss the importance of moisturizing with expectant parents and families of newborns. As dermatologists, supporting early skin health practices can have a lasting impact on the patient’s skin health across their lifespan.Watch Part 2 here for tips on managing adolescent and young adult patients, Part 3 here for strategies to optimize skin health in adults and middle-aged patients, and Part 4 here for guidance on caring for the older adult patient population—all for National Healthy Skin Month! https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-supporting-healthy-babies 178 2024-11-12T18:03:51.648Z yes https://dermsquared.com/videos/topical-conversations/microneedling-vitiligo-promising-option-repigmentation 2024-01-15T20:17:54.434Z https://image.mux.com/hRK00btnrTLlXLXpyvgLNR5rQf6q5lY3Y01IS8FFDA6i00/thumbnail.jpg Microneedling for patients with vitiligo: a promising option for repigmentation In this episode of Topical Conversations, Naiem Issa, MD, PhD, explores the use of microneedling as a promising approach to facilitate repigmentation in patients with vitiligo. Looking beyond topical anti-inflammatory agents in challenging cases After months or years of treatment, vitiligo may reach a stable phase or burn out, rendering topical anti-inflammatory agents, such as ruxolitinib, tacrolimus, and pimecrolimus, and topical and oral corticosteroids, ineffective in promoting repigmentation. Dr Issa emphasizes the need to shift focus towards melanocyte or melasome regeneration in these cases. Identifying melanocyte reservoirs: three key locations In these challenging cases, Dr Issa emphasizes the need to allow for melanocyte or melanosome regeneration and repigmentation. Melanocyte stem cell niches and reservoirs are pivotal for repigmentation, utilizing chemotaxis to enter vitiliginous lesions to begin proliferating and dropping pigment through melanosome generation. Dr Issa highlights 3 primary locations where stem cell niches are found: The hair follicle bulge: in the bulge, stem cells can awaken through a number of inflammatory cytokines, called the cytokine milieu, to grow, divide, and mature into melanocytes and migrate into vitiliginous lesions The outer edges of vitiliginous patches: with an active lesion, some melanocytes may persist at the rim The dermal papillae: some melanocytes and melanocyte precursors may be present below the epidermis; this is typically found on acral sites such as the hands and feet, which are often more difficult to repigment The role of microneedling: repigmentation stimulation Microneedling, utilizing controlled wounds typically ranging from 1.5 to 2.5 millimeters in depth, serves 2 crucial purposes in vitiligo therapy: Enhanced medication delivery: By creating microchannels, microneedling facilitates the effective delivery of medications, including topical anti-inflammatories and agents promoting regeneration like bimatoprost Proinflammatory milieu activation: The process triggers an increase proinflammatory milieu, involving cytokines such as platelet-derived growth factors and TNF beta. These signals jump-start the melanocyte and melanosome reservoirs, fostering an environment conducive to repigmentation Clinical insights: microneedling techniques Dr Issa shares his experience with microneedling using the skin pen, detailing a technique that uses it on the lesion itself and also extends use 1 cm beyond the vitiliginous lesion to maximize melanocyte recruitment and increase the chances of successful repigmentation. As a cost-effective alternative, Dr Issa highlights cases where manual microneedling, using an 18 or 20 gauge needle, has yielded impactful results at low cost. Microneedling as a viable step in vitiligo repigmentation Microneedling has emerged as a promising step in the therapeutic ladder for patients with vitiligo who have exhausted traditional treatments. By harnessing controlled wounds and activating a proinflammatory milieu, microneedling opens new avenues for repigmentation. https://dermsquared.com/videos/topical-conversations/microneedling-vitiligo-promising-option-repigmentation 274 2024-01-15T20:02:28.613Z yes https://dermsquared.com/videos/topical-conversations/patient-centered-care-vitiligo-navigating-conversation-treatment-goals 2023-10-09T16:47:06.046Z https://image.mux.com/4012M5iX9H4hJybF026X0000b00SwY6M4MnsqZK11gh57Rxg/thumbnail.jpg Patient-centered Care in Vitiligo: Navigating the Patient Conversation and Treatment Goals In this installment of Topical Conversations, Tina Bhutani, MD, MAS, provides her thoughts on the article, “Perspectives of Vitiligo Patients: Voices from National Vitiligo Conferences,” published in SKIN: The Journal of Cutaneous Medicine by O’Connell et al.Study background This study looked at surveys taken by participants who attended the virtual US World Vitiligo Day in 2020 and 2021. Study results When polled about acceptance of their disease, 40% responded that they are accepting of their vitiligo on most days. However, most participants (76% in 2020 and 92% in 2021) reported that they would like a cure for vitiligo. Impact on patient conversations and treatment approach Dr Bhutani comments on the importance for clinicians to recognize that even though a patient may be accepting of their condition, comfortable with it, and show it publicly (as 40% reported doing), they would still like to find a treatment that would decrease their disease burden. The survey showed that 20% of patients were interested in trying treatments even if they included moderate side effects. Dr Bhutani remarks that this highlights the importance of having open discussions with patients and considering individualized care, since some patients may be open to attempting more aggressive therapy while others are not interested in treatments or only willing to attempt treatments without side effects. The future of vitiligo treatments With many new treatments for vitiligo in the pipeline, Dr Bhutani reflects that this is an exciting time for patients and a good time for providers to start these conversations with patients to provide hope for this condition that has a significant impact on quality of life but has long been understudied. Read the full article in SKIN: The Journal of Cutaneous Medicine. Key points “Perspectives of Vitiligo Patients: Voices from National Vitiligo Conferences” was published in SKIN: The Journal of Cutaneous Medicine The study examined results of a poll that solicited information from participants regarding their quality of life with vitiligo Results showed that a majority of patients would like a cure for vitiligo, even though 40% reported they are accepting of their condition on most days 20% of patients were interested in trying treatments even with moderate side effects Clinicians should have open discussions with their patients with vitiligo and consider individualized care https://dermsquared.com/videos/topical-conversations/patient-centered-care-vitiligo-navigating-conversation-treatment-goals 84 2023-10-09T16:45:35.069Z yes https://dermsquared.com/videos/topical-conversations/future-of-psoriasis-care 2026-03-20T13:52:32.679Z https://image.mux.com/CFJuccnBiSLjHUdvE95N7YDkBgJvwbVQNdeq1pNeBuQ/thumbnail.jpg Oral Therapies and the Future of Psoriasis Care In this Experiences episode of Topical Conversations, Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale University, and Jason Hawkes, MD, Chief Scientific Officer and investigator at the Oregon Medical Research Center, explore the evolution of oral therapy in psoriasis care, from the early days of apremilast to the growing impact of selective TYK2 inhibition.Together, they trace how the field has moved from broad, nonspecific PDE4 blockade to the more targeted, allosteric TYK2 mechanism that bridges IL-23 and IL-17 signaling. Dr Hawkes outlines how TYK2 inhibition can influence downstream pathways, including IL-12 and type I interferons, potentially extending benefits beyond skin disease. The discussion also highlights recent data in psoriatic arthritis and real-world safety outcomes, with consistent tolerability and durable efficacy across challenging sites like scalp, nails, and palms.Both clinicians emphasize practical considerations—how to identify appropriate candidates for oral therapy, manage expectations around treatment onset, and communicate the distinct safety profile and monitoring needs of TYK2 inhibitors. They close by looking ahead to next-generation orals, including second-generation TYK2 inhibitors and oral IL-23 receptor blockers, which are narrowing the gap between biologic and oral efficacy.A grounded, forward-looking conversation on how oral innovation continues to reshape the psoriasis treatment landscape. https://dermsquared.com/videos/topical-conversations/future-of-psoriasis-care 1008 2025-11-13T14:42:21.589Z yes https://dermsquared.com/videos/topical-conversations/dupilumab-clinical-scenarios 2025-08-01T14:49:34.060Z https://image.mux.com/aZoZDD302kMIhP3xCkWnSVQWmXuXO301vvjL5LDOgpTek/thumbnail.jpg Dupilumab in Practice: Navigating Use Across Clinical Scenarios In this episode of Topical Conversations, David Rosmarin, MD, joins Mary Gail Mercurio, MD, to discuss practical approaches to treating atopic dermatitis (AD) with dupilumab. The conversation covers treatment selection, patient counseling, insurance navigation, and evolving data on safety and adjunctive options. When to initiate systemic therapy Both note that the threshold for initiating systemic therapy, particularly dupilumab, has decreased as confidence in its safety and efficacy continues to grow. The broad range of FDA-approved indications, including approval down to 6 months of age, can help reassure patients who are hesitant to begin biologic therapy. The lack of lab monitoring requirements is also a significant benefit for both patients and clinicians. Patient counseling and injection hesitancy Patient hesitation around injectables can often be addressed through hands-on education and support from office staff. Dr Mercurio highlights the importance of in-office instruction in the use of the injection device. The growing body of safety data in pregnancy is also discussed, with both clinicians emphasizing the importance of forthcoming registry data and growing real-world evidence supporting dupilumab’s use during pregnancy. Follow-up and documentation Follow-up frequency varies based on patient preference and disease severity, often extending to 6 to 12 months once stable. Both clinicians document body surface area (BSA), symptom severity, and impact on quality of life, such as interference with sleep or daily functioning. Insurance considerations While dupilumab is typically approved without significant barriers, both clinicians note challenges when BSA is below 10%. Documenting involvement of high-impact areas like the face and hands and the broader impact on quality of life can aid in securing coverage. Assessing response and treatment duration The decision to continue or switch therapy is patient-specific. Some improvement may be expected within 3 months; if no response is observed by 3 to 4 months, a change in therapy may be warranted, especially in more severe cases. Mild cases may allow for a longer trial period before considering alternative options. Adjunctive therapies and managing residual disease For patients with residual symptoms despite dupilumab, both clinicians use topical therapies—steroids or nonsteroidals—based on body site. Phototherapy is viewed as a beneficial option but may be inaccessible due to cost or insurance limitations. Tapinarof and roflumilast are emerging nonsteroidal options, though access can be restricted by formulary status. Approach to acute flares In select cases, a short course of oral corticosteroids may be used to control acute flares while initiating dupilumab, helping to bridge the gap until biologic response is achieved. Looking ahead The discussion concludes with anticipation for new therapeutic options, including oral JAK inhibitors, oral STAT6 inhibitors, and other novel mechanisms. Dupilumab remains a foundational therapy in AD management, with new data, particularly regarding pregnancy safety and additional indications, expected to further shape clinical practice. Key takeaways Dupilumab is increasingly used earlier in the treatment course of AD due to a favorable safety profile and lack of lab monitoring requirements Patient education and support can ease concerns around injectable administration Documentation of quality-of-life impact and involvement of special sites can improve insurance approval likelihood, particularly for patients with <10% BSA involvement Adjunctive therapies, including topical agents and phototherapy, are frequently used to manage residual disease Treatment response is typically evaluated within the first 3 to 4 months to guide continuation or change in therapy https://dermsquared.com/videos/topical-conversations/dupilumab-clinical-scenarios 544 2025-08-01T14:49:34.053Z yes https://dermsquared.com/videos/topical-conversations/bright-spots-2 2024-04-01T17:39:38.451Z https://image.mux.com/TGoOYHeZ4YMxaBbAI1N1GtUbfn02Xt3DH9FyEpoPIQaY/thumbnail.jpg Bright Spots: Exploring the Remittive Effect of Tapinarof for Plaque Psoriasis Welcome to Topical Conversations: Bright Spots, an illuminating 3-part series shedding light on tapinarof, a pioneering nonsteroidal topical treatment for plaque psoriasis. In Part 2, G Michael Lewitt, MD, is joined by Lauren Miller, PA-C, to discuss the unique features of tapinarof, a nonsteroidal topical treatment option for plaque psoriasis in adult patients. A unique remittive effect The pair discusses a unique differentiator of tapinarof, with evidence suggesting that patients may encounter a remittive effect upon discontinuation. In the PSOARING 3 trial, a 40-week, open-label, long-term extension study, patients (n=73) who entered the trial with clear skin maintained clear or almost clear skin for an average of 114 days before returning to a state of mild disease. A versatile alternative to steroidal therapies They also discuss the versatility of tapinarof, which can be used on any body part, including the scalp and intertriginous areas, and its minimal systemic absorption with no evidence of straie, tachyphylaxis, skin atrophy, or hypopigmentation. They underscore the advantages of tapinarof over traditional steroidal treatments, highlighting its safety and the potential to reduce the burden of polypharmacy. Real-world impact They conclude their conversation by sharing an overview of a real-world patient case, that of a 23-year-old student with psoriasis in the genital area. They detail the significant improvement in both symptoms and emotional well-being seen in the patient after 4 weeks of treatment with tapinarof, highlighting it as a unique and innovative addition to the psoriasis topical treatment landscape.Missed Part 1? Check it out here to learn about tapinarof's mechanism of action and the phase 4 results from the open-label trial for treatment in the head and neck region. https://dermsquared.com/videos/topical-conversations/bright-spots-2 668 2024-04-01T16:03:19.548Z yes https://dermsquared.com/videos/topical-conversations/type-2-inflammation-skin 2025-04-22T19:57:07.761Z https://image.mux.com/4Rrst902BFHdC6cvcSCuqnBR34ufIMxOvG01uZcddmZt8/thumbnail.jpg Type 2 Inflammation in Skin Conditions: A Clinical Perspective In this episode of Topical Conversations, Dr. Michael Cameron and Dr. Graham Litchman explore the pathophysiology of type 2 inflammation in dermatologic diseases and discuss how evolving treatment options are reshaping clinical practice. From atopic dermatitis (AD) and prurigo nodularis (PN) to chronic spontaneous urticaria (CSU), they break down the mechanisms of disease, targeted therapies, and emerging treatment strategies that are changing the way dermatologists approach inflammatory skin conditions. Understanding type 2 inflammation across dermatologic diseases Since the approval of dupilumab in 2017, research into type 2 inflammation has expanded dramatically. Dr. Litchman highlights how this shared inflammatory pathway connects conditions such as asthma, allergic rhinitis, AD, PN, and CSU, allowing dermatologists to educate patients on the systemic nature of their disease. Dr. Cameron emphasizes the complex immune dysregulation in type 2 diseases, particularly the cross-talk between inflammatory cells. He explains that IL-4 and IL-13, key drivers of AD and PN, are present not only on inflammatory cells but also on sensory nerves, contributing to chronic itch. Targeted therapies like dupilumab, tralokinumab, lebrikizumab, and nemolizumab work by interrupting these signaling pathways, leading to symptom relief. Emerging therapies and novel mechanisms of action The discussion shifts to next-generation treatments that go beyond blocking cytokine communication to directly targeting inflammatory cells. Dr. Litchman shares excitement about the potential of Bruton’s tyrosine kinase (BTK) inhibitors that prevent mast cell activation and degranulation; JAK1 inhibitors that have the potential to expand options for systemic inflammatory control; monoclonal antibodies that look to directly inhibit IL-5, IL-13, and eosinophils, offering new avenues for treatment; and OX40 ligand inhibitors, that work by eliminating pathogenic T cells rather than just blocking their signals. Dr. Cameron highlights key priorities in drug development, including longer dosing intervals (every 3 months), higher efficacy (bispecific and trispecific antibodies), and more oral treatment options. The role of dermatologists in managing CSU and PN CSU is often referred out, but both doctors agree that dermatologists should reclaim these patients. Dr. Cameron points out that many patients with CSU patients are also atopic, reinforcing that dermatologists are well-equipped to manage their care. With BTK inhibitors and anti-c-Kit therapies emerging, now is the time to bring CSU management back into dermatology practices. For PN, the approval of dupilumab and nemolizumab has been a breakthrough. Previously neglected due to a lack of therapeutic options, patients with PN now have access to effective, targeted treatments. Dr. Cameron emphasizes that many patients with PN also have coexisting atopic conditions, making these therapies beneficial beyond PN alone. Key takeaways: Type 2 inflammation plays a central role in several dermatologic conditions, including atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria Emerging treatments, including BTK inhibitors, JAK1 inhibitors, and OX40 ligand inhibitors, offer new approaches by targeting inflammatory cells directly rather than just blocking cytokines Prurigo nodularis treatment has advanced, with new options providing effective options for a previously difficult-to-manage condition It is crucial that dermatologists remain informed about new mechanisms of action to optimize individualized patient care as treatment options expand https://dermsquared.com/videos/topical-conversations/type-2-inflammation-skin 370 2025-03-05T17:08:22.039Z yes https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-managing-adolescent-and-young-adult-patients 2024-11-26T18:14:15.748Z https://image.mux.com/CTZsiCCfMMEqb401Gn6B56L01bWTOTyMQ00qeCsi02H51WY/thumbnail.jpg National Healthy Skin Month: Managing Adolescent and Young Adult Patients For National Healthy Skin Month, we’re spotlighting skin health practices across all stages of life. In this segment, Dr Nicholas Brownstone shares his expertise on managing patients in the adolescent and young adult demographic—a pivotal stage where dermatologists must consider not only physical health but also mental well-being. Understanding the adolescent perspective Dr Brownstone highlights that skin changes throughout life, as do our psychology and worldview. These shifts are particularly pronounced during adolescence, a time when many patients first develop social anxieties tied to their appearance. At this stage, patients are still forming their sense of identity, and even minor skin issues can feel monumental. Dermatologists must recognize the unique emotional weight that acne carries for this group and avoid dismissing their concerns—a practice Dr Brownstone refers to as “empathetic failure.” The psychological impact of acne According to Dr Brownstone, adolescence is often the life stage where acne has the greatest psychological impact. He emphasizes that even a single pimple can feel like “the end of the world” for these patients. This perspective supports the importance of taking their concerns seriously and tailoring treatment approaches to meet their emotional as well as physical needs. Pearls for treating acne in adolescents Dr Brownstone advises dermatologists to approach acne treatment in adolescents differently than in pediatric or adult patients. Key considerations include: Empathy first: Understanding the adolescent perspective and avoiding dismissive responses that could alienate patients Individualized treatment: Acknowledging that not all acne cases are equal and adjusting treatment plans accordingly Aggressive treatment when needed: Dr Brownstone suggests that even one pimple may justify aggressive treatment options, including isotretinoin, if the acne is perceived as life-ruining by the patient. Key takeaways for dermatologists As dermatologists, it’s crucial to consider both the physical and emotional impacts of acne on adolescent patients. Dr Brownstone encourages his colleagues to view this demographic through a compassionate lens, understanding their unique challenges and tailoring care to meet their needs effectively. By fostering empathy and delivering personalized care, dermatologists can make a profound difference in the lives of their adolescent patients, helping them navigate this critical stage with confidence and better skin health.Watch Part 1 here for expert insights on caring for dermatology's youngest patients, Part 3 here for strategies to optimize skin health in adults and middle-aged patients, and Part 4 here for guidance on caring for the older adult patient population—all for National Healthy Skin Month! https://dermsquared.com/videos/topical-conversations/national-healthy-skin-month-managing-adolescent-and-young-adult-patients 136 2024-11-15T18:01:36.865Z yes https://dermsquared.com/videos/topical-conversations/systemic-agents-skin-of-color 2025-09-16T21:00:43.416Z https://image.mux.com/rv1CsJZoSaqg5sC01gJZGf00Btzaif5HqUhbDQ5cbwK18/thumbnail.jpg Systemic Agents in Skin of Color Understanding Systemic Treatment in Patients with Skin of Color In this episode of Topical Conversations, Cheri Frey, MD, and Amy McMichael, MD, discuss the use of systemic agents for treating atopic dermatitis and other skin conditions in patients with skin of color. They highlight biological differences, challenges in disease assessment, and practical strategies for improving outcomes and access to care. Biologic Differences and Disease Presentation Patients with skin of color may have lower ceramide levels, contributing to conditions like eczema. Dr Frey and Dr McMichael discuss how atopic dermatitis can present differently, with less visible erythema and more lichenification, hypopigmentation, or dyschromia. This variation can complicate severity assessments and insurance approvals. Health Literacy and Access to Care Both physicians emphasize the importance of educating patients and their families about skin care and the safety of systemic therapies. Dr McMichael points out that socioeconomic factors and low health literacy can limit access to effective treatments. She underscores the need for outreach to primary care providers to ensure timely referrals to dermatologists. Tools and Severity Assessment Standard scoring tools that rely on visible erythema may underrepresent disease severity in skin of color. Dr McMichael advises focusing on symptoms like itching and lichenification to accurately capture disease burden and support treatment decisions. Early Intervention and Improved Outcomes Dr Frey advocates for earlier use of systemic treatments to break the itch-scratch cycle and prevent complications like dyschromia and nodular scars. Dr McMichael highlights the role of newer systemic agents targeting cytokine pathways, such as IL-4 and IL-13, which have transformed atopic dermatitis management. A Personal Success Story Dr Frey shares a memorable patient case: a young girl who felt too embarrassed by her skin to join cheerleading. After starting a systemic medication, she not only joined the team but excelled, demonstrating how timely intervention can restore confidence and quality of life. Key TakeawaysAtopic dermatitis often presents differently in patients with skin of color, requiring tailored assessment beyond visible erythema.Health literacy, socioeconomic factors, and provider education are key to improving access to systemic therapies.Systemic agents can break the itch-scratch cycle early, reducing complications and improving quality of life.Newer biologics targeting IL-4 and IL-13 offer safe and effective options for severe cases.Personal stories highlight the transformative impact of early, appropriate therapy. https://dermsquared.com/videos/topical-conversations/systemic-agents-skin-of-color 545 2025-07-01T13:42:19.744Z yes https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-scle-and-dermatomyositis 2024-02-27T19:46:26.872Z https://image.mux.com/28l01pz3i1e36mHuGlyLtyhZnyOfO7Qrh5JyCFc01UlxA/thumbnail.jpg Rare Diseases in Dermatology: SCLE and Dermatomyositis For Rare Disease Day on February 29, Topical Conversations will be exploring some of the rare diseases seen in dermatology. In this installment, Todd Schlesinger, MD, FAAD, FASMS, gives his perspective on subacute cutaneous lupus erythematosus (SCLE) and dermatomyositis. Watch Part 2 to hear Dr Naiem Issa discuss tuberous sclerosis complex and a breakthrough new treatment.Subacute cutaneous lupus erythematosus SCLE is a condition linked to systemic lupus erythematosus in 50% of patients; it may also be associated with Sjögren’s syndrome. SCLE manifests as a small, red, scaly papular eruption in sun-exposed areas, progressing to a psoriasiform or annular lesion. This photosensitive dermatosis is nonscarring and nonatrophic, with lesions healing without scarring but potentially leaving some dyspigmentation. Commonly affected regions include the shoulders, forearms, neck, and upper torso. Around 50% of patients with SCLE patients experience joint involvement, with often symmetrical arthralgias usually affecting small joints like wrists and hands. Dr Schlesinger notes that SCLE is a notably challenging condition in dermatology but expresses hope for new treatments in the pipeline, potentially ones that leverage existing medications used for psoriasis and atopic dermatitis. Dermatomyositis Dermatomyositis is a rare, idiopathic inflammatory disorder primarily affecting the skin and muscles but sometimes also affecting the joints, esophagus, lungs, and heart. It falls within the category of myositis, a rare group of diseases characterized by inflamed muscles, and poses challenges for dermatologists due to its complexity in both diagnosis and treatment. The condition is characterized by distinctive skin findings, including a heliotrope rash around the eyes, Gottron papules over the joints, and facial erythema over the cheeks and nasal bridge. Muscular involvement often leads to weakness, particularly in the proximal muscles. Treating patients with dermatomyositis and related myositic disorders poses diagnostic and therapeutic challenges, and Dr Schlesinger comments that this condition, along with the broader category of myositic disorders, has not received sufficient attention. He looks forward to innovation in this area to improve approaches to diagnosis and treatment. Overlapping pathways Dr Schlesinger also emphasizes the overlapping inflammatory pathways that SCLE and dermatomyositis share with the more common dermatologic conditions, especially alopecia areata, atopic dermatitis, and psoriasis. With a focus on research, innovation, and collaborative efforts, dermatologists can work to address the diagnostic and therapeutic challenges associated with these rare diseases in dermatology. https://dermsquared.com/videos/topical-conversations/rare-diseases-in-dermatology-scle-and-dermatomyositis 72 2024-02-26T18:54:14.445Z yes https://dermsquared.com/videos/topical-conversations/tips-for-managing-hair-loss-disorders-in-pediatric-patients 2024-09-10T17:54:45.022Z https://image.mux.com/ibb2q5xsJZp4472Smk02PiZnNETwXwJoPzYvYZcfV8HY/thumbnail.jpg Tips for Managing Hair Loss Disorders in Pediatric Patients Hair loss in pediatric patients can be particularly challenging, both for the child and their family. In this episode of Topical Conversations, pediatric dermatologist Lisa Swanson, MD, shares 3 practical tips to help dermatologists effectively diagnose and manage the most common forms of hair loss in children.Recognize tinea capitis as a leading cause of alopecia with scaling When faced with a child presenting alopecia and scalp scaling, dermatologists should assume tinea capitis (scalp ringworm) until proven otherwise. Tinea capitis is a fungal infection that requires prompt treatment to prevent worsening of symptoms and further hair loss. Dr Swanson emphasizes: Oral antifungals are essential: Topical treatments alone will not resolve the infection. First-line therapies include oral terbinafine or griseofulvin, both highly effective against the dermatophyte fungi that cause tinea capitis. Address loose anagen syndrome (LAS) in young children Loose anagen syndrome (LAS) is another common cause of hair loss in young children, particularly females aged 3 to 4 who have never needed a haircut, with hair that rarely grows past their shoulders. LAS is characterized by hair that easily pulls out of the scalp due to improper anchoring in the follicle during the anagen phase. Dr Swanson offers several key points for managing LAS: Reassure families: While concerning, LAS is typically a benign condition that often improves with age. Dr Swanson reassures parents that if their child is to experience hair loss, LAS is relatively mild, as it usually resolves spontaneously over time. Psychological impact: Despite its benign nature, LAS can still be distressing for children, particularly young girls who may struggle with short or thinning hair. Dermatologists should address this emotional aspect by providing families with reassurance and information on the condition’s self-limiting nature. Take alopecia areata (AA) seriously in pediatric patients Alopecia areata in children is an autoimmune condition with significant psychosocial consequences. Dr Swanson urges dermatologists to approach treatment for pediatric AA with the same seriousness as they would for adult patients, emphasizing that early intervention can make a profound difference. Key treatment strategies include: Topical corticosteroids and minoxidil foam: For younger children, intralesional corticosteroids are often avoided. Instead, Dr Swanson recommends topical corticosteroids, often combined with over-the-counter minoxidil foam to stimulate hair growth. Pulse prednisone therapy: In certain cases, Dr Swanson suggests considering pulse prednisone therapy, where a large dose of prednisone is administered for one weekend a month. This regimen can help manage inflammation and potentially slow the progression of AA. Low-dose oral minoxidil: For more severe or unresponsive cases, low-dose oral minoxidil may be used alongside pulse prednisone therapy to promote hair regrowth. Off-label JAK inhibitors: In cases of severe or extensive AA, Dr Swanson highlights the potential use of oral JAK inhibitors for pediatric patients, although currently, no JAK inhibitors are FDA-approved for children under 12. However, she notes that dermatologists can work with insurance to obtain off-label approval for this treatment, which may offer life-changing results for certain patients. Hair loss disorders in pediatric patients require a careful, individualized approach. By promptly diagnosing conditions like tinea capitis and appropriately managing others, such as LAS and AA, dermatologists can significantly improve both the clinical outcomes and quality of life for their young patients. https://dermsquared.com/videos/topical-conversations/tips-for-managing-hair-loss-disorders-in-pediatric-patients 137 2024-09-10T17:54:45.013Z yes https://dermsquared.com/videos/topical-conversations/proactive-strategies-counseling-patients-hs-flare-management 2024-04-10T20:43:32.529Z https://image.mux.com/xHBacFSe8DNF6CKOhjbfriTUOCnqrNnsmLztmB1OKq00/thumbnail.jpg Proactive Strategies: Counseling Patients on HS Flare Management In this quick-hitting installment of Topical Conversations, Andrea Murina offers a few tips on some first-visit essentials when counseling your patients on managing their flares associated with hidradenitis suppurativa (HS). The patient education conversationShe encourages dermatologists to initiate conversations about managing HS flares at the patient's first visit and advises educating patients on various ways to handle acute flares. She suggests advising patients to use warm compresses and utilize both topical and oral pain relievers to alleviate symptoms. Furthermore, Dr Murina encourages patients to return to the office if necessary, particularly if they require intralesional Kenalog injections or oral antibiotics. A proactive approach to empower patientsTo empower patients and give them a sense of control over their condition, Dr Murina suggests prescribing oral antibiotics for patients to have on hand in case of a flare-up. By proactively addressing flare management strategies, dermatologists can improve outcomes and enhance overall quality of life for patients with HS. https://dermsquared.com/videos/topical-conversations/proactive-strategies-counseling-patients-hs-flare-management 41 2024-04-10T18:42:13.862Z yes https://dermsquared.com/videos/topical-conversations/examining-benzene-benzoyl-peroxide-insights-latest-research 2024-07-18T19:40:58.419Z https://image.mux.com/zdwygPk27mRnYM00mKGPytPMEA9rtTTGf8amwOcMV8fg/thumbnail.jpg Examining Benzene in Benzoyl Peroxide: Insights into the Latest Research In this episode of Topical Conversations, John Barbieri, MD, MBA, FAAD, examines the safety concerns surrounding benzoyl peroxide, a common ingredient in acne treatment products. He reviews 2 new research studies that investigate the risks associated with benzoyl peroxide use, providing insights into its safety for routine clinical practice. Concerns raised by Valisure report on benzoyl peroxide In March 2024, Valisure released a report indicating that benzoyl peroxide products may contain benzene, a potential carcinogen, due to thermal decomposition under high temperatures. This raised concerns about the safety of benzoyl peroxide in clinical practice. Dr John Barbieri addresses these concerns by discussing 2 new research studies that explore the risks associated with benzoyl peroxide use. Analysis of blood benzene levels in benzoyl peroxide users The first study analyzed data from the National Health and Nutrition Examination Survey (NHANES), comparing blood benzene levels in individuals using benzoyl peroxide products with those who did not. The study matched participants on various risk factors for benzene exposure and found no detectable differences in benzene levels between the 2 groups. Additionally, for those with detectable benzene, the average levels were similar in both groups. Dr Barbieri notes that these findings suggest that benzoyl peroxide use does not lead to increased benzene levels in the body, providing reassurance about its safety in routine clinical use. Long-term cancer risk assessment in benzoyl peroxide users The second study utilized data from TriNetX, examining a cohort of over 50,000 individuals. The study matched benzoyl peroxide users with nonusers and monitored them for 10 years. The research did not identify any increased risk of malignancy, including leukemia, lymphoma, or solid organ tumors, among benzoyl peroxide users. Dr Barbieri comments that these results further support the safety of benzoyl peroxide in clinical practice, indicating no heightened cancer risk from its routine use. Overall safety of benzoyl peroxide in clinical practice Dr Barbieri concludes by commenting that together, these studies provide valuable data, suggesting that the routine use of benzoyl peroxide products for acne and other skin conditions appears to be relatively safe. He suggests that, based on these findings, patients and clinicians can feel reassured about the continued use of benzoyl peroxide in their treatment regimens. https://dermsquared.com/videos/topical-conversations/examining-benzene-benzoyl-peroxide-insights-latest-research 119 2024-07-18T19:40:58.410Z yes https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-part-3 2024-02-07T21:12:36.951Z https://image.mux.com/TlCrIHC00wz981RhPdW3MjJ44ax8hLZAKuNTE8PQPHbY/thumbnail.jpg Part 3—A Dermatologist’s Perspective: Updated Atopic Dermatitis Guidelines from the AAAAI/ACAAI Joint Task Force In the final segment of this Topical Conversations feature with Peter Lio, MD, FAAD, he continues his review of the latest updates to the atopic dermatitis management guidelines from the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force (AAAAI/ACAAI JTF). As part of the multidisciplinary guideline panel, Dr Lio offers a dermatologist’s overview of the updated guidelines. Watch Part 2 here, where Dr Lio comments on the guidelines regarding nonsteroidal agents and bleach baths, along with notable recommendations on topical ruxolitinib and elimination diets. Remission and proactive therapy Dr Lio begins by summarizing the guidelines’ conclusions on remission and proactive therapy, which he considers to be the most important framework shift in treating atopic dermatitis. The guidelines strongly recommend the use of proactive therapy with a calcineurin inhibitor or a mid-potency topical corticosteroid in areas that frequently flare as opposed to applying topical treatments only in response to flares. Intermittent use of steroidal or nonsteroidal topical therapies, 2 to 3 times weekly, can potentially maintain remission and reduce the frequency of flareups. Systemic therapies The guidelines also address systemic options for patients who are refractory to topical therapies, which is usually those with moderate-to-severe disease. These options include biologics such as dupilumab, tralokinumab, and lebrikizumab (currently available in Europe), oral JAK inhibitors upadacitinib, abrocitinib, and baricitinib (currently approved for use with atopic dermatitis outside the US), as well as phototherapy. The biologics and JAK inhibitors are all recommended in their proper context, as is cyclosporine. Interestingly, the guidelines recommend against the use of legacy immunosuppressants like azathioprine, methotrexate, and mycophenolate, noting that most well-informed patients prefer to avoid the potential harms and burdens they pose in exchange for modest benefits. Similarly, the guidelines recommend against the use of systemic corticosteroids. The panel inferred that patients place a higher value on avoiding harm and poor long-term control of atopic dermatitis than on the uncertain benefit conferred by systemic corticosteroids, with the often transient benefit and low-certainty evidence driving the conditional recommendation. Importantly, the overuse of systemic corticosteroids weighed against their routine use for flare management or bridge therapy. Exciting time, new guidelines, new ways of thinking about things, and a rich pipeline, which means our work is far from over. Dr Lio concludes with his excitement for the guideline’s fresh perspectives and the rich pipeline ahead for atopic dermatitis treatment. Watch Part 1 here Watch Part 2 here Key points: Proactive therapy in areas that frequently flare is strongly recommended to encourage and maintain remission Legacy immunosuppressants and systemic corticosteroids are recommended against, with patients perceiving the risk of adverse effects as outweighing the potential for modest benefits Overuse contributed to the recommendation against treatment with corticosteroids for routine flare management or bridge therapy https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-part-3 173 2024-02-07T21:12:36.940Z yes https://dermsquared.com/videos/topical-conversations/get-involved-with-camp-discovery 2024-01-29T18:44:56.543Z https://image.mux.com/jbfC00o82Y5ayoChAxtBf6CRTLh00OvB3QBFhghsDgNxA/thumbnail.jpg Get Involved with Camp Discovery In this special edition of Topical Conversations, Charlie Dunn, MD, provides an overview of the American Academy of Dermatology’s (AAD) Camp Discovery and how you can get involved with this uniquely valuable experience for pediatric patients. Applications are open until April 2, 2024, representing a chance to make a lasting impact on the lives of children with chronic skin conditions. What is Camp Discovery? Established in 1993 by the AAD, this multisite, weeklong program offers children living with chronic skin conditions a unique summer camp experience. Provided at no cost to families, Camp Discovery welcomes pediatric patients with conditions including eczema, psoriasis, vitiligo, alopecia, epidermolysis bullosa, ichthyosis, and more. An invaluable experience for children with chronic skin conditions Studies have demonstrated that after participating in Camp Discovery, children with chronic skin conditions have a better understanding of their condition, improved symptom control, better social functioning, and higher overall quality of life. Benefits for the clinician The benefits of Camp Discovery extend beyond the campers; medical volunteers also experience a substantial positive impact by participating. One study demonstrated that 97% of medical volunteers encountered skin conditions at Camp Discovery they had not previously seen, and 93% report it as one of the best rotations they’ve undertaken. Engaging in this program opens doors to networking opportunities, establishes lifelong mentor-mentee relationships, enhances knowledge of complex diseases, and fosters multidisciplinary communication. Importantly, this opportunity is not exclusively for pediatric specialists; volunteers include both adult and pediatric dermatologists who span medical, cosmetic, and surgical dermatology. How to get involved Be a volunteer: Sign up to be a medical volunteer and contribute your expertise to this life-changing experience. Refer your patients: Encourage your patients to apply and witness the transformative impact of Camp Discovery on their lives. Change a life: By participating, you have the power to make a positive difference in the lives of children. https://dermsquared.com/videos/topical-conversations/get-involved-with-camp-discovery 158 2024-01-29T18:44:56.538Z yes https://dermsquared.com/videos/topical-conversations/pdt-noninvasive-approach-to-ak-management 2025-10-20T22:32:08.531Z https://image.mux.com/nLnK102AQTLWie3MJ007imv00wamSNWJBVKKoQLgleoCJM/thumbnail.jpg PDT: A Noninvasive Approach to AK Management In this episode of Topical Conversations, Gary Goldenberg, MD, discusses photodynamic therapy (PDT) as a valuable tool in managing actinic keratoses (AKs). Reassessing AK treatment strategies AKs pose a significant challenge in dermatologic practice due to their potential progression to keratinocyte carcinomas, such as squamous cell carcinomas. Dr Goldenberg likens the conventional approach of treating each individual AK to pulling weeds out of a garden one by one. This analogy underscores the limitation of solely targeting visible lesions while neglecting subclinical AKs that may be present. Numerous studies support the existence of subclinical AKs, emphasizing the need for a treatment modality that addresses both the visible and invisible manifestations of these precancerous growths. Integrating PDT into your practice PDT is a valuable option for managing both visible and invisible subclinical AKs and is an easy treatment to integrate into a practice. The procedure involves the application of a PDT agent, chosen based on the provider’s preference, followed by a 30 to 60-minute wait. Next, patients are exposed to blue or red light, or laser devices if preferred. A proactive strategy to prevent skin cancer Dr Goldenberg encourages patients with multiple AKs to undergo PDT 2 to 4 times per year and views this proactive, regular approach as an investment in patients’ future health. By consistently reducing the number of visible and subclinical AKs, dermatologists aim to theoretically decrease the likelihood of developing keratinocyte carcinomas, offering effective long-term benefits to patients. https://dermsquared.com/videos/topical-conversations/pdt-noninvasive-approach-to-ak-management 85 2024-02-14T21:04:51.363Z yes https://dermsquared.com/videos/topical-conversations/dermatitis-and-clinical-perspective 2026-06-26T18:28:04.064Z https://image.mux.com/FHWt8czHMYJvHp3p1eu8xrAZ02hYrFQal1HPbBWofUkQ/thumbnail.jpg Tapinarof tolerability in psoriasis and atopic dermatitis: Follicular events, contact dermatitis, and clinical perspective In this episode of Topical Conversations, Linda Stein Gold, MD, and G. Michael Lewitt, MD, discuss the tolerability profile of tapinarof and how adverse events observed in clinical trials compare with their real-world experience treating patients with plaque psoriasis and atopic dermatitis.Tapinarof, an aryl hydrocarbon receptor (AhR) agonist, was initially approved in 2022 for adults with plaque psoriasis and was subsequently approved for atopic dermatitis in patients as young as 2 years of age. Through modulation of AhR signaling, tapinarof influences multiple pathways relevant to inflammatory skin disease, including cytokine signaling, oxidative stress, and skin barrier function.The discussion focuses on two adverse events that have received particular attention: follicular events and contact dermatitis.Tapinarof and the evolving role of nonsteroidal topical therapyHistorically, nonsteroidal topical therapies have often been incorporated into treatment regimens as adjunctive agents or during topical corticosteroid holidays, helping patients maintain disease control while reducing reliance on corticosteroids.Dr Lewitt notes that tapinarof has been used somewhat differently in clinical practice, serving not only as a maintenance therapy but also as a treatment capable of achieving disease control in appropriate patients. Dr Stein Gold agrees that the availability of newer nonsteroidal topical options has allowed for simpler treatment approaches in some patients, reducing the need for multiple topical medications with different roles within a treatment regimen.Tolerability profile of tapinarofBoth physicians note that application-site stinging and burning have been relatively uncommon in their experience with tapinarof, particularly compared with some earlier nonsteroidal topical therapies.Instead, the adverse events most frequently discussed in relation to tapinarof have been follicular events and contact dermatitis. While these events have been observed in both psoriasis and atopic dermatitis clinical trials, the incidence, severity, and clinical significance warrant closer examination.Folliculitis in plaque psoriasisDr Lewitt reviews findings from the psoriasis clinical trials, where folliculitis was reported in approximately 18% to 24% of patients during the 12-week treatment period.Importantly, the majority of cases were not characterized by inflammatory pustular lesions. Rather, they were more commonly described as hyperkeratotic or keratosis pilaris-like follicular changes. Most events were mild to moderate in severity, and treatment discontinuation due to folliculitis was uncommon.Follicular events in atopic dermatitisThe physicians contrast these findings with those observed in the atopic dermatitis trials, where follicular events were designated as an adverse event of special interest.In the 8-week atopic dermatitis trials, follicular events occurred less frequently than in the psoriasis studies, with reported rates of approximately 9% to 14%. As in the psoriasis trials, most events were mild to moderate in severity; discontinuation rates were below 1%.Dr Lewitt notes that his real-world experience has generally aligned with the clinical trial findings, with follicular events appearing less common among patients with atopic dermatitis than among patients with psoriasis. Dr Stein Gold reports a similar experience, noting that she has not observed folliculitis among her own patients with atopic dermatitis treated with tapinarof.Contact dermatitis: incidence and clinical considerationsContact dermatitis has also been reported during tapinarof treatment.Dr Lewitt notes that in the psoriasis clinical trials, contact dermatitis occurred in approximately 5% to 6% of patients, with discontinuation rates of approximately 1.5%. Based on the clinical characteristics of these reactions, he speculates that at least some cases may have represented irritant rather than allergic contact dermatitis.In the atopic dermatitis trials, rates of contact dermatitis were low, with both event rates and discontinuation rates below 1%. Notably, contact dermatitis was reported more frequently in the vehicle arm than in the tapinarof-treated arm.Dr Stein Gold notes that she has encountered contact dermatitis infrequently in clinical practice, reporting a single case among her patients with psoriasis and none among her patients with atopic dermatitis.Practical considerations for clinical useNeither physician views follicular events or contact dermatitis as a major barrier to prescribing tapinarof. Both note that these adverse events are generally uncommon, typically mild to moderate in severity, and infrequently lead to treatment discontinuation.Dr Lewitt notes that when discussing treatment expectations with patients, he mentions the possibility of these adverse events while emphasizing their generally manageable nature. Practical measures such as applying a thin layer of medication, minimizing application to occluded areas, wearing loose-fitting clothing when appropriate, and applying tapinarof after an emollient may help reduce the likelihood of unwanted drug spread to uninvolved skin.Clinical perspectiveThe discussion highlights that while follicular events and contact dermatitis can occur during tapinarof treatment, both events are typically mild to moderate in severity and rarely result in treatment discontinuation. The incidence of these adverse events appears lower in atopic dermatitis clinical trials than in psoriasis studies, and both physicians report real-world experiences that generally align with those observations.For clinicians considering nonsteroidal topical treatment options for chronic inflammatory skin disease, understanding the nature and clinical relevance of these adverse events may help inform treatment selection and patient discussions. https://dermsquared.com/videos/topical-conversations/dermatitis-and-clinical-perspective 898 2026-06-26T18:28:04.056Z yes https://dermsquared.com/videos/topical-conversations/part-2-integrating-mental-health-support-vitiligo-support-groups 2024-06-25T13:41:16.642Z https://image.mux.com/gH2u6Jt0102n5GowQXitdhi6G7qQXzVIIUgKn00AtFKlBk/thumbnail.jpg Part 2: Integrating Mental Health Support in Vitiligo Support Groups In this Topical Conversations special edition 4-part series, Richard Huggins, MD, dermatologist and member of the board of directors at the Global Vitiligo Foundation, is joined by Amaris Geisler, MD, Katie O’Connell, MS, and Tonja Johnson of the Beautifully Unblemished Vitiligo Support Group, to discuss their publication on the importance of vitiligo patient support groups and how these groups can provide value to both patients and providers. In Part 2, the conversation explores the critical importance of integrating mental health support within a support group setting. Providing a structured and safe space Support groups offer a structured environment where patients can share their thoughts on mental health topics, offering a valuable benefit to this population. These groups provide a community where individuals can discuss how vitiligo affects them personally, as well as its impact on their family members and caregivers. It is paramount when starting or joining a support group to create a safe space from day one. Setting clear ground rules ensures that all members feel comfortable discussing sensitive topics, coping with a new diagnosis, and managing vitiligo as a condition. Integrating mental health support One critical recommendation for designing an effective patient support group is to have a mental health provider connected to the group to address mental health wellness. While the physical aspects of vitiligo are important, the mental aspects are equally crucial. In typical clinical practice, patient interactions often last only 10 to 15 minutes, limiting the depth of conversation about how patients are coping with the mental health aspect of their condition. Support groups, however, offer a way for patients to connect and form a community where they can address these important topics. Having a mental health provider as part of the group can help facilitate discussions on mental well-being, providing a more comprehensive support system for patients. Continue to Part 3, where the discussion explores how support groups can provide invaluable educational insights for physicians and benefit clinical trial and research work. Missed Part 1? Check it out here. https://dermsquared.com/videos/topical-conversations/part-2-integrating-mental-health-support-vitiligo-support-groups 102 2024-06-20T19:16:31.061Z yes https://dermsquared.com/videos/topical-conversations/breaking-down-the-fda-mandated-changes-ipledge-program-isotretinoin 2024-01-03T17:12:28.535Z https://image.mux.com/EPnezbYatgqqiQOZO5z802300mr2aG6G01XuzY2uLSAgzY/thumbnail.jpg Breaking Down the FDA-Mandated Changes to the iPLEDGE Program for Isotretinoin The FDA has recently mandated significant modifications to the iPLEDGE program, which is designed to manage the risks associated with isotretinoin use. In this video, Dr John Barbieri of Brigham and Women’s Hospital and Harvard Medical School breaks down the details of the key updates. Streamlined Counseling for Individuals not of Childbearing Potential One of the most noteworthy changes is the elimination of monthly counseling documentation for individuals not of childbearing potential. Previously, this requirement added an unnecessary burden for both patients and clinicians. Under the new guidelines, counseling documentation will only be required at enrollment, potentially providing a substantial reduction in the frequency of patient visits. Dr Barbieri underscores how this change can enhance flexibility for clinicians, making it easier to prescribe isotretinoin and subsequently improve access to this crucial acne treatment. Removal of the 19-Day Lockout Period A second pivotal change involves the removal of the 19-day lockout period. Currently, patients face a stringent 7-day window to pick up their prescription; if missed, patients are required to wait 19 days before taking another pregnancy test. This measure, sometimes considered overly punitive to patients, is now being eliminated, aligning the iPLEDGE program with other similar programs. Under the new requirements, patients who miss the initial 7-day window can repeat a pregnancy test, granting them eligibility to receive the drug. This modification addresses issues related to pharmacy stock and prior authorization hurdles, ensuring patients can access the medication without unnecessary delays. Shift Towards Home Pregnancy Testing Another substantial update involves a shift from requiring CLIA-certified pregnancy tests to allowing home pregnancy testing for patients of childbearing potential. While the first 2 tests, to enroll the patient and after the 30-day waiting period, still need to occur in an office-based setting, subsequent tests after the initiation of isotretinoin can be conducted either in a medical setting or using a home pregnancy test. Dr Barbieri suggests steps to minimize falsification, such as having patients write their names and dates on the test, ensuring accuracy and convenience for patients. Anticipated Implementation These transformative changes are eagerly anticipated, and isotretinoin manufacturers have been given a 6-month window to respond to the FDA's recommendations. Dr Barbieri expresses hope that collaboration with stakeholders, including dermatologists, patients, and pharmacists, will be key to implementing changes that prioritize patient safety while ensuring continued and accessible isotretinoin treatment. https://dermsquared.com/videos/topical-conversations/breaking-down-the-fda-mandated-changes-ipledge-program-isotretinoin 179 2024-01-03T17:12:28.529Z yes https://dermsquared.com/videos/topical-conversations/ad-care-for-65 2025-10-17T20:32:47.600Z https://image.mux.com/Kt302ygZ3HMtLmkRmAreXNM6xGJMlwEyTPzBDnG6eMzw/thumbnail.jpg From “Brown Bag Review” to Biologics: AD Care for 65+ In this episode of Topical Conversations, Daniel Butler, MD, joins Adam Friedman, MD, to focus on an often under-recognized group: older adults with atopic dermatitis (AD). They explore why late-onset AD after 65 is more common than many clinicians may assume, how pruritus frequently outpaces visible inflammation in this cohort, and therapeutic considerations when dexterity limits, comorbidities, and polypharmacy complicate care.AD beyond childhoodDr. Friedman recalls the “rule of 3” from training when it comes to patients with childhood-onset AD: one third improve over time, one third remain the same, one third worsen; he also notes that approximately 20% of adults develop AD de novo, including those ≥65. In susceptible patients, skin senescence, barrier decline, and pH shifts can tip genetics into clinical disease. He emphasizes that recognizing new-onset AD or AD-like phenotypes in older adults and identifying it correctly is essential.Pruritus out of proportionDrs Friedman and Butler then highlight age-related presentation differences: in older adults, AD often manifests as more papular, less scaly, truncal-predominant disease with pruritus out of proportion to modest visible inflammation. They emphasize that this itch–rash discordance can lead clinicians to underestimate disease burden and its impact on sleep, mood, and daily functioning.Practical barriers: polypharmacy, access, applicationThey next discuss the importance of appropriately matching therapy to real-world constraints. They explain how polypharmacy can turn multistep topical regimens into the familiar “bag of creams” problem; twice-daily application may be unrealistic given mobility, reach, or vision limitations, and even injectables require assessing dexterity, comfort with needles, bruisability and infection risk, and the availability of caregiver support.Choosing treatments that work for this populationDrs Butler and Friedman agree that modern biologics have been transformative for AD treatment, with minimal drug–drug interactions, simple dosing intervals, and strong antipruritic/anti-inflammatory effects often reducing the need for multiple topicals or daily pills. Conversely, off-label antipruritics like gabapentinoids and SSRIs may pose renal and sedation risks in older adults.Closing pearls and “theranostics”They conclude their discussion with some practical pearls for managing this population, commenting that marked itch with modest dermatitis warrants a thoughtful differential, considering conditions like nonbullous pemphigoid and malignancy-related pruritus. After excluding more serious conditions, targeted biologics like dupilumab, lebrikizumab, and nemolizumab can act as “theranostics,” with response supporting a type 2 endotype and a lack of response redirecting the workup. Although older adults were under-represented in pivotal trials, Dr Friedman closes by emphasizing that dermatologists can be confident in safety and effectiveness in practice for this population.Key takeawaysAD can begin after 65: don’t dismiss late-onset disease in older adultsItch may far exceed visible inflammation: prioritize patient-reported pruritus and its impact on quality of lifeMatch regimen to reality: consider dexterity, vision, caregiver support, and polypharmacyBiologics can fit well for older adults: few interactions, interval dosing, strong itch and skin controlBe cautious with off-label antipruritics: renal/sedation risks are higher in this groupUse “theranostics “wisely: targeted biologic response can clarify the immunologic driver after serious causes are excluded https://dermsquared.com/videos/topical-conversations/ad-care-for-65 799 2025-10-17T20:32:47.587Z yes https://dermsquared.com/videos/topical-conversations/advancements-in-skin-cancer-management-2024-and-beyond 2024-02-02T14:04:49.425Z https://image.mux.com/V8022ezPTVRNHkGpWTUBZBnYrfYCJhWPdVfz3oBzAzRE/thumbnail.jpg Advancements in Skin Cancer Management: 2024 and Beyond In this episode of Topical Conversations, Todd Schlesinger, MD, FAAD, FASMS, looks ahead to provide an overview of the exciting developments in skin cancer management that are on the horizon. Immunotherapy revolutionizing advanced nonmelanoma skin cancer treatment Immunotherapy has emerged as a game-changer in the treatment of patients with advanced nonmelanoma skin cancer (NMSC). This therapeutic approach has marked a substantial boon for dermatologists, offering new hope for patients with the most advanced cases of NMSC. New noninvasive options for low-risk skin cancer For low-risk skin cancer, further developments in photodynamic therapy (PDT) are eagerly anticipated. This noninvasive approach shows particular promise for patients with basal cell carcinoma (BCC) and potentially squamous cell carcinoma (SCC). Additionally, recent research has been published on the noninvasive management of low-risk BCC and SCC and focused on sparing patients from undergoing multiple surgeries. This reflects a significant shift in the approach to treating skin cancer, with an emphasis on minimizing invasive procedures while ensuring effective management. Key points Immunotherapy is emerging as a transformative approach in advanced NMSC management Developments in PDT are at the forefront of noninvasive options for low-risk skin cancer Device- and energy-based treatments are anticipated as promising noninvasive options https://dermsquared.com/videos/topical-conversations/advancements-in-skin-cancer-management-2024-and-beyond 73 2024-02-02T14:04:49.419Z yes https://dermsquared.com/videos/topical-conversations/psoriasis-efficacy-safety-ixekizumab 2024-11-15T21:28:18.769Z https://image.mux.com/00x4ne52gfuJXi9Q02fxfkCBGeNXl00TpnoYAisQWHb4OA/thumbnail.jpg Psoriasis and IL-17 Inhibitors: Balancing Efficacy and Safety with Ixekizumab In this episode of Topical Conversations, Brad Glick, DO, and Jason Hawkes, MD, discuss the use of IL-17 inhibitors in managing psoriasis and psoriatic arthritis, with a focus on ixekizumab. Their conversation highlights the immunologic basis of IL-17, the safety and efficacy of ixekizumab, and its role in addressing the complex interplay of skin and joint symptoms in psoriatic disease. The role of IL-17 in psoriasis They begin by explaining that IL-17 plays a dual role in skin health. It provides natural protection against infections like candidiasis; however, excessive levels of IL-17 can drive keratinocyte hyperproliferation, leading to the scaling and plaque formation characteristic of psoriasis. Ixekizumab, by targeting IL-17A, helps normalize keratinocyte activity and significantly improves psoriasis symptoms. This mechanism of action also explains why some patients develop candidiasis during treatment, as blocking IL-17 reduces natural defenses against infections like candidiasis. Managing safety concerns While ixekizumab does not cause inflammatory bowel disease (IBD), it can exacerbate symptoms in patients with preexisting IBD. For patients who present with both psoriasis and IBD, clinicians need to carefully weigh the benefits of improved skin symptoms against the potential for worsening gastrointestinal issues. Monitoring and patient education are essential to ensure that risks are understood and managed effectively. Candidiasis, a known side effect of IL-17 inhibition, also requires consideration. By understanding the underlying immunologic mechanisms, dermatologists can counsel patients appropriately and address concerns about this potential complication. Efficacy of ixekizumab in psoriasis Clinical trials, including the UNCOVER studies, have demonstrated ixekizumab’s high efficacy in psoriasis treatment. The trials revealed significant rates of disease clearance, with about half of patients achieving PASI 100. These outcomes represent a substantial improvement over earlier treatments like methotrexate and TNF inhibitors. However, patient characteristics such as body weight can influence outcomes. For patients with higher body weights, efficacy may decrease, potentially due to the pro-inflammatory effects of adipose tissue. These findings highlight the importance of tailoring treatment approaches to individual patient profiles. Ixekizumab and psoriatic arthritis Psoriatic arthritis (PsA), a common comorbidity of psoriasis, remains challenging to treat. While ixekizumab and other IL-17 inhibitors have shown moderate efficacy in managing joint symptoms, they are highly effective for skin improvement. Dermatologists must set realistic expectations with patients, explaining that while dramatic skin improvements are likely, joint symptoms may respond more slowly or to a lesser degree. Exploring future approaches Emerging research is investigating the potential synergy of IL-17 inhibitors with GLP-1 receptor agonists. This approach aims to address systemic inflammation associated with obesity, which is linked to higher risks of diabetes, cardiovascular disease, and poorer psoriasis outcomes. By targeting both psoriasis and metabolic health, this strategy could offer comprehensive benefits, though further studies are needed to clarify its impact. Key takeaways for dermatologists Ixekizumab represents a significant advancement in psoriasis treatment, due to its high efficacy and targeted action. While considerations such as candidiasis risk and IBD management are important, this IL-17 inhibitor remains a strong option for dermatologists, with its potential for future innovations further underscoring its value in advancing patient care. https://dermsquared.com/videos/topical-conversations/psoriasis-efficacy-safety-ixekizumab 829 2024-11-15T21:28:18.760Z yes https://dermsquared.com/videos/topical-conversations/part-4-practical-guidance-on-navigating-support-groups 2024-06-25T16:12:20.414Z https://image.mux.com/U5GIFbcQ23NyqQb00Kv3ay1u400VNNRYnP8ASie7TK5hY/thumbnail.jpg Part 4: Practical Guidance on Navigating Support Groups In this Topical Conversations special edition 4-part series, Richard Huggins, MD, dermatologist and member of the board of directors at the Global Vitiligo Foundation, is joined by Amaris Geisler, MD, Katie O’Connell, MS, and Tonja Johnson of the Beautifully Unblemished Vitiligo Support Group, to discuss their publication on the importance of vitiligo patient support groups and how these groups can provide value to both patients and providers. In Part 4, the group gives an overview of the tips and resources detailed in their paper on starting and running a successful vitiligo support group. Insights from a patient and support group leader Tonja Johnson, patient advocate and executive director of the Beautifully Unblemished Vitiligo Support Group, shares her experiences and advice for those interested in starting a vitiligo support group. She emphasizes the importance of perseverance and patience, acknowledging the challenges but highlighting the potential for success in fostering a supportive community for patients with vitiligo. Practical guidance on support group management The conversation also highlights the comprehensive nature of the group’s publication, covering the background of support groups and previous research showing the positive impact of support groups on patient mental health. The manuscript includes detailed appendices with information on support group development processes, meeting agendas, legal considerations, promotion strategies, member engagement, and retention techniques. Key takeaways for support group leaders They also discuss the valuable resources and guidance for support group leaders detailed in their publication, including practical tips on running meetings, handling group dynamics and disagreements, promoting the group, recruiting new members, and maintaining member engagement and retention.For more on vitiligo support groups, check out the rest of the series here: Part 1, Part 2, Part 3 https://dermsquared.com/videos/topical-conversations/part-4-practical-guidance-on-navigating-support-groups 385 2024-06-24T19:58:13.465Z yes https://dermsquared.com/videos/topical-conversations/update-on-pathogenesis-of-vitiligo 2023-06-29T19:46:54.603Z https://image.mux.com/h01aU4YeCxJnahEHWVdjPyzeoql4ov9k6s8ffJAu3qpM/thumbnail.jpg Update on Pathogenesis of Vitiligo Update on Pathogenesis of Vitiligo https://dermsquared.com/videos/topical-conversations/update-on-pathogenesis-of-vitiligo 62 2023-06-29T19:46:54.598Z yes https://dermsquared.com/videos/topical-conversations/ixekizumab-pediatric-psoriasis 2024-10-30T23:49:34.226Z https://image.mux.com/Rug019aMcQyF02IOPNpSTajqF58z01nWXn2fjCvDR9EszM/thumbnail.jpg The Role of Ixekizumab in Pediatric Psoriasis Management In this episode of Topical Conversations, pediatric dermatologists Lisa Swanson, MD, and Karan Lal, DO, discuss managing psoriasis in pediatric patients and the advantages of ixekizumab and other biologics, providing insights into optimal treatment choices and addressing challenges unique to treating pediatric psoriasis. Psoriasis in pediatric patients is becoming more common, necessitating effective treatment options tailored to the specific needs of young patients. Recognizing psoriasis as more than just a skin condition—as a chronic, systemic inflammatory disease—is essential when considering therapeutic strategies, particularly systemic treatments. Pediatric psoriasis: a systemic disease requiring systemic treatments Psoriasis in children has significant impacts beyond the skin, affecting overall health and increasing the risk of comorbidities, including arthritis and metabolic conditions. Acknowledging this systemic nature makes systemic treatments, such as biologics, a vital part of comprehensive care for many pediatric patients. Dr. Swanson notes that 5 systemic treatments are approved for pediatric use, including 4 injectable options (etanercept, ixekizumab, secukinumab, and ustekinumab) and one oral option (apremilast). While effective, the usage of apremilast is often limited in younger children due to side effects like nausea and diarrhea and the common difficulty of swallowing pills. Ixekizumab: a preferred biologic for pediatric psoriasis For Dr. Lal, ixekizumab is often the first choice for treating pediatric psoriasis, and he has observed strong results in adults that translate well to younger patients. Ixekizumab’s once-monthly dosing is particularly beneficial for children and their families due to the simplified dosing regimen, which can help improve adherence and reduce the burden of frequent injections. Moreover, ixekizumab acts rapidly, which is a boon for both patients and their caregivers. Addressing psoriatic arthritis in pediatric patients Psoriatic arthritis may go undetected in patients with pediatric psoriasis, particularly before treatment begins. Dr. Lal shares that increased activity levels post-treatment sometimes reveal undiagnosed joint inflammation. Dr. Swanson also emphasizes the importance of examining nail health in pediatric patients with psoriasis, as nail psoriasis is associated with an increased risk of psoriatic arthritis. Ixekizumab’s efficacy in managing nail psoriasis offers an added advantage in this context, helping dermatologists improve overall patient outcomes. Citrate-free ixekizumab for pediatric patients The original formulation of ixekizumab was painful, which often posed a challenge in younger patients. However, a citrate-free formulation now available improves comfort for pediatric patients, making the injections more tolerable. Dr. Lal notes his strategy of using EMLA cream under a bandage prior to injection to ease discomfort for children, who often become accustomed to injections over time. Moving beyond topicals: a comprehensive approach to psoriasis Many children and families express frustration with topical treatments, particularly the “whack-a-mole” effect, where plaques reappear in new locations despite regular topical application. Ixekizumab helps to address the underlying systemic inflammation, allowing for better control over psoriasis with a simpler regimen. As Dr. Lal highlights, biologics like ixekizumab not only reduce dependence on topicals but also work well alongside other therapies, such as phototherapy, offering a versatile, multimodal approach that reduces the overall burden on patients and caregivers. Safety considerations: screening for inflammatory bowel disease One concern with IL-17 inhibitors such as ixekizumab is the potential activation of inflammatory bowel disease (IBD) in patients predisposed to it. While IL-17 inhibitors don’t cause IBD directly, they may unmask it in genetically susceptible patients. Dr. Swanson and Dr. Lal emphasize the importance of screening for IBD in pediatric patients with psoriasis before initiating an IL-17 therapy. To address this, Dr. Swanson collaborated with pediatric gastroenterologists and developed a set of screening questions and labs. She makes sure to question patients and caregivers on the following key areas: Family history of IBD Growth issues, as growth delays can indicate Crohn’s disease Nocturnal diarrhea or frequent bowel movements at night Pain during bowel movements, including rectal pain or fissures In addition to these questions, she considers 3 laboratory tests: CBC to check for anemia CRP, which is usually normal in psoriasis but may be elevated in IBD or psoriatic arthritis Fecal calprotectin, a noninvasive test with high sensitivity and specificity for intestinal inflammation Dr. Lal concurs, noting that the fecal calprotectin test, while sometimes challenging to obtain from pediatric patients, is a critical tool for assessing IBD risk, especially in younger children for whom biologics may be considered. Ixekizumab’s role in evolving pediatric psoriasis care As pediatric psoriasis rates rise, so does the need for safe, effective treatments that address the full spectrum of the disease’s impact. Ixekizumab’s rapid efficacy, once-monthly dosing, and now pain-free formulation make it a valuable option in pediatric dermatology. By considering both the physical and psychological needs of young patients, and carefully screening for potential complications like IBD, dermatologists can leverage ixekizumab to improve outcomes for children with psoriasis. https://dermsquared.com/videos/topical-conversations/ixekizumab-pediatric-psoriasis 647 2024-10-30T23:49:01.034Z yes https://dermsquared.com/videos/topical-conversations/patient-centered-care-exam-tips-for-hidradenitis-suppurativa 2024-04-10T20:45:13.127Z https://image.mux.com/cgfpkFc6Hd00ZCLGwPTbqFjNrV007llSYZPZ01EOP8CvJM/thumbnail.jpg Patient-Centered Care: Exam Tips for HS In this installment of Topical Conversations, Andrea T. Murina, MD, associate professor and residency program director at Tulane School of Medicine, offers a few quick-hitting tips on making the patient exam a comfortable and low-stress experience for those with hidradenitis suppurativa. Planning ahead to put the patient at ease Dr Murina emphasizes the significance of ensuring patient comfort throughout the examination process. To achieve this, she suggests several strategies. Firstly, providing patients with a gown and instructing them to undress ahead of time can help them feel more at ease in the exam room. Additionally, offering wound care supplies and any other necessary items in advance can further enhance their comfort and offer a convenient experience by anticipating their needs. Prioritizing patient comfort During the examination itself, Dr Murina stresses the importance of being gentle and careful with patients. She underscores the need for sensitivity to their potential pain and discomfort, encouraging practitioners to ask patients about their pain levels throughout the examination. By prioritizing patient comfort and attentiveness during the assessment of HS, dermatologists can create a supportive and reassuring environment that fosters trust and cooperation. https://dermsquared.com/videos/topical-conversations/patient-centered-care-exam-tips-for-hidradenitis-suppurativa 31 2024-04-03T16:58:33.463Z yes https://dermsquared.com/videos/topical-conversations/addressing-thyroid-concerns-vitiligo-patient-centered-perspective 2024-08-21T14:48:23.503Z https://image.mux.com/R3P5RiMh6EGIkLDUP9kpI77gCbVB1pWYKcCtOp4ziJ4/thumbnail.jpg Addressing Thyroid Concerns in Vitiligo: A Patient-Centered Perspective When patients with vitiligo ask about the potential link between thyroid issues and their condition, it’s essential for dermatologists to provide clear, accurate, and compassionate guidance. In this episode of Topical Conversations, Dr Seemal Desai emphasizes the importance of framing the conversation around thyroid disease rather than specifically focusing on thyroid cancer. Understanding the connection between vitiligo and thyroid disease A vitiligo diagnosis often prompts patients to inquire about its association with thyroid cancer. Dr Desai advises that while there is a recognized link between vitiligo and thyroid disease, it’s crucial to clarify that this connection does not necessarily equate to an increased risk of thyroid cancer. Instead, the focus should be on the broader spectrum of thyroid diseases like autoimmune thyroiditis. Screening and monitoring: a tailored strategy Dr Desai does not advocate for frequent, routine thyroid screening every 3 to 6 months for patients with vitiligo. Instead, he recommends conducting an initial screening at the first visit, including blood work to assess for thyroid function and any signs of autoimmune disease. Subsequent screenings should be based on the patient’s symptoms and overall progression. This individualized approach ensures that patients are not subjected to unnecessary tests while still receiving regular monitoring for potential thyroid issues. The patient-centered approach Counseling patients with vitiligo about the potential link to thyroid disease requires a balanced, patient-centered approach. By focusing on the broader spectrum of thyroid disease rather than just thyroid cancer, dermatologists can provide comprehensive care that addresses patients’ concerns while promoting long-term health. Dr Desai’s approach underscores the importance of individualized screening and careful monitoring, ensuring that patients receive the right care at the right time. https://dermsquared.com/videos/topical-conversations/addressing-thyroid-concerns-vitiligo-patient-centered-perspective 39 2024-08-21T14:48:23.492Z yes https://dermsquared.com/videos/topical-conversations/perspectives-on-vitiligo-insights-from-valiant-study 2023-10-09T16:43:16.889Z https://image.mux.com/INuTQuiwjvcqVnxTz9hqrN00wkpYDfrzAukC56jr1i024/thumbnail.jpg Perspectives on Vitiligo: Insights From the Global VALIANT Study In this installment of Topical Conversations, Dr. Iltefat Hamzavi sits down to discuss the results of the VALIANT study, which explored the natural treatment history of vitiligo and was published in the British Journal of Dermatology in July 2023.Vitiligo and the VALIANT studyThe VALIANT (Vitiligo and Life Impact Among International Communities) aimed to investigate the natural treatment history of vitiligo, a pigmentary disorder causing color loss in areas of the skin that can be socially stigmatizing for patients. The study focused on understanding the patient and healthcare provider experiences related to this condition.The study was based on a survey distributed globally across Africa, Asia, Latin America, North America, and Europe. Around 3,500 patients participated in a 25-minute survey, and around 1,200 clinicians (primary care physicians and dermatologists) completed a 30-minute survey. Results were then compared across the different populations.Patient profilesAmong the 3,541 patients who completed the full analysis, the average age was 38, and 59% of participants reported Fitzpatrick skin types I-III. The mean duration of the disease was 12.7 years, taking 2.4 years to receive a diagnosis. In survey participants, lesions appeared on the hands and face in about 40% and 38% of cases, respectively.Physician profilesOf the 1203 clinicians who completed the survey, 91% specialize in dermatology and 8% are primary care physicians or other care physicians. Around 60% identified themselves as vitiligo specialists. Clinician respondents had on average 8 years of experience treating vitiligo. Survey results: misdiagnosesOf the patients surveyed, 44% reported being misdiagnosed. Patients with vitiligo occurring on more than 5% of their body surface, patients with darker skin, and patients with facial lesions particularly noted difficulty with receiving a diagnosis.Misdiagnoses included sun damage, fungal infections, and atopic dermatitis. About 17% of both primary care physicians and dermatologists reported encountering patients referred to them who were misdiagnosed. While there were geographic variations among these findings, similar results were found globally.Survey results: treatmentFifty-seven percent of patients reported being told by their healthcare practitioner that their vitiligo could not be treated, and 44% reported they had given up on finding an effective treatment. Treatments that were reported to be used or suggested by the primary care physician or dermatologist were topical medications, photoprotection, laser therapy, and surgical options.Survey results: effective careTwo-thirds of patients reported receiving effective care, defined by the patient as a reduction or cessation of spread and repigmentation.A core element that patients sought to achieve was a reduction of the psychological burden of vitiligo, with mental effects of the disease going well beyond just what is happening in the skin.Implications for dermatologyThe results of the VALIANT study show that there is a profound burden associated with vitiligo with nearly half of patients reporting greater than 5% body surface area affected and a time of 2.4 years to diagnosis for a condition that should be easy to identify.The survey results also revealed that there is a common misperception that vitiligo cannot be treated. Although many publications have disproved this, it is nonetheless a widely held belief among both the patient community and healthcare practitioners.With these factors considered, this global survey emphasizes the significant frustration that is mounting among patients and the practitioners who treat them that can hopefully be addressed with future developments and advances in vitiligo education and management.To read the full study published in the British Journal of Dermatology, click here.Key points from the VALIANT studyIt is the first global survey to explore the natural history and treatment of vitiligo from both a patient and HCP perspective3,541 patients and 1,203 were surveyedMean time to diagnosis was 2.4 years45.2% of patients had >5% affected BSA44.9% of patients reported an initial misdiagnosesReported rates of misdiagnoses were greater among patients with darker skin, >5% affected BSA, and facial lesions56.7% of patients reported being told vitiligo could not be treated26.3% of HCPs did not believe an effective therapy for vitiligo exists44.6% of patients reported giving up on finding an effective therapyHCPs most commonly recommended prescription topicals, sun protection, and phototherapy, but comparatively few patients reported using these34.4% of patients reported having surgery or other procedures, but only 14% of surveyed HCPS recommended surgery https://dermsquared.com/videos/topical-conversations/perspectives-on-vitiligo-insights-from-valiant-study 340 2023-08-18T18:27:47.017Z yes https://dermsquared.com/videos/topical-conversations/frontal-fibrosing-alopecia-clinical-pearl-treating-challenging-condition 2024-04-15T18:55:55.999Z https://image.mux.com/7u00e7K5IHXn5B00UqFqHVtP00PAq2gw101WvU4008FOERgs/thumbnail.jpg Frontal Fibrosing Alopecia: A Clinical Pearl for Treating a Challenging Condition In this episode of Topical Conversations, Charlie Dunn, MD, shares a valuable pearl for the management of frontal fibrosing alopecia (FFA). FFA is a clinical variant of lichen planopilaris (LPP) characterized by slow, progressive perifollicular inflammation resulting in eventual complete hair loss, primarily at the frontotemporal hairline. While historically observed mainly in postmenopausal women, there are increasing reports of men and children being affected. The etiology remains unclear, although hormonal influences, autoimmunity, genetics, immune dysregulation, and environmental factors like sunscreen exposure are speculated to play a role. Navigating limited treatment strategies Due to a limited understanding of its pathogenesis, there is a lack of standardized, evidence-based therapies, making FFA challenging to treat. Commonly utilized treatments include high-potency corticosteroids, intralesional corticosteroid injections, topical and oral minoxidil, 5-alpha reductase inhibitors such as dutasteride and finasteride, hydroxychloroquine, and tetracycline antibiotics like doxycycline. For refractory cases, therapeutic options become even scarcer. Growing evidence on the role of the JAK pathway in FFA Recent translational research suggests the Janus kinase (JAK) pathway may play a crucial role in lichenoid inflammatory dermatoses, including FFA and LPP. One study demonstrated that levels of JAK1 and JAK3 were elevated in lesional skin of patients with LPP, and there is growing evidence supporting the use of JAK inhibitors, both orally and topically, as promising treatments for FFA and LPP. Several case series have demonstrated significant reductions in disease activity within 1 to 4 months of treatment with oral baricitinib, oral tofacitinib, topical tofacitinib, and topical ruxolitinib in varying doses. Treatment pearl: JAK inhibitors for improved outcomes A notable treatment pearl gleaned from the discussion is the potential efficacy of JAK inhibitors for FFA. The frontal hairline area tends to have thinner skin, making it more amenable to topical treatments. Additionally, patient compliance may be higher with topical therapies, as they typically do not require lab monitoring. Therefore, when faced with a challenging case of FFA, considering topical or oral JAK inhibitors may offer a promising treatment strategy for eligible patients. https://dermsquared.com/videos/topical-conversations/frontal-fibrosing-alopecia-clinical-pearl-treating-challenging-condition 234 2024-04-15T18:55:55.993Z yes https://dermsquared.com/videos/topical-conversations/long-term-treatment-ad-dupilumab 2024-11-07T18:22:13.282Z https://image.mux.com/4bybhaoQ00dCiktsF4Myr5m02gBkBCavfrISPHtZ02ncV4/thumbnail.jpg Optimizing Long-Term Treatment of Moderate Atopic Dermatitis with Dupilumab In this episode of Topical Conversations, Dr James Del Rosso and Dr Alexandra Golant explore the nuanced use of dupilumab in treating moderate atopic dermatitis (AD), particularly in long-term management. Their discussion provides valuable perspectives on patient education, managing treatment expectations, and the unique benefits of dupilumab for both pediatric and adult patients with AD. A paradigm shift in AD management Dr Golant highlights the impactful effect of dupilumab in treating AD, describing it as a major milestone in dermatology. Since its approval, dupilumab has significantly enhanced disease control for patients, with many individuals remaining clear for years. Initially approved for adults, dupilumab has extended its reach, now approved for use in children as young as 6 months. Addressing parental concerns in pediatric patients When discussing the treatment of young children, Dr Del Rosso posits a scenario where a one-year-old patient’s parents have attempted topical steroids or nonsteroidal therapies without success. Dr Golant emphasizes the importance of educating parents about the systemic nature of AD to create a more receptive environment for systemic therapy discussions. She refers to this as “disease state re-education,” which involves explaining AD's systemic inflammatory nature and discussing how dupilumab works to address inflammation on multiple fronts. Explaining Systemic Therapy to Parents For parents open to considering systemic therapy, Dr Golant often addresses the common concern of treatment duration, especially in younger patients. With dupilumab, the goal is not only to manage AD symptoms but to potentially influence the “atopic march” or the progression of allergic diseases over time. However, she notes that long-term outcomes are still being studied, particularly in infants and young children. Overcoming injection concerns Dr Del Rosso acknowledges that the injectable nature of dupilumab may initially deter some parents. However, he points out that the biweekly dosing schedule makes treatment less burdensome than the daily application of topical therapies. Dr Golant finds that once parents see the positive results, their hesitancy often diminishes, as they realize the level of control that systemic therapy can offer. The role of topicals in conjunction with systemic therapy While dupilumab allows many patients to reduce their reliance on topicals, Dr Golant describes them as “touch-up paint” for spot treatments that may still be necessary. In clinical practice, these topicals—such as corticosteroids and calcineurin inhibitors—are often used alongside dupilumab to help manage flare-ups or persistent areas of inflammation. Recognizing moderate AD as worthy of systemic intervention Dr Golant emphasizes that moderate AD can still have a high impact on patients' quality of life, even when the body surface area (BSA) affected is relatively low. For instance, severe eczema on the hands or face can cause significant discomfort and disrupt sleep, impacting daily life considerably. Dr Golant believes that patients with moderate AD often benefit substantially from systemic treatments like dupilumab and stresses the importance of assessing AD's impact on quality of life, rather than focusing solely on BSA affected. Dupilumab’s benefit for comorbid conditions One significant advantage of dupilumab is its efficacy across a range of atopic conditions. For patients with AD who also have nasal polyps, asthma, or eosinophilic esophagitis, dupilumab’s effects may extend to these conditions as well. Dr Golant recommends dermatologists take a thorough history to identify any additional comorbidities that dupilumab might positively impact, making it a versatile choice for many patients. Monitoring Progress and Setting Treatment Goals For tracking the progress of AD treatment in patients, Dr Del Rosso recommends the Atopic Dermatitis Control Tool as a practical and efficient way to assess symptom control. Dr Golant agrees, and also emphasized the importance of shared decision-making with patients and aligning on treatment goals and quality-of-life improvements. In follow-up visits, she discusses practical impacts on quality of life, such as improvements in sleep or reduced limitations in daily activities. Responding to questions on long-term use When asked how long patients or their children should remain on dupilumab, Dr Del Rosso explains that his approach has evolved. Rather than recommending indefinite use, he now focuses on achieving optimal disease control and leaving the decision to continue treatment flexible. This open-ended approach reassures patients and builds trust, as they can feel confident in stopping treatment if they are uncomfortable at any point. Key takeaways for dermatologists The conversation between Dr Golant and Dr Del Rosso underscores the importance of effective communication with patients and families about systemic therapy options like dupilumab. They emphasize the necessity of educating patients on the systemic nature of AD, addressing concerns around injectables, and recognizing that even moderate AD can warrant systemic treatment. https://dermsquared.com/videos/topical-conversations/long-term-treatment-ad-dupilumab 849 2024-11-07T18:22:13.260Z yes https://dermsquared.com/videos/topical-conversations/world-mental-health-day-dermatology-role-addressing-mental-health-impacts 2024-10-10T16:19:41.331Z https://image.mux.com/dr76N8f801y01RqaogSn9zqTJj00BaeUHVNHxQAcLdwXWE/thumbnail.jpg World Mental Health Day: Dermatology's Role in Addressing Mental Health Impacts In this episode of Topical Conversations, Dr Nick Brownstone highlights the critical role dermatologists play in addressing the mental health impact of skin conditions. For World Mental Health Day on October 10, Dr Brownstone emphasizes the importance of raising awareness about how dermatologic diseases affect patients' mental well-being. Mental health and skin disease: a quality-of-life issue Dr Brownstone opened by reminding dermatologists that while skin conditions like acne, psoriasis, atopic dermatitis, alopecia areata, and vitiligo may not be life-threatening, they can drastically reduce a patient's quality of life and urging his colleagues to consider the potential mental toll these conditions can take on patients. He stressed the importance of dermatologists taking a moment to ask their patients a simple but impactful question: Is this condition significantly affecting your quality of life? Many patients may be hesitant to proactively raise this issue, and such a question can open the door to discussions about their mental health and how their skin condition impacts their daily life. The connection between dermatology and mental health Dr Brownstone cited recent studies that have confirmed the negative mental health impacts associated with dermatologic conditions. One finding, published in JAMA Dermatology, demonstrated that patients with atopic dermatitis had a higher prevalence of suicidal ideation and attempts compared to the general population. He noted the seriousness of this finding, emphasizing that dermatologists must be mindful of these risks when treating patients with chronic skin diseases. Another study discussed by Dr Brownstone was the Global Valiant Study on vitiligo, also published in JAMA Dermatology. The study found that patients with vitiligo often find difficulty with everyday activities, such as choosing clothing or going to the beach, due to the psychological burden of their condition. These daily limitations, often overlooked, can severely impact their quality of life, highlighting the need for dermatologists to acknowledge the emotional and psychological effects of skin diseases. Addressing mental health in dermatology: simple and effective steps Dr Brownstone advised dermatologists to take 2 simple steps when a patient expresses that their skin condition is negatively impacting their mental health: Offer more aggressive therapy: For patients whose current treatments may not be addressing their symptoms sufficiently, considering more intensive options could help improve both their physical and mental well-being. Provide mental health support: If a patient's condition is having a severe psychological impact, dermatologists should not hesitate to recommend mental health resources. Dr Brownstone emphasized the value of referring patients to therapists or connecting them with patient support organizations. He mentioned several helpful resources, including the National Psoriasis Foundation, National Eczema Foundation, Vitiligo Research Foundation, and Global Vitiligo Foundation, all of which offer support and community for patients dealing with the emotional burden of their skin conditions. World Mental Health Day: a reminder for all healthcare providers Dr Brownstone concluded the discussion by urging his colleagues to always be mindful of the mental health aspects of skin conditions, reminding dermatologists to ask about mental health regularly and act when necessary. By addressing the often-overlooked psychological toll that skin diseases can take, dermatologists can help improve not only their patients' skin health but also their overall well-being, making a lasting difference in their quality of life. https://dermsquared.com/videos/topical-conversations/world-mental-health-day-dermatology-role-addressing-mental-health-impacts 136 2024-10-10T16:19:41.324Z yes https://dermsquared.com/videos/topical-conversations/treatment-goals-in-atopic-dermatitis 2025-10-01T18:01:26.244Z https://image.mux.com/l01ljciB2ClqFPzgWuafhNOPcMYSul9LST011RycQB7nI/thumbnail.jpg Spotting the Systemic Candidate: Rethinking Treatment Goals in Atopic Dermatitis In this episode of Topical Conversations, Nicholas Brownstone, MD, is joined by Peter Lio, MD, for a candid fireside chat on systemic therapies for atopic dermatitis (AD). Together, they explore why these treatments remain underutilized, how dermatologists can better identify systemic candidates, and what expanding therapeutic options mean for personalized patient care.Why systemic therapy remains underusedDr Lio emphasizes that dermatology has only had FDA-approved systemic options for AD for about a decade. Before that, therapies were mostly off-label and carried significant safety concerns. Despite advances, hesitation persists, often due to lingering perceptions of systemics as high-risk. While topical therapies remain foundational, Dr Lio argues that dermatologists should raise their expectations: improvement alone is not enough if patients still struggle with sleep, concentration, or recurrent flares.Recognizing candidates for systemic therapySystemic therapy candidacy extends beyond visible lesions. Dr Brownstone stresses the importance of a full history and physical exam, while Dr Lio highlights tools such as the Atopic Dermatitis Control Tool to uncover quality-of-life impairments that might otherwise be missed. Sensitive areas, such as the face and hands, can also justify systemic consideration even in patients who appear mild or moderate by standard measures.Overcoming hesitation and leveraging biologicsTraditional systemic agents like methotrexate or cyclosporine created a culture of caution due to safety concerns. Today’s biologics for atopic dermatitis (dupilumab, lebrikizumab, tralokinumab, and nemolizumab) offer safer, more convenient alternatives. Dr Lio notes that all are effective and generally well tolerated, with subtle differences in efficacy, speed of response, and side effect profiles that can guide treatment selection. Importantly, dermatologists can reassure patients about the possibility of dose spacing or eventual pauses once durable control is achieved.Looking ahead: patient-centered goalsBoth dermatologists agree that systemic therapy allows for elevated treatment targets, shifting from “good enough” improvement to clear skin and normalized quality of life. Positive patient experiences with systemic therapies build trust, improve adherence, and empower dermatologists to offer individualized care strategies.Key takeawaysSystemic underuse: Despite multiple safe and efficacious systemic agents now approved, many patients with AD patients remain undertreated; dermatologists should consider whether their patients’ disease burden justifies escalationRecognizing systemic candidates: Look beyond objective scores; QoL measures and disease location matter.Biologics today: Modern systemic therapies are safe, effective, and more convenient than older optionsPersonalized treatment choices: Each biologic offers unique attributes that can be tailored to patient needsTreatment flexibility: Dose spacing or temporary pauses may be possible in well-controlled patients https://dermsquared.com/videos/topical-conversations/treatment-goals-in-atopic-dermatitis 837 2025-10-01T18:01:26.233Z yes https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-2023 2024-02-06T21:11:00.039Z https://image.mux.com/at2D3N7MO02lOXO7rC00XUiCwDBgKeu00Y02AYtEUnGAkmM/thumbnail.jpg Part 1—A Dermatologist’s Perspective: Updated Atopic Dermatitis Guidelines from the AAAAI/ACAAI Joint Task Force Joint Task Force In Part 1 of this Topical Conversations feature with Peter Lio, MD, FAAD, he introduces the latest updates to the atopic dermatitis management guidelines from the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force (AAAAI/ACAAI JTF). Guidance addressing atopic dermatitis management was last issued by the AAAAI/ACAAI JTF in 2012. As part of the multidisciplinary guideline panel, Dr Peter Lio offers a dermatologist’s overview of the updated guidelines. Guideline design The guidelines employed systematic reviews of evidence, ensuring a robust foundation for recommendations. They reflect adherence to rigorous guideline development processes and prominent utilization of the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) framework. A key strength is the engagement of a multidisciplinary panel, which incorporated the expertise of dermatologists, allergists, primary care practitioners, and allied health professionals. Crucially, the guidelines also prioritized the voices of patients and caregivers throughout the entire development process. Inclusiveness is highlighted throughout, with a focus on addressing atopic dermatitis in patients with skin of color and health disparities. There is also an emphasis on clear translation, underscoring the commitment to providing clinically actionable and contextually relevant recommendations and steering away from impractical or theoretical advice. The guidelines are designed with practicality in mind, framed in the form of questions to facilitate easy implementation in real-world practice. Moisturizers A key point the guidelines address is the significance of moisturizers in atopic dermatitis care, highlighting that the best moisturizer is one that patients will consistently use. Shared decision-making is crucial in discussing the risks, benefits, and tradeoffs of different types of treatments, including moisturizers, and with moisturizer recognized as a centerpiece of atopic dermatitis care, the emphasis is on patients finding one they like and will use regularly. Topical therapies A second key point underscores the importance of topical corticosteroids as a mainstay of therapy. Topical corticosteroids are recommended as a first-line treatment in patients for whom moisturization and avoidance of irritants are not sufficient. Topical corticosteroids have been shown to be very effective, easily accessible, and generally safe when used correctly. They’re also strongly recommended for continued intermittent therapy to prevent future flare-ups. Topical nonsteroidal options and elimination diets Watch Part 2 to hear Dr Peter Lio discuss the updated guidelines for elimination diets and nonsteroidal agents, including topical calcineurin inhibitors and PDE-4 inhibitors, and the noteworthy guidance on the use of topical JAK inhibitors. Key points The AAAAI/ACAAI Joint Task Force updates to the clinical guidelines for atopic dermatitis were developed by a multidisciplinary panel and incorporated the expertise of dermatologists Updates were designed to be clinically actionable for implementation in real-world practice The guidelines conclude that the best moisturizer for atopic dermatitis is one patients will use consistently Topical corticosteroids remain a mainstay of atopic dermatitis therapy due to their effectiveness, accessibility, and safety https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-2023 210 2024-02-05T19:57:56.211Z yes https://dermsquared.com/videos/topical-conversations/closing-gap-gpp-treatment-spesolimab 2024-09-25T15:37:44.386Z https://image.mux.com/wblJHJRSCxpu6LsvSlb201U00bbQ9WGN91z8Ll9uZ00Zew/thumbnail.jpg Closing the Gap in GPP Treatment: Clinical Perspectives on Spesolimab In this episode of Topical Conversations, Brad P. Glick, DO, MPH, and Aaron Farberg, MD, explore the advancements in treating generalized pustular psoriasis (GPP) with the introduction of subcutaneous spesolimab. They discuss the chronic nature of GPP, the trial data that led to the drug’s approval, and its significant impact on the treatment landscape and patient experience. A targeted agent for a challenging condition The conversation begins with an overview of spesolimab IV, highlighting its significance as the first FDA-approved systemic therapeutic agent for acute GPP flares. They discuss the challenges in managing this chronic, heterogeneous condition, which previously lacked specific therapeutic options, noting that spesolimab now provides a targeted treatment for the quiescent yet active phases of the disease. Addressing the educational gap and increased GPP awarenessDr Farberg notes that he anticipates an increase in GPP diagnosis and treatment as awareness and education improve. He stresses the importance of having an effective, approved medication for GPP, noting the substantial impact compared to older, less targeted treatments. He also discusses the recent approval of subcutaneous spesolimab, which offers a new dosing option for sustained disease management between flares. Clinical insights on GPP management Dr Glick shares his clinical experiences managing GPP, particularly in acute settings such as hospitals and emergency rooms. He underscores the IL-36 pathway’s pivotal role in GPP pathogenesis and how spesolimab effectively targets this pathway. He highlights the transition from IV dosing in acute flares to subcutaneous dosing for ongoing disease control, enhancing long-term patient outcomes. Effisayil-2 data: chronic GPP treatment insights The conversation then addresses the Effisayil-2 trial data, a randomised, placebo-controlled, dose-finding phase 2b trial that assessed the efficacy and safety of spesolimab for GPP flare prevention. The study identified a higher dose every 4 weeks as most effective in preventing flares and maintaining disease control. This dosing regimen, which kept about 90% of subjects clear at 48 weeks, offers a promising long-term management strategy for this often unpredictable disease. Comparing IV and subcutaneous dosing Addressing a common clinical question, Drs Glick and Farberg discuss the differing roles of IV and subcutaneous spesolimab and whether subcutaneous dosing can be used in place of intravenous. The subcutaneous dose is 150 mg, while the IV dose is 900 mg; achieving the same bioavailability with subcutaneous dosing would require a high number of injections, highlighting the distinct roles of each. Dr Farberg recommends the IV version for acute flares due to its higher dosage and rapid effect. Dr Glick concurs, noting that patients with acute GPP require aggressive treatment, whereas subcutaneous dosing is ideal for maintaining stability between flares. The necessity of ongoing GPP management and flare prevention Dr Farberg emphasizes the importance of treating the chronic aspects of GPP to prevent flares, which significantly impact patients’ quality of life. The Effisayil-2 trial supports proactive management to mitigate these severe episodes and improve long-term outcomes. Safety and efficacy of subcutaneous spesolimab The doctors review safety and efficacy data from the Effisayil-1 and Effisayil-2 trials. While some patients experienced fatigue, infections, flu-like symptoms, and injection site reactions with the IV drug, the subcutaneous dosing showed fewer side effects, with some urinary tract infections being the most notable. Quality of life improvements The stable dosing regimen of subcutaneous spesolimab greatly enhances the quality of life for patients, their families, and caregivers. It simplifies the treatment process, making disease management more feasible and maintaining almost clear or clear conditions. This underscores the importance of having both IV and subcutaneous options, providing flexibility and comprehensive care for patients with GPP. Drs Glick and Farberg conclude that the availability of both IV and subcutaneous spesolimab marks a significant advancement in GPP management. These therapies not only improve patient outcomes but also enhance the overall treatment experience, offering improved quality of life for those affected by this challenging condition. https://dermsquared.com/videos/topical-conversations/closing-gap-gpp-treatment-spesolimab 829 2024-07-08T14:37:54.945Z yes https://dermsquared.com/videos/topical-conversations/toolbox-for-atopic-dermatitis 2026-06-15T13:24:17.688Z https://image.mux.com/4MN00d00h81pD900yWzLIn00VB6pKujU8JxNlTb1skMxZMc/thumbnail.jpg The Adjunctive Toolbox for Atopic Dermatitis Skin care, diet, supplements, probiotics, and microbiome-directed strategies in clinical contextAfter establishing why adjunctive strategies matter in atopic dermatitis care, Cynthia Trickett, PA-C, and Peter Lio, MD, turn to the practical questions clinicians hear constantly: Do natural oils have a role? How much does diet really matter? What about probiotics, vitamin D, hypochlorous sprays, or antimicrobial cleansers?For Dr Lio, skin care and barrier repair are so central to the biologic therapy treatment plan that he’s coined the term “Advanced Dermatologic Care,” or ADC, to describe the intentional use of OTC topicals, cleansers, moisturizers, written eczema action plans, and other supportive strategies that help patients and families understand what to do day to day and during flares. The conversation moves through natural oils, black tea compresses, diet myths, the risks of over-restriction, vitamin D supplementation, probiotics, and emerging microbiome-directed approaches, always returning to the same clinical foundation of evidence, safety, practicality, and individualized recommendations that support quality of life.Of the many adjunctive options patients may ask about, Dr Lio says, “part of our job is to try to filter them down into things that have some evidence, that are safe and are practical.” This discussion makes space for it all, and contextualizes what may be overstated, unproven, or potentially harmful. He reminds clinicians not to chase every trend, but to help build an adjunctive plan that protects the barrier, respects the microbiome, and avoids doing harm. Upcoming: In Part 3, Trickett and Dr Lio turn from what clinicians can add to how they can do it safely, with practical guidance on supplement quality, follow-up, treatment monitoring, and patient-led decision-making. Question: In discussing skin care and barrier repair for patients with atopic dermatitis, which approach does Dr Lio emphasize? Recommending any gentle moisturizer, since OTC selection has little effect on outcomes Avoiding OTC products once a patient begins biologic therapy Using a prescriptive, written plan that includes cleansers, moisturizers, and flare/rescue steps Reserving emollients and cleansers for patients with mild disease only Rationale: Dr Lio describes OTC skin care as a meaningful part of the treatment plan, not a generic add-on. He emphasizes being specific about cleansers and moisturizers, considering patient preference and tolerability, and using a written eczema action plan. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } Question: Which statement best reflects Dr Lio’s approach to diet and elimination diets in atopic dermatitis? Most patients with AD have food-triggered disease and should begin with broad elimination diets Diet is irrelevant in AD and should not be discussed unless allergy testing is positive Skin control should often come first, because uncontrolled disease can make it difficult to assess whether diet is contributing Gluten and dairy elimination should be recommended routinely before topical or systemic treatment Rationale: Dr Lio acknowledges that diet can matter for some patients, but he describes true food-triggered AD as uncommon. He cautions against broad elimination diets, especially in children, and notes that when the skin is already raging, it can be difficult to know whether diet is actually driving symptoms. His approach is to first regain skin control, then reassess whether specific dietary triggers appear relevant. document.querySelectorAll('.mcq-block').forEach(function(block) { const correct = block.getAttribute('data-correct'); const form = block.querySelector('.mcq-form'); const feedback = block.querySelector('.mcq-feedback'); const resultText = block.querySelector('.mcq-result'); form.addEventListener('change', function(e) { const selected = e.target.value; // Log to console (optional) console.log("Selected answer:", selected); // Show feedback feedback.style.display = 'block'; if (selected === correct) { resultText.textContent = "Correct!"; resultText.style.color = "green"; } else { resultText.textContent = "Incorrect"; resultText.style.color = "red"; } }); }); .mcq-block { padding: 1rem; border: 1px solid #ddd; border-radius: 10px; margin: 1.5rem 0; background: #fafafa; } .mcq-question { margin-bottom: 0.75rem; } .mcq-feedback p { margin: 0.3rem 0; } https://dermsquared.com/videos/topical-conversations/toolbox-for-atopic-dermatitis 985 2026-06-15T13:24:17.675Z yes https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-part-2 2024-02-07T21:13:11.725Z https://image.mux.com/dOIvx8uOX4clRdiVrtfRjBRepq01dCG2Y8Kyjlh1TiWQ/thumbnail.jpg Part 2—A Dermatologist’s Perspective: Updated Atopic Dermatitis Guidelines from the AAAAI/ACAAI Joint Task Force In Part 2 of this Topical Conversations feature with Peter Lio, MD, FAAD, he continues his review of the latest updates to the atopic dermatitis management guidelines from the American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force (AAAAI/ACAAI JTF). As part of the multidisciplinary guideline panel, Dr Lio offers a dermatologist’s overview of the updated guidelines. Watch Part 1 here, where Dr Lio details the guideline design and the recommendations issued for moisturizers and topical therapies. Nonsteroidal agents In patients with uncontrolled atopic dermatitis that is refractory to moisturization alone, the guidelines state there is high-quality evidence supporting the use of topical calcineurin inhibitors tacrolimus and pimecrolimus. Crisaborole, a topical PDE-4 inhibitor, is recommended over usual care alone, supported by high-certainty evidence. While crisaborole is generally safe and well tolerated, patients may experience stinging and burning; considering this, Dr Lio emphasizes the importance of shared decision-making when selecting a treatment course. Topical JAK inhibitors Notably, the guidelines recommend against the use of the topical JAK inhibitor ruxolitinib, though it is a conditional recommendation with low-certainty evidence. While topical ruxolitinib is shown to be safe for use in clinical practice, Dr Lio notes that the perceived safety profile contributed to the recommendation against use. While he does use topical ruxolitinib in his own practice, he notes that he has encountered patients who express concern with the drug’s boxed warning. This recommendation reflects the consideration of the patient voice throughout the development of these guidelines. Bleach baths The guidelines also cover treatment with dilute bleach baths, with Dr Lio noting that while there is now good evidence that they are not antibacterial, they may still confer benefits. The guidelines conclude that dilute bleach baths may be potentially beneficial due to their anti-inflammatory and anti-itch properties and benefits to the skin barrier, but that they are best reserved for cases of moderate to severe atopic dermatitis. Elimination diets Elimination diets have been a point of contention in AD management. Many patients with AD undergo food allergy testing and elimination diets, but recent understanding challenges this approach, which is that avoiding foods may increase the risk of developing true IGE-mediated food allergies. Consequently, the guidelines recommend against the use of elimination diets compared to an unrestricted diet, suggesting that most individuals employing such strategies may experience little to no benefit. This recommendation is seen as a powerful statement from allergists for both clinicians and patients. Part 3 Stay tuned for Part 3 where Dr Peter Lio discusses the updated guidelines for remission and maintenance of remission using proactive therapies to prevent flareups and systemic therapies, including a noteworthy recommendation regarding systemic corticosteroids. Watch Part 1 here Key points The AAAAI/ACAAI Joint Task Force updates to the clinical guidelines for atopic dermatitis were developed by a multidisciplinary panel and incorporated the expertise of dermatologists The guidelines support the use of nonsteroidal agents but emphasize the importance of shared decision-making when selecting treatment Use of topical ruxolitinib is conditionally recommended against due to patient perception of its safety profile Bleach baths are concluded to be potentially beneficial for cases of moderate to severe atopic dermatitis Elimination diets are recommended against, as they may confer little to no benefit to patients https://dermsquared.com/videos/topical-conversations/dermatologist-perspective-updated-ad-guidelines-part-2 241 2024-02-06T20:29:34.417Z yes https://dermsquared.com/videos/topical-conversations/personalized-care-gpp-flares-maintenance 2024-05-31T18:32:46.837Z https://image.mux.com/9XgvdmuEdBLeQ01VmNHkO011zZGwJsfXsr43dsQ4DQU7k/thumbnail.jpg Personalized Care in GPP: From Flares to Maintenance In this episode of Topical Conversations, Jason Hawkes, MD, MS, and Saakshi Khattri, MD, discuss the complexities of generalized pustular psoriasis (GPP) and how the treatment landscape has changed with the approval of a novel targeted therapy that treats acute flares through intravenous administration and ongoing symptoms via maintenance therapy with subcutaneous injections, effectively managing the chronic manifestations of the condition. Clinical presentation of a challenging condition The conversation begins with an overview of GPP, highlighting its clinical presentation with sterile pustules on an erythematous background and its sudden onset. Historically, GPP has been rare and often difficult to diagnose, sometimes being mistaken for other conditions. Dr Khattri adds to this by discussing the inflammatory nature of GPP, its symptoms including pain, itching, and systemic involvement, and its distinction from plaque psoriasis. A distinct mechanism of disease The conversation then addresses the immunological differences between GPP and plaque psoriasis. Dr Hawkes explains that while plaque psoriasis is primarily driven by cytokines IL-23 and IL-17, GPP is driven by IL-36, leading to keratinocyte proliferation and recruitment of neutrophils. This distinction is crucial as it affects treatment approaches, with traditional psoriasis treatments often ineffective for GPP. Emergence of a novel therapy They discuss the challenges in managing GPP before the approval of the targeted therapy spesolimab, an IL-36 receptor antibody. Historically, treatment options were limited, and management relied on adapting treatments for plaque psoriasis. Dr Hawkes highlights the complexity of GPP management, noting the overlap with plaque psoriasis and the need for personalized care. He emphasizes the significance of having targeted treatments like spesolimab, which can effectively address the underlying immune pathways driving GPP. The patient experience and counseling tips Dr Khattri shares her experience using spesolimab in practice, sharing the case of a patient who she transitioned from intravenous spesolimab to subcutaneous injections to manage the patient’s ongoing symptoms beyond flares. She also shares how she manages patient expectations on the treatment and course of GPP, comparing it to hypertension in that it requires maintenance therapy to keep symptoms under control. She emphasizes that while flares are a significant aspect of the disease, they are just one part of the overall picture. Full-spectrum management of GPP Finally, they discuss practical tips for managing GPP, with Dr Khattri emphasizing the importance of recognizing it as a treatable condition now with the availability of an approved medication. She advises colleagues to consider spesolimab for both acute flares and maintenance therapy, reflecting on the positive impact of having both intravenous and subcutaneous treatment options for patients with GPP. https://dermsquared.com/videos/topical-conversations/personalized-care-gpp-flares-maintenance 617 2024-05-31T18:32:46.831Z yes https://dermsquared.com/videos/topical-conversations/high-risk-cscc-management 2025-08-12T18:15:25.320Z https://image.mux.com/j6khaej3eYMMtKQcRwh02Ogdw2WJ7hjHZNjil8NCLo01U/thumbnail.jpg High-Risk Cutaneous Squamous Cell Carcinoma: Refining Risk Stratification and Management In this episode of Topical Conversations, Laura Ferris, MD, and Désirée Ratner, MD, discuss approaches to identifying and managing high-risk cutaneous squamous cell carcinoma (cSCC), with a focus on integrating traditional staging systems and molecular testing to guide treatment decisions.Defining high-risk cSCC Historically, high-risk cSCC was defined by a combination of clinical and histologic features, such as tumor location on the head or neck, ill-defined borders, aggressive growth patterns, immunosuppression, or perineural invasion. The NCCN has since formalized a list of high-risk features, and staging systems such as AJCC and BWH now provide structured frameworks for evaluation. While these systems differ (for example, BWH includes poor differentiation as a criterion while AJCC does not) both have improved risk prediction compared to earlier approaches. Molecular testing with the 40-GEP assay Molecular assays such as the 40-GEP test offer additional prognostic refinement by evaluating gene expression within an individual tumor. The test categorizes patients as Class 1 (low risk), Class 2A (intermediate but clinically comparable to high risk in AJCC/BWH), or Class 2B (very high risk). Both physicians note the value of this tool in identifying patients who may benefit from closer surveillance or more aggressive therapy, as well as in de-escalating treatment for patients with low-risk results. Implications for treatment decisions Data suggest that patients with Class 2B tumors have significantly lower metastasis-free survival compared with Class 1 tumors, particularly in high-risk NCCN groups. Retrospective evidence indicates that Class 2B patients may derive the greatest benefit from adjuvant radiation therapy. Conversely, a Class 1 result may support omitting radiation in favor of close monitoring. The test also informs decisions regarding alternative systemic treatments such as immunotherapy for patients who are not candidates for radiation. Multidisciplinary integration and clinical pearls Dr Ratner emphasizes the benefit of sharing 40-GEP results with multidisciplinary oncology teams to individualize treatment plans and emphasizes ensuring adequate tissue sampling to allow molecular testing. The clinicians emphasize that results can be unexpected, even for experienced clinicians; thus, incorporating both staging systems and molecular tools can help optimize outcomes through more precise risk stratification and tailored management strategies. Key takeaways High-risk cSCC classification is evolving, with AJCC and BWH staging systems providing structured frameworks for clinical and histologic risk assessment The 40-GEP molecular assay refines prognosis by evaluating gene expression, categorizing patients into low, intermediate, or very high-risk groups Class 2B tumors as defined by the 40-GEP test carry a significantly higher risk of recurrence and metastasis and may benefit most from adjuvant radiation Class 1 results can support de-escalation of therapy in patients who may otherwise be overtreated Molecular results can inform multidisciplinary discussions and guide individualized treatment strategies https://dermsquared.com/videos/topical-conversations/high-risk-cscc-management 881 2025-08-08T19:11:42.523Z yes https://dermsquared.com/videos/topical-conversations/exploring-emerging-dermatology-devices-and-treatments-in-2025 2025-01-07T21:07:47.813Z https://image.mux.com/jRYpLxcMdubNrBBBEir4kLjAksurrvi2lPeZdz00KUQI/thumbnail.jpg Exploring Emerging Dermatology Devices and Treatments in 2025 In this episode of Topical Conversations, Dr Stephen Lewellis provides an insightful overview of the evolving landscape of dermatology devices and treatments to watch in 2025. Sharing his personal insights and experiences, Dr Lewellis highlights how these innovations can enhance patient outcomes and help dermatologists distinguish their practice by offering unique and forward-thinking options that patients may not encounter elsewhere. AviClear for acne Dr Lewellis begins by discussing AviClear, a 1726-nanometer laser device FDA cleared for treating acne of all severities. He highlights its best use cases, including moderate to severe inflammatory acne and patients who cannot or do not wish to take isotretinoin. Treatment overview: Three treatments over 2 months with optimal results typically appearing 6 to 12 months post-treatment Patient counseling: Emphasize patience and realistic expectations for long-term improvement Cost consideration: Though not covered by insurance, it may be more affordable than isotretinoin in some cases Dr Lewellis advises dermatologists to consider AviClear as part of their practice or refer patients to trusted colleagues who offer this treatment to provide comprehensive care. excel V+ Plus for versatile needs The excel V+ device features the Laser Genesis treatment mode, which uses 532- or 1064-nanometer lasers to induce dermal heating. Treatment benefits: Improved complexion, reduced pore size, and some acne improvement with minimal downtime Expectations: While optimal results require 6 to 8 treatments, even 1 to 2 sessions can provide improvement Applications: Beyond aesthetics, excel V+ can treat rosacea, inflammatory acne, and more, making it a versatile addition to a dermatology practice Swift for refractory warts Swift uses focused microwave energy to treat warts, especially plantar warts, by inducing a heat response that stimulates an immune reaction against the virus. Advantages: Less painful than cryosurgery with no post-treatment wound formation Key use case: Can be effective for refractory warts across the body Dr Lewellis notes that Swift is a niche offering that can help dermatologists stand out in their communities. YCANTH for molluscum contagiosum While not a device, YCANTH is a standardized form of cantharidin for molluscum contagiosum. Treatment highlights: Reliable, controlled results with treatments every 3 weeks as needed Controversy: While compounded cantharidin remains an option, consistency and robust data make YCANTH worth considering for patients Setting your practice apart Dr Lewellis concludes by advising that incorporating innovative devices and treatments such as AviClear, excel V+, and Swift, along with in-office options like YCANTH, represents an opportunity for dermatologists to differentiate their practices in 2025. These technologies offer cutting-edge solutions that can improve patient outcomes and expand treatment options. Exploring and integrating these advancements can help establish a practice as a leader in forward-thinking dermatologic care, enhancing both patient satisfaction and professional reputation within the community. https://dermsquared.com/videos/topical-conversations/exploring-emerging-dermatology-devices-and-treatments-in-2025 730 2025-01-03T19:58:33.780Z yes https://dermsquared.com/videos/topical-conversations/what-dermatologists-should-know 2025-11-21T15:18:51.045Z https://image.mux.com/01V3k3oe0002ONir01QjNrxQVLSvejI4Q7HMz6nDHnPcqNU/thumbnail.jpg Decoding the Bimekizumab SI/B Warning: What Dermatologists Should Know In this episode of Topical Conversations, Bruce E. Strober, MD, PhD, joins April Armstrong, MD, MPH, to explore the origins and clinical relevance of the suicidal ideation and behavior (SI/B) warning in the bimekizumab label. With bimekizumab now approved in dermatology for adults with moderate to severe plaque psoriasis and moderate to severe hidradenitis suppurativa (HS), many clinicians are asking whether this warning reflects a meaningful safety signal or a cautious interpretation of tightly monitored trial data.Where did the SI/B language come from?Dr Armstrong explains that the warning appears in the “Warnings and Precautions” section, advising clinicians to weigh risks and benefits in patients with a history of severe depression or SI/B and to monitor for new or worsening symptoms. Importantly, the label states that a causal association has not been established.She explains the likely origin of the language: highly sensitive, prospective monitoring in the bimekizumab trials. Compared with older psoriasis studies, these trials used more rigorous tools, such as the Columbia Suicide Severity Rating Scale (C-SSRS), capturing even passive ideation. In psoriasis trials, SI/B rates were 1.8% for bimekizumab vs 0.6% for placebo, but with wide confidence intervals crossing 1, signaling no clear statistical difference.In HS trials, confidence intervals were again wide and without consistent patterns in suicidal behavior. Across psoriatic arthritis, ankylosing spondyloarthritis, and nonradiographic axial spondyloarthritis studies, short-term data did not show elevated SI/B rates with bimekizumab.Interpreting the findings: context is criticalDr Strober emphasizes that no suicides occurred in the trials; the flagged events involved passive ideation captured through structured questionnaires and not clinical suicide attempts or behaviors.To contextualize, Dr Armstrong reviews background SI/B rates in psoriasis. Patients with psoriasis exhibit roughly double the risk of suicidal ideation and elevated risk of attempts vs the general population, particularly in patients with moderate to severe disease. Across psoriasis studies, SI/B event rates range from 0.1%–0.5% per 100 patient-years.Bimekizumab’s aggregated phase 2/3 psoriasis data show an SI/B rate of ~0.13% per 100 patient-years, aligning with background disease rates.How does bimekizumab compare with other biologics?Notably, SI/B rates for bimekizumab appear comparable to, or lower than, rates reported in trials of IL-17 inhibitors (such as secukinumab and ixekizumab) and IL-23 inhibitors. Dr Strober highlights that nothing in the bimekizumab dataset distinguishes it from patterns seen with other biologics across clinical development programs.Insights from depression measures in the trialsDr Armstrong points out that depression severity, measured by PHQ-9, improved substantially with bimekizumab in clinical trials. Additional key details include no dose–response relationship for SI/B, no clustering shortly after dosing, and many events adjudicated as not drug-related.Long-term extension and emerging real-world data have not revealed a new or consistent SI/B signal.A clinician’s approach to counseling and monitoringDr. Armstrong closes by noting that depression severity improved, on average, for bimekizumab-treated patients as measured by PHQ-9 scores. Still, because the language appears in the label, she recommends dermatologists approach patient discussions with clarity: contextualize the data, acknowledge the broader mental health burden in psoriasis, and continue standard monitoring for mood changes as part of comprehensive care.Key takeawaysThe bimekizumab SI/B warning is precautionary, and a causal relationship has not been establishedEvent rates in bimekizumab trials align with background SI/B rates expected in moderate–severe psoriasis populationsNo completed suicides or clear dose-related patterns were identified across the clinical programComparable or lower SI/B rates have been observed relative to other IL-17 and IL-23 inhibitorsPHQ-9 scores improved with treatment, suggesting overall positive effects on patient well-beingClinicians should contextualize the label language when counseling patients, especially given psoriasis’ intrinsic psychiatric comorbidity burdenStandard monitoring for depression remains appropriate, but current evidence does not indicate a unique or elevated SI/B risk with bimekizumab https://dermsquared.com/videos/topical-conversations/what-dermatologists-should-know 599 2025-11-21T15:18:51.035Z yes https://dermsquared.com/videos/topical-conversations/control-in-atopic-dermatitis 2026-05-20T16:44:45.219Z https://image.mux.com/R54C5Yk9O9vB7PAY4Pm6Z00dBnHa0202gnhC8tajxaWDek/thumbnail.jpg Off the Rollercoaster: Rethinking Control in Atopic Dermatitis There was a time when treating atopic dermatitis (AD) meant managing the peaks—calming a flare, then waiting for the next one to arrive. But as Elizabeth (Lisa) Swanson, MD, and E James Song, MD, describe, the disease doesn’t really turn off. AD settles, simmers, then resurfaces, more like a smoldering fire than something episodic. And once you start to see it that way, the goal becomes about stabilizing what’s happening over time instead of reacting to the moment.In this conversation, Drs Swanson and Song work through their approaches in clinic: lowering the threshold for biologics, rethinking what “controlled” actually means, and recognizing how much of the disease lives outside of what’s visible. The aim is getting patients off the rollercoaster, reducing the constant negotiation with their skin, and moving toward something steadier, more livable, and more honest to the disease itself. https://dermsquared.com/videos/topical-conversations/control-in-atopic-dermatitis 883 2026-05-01T15:35:35.724Z yes https://dermsquared.com/videos/topical-conversations/psoriasis-care-across-indications 2025-09-26T22:00:37.059Z https://image.mux.com/Th4RKl7tu00xANO6hK02ydVsfi17t1RPtLC8xG5kf9rBc/thumbnail.jpg The Axial Advantage: Expanding Psoriasis Care Across Indications In this episode of Topical Conversations, E. James Song, MD, speaks with Tina Bhutani, MD, about bimekizumab and its growing list of indications, including psoriasis, psoriatic arthritis (PsA), axial spondyloarthropathies, and hidradenitis suppurativa (HS), highlighting how this therapy may help dermatologists address the multifaceted needs of patients.Why another biologic?Dr Song opens by noting that bimekizumab is now the twelfth biologic approved for psoriasis, prompting the question of why additional biologics are still needed. Dr Bhutani stresses that despite the abundance of options, many patients cycle through therapies due to inadequate response or secondary failure. Moreover, patients often present with comorbidities such as joint disease that require broader treatment coverage, demonstrating the value of having multiple biologics available to personalize care.Bimekizumab in psoriatic arthritisPsA presents unique challenges, with many patients responding inconsistently or slowly to traditional therapies. Dr Bhutani explains that even when skin clearance is achieved, joint symptoms often remain uncontrolled. They explain that bimekizumab provides another option for these patients, adding to the armamentarium for both dermatologists and rheumatologists managing PsA.Addressing axial spondyloarthropathiesThe conversation turns to axial disease, specifically radiographic axial spondyloarthritis (axSpA, also known as ankylosing spondylitis) and nonradiographic axSpA (nr-axSpA). Dr Bhutani explains that these conditions involve inflammation of the central joints, particularly the spine and sacroiliac joints. Historically, treatment was limited until radiographic changes became apparent.Dr Song highlights the significance of bimekizumab’s approval for nr-axSpA, which allows earlier intervention before structural damage occurs. He contrasts IL-23 inhibitors, which have limited efficacy in axial disease, with IL-17 inhibitors like bimekizumab, which demonstrate consistent benefit across both peripheral and axial domains. Together, Drs Song and Bhutani emphasize that bimekizumab covers nearly all GRAPPA domains (skin, nails, enthesitis, dactylitis, peripheral joints, and axial disease) making it a versatile option for patients with overlapping manifestations.Expanding to hidradenitis suppurativaThe discussion closes with a look at bimekizumab’s approval in HS, a often difficult condition to manage. Dr Bhutani shares her clinical experience, noting rapid improvements in pain and inflammatory lesions, with the potential to reduce long-term complications such as scarring and tunneling. She emphasizes that patients with HS stand to benefit greatly from having more therapeutic options in what remains an area of significant unmet need.Key takeawaysOngoing need for new biologics: Despite many approved options, patients often require alternative therapies due to nonresponse or secondary failurePsA management: Bimekizumab offers an additional option for patients with joint diseaseAxial disease coverage: Approval in nr-axSpA allows earlier intervention and highlights IL-17 inhibitors as more effective than IL-23 inhibitors in axial domainsComprehensive domain coverage: Bimekizumab has potential to address nearly all GRAPPA domains, offering broad utility in patients with overlapping manifestationsHS treatment: Bimekizumab provides meaningful benefit in a challenging disease, with potential to improve quality of life and prevent long-term complications https://dermsquared.com/videos/topical-conversations/psoriasis-care-across-indications 564 2025-09-26T21:40:32.191Z yes https://dermsquared.com/videos/clinical-trial-coverage/thrive-aa1-clinical-trial 2025-09-10T15:12:38.843Z https://image.mux.com/KAbintt6TLqYfS3sfq5s64W7x1xjDs5b008WQl36B00fQ/thumbnail.jpg THRIVE-AA1 Clinical Trial THRIVE-AA1 Clinical Trial https://dermsquared.com/videos/clinical-trial-coverage/thrive-aa1-clinical-trial 220 2025-09-10T15:12:38.836Z yes https://dermsquared.com/videos/under-your-skin/interview-with-muneeb-shah-do 2024-03-06T16:20:52.110Z https://image.mux.com/y3wL5SEtvPpAq9Jo63rdKQSunkv9m4PhYaREkN4lLcY/thumbnail.jpg Interview with Muneeb Shah, DO In this episode of Under Your Skin, host Nicholas Brownstone, MD, chats with Muneeb Shah, DO, to explore some valuable advice for residents, effective time management techniques, and strategies for advertising your practice. What advice would you give someone just beginning residency? Dr Shah begins by reflecting on his residency experience, likening it to "drinking from a fire hose" due to the overwhelming influx of information. His key advice to residents is to seize this period as a valuable learning opportunity. He emphasizes the importance of asking questions and seeking insights not only on clinical matters but also on aspects like billing and operations. He encourages residents to attend conferences, network, and absorb as much knowledge as possible, as the intensity of post-residency responsibilities may leave little room for catching up on missed learning opportunities. What are your most useful time management techniques? Acknowledging his own journey to improve time management, Dr Shah underscores the significance of building a supportive team. Delegating tasks that may not be the best use of one's time to qualified team members, whether an office manager or medical assistant, allows for more efficient and strategic use of time. Additionally, he advocates for creating systems within the office to streamline patient interactions, suggesting the implementation of codes to prompt assistance when spending excessive time with a patient. Dr Shah's insights highlight the long-term benefits of optimizing team dynamics and establishing efficient office protocols. How do you advertise your practice? Dr Shah acknowledges the benefit having a large social media following has in attracting patients; however, he notes that patients discovered through social media tend to be more complex. They often seek him out after other dermatologists were unable to solve difficult-to-treat issues and have higher expectations. He also notes that despite having a large social media following, targeting a specific geographic area remains a challenge. Considering that, Dr Shah does not dismiss traditional advertising methods like door-to-door marketing and business card distribution to local family physicians and businesses, noting that he has seen significant success with these tactics. https://dermsquared.com/videos/under-your-skin/interview-with-muneeb-shah-do 317 2024-02-20T17:36:57.038Z yes https://dermsquared.com/videos/under-your-skin/interview-gabriela-maloney 2025-01-31T14:57:00.482Z https://image.mux.com/3Elk00YY02y2WhuYPf7POorxzKLDdt00cA3UFWd5tvLPvs/thumbnail.jpg Interview with Gabriela Maloney, DO - Practicing dermatology and staying efficient in clinic In this episode of Under Your Skin, Dr. Nick Brownstone chats with Dr. Gabriela Maloney about her journey from Brazil to Wisconsin, her favorite thing about being a dermatologist, tips for staying efficient in the clinic, and how she counsels patients on a common misperception in dermatology.What was your journey like from growing up in Brazil to practicing dermatology in Wisconsin?Dr. Maloney explains that when she was 15, she received a scholarship to become a high school exchange student and later also received a college scholarship. She wanted to pursue medical school but first needed to save some money. After working for 2 years at a biotech company, she saved enough to apply to medical school. After medical school, she had an opportunity to work in Wisconsin, which she describes as a family-friendly place with very nice people.What’s your favorite thing about being a dermatologist?Dr. Maloney explains that she loves the variety of patients dermatologists see, from newborns to the elderly. With a wide array of conditions to treat surgically, cosmetically, and medically, there are no repetitive days in dermatology. With many systemic diseases that can show up in the skin, she feels dermatology especially encourages doctors to retain and use the knowledge they learned in medical school daily. She finds it very rewarding to make a positive impact on patients’ quality of life.How do you stay efficient in clinic?Dr Maloney notes that to stay efficient in clinic, she makes sure to look at her schedule ahead of time, highlight potential derailments, and prepare her staff. She schedules surgeries 10 minutes ahead of when she wants patients to arrive, so if they are late, it doesn’t impact her daily schedule and they have sufficient time to get checked in, prepped, and consented. She also does her large cosmetic procedures right before lunch; with this tactic, if patients have a vasovagal episode or need more recovery time, they can be safely kept in the room without derailing the day.What’s a common misperception you hear from patients, and how do you address it?Dr. Maloney finds that many patients with melasma think they don’t need daily sunscreen because they don’t spend much time outside. She explains to patients that even if they think they don’t go outside, we all inevitably take the trash out, walk our dogs, get the mail, or chat with a neighbor, all of which add to daily sun exposure contributing to melasma. She counsels patients to keep their sunscreen next to their toothbrushes to encourage daily application. https://dermsquared.com/videos/under-your-skin/interview-gabriela-maloney 219 2023-08-22T18:17:57.259Z yes https://dermsquared.com/videos/under-your-skin/interview-tina-bhutani 2025-01-31T14:53:10.372Z https://image.mux.com/8rGW4jW02C5f5026f34wJZHuZ02Ux003FUHkuI7wgVoy02H4/thumbnail.jpg Interview with Tina Bhutani, MD - Time management and avoiding burnout In this episode of Under Your Skin, Dr Nick Brownstone chats with Dr Tina Bhutani to hear about the rarest disease she’s encountered in her career and to get some tips on time management and avoiding burnout.What’s the rarest disease you’ve seen in your career?Dr Bhutani describes a case of Sneddon-Wilkinson disease, or subcorneal pustular dermatosis, a very rare and difficult-to-diagnose condition involving a combination of clinical and pathological diagnoses.What’s your favorite time management technique?Dr Bhutani’s favorite time management tip is to create a list with patients, especially new patients, as soon as a visit begins. She has patients make a checklist of everything they want to discuss and then prioritize the top 2 items. She’ll discuss those 2 topics during the visit and bring patients back for a follow-up visit to discuss the remainder a few weeks later. She explains that this technique helps set expectations while still ensuring the patient feels their needs are being met.How do you avoid burnout?Dr Bhutani avoids burnout by prioritizing and scheduling self-care, whether it’s workout sessions or time with family and friends. She puts these events on her calendar and treats them like any other important meeting. She makes a point not to cancel and holds herself accountable for her own self-care. https://dermsquared.com/videos/under-your-skin/interview-tina-bhutani 118 2023-05-01T16:14:38.259Z yes https://dermsquared.com/videos/under-your-skin/interview-with-raj-chovatiya 2024-03-06T16:20:02.862Z https://image.mux.com/dbosKwBly3MEBW00rGYSmt3Jm3ly02vXeMedOGf8qD016Y/thumbnail.jpg Interview with Raj Chovatiya, MD, PhD In this episode of Under Your Skin, host Dr Nicholas Brownstone chats with Dr Raj Chovatiya about a tip for improving efficacy in your practice, advice for residents on their first day, and exciting innovations in dermatology. What’s one change you’ve made in your practice in the last 5 years that had the biggest effect on your efficacy? Dr Chovatiya remarks that he loves balancing clinical work and research but faces a dilemma of how to combine the 2 while using all hours of his day efficiently. He advises that dermatologists should find a way to make clinic work for them. If there are research questions they’re interested in, they should find a way to relate it to their patients and work those efforts into their clinical time. For Dr Chovatiya, he builds efforts to understand the burden of inflammatory skin disease and issues facing patients with skin of color into each of his encounters, which saves him time and makes him feel as if he is combining 2 things he loves on a day-to-day basis. If you could go back in time to your first day of residency, what advice would you give yourself? Dr Chovatiya advises residents that they never know which direction their future careers may take, so they should be open to exploring opportunities they may not otherwise think about. He reflects on aspects of his career he’s been involved with relating to clinical interest, partners in industry, and research work, and notes that he wouldn’t have been able to predict some of the direction his career has taken. He advises that remaining open to serendipitous opportunities can lead to surprising results. Which innovation in dermatology are you most excited about? Dr Chovatiya is enthusiastic that topical medications are becoming important again. As someone who does a lot of work with inflammatory disease, including psoriasis, hidradenitis suppurativa, and eczema, he notes that while there have been huge developments in systemic and biologic therapies, dermatologists have still been using the same topicals that have been in use for many years. He comments on promising new investments in the last several years in mechanisms of action, vehicles, and issues relating to patient adherence with topicals. He notes that this is exciting because topical treatments are the mainstay of dermatologists; many patients have conditions in the mild-to-moderate range where topicals are the right choice. He hopes to see that investment in topical therapies continue to grow over the next decade. https://dermsquared.com/videos/under-your-skin/interview-with-raj-chovatiya 189 2023-10-17T13:31:55.340Z yes https://dermsquared.com/videos/under-your-skin/teledermatology-insights-reimbursement-challenges-finding-balance-susan-taylor 2024-08-09T13:56:01.601Z https://image.mux.com/QicBl3sSobB4nYgBxw015qNe8zjCgrs5QlAiMmADFOeM/thumbnail.jpg Teledermatology Insights, Reimbursement Challenges, and Finding Balance with Dr Susan Taylor In this episode of Under Your Skin, host Dr Nicholas Brownstone sits down with Dr Susan Taylor to get her perspectives on the evolving field of dermatology. Dr Taylor shares her thoughts on the growing role of teledermatology, the pressing issue of reimbursement that challenges the sustainability of dermatology practices, and how she personally finds balance in her demanding career. The rise of teledermatology Dr Taylor emphasizes the growing significance of teledermatology, particularly since the onset of the COVID-19 pandemic. She highlights that teledermatology has become an essential tool for improving patient access to dermatologic care. For patients who find it challenging to take time off work, teledermatology offers a convenient alternative. They can easily consult with dermatologists during their lunch breaks or even from a private space in their workplace. Dr Taylor stresses that the key benefit of teledermatology is its ability to increase and improve access to dermatologic care, a factor that remains crucial in today's health care landscape. A critical issue facing dermatology Dr Taylor identifies reimbursement as the most critical issue currently confronting dermatology. She points out that while other health care sectors, such as hospitals and skilled nursing centers, have received inflationary updates in their reimbursements, dermatologists have not seen similar adjustments. The lack of updates in Medicare reimbursements has created a significant financial strain on dermatology practices. Dr Taylor warns that this could ultimately affect the quality of care patients receive. The financial pressure makes it increasingly difficult for private practitioners to keep their practices open, pay their staff, and maintain the necessary resources to provide patient care. She underscores that advocating for better reimbursement rates should be the top priority for the American Academy of Dermatology and dermatologists nationwide. Balancing work and relaxation Dr Taylor then shares her personal approach to unwinding after a long day. She enjoys walking to and from work, which helps her process the events of the day and decompress. Additionally, she finds relaxation in spending quality time with her husband, particularly by going out to dinner together. This routine allows her to maintain a healthy work-life balance and recharge for the challenges of the next day. https://dermsquared.com/videos/under-your-skin/teledermatology-insights-reimbursement-challenges-finding-balance-susan-taylor 169 2024-08-09T13:56:01.594Z yes https://dermsquared.com/videos/under-your-skin/interview-with-andrea-murina 2025-01-29T17:59:20.347Z https://image.mux.com/iYOcm01nKpyMEtr7evNw2Oh7F101gpnDXlCdaLp9oRb5w/thumbnail.jpg Interview with Andrea T. Murina, MD - Time management, demanding patients, and more! In this installment of Under Your Skin, host Nicholas Brownstone, MD, chats with Andrea Murina, MD, to get tips on time management and dealing with demanding patients. Dr Murina also shares her thoughts on what condition dermatology still needs better treatments for. What’s your favorite time management technique in clinic? Dr. Murina finds that getting an early start to her day helps her to best manage her time. She also provides some tips on writing notes. She shares her technique of setting aside a block of time to work on them; if she doesn’t finish her notes within that block, she moves the remainder of that task to the next day. She finds that unfinished work makes her more focused the next day and helps increase her efficiency. How do you deal with demanding patients? Dr. Murina values challenging patients because they teach valuable lessons. One such lesson she has learned from her demanding patients is the importance of listening. She finds that taking the time to sit down and actively listen is the best way to bring down the intensity of a demanding patient. What condition in dermatology do we still need better treatments for? Dr. Murina feels the biggest gap in dermatology currently is treatment for hidradenitis suppurativa. There is currently only one FDA-approved biologic for this condition, and all other treatments for it are off label. She emphasizes that dermatology needs more FDA-approved medications in this area. https://dermsquared.com/videos/under-your-skin/interview-with-andrea-murina 114 2023-09-19T20:31:21.817Z yes https://dermsquared.com/videos/under-your-skin/interview-ben-lockshin 2025-01-31T14:55:38.239Z https://image.mux.com/YZRuou1yqP900cj2MF9vO01kEUAQQM02zvocFjZF00h9YII/thumbnail.jpg Interview with Benjamin Lockshin, MD - Advertising a practice and more In this episode of Under Your Skin, Dr Nick Brownstone sits down with Dr Benjamin Lockshin to get advice on advertising a practice, learn what specialty Dr Lockshin would practice if he couldn’t be a dermatologist, and hear tips on how to avoid burnout.How do you advertise your practice?Dr Lockshin explains that at his practice, they don’t do formal advertising. Rather, he reaches out to community doctors to ensure he develops a relationship with those providers. He believes that taking care of patients effectively and letting the patients do the advertising is the most effective way to grow a successful practice.If you couldn’t be a dermatologist, what other specialty would you practice?Dr Lockshin feels his personality and mindset would work well with urology. He explains that urology shares many similarities with dermatology; you can manage patients with acute problems or over the course of many years. There is also a surgical component as well as a medical component to both specialties.How do you avoid burnout?Dr Lockshin suggests adding variety to your daily and weekly activities to help avoid burnout. He runs a clinical trial center and consults and speaks for several companies, which allows him to vary his weekly schedule. https://dermsquared.com/videos/under-your-skin/interview-ben-lockshin 115 2023-02-15T16:46:45.000Z yes https://dermsquared.com/videos/under-your-skin/interview-neal-bhatia 2024-06-26T14:31:10.774Z https://image.mux.com/WnL4NFqW3SGO5pGJYcx8gXhP3dPXhNcdYvhabx00v4jI/thumbnail.jpg Interview with Neal Bhatia, MD In this episode of Under Your Skin, Dr Nick Brownstone chats with Dr Neal Bhatia about giving advice to a first-year dermatology resident, innovations in dermatology, and advice on communicating a serious diagnosis to a patient.If you could go back in time, what advice would you give yourself as a first-year dermatology resident?Dr Bhatia explains that he would discuss expectations and emphasize that a first job may not be a last job.He would also advise a first-year dermatology resident to create a niche for themselves. They should aim to learn about everything but also create a specialty and stay in a niche that they can be proud of and dig into deeply.Dr Bhatia also acknowledges that academic demands are high in residency; he would advise a first-year resident to try to find a balance while keeping their foot on the gas and off the brake.What innovations in dermatology are you most excited about?Over the course of his career, Dr Bhatia has enjoyed watching innovations develop around Janus kinase inhibitors, biologics, and strategies and options to manage itch.He recalls being groomed on topical steroids and innovations focused on active ingredients, but comments that now, the vehicles of the topicals are getting attention. He also praises the approach of thinking about the process of disease.Dr Bhatia also encourages dermatologists to put patients’ interests forward, get out from their own shadow, and learn to be aggressive again.How do you communicate a serious diagnosis to your patients?Dr Bhatia emphasizes the importance of communicating serious diagnoses in person. He encourages physical touch and eye contact when discussing the severity of a diagnosis. He advises against relaying a serious diagnosis over the phone, since patients in that scenario may not absorb any information besides the negative news and may begin doing research on their own; he encourages dermatologists to be prepared on how to talk to patients about what’s ahead and the management plan for their diagnosis.He reiterates that putting your hands on patients is vital; he refers to dermatology as 3D and emphasizes the importance of being present with your patients. He has advised residents that they shouldn’t leave the exam room without some physical touch with their patients, even if that means just shaking hands.Dr Bhatia comments that delivering bad news is part of being present with patients and that it’s important to relate that you’re not just delivering the bad news, you are part of the solution as well. https://dermsquared.com/videos/under-your-skin/interview-neal-bhatia 201 2023-01-18T16:26:31.000Z yes https://dermsquared.com/videos/under-your-skin/interview-with-andrew-alexis-md-mph 2024-04-30T13:29:22.478Z https://image.mux.com/cofRoeXhv7OUNrTnt004rptaHRDwoC49iMxVtKZ3O400c/thumbnail.jpg Interview with Andrew Alexis, MD, MPH In this episode of Under Your Skin, host Nicholas Brownstone, MD, chats with guest Andrew Alexis, MD, MPH, about the public perception of dermatology, therapeutic gaps for challenging pigmentary conditions, and balancing aesthetics and medical dermatology in the clinic. The incomplete public perception of dermatology They begin by discussing the public perception of dermatology, noting that the general public may not fully grasp the extent of dermatologists' contributions. Dr Alexis highlights the diversity of the specialty and its profound impact on individuals' lives. He emphasizes that dermatology encompasses a wide spectrum of care, ranging from aesthetics to inflammatory conditions, infectious diseases, and diagnosing internal diseases through cutaneous manifestations, noting the myriad ways in which dermatologists positively influence patients' well-being. Therapeutic gaps for pigmentary disorders Transitioning to therapeutic considerations, Dr Alexis acknowledges the remarkable recent advancements in dermatology. However, he underscores the persistent need for better therapies, particularly for pigmentary conditions such as lichen planus pigmentosus and erythema dyschromicum perstans, or ashy dermatosis. These challenging conditions pose treatment difficulties due to limited therapeutic options, and Dr Alexis expresses hope for future breakthroughs in identifying new targets and developing effective therapies to address these unmet needs. The intersection of aesthetics and medical dermatology Shifting focus to aesthetic dermatology, Dr Alexis provides insights into the evolving landscape of his practice. He shares that approximately 40% of his time is dedicated to performing aesthetic procedures, such as lasers, peels, and injectables, and that he anticipates a continued increase in the demand for aesthetic services over time. Many of Dr Alexis' aesthetics patients initially sought medical dermatology care but later returned for aesthetic procedures to address additional concerns. This trend underscores the intersection between medical and aesthetic dermatology and highlights the expanding role of dermatologists in meeting patients' diverse needs. https://dermsquared.com/videos/under-your-skin/interview-with-andrew-alexis-md-mph 174 2024-04-30T13:29:22.473Z yes https://dermsquared.com/videos/under-your-skin/interview-jane-bellet 2023-08-09T18:09:37.558Z https://image.mux.com/ieUl3g2BH88gS8wELMp1CuQ8Ms2aW2Jrlb3rQl9iciM/thumbnail.jpg Interview with Jane S. Bellet, MD In this episode of Under Your Skin, Dr. Nick Brownstone sits down with Dr. Jane Bellet to hear about a common misperception she hears from her patients, her best tip for treating hemangiomas in pediatric patients, and her opinion on what condition we need better treatments for in dermatology.What is the most common misperception you hear from your patients?The most common misperception Dr. Bellet hears from her patients is that they shouldn’t apply sunscreen to babies under 6 months of age. She advises her patients that while babies should still be shaded and wear protective clothing outside, it’s essential to use a physical blocker with zinc oxide or titanium dioxide to prevent sunburn.What is your best tip for treating pediatric patients with hemangiomas?Dr Bellet advises that the most important thing to do when treating a hemangioma in pediatric patients is to treat early. She emphasizes that doctors should not delay referring patients to a pediatric dermatologist as young as possible since treatments for hemangiomas work better when the patients are younger.Which conditions do we need better therapies for in dermatology?In Dr. Bellet’s opinion, dermatology needs better therapies for nail lichen planus. Dermatologists often struggle to treat it, and she hopes that in the future, better treatment options will develop. https://dermsquared.com/videos/under-your-skin/interview-jane-bellet 87 2023-08-09T18:09:37.553Z yes https://dermsquared.com/videos/under-your-skin/interview-with-alexandra-k-golant-md 2023-10-17T13:33:32.177Z https://image.mux.com/g83v9GLxVdPNym6DfTcIfWEba6fVoALnyu1IWdPhjZg/thumbnail.jpg Interview with Alexandra K. Golant, MD In this episode of Under Your Skin, host Nicholas Brownstone, MD, gets to know Alexandra Golant, MD, as they discuss her favorite thing about being a dermatologist, her favorite disease to treat, and her best tip for treating patients with inflammatory skin disease. What’s your favorite thing about being a dermatologist? Dr Golant encourages residents who come through her program to remember how lucky they are and to take the drive they have when applying to the program and carry it with them throughout their careers. She feels that dermatology is a very special, relationships-based specialty; she values the ability to take care of so many patients throughout the day and that each of her colleagues can curate their own mixture of patient care, research, and resident education. She also appreciates being able to speak and meet colleagues nationally and internationally and finds that the opportunity to do so makes dermatology particularly meaningful. What’s your favorite disease to treat and why? Dr Golant loves treating inflammatory skin disease, especially atopic dermatitis. She reflects that dermatologists may now take for granted the availability of advanced systemic therapeutics, but that until very recently, patients with atopic dermatitis were ignored from a therapeutic standpoint and had very limited treatment options. She appreciates the ability to positively impact a patient by helping to restore their quality of life; in some cases, patients are enabled to experience life as if they don’t have atopic dermatitis, which for some patients, has been affecting them since childhood. As atopic dermatitis treatments have emerged for younger and younger patients, Dr Golant remarks that the ability to intervene earlier during the stage when children are developing self-esteem and managing school performance makes for a powerful doctor-patient relationship that she greatly values. What is your best tip for treating a patient with inflammatory skin disease? Dr Golant’s best tip for treating patients with these conditions is to actively listen and take time to ask patients what is driving their suffering. By learning each patient’s unique priorities, you can tailor your treatment to suit them and get the best result possible. https://dermsquared.com/videos/under-your-skin/interview-with-alexandra-k-golant-md 171 2023-10-03T15:58:35.924Z yes https://dermsquared.com/videos/under-your-skin/interview-with-james-q-del-rosso-do 2024-04-02T18:12:11.360Z https://image.mux.com/qW82mwyCIc7GQnvSrLVCDRFcp00aJhdeDMZBPoMVn7J00/thumbnail.jpg Interview with James Q. Del Rosso, DO In this episode of Under Your Skin, host Nicholas Brownstone, MD, chats with James Q. Del Rosso, DO, who shares anecdotes and insights from his dermatology career on rare diseases, the benefits of being a dermatologist, and the outlook on treatments for challenging conditions. Encounters with a rare disease Dr Del Rosso recounts an anecdote from his internship when he encountered a patient with a rare disease he had never seen before—cytophagic histiocytic panniculitis (CHP). Despite its rarity, Dr Del Rosso encountered CHP again the following year, where, as a first-year resident, he was able to surprise a leading dermatologist by correctly diagnosing this rare condition. The dermatologist’s advantage Dr Del Rosso highlights the autonomy and diversity the field offers. Dermatologists have the flexibility to cater to patients of all ages and can choose to specialize in various areas such as cosmetic, medical, or surgical dermatology. This autonomy extends to their practice setting and scheduling, allowing for a fulfilling and adaptable career. Advancing care for challenging conditions Discussing areas where better medications are needed, Dr Del Rosso reflects on past challenges with conditions like hidradenitis suppurativa, vitiligo, and alopecia areata, where treatment options were limited. However, he expresses optimism about recent advancements in medication development, particularly in JAK inhibitors and monoclonal antibodies. He emphasizes the significant strides being made, providing much-needed additions to the dermatologist’s toolbox when treating patients with these challenging conditions https://dermsquared.com/videos/under-your-skin/interview-with-james-q-del-rosso-do 207 2024-04-02T18:12:11.352Z yes https://dermsquared.com/videos/under-your-skin/interview-with-lisa-swanson-md 2024-06-26T14:35:40.572Z https://image.mux.com/yoo6hiI59QQM4bZd3aC02mA7nV77902hp56nhCq7ET6j00/thumbnail.jpg Interview with Lisa Swanson, MD In this installment of Under Your Skin, host Nicholas Brownstone, MD, sits down with Lisa Swanson, MD, to hear her commentary on what she loves most about being a dermatologist, her tips on dealing with demanding patients, and what conditions we still need better treatments for in dermatology. A passion for dermatology Dr Swanson's journey into dermatology is deeply rooted in childhood experiences growing up with her urologist father. She was exposed to the medical world early through manually organizing and filing her father's research articles and was impacted by his perspectives on medical practice, which became a driving force in her decision to become a doctor. Dr Swanson sees herself practicing in the "golden age of dermatology," driven by the profound impact dermatologists can have on improving patients' lives. Dealing with demanding patients Addressing the challenge of demanding patients, Dr Swanson emphasizes 2 crucial elements: listening and accessibility. As a pediatric dermatologist, she makes sure to allocate ample time for appointments with potentially demanding parents. This ensures that she’s able to listen thoroughly to their concerns without these extended encounters impacting her ability to stay on schedule in clinic. Regarding accessibility, Dr Swanson encourages email communication with her more demanding patients, establishing a connection that helps diffuse tension by offering them an easy way to ask questions. Drs Brownstone and Swanson acknowledge that doctors may be hesitant to share contact information in this way for fear that patients will abuse it; however, they both agree that patients are usually reassured simply by having access to this valuable outlet and thus rarely overuse it. Improving the treatment landscape for challenging conditions Dr Swanson identifies 3 conditions in need of better treatment options in dermatology. Hidradenitis suppurativa presents challenges for many patients despite existing treatments, though she anticipates more solutions in the coming years. She also feels alopecia areata and vitiligo need improved medication options. However, both appear to be on the cusp of a treatment revolution, particularly with the promising developments in JAK inhibitors. https://dermsquared.com/videos/under-your-skin/interview-with-lisa-swanson-md 298 2024-03-05T14:45:11.296Z yes https://dermsquared.com/videos/under-your-skin/interview-with-gary-goldenberg-md 2024-01-23T16:53:38.491Z https://image.mux.com/WfAM6U02tK3LdckFgbFqZx00WnLF6nMw8BXRetzFBGqeQ/thumbnail.jpg Interview with Gary Goldenberg, MD In this episode of Under Your Skin, host Nicholas Brownstone, MD, chats with Gary Goldenberg, MD, about a tip for improving practice efficiency, dealing with demanding patients, upcoming innovations in dermatology, and his unique work-life balance. What change have you made in your practice in the last 5 years that has had the biggest impact on your efficacy? One standout modification Dr Goldenberg made in his practice was introducing private-label skincare. He emphasizes the importance of addressing patients' skin care, considering it a fundamental aspect sometimes overlooked by dermatologists. In his practice, it's now a routine question for every patient, and he’s able to offer them curated regimens available for purchase in the office. He notes that offering private-label skin care can be done relatively inexpensively, enhances patient care, and allows dermatologists to have a clear view of the products their patients are using. How do you deal with demanding patients? When dealing with demanding patients, Dr Goldenberg advocates for setting clear expectations from the start. For instance, managing expectations is crucial in cases like hair loss, where realistic outcomes need to be communicated. He emphasizes the significance of active listening. When patients come to him with many areas of concern, he has them make a list of their priorities and they address them accordingly. By transforming challenging situations into positive interactions, he notes that demanding patients often become some of the most valuable. What innovations in dermatology are you most excited about? Dr Goldenberg predicts that dermatology is on the brink of a regenerative medicine revolution. Beyond just platelet-rich plasma, he anticipates advancements in stem cells and exosomes that hold promise across various aspects of medicine. He notes that these products are still considered experimental, but that the potential for regenerating collagen, elastic fibers, skin cells, and hair opens up new avenues for improving patients' lives. What advice do you have for other husband/wife dermatology couples who practice? Dr Goldenberg, who is in practice with his wife, highlights the advantages of their partnership, noting that they can cover for each other and share common goals of patient care and practice success. He comments that having the same boss at home and in the office promotes harmony and is his preferred way to navigate his professional and personal spheres. https://dermsquared.com/videos/under-your-skin/interview-with-gary-goldenberg-md 230 2024-01-23T16:21:51.575Z yes https://dermsquared.com/videos/under-your-skin/interview-brian-s-kim 2023-08-14T20:41:39.596Z https://image.mux.com/tWX3YjFT7cVRY17P5ei9KiFrDfthRVLpjTNqKH01tVR8/thumbnail.jpg Interview with Brian S. Kim, MD, MTR In this episode of Under Your Skin, Dr Nick Brownstone chats with Dr Brian Kim to ask about the rarest disease he’s seen in his career and hear his thoughts on the future of dermatology.What’s the rarest disease you’ve seen in your career?Dr Kim describes the case of a pediatric patient with eczema who was referred for molluscum in the setting of eczema. Dr Kim suspected an immunodeficiency due to the extent of the patient’s molluscum and discovered the patient had a mutation in the CARD11 protein. The patient was within a cohort of the first patients with a CARD11 deficiency.How will dermatology be practiced 10 years from now?Dr Kim predicts 3 major shifts in the practice of dermatology over the next 10 years. First, he believes more specialization will develop, which will result in more delegation. Second, he anticipates that artificial intelligence will play a role in dermatology. Last, he foresees that randomized trials will lose some significance as targeted therapeutics continue to emerge.Which conditions do we need better treatments for?Dr Kim emphasizes that dermatology needs better treatment for chronic itch. He feels there is a significant misunderstanding about itch being unimportant even though it’s the most common symptom seen in dermatology. https://dermsquared.com/videos/under-your-skin/interview-brian-s-kim 137 2023-06-15T18:20:32.408Z yes https://dermsquared.com/videos/under-your-skin/interview-with-joslyn-sciacca-kirby-md-med-ms 2025-01-29T17:59:50.845Z https://image.mux.com/Nqtl2Qh00Paivh49vMSe7fF584VvHGo02TwLEGl475kMw/thumbnail.jpg Interview with Joslyn R. Sciacca Kirby, MD, MEd, MS - Burnout, time management, and more! In this episode of Under Your Skin, host Dr Nicholas Brownstone engages in a conversation with Dr Jocelyn Kirby to explore strategies for avoiding burnout, time management techniques in clinic, and advice for dermatology residents. How do you avoid burnout? One key insight from Dr Kirby is the significance of staying connected to the purpose behind her work—the patients. By seeing patients as individuals rather than just by appointment times or medical conditions, she finds a deeper sense of fulfillment. Taking the time to understand her patients on a personal level becomes a meaningful antidote to burnout. What is your favorite time management technique in clinic? When discussing time management techniques in the clinic, Dr Kirby acknowledges the inevitability of occasionally falling behind schedule. Despite this, she stresses the importance of being present in the moment with each patient. By focusing entirely on the individual she is currently counseling, she avoids distractions related to previous or upcoming appointments, ensuring that each patient receives her full attention and care. If you could go back in time to your first day as a dermatology resident, what advice would you give yourself? Reflecting on her own journey as a dermatology resident, Dr Kirby recognizes the prevalence of imposter syndrome among her peers. She collaborated on a project with a colleague, Dr Paul Riegen, and discovered that around 90% of dermatology residents experience imposter syndrome, a phenomenon that often extends beyond residency. Her advice to her younger self is to recognize her worth, acknowledge the hard work that brought her to where she is, and trust in the respect and support of her colleagues. This self-assurance, she believes, is key to sustained success in the field. https://dermsquared.com/videos/under-your-skin/interview-with-joslyn-sciacca-kirby-md-med-ms 190 2024-01-09T14:18:52.262Z yes https://dermsquared.com/videos/under-your-skin/interview-ted-lain 2023-08-14T20:53:44.974Z https://image.mux.com/slqKDVYHFm15BUTQz5G00rrkQTbXvYrFrvSiZ8cgxPPA/thumbnail.jpg Interview with Edward (Ted) Lain, MD, MBA In this episode of Under Your Skin, Dr Nick Brownstone sits down with Dr Ted Lain for a quick Q&A session covering Dr Lain’s favorite thing about being a dermatologist, his perception of the biggest challenge facing dermatology, and his thoughts on how dermatology will evolve in the future.What’s your favorite thing about being a dermatologist? Dr Lain explains that his favorite thing about being a dermatologist is the clinical trials and research. Being a dermatologist allows him to focus on aesthetic, cosmetic, and medical dermatologic research.What’s the biggest challenge facing dermatology?In Dr Lain’s opinion, the biggest challenge currently facing dermatology is the economy and the economic headwinds. He advises dermatologists to focus on core business strategy principles to survive and thrive.How do you think dermatology practice will evolve over the next 10 years?Dr Lain believes that over the next 10 years, artificial intelligence will elevate and augment what dermatologists are able to achieve in terms of diagnosis and treatment. https://dermsquared.com/videos/under-your-skin/interview-ted-lain 98 2023-06-15T18:15:52.863Z yes https://dermsquared.com/videos/under-your-skin/interview-with-doris-day-md-faad 2024-06-26T14:35:55.321Z https://image.mux.com/WrZFWP7Zwl01EAkzTmVll0102hCVKPspcWdt902fkTUH5bE/thumbnail.jpg Interview with Doris Day, MD, FAAD In this episode of Under Your Skin, host Nicholas Brownstone, MD gets to know Doris Day, MD, FAAD, a dermatologist specializing in laser, cosmetic, surgical, and aesthetic dermatology. Dr Day offers tips on guiding conversation with difficult patients, gives her thoughts on an emerging trend in dermatology, and shares her approach to a healthy work-life balance. Understanding the demanding patient and guiding the conversation Dr Day approaches interactions with demanding patients with empathy and understanding. Rather than viewing them as difficult, she recognizes their need to be heard and understood. By empathizing with their anxieties, expectations, and budget constraints, she transforms demanding patients into supportive allies. She also believes in transparent communication and education. Instead of persuading patients into treatments, she informs them about their options and recommends a holistic approach. Starting conversations with compliments helps ease tension and facilitates open dialogue. By striking a balance between meeting patients where they are and being honest about what can be achieved, Dr Day guides conversations with these patients effectively. Sometimes, she acknowledges when she might not be the right fit for a patient, prioritizing ethical practice over profit. A trend towards dermatology’s expanding scope When discussing emerging trends in dermatology, Dr Day says she looks forward to the expanding scope of the field. She emphasizes the importance of recognizing the value of appearance, noting that while many common dermatologic conditions are not life-threatening, they still profoundly impact a patient’s overall well-being and self-confidence. As the population gains a better understanding of general health, Dr Day foresees a future where dermatologists play a crucial role in enhancing healthspan through a holistic approach that integrates skin care, lifestyle modifications, and preventive healthcare. Avoiding burnout with an integrated approach to life To avoid burnout, Dr Day advocates for an integrated approach to life. Balancing her professional commitments with personal interests, such as family, allows her to find fulfillment. She advises against setting goalposts that must be achieved before pursuing the next goal and instead suggests a more balanced approach to the work-life relationship. She emphasizes the need to compartmentalize stress and prioritize self-care. By consciously separating work-related concerns from personal life, Dr Day maintains emotional well-being and prevents burnout. https://dermsquared.com/videos/under-your-skin/interview-with-doris-day-md-faad 319 2024-03-19T19:28:37.900Z yes https://dermsquared.com/videos/under-your-skin/interview-with-natasha-atanaskova-mesinkovska 2025-01-31T14:44:40.611Z https://image.mux.com/CFdhTjEhELHeSRRBQ5UXfHFm6K2Lyy8LwDSev8Dk3WU/thumbnail.jpg Interview with Natasha Mesinkovska, MD, PhD - Office efficiency and more In this installment of Under Your Skin, Dr. Nick Brownstone chats with Dr. Mesinkovska about her favorite disease to treat and which innovations in dermatology she’s most excited about. He also gets a helpful tip on one way to increase efficiency in the office. What is your favorite disease to treat and why? Dr. Mesinkovska replies that her favorite disease to treat is alopecia areata because dermatologists finally have a treatment for it. With JAK inhibitors revolutionizing the field, she finds it very satisfying to be able to assure her patients that there is now a treatment available. She also notes the positive effects of dupilumab for children with atopic dermatitis. She comments that with the development of baricitinib, the field of alopecia areata has experienced a game-changing event. She also reflects on the positive developments for other types of alopecia that have benefitted from the development of oral minoxidil. She remarks that she’s hopeful more JAK inhibitors will enter the market. What innovations in dermatology are you most excited about? Dr. Mesinkovska remarks that she’s happy treatment for chronic inflammatory diseases has shifted from injectables to oral treatments taken daily and that dermatologists are able to treat people more effectively with fewer injections. In the realm of aesthetic devices, she is also pleased about the development of micro-coring technology, which uses needles big enough to puncture skin and remove tissue but heal without a scar. She remarks that this technology can likely help tighten not only faces, but bodies as well. In the past 5 years, what is 1 thing you’ve done to increase your efficiency in the office? Dr. Mesinkovska explains that she realizes what she likes to do and how many people she wants to see, and she accomplishes this by recognizing her own worth. She comments on the urge doctors often have to be people-pleasers but recognizes that she can raise her own value by raising her prices and choosing to see 1 patient instead of 3. This allows her to dedicate more time to that patient and leave the exam room feeling less burnt out while not sacrificing any value monetarily. https://dermsquared.com/videos/under-your-skin/interview-with-natasha-atanaskova-mesinkovska 200 2023-09-12T19:14:28.620Z yes https://dermsquared.com/videos/under-your-skin/interview-with-mark-kaufmann-md-faad 2024-05-21T19:36:58.662Z https://image.mux.com/jvmZKtlsHChQnJ202V54kLOppEgNgS1dcVEmhuk9btQk/thumbnail.jpg Interview with Mark Kaufmann, MD, FAAD In this episode of Under Your Skin, host Dr Nicholas Brownstone explores the future of dermatology with past President of the American Academy of Dermatology Dr Mark Kaufmann, MD, FAAD. Together, they speculate on the integration of telehealth and technology into dermatologic practice and the potential impact on patient care over the next decade. Telehealth: necessity or preference? During the COVID-19 pandemic, telehealth emerged as a necessary tool rather than an optional clinical offering. Dr Kaufmann reflects on this period, acknowledging that while many practitioners and patients may have initially viewed telehealth with skepticism due to technological limitations, its adoption was crucial for the continuity of patient care. Looking ahead, he sees telehealth evolving into a sophisticated triage mechanism, efficiently identifying patients who require urgent in-person consultations while providing virtual care for others. Integrating technology into dermatologic practice Dr Kaufmann acknowledges the increasing role of technology in dermatology. He notes that while some fear that technology and artificial intelligence have the potential to replace jobs, he believes that technology will serve as a valuable assistant, particularly in addressing cognitive challenges that many doctors face rather than replacing procedural aspects of care. He predicts that incorporating technology into clinical activities will become standard practice, enhancing rather than supplanting the role of dermatologists and other medical staff. The future of dermatology: a technological evolution Discussing the next decade, Dr Kaufmann highlights the dynamic nature of health care evolution, noting that while practitioners may not always dictate practice changes, the demand for quality dermatologic care remains constant. Driven by patient preferences and technological advancements, the delivery of care is poised for transformation. Dr. Kaufmann speculates on the influence of patient preferences, noting the inclination of younger generations towards virtual interactions. As technology continues to advance, the landscape of dermatology will evolve, offering exciting prospects for practitioners and patients alike. https://dermsquared.com/videos/under-your-skin/interview-with-mark-kaufmann-md-faad 217 2024-05-21T19:36:58.656Z yes https://dermsquared.com/videos/under-your-skin/interview-with-terrance-cronin-jr-md 2025-01-31T14:42:51.023Z https://image.mux.com/Lt7nXvQ4GpKVZNyqunYyBuuZ2B1227WNMGvTjDtwZso/thumbnail.jpg Interview with Terrance A. Cronin Jr, MD - Physician reimbursement and more In this episode of Under Your Skin, host Dr Nicholas Brownstone is joined by Dr Terrence A. Cronin Jr, the president of the American Academy of Dermatology for the 2023-2024 term, to discuss the impact of social media on dermatology, strategies to avoid burnout, and one of the most pressing challenges facing dermatologists today—physician reimbursement. Social media's influence on dermatology One significant topic discussed in the episode is the influence of social media on the field of dermatology. Dr Cronin expresses concern about individuals presenting themselves as skin experts without the necessary background or education, spreading misinformation through platforms like TikTok and Instagram. To counter this, the American Academy of Dermatology (AAD) has initiated the "Your Dermatologist Knows" program, which features ambassadors who actively address public concerns on AAD social media sites with scientifically studied and professional responses. The goal is to combat misinformation and ensure accurate information reaches the public. Additionally, Dr Cronin cautions dermatologists who engage with social media regarding maintaining their professional standing, noting that involvement in social media may be perceived as unprofessional or lead to the inadvertent sharing of information that could be used against dermatologists in their professional future. Combating burnout in dermatology Dr Cronin emphasizes the importance of dermatologists finding outlets beyond their daily work to prevent burnout. Given that dermatologists are visual learners who excel at recognizing patterns, he suggests engaging in activities slightly outside the norm. His recommendations include exploring artistic outlets such as music or creative writing. These activities can serve to stretch creativity and reengage the part of the brain worn down by day-to-day work. The biggest challenge facing dermatology today The central issue highlighted in the episode is the broader challenge facing dermatology and the medical profession in general. Dr Cronin points out that physicians, including dermatologists, are grappling with inflation and physician reimbursement cuts imposed by the government. Physicians are notably the only group within the medical-industrial complex not receiving an inflationary update from the federal government. As inflation rises, hospitals, nursing homes, and inpatient and outpatient facilities receive increased payments, creating a financial gap that physicians struggle to bridge. The episode concludes with a call to action, urging physicians and patients alike to reach out to their congressmen and advocate for change. AAD members can visit https://takeaction.aad.org/ to easily contact their congressmen and can also advocate on social media with the hashtag #fixmedicarenow to add their voices to this vital call for action. https://dermsquared.com/videos/under-your-skin/interview-with-terrance-cronin-jr-md 310 2024-02-06T15:46:01.931Z yes https://dermsquared.com/videos/under-your-skin/interview-with-david-pariser-md 2024-06-11T20:06:54.294Z https://image.mux.com/dxryTe01aA5GuiyRbMLPBceKROr7XpGllM006BBGm00b58/thumbnail.jpg Interview with David Pariser, MD In this episode of Under Your Skin, host Nicholas Brownstone, MD, gets to know David Pariser, MD, a practicing dermatologist for over 40 years and the senior physician at Pariser Dermatology Specialists. They discuss a valuable tip for improving practice efficiency, Innovations on the horizon for dermatology, and the diverse appeal of the specialty. A strategic addition to the workflow to improve efficiency Dr Pariser has significantly improved his efficiency by incorporating medical scribes into his workflow. These scribes accompany the practitioner into the treatment room for each patient visit. While the doctor engages with the patient, the scribe diligently documents the encounter using macros, ensuring that the note is often completed by the time the doctor leaves the room. This system allows the doctor to electronically sign off on the note, send prescriptions immediately, and complete billing processes before the patient exits the office. This approach has been transformative, enabling Dr Pariser to see more patients without compromising the quality of care. With an EHR system, it typically takes about 3 minutes to document a patient’s chart. For a dermatologist seeing 30 patients, that adds up to 1.5 hours of charting. By utilizing scribes, this time can be redirected towards seeing additional patients, easily offsetting the cost of hiring a scribe and enhancing overall practice efficiency. Outlook on the future of dermatology Dr Pariser is particularly enthusiastic about the advancements in personalized medicine. Precision diagnostic testing and testing to help identify the most effective medications for individual patients, represents the future of dermatologic care. This approach promises to tailor treatments to each patient's unique needs, enhancing outcomes and optimizing therapeutic strategies. The unique rewards of dermatology Dr Pariser's passion for dermatology stems from its diverse and dynamic nature. Dermatology is a "cradle-to-grave" specialty, encompassing surgery, pathology, cosmetics, pediatrics, and adult care. Dermatologists manage a wide spectrum of medical and surgical conditions, ensuring that every day is different and every patient encounter is unique. https://dermsquared.com/videos/under-your-skin/interview-with-david-pariser-md 156 2024-06-11T20:06:54.287Z yes https://dermsquared.com/videos/under-your-skin/interview-with-sandra-lee-md 2024-04-16T17:27:00.708Z https://image.mux.com/XWpDMNvMZyEhJNLgEE8goCqcIHu5ckrU7fP8TBbWlsE/thumbnail.jpg Interview with Sandra Lee, MD In this episode of Under Your Skin, host Nicholas Brownstone, MD, gets to know renowned dermatologist and social media sensation Sandra Lee, MD, known by her fans as Dr Pimple Popper. Delving beyond dermatology, the duo explores alternative career paths, relaxation techniques after a hectic day in the clinic, and the best part of Dr Pimple Popper's unique role. Exploring alternative career paths When considering alternative career choices beyond dermatology, Dr Lee shares 2 possibilities. Firstly, she entertains the notion of a professional potato chip tester, drawn to the allure of indulging in salty snacks. Secondly, she contemplates a career in marketing, relishing the opportunity to exercise creativity and conceptualize innovative ideas. Finding balance in a busy profession Reflecting on methods to unwind post-clinic, Dr Lee details the significance of finding balance amidst the demands of professional and personal life. For Dr Lee, that means quality time with her family and cats; she also emphasizes the importance of finding time for self-care during a busy schedule. A fulfilling benefit of social media stardom Dr Lee finds fulfillment in her interactions with her young fans. She recounts instances of children visiting her office for birthday celebrations or casual encounters, inspired by the prospect of pursuing dermatology as a future vocation. Dr Lee finds profound gratification in fostering their interest in dermatology, underscoring the enduring impact of her role on future practitioners. https://dermsquared.com/videos/under-your-skin/interview-with-sandra-lee-md 186 2024-04-16T17:27:00.701Z yes https://dermsquared.com/videos/dermbusters/dermbusters-dawn-sammons 2023-09-12T19:38:33.857Z https://image.mux.com/e1FN1aCv3N8mSD51Ty9H4G00y1NCj0198bkJg0200mTxbOw/thumbnail.jpg Dermbusters: Dawn L. Sammons, DO In this episode of Dermbusters, Dr. Nick Brownstone asks Dr. Dawn Sammons how she dispels myths often heard from patients about tanning and tretinoin use.Does a base tan prevent sunburn?First, Dr. Brownstone asks Dr. Sammons what she says to patients who believe getting a base tan prevents sunburn and the need for sunscreen. She explains to her patients that while a base tan may provide a very slight level of SPF, it does not prevent the need for sunscreen, and pretanning ultimately increases the amount of sun damage patients get. For patients still desiring the look of a base tan, she advises a spray tan. She notes that with social media often promoting misconceptions about base tans, dermatologists must work to help dispel these notions among their patients.Does tretinoin make you more sun-sensitive?Next, Dr. Brownstone chats with Dr. Sammons on the belief that tretinoin makes the skin more sun-sensitive. She states that while true, the slight decrease in minimum effective dose associated with topical retinoid use is not time-sensitive, and that skin won’t be any more sensitive in the daylight hours than in the evening. Considering this, she questions the reasoning dermatologists have for instructing patients to apply retinoid at night. Dr. Sammons explains that she encourages patients to apply their retinoid at whatever time they are most likely to adhere to. In her experience, her younger patients tend to have more consistent routines in the morning as opposed to at bedtime.She concludes by explaining that historically, retinoids were photolabile and thus deactivated by sunlight. As a result, dermatologists instructed patients to apply retinoids at night. Currently, however, all preparations are micronized and photostable for up to 8 hours, which is sufficient time for retinoid to be absorbed. https://dermsquared.com/videos/dermbusters/dermbusters-dawn-sammons 276 2023-06-29T19:46:09.239Z yes https://dermsquared.com/videos/dermbusters/dermbusters-cheri-frey-md 2024-03-12T17:19:46.787Z https://image.mux.com/yWqgQ9jked00lhMFiSzyY00IKbSoCn01Du00GrpSZ018qbWo/thumbnail.jpg Dermbusters: Cheri Frey, MD In this episode of Dermbusters, host Nicholas Brownstone, MD, chats with Cheri Frey, MD, about some common misperceptions they often hear from their patients.Dr Frey shares some suggestions on how to counsel patients on 2 significant topics: retinol use for patients with sensitive skin and moisturizing for patients with acne.Myth 1: Patients with sensitive skin can’t use retinol for acne.Dr Frey addresses a common myth that dermatologists often hear from their patients: that they shouldn’t use retinol to treat acne if they have sensitive skin. She offers a few suggestions for dispelling this misperception when speaking with patients.Tips for counseling your patients:Advise eligible patients to try an over-the-counter retinol that’s not as strong or harsh as prescription-strength retinoidsExplain application strategies such as the sandwich method, which involves applying retinol between 2 layers of moisturizer, and short-contact application, where retinol sits on the skin for a few minutes before being washed offExpress the importance of retinol as a cornerstone of acne treatment and reassure patients there is always a way to incorporate it as a therapyMyth 2: Patients with acne can’t moisturize their skin.Dr Brownstone and Dr Frey next cover another common myth often heard from patients: that moisturizing can exacerbate acne.Dr Frey stresses the importance of moisturization for patients with acne and serves up a few tips to use in patient conversations when addressing this topic.Tips for counseling your patients:Explain the barrier disruption that occurs in patients with acne and how it can cause more irritation and inflammation; advise patients that moisturizing can mitigate this disruption to the top layer of skinEducate patients on the drying nature of retinols and other acne-fighting ingredients; emphasize the importance of keeping skin hydrated so patients can tolerate their acne medications https://dermsquared.com/videos/dermbusters/dermbusters-cheri-frey-md 122 2024-03-12T17:19:46.781Z yes https://dermsquared.com/videos/dermbusters/dermbusters-gabriela-maloney-do 2024-08-13T19:44:11.291Z https://image.mux.com/gZYqgTXZNr9aE9GEzckeGd00xBdw00S9uAkk167kEjlOU/thumbnail.jpg Dermbusters: Gabriela Maloney, DO In this episode of Dermbusters, host Nicholas Brownstone, MD, and guest Dr Gabriela Maloney, DO, tackle common dermatologic myths often heard from their patients. Dr Maloey provides practical advice for clinicians to effectively counsel patients on 2 key topics: the link between diet and acne and the belief that sunscreen applications leads to vitamin D deficiency. Myth 1: Fried foods and chocolate increase the risk of acne Dr Maloney addresses the long-standing belief that diet, particularly fried foods and chocolate, plays a significant role in acne development. Historically, a 1969 study concluded that there was no direct link between acne and diet, which shifted the focus away from dietary factors. However, recent studies have revisited this topic, with some suggesting that foods high in glycemic index and fat content might exacerbate acne. Specifically, interventional studies have indicated that reducing glycemic load can potentially decrease inflammation and acne severity. Tips for counseling patients: Focus on glycemic index: Advise patients to pay attention to their diet’s glycemic index, which may be more relevant to acne management than specific foods like chocolate or fried items. Encourage a healthy diet: Recommend a balanced diet while still allowing flexibility for individual preferences, such as gluten-free or keto diets. Follow treatment plans: Emphasize the importance of adhering to prescribed acne treatments, as dietary changes alone are unlikely to resolve acne completely. Myth 2: Wearing sunscreen leads to vitamin D deficiency A common concern is that sunscreen use can lead to vitamin D deficiency. Dr Maloney explains that this fear should not prevent patients from using sunscreen and highlights that diet plays a crucial role in maintaining adequate vitamin D levels. Tips for counseling patients: Emphasize the role of diet: Explain that vitamin D can be adequately obtained through a balanced diet, eliminating the need to forego sunscreen. Highlight the risks of sun exposure: Stress that the risk of skin cancer from sun exposure outweighs the risk of vitamin D deficiency from using sunscreen. Tune in to the episode to hear Dr Maloney and Dr Brownstone provide valuable insights for dermatologists to guide patients more effectively and counter common misconceptions. https://dermsquared.com/videos/dermbusters/dermbusters-gabriela-maloney-do 219 2024-08-13T19:44:11.283Z yes https://dermsquared.com/videos/dermbusters/dermbusters-anthony-rossi-md 2024-02-14T21:15:57.200Z https://image.mux.com/dCXAoMiKAmk58xwL4phemUwsf02cet7tLxqhKnkTw00600/thumbnail.jpg Dermbusters: Anthony Rossi, MD In this episode of Dermbusters, host Nicholas Brownstone, MD, chats with Anthony Rossi, MD, about some common misperceptions they often hear from their patients. Dr Rossi shares some suggestions on how to counsel patients on 3 significant topics: a misconception surrounding higher-percentage medications, the proper use of facial cleansers, and the necessity of wearing sunscreen during the winter months. Myth 1: Higher-percentage ingredients mean a medication is more efficacious. Dr Rossi begins by addressing the prevalent belief that higher percentages of ingredients in medications indicate greater efficacy. Contrary to this notion, he emphasizes that the right amount, rather than the highest percentage, is the key to achieving optimal results. Patients are advised to focus on key or active ingredients, striking a balance between not being the first or last listed in a formulation. Striving for a middle ground ensures effectiveness without causing unnecessary irritation. Tips for counseling your patients: Advise them to look at their product’s ingredient list. The active ingredient should neither be the first nor the last listed. Being the first suggests it's the highest percentage, while being the last indicates it's the lowest. Suggest they aim to find a product with the active ingredient listed somewhere in the middle. Caution them that certain ingredients, such as vitamin C, can actually be irritating in higher concentrations. Myth 2: You must wash your face for 60 seconds for maximum effectiveness. Dr Rossi supports this popular notion that washing the face for at least 60 seconds maximizes impact, with one important caveat: water alone is not an effective cleanser. He emphasizes the importance of a good cleanser and advises patients to focus on contact time; he recommends keeping cleanser on the face for at least 60 seconds to allow the active ingredient to work. Tips for counseling your patients: Advise patients not to wash with water alone, especially if they wear makeup or live in an urban environment and are exposed to daily pollution. Suggest they apply their cleanser, let it become sudsy, then brush their teeth before washing it off. This ensures the cleanser is making contact with their skin for at least one minute. Myth 3: Sunscreen isn’t necessary in the winter. Next, Dr Rossi addresses a myth that dermatologists hear often: sunscreen isn’t necessary in the winter or on cloudy days. Dr Rossi underscores that significant amounts of both UVA and UVB rays can still reach the skin even in the winter months and that sun protection is still important. Tips for counseling your patients: Show them images from the New England Journal of Medicine article “Unilateral Dermatoheliosis” by Gordon et al, which showcases photoaging on one side of a truck driver’s face and serves as an impactful visual aid that UVA can be transmitted through window glass.Explain that the light reflection from snow can amplify sun exposure when engaging in outdoor winter activities. Advise them to look for a sunscreen that offers both an SPF of 30 or higher and UVA protection. https://dermsquared.com/videos/dermbusters/dermbusters-anthony-rossi-md 312 2024-02-13T19:16:59.641Z yes https://dermsquared.com/videos/dermbusters/dermbusters-aaron-farberg 2023-08-15T15:34:07.500Z https://image.mux.com/yup025IvIBVWxGT6SS00x7SJkBSbwGwMOmLi1HouhVV8A/thumbnail.jpg Dermbusters: Aaron Farberg, MD In this episode of Dermbusters, Dr. Nick Brownstone chats with Dr. Aaron Farberg how he busts myths often heard from patients surrounding sunscreen use and scarring.Is a higher SPF sunscreen always better?First, Dr. Brownstone asks Dr. Farberg how he counsels patients who believe a higher SPF sunscreen is always better. Dr. Farberg explains that when he chats with patients about sunscreen use, he emphasizes that the best sunscreen is whichever one they will use consistently.He tells his patients that an SPF of 30 is sufficient if they are using it correctly; however, he notes that most people do not, either by not applying enough or not reapplying their sunscreen. Considering that, he advises his patients to select the highest SPF sunscreen they can find to give themselves a margin of safety.Is a barely noticeable scar the mark of a good surgeon?Next, Dr. Brownstone inquires about a misconception regarding scarring that he often hears from patients: that a barely noticeable scar is the mark of a good surgeon. Dr. Farberg emphasizes that for patients who hold this belief, managing expectations is key and advises them that they should expect a scar.He describes his system of measuring scars by distance—whether the scar is visible from 3 feet, 30 feet, or 300 feet—and that he explains to his patients that he aims for scars that can only be visible from 3 feet away. https://dermsquared.com/videos/dermbusters/dermbusters-aaron-farberg 164 2023-06-29T19:46:02.762Z yes https://dermsquared.com/videos/dermbusters/dermbusters-brandon-adler-md 2024-06-07T18:28:45.291Z https://image.mux.com/701ayN5b2xyCuM5OnBZ2beyQM5CeW85Sl4wTueG9V1Hw/thumbnail.jpg Dermbusters: Brandon Adler, MD In this episode of Dermbusters, host Nicholas Brownstone, MD, sits down with Brandon Adler, MD, to address some common misperceptions they often hear from their patients. Dr Adler shares how he tackles 2 pressing concerns that dermatologists frequently encounter from their patients: the efficacy and safety of natural products, and the concerns surrounding ingredients in sunscreens. Myth 1: Natural products are always better There is a growing trend among patients towards seeking out natural products, both homemade and store-bought, with the belief that they are inherently better and safer than traditional products. Drawing from his experience running a contact dermatitis clinic, Dr Adler shares that he often sees patients who develop allergic reactions to natural ingredients, such as essential oils. Tips for counseling your patients: Explain that studies demonstrate the rates of contact allergy and irritation are at least comparable between natural and traditional products Mention that while natural products can be effective, each patient is unique and may develop sensitivities or allergies to certain ingredients Dispel the belief that natural always equals good; to illustrate the point effectively, share an analogy relating natural products to poison oak, which, while natural, is not something you want on your skin Myth 2: Harmful ingredients in sunscreens outweigh its benefit Many patients voice concerns about harmful ingredients in sunscreens, with some avoiding sunscreen use altogether to mitigate risks. Dr Adler shares a few tips on how he talks to patients on this issue. Tips for counseling your patients: Explain that while chemical or organic blockers found in many sunscreens have been shown in studies to be systemically absorbed into the body, there is no evidence of any associated adverse effects to date, and these agents have been used safely for decades For patients still concerned about systemic absorption, recommend zinc- and titanium-based physical or mineral sunscreens, which have not shown to be absorbed and therefore don’t carry the same potential implications as chemical blockers For patients with environmental concerns, physical sunscreens can also be recommended Emphasize that the risk of skin cancer is significantly greater than the potential risk of harmful ingredients in sunscreens Tune in to the episode to hear Dr Adler’s approach to individualized patient care and hear his practical solutions for addressing common patient concerns. https://dermsquared.com/videos/dermbusters/dermbusters-brandon-adler-md 222 2024-06-07T18:20:59.175Z yes https://dermsquared.com/videos/dermbusters/dermbusters-katherine-glaser-md 2024-04-09T19:08:03.662Z https://image.mux.com/hLJJoVH349006Q01FT4984FObTf8htUNkhSNiWTyJfeYc/thumbnail.jpg Dermbusters: Katherine Glaser, MD In this episode of Dermbusters, host Nicholas Brownstone, MD, sits down with Katherine Glaser, MD, a dermatologic surgeon specializing in Mohs surgery, about some common misperceptions heard from both colleagues and patients. Dr Glaser shares some insights on 2 frequently misunderstood topics: the use of lidocaine with epinephrine in the fingers and toes and the role of sunscreen in vitamin D absorption. Myth 1: Dermatologists should not use lidocaine with epinephrine in the fingers and toes. Contrary to a commonly held belief among dermatologists, Dr. Glaser emphasizes that there is robust data supporting the safe use of lidocaine with epinephrine in the fingers and toes. Despite concerns about vascular ischemia and resulting necrosis, studies from both dermatology and plastic surgery literature demonstrate the safety of lidocaine with epinephrine. Tips for advising colleagues: Share the existing data and research findings that support the safe use of lidocaine with epinephrine in the fingers and toes Highlight the lack of reported cases of ischemia with traditional lidocaine with epinephrine and contrast it with cases involving other substances, high concentrations of epinephrine, and improper tourniquet use Emphasize the importance of adhering to safe injection practices, proper dosage, and avoiding direct arterial injection to mitigate any potential risks Myth 2: Sunscreen should not be used because it prevents absorption of vitamin D. Next, Dr Glaser addresses a common myth that dermatologists often hear from their patients: that they shouldn’t use sunscreen because it prevents them from absorbing an adequate amount of vitamin D. While sunscreen does block the UVB rays that aid in vitamin D synthesis, the AAD advises against UV exposure solely for the purpose of absorbing vitamin D. Tips for counseling your patients: Explain that while sunscreen may affect vitamin D absorption, it's not a reason to skip it Highlight alternative sources of vitamin D, such as diet and supplements Encourage wearing sunscreen consistently and correctly Stress the importance of protecting the skin from harmful UV rays to prevent skin damage and reduce the risk of skin cancer https://dermsquared.com/videos/dermbusters/dermbusters-katherine-glaser-md 331 2024-04-09T19:08:03.651Z yes https://dermsquared.com/videos/dermbusters/dermbusters-elizabeth-swanson-md 2024-03-06T16:21:07.251Z https://image.mux.com/bri4Mpidybo6a4H8T8M6fcsRz3XNTOPLCRTi3KwKtyY/thumbnail.jpg Dermbusters: Elizabeth Swanson, MD Join Dr Nick Brownstone in this episode of Dermbusters, where he chats with Dr Elizabeth Swanson to address some common misperceptions surrounding the use of Accutane that they often hear from both colleagues and patients. Are monthly labs for Accutane needed for safety? No. Dr Swanson notes that she has been in practice for over 12 years, and when she was in training, providers did do labs every month for patients taking Accutane, including a liver function test, a lipid panel, and sometimes a CBC. Since she’s been practicing, the guidelines for Accutane have recommended less and less monitoring over time. She references an article published in JAMA Dermatology that recommended testing only for alanine aminotransferase (ALT) and triglycerides at baseline and again at 2 months or after peak dose is reached. Dr Swanson comments that testing only twice for 2 things is great news for patients. Dr Brownstone asks Dr Swanson how she counsels patients when they want additional labs performed to ensure the medication isn’t causing side effects. She remarks that her patients never request that, and she generally finds they are very pleased to only need minimal blood draws for monitoring. Does Accutane increase the risk of suicidal behavior or depression? Dr Swanson notes that this is a very controversial topic. When she addresses this with her patients and their families, she explains that there were some initial concerns about suicidal behavior and depression in patients with Accutane, but because of these concerns, it has been extensively studied in tens of thousands of patients. Those studies found that most patients actually notice an improvement in their mood due to clearer skin and improved self-esteem and confidence. As a pediatric dermatologist, Dr Swanson prescribes Accutane daily; she reassures her patients and their families that in her years of practice, she has had only 6 patients who exhibited signs of depression and had to stop the medication. She concludes by noting that while these side effects do occur rarely, the studies support patients seeing an improvement in their mood. https://dermsquared.com/videos/dermbusters/dermbusters-elizabeth-swanson-md 182 2023-10-10T14:41:59.481Z yes https://dermsquared.com/videos/dermbusters/dermbusters-g-michael-lewitt 2023-09-12T19:39:13.160Z https://image.mux.com/UcRtbZadb8gGt5u022vbEBbeOWgf02M3102kpcDaYVYuKc/thumbnail.jpg Dermbusters: G. Michael Lewitt, MD In this installment of Dermbusters, Dr. Nick Brownstone sits down with Dr. G. Michael Lewitt to get his thoughts on blood monitoring for patients prescribed biologics and to discuss how he advises patients who believe tretinoin must be applied at night. Do dermatologists have to check CBCs and LFTs with all biologics? Dr. Lewitt explains that from looking at the data, it’s likely not necessary to monitor CBCs and LFTs for patients who are prescribed a biologic. He estimates that half of the biologic prescribers across the US do this type of monitoring for patients taking a biologic, and the other half do not. He recalls that when the IL-17s came out, there were a few incidences of neutropenia and leukopenia observed which led to a trend of blood monitoring every 6 months; however, he then found he did not see any more abnormalities across the following 2 years and felt that as a result, this type of monitoring was wasting his time and patients’ healthcare funds. He now checks CBCs and LFTs annually for patients taking a biologic. When counseling his patients on this topic, he emphasizes to them that they have a chronic skin condition and should receive age- and disease-state-appropriate blood monitoring, like TSH and fasting limit profiles, at intervals recommended by their primary care physicians. In sum, he emphasizes that the necessity of checking CBCs and LFTs for patients taking a biologic is largely a myth. Do topical retinoids have to be applied at night? Dr. Lewitt explains that of the 4 current generations of retinoids, the original tretinoin and tretinoin derivates were photolabile, while generations 2 though 4 are photostable. Historically, patients were encouraged to apply retinoids at night because as soon as they were exposed to sun in the morning, the medication became inactivated. Even though the newer generations of retinoids are photostable, Dr. Lewitt still prefers nighttime application. With the most common side effect being retinoid dermatitis or irritation, he finds that with evening application, he can then troubleshoot in the mornings to ensure there isn’t any scale appearing on his nose or eyes. However, from a pharmacodynamic standpoint, generations 2 though 4 do not need to be applied at night. He advises his patients that the best time to apply it is whenever they can best remember and recommends applying it at the same time they brush their teeth to establish a routine. https://dermsquared.com/videos/dermbusters/dermbusters-g-michael-lewitt 189 2023-09-12T19:36:32.335Z yes https://dermsquared.com/videos/dermbusters/dermbusters-emmy-graber-md-mba 2024-05-07T17:27:51.447Z https://image.mux.com/18hhkarhrNfKZQ9lFi02sI3JhmFcGAvlu01alnGpFrfVw/thumbnail.jpg Dermbusters: Emmy Graber, MD, MBA In this episode of Dermbusters, host Nicholas Brownstone, MD, chats with acne and rosacea expert Emmy Graber, MD, MBA, about some common misperceptions they often hear from their patients. Dr Graber shares some tips on counseling patients on 2 topics: how diet impacts acne and advising patients on isotretinoin to wait 6 to 12 months before getting cosmetic procedures. Myth 1: Fried and fatty foods cause acne. Dr Graber addresses the widespread belief among patients that fried and fatty foods can induce acne. She acknowledges the challenges of studying diet’s impact on acne but shares a few tips on counseling patients based on published data. Tips for counseling your patients: Explain to patients that while some studies suggest a correlation between high-glycemic foods and acne for some individuals, the association is not universal Emphasize the role of dairy products, particularly skim milk products, in exacerbating acne for some patients For patients who can identify specific dietary triggers, give them the option of avoiding that food Emphasize the uniqueness of individual responses to dietary triggers rather than making blanket statements Myth 2: Patients must wait at least 6 months following the use of isotretinoin before having any cosmetic or surgical procedures. Dr Brownstone and Dr Graber then discuss advising patients on isotretinoin on the often-recommended waiting period before undergoing any cosmetic or surgical procedures. Dr Graber challenges the traditional notion of waiting 6 to 12 months, relating a few discussion points to share with patients. Tips for counseling your patients: Cite a systematic review of over 32 studies and 1400 procedures1 that found no evidence supporting the need for a prolonged delay for cosmetic procedures following isotretinoin use Advise patients that procedures like visible light lasers, hair removal, superficial chemical peels, and fractional and ablative lasers are safe while on isotretinoin Counsel patients to follow the waiting period and delay more intense procedures like nonfractional lasers, deep dermabrasions, and deep chemical peels until there is more data available to support the safety of such procedures while on isotretinoin Mention potential benefits of pulsed dye laser treatments for acne for patients concurrently on isotretinoin, noting not only safety but potentially improved outcomes Tune in to the episode to hear the full details on Dr Graber’s informed approach to counseling patients that embraces evidence-based practices to optimize care. Reference Spring LK, Krakowski AC, Alam M, et al. Isotretinoin and timing of procedural interventions: a systematic review with consensus recommendations. JAMA Dermatol. 2017;153(8):802-809. doi:10.1001/jamadermatol.2017.2077 https://dermsquared.com/videos/dermbusters/dermbusters-emmy-graber-md-mba 280 2024-05-07T17:24:25.022Z yes https://dermsquared.com/videos/dermbusters/dermbusters-carly-elston 2023-08-15T15:29:36.708Z https://image.mux.com/4iucZVqXTXR2FkD00yhdmCejyA2C4zwL8m8ruSN02mAXk/thumbnail.jpg Dermbusters: Carly Elston, MD Do patients with skin of color need sunscreen?First, Dr. Brownstone asks Dr. Elston how to advise patients with skin of color who believe they don’t need sunscreen. Dr. Elston references studies that show not only do patients with skin of color get skin cancer, they also tend to get diagnosed later and have higher mortality.She details a study that examined melanoma survival among White, Hispanic, Asian, and Black women, which demonstrated that those with skin of color had lower survival rates, with Black women having the lowest.To encourage sunscreen use among her patients with skin of color, Dr. Elston recommends products that will be more cosmetically favorable on pigmented skin; some of the physical blockers can be challenging, so she often recommends sunscreens that are in a clear- or a gel-base that will rub in.If a topical medication isn’t burning, does that mean it’s not working?Next, Dr. Brownstone chats with Dr. Elston on a common misperception heard from patients—if a topical medication isn’t burning, it isn’t working.Dr. Elston explains that many medications burn or sting because of what’s in the vehicle, like lactic acid affecting patients who are sensitive to cosmetic products or propylene glycol causing an irritant effect. She explains to patients that the resulting stinging is not a result of the products’ efficacy. She also explains that other drugs cause burning because of the drug effect, for example, topical calcineurin inhibitors causing a capsaicin-like burning reaction that often gets better the longer patients use them. She helps dispel this common misconception by advising patients that these medications work just as well when the burning stops. https://dermsquared.com/videos/dermbusters/dermbusters-carly-elston 210 2023-08-15T15:29:36.702Z yes https://dermsquared.com/videos/dermbusters/dermbusters-daniel-butler-md 2024-03-06T16:20:22.671Z https://image.mux.com/z7blF02t502UO31A3tEdPx9XyUavIZZs25I007jZYtX6PQ/thumbnail.jpg Dermbusters: Daniel Butler, MD In this episode of Dermbusters, our host, Nicholas Brownstone, MD, chats with Daniel Butler, MD, to discuss how he counsels patients who come to him with some common misperceptions dermatologists often hear. In this installment, Dr Butler addresses myths on scalp massage for baldness and contact dermatitis arising from deodorant use. Can scalp massage help prevent baldness? One common misperception dermatologists often hear from their patients is the belief that increasing blood flow to the scalp via scalp massage can prevent baldness. Dr Butler advises patients on the complexity of hair growth, emphasizing that just increasing blood flow to the scalp is not a cure-all for hair loss. He notes that there are some small studies that suggest scalp massage may marginally increase hair thickness; however, he clarifies that this does not equate to a viable solution for those with androgenic alopecia. Can deodorant cause contact dermatitis? Another common query from patients is whether deodorant can trigger contact dermatitis. Dr Butler addresses this concern by acknowledging that certain deodorants can indeed lead to contact dermatitis, but he emphasizes the importance of ruling out other potential causes for rashes before attributing them solely to deodorant use. Importantly, he reassures patients who don’t have existing rashes that using deodorant or antiperspirant should not be a cause for concern. When we get rashes in the armpits, patients often question what’s touching them there that can cause it. Some deodorants have been known to cause contact dermatitis, but there are other things that need to be ruled out first and foremost. If you have a rash in that area, it’s important to know that deodorant can be contributing to that. However, if you don’t have a rash and you’re using a deodorant or antiperspirant, don’t worry that it will then cause contact dermatitis. https://dermsquared.com/videos/dermbusters/dermbusters-daniel-butler-md 172 2024-01-16T13:52:54.774Z yes https://dermsquared.com/videos/career-services/why-you-should-invest-in-my-derm-recruiter 2024-03-28T19:15:02.610Z https://image.mux.com/hYQYFxh01An6HtMRD44JI700dm74MkhpiaHyLm01tXD00aY/thumbnail.jpg Why You Should Invest In myDermRecruiter Why You Should Invest In myDermRecruiter https://dermsquared.com/videos/career-services/why-you-should-invest-in-my-derm-recruiter 38 2024-03-28T19:11:50.398Z yes https://dermsquared.com/videos/career-services/when-you-partner-with-us-as-a-candidate-you-re-in-good-hands 2024-03-28T19:17:43.313Z https://image.mux.com/rToeAVSDQ02q4Gj4hnF00t02FPB6D4io48XI4R2VGWnS2E/thumbnail.jpg When you partner with us as a candidate, you're in good hands! When you partner with us as a candidate, you're in good hands! https://dermsquared.com/videos/career-services/when-you-partner-with-us-as-a-candidate-you-re-in-good-hands 23 2024-03-28T19:17:43.265Z yes https://dermsquared.com/videos/discourses-in-dermatology/four-years-data-tyk2-inhibition 2025-10-29T15:15:40.182Z https://image.mux.com/1GGu1602M200jenG84xsRwEtlpJW02D7Ui01LDULsZa62X00/thumbnail.jpg Four Years of Data: Durability and Distinction with TYK2 Inhibition In this video, Michael Cameron, MD, shares four years of data on TYK2 inhibition in psoriasis care, highlighting the durability and safety that continue to reinforce confidence in this once-daily oral therapy. He explains how TYK2’s selective allosteric mechanism differentiates it from traditional JAK inhibitors—helping to account for its clean long-term safety profile—and discusses where oral therapy fits into practice today. With insights on sustained PASI responses, special-site efficacy, and real-world convenience, Dr. Cameron outlines why TYK2 inhibition remains a distinct and durable option for systemic-eligible patients. https://dermsquared.com/videos/discourses-in-dermatology/four-years-data-tyk2-inhibition 190 2025-10-29T12:52:59.170Z yes https://dermsquared.com/videos/discourses-in-dermatology/depression-and-suicidality-risk 2025-11-19T20:30:06.973Z https://image.mux.com/aJ00KQl02SybZFoTDEgu9inxHhZaT9brpL4osmwEiWfZE/thumbnail.jpg Part 1: Psoriasis and Mental Health: Understanding Depression and Suicidality Risk This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. Psoriasis and the psychiatric comorbidityIn Part 1, Mark Lebwohl, MD, is joined by Rick Fried, MD, PhD, both a dermatologist and a clinical psychologist, to examine the deep and often underappreciated mental health impact of psoriasis. They open with a reminder that multiple dermatologic diseases influence mental health, with psoriasis being among the most studied but far from the only condition with significant psychiatric burden.Dr Lebwohl also outlines 4 dermatologic therapies that carry warnings related to suicidality: brodalumab, isotretinoin, apremilast, and bimekizumab. He notes that concerns about these warnings can meaningfully impact prescribing behavior.The baseline mental health status of patients with psoriasisDr Fried highlights extensive evidence showing that patients with psoriasis have substantially elevated rates of depression, anxiety, suicidal ideation, and completed suicides. Importantly, he notes psoriasis itself is an independent risk factor for these outcomes.He explains that multiple studies show that when psoriasis improves, associated depression and suicidality often also improve, sometimes dramatically, suggesting that treatment of the skin disease can be a direct, positive intervention for a patient’s mental health.Dr Lebwohl reinforces this point with data from a large survey demonstrating that major depression occurs more frequently among people with psoriasis than in the general US population, illustrating the need for dermatologists to recognize and address this burden.When mental health improves with skin disease controlDrawing from his psychology practice, Dr Fried shares that patients with severe psoriasis who have a history of depression or suicidality often benefit the most from highly effective dermatologic treatment, despite clinicians’ hesitations to prescribe when these treatments carry suicidality warnings. These patients frequently experience relief not only from their skin symptoms but also from the social, emotional, family, and intimate impacts of the disease.By the time patients reach dermatology care, many have endured years of topical prescription and over-the-counter treatment failures. He finds that simply engaging with a clinician who demonstrates empathy and confidence in a treatment plan can be impactful for these patients.The dermatologist’s role: life-saving potential through effective treatmentDr Lebwohl stresses that dermatologists may be uniquely positioned to save lives by rapidly improving severe psoriasis with highly efficacious therapy, even if the medication carries a suicidality warning. He notes that FDA labeling reflects a requirement to list all potential events, not proven causation, and that withholding effective therapy due to fear of labeling language may harm patients who need rapid control the most.Dr Fried agrees, emphasizing transparency and informed consent alongside a broader perspective: while labels enumerate theoretical risks, they do not list the severe consequences of undertreatment, including worsening psychiatric burden.Both clinicians highlight that untreated psoriasis is associated with worsening systemic and psychiatric outcomes and that dermatologists should be motivated to act quickly and aggressively when indicated.Closing thoughtsThey conclude by reviewing data demonstrating that biologics across classes are associated with lower rates of suicidal ideation and completed suicides compared to untreated psoriasis and compared to the general population. Studies from the past 20 years consistently show that untreated psoriasis is associated with more than a doubling in suicidal ideation and an approximate 20% increase in completed suicides.Key takeawaysPsoriasis independently increases the risk of depression, anxiety, suicidal ideation, and suicideEffective treatment, especially biologic therapy, can meaningfully reduce psychiatric symptomsDermatologists play a critical role in addressing both physical disease and its mental health consequencesSuicidality warnings on dermatologic drugs reflect reporting requirements, not proven causalityEarly, effective, empathetic intervention can improve quality of life across emotional, social, and physical domainsClick here to view the other videos in the series. https://dermsquared.com/videos/discourses-in-dermatology/depression-and-suicidality-risk 605 2025-11-19T20:30:06.961Z yes https://dermsquared.com/videos/discourses-in-dermatology/a-review-of-dermoscopy-techniques 2026-02-06T15:21:27.476Z https://image.mux.com/q6A01H01LekocOj7eFf6MWimt01hSoyJkuoIW4AxSbhDjI/thumbnail.jpg A Review of Dermoscopy Techniques With Michelle Tarbox, MD In a hands-on Winter Clinical workshop, Michelle Tarbox, MD, walked through practical ways to get more out of every dermoscopic exam, focusing less on memorizing patterns and more on how and when to use specific techniques.She revisits one of the most common pitfalls in dermoscopy: relying on a single viewing mode. By deliberately toggling between polarized and non-polarized light, clinicians can surface different diagnostic clues—using non-polarized dermoscopy to better visualize milia-like cysts and comedo-like openings, and polarized dermoscopy to highlight vessels and chrysalis structures.Dr. Tarbox also discusses contact versus non-contact dermoscopy, emphasizing that each has distinct clinical advantages depending on what you’re evaluating. For suspected actinic keratoses on the head and neck—particularly pigmented AKs that can mimic lentigo maligna—she recommends starting with dry, non-polarized dermoscopy to identify characteristic surface scale. In contrast, pigmented lesions benefit from contact or polarized dermoscopy, which allows clearer visualization of deeper structures across both benign and malignant neoplasms.Lastly, she clarifies an important diagnostic distinction: chrysalis structures are only visible with polarized light, while a negative pigment network represents a separate finding that serves as a warning signal for potential melanoma. Taken together, these are small technical adjustments with meaningful clinical impact and reminders that dermoscopy works best when approached deliberately, with flexibility and context. https://dermsquared.com/videos/discourses-in-dermatology/a-review-of-dermoscopy-techniques 89 2026-02-06T15:21:27.468Z yes https://dermsquared.com/videos/discourses-in-dermatology/decision-making-in-cutaneous-melanoma 2026-04-28T20:34:02.782Z https://image.mux.com/sLdrKjrHGuDrJlLwJlVvNzaAwTasidX3usLEaUhpQEk/thumbnail.jpg Integrating 31-GEP Testing into SLNB Decision-Making in Cutaneous Melanoma This video is Part 2 of a 4-part expert series designed to strengthen clinician confidence in the use of the 31-gene expression profiling (31-GEP) test for prognostic assessment in cutaneous melanoma. Across the series, David Cotter, MD, PhD, addresses common questions and hesitations around molecular prognostic testing to support more consistent and effective integration of 31-GEP into routine dermatologic practice.Expert consensus statementIntegration of 31-GEP testing with traditional staging methods can accurately inform the decision to recommend sentinel lymph node biopsy (SLNB).This consensus statement comes from the expert panel publication “31-Gene expression profiling for cutaneous melanoma: an expert consensus panel” and serves as the foundation for this discussion.SLNB as a critical, but imperfect, decision pointSLNB remains a key step in melanoma staging, but decision-making is not always straightforward in borderline cases. Dr Cotter highlights scenarios frequently encountered in practice, where estimated risk falls near clinical thresholds and management varies.For example:T1B melanomas (0.8–1.0 mm or <0.8 mm with high-risk features): ~5%–10% risk of nodal positivity T2A melanomas (~1.0 mm, nonulcerated): >10% risk of nodal positivityAlthough a ≥10% risk often supports proceeding with SLNB, these estimates are population-based. In practice, patient-specific factors, such as comorbidities or surgical candidacy, introduce additional nuance, contributing to variability in care. The “gray zone” in current guidelinesCurrent guidance generally avoids SLNB in patients with less than a 5% likelihood of nodal positivity. However, this threshold reflects an inherent limitation in the available tools.Among melanomas <1 mm:The average likelihood of nodal positivity is ~5.3% The false-negative rate of SLNB is also ~5% In effect, these values offset one another. Clinically, this means that when SLNB is deferred in this population, a small proportion of patients with occult metastatic melanoma may not be identified at diagnosis. This tradeoff highlights a gap in precision when relying on population-level risk estimates alone. Refining risk stratification with 31-GEP31-GEP testing offers a more individualized approach to risk assessment, particularly in intermediate-risk groups such as T1B melanomas. By incorporating tumor biology, it helps refine which patients may benefit from SLNB.Data discussed in this segment demonstrate that:Use of 31-GEP in T1B patients improves the true-to-false negative ratio to approximately 35:1 When combined with T staging, patients identified as having <5% risk by 31-GEP may safely avoid SLNB without missing node-positive disease These findings suggest that integrating 31-GEP into clinical workflows can improve patient selection and reduce uncertainty in borderline cases. Moving beyond static measures: the role of tumor biologyTraditional staging relies on histopathologic features such as Breslow depth and ulceration; these factors are important, but inherently limited to a single timepoint.31-GEP evaluates gene expression patterns to better characterize tumor behavior. This approach allows clinicians to move beyond population-based estimates and incorporate individualized biologic risk into decision-making.As Dr Cotter describes, the combination of clinicopathologic staging and 31-GEP results supports a more comprehensive and patient-specific framework for care. Key takeawaysSLNB decision-making remains nuanced, particularly in intermediate-risk melanoma Guideline thresholds reflect tradeoffs, including the potential to miss a small subset of node-positive patients31-GEP provides biologic risk stratification, complementing traditional staging measuresIntegration of 31-GEP with T staging can improve patient selection for SLNB and may reduce unnecessary proceduresIndividualized risk assessment is essential, particularly in patients with borderline indications or competing clinical considerations https://dermsquared.com/videos/discourses-in-dermatology/decision-making-in-cutaneous-melanoma 304 2026-04-28T19:48:11.182Z yes https://dermsquared.com/videos/discourses-in-dermatology/Dupixent-Innovation-V1 2026-02-04T20:58:47.604Z https://image.mux.com/Q8Ens01B5QQMlO5m00t64WnQH1TYln75VzdQL8ds00xiIs/thumbnail.jpg Recognizing Bullous Pemphigoid Earlier in Clinical Practice Bullous pemphigoid (BP) is most often a disease of older adults—patients who frequently carry multiple comorbidities and have limited tolerance for broad immunosuppression. For years, systemic corticosteroids remained the mainstay of treatment, despite well-known safety concerns in this vulnerable population.In this video, Prince Adotama, MD, Assistant Professor at NYU Grossman School of Medicine, shares clinical perspectives on how BP presents in real-world practice and how newer targeted options are changing the treatment landscape. From recognizing nonclassic presentations to navigating emerging therapies, Dr Adotama walks through key considerations for safely managing BP today. https://dermsquared.com/videos/discourses-in-dermatology/Dupixent-Innovation-V1 112 2026-02-04T20:58:41.856Z yes https://dermsquared.com/videos/discourses-in-dermatology/the-pivotal-study 2026-03-25T15:37:05.065Z https://image.mux.com/VpvNhGYVTD6LFkf601b28HC801puHuLOSjZCzWrjbma2g/thumbnail.jpg Cosibelimab in Advanced Cutaneous Squamous Cell Carcinoma: ≥2-Year Follow-Up from the Pivotal Study This video is sponsored by Sun Pharma. Its content is editorially independent of the sponsor. In this video segment, Rahul Ladwa, Medical Oncologist, reviews the updated ≥2-year follow-up results from the pivotal open-label study evaluating cosibelimab in advanced cutaneous squamous cell carcinoma (cSCC).For dermatologists increasingly involved in the longitudinal management of high-risk and advanced cSCC, this discussion offers practical context on efficacy and safety, particularly in an older, comorbid population where tolerability matters.From limited options to immune checkpoint inhibitionUntil the emergence of immune checkpoint inhibitors, systemic options for advanced cSCC were limited. PD-1 pathway blockade significantly shifted the treatment paradigm.Cosibelimab is currently the only FDA-approved PD-L1 inhibitor for advanced cSCC. Unlike PD-1 inhibitors, cosibelimab directly blocks PD-L1 and also targets B7.1, enhancing T-cell activation. In addition, its fully human monoclonal antibody structure enables antibody-dependent cellular cytotoxicity, offering a mechanistic distinction within the immunotherapy landscape.The agent received FDA approval in 2024 following results from its pivotal phase 1 program in advanced malignancies, including cSCC.Study design: pivotal phase 1 programThis was a multicenter, global, nonrandomized phase 1 study with 2 components:Part 1: Dose evaluation in advanced malignanciesPart 2: Dose expansion cohorts in advanced cSCCCohortsGroup 1: Metastatic cSCC (800 mg IV every 2 weeks)Group 2: Locally advanced, inoperable cSCC (800 mg IV every 2 weeks)Group 3: Metastatic cSCC (1200 mg IV every 3 weeks)A total of 192 patients were enrolled:78 in Group 158 in Group 256 in Group 3Efficacy analyses focused on Groups 1 and 2. Safety was evaluated across all 3 cohorts.Primary endpointOverall response rate (ORR)Independent central radiologic review (RECIST v1.1)WHO digital classification (including photography-based assessment)The JAAD update incorporated:An additional 16 months of follow-upUpdated safety analyses (measured by treatment-emergent adverse events)Patient populationAmong 109 efficacy-evaluable patients:Median age: 70sPredominantly male and CaucasianMost had ECOG 0–1Many had prior surgery or radiotherapyFew had received prior systemic therapyEfficacy: responses that deepen over timeOverall response rateMetastatic cSCC (Group 1): 50%Locally advanced cSCC (Group 2): 54.8%Complete response ratesGroup 1: 12.8%Group 2: 25.8%Notably, complete response rates improved compared to the initial publication:Group 1 increased from 7.7%Group 2 increased from 9.7%This suggests that responses continue to deepen with extended follow-up, a clinically meaningful observation for dermatologists monitoring patients over time.Safety: a critical consideration in this populationTreatment-emergent adverse events were common, as expected with immunotherapy. However, Grade 3 immune-related AEs only occurred in about 3.6% of patients.In an elderly population with frequent comorbidities, tolerability is especially important. Adverse events can have outsized impact in patients with baseline cardiovascular, pulmonary, metabolic, or transplant-related complexities.Dr Ladwa emphasizes that safety must be weighed carefully in patients with complex comorbidities like immunosuppression or organ transplantation; in such scenarios, nuanced risk–benefit discussions remain essential.Key takeawaysCosibelimab is the only FDA-approved PD-L1 inhibitor for advanced cSCCUpdated ≥2-year follow-up data demonstrate:ORR ~50–55%Increasing complete response rates over timeGrade 3 immune-related AEs occurred in 3.6% of patientsSafety profile is particularly relevant in older, comorbid patientsUnderstanding mechanism and long-term data can support confident multidisciplinary discussions and prescribing decisionsFor additional details, clinicians are encouraged to review the full publications accompanying this analysis. https://dermsquared.com/videos/discourses-in-dermatology/the-pivotal-study 492 2026-03-25T13:49:34.312Z yes https://dermsquared.com/videos/discourses-in-dermatology/discover-vtama-next-generation-treatment-plaque-psoriasis 2024-10-07T20:52:47.550Z https://image.mux.com/8tTlnAjaKYX6SMGcRNsY13H6kBifP34iLrph02TyDGLw/thumbnail.jpg Discover VTAMA: A Next-Generation Treatment for Plaque Psoriasis In this video, Dr Mona Shahriari, dermatologist and Assistant Clinical Professor at Yale University, explores tapinarof cream 1%, or VTAMA, a novel topical treatment for plaque psoriasis. She discusses VTAMA's unique mechanism as an aryl hydrocarbon receptor agonist, which specifically targets key pathways involved in psoriasis—reducing inflammation and oxidative stress and improving skin barrier function.Dr Shahriari reviews VTAMA alongside traditional corticosteroids, highlighting its lack of systemic side effects, absence of usage restrictions, and suitability for sensitive skin areas. Dr Shahriari also details VTAMA’s accessibility, including the patient savings program. Watch the full video to see why Dr Shahriari considers VTAMA a new standard in psoriasis care, offering patients a powerful option for managing their condition.IMPORTANT SAFETY INFORMATIONVTAMA cream is for use on the skin (topical) only. Do not use VTAMA cream in your eyes, mouth, or vagina. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. https://dermsquared.com/videos/discourses-in-dermatology/discover-vtama-next-generation-treatment-plaque-psoriasis 299 2024-10-07T20:52:47.544Z yes https://dermsquared.com/videos/discourses-in-dermatology/oral-option-psoriasis-care 2025-10-20T17:50:44.156Z https://image.mux.com/U9cUuK1rU6WHc01BCUENy3dcoUyK5yuZ9E502dWUI182k/thumbnail.jpg What an Oral Option Means for Psoriasis Care In this video, Ben Lockshin, MD, shares his perspective on the evolving role of oral therapies in psoriasis care. He highlights how a once-daily oral option offers strong efficacy, durability, and safety, while also meeting patient demand for alternatives to injections. With practical insights on tolerability, monitoring, and long-term outcomes, Dr Lockshin explains why oral therapy is becoming an important first-line consideration for patients eligible for systemic treatment. https://dermsquared.com/videos/discourses-in-dermatology/oral-option-psoriasis-care 155 2025-10-20T17:50:44.147Z yes https://dermsquared.com/videos/discourses-in-dermatology/launch-alert-anzupgo 2025-09-09T20:20:42.876Z https://image.mux.com/b9nulaDMvMw1Byc2Kvsn1ADezcP6h3b02tSgX2MEuYIM/thumbnail.jpg LAUNCH ALERT: FDA Approves Anzupgo (Delgocitinib) Cream for Moderate-to-Severe Chronic Hand Eczema in Adults Update (September 2025): Anzupgo is now commercially available and can be prescribed in the United States. Following FDA approval in July 2025, the therapy has officially entered the market and is accessible to clinicians for eligible patients. Watch as James Q. Del Rosso, DO, reviews clinical trial data, mechanism of action, safety, and more. The US Food and Drug Administration has approved Anzupgo (delgocitinib) cream (20 mg/g) for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults who are not adequately controlled with topical corticosteroids or for whom such treatment is not advisable. This represents the first FDA-approved therapy specifically indicated for CHE. Mechanism of action Anzupgo is a topical pan-Janus kinase (JAK) inhibitor, targeting JAK1, JAK2, JAK3, and tyrosine kinase 2. It modulates multiple cytokine signaling pathways involved in the pathophysiology of CHE via inhibition of the JAK-STAT pathway, with topical administration limiting systemic exposure. Clinical trial insights FDA approval was supported by results from two identical randomized, double-blind, vehicle-controlled trials (DELTA 1 and DELTA 2) involving 960 adults with moderate-to-severe CHE. Primary endpoint: Investigator’s Global Assessment for Chronic Hand Eczema Treatment Success (IGA-CHE TS) at Week 16:DELTA 1: 20% with Anzupgo vs 10% with vehicle (p=0.006)DELTA 2: 29% with Anzupgo vs 7% with vehicle (p<0.0001)Key secondary endpoint (≥4-point reduction in severity of itch and pain as measured by the Hand Eczema Symptom Diary):Itch: 47% of Anzupgo-treated patients in both DELTA 1 and DELTA 2 achieved this reduction at Week 16, vs 23% and 20% with cream vehicle (p<0.0001).Pain: 49% of Anzupgo-treated patients in both trials achieved this reduction at Week 16, vs 28% and 23% with cream vehicle (p<0.0001). Safety profile The safety profile of Anzupgo was comparable to that of vehicle. Adverse events occurring in ≤ 1% of patients included application site pain, paresthesia, erythema, pruritus, and bacterial skin infections. Patients completing 16 weeks of treatment in the DELTA 1 and DELTA 2 trials were eligible to enter DELTA 3, a 36-week open-label extension assessing long-term safety. Product availability Anzupgo has been launched in multiple international markets and is expected to be made available in the US soon. https://dermsquared.com/videos/discourses-in-dermatology/launch-alert-anzupgo 520 2025-08-06T15:41:04.182Z yes https://dermsquared.com/videos/discourses-in-dermatology/bimekizumab-for-plaque-psoriasis-insights-into-efficacy-safety-and-dosing 2024-02-08T17:49:02.162Z https://image.mux.com/Myu40001iMuID76gZNMKZa1ToQ02E7l02QJP4Pq3x4vG9qY/thumbnail.jpg Bimekizumab for Plaque Psoriasis: Insights into Efficacy, Safety, and Dosing In this episode of Discourses in Dermatology, Alice Gottlieb, MD, PhD, and James Q Del Rosso, DO, discuss bimekizumab, which has emerged as a distinctive and highly efficacious treatment option for psoriasis. Tune in to hear their comments on its unique features, efficacy, safety profile, and dosing advantages. What makes bimekizumab different? Dr Gottlieb describes the unique features that distinguish bimekizumab from other psoriasis treatments, noting the high level of efficacy that has been demonstrated in rigorous comparator studies and shown to be more efficacious than adalimumab and secukinumab. It is also currently the only IL-17 blocker with every-8-weeks dosing, which puts it in the range of the IL-23 blockers. Bimekizumab also possesses a novel mechanism of action as an IL-17A and F blocker, whereas agents like secukinumab and ixekinumab are IL-17A blockers only. Efficacy Dr Gottlieb notes that the majority of patients on bimekizumab reach PASI 75 by week 4, with Dr Del Rosso commenting that 4 out of 10 have been shown to achieve PASI 90 after a single dose. In a New England Journal of Medicine comparator study, 86% of patients taking bimekizumab achieved PASI 90 vs 47% of patients on adalimumab. Safety profile Candida In clinical trials, candida infections occurred more frequently in the bimekizumab group than in the placebo group, however, Dr Gottlieb notes that bimekizumab is a more potent drug than ixekinumab or secukinumab, thus a higher incidence of candida is to be expected and not cause for concern. Suicidal ideation and behavior Regarding the package insert statements on depression and suicide, Dr Gottlieb notes that the associated confidence interval numbers reflect that these potential adverse effects do not pose a significant concern. Liver function Treatment with bimekizumab was associated with increased incidence of liver enzyme elevations compared to treatment with placebo in randomized clinical trials. However, Dr Gottlieb notes that there have been rigorous double-blind, placebo-controlled comparator studies on bimekizumab against adalimumab, secukinumab, and ustekinumab, and bimekizumab did not demonstrate a higher incidence of liver function issues, with the incidence being low across all drugs in the studies. Tuberculosis Evaluating patients for tuberculosis prior to initiating treatment with bimekizumab is required; Dr Gottlieb typically opts to repeat the screen once per year. Inflammatory bowel disease Inflammatory bowel disease (IBD) has been reported in patients treated with IL-17 blockers, though Dr Gottlieb comments that the risk is relatively minimal. However, she notes that for patients with active IBD or a strong family history of IBD, she would likely consider an alternative therapy. Dosing The recommended dosing schedule for bimekizumab is administration of 320 mg (two 160-mg injections) at weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. Dr Gottlieb remarks that this dosing schedule is one of the most notable advantages of bimekizumab, noting that it is currently the only IL-17-targeting agent that allows an every-8-weeks dosing schedule at maintenance. She commends the flexibility of adjusting dosing to every 4 weeks for patients weighing ≥120 kg. Key points: Bimekizumab has demonstrated better efficacy than adalimumab and secukinumab in comparator studies Bimekizumab possesses a novel mechanism of action as both an IL-17A and F blocker Potential adverse effects such as candida infections, suicidal ideation and behavior, and liver biochemical abnormalities may not pose significant cause for concern in patients taking bimekizumab For patients with active IBD or a strong family history of IBD, alternative therapies may be considered The recommended dosing for bimekizumab is a major advantage over other treatments, offering a convenient and flexible schedule https://dermsquared.com/videos/discourses-in-dermatology/bimekizumab-for-plaque-psoriasis-insights-into-efficacy-safety-and-dosing 406 2024-02-08T17:49:02.155Z yes https://dermsquared.com/videos/discourses-in-dermatology/the-oral-conversation-how-we-talk-to-patients-about-systemic-therapy-today 2025-12-19T18:20:21.940Z https://image.mux.com/YsmqAzLzn01h6xDRNYiPisMr4pxucAqYaI01RbwWHRDfE/thumbnail.jpg The Oral Conversation: How We Talk to Patients About Systemic Therapy Today This session concludes the Exploring What's Next In Psoriasis Care Innovation Experience with a practical discussion on how clinicians guide patients through systemic therapy choices for psoriasis. Dr. Shahriari and Dr. Cameron explored how they set expectations, address patient hesitancy, clearly explain oral treatment options, and maintain engagement throughout the treatment journey. The conversation offers a real-world, conversational look at the language and strategies that help patients feel informed, confident, and supported in their care decisions. https://dermsquared.com/videos/discourses-in-dermatology/the-oral-conversation-how-we-talk-to-patients-about-systemic-therapy-today 1851 2025-12-19T18:20:21.934Z yes https://dermsquared.com/videos/discourses-in-dermatology/psoriasis-mechanism-of-disease-pathogenesis 2023-10-12T17:13:06.544Z https://image.mux.com/F01E1wt502IgER4eCwh01i89TxhRgxvudSnAd00ML7DWNCg/thumbnail.jpg Psoriasis mechanism of disease: Pathogenesis In this installment of Discourses in Dermatology, Dr Andrew Blauvelt, a dermatologist from Portland, Oregon and investigator at Oregon Medical Research Center, sits down with Dr Jason Hawkes, a medical dermatologist from Sacramento, California, to discuss the pathogenesis of psoriasis. Over the course of their conversation, they provide an overview of the immunology of psoriasis, explore the relationship between IL-23 and IL-17, highlight the isoforms that dermatologists need to know, and examine the role of TNF in the pathogenesis of psoriasis.Overview of the immunology of psoriasisDr Hawkes begins with a high-level overview and considers the primary signal that drives the clinical features of psoriasis dermatologists see in the clinic. He notes that IL-17, both IL-17A and IL-17F, is the cytokine that drives the hyperproliferative effects in psoriasis, with IL-23 helping sustain those T cells and making high levels of IL-17. He comments that this serves as the predominant role of what drives psoriasis.Another aspect he considers is the skin once it’s been activated. Once it’s in the hyperproliferative state, it begins making its own signals like IL-17C, IL-19, and CCL20, which go back to the immune system to reactivate dendritic cells and T-cells. This is a feed-forward cycle that begins with the IL-23 and IL-17 axis activating the skin cells and signals coming back that activate the dendritic cells and T cells further, creating a chronic cycle of disease. This serves as the framework by which we can then examine the nuances of psoriasis.Key points:IL-17 (both A and F) is the cytokine that drives the hyperproliferative effects in psoriasisIL-23 helps to sustain T-cells and make high levels of IL-17The IL-23 and IL-17 axis activates skin cells with signals coming back that activate dendritic cells and T cells, which creates a feed-forward cycle that promotes a chronic cycle of disease The relationship between IL-23 and IL-17Dr Hawkes remarks that he views IL-23 as the regulatory signal that helps T cells differentiate into IL-17-producing T cells. Th17 is commonly discussed, but T-17 must also be mentioned since it includes both the CD4+ and CV8+ T cells. He summarizes the relationship between IL-23 and IL-17 by explaining that IL-23 is upstream of IL-17 and helps T cells differentiate into IL-17 high-producing cells. From IL-17-producing T cells, we see both IL-17A and IL-17F. Dr Hawkes also mentions IL-17C, which is produced by keratinocytes as opposed to IL-17A and F which come from T cells.Key pointsIL-23 is the regulatory signal that helps T cells differentiate into IL-17-producing cellsIL-17A and IL-17F come from IL-17-producing T cellsIL-17C is produced by keratinocytes Isoforms that dermatologists need to knowDr Blauvelt comments on the number of different isoforms included in A though F and asks Dr Hawkes which key IL-17 cytokines are important for dermatologists to know about when it comes to the pathogenesis of psoriasis.Dr Hawkes explains that there are 6 dimeric cytokines in the IL-17 family, IL-17 A through IL-17 F. These cytokines can pair, so there may be an IL-17 AA homodimer or an AF for example, which is relevant in driving psoriasis. He notes that not much is known about IL-17 B, D, E.He identifies 3 cytokines that are important for dermatologists to pay attention to. IL-17A and IL-17 F are primarily produced by the T cells. The AA homodimer, the AF heterodimer, and the FF homodimer are the key signals from the T cell compartment.From the keratinocytes, we see IL-17 C.He remarks that we don’t yet know the role of the other IL-17 cytokines play in psoriasis, but IL-17 A, F, and C drive the predominant features we see in the immune compartment and in the keratinocyte or epidermal compartment.Key pointsThere are 6 dimeric cytokines in the IL-17 family (A-F)These cytokines can pair, which is relevant in driving psoriasisIL-17A, F, and C drive the predominant features of psoriasis The role of TNF in psoriasis pathogenesisDr Blauvelt continues the conversation by introducing tumor necrosis factor (TNF). He believes TNF is made all over as opposed to specifically upstream, midstream, or downstream and asks Dr Hawkes for his input on where TNF fits into the psoriasis pathogenesis picture.Dr Hawkes agrees and describes TNF as a very potent proinflammatory signal and a cytokine that changes thousands of genes compared to hundreds with IL-17 and IL-23. This creates a big activating system. There are portions of it upstream; plasmacytoid dendritic cells make high levels of interferon and the myeloid or mature dendritic cells make high levels of TNF, but we also see TNF working much further downstream.He references research from Dr James Krueger’s laboratory that has shown IL-17 has its own impact on the skin as does TNF being proinflammatory, but together, that synergy creates a much more powerful impact. We see other cytokines as working with those predominant signals with IL-23 and IL-17, and they’re working to potentiate or amplify the proinflammatory effect.Dr Hawkes notes that many residents have asked how TNF inhibitors work if IL-23 and IL-17 are so central. He replies that the blockade of TNF helps to indirectly reduce levels of IL-17 because it’s an upstream signal like IL-23. By blocking it, it also blocks the potentiating effects and magnifying synergistic effects that IL-17 has on the skin driving hyperproliferation. Because it’s broad acting, it works in different levels.He also comments on the downside of TNF having that broader impact versus more targeted agents. He describes this as immune collateral damage, but it’s also not a very strong potent inhibitor of that central pathway of IL-17 and IL-23. Those targeted agents have a better way of shutting off the driving signal.Dr Blauvelt concludes by describing TNF blockers as anti-inflammatory in general, which is why they work for a variety of inflammatory diseases. and IL-17s and IL23s as much more targeted to psoriatic inflammation, which is why we don’t see a lot of the side effects seen with TNF blockers.Key pointsTNF is a potent proinflammatory signal and cytokine that changes thousands of genes, creating a large activation systemThe synergy between IL-17 and TNF creates a powerful impactTNF indirectly reduces levels of IL-17, thus blocking magnifying synergistic effects that IL-17 has on driving hyperproliferationThe broad impact of TNF can be described as immune collateral damageIL-17s and IL-23s are much more targeted to psoriatic inflammation versus TNF blockers, which are anti-inflammatory in general https://dermsquared.com/videos/discourses-in-dermatology/psoriasis-mechanism-of-disease-pathogenesis 508 2023-10-12T15:53:03.543Z yes https://dermsquared.com/videos/discourses-in-dermatology/warnings-in-daily-practice 2025-12-05T13:52:42.362Z https://image.mux.com/P88A3500a2orv301Z9AWTKcxrE1rNWxTRkrEcwuROwFPE/thumbnail.jpg Part 4: How Dermatologists Approach SI/B Warnings in Daily Practice This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. In this final installment, Mark Lebwohl, MD, welcomes Andrea Murina, MD, to reflect on the themes from the first 3 videos and to discuss how suicidality warnings influence real-world dermatology practice. Their conversation offers a clinic-centered perspective on how to address these warnings efficiently, accurately, and compassionately with patients.Balancing efficacy, safety, and communicationDr Lebwohl begins by reviewing the 4 dermatologic therapies with suicidality warnings (brodalumab, apremilast, isotretinoin, and bimekizumab), and asks Dr Murina how these labels affect prescribing in her clinic. She shares that it is, in fact, very easy to prescribe these medications because they are among the most effective treatments available for psoriasis, acne, and hidradenitis suppurativa (HS). For her, addressing suicidality warnings head-on has become routine. Echoing insights from earlier discussions with Dr Fried, she emphasizes that these warnings reflect reported events rather than causal relationships and that the therapeutic benefits of these agents often far outweigh theoretical risks. Effective counseling, she notes, is a central part of patient care.Practical counseling: efficient, clear, and grounded in evidenceBoth clinicians agree that dermatologists rarely have significant time to discuss labeling language in depth. Instead, they focus on straightforward, data-based explanations. Dr Lebwohl shares that for apremilast and bimekizumab, where the data show no increased risk of suicidality, he typically does not raise the issue unless patients ask. When they do, he explains that in bimekizumab trials there was only one reported case of completed suicide, and no causal link has been established.Dr Murina takes a similar approach, reassuring patients that available evidence does not support a drug-related risk and redirecting the conversation to the well-documented mental health burden of the diseases being treated. For patients with severe psoriasis, acne, or HS, untreated disease often exerts far greater psychological and quality-of-life consequences than the medications themselves.Medication-specific considerationsThe clinicians then walk through specific agents:Brodalumab: Because of the REMS program requirements, Dr Lebwohl spends more time counseling patients, though he notes that trial data showed improved mental health outcomes compared with placebo. He emphasizes that the suicides observed in development were far more likely related to lifestyle and baseline psychiatric factors than to the drug.Isotretinoin: Given public awareness and concerns around teratogenicity, he routinely reviews safety considerations. In practice, he finds patients overwhelmingly pleased with its effectiveness.Apremilast and bimekizumab: Dr Murina shares that she tends to do minimal counseling unless patients raise concerns. For bimekizumab, especially in HS where treatment options are limited and disease burden is high, she is confident in framing it as a highly efficacious choice that can rapidly improve quality of life.Across all medications, she asks simple, direct questions at follow-up visits (“How has your mood been?” “Feeling down or less interested in activities?”) and reassures patients that she is part of their care team and prepared to adjust therapy if needed.Striking the right balance: guidance and shared decision-makingDr Murina expresses the importance of shared decision-making but also highlights the need for clinicians to have a clear, confident treatment recommendation. Dr Lebwohl adds that many patients already recognize the emotional toll of their psoriasis or HS and welcome highly effective treatment even when a label contains a warning.They close by reminding colleagues that these medications are straightforward to prescribe and that package inserts reflect FDA reporting requirements, not proven causality. With thoughtful, efficient counseling, dermatologists can help patients access effective therapy without unnecessary hesitation.Key takeawaysDermatologic therapies with suicidality warnings remain among the most effective treatments for acne, psoriasis, and HSFDA-required labeling reflects reported events, not proven causal relationshipsConcise, evidence-based counseling helps address patient concerns without overwhelming the visitUntreated inflammatory skin disease often poses greater mental health risks than treatmentWith thoughtful patient communication, clinicians can safely and effectively prescribe these therapies while supporting overall well-beingClick here to view the other videos in the series. https://dermsquared.com/videos/discourses-in-dermatology/warnings-in-daily-practice 601 2025-12-05T13:52:42.354Z yes https://dermsquared.com/videos/discourses-in-dermatology/outcomes-with-remibrutinib 2026-02-17T17:31:38.770Z https://image.mux.com/WKncOapC00qrcXhCyKqCr9muraQnd9RN01tVXFyR5SPsM/thumbnail.jpg Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib Nicholas Brownstone, MD, takes a closer look at what disease activity actually does over time in chronic spontaneous urticaria (CSU), drawing on two Phase 3 analyses from the REMIX-1 and REMIX-2 program. Rather than focusing on a single endpoint, he walks through patient-level shifts in UAS7 disease activity bands, tracing how patients moved from severe or moderate disease toward well-controlled states and complete response across 52 weeks of treatment with remibrutinib. The video highlights how quickly these changes emerged, often within the first week, and how they were sustained through the open-label extension, including among patients who initially received placebo and later transitioned to active therapy. Together, the data offer a clinically grounded view of response durability, variability, and real-world relevance for an oral BTK inhibitor in patients with CSU who remain symptomatic despite second-generation H1 antihistamines. https://dermsquared.com/videos/discourses-in-dermatology/outcomes-with-remibrutinib 198 2026-02-17T17:31:38.763Z yes https://dermsquared.com/videos/discourses-in-dermatology/tapinarof-in-atopic-dermatitis 2026-05-27T13:24:02.127Z https://image.mux.com/pmyYb8yI00B02u2W4gtYgvz01800GZ5QHIba6d7WJsTe00xM/thumbnail.jpg Tapinarof in Atopic Dermatitis: Insights From Pooled Phase 3 Data In this segment, Linda Stein Gold, MD, reviews pooled data presented at the 2026 Annual Meeting of the American Academy of Dermatology evaluating the efficacy and safety of tapinarof 1% cream in children and adults with atopic dermatitis (AD). The analysis combined findings from the ADORING 1 and ADORING 2 phase 3 clinical trials, providing a broader look at treatment outcomes across patients with moderate to severe disease.Tapinarof and the aryl hydrocarbon receptor pathwayDr Stein Gold begins by reviewing the background of tapinarof, a nonsteroidal topical therapy initially approved in 2022 for psoriasis in adults and later approved in 2024 for atopic dermatitis in patients as young as 2 years of age.Tapinarof functions as an aryl hydrocarbon receptor agonist, representing a novel mechanism of action among topical therapies for AD. Activation of this pathway helps downregulate proinflammatory cytokines, including Th2 cytokines that play a central role in AD pathophysiology. ADORING 1 and ADORING 2 trial designThe pooled analysis incorporated data from ADORING1 and ADORING 2, two identically designed phase 3 studies conducted across different investigators, sites, and patients.Eligible patients were 2 years of age or older with moderate to severe atopic dermatitis, an Eczema Area and Severity Index (EASI) score of at least 6, and body surface area (BSA) involvement ranging from 5% to 35%. Dr Stein Gold notes that patients at the higher end of the BSA range could reasonably be considered candidates for systemic therapy in routine practice. Average baseline BSA involvement across the studies was approximately 16% to 17%.Participants were randomized in a 2:1 ratio to receive tapinarof 1% cream or vehicle once daily for 8 weeks. Investigators evaluated both efficacy and safety outcomes at the conclusion of treatment.The primary endpoint focused on achieving clear or almost clear skin, defined as at least a 2-grade improvement. Additional endpoints included itch reduction, EASI50/75/90 responses, and other standard efficacy assessments.Early efficacy signals observed by week 1Dr Stein Gold highlights that separation between active treatment and vehicle was observed as early as week 1.By week 8, nearly 46% of patients receiving tapinarof achieved clear or almost clear skin in the pooled analysis. Improvements continued consistently throughout the treatment period, with ongoing separation from vehicle across the 8-week study duration.Itch reduction and low pruritus scoresThe analysis also demonstrated early and sustained improvements in itch.Investigators evaluated the standard ≥4-point reduction in peak pruritus numerical rating scale (NRS) scores and observed statistically significant separation from vehicle beginning at week 1. By week 8, just under 60% of patients achieved this level of itch improvement.Dr Stein Gold also points to an additional itch endpoint that is less commonly evaluated in topical AD studies: achievement of a peak pruritus NRS score of 1 or lower, representing minimal or nearly absent itch. Separation from vehicle again emerged by week 1, and by week 8, nearly one-third of patients achieved this low itch threshold.EASI responses across multiple thresholdsThe pooled data also showed robust EASI responses over the course of treatment.Separation from vehicle was observed as early as week 1 for both EASI50 and EASI75 responses. By week 8:~78% of patients achieved EASI50 ~58% achieved EASI75 ~30% reached EASI90 Safety profile remained consistentFrom a safety standpoint, most treatment-emergent adverse events (TEAEs) were reported as mild to moderate in severity.The most commonly reported adverse events included folliculitis, headache, upper respiratory infection, and nasopharyngitis. Discontinuation rates due to TEAEs remained low throughout the studies.Expanding the topical treatment armamentarium in ADIn closing, Dr Stein Gold emphasizes that the pooled ADORING data demonstrate tapinarof cream to be a safe and effective nonsteroidal topical option for patients with moderate to severe atopic dermatitis, including pediatric patients down to age 2.Key takeawaysPooled data from the ADORING 1 and ADORING 2 trials evaluated tapinarof 1% cream once daily in patients aged 2 years and older with moderate to severe atopic dermatitis Tapinarof is a nonsteroidal aryl hydrocarbon receptor agonist that targets inflammatory pathways involved in AD Separation from vehicle was observed as early as week 1 across multiple efficacy endpoints By week 8, nearly 46% of patients achieved clear or almost clear skin Just under 60% of patients achieved a ≥4-point itch reduction, and nearly one-third reached a peak pruritus NRS score of ≤1 Week 8 EASI responses included approximately 78% achieving EASI50, 58% achieving EASI75, and 30% achieving EASI90 Most treatment-emergent adverse events were mild to moderate, and discontinuation rates due to TEAEs were low https://dermsquared.com/videos/discourses-in-dermatology/tapinarof-in-atopic-dermatitis 293 2026-05-27T13:05:55.244Z yes https://dermsquared.com/videos/discourses-in-dermatology/bimekizumab-for-plaque-psoriasis-its-impact-in-clinical-practice 2024-03-19T14:26:51.876Z https://image.mux.com/ZGMuS2r0001Hp01PYR01YX37PBF02ZiF8xSZYRqf8ZIv02dlA/thumbnail.jpg Bimekizumab for Plaque Psoriasis: Its Impact in Clinical Practice In this installment of Discourses in Dermatology, G. Michael Lewitt, MD, and Omar Noor, MD, FAAD, discuss bimekizumab, highlighting the remarkable patient outcomes observed in their clinical practices, how it stands out in a crowded treatment landscape, and its significant implications for psoriasis management. A unique mechanism of action Psoriasis intricately involves pathways like IL-23, IL-17, and TNF alpha, with specific immune cells perpetuating the inflammatory cascade. Recognizing the diverse isomers of IL-17, particularly IL-17A and IL-17F, forms the foundation of bimekizumab's approach. Unlike other medications that target solely IL-17A or the IL-17 receptor, bimekizumab is a pioneering treatment that addresses both IL-17A and F, presenting a novel mechanism of action. Histological studies reveal elevated levels of IL-17F in psoriatic lesions, underscoring the significance of dual IL-17A and F inhibition. By precisely targeting these predominant isoforms, bimekizumab demonstrates enhanced efficacy in mitigating inflammation. Patient success stories in clinical practice Highlighting patient anecdotes, Dr Noor and Dr Lewitt underscore bimekizumab’s efficacy in challenging cases, from individuals resistant to conventional therapies to those weary from a carousel of treatments. Both Dr Lewitt and Dr Noor share that their patients on bimekizumab showed significant clearance of psoriatic lesions by the time they returned for a 4-week follow-up and were able to rekindle a sense of optimism toward their treatment journeys after multiple failed responses to other therapies. Counseling patients on adverse events Addressing concerns about adverse events, Dr Noor advocates for comprehensive patient communication. Acknowledging the increased rates of anxiety and depression at baseline in patients with psoriasis, he emphasizes the importance of prioritizing discussions on emotional well-being alongside treatment efficacy. He encourages colleagues to address any relevant medical history of major depressive disorders or antidepressant use to ensure bimekizumab is the right fit for a given patient. An approach to monitoring In terms of monitoring, Dr Noor adheres to standard biologics protocols, conducting CBC, CMP, and QuantiFERON-TB Gold tests at baseline along with an acute hepatitis panel to exclude the possibility of hepatitis B in patients. Dr Noor’s personal recommendation is to follow up with another CMP or LFT at 6 to 12 weeks, and if levels remain stable, repeat yearly going forward. A convenient dosing schedule The recommended dosing schedule for bimekizumab is administration of 320 mg (two 160-mg injections) at weeks 0, 4, 8, 12, and 16, then every 8 weeks thereafter. Notably, this dosing schedule is unique to bimekizumab, offering an appealing option to patients who are concerned about the frequency of medication administration. This approach not only enhances patient compliance but also accommodates individual needs, particularly in the case of overweight patients who may need to remain on an every-4-week dosing schedule. Standing out in a crowded landscape Drs Lewitt and Noor conclude their discussion by reflecting on the crowded psoriasis treatment landscape. Despite the many options available, they acknowledge that persistent unmet needs remain. They remark that bimekizumab stands out by effectively addressing these needs through its distinct mechanism of action, rapid efficacy, and favorable safety profile, allowing them to maintain the commitment to prioritizing patient well-being amid the evolving landscape of psoriasis therapeutics. https://dermsquared.com/videos/discourses-in-dermatology/bimekizumab-for-plaque-psoriasis-its-impact-in-clinical-practice 987 2024-03-19T14:12:51.680Z yes https://dermsquared.com/videos/discourses-in-dermatology/intention-in-aesthetic-assessment 2026-02-06T15:44:51.291Z https://image.mux.com/b4hqn8xp9zLbrgQGf4uc5BOAEs9AJt4jVKNJvOGPsjg/thumbnail.jpg Leading With Intention in Aesthetic Assessment In a live patient workshop at Winter Clinical Hawaii, Glynis Ablon, MD, walked through her approach to injectables. First, she always starts with what the patient wants, then steps back to evaluate facial structure from skin to bone.Rather than treating surface concerns in isolation, Dr. Ablon emphasizes understanding facial morphology, the layered anatomy of aging, and the importance of symmetry when planning fillers and neuromodulators. That requires aligning vision with the patient early, staging treatments over time to avoid overcorrection, and reassessing goals at follow-up visits.She also reminds clinicians that injectables are just one part of a broader aesthetic strategy—often working alongside lasers and other modalities to address texture, laxity, and overall skin quality. The goal is not simply technical precision, but outcomes that feel natural for patients and sustainable for physicians. https://dermsquared.com/videos/discourses-in-dermatology/intention-in-aesthetic-assessment 177 2026-02-06T15:44:51.284Z yes https://dermsquared.com/videos/discourses-in-dermatology/patients-with-plaque-psoriasis 2026-06-12T13:28:25.821Z https://image.mux.com/aall34ILk9q8CyWsgqEvG8MFfn4J12dPCvsR8RMXb024/thumbnail.jpg Tailoring Biologic Care for Medicare Patients With Plaque Psoriasis In this Expert Therapeutic Update Session, Scott Gottlieb, MD, discusses ILUMYA® for Medicare patients living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.The presentation focuses on the practical access considerations that often shape biologic selection in older patients, including Medicare Part B coverage, health care provider administration, and the option to use either buy and bill in the office or an alternate site of care. Dr Gottlieb also reviews clinical data from the reSURFACE trials, including long-term efficacy and safety findings, with attention to outcomes in patients aged 65 years and older.For clinicians managing plaque psoriasis in Medicare populations, the session offers a thorough look at how coverage, administration, adherence, and safety considerations can all factor into treatment decisions. https://dermsquared.com/videos/discourses-in-dermatology/patients-with-plaque-psoriasis 1134 2026-06-12T13:26:05.561Z yes https://dermsquared.com/videos/discourses-in-dermatology/hs-disease-course 2026-03-25T15:15:02.787Z https://image.mux.com/mgNunthOsSZcXvTF7TAz8zyRLP0202oxLMHOc8n00o01HpM/thumbnail.jpg Earlier Treatment, Different Outcomes: Secukinumab and the HS Disease Course When does timing actually change outcomes in hidradenitis suppurativa? Dr. Brownstone walks through why earlier intervention with secukinumab may shift the trajectory, not just the symptoms.In this overview, Nicholas Brownstone, MD, focuses on a post hoc analysis from the SUNSHINE and SUNRISE trials, looking at how disease duration and severity shape response to secukinumab. The signal is consistent: patients treated earlier in their disease course, particularly those with less advanced Hurley staging, were more likely to reach higher thresholds of response, including HiSCR100. It’s a useful reframing of a familiar challenge in HS. Not just whether a therapy works, but when it’s introduced, and what may be lost as disease progresses. Watch the breakdown, then explore the full poster for a closer look at the data. https://dermsquared.com/videos/discourses-in-dermatology/hs-disease-course 172 2026-03-25T15:14:49.754Z yes https://dermsquared.com/videos/discourses-in-dermatology/treatment-landscape 2026-03-18T17:17:11.329Z https://image.mux.com/JjG8W2OqmWBDfi5OfDVgw029eAphJcsC5t02wkAPnkWjs/thumbnail.jpg Bullous Pemphigoid: The Evolving Treatment Landscape Bullous pemphigoid (BP) management has changed dramatically over the past several decades. What was once a treatment landscape dominated by systemic corticosteroids has steadily evolved as clinicians have gained a deeper understanding of the disease itself.In this conversation, Prince Adotama, MD, Assistant Professor at NYU Grossman School of Medicine, sits down with Naveed Sami, MD, Professor of Dermatology and Medicine at the University of Central Florida, to discuss how the science behind BP is reshaping clinical care. The two walk through how advances in immunology—particularly the recognition of IL-4 and IL-13 signaling in BP—have opened the door to more targeted therapies designed to control disease without broadly suppressing the immune system.The discussion also highlights why treatment decisions in BP are rarely straightforward. Many patients are older and medically complex, often managing multiple comorbidities and medications. In this setting, clinicians must weigh disease control against safety, considering not only efficacy but also the risks associated with steroids, immunosuppressive therapies, and polypharmacy.Drs Adotama and Sami also explore where newer biologic therapies are beginning to fit into the treatment landscape, including the recent FDA approval of dupilumab for bullous pemphigoid. Along the way, they discuss practical clinical considerations, from treatment response and remission goals to the role of combination therapy and emerging therapies on the horizon.Together, their conversation reflects a broader shift in dermatology. As our understanding of disease biology improves, treatment strategies are becoming more precise, more individualized, and increasingly focused on improving both disease control and quality of life for patients living with BP. https://dermsquared.com/videos/discourses-in-dermatology/treatment-landscape 503 2026-03-18T17:17:11.322Z yes https://dermsquared.com/videos/discourses-in-dermatology/approach-to-filler-safety 2026-03-26T13:27:16.299Z https://image.mux.com/sFd2cz5TKGj6C2Xd5dnKVUP6scRkQxBvpsFeF6nIax4/thumbnail.jpg Injecting on Bone: A Practical Approach to Filler Safety A simple adjustment in technique that can make a meaningful difference in filler safety. https://dermsquared.com/videos/discourses-in-dermatology/approach-to-filler-safety 44 2026-03-26T13:27:16.291Z yes https://dermsquared.com/videos/discourses-in-dermatology/when-to-act 2026-04-17T15:28:02.023Z https://image.mux.com/9FECgKmYPZYsQH4XjeuOe01FJIkQv02ZXGOi56i9UMw200/thumbnail.jpg Who to Look for and When to Act Omar Noor, MD, focuses on the patients who might otherwise be easy to miss. The small signals that, taken together, start to shift suspicion toward joint disease. It all hinges on asking better questions and asking them consistently. From there, treatment becomes a matter of fit. Oral options don’t replace biologics, and they’re not positioned to outperform other systemic therapies. But they do offer a meaningful option for certain patients, particularly when simplicity, preference, and adherence come into play. https://dermsquared.com/videos/discourses-in-dermatology/when-to-act 152 2026-04-17T15:28:02.017Z yes https://dermsquared.com/videos/discourses-in-dermatology/vtama-lecture-recap-video 2025-10-31T19:50:30.214Z https://image.mux.com/9frMfn007aflHpVROlCqiW8F2VZx6eTbwnF1q8C4heRk/thumbnail.jpg Fall Clinical Continuity Experience - Vtama - Lecture Recap Video At Fall Clinical 2025, Peter Lio, MD, explored the changing landscape of topical therapy in atopic dermatitis, emphasizing that topicals remain the cornerstone of treatment—even as new agents expand the toolbox. Here, he highlights the clinician’s role as a “steward of steroids,” and notes the growing importance of nonsteroidal anti-inflammatory agents and value of structured eczema action plans that combine rescue therapy with long-term maintenance to help patients stay clear safely and consistently. https://dermsquared.com/videos/discourses-in-dermatology/vtama-lecture-recap-video 35 2025-10-31T19:50:25.107Z yes https://dermsquared.com/videos/discourses-in-dermatology/tildrakizumab-in-psoriasis 2026-02-09T14:01:56.130Z https://image.mux.com/33X00m6DRWb8y01L4bSxNyjkrsVD01yJ02UxNO1QLWbv02W8/thumbnail.jpg Tildrakizumab in Psoriasis: Adherence, Persistence, and the Role of In-Office Administration In this video segment, George Han, MD, PhD, explores whether the site of biologic administration meaningfully influences adherence, persistence, and long-term outcomes in plaque psoriasis. Using tildrakizumab as a real-world case study, he reframes in-office administration from a perceived inconvenience into a potential clinical advantage, supported by emerging adherence and persistence data.At the heart of the discussion is a familiar tension in psoriasis care: most biologics are self-administered at home, but does administration site actually matter when it comes to keeping patients on therapy and maintaining durable disease control?Adherence: removing the guessworkDr Han emphasizes a reality dermatology providers see often: for most patients, starting a biologic for psoriasis is a long-term, often lifelong, commitment. While patients may achieve clearance and feel confident early on, interruptions in therapy are common. When biologics are stopped, relapse is typical, and when the same drug is restarted, it may not work as well as before, potentially due to anti-drug antibodies or other factors.This creates a clinical challenge. When medications are self-administered at home, missed or misfired doses may not come to light until disease worsens. In contrast, in-office administration gives providers confidence in when and how doses are delivered, with clear documentation and fewer unknowns.That clarity becomes especially important when a patient is not responding as expected. Is the issue loss of efficacy, or was adherence inconsistent? In-office dosing removes one major variable from that equation.Persistence: staying on therapy long termDr Han distinguishes adherence from persistence, noting that persistence refers to how long a patient remains on a given therapy. Despite consistent counseling on the importance of staying on biologics, real-world data suggest that approximately half of patients discontinue treatment within one to two years.1,2Persistence matters clinically and economically. Switching biologics increases the risk of adverse effects and is costly, with first-year biologic expenses typically higher than subsequent years. From both a patient-care and practice perspective, keeping patients on an effective therapy is a priority.Across treatment classes, persistence challenges remain. Studies show that oral systemic therapies fare only modestly better, with adherence around 58%, and more than half of patients discontinuing within 6 months,3,4 often due to tolerability issues such as gastrointestinal side effects or headaches, based on Dr Han’s clinical experience.In-office administration as a clinical advantageDr Han highlights real-world data on tildrakizumab, an IL-23 inhibitor indicated for health care provider administration. In observational studies, more than half of patients remained on therapy at 12 months, with a median time to discontinuation of approximately 22 months, alongside high adherence rates.5He suggests that in-office administration plays a meaningful role. Scheduled visits allow practices to proactively manage logistics, coordinate access and paperwork, send reminders, and ensure doses are administered correctly and on time. This infrastructure supports adherence while reducing the burden on patients who may be hesitant, forgetful, or uncomfortable with self-injection.Dr Han also notes the opportunity to maximize these visits by pairing injections with skin exams or disease check-ins, improving continuity of care. For patients with prior suboptimal responses, in-office dosing removes uncertainty and allows providers to focus on true treatment efficacy rather than adherence concerns.A broader perspectiveDr Han concludes by emphasizing that the expanding psoriasis armamentarium has meaningfully improved clearance rates, durability, and quality of life for patients. As clinicians, the goal is not only to select an effective therapy, but also to choose a delivery model that aligns with patient behavior and real-world needs.For patients who struggle with self-administration or consistency, bringing treatment into the office can be a practical, patient-centered strategy to support adherence, persistence, and long-term outcomes.Key takeawaysAdherence and persistence remain major challenges in psoriasis care, regardless of treatment classIn-office administration removes uncertainty around dosing and helps clarify whether lack of response reflects adherence or true treatment failureReal-world data on tildrakizumab suggest strong adherence and persistence, potentially supported by clinician-administered dosing and structured follow-upFor patients who struggle with self-injection or consistency, in-office administration can be a practical strategy to support durable long-term outcomesReferences:Doshi JA, Takeshita J, Pinto L, et al. Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. J Am Acad Dermatol. 2016;74(6):1057-1065.e4. doi:10.1016/j.jaad.2016.01.048Yeung H, Wan J, Van Voorhees AS, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol. 2013;68(1):64-72. doi:10.1016/j.jaad.2012.06.035Das AK, Chang E, Paydar C, Broder MS, Orroth KK, Cordey M. Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic. Dermatol Ther (Heidelb). 2023;13(9):1973-1984. doi: 10.1007/s13555-023-00967-3. Erratum in: Dermatol Ther (Heidelb). 2023 Sep;13(9):1985. doi: 10.1007/s13555-023-00984-2. PMID: 37392261; PMCID: PMC10442297.Schmidt L, Wang CA, Patel V, et al. Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors. Dermatol Ther (Heidelb). 2023;13(9):2019-2030. doi:10.1007/s13555-023-00975-3Han G, Zanardo E, Simpson R, et al. Treatment patterns in patients with moderate-to-severe psoriasis treated with biologics. Poster presented at: American Academy of Dermatology Annual Meeting; March 2025; Orlando, FL. https://dermsquared.com/videos/discourses-in-dermatology/tildrakizumab-in-psoriasis 635 2026-02-02T18:51:30.972Z yes https://dermsquared.com/videos/discourses-in-dermatology/treating-moderate-to-severe-hs 2026-02-17T17:36:38.928Z https://image.mux.com/uzcWLgrR3BruXhD00YRdFzlsikSwNwX4oelAzzYpy2gU/thumbnail.jpg What Four Years Can Tell Us About Treating Moderate to Severe HS Nicholas Brownstone, MD, walks us through the four-year efficacy and safety data for continuous secukinumab in moderate to severe hidradenitis suppurativa (HS), drawing directly from the SUNSHINE and SUNRISE core and extension trials. His overview focuses on clinically meaningful endpoints reported through Week 204, including sustained HiSCR responses over time, persistent reductions in draining tunnel count, and tolerability over four years of continuous treatment, which is especially relevant in a chronic, relapsing disease where patients often need long-term therapy. https://dermsquared.com/videos/discourses-in-dermatology/treating-moderate-to-severe-hs 210 2026-02-17T17:36:38.919Z yes https://dermsquared.com/videos/discourses-in-dermatology/treat-ad-long-term 2026-06-01T15:18:05.830Z https://image.mux.com/h01m1gdt4Vu3lUA1LFl1BlyhW5Xei71PuwBnkUHLT8PI/thumbnail.jpg What Changes When You Treat AD Long Term In this closing recap, Elizabeth (Lisa) Swanson, MD, distills the shift many clinicians are making in practice: thinking beyond body surface area, recognizing AD as a chronic inflammatory disease rather than a series of isolated flares, and knowing when the burden of treatment itself signals it’s time to move beyond topicals. The goal, she argues, is not simply controlling a rash, but giving patients a steadier life outside the constant anticipation of the next flare. https://dermsquared.com/videos/discourses-in-dermatology/treat-ad-long-term 248 2026-06-01T15:18:05.821Z yes https://dermsquared.com/videos/discourses-in-dermatology/persistence-with-tildrakizumab 2026-05-15T14:13:48.242Z https://image.mux.com/ithTdXOlKcB01ugDJMt01g1N7TNT9TaURZ94JzHT6aIc8/thumbnail.jpg Plaque Psoriasis in Medicare Patients: Real-World Persistence with Tildrakizumab In this installment of Discourses in Dermatology, April Armstrong, MD, MPH, reviews a real-world study presented at the American Academy of Dermatology Annual Meeting examining continuity of care among Medicare patients with plaque psoriasis treated with tildrakizumab and other therapeutic classes.Why this population mattersOlder adults with psoriasis represent a clinically complex population. Many patients have longer disease duration, multiple comorbidities, and are managing polypharmacy. These factors, combined with access-related challenges, can make sustained treatment particularly difficult. In this setting, persistence becomes central to long-term disease control.Psoriasis as a chronic disease: why continuity mattersPsoriasis requires consistent, long-term management. While short-term efficacy is important, real-world continuity over time is often what determines whether patients achieve and maintain control.For dermatologists, this shifts part of the clinical focus toward understanding how therapies perform outside of controlled trial settings, particularly in populations where adherence and persistence may be harder to maintain.Study overview: real-world data in an older populationThe study reviewed was a large, longitudinal, claims-based analysis including approximately 17,000 patients across multiple treatment classes, including IL-23 inhibitors, IL-17 inhibitors, TNF inhibitors, and PDE-4 inhibitors. The analysis specifically focused on a Medicare population with plaque psoriasis. Notably, patients had a Charlson Comorbidity Index of approximately 1.2 to 1.3, reflecting a meaningful comorbidity burden.The primary objective was to evaluate treatment persistence and time to discontinuation, with a specific focus on tildrakizumab.Key findings: persistence and time to discontinuationAt 12 months, persistence with tildrakizumab was approximately 70%, compared with roughly 36% to 60% among other therapies evaluated.At 24 months, more than half of patients remained on tildrakizumab, an important observation in a population where long-term continuity is often difficult to achieve.Tildrakizumab demonstrated a median time to discontinuation of approximately 29 months, compared with a range of about 7 to 18 months for other therapies.The role of care delivery and follow-upOne factor highlighted in the discussion is the potential impact of care delivery models. As an in-office, injection-based therapy, tildrakizumab may facilitate more frequent interaction between patients and the health care system.These built-in touchpoints can support ongoing monitoring, reinforcement of treatment plans, and earlier identification of issues that may lead to discontinuation.Clinical perspective: reframing treatment goalsThese findings contribute to a broader shift in how dermatologists think about therapy selection. The question is not only whether a treatment works, but whether patients are able to remain on therapy over time.For older adults with psoriasis, durability and persistence become key considerations alongside efficacy and safety. Data like these can help inform upfront decision-making and set more realistic expectations for long-term management.In a population where treatment discontinuation is common, the level of continuity observed with tildrakizumab may help reframe what sustained management can look like in clinical practice.Key takeawaysMedicare patients with psoriasis often face higher clinical complexity, which can make long-term treatment persistence challenging Real-world continuity of care is a critical component of effective psoriasis management In this large claims-based study, tildrakizumab demonstrated higher persistence at 12 and 24 months compared with other treatment classes Median time to discontinuation was longer with tildrakizumab, suggesting greater durability in this population In-office administration may support continuity through more consistent patient follow-up and engagement These findings highlight the importance of considering persistence and long-term use when selecting therapy for older adults with psoriasis https://dermsquared.com/videos/discourses-in-dermatology/persistence-with-tildrakizumab 276 2026-05-15T14:13:48.230Z yes https://dermsquared.com/videos/discourses-in-dermatology/systemic-disease 2026-04-17T15:26:59.247Z https://image.mux.com/EGx7e5DsAO6I82I02YPJ1iDxrty01esluULiOen2xJz00Y/thumbnail.jpg What Changes When We Treat Psoriasis as Systemic Disease? Psoriasis and psoriatic arthritis are understood as connected but often managed separately. Brad Glick, DO, MPH, walks through why that separation starts to break down in practice. Nearly a third of patients with psoriasis will develop joint involvement, many of whom remain undiagnosed. That reality demands screening become more intentional. Asking about morning stiffness, fatigue, joint swelling, or subtle changes that might otherwise be missed. With an oral TYK2 inhibitor that has demonstrated activity across both skin and joints, the conversation moves from what we treat to how we identify patients, when to intervene, and how we think about psoriasis as a systemic disease from the start. https://dermsquared.com/videos/discourses-in-dermatology/systemic-disease 422 2026-04-17T15:26:59.230Z yes https://dermsquared.com/videos/discourses-in-dermatology/bimzelx-in-focus 2024-12-28T03:19:02.524Z https://image.mux.com/9H2y9kmx3veUi02Vj7NIYBP0201sNUoSEkXmFvmhnkwi6w/thumbnail.jpg Bimzelx in Focus: Versatile Care for Enhanced Dermatologic Outcomes In this video, Dr James Song, Director of Clinical Research and Associate Chief Medical Officer at Frontier Dermatology, provides an in-depth look at Bimzelx (bimekizumab), a novel biologic with 5 approved indications, including 3 with significant impact on dermatology: plaque psoriasis, psoriatic arthritis, and hidradenitis suppurativa (HS).Dr Song explores Bimzelx’s unique position as the first and only FDA-approved dual inhibitor of IL-17A and IL-17F, explaining the science behind this innovative mechanism of action. He discusses how this approach delivers rapid and sustained efficacy, a consistent safety profile, and robust clinical outcomes, with key highlights including improvements in PASI scores, durability of response, and real-world insights into patient care.Watch the full video to learn why Dr Song considers Bimzelx a valuable option for psoriasis management and a powerful tool for dermatologists aiming to achieve enhanced patient outcomes.IMPORTANT SAFETY INFORMATIONSuicidal Ideation and BehaviorBIMZELX may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B. Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment.InfectionsBIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX. Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves.TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients for signs and symptoms of active TB during and after treatment.Liver Biochemical AbnormalitiesElevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded. Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis.Inflammatory Bowel DiseaseCases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.ImmunizationsPrior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.MOST COMMON ADVERSE REACTIONSMost common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue.Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections.Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection. https://dermsquared.com/videos/discourses-in-dermatology/bimzelx-in-focus 479 2024-12-28T03:18:57.425Z yes https://dermsquared.com/videos/discourses-in-dermatology/vtama-new-standard-psoriasis-management 2024-10-07T20:52:52.408Z https://image.mux.com/QVfMAmjXnoqtxVNENex6iw01UZrGUn97JsUigdOZeJ00Q/thumbnail.jpg VTAMA: A New Standard in Psoriasis Management In this video, Dr Mona Shahriari, dermatologist and Assistant Clinical Professor at Yale University, explores tapinarof cream 1%, or VTAMA, a novel topical treatment for plaque psoriasis. She discusses VTAMA's unique mechanism as an aryl hydrocarbon receptor agonist, which specifically targets key pathways involved in psoriasis—reducing inflammation and oxidative stress and improving skin barrier function.Dr Shahriari reviews VTAMA alongside traditional corticosteroids, highlighting its lack of systemic side effects, absence of usage restrictions, and suitability for sensitive skin areas. Dr Shahriari also details VTAMA’s accessibility, including the patient savings program. Watch the full video to see why Dr Shahriari considers VTAMA a new standard in psoriasis care, offering patients a powerful option for managing their condition.IMPORTANT SAFETY INFORMATIONVTAMA cream is for use on the skin (topical) only. Do not use VTAMA cream in your eyes, mouth, or vagina. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu). Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. https://dermsquared.com/videos/discourses-in-dermatology/vtama-new-standard-psoriasis-management 299 2024-10-07T20:52:52.402Z yes https://dermsquared.com/videos/discourses-in-dermatology/exploring-my-path-melanoma-test 2024-05-01T13:47:21.254Z https://image.mux.com/v4C4xbDhqOrXydrf7jeIFyohDD02QBmGapsv7At25qNg/thumbnail.jpg Exploring the MyPath Melanoma Test for Guiding Management and Care Decisions in Patients with Ambiguous Lesions In this installment of Discourses in Dermatology, Aaron Farberg, MD, gives an in-depth overview of the MyPath Melanoma test, a gene expression profile (GEP) test designed to aid in the diagnosis of ambiguous cutaneous melanocytic lesions and inform patient management and treatment decisions. Dr Farberg explains the importance of ancillary testing, particularly in cases where there is a lack of clinicopathological correlation, and how the MyPath Melanoma test can provide objective information to help clinicians classify ambiguous lesions of unknown potential. He also details how to incorporate the test into clinical practice, gives an overview of the MyPath Melanoma report guide, and details the patient-focused financial assistance and insurance billing services available. Finally, he reviews the case of a 27-year-old woman with a high clinical concern for melanoma and atypical histopathology, detailing how the MyPath Melanoma test impacted diagnosis and clinical care in a real-world example. https://dermsquared.com/videos/discourses-in-dermatology/exploring-my-path-melanoma-test 1098 2024-05-01T13:47:21.248Z yes https://dermsquared.com/videos/discourses-in-dermatology/insights-from-dr-del-rosso 2026-01-06T15:31:25.155Z https://image.mux.com/6tLKngez9Z8ShbBgKka8XglkKkX4bA6oFONfxfXhlRs/thumbnail.jpg Advancing Bullous Pemphigoid Care: Clinical Insights From Dr. Del Rosso Hear from Dr. James Q Del Rosso as he walks through recent advances in the treatment of bullous pemphigoid, with a focus on how dupilumab is reshaping disease management strategies for adult patients. https://dermsquared.com/videos/discourses-in-dermatology/insights-from-dr-del-rosso 1380 2026-01-06T15:31:25.145Z yes https://dermsquared.com/videos/discourses-in-dermatology/inflammatory-and-biochemical-pathways 2025-11-19T20:30:25.770Z https://image.mux.com/Q5AUqPgvWLJllAwiAg5ijzIjvwjJo7027VGOsOidij00s/thumbnail.jpg Part 2: Psoriasis and Mental Health: The Inflammatory and Biochemical Pathways This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. The inflammation–depression connectionIn Part 2, Drs Lebwohl and Fried deepen their exploration by discussing the biochemical basis linking psoriasis and depression. Dr Lebwohl begins with an intriguing observation: bupropion, a well-known antidepressant, is also a TNF inhibitor, illustrating biochemical overlap between inflammatory pathways and mood regulation.Some inflammatory mediators elevated in psoriasis are also implicated in depression, suggesting a shared biological landscape beyond the psychosocial burden of visible skin disease.Is depression in psoriasis biologic, psychologic, or both?Dr Fried addresses a longstanding question: are psychiatric symptoms in psoriasis primarily due to disease burden, or are they driven by central biologic mechanisms?He emphasizes that the answer is unequivocally both. Inflammatory cytokines released from skin lesions enter the systemic circulation, cross the blood–brain barrier, and alter neurotransmitter uptake, affecting serotonin, norepinephrine, and dopamine. These changes directly contribute to mood symptoms.This dual mechanism reinforces that addressing inflammation can also address psychiatric symptoms.Future directions: neurotransmitter testing and combined therapiesDr Fried discusses emerging possibilities for objectively measuring neurotransmitters through blood, urine, or imaging strategies. If clinicians could quantify depletion in patients with inflammatory skin disease, they might feel more confident pairing SSRIs or SNRIs with biologics when needed.He highlights growing evidence that depression is, in part, an inflammatory disorder and that antidepressants themselves have anti-inflammatory effects, making them strong potential partners to biologic therapy.Examining suicidality concerns with bimekizumabThe conversation shifts to the suicidality warning for bimekizumab, one of the fastest and most effective psoriasis therapies available. Dr Lebwohl reviews a publication by Blauvelt et al that examined Phase 2 and 3 clinical trial data and found no increased risk of suicidality in patients treated with bimekizumab compared to the general population and compared to patients treated with other IL-17 or IL-23 inhibitors.Despite this, the warning remains on the label, and some clinicians avoid prescribing it. Dr Lebwohl cautions that this hesitancy may prevent high-need patients from accessing a highly effective treatment.Psychological improvement with effective therapyDr Lebwohl closes by sharing another notable trial finding: in pivotal trials, among patients receiving bimekizumab, 93% reported no or minimal depression, compared with 81% of placebo-treated patients. This reinforces that improving skin disease can significantly improve psychological well-being.Key takeawaysPsoriasis and depression may share overlapping inflammatory pathwaysInflammatory cytokines can influence neurotransmitter activity and moodTreating systemic inflammation can improve both skin and psychiatric symptomsClinical trial data show no increase in suicidality with bimekizumab compared with placebo, the general population, or other biologicsClick here to view the other videos in the series. https://dermsquared.com/videos/discourses-in-dermatology/inflammatory-and-biochemical-pathways 577 2025-11-19T20:30:25.761Z yes https://dermsquared.com/videos/discourses-in-dermatology/psoriasis-mechanism-of-disease-genetics 2023-09-13T11:18:20.288Z https://image.mux.com/ykkWnnIQ6CX02MwnIfLuwMepAALTd3c02WqnPJ5sY1AGo/thumbnail.jpg Psoriasis mechanism of disease: Genetic, environmental, and lifestyle factors In this installment of Discourses in Dermatology, Dr. George Han, Director of Clinical Research at Northwell Health in New York, sits down with Dr. Andrew Blauvelt, Investigator at Oregon Medical Research Center, to discuss the genetic, environmental, and lifestyle factors that influence psoriasis. They also explore the comorbidities associated with psoriasis and how they play into the role of psoriatic disease.The role of genetics in psoriasisDr. Han begins by asking Dr. Blauvelt what role genetics really plays in the development of psoriasis.Dr. Blauvelt references the first genetic study published on psoriasis, spearheaded by Danish researchers in the Faroe Islands in 1963, which found evidence of a genetic component to psoriasis in the local island population. He also comments on a key study examining identical twins that revealed strong evidence in favor of a genetic component to psoriasis.Dr. Blauvelt notes that while there is a genetic component to psoriasis, it’s not a Mendelian disease. Rather, there are 70 to 80 susceptibility genes that have been identified that either confer a risk for psoriasis or confer some protection.With those factors considered, he explains to his patients that while there is indeed a significant genetic component, it does not account for the entire picture of psoriasis. He estimates that approximately 40% of patients have a family history of the condition but suggests that even those without a family history may still have a genetic predisposition due to a combination of genes inherited from their parents. To summarize, he reiterates that psoriasis is a complex condition with a genetic component with other factors also involved in its development.Key pointsA seminal study demonstrating the genetics of psoriasis was conducted by Danish researchers on the Faroe Islands in 1963Twin studies have also revealed strong evidence in favor of a genetic component to psoriasisPsoriasis is not a Mendelian disease, but is influenced by 70 to 80 susceptibility genesWhile there is a significant genetic component to psoriasis, it does not account for the entire pictureEnvironmental influences on psoriasisDr. Han continues the conversation by asking Dr. Blauvelt about the environmental influences on psoriasis that may encourage psoriasis in susceptible individuals.Dr. Blauvelt replies by giving more background on the genetics of psoriasis, explaining that there are 2 types of psoriasis as it relates to genetics. The first type is a result of genes that tend to run in families, with HLA-Cw6 being the most common. With this type, there is usually an earlier onset in the late teens or early 20s. The second type tends to manifest in the early 40s, and those patients tend not to have a family history of the condition. Rather, this type of psoriasis tends to be more associated with metabolic syndrome, diabetes, or hypertension.Dr. Blauvelt then begins delving into some of the well-known influences on psoriasis, including stress, infections like strep throat, and certain medications. He specifically mentions lithium and interferon stimulators, remarking that Aldara cream can stimulate psoriasis locally.He comments that the most common influences on psoriasis he has seen in his career have been strep throat, stress, and cold weather. He advises patients that any kind of stressor on the body, whether emotional or physical stress from temperature, medication, or infection, can trigger the psoriasis immune response.Key pointsInfluences on psoriasis can include stress, infections, and certain medicationsLithium and interferon stimulators can affect psoriasisCold weather can also trigger the psoriasis immune responseComorbidities of psoriasisDr. Blauvelt comments that the list of comorbidities associated with psoriasis has become quite long and can be overwhelming for healthcare providers who are unsure how to counsel patients on this topic.He describes his approach to speaking with patients and how he always discusses the 2 most important psoriasis comorbidities, psoriatic arthritis and heart disease, at their first visit. When discussing psoriatic arthritis, he explains that it is the most common comorbidity and will affect treatment choice, and that is an important facet for patients to consider and understand. In his experience, some patients with psoriasis are unaware that they are at risk for arthritis and thus it should be discussed early on.Dr. Blauvelt also makes sure to discuss heart disease with his patients and emphasize the seriousness of it. He references the literature that is now available on psoriasis as an independent risk factor for heart disease and says it also suggests that the risk of heart disease can be reduced if an impact can be made on the skin.He mentions large databases that suggest TNF blockers may reduce the risk of cardiovascular events but that we don’t yet have that same kind of data for IL-17s and IL-23s. He also references studies conducted at the NIH that put patients on biologics for one year and measured their atherosclerotic plaques. Those studies demonstrated that IL-17 blockers were the best class of drugs in terms of improving atherosclerosis in patients with psoriasis. While they don’t prevent heart attack and stroke, it’s strong evidence that these therapies are having positive outcomes.Key pointsThe long list of comorbidities associated with psoriasis can make it overwhelming to counsel patientsThe 2 most important comorbidities to discuss with patients are psoriatic arthritis and heart diseasePsoriatic arthritis should be discussed with patients at their first visit, since it’s the most common comorbidity and can affect treatment choiceLiterature suggests that psoriasis is an independent risk factor for heart disease and that the risk of heart disease can be reduced if an impact can be made on the skinLarge databases suggest TNF blockers may reduce risk of cardiovascular eventsNIH studies demonstrated that IL-17 blockers were the best class of drugs in improving atherosclerosis in patients with psoriasisMental health as a comorbidity of psoriasisDr. Han continues the conversation by asking Dr. Blauvelt his thoughts on mental health and psoriasis and how he approaches this discussion with patients.Dr. Blauvelt references his involvement in one of the first multidisciplinary clinics for psoriasis in the United States that included dermatology, rheumatology, and psychiatry. When he asked patients about their mental health, they often reported they were depressed and anxious due to the condition. He found many were hesitant to be referred to the psychiatry clinic because they felt that if their psoriasis cleared, their mental health would improve, which demonstrates there is a component to the condition that can cause angst and depression.He remarks that practitioners can assume quality of life is impaired for patients with psoriasis and that patients are likely to score poorly on quality-of-life measures and depression scales. He emphasizes that this should not be ignored and that it’s important to listen to patients and monitor for signs of severe depression and suicidal ideation. Dr. Han concludes by agreeing on the importance of listening and caring for the whole patient.Key pointsThere is a component to psoriasis that can cause angst and depression among patients with the conditionPatients with psoriasis will often have impaired quality of life and score poorly on quality-of-life measures and depression scalesIt’s vital to listen to patients and monitor them for signs of severe depression and suicidal ideation https://dermsquared.com/videos/discourses-in-dermatology/psoriasis-mechanism-of-disease-genetics 765 2023-09-13T11:18:20.284Z yes https://dermsquared.com/videos/discourses-in-dermatology/up-in-real-decisions 2026-04-17T15:28:40.119Z https://image.mux.com/Ap7YrClKYE3CrMCytsXaVYE200A4V3mXwzJpSz5n0100jc/thumbnail.jpg How Oral TYK2 Inhibition Is Showing Up in Real Decisions Once you move past mechanism, the question becomes simpler and harder at the same time: where does this actually fit? In this conversation, Benjamin Lockshin, MD, and Michael Cameron, MD, walk through how they’re using TYK2 inhibition in practice—who gets it, when they start, and where it sits alongside biologics and other systemic options. For some patients, it’s a first-line consideration. Those with milder joint involvement alongside psoriasis. Patients who prefer to start with an oral option, or those who don’t quite fit the thresholds that typically push toward biologics. For others, it’s additive—layered onto a biologic in partial responders, used in harder-to-treat areas like palmoplantar disease or in patients where weight may affect response.Running through the discussion is a familiar nuance: when to manage independently and when to refer, how much to act on early or vague joint symptoms, and how to balance simplicity with a growing number of treatment choices. Less about defining a fixed place in the algorithm, more about understanding where it becomes useful across different types of patients. https://dermsquared.com/videos/discourses-in-dermatology/up-in-real-decisions 639 2026-04-17T15:28:40.112Z yes https://dermsquared.com/videos/discourses-in-dermatology/and-choosing-treatment 2026-03-18T17:22:28.290Z https://image.mux.com/OhC2LPvjKRMMSp37rG4jzlzz7oBUMXx02kgFcFuIyH8o/thumbnail.jpg Confirming BP Diagnosis and Choosing Treatment Bullous pemphigoid (BP) is often suspected clinically but confirming the diagnosis and deciding how to treat it requires a thoughtful, stepwise approach.In this video, Naveed Sami, MD, Professor of Dermatology and Medicine at the University of Central Florida, walks through what happens after bullous pemphigoid enters the differential. From biopsy and immunofluorescence testing to the role of serologic markers, he outlines how clinicians can establish the diagnosis with confidence before moving into treatment decisions.Dr Sami also discusses the broader clinical picture that often accompanies BP. Because many patients are older and medically complex, treatment choices must balance disease control with safety. He reviews how clinicians typically assess disease severity, when traditional therapies such as systemic corticosteroids or antibiotic–nicotinamide combinations may be considered, and how emerging targeted approaches are beginning to shift the treatment landscape.Ultimately, managing BP requires more than recognizing the disease itself. It means understanding the patient in front of you—their comorbidities, medications, and risk profile—and choosing therapies that control disease while minimizing harm. https://dermsquared.com/videos/discourses-in-dermatology/and-choosing-treatment 462 2026-03-18T17:22:28.283Z yes https://dermsquared.com/videos/discourses-in-dermatology/supporting-the-31-gep-test 2025-12-19T19:21:04.356Z https://image.mux.com/zYDjPYS01nah00CkakkS47qiAOqtBTJF4YWAc00wgi028K4/thumbnail.jpg Advancing Melanoma Prognostics: Clinical Evidence Supporting the 31-GEP Test This video is Part 1 of a 4-part expert series designed to strengthen clinician confidence in the use of the 31-gene expression profiling (31-GEP) test for prognostic assessment in cutaneous melanoma. Across the series, David Cotter, MD, PhD, addresses common questions and hesitations around molecular prognostic testing to support more consistent and effective integration of 31-GEP into routine dermatologic practice.Expert consensus statementMultiple studies (including prospective studies) have demonstrated clinical efficacy for the 31-GEP test in providing consistent and accurate prognostic information for invasive melanoma.This consensus statement comes from the expert panel publication “31-Gene expression profiling for cutaneous melanoma: an expert consensus panel” and serves as the foundation for this discussion.Addressing historical hesitancy around prognostic testingIn this video, Dr Cotter reviews the consensus findings and addresses why prognostic testing has historically been met with some skepticism in dermatology. Unlike diagnosis and treatment, which are central to dermatology training, prognostication has not traditionally played a major role in clinical decision-making for melanoma.While dermatologists are accustomed to robust clinical trial data guiding therapeutic choices, applying a similar evidence-based framework to prognostic tools has felt less intuitive. Dr Cotter emphasizes that the growing body of data supporting 31-GEP directly addresses these concerns and supports its clinical validity and real-world relevance.The evidence base supporting 31-GEPMore than 50 peer-reviewed publications have evaluated the 31-GEP test across retrospective studies, cohort analyses, and prospective datasets. Collectively, these studies demonstrate the test’s ability to identify patients at increased risk for sentinel lymph node positivity, recurrence, distant metastasis, and melanoma-specific mortality beyond traditional clinicopathologic factors.Dr Cotter highlights a pivotal 2023 prospective real-world study that linked outcomes from prospectively tested patients with data from the SEER database. The study confirmed that the test performed in real-world settings as predicted by earlier retrospective trials. Patients with a Class 2B result demonstrated approximately a 7-fold increased risk of death from metastatic melanoma. Importantly, patients who underwent 31-GEP testing also showed a 29% decreased likelihood of dying from melanoma overall.Updated prospective data and clinical interpretationDr Cotter also reviews updated data presented at ASCO 2025, which included additional patients and extended follow-up. The updated analysis confirmed consistent test performance while refining risk estimates. Patients who underwent 31-GEP testing demonstrated a 32% increased likelihood of survival compared with prior estimates of 29%.Notably, Class 2B patients were shown to have a 4-fold increased risk of death from metastatic melanoma, compared with the previously reported 7-fold risk. Dr Cotter suggests this shift may reflect earlier identification of high-risk patients and more appropriate downstream interventions, including surveillance imaging, sentinel lymph node biopsy, and consideration of adjuvant or neoadjuvant therapy.What clinical efficacy means for prognostic testingClinical efficacy for a prognostic test refers to consistent, reproducible performance that clinicians can rely on when making management decisions. Dr Cotter emphasizes that reproducibility across independent studies is essential for building confidence.He reviews data demonstrating that traditional AJCC 8 staging alone may fail to adequately risk-stratify certain early-stage patients. In SEER-based analyses, stage IA and IB patients did not always separate cleanly by outcomes. When 31-GEP results were layered onto standard staging, meaningful risk stratification emerged.Why this matters in clinical practiceDr Cotter brings the discussion back to day-to-day practice. While Stage I melanoma is associated with approximately 98% melanoma-specific survival, the remaining 2% represent a substantial number of patients nationally. Among the estimated 70,000 to 80,000 Stage I melanoma diagnoses each year in the US, this translates to 1400 to 1600 melanoma-related deaths that are not adequately predicted by standard staging alone.The 31-GEP test provides additional prognostic information to support decisions around follow-up intensity, referral to surgical or medical oncology, and surveillance imaging. Dr Cotter notes that he now uses the test routinely for all patients with melanoma in his practice because of its impact on clinical decision-making.Key takeawaysThe 31-GEP test has demonstrated consistent clinical efficacy across retrospective and prospective studiesProspective real-world data confirm that 31-GEP performs as predicted outside of clinical trial settingsUpdated ASCO data suggest improved survival among tested patients, possibly reflecting more informed clinical interventionThe test augments AJCC 8 staging by identifying high-risk patients within early-stage melanomaPrognostic insight from 31-GEP can inform surveillance, referral, and treatment discussions in routine practice https://dermsquared.com/videos/discourses-in-dermatology/supporting-the-31-gep-test 413 2025-12-19T19:19:23.316Z yes https://dermsquared.com/videos/discourses-in-dermatology/topical-truths-managing-ad-in-the-real-world 2025-12-19T18:13:09.608Z https://image.mux.com/3E00L00vXETOy01919vbosJ1uLaOd4JQ6Pq1FlNoPbNbr8/thumbnail.jpg Topical Truths: Managing AD in the Real World This Instagram Live session features a practical, results-driven discussion on newer topical therapies for atopic dermatitis, as Dr. Song and Dr. Lio share clinical pearls and real-world decision-making strategies aimed at improving patient outcomes. The conversation sharpens atopic dermatitis treatment discussions and extends key Fall Clinical conference breakthroughs. From emerging topical data to insights on systemic options, the discussion builds on what began in Las Vegas—transforming expert insight into actionable takeaways for clinical practice. https://dermsquared.com/videos/discourses-in-dermatology/topical-truths-managing-ad-in-the-real-world 1314 2025-12-19T18:13:09.599Z yes https://dermsquared.com/videos/discourses-in-dermatology/navigate-si-b-warnings-with-patients 2025-11-19T20:30:45.650Z https://image.mux.com/SHgtHqpP00RXrq3V5Br010035MDJwpbnK01PB18VgDTZth00/thumbnail.jpg Part 3: Psoriasis and Mental Health: How to Navigate SI/B Warnings With Patients This 4-part video series brings together leading dermatologists to explore the intersection of mental health and chronic skin disease, a connection that continues to gain recognition in both research and clinical practice. Across the series, experts examine how psychiatric comorbidities influence dermatologic outcomes, review data on the mental health impact of chronic inflammatory conditions, and discuss how dermatologists can thoughtfully address these concerns in patient care. A practical framework for patient conversationsIn Part 3, Drs Lebwohl and Fried turn to the clinician–patient dialogue around therapies that carry suicidal ideation/behavior warnings (SI/B). Dr Lebwohl describes his efficient and effective approach, designed to give patients clarity without overwhelming them.He notes that many patients research their medications and inevitably encounter suicidality language. His strategy involves succinctly explaining that the FDA must list every reported event, even when trial data explicitly state there is no causal association. He then grounds the conversation in data; for example, highlighting that bimekizumab-treated patients demonstrated significantly better mental health outcomes than those on placebo.Reframing the risk: the cost of undertreatmentBoth clinicians emphasize that severe psoriasis itself is associated with increased depression, anxiety, suicidal ideation, and suicide. Effective treatment is a powerful tool for reversing these risks.Dr Lebwohl stresses that when patients are depressed, withholding high-efficacy therapies because of labeling language may cause greater harm. The act of rapidly improving their disease is often the first step toward improving their mental well-being.Communication style: clear, confident, and compassionateDr Fried reinforces the importance of clarity and empathy in these conversations. While shared decision-making is essential, many patients still look to their clinician for a straightforward recommendation.Both experts recommend a structured approach:Acknowledge the SI/B languageExplain the FDA’s reporting requirementsClarify that available data show no causal relationshipHighlight that treating the inflammatory disease can improve mental healthRecommend the therapy you believe is best for the patientThis entire process, Dr Lebwohl notes, takes about one minute in practice.Key takeawaysDermatologists should address SI/B language proactively and confidently with patientsFDA-required labeling reflects reported events, not causationEffective psoriasis treatment reduces psychiatric symptoms and riskClear, compassionate communication strengthens trust and decision-makingPatients often benefit from direct guidance on the clinician’s recommendationClick here to view the other videos in the series. https://dermsquared.com/videos/discourses-in-dermatology/navigate-si-b-warnings-with-patients 592 2025-11-19T20:30:45.641Z yes https://dermsquared.com/videos/discourses-in-dermatology/locally-advanced-basal 2026-01-21T00:13:39.861Z https://image.mux.com/Yq4POKibUq6oLGVhXxqYq7I02cb8iD5e7NUA773KVaqk/thumbnail.jpg Strengthening Confidence in Hedgehog Inhibitors for Locally Advanced Basal Cell Carcinoma This video is sponsored by Sun Pharma. Its content is editorially independent of the sponsor.This expert video series is designed to support dermatologist confidence in the use of Hedgehog inhibitors (HHIs) for the management of locally advanced basal cell carcinoma (laBCC). In this segment, Shannon Trotter, DO, reviews key findings from the 2025 Journal of Drugs in Dermatology (JDD) expert consensus panel, addressing common questions around patient selection, efficacy, safety, and practical differences between the two available HHIs, vismodegib and sonidegib.With two HHIs now available, dermatologists are increasingly tasked with distinguishing how these agents compare, when to use them, and how to counsel patients effectively. Dr Trotter walks through three foundational consensus statements to help guide real-world decision-making.Defining locally advanced BCC: why consensus mattersBefore reviewing treatment guidance, Dr Trotter notes that there is no single, universally accepted definition of laBCC. Disease classification often reflects a combination of tumor-related and patient-related factors, including tumor size, anatomic location (particularly high-function or cosmetically sensitive areas such as the eyelids, nose, ears, and lips), aggressive histologic subtypes, and patient suitability for surgery or radiation. This variability underscores the need for consensus-driven guidance to support consistent and confident care.Consensus statement 1Basal cell carcinoma surgery can lead to aesthetic and functional morbidity when tumors are in anatomically sensitive areas or large size. Hedgehog inhibitors can be used to decrease the size of tumors prior to surgery or as a primary treatment so that surgical outcomes are functionally and aesthetically optimized.Dr Trotter emphasizes that many patients present with BCC in locations where surgery may result in significant functional impairment or cosmetic morbidity. In these cases, HHIs can be used neoadjuvantly to shrink tumors prior to surgery or as primary therapy when surgery is not optimal.Clinical trials of both approved HHIs have demonstrated meaningful and durable responses in laBCC. Although there are no head-to-head trials comparing vismodegib and sonidegib, analyses using comparable RECIST criteria show similar complete response rates. These data support the use of HHIs not only as adjuncts to surgery, but also as effective primary treatment options for appropriately selected patients.Consensus statement 2Patients should be counseled about the most common potential side effects of alopecia, taste alterations, and muscle spasms. Other less common adverse events include but are not limited to, gastrointestinal disorders.Historically, tolerability has been a major reason for treatment interruption or discontinuation with HHIs. Dr Trotter stresses the importance of early, proactive counseling to improve adherence. The most common adverse effects include alopecia, dysgeusia, muscle spasms, and fatigue, and patients benefit from understanding not only what to expect, but when side effects are likely to occur.She explains that differences in molecular structure contribute to variation in side effect onset between agents, with vismodegib typically associated with earlier onset and sonidegib with later onset. Practical mitigation strategies may include preventive or early interventions for muscle cramps, dietary counseling for taste changes, and discussion of options for alopecia. Setting expectations and distinguishing between preventable versus manageable effects can meaningfully improve persistence with therapy.Consensus statement 3Sonidegib is associated with a lower rate of and longer median time to onset of adverse effects than vismodegib.Dr Trotter reviews data showing that sonidegib is associated with lower rates of muscle spasms, dysgeusia, and alopecia, as well as a longer median time to onset of these adverse effects compared with vismodegib. These differences are attributed to distinct pharmacokinetic and molecular properties.Clinically, this matters when tailoring therapy. Patients doing well on vismodegib may continue treatment, while those struggling with tolerability may benefit from switching to sonidegib. Understanding these distinctions allows dermatologists to individualize therapy rather than abandoning HHI treatment altogether.Key takeawaysLocally advanced BCC lacks a single definition, making consensus-driven guidance essentialHedgehog inhibitors can be used as neoadjuvant or primary therapy to optimize functional and aesthetic outcomesBoth approved HHIs demonstrate meaningful and durable efficacy in laBCCEarly, proactive counseling on side effects improves adherence and persistenceSonidegib is associated with lower rates and delayed onset of common adverse effects compared with vismodegibUnderstanding practical differences between HHIs supports individualized, patient-centered treatment decisionsFor additional consensus statements and deeper discussion, clinicians are encouraged to review the full 2025 JDD consensus publication. https://dermsquared.com/videos/discourses-in-dermatology/locally-advanced-basal 513 2025-12-19T21:01:54.910Z yes https://dermsquared.com/videos/discourses-in-dermatology/shows-in-csu 2026-03-25T15:17:28.513Z https://image.mux.com/Yy01ZPP01MKMLDyfPI6iw6bY2srQ9iGJHmvHdhrpdJfHs/thumbnail.jpg Fast Relief, Sustained Control: What Remibrutinib Shows in CSU How quickly can we meaningfully change symptoms in CSU, and does it last? Dr. Brownstone breaks down what the REMIX data suggest about speed, durability, and real-world relevance.In this explainer, Nicholas Brownstone, MD, walks through pooled phase 3 data from REMIX-1 and REMIX-2, focusing on what clinicians tend to notice first: how fast patients feel better. Improvements in UAS7, itch, and hive severity begin as early as week 1, with separation from placebo that continues through week 24 and holds out to week 52. Just as important, patients who started on placebo and later transitioned to remibrutinib reached similar levels of symptom control by the end of the study—pointing to both consistency and durability over time. The full poster adds context on safety and tolerability, but the takeaway here is straightforward: rapid onset paired with sustained control in a population that often cycles through incomplete responses. https://dermsquared.com/videos/discourses-in-dermatology/shows-in-csu 162 2026-03-25T15:17:28.507Z yes https://dermsquared.com/videos/practice-support/what-is-pams-why-attend 2025-06-04T19:38:03.885Z https://image.mux.com/qfNtUkLDtnTcFMBHaujWOopL1zZaDODkxMba023ogZQk/thumbnail.jpg What is PAMS and why should I attend? Locations + Dates:Columbus, OH - 6/28/25 - Register now!Las Vegas, NV - 11/8/25 - Register now!Join your peers at the Patient Access Management Summit (PAMS)Practical Education:Attendees gain insights into the appeals process, formulary requirements (FRMs), VSAs, and other elements of managing patient access.Networking & Community:A major benefit is networking with peers in the field and exchanging practical knowledge and strategies. https://dermsquared.com/videos/practice-support/what-is-pams-why-attend 76 2025-05-02T19:24:38.236Z yes https://dermsquared.com/videos/practice-support/certification-for-practice-access-management-cpam 2024-12-11T17:43:48.306Z https://image.mux.com/cQuDctCBEI5ee5JHekhY00rPGBeIA4ar6dtD7014ekBdE/thumbnail.jpg Stay Current and Connected: Get Certification for Practice Access Management (C-PAM) Today! Learn why Tommie Major, Biologic Coordinator and member of the PAMS Steering Committee, believes C-PAM certification is essential for staying up to date and building connections within the access management community. Don’t wait—register now and become C-PAM certified today! https://dermsquared.com/videos/practice-support/certification-for-practice-access-management-cpam 86 2024-11-20T18:01:29.587Z yes https://dermsquared.com/videos/practice-support/become-leader-patient-access-cpam 2024-12-11T17:41:15.914Z https://image.mux.com/iy3LGYpNUVbe3vNl01rkHN1RhGEx2R01gPTxgIGfSI1mo/thumbnail.jpg Become a Leader in Patient Access with C-PAM! Learn why Janelle Ball, Founder and CEO of BC Educators believes that certification for C-PAM Foundational Level today prepares you for the Intermediate and Advanced levels coming soon. This will give you the confidence you need in your role today and the ability to take your career to the next level as the new levels of C-PAM are launched in 2025.Check out the Foundational Course to start today! https://dermsquared.com/videos/practice-support/become-leader-patient-access-cpam 75 2024-12-11T16:41:51.042Z yes https://dermsquared.com/videos/practice-support/g2211-what-is-it-and-when-to-use-it 2024-07-19T15:10:52.929Z https://image.mux.com/9qBGTl4Yliqwx2Xa5Bixm3stC19tt1M4o2d029Jd00of4/thumbnail.jpg Coding Corner: G2211 - What It Is and When To Use It Coding Corner: G2211 - What It Is and When To Use It https://dermsquared.com/videos/practice-support/g2211-what-is-it-and-when-to-use-it 432 2024-07-16T19:16:20.124Z yes https://dermsquared.com/videos/practice-support/bill-takeaways-from-pams 2025-12-12T17:50:31.947Z https://image.mux.com/wGyvwv1tNIsjxM02FIBxMmHQZ0021hZHRI3MMaNEkIFI4/thumbnail.jpg Top 5 Buy & Bill Takeaways from PAMS With an eye for what actually works in busy dermatology practices, clinical pharmacist Aly York Minter shares her five most actionable buy and bill takeaways from Patient Access Management Summit (PAMS). She highlights why strong communication loops are the backbone of successful programs, how knowing your payers “cold” saves more time than any tool, and why inventory control and documentation shape both speed and accuracy.Minter offers concrete strategies—weekly check-ins, shared dashboards, benefit verification, chart-note templates, and reusing successful appeals—that help prevent denials before they start. She closes by underscoring the role of empowered teams: when physicians, coordinators, and billing staff all understand their lane, access becomes smoother and patients get on therapy faster. https://dermsquared.com/videos/practice-support/bill-takeaways-from-pams 264 2025-12-12T17:50:31.941Z yes https://dermsquared.com/videos/practice-support/improving-efficiencies-professional-growth-pams-chicago 2026-01-13T21:19:02.462Z https://image.mux.com/shEOkwT2eYj02SkNS9JhZ002k4qTzi02qKdCrogv15wwVI/thumbnail.jpg Improving Efficiencies and Professional Growth at PAMS Chicago Register now! Patient Access Management Summit (PAMS) in ChicagoWhere: The Westin Michigan Avenue Chicago909 North Michigan AvenueChicago, IL 60611When: April 25, 2026Earn up to $500 in consulting fees!$200 for completing C-PAM Foundational curriculum$200 for attending the sessions in full$100 for completing a post-conference evaluation https://dermsquared.com/videos/practice-support/improving-efficiencies-professional-growth-pams-chicago 43 2026-01-09T16:02:59.523Z yes https://dermsquared.com/videos/practice-support/value-cpam-certification-for-access-professionals 2025-01-31T15:11:51.641Z https://image.mux.com/jpuv9lp64kFlL5wTatQ7bRh01ORfMtqPvPsmLmajftsc/thumbnail.jpg The Value of C-PAM Certification for Access Professionals View why Jennifer Fields, RMA, PACS, and member of the PAMS Steering Committee believes that certification through C-PAM enables you to train to the highest levels and advance your professional career within the community of Access Professionals.Check out the Foundational Course to start today! https://dermsquared.com/videos/practice-support/value-cpam-certification-for-access-professionals 72 2024-11-25T16:22:41.433Z yes https://dermsquared.com/videos/practice-support/patient-first-communication-introduction 2024-10-11T15:32:42.625Z https://image.mux.com/f6800nybsU02zLBXt8PoWANn8pbMbgm02ovxyado3g2l7M/thumbnail.jpg Patient-First Communication Introduction Patient-First Communication Introduction https://dermsquared.com/videos/practice-support/patient-first-communication-introduction 72 2024-10-10T00:13:52.003Z yes https://dermsquared.com/videos/practice-support/gaining-expertise-prior-authorizations-biologics-pams-chicago 2026-01-13T21:36:56.220Z https://image.mux.com/ctsR46blv6wuSNlPt3oHm8Xyvu6CxaRApPdKi4JXhAY/thumbnail.jpg Gaining Expertise in Prior Authorizations and Biologics at PAMS Chicago Register now! Patient Access Management Summit (PAMS) in ChicagoWhere: The Westin Michigan Avenue Chicago909 North Michigan AvenueChicago, IL 60611When: April 25, 2026Earn up to $500 in consulting fees!$200 for completing C-PAM Foundational curriculum$200 for attending the sessions in full$100 for completing a post-conference evaluation https://dermsquared.com/videos/practice-support/gaining-expertise-prior-authorizations-biologics-pams-chicago 44 2026-01-09T16:09:51.969Z yes https://dermsquared.com/videos/practice-support/making-it-work-for-your-practice 2025-12-12T17:50:06.152Z https://image.mux.com/0201H02B02uJFLU02GSaIilEIlpZIgb57ohjjHZeluv5QyU00/thumbnail.jpg Buy & Bill Done Right: Making It Work for Your Practice In this short, practical walkthrough, Mark Kaufmann, MD, breaks down what buy and bill really looks like in today’s dermatology landscape, and why it’s worth reconsidering as reimbursements tighten. He explains how the model works, why biologics are often the best place to begin, and how bringing the full drug lifecycle in-house can streamline care, shorten wait times, and stabilize practice revenue.Dr Kaufmann highlights the essentials: choosing the right medications, understanding which payers permit buy and bill, preparing for cash-flow demands, maintaining tight inventory controls, and documenting with precision. He also underscores the infrastructure required—clear staff roles, accurate coding, and periodic auditing to ensure financial viability.A grounded, concise guide to when buy and bill makes sense, and how a practice can implement it with confidence. https://dermsquared.com/videos/practice-support/making-it-work-for-your-practice 161 2025-12-12T17:50:06.142Z yes https://dermsquared.com/videos/practice-support/increasing-access-specialty-therapeutics-attending-pams-chicago 2026-01-13T21:05:33.108Z https://image.mux.com/idc02UZb4Tc3T01005DiyHsc4seFZO01E0101H00SI1ceYSkuU/thumbnail.jpg Increasing Access to Specialty Therapeutics by Attending PAMS Chicago Register now! Patient Access Management Summit (PAMS) in ChicagoWhere: The Westin Michigan Avenue Chicago909 North Michigan AvenueChicago, IL 60611When: April 25, 2026Earn up to $500 in consulting fees!$200 for completing C-PAM Foundational curriculum$200 for attending the sessions in full$100 for completing a post-conference evaluation https://dermsquared.com/videos/practice-support/increasing-access-specialty-therapeutics-attending-pams-chicago 51 2026-01-09T16:00:00.271Z yes https://dermsquared.com/videos/practice-support/elevate-practice-certification-patient-access-management 2024-12-11T17:44:30.590Z https://image.mux.com/b4ovAphn3We3pRsrzKDvUZzPG7Wk00gBqF61Dktz1RCI/thumbnail.jpg Elevate Your Practice with Certification for Patient Access Management (C-PAM) for Your Team Discover why Dr Mark Kaufmann believes in the importance of certifying your patient access management team—for the benefit of both your practice and your patients. Share this opportunity with your practice management and access teams and encourage them to become C-PAM certified today—at no cost to you or your staff! https://dermsquared.com/videos/practice-support/elevate-practice-certification-patient-access-management 94 2024-11-20T18:09:21.527Z yes https://dermsquared.com/videos/practice-support/from-therapy-to-patient-access-at-pams-chicago 2026-01-13T21:28:01.379Z https://image.mux.com/YjsqZOUD8tJjMm6oOW2RW1XwrN02DHOGfe02AXFZYqw68/thumbnail.jpg From Therapy to Patient Access at PAMS Chicago Register now! Patient Access Management Summit (PAMS) in ChicagoWhere: The Westin Michigan Avenue Chicago909 North Michigan AvenueChicago, IL 60611When: April 25, 2026Earn up to $500 in consulting fees!$200 for completing C-PAM Foundational curriculum$200 for attending the sessions in full$100 for completing a post-conference evaluation https://dermsquared.com/videos/practice-support/from-therapy-to-patient-access-at-pams-chicago 40 2026-01-09T16:05:53.797Z yes https://dermsquared.com/videos/practice-support/networking-and-learning-tips-tricks-pams-chicago 2026-01-13T20:11:06.258Z https://image.mux.com/6W5WmvuDYirVXqONhrxI02DqjdtC57NHVntQdKmyZuw8/thumbnail.jpg Networking and Learning Tips & Tricks at PAMS Chicago Register now! Patient Access Management Summit (PAMS) in ChicagoWhere: The Westin Michigan Avenue Chicago909 North Michigan AvenueChicago, IL 60611When: April 25, 2026Earn up to $500 in consulting fees!$200 for completing C-PAM Foundational curriculum$200 for attending the sessions in full$100 for completing a post-conference evaluation https://dermsquared.com/videos/practice-support/networking-and-learning-tips-tricks-pams-chicago 61 2026-01-09T15:55:51.985Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/navigating-treatment-challenges-in-pediatric-dermatology 2026-02-05T15:09:09.706Z https://image.mux.com/w018VricroYlFjZVXih02P8mKdIxderMONURySYVYN009Y/thumbnail.jpg Navigating Treatment Challenges in Pediatric Dermatology Lawrence F. Eichenfield, MD, provided an engaging overview of how pediatric dermatology is rapidly evolving, with a focus on improving long-term outcomes through earlier diagnosis and more targeted therapies. In pediatric psoriasis, he emphasized the growing demand for effective oral options beyond traditional immunosuppressants. Promising phase 2 data were presented for icotrokinra, a novel oral IL-23 receptor–blocking peptide that achieved clear or almost clear skin in nearly 90% of adolescents by 24 weeks, with a favorable safety and tolerability profile. These results signal a potential shift toward convenient, noninjectable systemic options for children.Juvenile lichen sclerosus was highlighted as a frequently underrecognized condition with important lifelong implications. Dr Eichenfield underscored that lichen sclerosus rarely resolves at puberty, with most patients continuing to have active disease and structural changes into adolescence and adulthood. He stressed the importance of early recognition and sustained treatment with super–high-potency topical corticosteroids, even in asymptomatic patients, noting that consistent therapy significantly reduces long-term anatomic damage.The session concluded with advances in precision medicine and evolving disease definitions. In atopic dermatitis, the Identity Study was introduced as a novel approach using noninvasive gene expression profiling to predict which children are most likely to respond to JAK inhibitors versus Th2-targeted therapies, allowing for faster clearance and improved itch control. Dr Eichenfield also discussed the shift from Mycoplasma-induced rash and mucositis to reactive infectious mucocutaneous eruption, reflecting the broader range of infectious triggers now recognized. Management focuses on treating the underlying infection and controlling severe mucositis with systemic anti-inflammatory or immunomodulatory therapies, reinforcing the need for timely diagnosis and aggressive intervention in complex pediatric cases. https://dermsquared.com/videos/wch-2026-conference-highlights/navigating-treatment-challenges-in-pediatric-dermatology 133 2026-02-05T15:09:09.195Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/let-s-nail-this-down-modern-approaches-to-onychomycosis 2026-02-05T15:10:05.785Z https://image.mux.com/xsNAGAmmHH3G3h7EM9Jv02tbWp02P00xlRDilaa3MMHKtw/thumbnail.jpg Let's Nail this Down: Modern Approaches to Onychomycosis Boni E. Elewski, MD presented a streamlined, five-step framework for managing onychomycosis, beginning with accurate bedside diagnosis. Key clinical clues include asymmetric nail involvement, a history of tinea pedis, distal onycholysis, and yellow, white, or brown subungual debris. She highlighted specific diagnostic features such as dermatophytomas and collarettes of scale, which can strongly suggest dermatophyte infection. Laboratory confirmation remains essential, with KOH testing or PAS/GMS staining used to identify fungal elements, and fungal culture or PCR required to determine the causative organism. When hyphae are present, the likelihood exceeds 90% that Trichophyton rubrum is responsible.Treatment decisions were framed around disease severity and patient factors, with options including oral therapy, topical therapy, or combination approaches. Oral antifungals such as terbinafine, itraconazole, and fluconazole remain mainstays for moderate-to-severe disease, while topical agents like efinaconazole, tavaborole, and ciclopirox are best suited for mild cases or as adjunctive therapy. Dr Elewski emphasized important safety considerations, particularly with itraconazole, including drug–drug interactions, absorption requirements, and cardiac risk. Monitoring response is critical, as toenails grow slowly; patients should demonstrate several millimeters of healthy new nail growth within 3–4 months of treatment initiation.The session concluded with a focus on preventing reinfection, a common cause of treatment failure. Dr Elewski stressed aggressive management of concomitant tinea pedis and patient education on behavioral modifications, such as avoiding barefoot exposure in public spaces. By combining accurate diagnosis, tailored antifungal therapy, realistic expectations, and preventive strategies, clinicians can significantly improve long-term outcomes in patients with onychomycosis. https://dermsquared.com/videos/wch-2026-conference-highlights/let-s-nail-this-down-modern-approaches-to-onychomycosis 135 2026-02-05T15:10:05.776Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/whats-new-in-dermatology-online-journal-and-skin 2026-02-05T15:11:46.258Z https://image.mux.com/MtorVs9BTFZDZOtRDDVCqspl00G02h9ViJ3xbFX62XhoY/thumbnail.jpg What's New in Dermatology Online Journal and SKIN April W. Armstrong, MD, MPH, Editor-in-Chief of Dermatology Online Journal, presented a curated review of notable and high-interest articles recently published in Dermatology Online Journal and SKIN, highlighting atypical case reports and emerging therapeutic approaches for refractory dermatologic conditions. Dr Armstrong emphasized how these publications surface early clinical insights and practical lessons that can inform real-world dermatology practice.The presentation featured several complex diagnostic cases drawn from recent publications, including a pediatric patient with painful facial ulcers initially resembling pyoderma gangrenosum who was ultimately diagnosed with granulomatosis with polyangiitis after biopsy and imaging, underscoring the importance of reconsidering diagnoses in refractory ulcerative disease. Additional cases included Parry Romberg syndrome presenting as progressive facial atrophy, with complete cutaneous resolution reported following treatment with upadacitinib. Together, these cases illustrated how uncommon diseases may present subtly and evolve over time, requiring reassessment when standard therapies fail.Dr Armstrong also highlighted published case reports describing off-label use of targeted therapies, particularly Janus kinase inhibitors, across a range of inflammatory and immune-mediated conditions. Examples included reports of abrocitinib for localized granuloma annulare, upadacitinib for pyoderma gangrenosum and drug-induced subacute cutaneous lupus erythematosus, as well as ivermectin for childhood granulomatous periorificial dermatitis refractory to conventional therapy. Emerging topical approaches were also reviewed, including roflumilast cream for cutaneous lichen planus in patients with limited tolerance for topical corticosteroids. Collectively, these articles highlight how peer-reviewed case literature can expand therapeutic considerations for rare and treatment-resistant disease. https://dermsquared.com/videos/wch-2026-conference-highlights/whats-new-in-dermatology-online-journal-and-skin 208 2026-02-05T15:11:46.253Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/the-il-13-story-in-atopic-dermatitis-characterizing-pathways-and-therapeutic-performance 2026-02-05T15:10:44.095Z https://image.mux.com/xlX2k3ahi2QYrTOfzfGRg2omy0021Jq3d021ziJYe28jQ/thumbnail.jpg The IL-13 Story in Atopic Dermatitis: Characterizing Pathways and Therapeutic Performance The presentation positioned interleukin-13 (IL-13) as a dominant cytokine in atopic dermatitis, driving inflammation, barrier dysfunction, dysbiosis, and chronic itch. Unlike IL-4, IL-13 remains elevated even in nonlesional, normal-appearing skin, helping explain persistent disease activity between flares. IL-13 levels closely correlate with both disease severity and chronicity, and its direct role in itch signaling makes it a key therapeutic target in AD.Differences among IL-13–directed biologics were reviewed, including dupilumab, which blocks IL-4 and IL-13 signaling via IL-4Rα, and the IL-13 - specific agents tralokinumab and lebrikizumab, which bind distinct sites on the IL-13 cytokine. Notably, lebrikizumab demonstrates substantially higher binding affinity for IL-13 and offers dosing flexibility, with data supporting every-four-week and even extended every-eight-week maintenance dosing in select patients. Age approvals also vary, with dupilumab approved down to infancy, while tralokinumab and lebrikizumab are approved for adolescents and adults.The session addressed real-world management challenges, including treatment switching. Data from the ADapt trial showed that patients discontinuing dupilumab due to ocular or facial adverse events experienced effective disease control after switching to lebrikizumab without recurrence of those side effects. Emerging evidence also suggests JAK inhibitors may be particularly helpful for resolving dupilumab-associated ocular and facial inflammation. Looking ahead, several next-generation IL-13 - targeted therapies, including trispecific agents, are in development, signaling continued refinement of precision therapy in AD. https://dermsquared.com/videos/wch-2026-conference-highlights/the-il-13-story-in-atopic-dermatitis-characterizing-pathways-and-therapeutic-performance 131 2026-02-05T15:10:44.089Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/late-breakers-in-immunobullous-diseases 2026-02-05T15:10:56.443Z https://image.mux.com/4GVsTiRDAZYSuTvrkoI2MX2lriVg02dd5VXtfrog9cyg/thumbnail.jpg Late Breakers in Immunobullous Diseases Matthew Vesely, MD delivered a focused update on the rapidly evolving treatment landscape for immunobullous diseases, emphasizing that bullous pemphigoid (BP) has firmly entered the targeted-therapy era. BP, driven by IgG and IgE autoantibodies against BP180 and BP230, is now treated with biologic agents that more precisely address type 2 inflammation. A major milestone is the FDA approval of dupilumab in June 2025, which blocks IL-4 and IL-13 signaling and achieved disease control in nearly 90% of patients within four weeks. Additional targeted options such as omalizumab, particularly effective in IgE-mediated disease, along with IL-13 inhibitors and JAK inhibitors, are expanding steroid-sparing strategies for BP management.In contrast, pemphigus remains more challenging than anticipated. Rituximab continues to be the cornerstone of therapy, with long-term data confirming superior remission rates compared with corticosteroids alone. Encouraging studies of ultralow-dose rituximab suggest similar efficacy with potentially improved safety. However, the session also addressed recent setbacks, noting the failure of phase 3 trials for efgartigimod and rilzabrutinib, leading to discontinuation of development for pemphigus. Looking ahead, Dr Vesely highlighted emerging precision approaches, including deeper B-cell–directed therapies such as daratumumab and investigational cellular therapies, with the ultimate goal of biomarker-driven maintenance to prevent relapse. While not yet ready for routine practice, these advances signal continued progress toward more personalized care in immunobullous disease. https://dermsquared.com/videos/wch-2026-conference-highlights/late-breakers-in-immunobullous-diseases 150 2026-02-05T15:10:56.436Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/you-lichen-this-management-of-lichenoid-disease-lpp-and-more 2026-02-05T15:11:26.152Z https://image.mux.com/MdOwiKc73AsX9mnKf9SlmjYPEM1hVp92WAWZGU13f3k/thumbnail.jpg You Lichen This? Management of Lichenoid Disease, LPP, and More Daniela Kroshinsky, MD, MPH delivered a comprehensive clinical update on the diagnosis and management of lichenoid diseases, including lichen planus (LP), lichen planus pigmentosus (LPP), and immune checkpoint inhibitor–associated lichenoid eruptions. Dr Kroshinsky reviewed the heterogeneity of LP subtypes and emphasized the importance of evaluating for mucosal involvement, which can occur in a majority of patients with cutaneous disease and may carry risks such as dysphagia, strictures, and squamous cell carcinoma.Systemic treatment options for refractory LP were highlighted, with particular focus on emerging data for Janus kinase (JAK) inhibitors and oral apremilast. Evidence from a systematic review of 56 patients demonstrated that JAK inhibitors produced clinical responses within days to weeks across LP subtypes, though patient selection remains important given reported risks of venous thromboembolism, cardiovascular events, malignancy, and serious infection. A pilot study of apremilast in moderate-to-severe cutaneous LP showed improvement in all treated patients by 12 weeks, with headaches and nausea identified as the most frequent adverse effects. Traditional systemic agents, including cyclosporine, were also reviewed as effective options with rapid onset when appropriately dosed and monitored. Dr Kroshinsky also addressed management strategies for lichenoid eruptions associated with immune checkpoint inhibitors, which can occur in up to 17% of patients receiving immunotherapy. Long-term systemic corticosteroids were discouraged due to potential attenuation of antitumor efficacy, with low-dose methotrexate and systemic retinoids identified as commonly used nonsteroidal maintenance therapies. Emerging biologic options were discussed with emphasis on using the most targeted therapy possible to limit broader immune suppression. The presentation concluded with therapeutic updates for LPP, underscoring the importance of early intervention and reviewing data supporting isotretinoin, oral tranexamic acid, and low-fluence Q-switched Nd:YAG laser toning as treatment options for stable disease. https://dermsquared.com/videos/wch-2026-conference-highlights/you-lichen-this-management-of-lichenoid-disease-lpp-and-more 75 2026-02-05T15:11:26.146Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/new-and-noteworthy-in-psoriasis 2026-02-05T15:08:45.480Z https://image.mux.com/D5KwNwvaKmrLz9I700eAGQ501XDmekRPIPfGCekXsfZ02M/thumbnail.jpg New and Noteworthy in Psoriasis April W. Armstrong, MD, MPH, reviewed major recent developments shaping modern psoriasis management, beginning with the first consensus definition of on-treatment remission established through a Delphi process led by the National Psoriasis Foundation. This consensus defines remission as maintaining BSA 0% or IGA 0 for at least six months, providing a standardized, clinically meaningful target for long-term disease control and a consistent benchmark for evaluating durability across therapies and clinical trials.Dr Armstrong also highlighted emerging oral therapies that are redefining expectations for systemic treatment. Icotrokinra, a novel targeted oral peptide that selectively inhibits IL-23 signaling, demonstrated superior efficacy compared with deucravacitinib in the ICONIC-ADVANCE trials, achieving higher rates of IGA 0/1 and PASI 90 at Weeks 16 and 24. Additional ICONIC data showed robust PASI 90 responses in adults and durable maintenance of PASI 75 and PASI 90 through 52 weeks in adolescents, supporting both potency and durability across age groups. Long-term extension data for the TYK2 inhibitor deucravacitinib demonstrated stable efficacy and a favorable safety profile through five years, including benefit in patients with psoriatic arthritis. Dr Armstrong also reviewed emerging data for highly selective TYK2 inhibitors such as envudeucitinib, which achieved stringent treat-to-target thresholds in a majority of patients at one year. Together, these advances reflect a shift toward precise, durable, and patient-friendly oral therapies that align with newly established remission goals in psoriasis. https://dermsquared.com/videos/wch-2026-conference-highlights/new-and-noteworthy-in-psoriasis 181 2026-02-05T15:08:45.467Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/cutting-edge-practical-tips-for-surgical-management-of-skin-cancer 2026-02-05T15:11:35.624Z https://image.mux.com/J5wHMqHTwC00nWeXCmBNABMKzyjcPUKEhidjU3uisdWk/thumbnail.jpg Cutting Edge: Practical Tips for Surgical Management of Skin Cancer Todd Schlesinger, MD emphasized that optimal reconstruction begins before the first incision, with careful attention to tissue mechanics and wound tension. He highlighted practical techniques such as identifying lines of maximal extensibility rather than relying solely on relaxed skin tension lines, maintaining closure tension below 4 N/cm to prevent hypertrophic scarring, and strategic undermining to preserve perforator vessels. Flap refinements, including the use of M-plasty at pivot points, were presented as effective methods to improve reach and reduce contour deformities, while advanced suturing techniques such as the set-back dermal approach were shown to offload tension and promote durable eversion.The session also addressed situations in which grafts offer advantages over flaps, particularly in cosmetically sensitive areas or medically complex patients. Key pearls included epidermal fenestration to prevent graft lift-off and the use of vacuum-assisted bolsters during the critical first 72 hours to support graft imbibition. Postoperative scar optimization strategies were reviewed, including prolonged taping for mechanical support and proactive counseling that scar maturation may take up to 18 months, helping to align patient expectations with normal wound biology.Beyond reconstruction, Dr Schlesinger stressed the importance of integrated oncologic planning. Surgeons were cautioned against operating first in advanced disease, instead coordinating neoadjuvant systemic therapy or radiation when appropriate and using immunostains for precise melanoma margin assessment. Regulatory updates on skin substitutes and the role of adjuvant photodynamic therapy for surrounding actinic damage further reinforced a comprehensive, multidisciplinary approach to skin cancer management. https://dermsquared.com/videos/wch-2026-conference-highlights/cutting-edge-practical-tips-for-surgical-management-of-skin-cancer 104 2026-02-05T15:11:35.618Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/actinic-keratoses-and-pdt 2026-02-05T15:11:06.691Z https://image.mux.com/Tt7r00kE54orw6701zsPlioNETcpnAsgIXJ4JUnhpxEJk/thumbnail.jpg Actinic Keratoses and PDT Neal Bhatia, MD opened by underscoring the growing global burden of non-melanoma skin cancer (NMSC), which now causes more annual deaths than melanoma. Because the vast majority of invasive squamous cell carcinomas arise from background actinic damage and clinicians cannot predict which individual AK will progress, he emphasized a proactive field-treatment strategy rather than lesion-by-lesion destruction. Advances in topical therapy support this approach, including tirbanibulin 1% ointment, now approved for larger treatment fields and shown to induce apoptosis with less inflammation, and combination calcipotriol plus 5-fluorouracil, which enhances antitumor immunity and significantly lowers long-term SCC risk.Photodynamic therapy (PDT) remains a highly effective field treatment, with pivotal studies of 10% ALA gel plus red light demonstrating durable clearance rates exceeding 80% at 12 months. Expanded FDA approval now allows treatment of larger surface areas with excellent tolerability, and PDT continues to show strong efficacy in facial SCC in situ and superficial basal cell carcinoma. Dr Bhatia addressed common barriers to PDT adoption, particularly treatment-related pain, sharing practical mitigation strategies such as cooling measures, antihistamines, anxiolytics, and emerging short-contact protocols that preserve efficacy while improving patient comfort, especially on the face.The session concluded with pragmatic office pearls, including structuring PDT as a dedicated service line with streamlined scheduling, seasonal timing considerations, and appropriate CPT coding when clinicians directly administer therapy. Dr Bhatia emphasized that when used thoughtfully, PDT is not only an effective AK treatment but also a powerful preventive tool against future skin cancer. https://dermsquared.com/videos/wch-2026-conference-highlights/actinic-keratoses-and-pdt 52 2026-02-05T15:11:06.683Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/advances-and-applications-in-chronic-spontaneous-urticaria-care 2026-02-05T15:08:55.432Z https://image.mux.com/clR3mlkj6gGk97XktexrT4ik3RNRxQ01I1rPTFPLUDsk/thumbnail.jpg Advances and Applications in Chronic Spontaneous Urticaria Care Chronic spontaneous urticaria (CSU) affects up to 80% of patients with chronic urticaria and is defined by recurrent hives and/or angioedema lasting longer than six weeks without an identifiable trigger. Naiem Issa, MD, and Dawn Merritt, DO, reviewed key clinical features, including pruritic wheals and angioedema that often burn and may persist for up to 72 hours. They emphasized use of the 7-Day Urticaria Activity Score (UAS7) as the gold standard for assessing disease severity and treatment response. The presenters also highlighted the autoimmune underpinnings of CSU, driven by both IgE-dependent and IgE-independent mechanisms that activate mast cells and basophils.Management was framed as a clear treatment ladder, starting with second-generation H1 antihistamines and rapid up-dosing when control is inadequate. If symptoms persist after 2–4 weeks, escalation to advanced therapies such as omalizumab, dupilumab, or remibrutinib is recommended, with cyclosporine reserved for refractory disease. Emerging data for dupilumab demonstrated meaningful reductions in itch and hives regardless of baseline IgE, while remibrutinib showed rapid onset of action, with more than half of patients achieving well-controlled disease within three weeks. The session closed with practical pearls: escalate early, continue antihistamines when adding biologics, maintain therapy for 6–12 months after complete clearance, and reassure patients that CSU is not allergy-driven despite common triggers like stress or heat. https://dermsquared.com/videos/wch-2026-conference-highlights/advances-and-applications-in-chronic-spontaneous-urticaria-care 99 2026-02-05T15:08:55.426Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/blister-breakthroughs-emerging-targeted-therapies-for-bullous-pemphigoid 2026-02-05T15:10:23.024Z https://image.mux.com/UfW7raS1sDvm3QjmTlwH72RI66CB9fja3flONr57B6Q/thumbnail.jpg Blister Breakthroughs: Emerging Targeted Therapies for Bullous Pemphigoid Prince Adotama, MD and Mark Lebwohl, MD provided a comprehensive update on bullous pemphigoid (BP), a rare autoimmune blistering disease that predominantly affects older adults. They reviewed the underlying pathophysiology, in which autoantibodies against BP180 and BP230 disrupt dermal–epidermal adhesion and trigger a robust inflammatory cascade involving eosinophils, neutrophils, and Th2 cytokines such as IL-4 and IL-13. Disease severity closely correlates with elevated IgE levels and eosinophilia, helping explain the intense pruritus and blister formation seen in affected patients. The presenters emphasized that BP often presents atypically, with more than half of patients initially developing nonbullous eczematous or urticarial lesions, underscoring the need for heightened diagnostic suspicion.The session also highlighted growing awareness of drug-induced BP, with more than 50 medications implicated. Notably, DPP4 inhibitors used in type 2 diabetes are associated with a threefold increased risk, and immune checkpoint inhibitors have also been linked to disease onset. While traditional management still includes high-potency topical steroids and short-term systemic corticosteroids with immunomodulators, the treatment landscape is rapidly changing. Dupilumab, approved in June 2025 for adult BP, has demonstrated rapid disease control in the majority of patients, with a favorable safety profile and significant steroid-sparing benefits. Additional targeted options, including omalizumab and rituximab, have shown strong efficacy in selected patients, particularly those with high IgE levels or refractory disease.Overall, the presenters emphasized that targeted biologic therapies are transforming BP care by improving disease control while minimizing the long-term risks of systemic corticosteroids. This shift marks a new era in BP management, prioritizing precision therapy, safety, and durable remission in a vulnerable patient population. https://dermsquared.com/videos/wch-2026-conference-highlights/blister-breakthroughs-emerging-targeted-therapies-for-bullous-pemphigoid 132 2026-02-05T15:10:23.016Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/coding-like-a-pro 2026-02-05T15:11:58.106Z https://image.mux.com/jKGrB02dIc2Jq3dxs4oEKZasWJfkBheMm3FLwF8teuOQ/thumbnail.jpg Coding Like a Pro Mark D. Kaufmann, MD delivered a detailed analysis of the economic realities facing dermatology in 2026, focusing on reimbursement trends, inflation, and key CPT coding updates that directly affect clinical practice. Dr Kaufmann emphasized that although demand for dermatologic care continues to grow, declining Medicare reimbursement, particularly when adjusted for inflation, represents one of the most significant threats to the sustainability of independent practices.A central theme of the presentation was the long-term erosion of physician payment. Dr Kaufmann reviewed data showing that the Medicare physician conversion factor in 2026 remains lower than levels seen more than two decades ago, translating to a substantial inflation-adjusted decrease in reimbursement. He highlighted how common dermatologic procedures, including Mohs surgery and destruction of premalignant lesions, have experienced significant real-dollar payment declines over time. The presentation also outlined important 2026 coding updates, including the removal of the term “acne surgery” in favor of CPT 10040 for extractions, new restrictions on ultrasound image guidance billing for superficial radiation therapy, and updated payment rates for skin substitute products. Utilization challenges were also discussed, including overestimation of the complexity add-on code G2211.Dr Kaufmann concluded by emphasizing that while the need for high-quality dermatologic care will persist, practice models must evolve to remain financially viable. He encouraged clinicians to move beyond basic billing practices by fully understanding the fee schedule, appropriately applying complexity codes when assuming ongoing care, and leveraging medical billing strategies such as buy-and-bill models to help offset continued reimbursement pressure. https://dermsquared.com/videos/wch-2026-conference-highlights/coding-like-a-pro 39 2026-02-05T15:11:58.100Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/mission-possible-managing-scarring-alopecia 2026-02-05T15:09:44.266Z https://image.mux.com/TzslUGpQ2luoAV00lgaf01zVffmBquSesGQwJzQpYZWzU/thumbnail.jpg Mission Possible? Managing Scarring Alopecia Jerry Shapiro, MD provided a clinical deep dive into cicatricial (scarring) alopecias, underscoring the critical distinction between scarring and non-scarring hair loss: once follicles are destroyed, regrowth is no longer possible. He emphasized the importance of early recognition and aggressive intervention to prevent permanent hair loss. Advanced diagnostic tools were highlighted, including trichoscopy to identify hallmark features such as loss of follicular ostia, perifollicular scale, and blue-grey dots, as well as AI-driven trichometric analysis (HairMetrix) to objectively measure disease progression and guide individualized treatment plans.The session reviewed key lymphocytic scarring alopecias, including lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and central centrifugal cicatricial alopecia (CCCA). Treatment algorithms for LPP incorporate intralesional triamcinolone acetonide, combination topical therapies, and systemic agents including JAK inhibitors. In FFA, which predominantly affects postmenopausal women and frequently involves eyebrow loss, Dr Shapiro discussed data linking certain sunscreens and moisturizers to increased risk and advised mineral-based alternatives. Facial papules associated with FFA were shown to respond well to oral isotretinoin. For CCCA, emerging data on topical and low-dose oral metformin demonstrated improvement in fibrosis by downregulating profibrotic gene pathways, representing a promising therapeutic advance.Neutrophilic scarring alopecias, including folliculitis decalvans and dissecting cellulitis, were also addressed, with refractory cases responding to biologics such as adalimumab or baricitinib. Practical pearls included the use of low-dose doxycycline to reduce inflammation with fewer gastrointestinal side effects, adjusting intralesional steroid concentrations based on scalp location, and monitoring for rare complications such as central serous chorioretinopathy following steroid injections. Dr Shapiro concluded by cautioning that hair transplantation should only be considered after more than two years of disease quiescence to avoid disease reactivation, reinforcing that in scarring alopecia, success hinges on stopping progression early rather than restoring lost hair. https://dermsquared.com/videos/wch-2026-conference-highlights/mission-possible-managing-scarring-alopecia 155 2026-02-05T15:09:44.260Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/chronic-hand-eczema-check-in-latest-treatments-for-troubled-hands 2026-02-05T15:10:33.838Z https://image.mux.com/RtQpLBUqA02giao01hHu9vv8igtdk9ccBH6rjADgYvN7c/thumbnail.jpg Chronic Hand Eczema Check-In: Latest Treatments for Troubled Hands Alexandra Golant, MD and E. James Song, MD reviewed chronic hand eczema (CHE) as a heterogeneous and often refractory condition, defined by disease lasting longer than three months or recurring multiple times within a year. They emphasized that CHE is frequently multifactorial, with nearly half of patients exhibiting overlapping subtypes such as atopic and irritant contact dermatitis. Despite varied clinical presentations, inflammation across CHE subtypes is largely driven by cytokines signaling through the JAK-STAT pathway, helping explain the chronicity and treatment resistance seen in many patients.Accurate diagnosis remains essential and includes distinguishing etiologic subtypes from clinical morphologies, along with routine consideration of patch testing to identify relevant allergens. However, the presenters noted that allergen avoidance alone often provides incomplete relief, underscoring the need for more effective therapies. A major advance discussed was the approval of delgocitinib 2% cream in 2025, a topical pan-JAK inhibitor for adults with moderate-to-severe CHE inadequately controlled with topical corticosteroids. Data from the DELTA trials demonstrated significant improvements in skin clearance, itch, and pain across multiple CHE subtypes, including hyperkeratotic disease, with minimal systemic absorption and a favorable safety profile.Additional emerging options were also reviewed, including topical ruxolitinib for rapid itch reduction, biologics such as dupilumab and tralokinumab for atopic-driven disease, and investigational oral agents like abrocitinib and roflumilast. The session concluded with practical management pearls, emphasizing the limitations of long-term topical corticosteroid use and the importance of individualized, subtype-driven treatment strategies to achieve durable control and improved hand function. https://dermsquared.com/videos/wch-2026-conference-highlights/chronic-hand-eczema-check-in-latest-treatments-for-troubled-hands 130 2026-02-05T15:10:33.828Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/updates-in-sunscreens-and-other-photoprotection 2026-02-05T15:12:09.789Z https://image.mux.com/ckuKwjw5bInvJxwLIEOM6PbSwQtPd7PX9sGet9ZnBlg/thumbnail.jpg Updates in Sunscreens and Other Photoprotection Roger I. Ceilley, MD presented an update on advances in sunscreen technology, focusing on emerging strategies that go beyond ultraviolet (UV) blocking to address cumulative photodamage. Dr Ceilley reviewed data from a 12-week clinical study evaluating a tinted mineral-based SPF50 sunscreen formulated with photolyase, antioxidants, and peptides, highlighting the concept of combining photoprotection with active DNA repair support in daily practice.The pilot study included 20 adults with Fitzpatrick skin types II–IV who applied the sunscreen daily for 12 weeks. Investigator assessments demonstrated progressive aesthetic improvement, with over half of participants showing improvement by Week 6 and more than 80% by Week 12 based on the Investigator Global Aesthetic Improvement Scale. Patient-reported outcomes mirrored these findings, with a majority reporting improved skin appearance over the study period. Statistically significant improvements were also observed in skin radiance, overall facial aesthetics, and skintone evenness, as measured by standardized grading scales.Dr Ceilley emphasized that while endogenous DNA repair mechanisms exist, they may be insufficient to fully counteract ongoing UV exposure. The study supports the role of sunscreens that incorporate photolyase, antioxidants, and peptides as well-tolerated daily options that both protect against UV radiation and address visible signs of photoaging. These findings highlight an evolving approach to photoprotection that integrates prevention and repair within a single topical formulation. https://dermsquared.com/videos/wch-2026-conference-highlights/updates-in-sunscreens-and-other-photoprotection 103 2026-02-05T15:12:09.784Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/approach-to-challenging-cases-in-hs 2026-02-05T15:11:16.417Z https://image.mux.com/S6rAuKzjLnouyvdMyiIynWhZ67JdEOAqllblch4YEuM/thumbnail.jpg Approach to Challenging Cases in HS Hadar Lev-Tov, MD reframed the management of severe hidradenitis suppurativa (HS) by cautioning against the common “beginner error” of relying on single-agent therapy. HS is a multifactorial disease driven by follicular occlusion, rupture, chronic inflammation, and sinus tract formation, requiring clinicians to address multiple disease drivers simultaneously. Effective management often involves combination therapy that integrates medical treatments such as antibiotics, biologics, and hormonal agents with procedural interventions, intralesional steroids, antiseptic washes, and laser or surgical approaches to achieve meaningful disease control.For patients with Hurley stage II or III disease, Dr Lev-Tov highlighted the role of specialized inpatient care to disrupt the vicious cycle of recurrent flares and emergency department visits. Data demonstrate that dermatology-led admissions significantly reduce length of stay compared with internal medicine services and facilitate earlier initiation of biologic therapy after discharge. He also stressed the importance of correctly defining disease flares, noting that true flares represent measurable increases in inflammatory lesions rather than slow or incomplete response to therapy, and emphasized setting realistic expectations and appropriate follow-up intervals early in care.Procedural excellence was highlighted with deroofing as a tissue-sparing option for selected lesions, showing high patient satisfaction and durable non-recurrence rates. Additional considerations included addressing patient-driven dietary modifications, acknowledging limited HS-specific evidence, and incorporating clinical trial enrollment early in the treatment course. Dr Lev-Tov concluded that successful HS management requires coordinated, aggressive, and individualized care to achieve durable improvement in this challenging patient population. https://dermsquared.com/videos/wch-2026-conference-highlights/approach-to-challenging-cases-in-hs 111 2026-02-05T15:11:16.410Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/cutaneous-lupus-erythematosus-story-dermatologists-need-to-know 2026-02-05T15:09:53.530Z https://image.mux.com/54ZZkaSPF02X700hYGRBoKOdYioziH2EuMyNsFVTu801CA/thumbnail.jpg Not Just Skin Deep: The Cutaneous Lupus Erythematosus Story Dermatologists Need to Know Scott Elman, MD and Joseph F. Merola, MD emphasized that cutaneous lupus erythematosus (CLE) should not be viewed simply as “systemic lupus of the skin,” as many CLE subtypes have distinct pathogenesis, clinical courses, and treatment needs. They reviewed the major CLE subtypes—acute (ACLE), subacute (SCLE), and chronic (CCLE), including discoid lupus and lupus profundus—and highlighted the wide variability in systemic lupus overlap, ranging from more than 90% in ACLE to approximately 5% in localized discoid disease. Despite this heterogeneity, CLE carries a profound disease burden, with quality-of-life impairment comparable to or worse than major systemic medical conditions.The presenters stressed the importance of structured monitoring to detect evolving systemic disease, introducing the practical “LABS FOR SLE” mnemonic to guide routine evaluation. Treatment was framed as a rapidly evolving ladder, moving well beyond antimalarials alone. While methotrexate and mycophenolate remain important second-line options, newer targeted therapies are reshaping CLE management. Anifrolumab has demonstrated sustained improvements in skin disease by blocking type I interferon signaling, while emerging agents such as litifilimab, deucravacitinib, and enpatoran offer promising, more precise immune modulation with encouraging skin-specific outcomes.The session concluded with a call for strategic, multidisciplinary care. Treatment selection should be guided by comorbidities, systemic involvement, and patient-specific goals, with close collaboration between dermatology and rheumatology to address both systemic risk and skin-driven morbidity such as scarring and dyspigmentation. Drs Elman and Merola reinforced that with growing therapeutic options and better disease understanding, dermatologists are uniquely positioned to lead the comprehensive care of patients with CLE. https://dermsquared.com/videos/wch-2026-conference-highlights/cutaneous-lupus-erythematosus-story-dermatologists-need-to-know 203 2026-02-05T15:09:53.521Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/beyond-metrocream-and-doxycycline-up-your-game-in-rosacea-treatment 2026-02-05T15:10:14.602Z https://image.mux.com/VyV1qeD3I9yYdvSiYi1ojR01E802UAT86pTWpa00Ohs5OI/thumbnail.jpg Beyond Metrocream and Doxycycline: Up your Game in Rosacea Treatment Linda Stein Gold, MD reframed rosacea management using the ROSCO 2019 feature-based treatment algorithm, which moves away from traditional subtyping and instead targets individual clinical features. Persistent facial erythema is best addressed with optimized skincare, α-adrenergic agents, or devices, while inflammatory papules and pustules are treated with targeted topical therapies such as ivermectin, azelaic acid, or metronidazole, and systemic agents including doxycycline or isotretinoin. Telangiectasias typically require procedural intervention, and phymatous changes may respond to isotretinoin when inflamed or surgical management when fibrotic.Advances in erythema control were highlighted with α-adrenergic agonists brimonidine and oxymetazoline, both shown to significantly reduce background redness, with practical tips to minimize irritation through conservative dosing. For papulopustular rosacea, Dr Stein Gold emphasized that tetracyclines act through anti-inflammatory rather than antimicrobial effects, paving the way for non-antibiotic formulations. Promising therapies included low-dose extended-release minocycline (DFD-29), which demonstrated early efficacy without disrupting the microbiome, and microencapsulated benzoyl peroxide, designed to reduce irritation while maintaining efficacy. Topical ivermectin was highlighted for its dual anti-inflammatory and anti-parasitic activity and superior performance compared with metronidazole.The session underscored the importance of aiming for complete clearance (IGA 0), as patients who achieve “clear” disease experience longer remission than those who are only “almost clear.” Dr Stein Gold also flagged emerging safety considerations, noting reports of rosacea fulminans and acneiform eruptions following initiation of TYK2 inhibitors in patients with underlying rosacea. Overall, the presentation reinforced that precision, patience, and feature-driven therapy are key to achieving durable rosacea control. https://dermsquared.com/videos/wch-2026-conference-highlights/beyond-metrocream-and-doxycycline-up-your-game-in-rosacea-treatment 66 2026-02-05T15:10:14.592Z yes https://dermsquared.com/videos/wch-2026-conference-highlights/modern-approaches-to-treating-melasma 2026-02-05T15:09:33.676Z https://image.mux.com/LHT1uWVmUm4Vy78Wi01qPv00wAKPFVpaZUtLS3qv007His/thumbnail.jpg Modern Approaches to Treating Melasma Susan C. Taylor, MD, presented a comprehensive update on contemporary melasma management, emphasizing evolving concepts in pathogenesis and evidence-based treatment strategies. Dr Taylor reviewed the growing understanding that melasma is a multifactorial disorder driven by ultraviolet and visible light exposure, epidermal melanocyte activation, and clinically relevant vascular component characterized by increased vessel number, density, and angiogenesis. These mechanisms help explain disease chronicity, relapse, and treatment A central focus of the presentation was the international Delphi consensus on melasma management, developed by 38 experts from 11 countries to standardize diagnosis, monitoring, and treatment. The consensus identified Wood’s lamp examination as a favored method for assessing extent and severity, with dermoscopy accepted for differential diagnosis. Photoprotection was emphasized as foundational therapy, with the “ideal” sunscreen providing protection against UVA, UVB, and visible light, and optional inclusion of antioxidants or depigmenting agents to enhance efficacy. For treatment, triple-combination therapy with hydroquinone, tretinoin, and fluocinolone acetonide was reaffirmed as the gold-standard first-line option for moderate-to-severe melasma, while azelaic acid, antioxidants, and non-hydroquinone agents were highlighted as alternatives or maintenance options. Oral tranexamic acid, chemical peels, microneedling, and energy-based devices were reserved for refractory disease within a stepwise algorithm. Dr Taylor also reviewed comparative clinical trial data for newer non-hydroquinone therapies. A randomized non-inferiority trial demonstrated that a 2-Mercaptonicotinoyl Glycine–containing serum achieved similar improvements in mMASI compared with hydroquinone 4%, with fewer local reactions. Additional studies showed that thiamidol and topical metformin produced MASI reductions comparable to hydroquinone-based regimens, supporting their role as effective alternatives in select patients. Collectively, the data reinforce a modern treatment framework that combines standardized photoprotection, targeted topical therapy, and vascular-directed interventions to address both pigment production and relapse risk in melasma. https://dermsquared.com/videos/wch-2026-conference-highlights/modern-approaches-to-treating-melasma 64 2026-02-05T15:09:33.669Z yes https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-2-video-recap 2026-03-10T13:50:53.129Z https://image.mux.com/TLEZH1ti9NngUdAdt1s800oC8u01HGF7WtSESnyyk02uP8/thumbnail.jpg WCM26 Day 2 Video Recap Steven Daveluy, MD, James Q. Del Rosso, DO and Andrea T. Murina, MD provided a clinically focused update on hidradenitis suppurativa, emphasizing early intervention, integration of biologic and procedural therapies, and emerging targeted treatments.Shawn Kwatra, MD and Dawn Merritt, DO provided a clinically focused update on chronic spontaneous urticaria, reviewing autoimmune mechanisms, stepwise treatment strategies, and emerging biologic and BTK-targeted therapies. https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-2-video-recap 203 2026-03-10T13:50:53.124Z yes https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-1-video-recap 2026-03-10T13:50:40.026Z https://image.mux.com/Gl4Y3NsPKO602SpJ5VnpsPIIjPoszFY8vNlklmT0001PvU/thumbnail.jpg WCM26 Day 1 Video Recap Mona Shahriari, MD and Susan C. Taylor, MD presented a visual and clinically focused guide to diagnosing prurigo nodularis in skin of color, highlighting its neuroimmune pathophysiology, disproportionate disease burden, distinct clinical features in melanin-rich skin, and the rapid, durable efficacy of newly approved targeted biologics.Raj Chovatiya, MD, PhD and Mona Shahriari, MD presented an interactive, case-based session focused on optimizing atopic dermatitis treatment through mechanism-driven biologic selection, individualized dosing strategies, and practical management of real-world clinical challenges. https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-1-video-recap 136 2026-03-10T13:50:35.275Z yes https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-3-video-recap 2026-03-10T13:51:03.753Z https://image.mux.com/sfTcReyGCBdVwk02Hy2FE021M00FAkAt02iLTGqsFuWQYRo/thumbnail.jpg WCM26 Day 3 Video Recap Final day highlights from Miami! Our Day 3 recap video captures the closing masterclasses, final clinical pearls, and the community connections that defined our last day in Miami. https://dermsquared.com/videos/wcm-2026-conference-video-highlights/wcm-26-day-3-video-recap 73 2026-03-10T13:51:03.748Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp-25-whats-new-in-the-medicine-chest 2025-06-02T15:10:36.118Z https://image.mux.com/OpnqXJ3wJqnbKAMK37z9Klt5GYTsm8TDvOxGqU2MJv4/thumbnail.jpg FCPANP25 What’s New in the Medicine Chest James Del Rosso, DO, lit up the room with a rapid-fire tour of dermatology’s hottest updates, spanning acne, inflammatory skin conditions, and skin cancer. He kicked things off with tirbanibulin, now approved for large-field treatment of actinic keratosis (up to 100 cm²), then explored the latest updates on atopic dermatitis, highlighting long-term data on dupilumab (including re-initiation after discontinuation), and shared exciting efficacy results from IL-13 inhibitors tralokinumab and lebrikizumab, as well as JAK inhibitors upadacitinib and abrocitinib. Next up: alopecia areata—where Dr Del Rosso showcased groundbreaking data on deuruxolitinib, baricitinib, and ritlecitinib, while urging providers to look beyond the SALT score and focus on patient-centered outcomes. He maintained the momentum with an update on hidradenitis suppurativa (HS), highlighting emerging insights into risk factors and disease mechanisms, as well as recent advances in treatment. These include FDA-approved monoclonal antibody therapies such as the IL-17 inhibitors secukinumab and bimekizumab, along with the investigational JAK1 inhibitor povorcitinib, which is currently in Phase 3 trials for moderate to severe HS. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp-25-whats-new-in-the-medicine-chest 157 2025-06-02T15:10:36.110Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-cme-satellite-symposium-chronic-spontaneous-urticaria 2025-06-02T15:10:06.746Z https://image.mux.com/9L9Dd7clO76Oki00Ol00cnZlGDIM4011DxZyP016q5NfNxQ/thumbnail.jpg FCPANP25 CME Satellite Symposium: Chronic Spontaneous Urticaria Jason Hawkes, MD, MS, FAAD, and Kristin Sokol, MD, MS, MPH, delivered a comprehensive review of chronic spontaneous urticaria (CSU), covering everything a dermatology provider needs to know—from diagnosis to emerging treatments. They defined CSU as chronic urticaria lasting more than six weeks, without an identifiable trigger, and characterized by wheals that typically resolve within 24 hours. The speakers discussed the latest clinical efficacy data on new and emerging CSU therapies, offered strategies for managing associated safety concerns, and provided guidance on personalizing treatment plans. The presentation reviewed the stepwise treatment approach to CSU developed as a joint initiative from allergy and dermatology organizations, which recommends beginning with second-generation antihistamines and progressing to omalizumab and cyclosporine, with omalizumab receiving the highest recommendation based on robust evidence. A meta-analysis of 67 real-world studies found no cases of anaphylaxis in omalizumab-treated CSU patients, with common adverse effects limited to headache, nasopharyngitis, and arthralgia. The lecture continued to discuss newly approved FDA therapies such as dupilumab, shown effective in the Phase 3 LIBERTY-CUPID Study C. Lastly, the lecture covered new CSU investigational medications such as remibrutinib, a highly selective BTK inhibitor supported by the REMIX-1 and -2 trials, along with several other agents currently in clinical trials. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-cme-satellite-symposium-chronic-spontaneous-urticaria 236 2025-06-02T15:10:06.739Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/oldies-but-goodies-systemic-when-and-if-to-use 2025-06-02T15:10:46.213Z https://image.mux.com/2i37tcCrnIKfsIpu1029L5h54mpGf4QyQvi2XkJRyCi00/thumbnail.jpg Oldies But Goodies: Systemic, When and If to Use While dermatology continues to evolve with cutting-edge therapies, Kristien Kucera, PA-C reminded us that the “oldies but goodies”—methotrexate (MTX), cyclosporine, and acitretin—still hold an essential place in clinical practice. She delivered a thorough, practical review of each medication’s mechanism of action, efficacy, contraindications, adverse effects, and monitoring protocols. For MTX, she detailed its historical background, dosing strategies, use of test doses, folic acid supplementation, baseline and ongoing lab work, and critical drug interactions that increase toxicity risk. Cyclosporine was reviewed with equal depth, including its transition from transplant medicine to dermatology. Acitretin’s use was discussed with attention to dosing nuances, teratogenic risks, and long-term safety. This session offered a high-yield refresher on integrating these time-tested agents into modern dermatologic care. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/oldies-but-goodies-systemic-when-and-if-to-use 73 2025-06-02T15:10:46.207Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/seminar-in-depth-the-clinician-s-case-based-guide-to-gene-expression-profiling-in-skin 2025-06-02T15:10:31.403Z https://image.mux.com/F6vfii025IH01WFON5qBlEIykojYsJh442fTCoasJq9q8/thumbnail.jpg Seminar-in-Depth: The Clinician’s Case-Based Guide to Gene Expression Profiling in Skin In this dynamic session, Harrison Nguyen, MD, and Darrell S. Rigel, MD, MS, walked the audience through the latest in personalized skin cancer management using the 31-GEP test for melanoma and 40-GEP test for cutaneous squamous cell carcinoma. Through real-world cases, they demonstrated how GEP testing provides powerful, guideline-informed insights—independent of traditional tumor features—to refine prognosis and guide treatment. The 31-GEP test, validated for Stage I–III melanoma, offers a 5-year recurrence risk based on 31 gene expressions, while the 40-GEP test stratifies SCC patients into risk classes that help predict both metastatic potential and the potential benefit from adjuvant radiation. Attendees also learned that patient enthusiasm for this testing is high—90% express a desire for it, and those who receive results, even high-risk ones, report no decision regret. This lecture offered valuable, clinically applicable insights into the evolving role of molecular diagnostics in dermatologic oncology. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/seminar-in-depth-the-clinician-s-case-based-guide-to-gene-expression-profiling-in-skin 327 2025-06-02T15:10:31.396Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/top-psychologically-informed-tips-to-maximize-practice-efficiency 2025-06-02T15:24:16.890Z https://image.mux.com/rVlrTtaPliAxsqgs73QDORYUoRiaUYQyJ5bEbaPk00q4/thumbnail.jpg Top Psychologically Informed Tips to Maximize Practice Efficiency In this insightful lecture, Evan Rieder, MD, dual board-certified in dermatology and psychiatry, shared practical, psychologically informed tips to help dermatologists navigate some of the most complex patient encounters. From setting time boundaries and regaining control of talkative patients, to recognizing when a mental health referral is needed, Dr Rieder broke down real-world strategies that enhance clinic efficiency and safeguard both patient and provider. He highlighted tools like “verbal valium” (breathing techniques, guided imagery, ASMR), emphasized the importance of screening for body dysmorphic disorder, and encouraged attendees to know their limits, offering guidance on when to ask for help or even resign from care. This talk reminded the audience that some of the hardest dermatology cases go beyond making a difficult diagnosis, and that effectively utilizing psychiatric principles in practice can improve patient care. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/top-psychologically-informed-tips-to-maximize-practice-efficiency 103 2025-06-02T15:10:26.557Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/aprep-psoriatic-disease-workshop 2025-06-02T15:10:18.956Z https://image.mux.com/QscESsDcDxxhgbLXBASgStJjRFeyEwRBBfNt2jaKCEw/thumbnail.jpg A-PReP Psoriatic Disease Workshop In this workshop on psoriasis, Lauren Miller, PA-C, and TJ Chao, PA-C, collaborated with the National Psoriasis Foundation to deliver an informative and engaging session covering the full spectrum of psoriasis care. The session began with an in-depth overview of the diagnosis of psoriasis. The presenters discussed the pathogenesis of the disease, emphasizing the role of genetic and environmental triggers in activating the Th17/IL-23 inflammatory pathway. They highlighted the significant burden of disease, affecting over 8 million people in the United States and 125 million worldwide. The workshop explored common comorbidities such as psoriatic arthritis, underscoring the importance of early recognition and management. After a brief intermission, the session resumed with a review of current treatment modalities and clinical guidelines for screening and treatment. Attendees were guided through illustrative case studies and clinical examples showcasing the diverse phenotypes of psoriasis, including scalp, inverse, guttate, erythrodermic, pustular, palmar/plantar, nail, and genital psoriasis. This comprehensive session provided attendees with practical tools and insights to better manage patients with psoriasis in clinical practice. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/aprep-psoriatic-disease-workshop 79 2025-06-02T15:10:18.935Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-aesthetics-workshop 2025-06-02T15:10:10.484Z https://image.mux.com/IfXcCNZqU4NmOoCXwW202BjUFglsUHfN6z013qe3dcLH00/thumbnail.jpg FCPANP25 Aesthetics Workshop The aesthetics workshop was a highlight of the conference, thanks to the dynamic trio of Heather Gates, PA-C, Tanya Patron, PA-C, and Gary Rubin, PA-C. Their expert-led sessions seamlessly blended informative lectures with live patient demonstrations, offering attendees a practical and engaging experience in aesthetic dermatology.Tanya Patron, PA-C, opened the workshop with a comprehensive session on the nonsurgical nose job. She expertly reviewed nasal anatomy, emphasizing critical vascular structures to avoid, and addressed one of the most serious risks of nasal filler—filler-associated blindness. Her thoughtful discussion included both prevention strategies and management techniques. Tanya also shared key pearls on achieving optimal technique, followed by examples that showcased the precision and artistry required for safe, effective results.Next, Gary Rubin, PA-C, delivered an in-depth dive into filler rheology—the study of how dermal fillers deform and flow based on their viscoelasticity and cohesivity, providing injectors with a deeper understanding of how different fillers behave and perform within facial tissues. He broke down complex concepts such as concentration, water affinity, cohesivity, G prime (G'), crosslinking, viscosity, and tan delta. Attendees walked away with a better understanding of how these properties impact filler performance and how to use this knowledge to make strategic product choices for optimal results.Heather Gates, PA-C, then took the stage to address neuromodulator complications. Her session covered recognition and management of challenging outcomes such as paradoxical masseteric bulging, lip ptosis, anisocoria, and eyelid ptosis. Her practical tips and clear explanations empowered attendees to practice more safely and confidently. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-aesthetics-workshop 295 2025-06-02T15:10:10.468Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/therapeutic-pearls-fcpanp25 2025-06-02T15:10:51.101Z https://image.mux.com/DOhJMUiKXDmyVJv2U2kSXGo5l2SsnhZHxd7bqMYVAFE/thumbnail.jpg Therapeutic Pearls FCPANP25 Mark Lebwohl, MD, delivered a highly anticipated, high-yield presentation packed with clinical pearls and cutting-edge data. He began by highlighting new data on emerging treatments for basal cell carcinoma, including research on the use of L-carnitine to reduce muscle cramps in patients taking vismodegib. Dr Lebwohl then transitioned to psoriasis, discussing new guidelines from the Medical Board of the National Psoriasis Foundation. These guidelines offer crucial direction for clinicians on whether to pause specific systemic immunomodulatory therapies in patients with psoriasis and psoriatic arthritis undergoing procedures. He went on to cover other essential regulatory updates related to the increasing use of immunomodulatory agents in dermatology, including the important issue of live vaccine administration in these patients. On the topic of vaccinations, Dr Lebwohl delved into timely discussions around herpes zoster vaccination, the elevated risk of herpes zoster among older patients with immune-mediated diseases, COVID-19 vaccination considerations in patients with psoriasis, and broader vaccination recommendations for adults receiving biologic and oral therapies for psoriasis. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/therapeutic-pearls-fcpanp25 112 2025-06-02T15:10:51.095Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/immunology-101-the-pathways-driving-dermatologic-therapies 2025-06-02T15:10:41.571Z https://image.mux.com/7J7rA31aIhJDHt6eu02c8Z5a6WgZXCALNS3tvGVQkYjA/thumbnail.jpg Immunology 101: The Pathways Driving Dermatologic Therapies Immunology plays a significant role in dermatology, helping clinicians understand the mechanisms underlying many skin conditions and supporting the use of targeted cytokine therapies. In this lecture, Jason Hawkes, MD, MS, FAAD, shared a wealth of information to help dermatology providers learn and review the complex immunologic processes relevant to clinical practice. He offered clear explanations and illustrative diagrams of immune system pathways, while drawing clinical connections to conditions such as acne, atopic dermatitis, psoriasis, generalized pustular psoriasis, and chronic spontaneous urticaria. Dr Hawkes also demonstrated how many of the latest treatments fit into these pathways, making the content both accessible and directly applicable to patient care. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/immunology-101-the-pathways-driving-dermatologic-therapies 121 2025-06-02T15:10:41.566Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-surgical-workshop 2025-06-02T15:10:14.361Z https://image.mux.com/l100UC02csNNgHxSH02UpWF9rjDvJeXaRvFGG024oq02Azlk/thumbnail.jpg FCPANP25 Surgical Workshop Tristan Hasbargen, PA-C, delivered an engaging and highly practical workshop and lecture on essential surgical dermatology skills, guiding attendees through biopsy techniques, scalpel and suture selection, incision and drainage tips, excision methods, and suturing approaches with a focus on avoiding common pitfalls and maximizing clinical success. Through clear, step-by-step diagrams and real-case visuals, he demystified punch sizes, suture types, and flap techniques—including advancement, rotation, and transposition flaps—offering not just the "how," but the "why" behind each choice. Attendees walked away with a toolkit of surgical pearls, visual demonstrations, and a deeper understanding of when and how to apply these skills for optimal outcomes. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/fcpanp25-surgical-workshop 96 2025-06-02T15:10:14.354Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/why-you-should-check-out-the-spot-check-podcast 2025-09-23T19:10:58.080Z https://image.mux.com/WK0018QpPZVy00UaFS65IbLXqw029yVlA1xVb4ol1O4Ras/thumbnail.jpg Why you should check out The Spot Check Podcast! Why you should check out The Spot Check Podcast! https://dermsquared.com/videos/fcpanp-2025-conference-highlights/why-you-should-check-out-the-spot-check-podcast 223 2025-09-23T19:10:58.072Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/how-to-be-an-hs-hero 2025-06-02T15:24:38.088Z https://image.mux.com/dTeXH99yy7dmp4GX1pnU00qSxf01roFTYD02l2T8FiyE01E/thumbnail.jpg How to be an HS Hero Hidradenitis suppurativa (HS) remains one of the most challenging conditions in dermatology—not just clinically, but in its profound impact on patients’ physical, emotional, and social well-being. Curtis Chen, PA-C shared practical strategies for improving care, including how to navigate tough conversations around weight loss, fertility, and the often-asked question of whether HS can be cured. He also showcased impressive clinical outcomes using deroofing, offering both hope and real-world clinical insight. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/how-to-be-an-hs-hero 83 2025-06-02T15:11:04.507Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/drug-induced-skin-disorders 2025-06-02T15:23:53.938Z https://image.mux.com/00600YGTf0102G5MkZmrJngZTtcpsNkdeMMZLjsorO6Ze02k/thumbnail.jpg Drug Induced Skin Disorders Dr Scott Jackson explored how common medications can lead to protean cutaneous morphologies, often mimicking different skin diseases. He highlighted some of the most-talked-about drug-induced cutaneous disorders and provided some classical and some surprising associations. The session began with a discussion of drug-induced dermatomyositis (DM), which has been associated with hydroxyurea, immune checkpoint inhibitors, and statins. Statins received particular attention. Although typically used to lower cholesterol through inhibition of HMG-CoA reductase, statin exposure can trigger an autoimmune response, leading to the production of anti–HMGCR antibodies. These antibodies target muscle tissue, resulting in necrotizing autoimmune myositis and a cutaneous eruption that overlaps with features of DM.Next, Dr Jackson covered drug-induced cutaneous lupus (DI-SCLE). Over the past decade, several medications have been implicated, including anti-TNF alpha agents, immune checkpoint inhibitors, and proton pump inhibitors (PPIs). Notably, PPIs have been increasingly linked to a wide range of cutaneous reactions, from fixed drug eruptions to acute generalized exanthematous pustulosis (AGEP).He then discussed drug-induced asteatosis and eczematous dermatoses, citing associations between statins and diuretics with xerosis cutis, amlodipine with stasis dermatitis, calcium channel blockers with eczema, statins with eczematous dermatitis, and IVIG with dyshidrotic eczema. The lecture continued with an overview of drug associations with psoriasiform dermatitis and drug-induced psoriasis, including lithium, antimalarials, oral and topical beta-blockers, terbinafine, and, more recently, checkpoint inhibitors, TNF–alpha inhibitors, and bupropion. Dr Jackson also addressed drug-induced alopecia areata (DI-AA) associated with some of the most common monoclonal antibody therapies in dermatology. Drug-induced bullous pemphigoid (DI-BP) was another major topic. In one retrospective review, 20% of BP cases were drug-induced. Suspected culprits were dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors), furosemide, monoclonal antibodies used for psoriasis, and immune checkpoint inhibitors. The lecture concluded with a comprehensive review of other drug-related dermatologic conditions, including fixed drug and food eruptions, lichenoid drug eruptions, drug-induced pseudo-lymphoma, pseudo-porphyria, DRESS syndrome, drug-induced vascular disorders, and drug-induced delusional parasitosis. Overall, through his lecture Dr Jackson emphasized the importance of maintaining a high index of suspicion for drug-induced causes when evaluating dermatologic conditions. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/drug-induced-skin-disorders 45 2025-06-02T15:11:09.095Z yes https://dermsquared.com/videos/fcpanp-2025-conference-highlights/acne-across-all-ages-treating-pediatric-adult-and-hormonal-acne 2025-06-02T15:11:00.455Z https://image.mux.com/5ezfyobrUf6XKY6XK5HBZoUXTT1vIrBGfWSz00P2RG2w/thumbnail.jpg Acne Across All Ages: Treating Pediatric, Adult, and Hormonal Acne Acne is a common diagnosis for dermatology providers, yet its management can be surprisingly complex—both in distinguishing it from similar conditions and in tailoring treatment across diverse age groups. Julie Harper, MD, delivered a clear and practical talk on acne management from neonates to adults. She began by covering neonatal (0–6 weeks) and infantile acne (6 weeks–1 year), highlighting a key question: when is isotretinoin appropriate in young children? Dr Harper then addressed another challenging area: acne management during pregnancy and lactation. She walked through the timing and reintroduction of isotretinoin postpartum, and reviewed the risks associated with tetracyclines and spironolactone. To simplify safe prescribing, she shared a helpful mnemonic: “3 for 3 trimesters,” referring to three topical treatments (azelaic acid, benzoyl peroxide, clindamycin—ABC) and three antibiotics (amoxicillin [not in the first trimester], azithromycin, cephalexin, clindamycin, and erythromycin [not estolate, and not in the first trimester]—ACE). Finally, she turned to acne in non-pregnant, non-lactating adults, covering both established and emerging therapies. These included oral contraceptives, spironolactone, and clascoterone cream 1%, with thoughtful discussion of their benefits, drawbacks, and appropriate use. https://dermsquared.com/videos/fcpanp-2025-conference-highlights/acne-across-all-ages-treating-pediatric-adult-and-hormonal-acne 62 2025-06-02T15:11:00.448Z yes https://dermsquared.com/videos/dermbits/requesting-newer-therapies 2026-04-02T16:21:31.743Z https://image.mux.com/D71BhzIwm00w9U00MCQfAbx8AhBtvh9dFysK6clHgM1KE/thumbnail.jpg How do you document treatment goals when requesting newer therapies? How do you document treatment goals when requesting newer therapies? https://dermsquared.com/videos/dermbits/requesting-newer-therapies 37 2026-04-02T14:30:50.835Z yes https://dermsquared.com/videos/dermbits/dermbits-did-the-phase-3-pivotal-studies-for-roflumilast-specifically-evaluate-itch-reduction-arcp22 2022-09-29T00:16:50.000Z https://image.mux.com/HlCGyNsh02miwsUUbHVGNQJ1XQ2fklERcOL01AaeLOt00U/thumbnail.jpg Did the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction? Did the Phase 3 pivotal studies for roflumilast specifically evaluate itch reduction? https://dermsquared.com/videos/dermbits/dermbits-did-the-phase-3-pivotal-studies-for-roflumilast-specifically-evaluate-itch-reduction-arcp22 40 2022-09-29T00:16:50.000Z yes https://dermsquared.com/videos/dermbits/what-role-lebrikizumab-play-managing-chronic-itch-atopic-dermatitis 2024-10-01T16:26:33.088Z https://image.mux.com/XDc3VsoYW01TjjxIul1UoSuJJB201WeFyjpOfx00rShPOU/thumbnail.jpg What role does lebrikizumab play in managing chronic itch associated with atopic dermatitis? What role does lebrikizumab play in managing chronic itch associated with atopic dermatitis? https://dermsquared.com/videos/dermbits/what-role-lebrikizumab-play-managing-chronic-itch-atopic-dermatitis 69 2024-10-01T16:26:33.081Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-role-of-diet-and-environment-in-the-pathogenesis-of-ad-ADRC00085-adrc23 2023-02-20T00:22:37.000Z https://image.mux.com/TXTP01Y4f3Bogr01QBp77PkTsg5TvwU3UWaDuRULnbVOw/thumbnail.jpg What is the role of diet and environment in the pathogenesis of AD? What is the role of diet and environment in the pathogenesis of AD? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-role-of-diet-and-environment-in-the-pathogenesis-of-ad-ADRC00085-adrc23 29 2023-02-20T00:22:37.000Z yes https://dermsquared.com/videos/dermbits/what-ingredients-do-you-like-products-treat-plaque-psoriasis 2023-05-31T20:00:11.541Z https://image.mux.com/02R011yv26Eh028ZgR024SOYeuaN8UOWopMvWM50002SUqm58/thumbnail.jpg What ingredients do you like to see in the products you use to treat plaque psoriasis? What ingredients do you like to see in the products you use to treat plaque psoriasis? https://dermsquared.com/videos/dermbits/what-ingredients-do-you-like-products-treat-plaque-psoriasis 74 2023-05-31T20:00:11.536Z yes https://dermsquared.com/videos/dermbits/balancing-care-and-paperwork 2026-02-02T15:22:31.612Z https://image.mux.com/HFywLF502N8Wwl1Z8ebs00xVhTrVgrZAntdjFNMSd02AUo/thumbnail.jpg What’s your top access tip for new clinicians balancing care and paperwork? What’s your top access tip for new clinicians balancing care and paperwork? https://dermsquared.com/videos/dermbits/balancing-care-and-paperwork 72 2026-02-02T15:22:31.606Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-compare-calcineurin-inhibitors-steroids-22 2023-04-28T19:54:44.530Z https://image.mux.com/CtxGKvWlYQqeWIVICvahq014B6KrbSWABWufVBlvG3mw/thumbnail.jpg How does ruxolitinib compare with topical calcineurin inhibitors and topical steroids? How does ruxolitinib compare with topical calcineurin inhibitors and topical steroids? https://dermsquared.com/videos/dermbits/ruxolitinib-compare-calcineurin-inhibitors-steroids-22 48 2022-01-31T22:14:30.000Z yes https://dermsquared.com/videos/dermbits/dermbits-combine-topical-ruxolitinib-systemic-therapies-ADRC00052-adrc22 2022-07-27T21:34:26.000Z https://image.mux.com/xK9fU9qey302z44XMdSdmv4rwB6n2xjsUSNZesX02WZdY/thumbnail.jpg Do you ever combine topical ruxolitinib with other systemic therapies? Do you ever combine topical ruxolitinib with other systemic therapies? https://dermsquared.com/videos/dermbits/dermbits-combine-topical-ruxolitinib-systemic-therapies-ADRC00052-adrc22 39 2022-07-27T21:34:26.000Z yes https://dermsquared.com/videos/dermbits/excited-about-delgocitinib 2023-04-28T19:06:32.984Z https://image.mux.com/UBt01MMuLzW01dwK2mZ7iTy7Vv02R5zNZ026lTluBKG902fA/thumbnail.jpg Are you excited about delgocitinib? Are you excited about delgocitinib? https://dermsquared.com/videos/dermbits/excited-about-delgocitinib 31 2021-06-04T19:39:29.000Z yes https://dermsquared.com/videos/dermbits/efficacy-outcomes-topical-roflumilast-most-compelling-22 2023-04-28T20:27:44.780Z https://image.mux.com/OI02LJOUjlK5fl7HAtNfSkt022BfTj29yEk3EDfrUNk4U/thumbnail.jpg Which efficacy outcomes for topical roflumilast do you find most compelling and why? Which efficacy outcomes for topical roflumilast do you find most compelling and why? https://dermsquared.com/videos/dermbits/efficacy-outcomes-topical-roflumilast-most-compelling-22 50 2022-08-30T23:09:45.000Z yes https://dermsquared.com/videos/dermbits/role-of-inflammation-pathogenesis-of-vitiligo 2025-05-01T13:44:06.280Z https://image.mux.com/Qk800pLvo6Uc92KiVbfWOKLYu5F68X2Iv8CI02bMkVIIQ/thumbnail.jpg What is the role of inflammation in the pathogenesis of vitiligo? What is the role of inflammation in the pathogenesis of vitiligo? https://dermsquared.com/videos/dermbits/role-of-inflammation-pathogenesis-of-vitiligo 69 2025-05-01T13:44:06.268Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-of-ritlecitinib 2024-10-01T14:14:54.685Z https://image.mux.com/3g8LjTZMzE00fpgbugk02REvTh02Y9lUFFzGhcl702lrxiQ/thumbnail.jpg What is the mechanism of action of ritlecitinib? What is the mechanism of action of ritlecitinib? https://dermsquared.com/videos/dermbits/mechanism-of-action-of-ritlecitinib 35 2024-10-01T14:14:54.679Z yes https://dermsquared.com/videos/dermbits/spf-still-matter-in-real-world-use 2025-11-14T15:26:33.376Z https://image.mux.com/yaDAcPFFTAyw3rlyKr3mr2W026Fl3YtApkSMHyj00I00Og/thumbnail.jpg Why does a higher SPF still matter in real-world use? Why does a higher SPF still matter in real-world use? https://dermsquared.com/videos/dermbits/spf-still-matter-in-real-world-use 71 2025-11-14T15:26:33.367Z yes https://dermsquared.com/videos/dermbits/combine-tapinarof-and-calcineurin-inhibitors-22 2023-04-28T19:58:22.321Z https://image.mux.com/8n4tj1WoFHeiTVq8OnOQlSvpwCvR7nF005srAljfBw5E/thumbnail.jpg Can you combine tapinarof and calcineurin inhibitors? Can you combine tapinarof and calcineurin inhibitors? https://dermsquared.com/videos/dermbits/combine-tapinarof-and-calcineurin-inhibitors-22 51 2022-02-01T00:49:40.000Z yes https://dermsquared.com/videos/dermbits/failure-or-selectively 2026-03-06T16:27:06.647Z https://image.mux.com/n8m8X0045E1IcyWyYeodyJHeqdsjBvALebQ01Uzt3M42U/thumbnail.jpg Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively? Where in the treatment journey do you see the AdvanceAD-TX test fitting? Before escalation, after failure, or selectively? https://dermsquared.com/videos/dermbits/failure-or-selectively 44 2026-03-06T16:27:06.641Z yes https://dermsquared.com/videos/dermbits/review-worth-pursuing 2026-05-04T20:18:29.966Z https://image.mux.com/SL2gTf2XpK7Len6OrqnfG3BcHj7R3PqHwGBPrppBCeo/thumbnail.jpg When is a peer-to-peer review worth pursuing? When is a peer-to-peer review worth pursuing? https://dermsquared.com/videos/dermbits/review-worth-pursuing 85 2026-05-04T20:18:29.960Z yes https://dermsquared.com/videos/dermbits/dermbits-advantages-topical-roflumilast-over-traditional-topical-corticosteroids-treatment-psoriasis-arcp22 2022-09-28T21:26:24.000Z https://image.mux.com/wgCNHqmRDE6pDrO01utuPzQzwJCoBlMLKlTMp1p2l33Y/thumbnail.jpg What are the advantages of topical roflumilast over traditional topical corticosteroids in the treatment of psoriasis? What are the advantages of topical roflumilast over traditional topical corticosteroids in the treatment of psoriasis? https://dermsquared.com/videos/dermbits/dermbits-advantages-topical-roflumilast-over-traditional-topical-corticosteroids-treatment-psoriasis-arcp22 52 2022-09-28T21:26:24.000Z yes https://dermsquared.com/videos/dermbits/how-vitiligo-distinguished-contact-leukoderma 2025-05-01T13:44:55.029Z https://image.mux.com/J02W3HXUCPvXScn858K2cCUYPtSH00DqfcHBpq5gJ3AW8/thumbnail.jpg How can vitiligo be distinguished from contact leukoderma? How can vitiligo be distinguished from contact leukoderma? https://dermsquared.com/videos/dermbits/how-vitiligo-distinguished-contact-leukoderma 59 2025-05-01T13:44:55.020Z yes https://dermsquared.com/videos/dermbits/what-are-some-known-triggers-of-gpp 2023-06-30T17:23:40.945Z https://image.mux.com/G02i1E41KXLve01dDCrIWEydfuAzL701f9o3972dOJe5rQ/thumbnail.jpg What are some known triggers of GPP? What are some known triggers of GPP? https://dermsquared.com/videos/dermbits/what-are-some-known-triggers-of-gpp 39 2023-06-27T17:27:35.140Z yes https://dermsquared.com/videos/dermbits/how-it-functions-on-the-skin 2026-05-22T13:18:10.660Z https://image.mux.com/crHJTM7eLaTNonhckF1vxdx4SnAlpct6UIgudbXI2SE/thumbnail.jpg When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin? When you’re introducing Cordran Tape to someone unfamiliar with it, how do you describe what it is in practical terms, both in terms of its physical form and how it functions on the skin? https://dermsquared.com/videos/dermbits/how-it-functions-on-the-skin 101 2026-05-22T13:18:10.652Z yes https://dermsquared.com/videos/dermbits/what-are-some-of-the-dermoscopic-features-of-vitiligo 2025-04-02T16:22:00.705Z https://image.mux.com/1C2LM00A4jaW02o12UAeV7Ukhu6JpCyebNYOlzHsYgOIw/thumbnail.jpg What are some of the dermoscopic features of vitiligo? What are some of the dermoscopic features of vitiligo? https://dermsquared.com/videos/dermbits/what-are-some-of-the-dermoscopic-features-of-vitiligo 29 2025-04-02T16:22:00.698Z yes https://dermsquared.com/videos/dermbits/how-approach-biopsying-suspicious-lesions-and-techniques 2025-03-03T14:11:47.069Z https://image.mux.com/k2rS00E02eed5fo025jLSDcKN00ZKupATUwnFzs2h7RJV600/thumbnail.jpg How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes? How do you approach biopsying suspicious lesions, and what techniques yield the best diagnostic outcomes? https://dermsquared.com/videos/dermbits/how-approach-biopsying-suspicious-lesions-and-techniques 69 2025-03-03T14:11:47.054Z yes https://dermsquared.com/videos/dermbits/current-treatment-approaches 2026-05-22T13:19:47.589Z https://image.mux.com/l6WIZs16swhwguk8KflsZIOxtq8LtLe6wHd6YcmlzJc/thumbnail.jpg With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches? With so many newer topical options available, where do you see Cordran Tape fitting into current treatment approaches? https://dermsquared.com/videos/dermbits/current-treatment-approaches 65 2026-05-22T13:19:47.581Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-cutaneous-lupus-22 2023-04-28T20:03:34.486Z https://image.mux.com/L6x2GCR9oLXBH00x01I6418frbKKmSJMMfnxcAxo9BmPM/thumbnail.jpg Does ruxolitinib work for cutaneous lupus? Does ruxolitinib work for cutaneous lupus? https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-cutaneous-lupus-22 18 2022-01-31T21:57:08.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-for-ruxolitinib-for-vitiligo 2024-03-06T16:03:21.656Z https://image.mux.com/4GoxzFSJXL01V17uVgwgnJ2Z3KzZ4ax2t3rqi6g7p3b00/thumbnail.jpg What is the mechanism of action for ruxolitinib for vitiligo? What is the mechanism of action for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-for-ruxolitinib-for-vitiligo 67 2024-03-06T16:03:21.651Z yes https://dermsquared.com/videos/dermbits/do-you-consider-imaging-patients-with-class-2a-2b-results-40-gep-test 2023-11-17T16:51:23.854Z https://image.mux.com/02bJ7gdn71BDWtbmFU5C02M2WgdxzXoKYfgrD8nPnaRvg/thumbnail.jpg Do you consider imaging for patients with class 2a or 2b results on the 40-GEP test? Do you consider imaging for patients with class 2a or 2b results on the 40-GEP test? https://dermsquared.com/videos/dermbits/do-you-consider-imaging-patients-with-class-2a-2b-results-40-gep-test 17 2023-11-17T16:37:22.751Z yes https://dermsquared.com/videos/dermbits/concerns-use-il-23-il-17-inhibitors-cscc 2023-04-28T19:27:33.834Z https://image.mux.com/ksbWeAJ7n4psaiM1hcdrLNGnWbPNchSplzvrliSrWiE/thumbnail.jpg Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)? Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)? https://dermsquared.com/videos/dermbits/concerns-use-il-23-il-17-inhibitors-cscc 62 2021-10-19T16:42:49.000Z yes https://dermsquared.com/videos/dermbits/patient-examples-success-using-topical-roflumilast 2023-08-31T20:39:26.243Z https://image.mux.com/FC8PHW1NER996ndQC26h5jssn89EKLAgXArcHWasqxI/thumbnail.jpg What are some patient examples you’ve had success with using topical roflumilast? What are some patient examples you’ve had success with using topical roflumilast? https://dermsquared.com/videos/dermbits/patient-examples-success-using-topical-roflumilast 40 2023-08-31T20:39:26.237Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-cantharidin 2023-11-09T21:34:30.984Z https://image.mux.com/SNQQtxONrqSHb6dKVmhBgaK6E5HHRHEX4IJkQOYN3Bg/thumbnail.jpg What is the recommended dosing regimen for cantharidin? What is the recommended dosing regimen for cantharidin? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-cantharidin 31 2023-11-09T21:34:30.977Z yes https://dermsquared.com/videos/dermbits/dosing-regimen-speed-of-response-bimekizumab-other-biologics 2024-01-03T17:23:00.776Z https://image.mux.com/yXnSuNseiHgRjEAybCh7J36IlzHi9x7hf8yJktzjX01E/thumbnail.jpg How does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis? How does the dosing regimen and speed of response of bimekizumab compare to other biologics for psoriasis? https://dermsquared.com/videos/dermbits/dosing-regimen-speed-of-response-bimekizumab-other-biologics 55 2024-01-03T17:23:00.770Z yes https://dermsquared.com/videos/dermbits/patient-support-programs-ruxolitinib-vitiligo 2024-05-31T13:33:58.516Z https://image.mux.com/ixtNGXaKrkmHh3EhIQRAC2D321iQ4EkeEM01Fak1jg00E/thumbnail.jpg Are there any patient support programs available for ruxolitinib for vitiligo? Are there any patient support programs available for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/patient-support-programs-ruxolitinib-vitiligo 25 2024-05-31T13:33:58.511Z yes https://dermsquared.com/videos/dermbits/describe-the-formulation-vehicle-for-topical-roflumilast 2023-11-01T21:22:36.813Z https://image.mux.com/JdSWwkfieauf8DNuDVJm5jTRW5hWc5lV02sHzsNtU3Vk/thumbnail.jpg How would you describe the formulation/vehicle for topical roflumilast? How would you describe the formulation/vehicle for topical roflumilast? https://dermsquared.com/videos/dermbits/describe-the-formulation-vehicle-for-topical-roflumilast 19 2023-11-01T21:22:36.809Z yes https://dermsquared.com/videos/dermbits/does-delgocitinib-boxed-warning-safety-concerns 2025-08-08T19:56:44.592Z https://image.mux.com/pIJNoaApuTXq00vHur01l017TkU00LYSOmjHHNTF8OOjjjQ/thumbnail.jpg Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of? Does delgocitinib cream carry a boxed warning, and are there any major safety concerns clinicians should be aware of? https://dermsquared.com/videos/dermbits/does-delgocitinib-boxed-warning-safety-concerns 51 2025-08-08T19:56:44.585Z yes https://dermsquared.com/videos/dermbits/barriers-to-adopting-the-i31-slnb-score 2025-07-02T19:42:35.705Z https://image.mux.com/DHSR01vWSVt2dU1EXcXeu9A6HK201BhQ76DCUTSUKtOqg/thumbnail.jpg What are some of the barriers to adopting the i31-SLNB score in community dermatology practices? What are some of the barriers to adopting the i31-SLNB score in community dermatology practices? https://dermsquared.com/videos/dermbits/barriers-to-adopting-the-i31-slnb-score 81 2025-07-01T14:14:12.617Z yes https://dermsquared.com/videos/dermbits/in-what-scenarios 2026-04-13T19:10:37.084Z https://image.mux.com/g1CCeLZbOry02B3W2okrOXoEfoZSn00VCbhGNRX7Z2JRM/thumbnail.jpg Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios? Do you ever use apremilast in combination with topical therapy, and if so, in what scenarios? https://dermsquared.com/videos/dermbits/in-what-scenarios 89 2026-04-13T19:10:37.078Z yes https://dermsquared.com/videos/dermbits/dermbits-how-has-the-40-gep-test-been-used-by-my-colleagues-WCM2300014-scc23 2023-06-29T16:36:30.201Z https://image.mux.com/E00j6DHckZeUZPsRdFFwZWlvzXKgxOVYjn8n54WY4Lso/thumbnail.jpg How has the 40-GEP test been used by my colleagues? How has the 40-GEP test been used by my colleagues? https://dermsquared.com/videos/dermbits/dermbits-how-has-the-40-gep-test-been-used-by-my-colleagues-WCM2300014-scc23 49 2023-06-29T16:36:30.193Z yes https://dermsquared.com/videos/dermbits/dermbits-have-you-heard-about-reports-of-crystals-in-ruxolitinib-cream 2022-10-28T22:10:04.000Z https://image.mux.com/v00OOw5YhR9f9HUmZxPOr102GBb00LmMCfaldVUpYpUJA00/thumbnail.jpg Have you heard about reports of crystals in ruxolitinib cream? Have you heard about reports of crystals in ruxolitinib cream? https://dermsquared.com/videos/dermbits/dermbits-have-you-heard-about-reports-of-crystals-in-ruxolitinib-cream 19 2022-10-28T22:10:04.000Z yes https://dermsquared.com/videos/dermbits/which-patients-higher-risk-contracting-molluscum-contagiosum 2023-11-09T21:34:14.324Z https://image.mux.com/Y4P02W98GwgSidgxQ02n009gdg9nzKvNw8xJi8dyN3O9Qg/thumbnail.jpg Which patients are at higher risk of contracting molluscum contagiosum? Which patients are at higher risk of contracting molluscum contagiosum? https://dermsquared.com/videos/dermbits/which-patients-higher-risk-contracting-molluscum-contagiosum 50 2023-11-09T21:34:14.316Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-of-lebrikizumab 2024-10-01T16:26:53.496Z https://image.mux.com/hZFj6DaZzdrlNvJndOrRNMfE500UZheXnfZd7sFX4HZk/thumbnail.jpg What is the mechanism of action of lebrikizumab? What is the mechanism of action of lebrikizumab? https://dermsquared.com/videos/dermbits/mechanism-of-action-of-lebrikizumab 42 2024-10-01T16:26:53.487Z yes https://dermsquared.com/videos/dermbits/boxed-warnings-evidence-associated-jak-inhibitors-22 2023-04-28T19:53:58.024Z https://image.mux.com/01bnO5SiQ2xy37eQTUY01ibMvPoTq1cojw01sAPRvMz8fo/thumbnail.jpg Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors? Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors? https://dermsquared.com/videos/dermbits/boxed-warnings-evidence-associated-jak-inhibitors-22 46 2022-01-31T22:16:34.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-lebrikizumab 2024-12-02T16:28:09.338Z https://image.mux.com/02fOBVMuG3T701n3dlKNEWiONKXV00ylOZzPc38Vufm900A/thumbnail.jpg What is the dosing regimen for lebrikizumab? What is the dosing regimen for lebrikizumab? https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-lebrikizumab 41 2024-12-02T16:28:09.330Z yes https://dermsquared.com/videos/dermbits/symptomatic-disease 2026-07-01T13:49:42.728Z https://image.mux.com/xVeMMskq8LpXuAICxBkieqzg5xH73a4NrnPC0001HTywE/thumbnail.jpg What documentation supports treatment escalation in stable but symptomatic disease? What documentation supports treatment escalation in stable but symptomatic disease? https://dermsquared.com/videos/dermbits/symptomatic-disease 68 2026-07-01T13:49:42.716Z yes https://dermsquared.com/videos/dermbits/pregnant-patients-ruxolitinib-cream 2023-04-28T19:29:36.751Z https://image.mux.com/LzJF40102k01l3ki5nw5tuTuLgqc43BO02MWfsYcS6Y4qlA/thumbnail.jpg Can pregnant patients use ruxolitinib cream? Can pregnant patients use ruxolitinib cream? https://dermsquared.com/videos/dermbits/pregnant-patients-ruxolitinib-cream 68 2021-11-17T20:32:16.000Z yes https://dermsquared.com/videos/dermbits/difficult-for-patients 2025-10-20T17:27:27.430Z https://image.mux.com/EFVBY3zesZlXRa5ARnuBfB6P01GYoEiR4EUmEjsmaPaE/thumbnail.jpg Is home-based NB-UVB device setup difficult for patients? Is home-based NB-UVB device setup difficult for patients? https://dermsquared.com/videos/dermbits/difficult-for-patients 62 2025-10-13T20:14:28.639Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis-vitiligo-ruxolitinib-cream-efficacy-22 2023-04-28T20:10:18.773Z https://image.mux.com/wxH68sNPREbICyZUT22SrQ1CC1uFMcZg1PIJkCFsJXs/thumbnail.jpg Atopic dermatitis and vitiligo are very different disease states clinically. How is it that topical ruxolitinib cream shows efficacy in both of them? Atopic dermatitis and vitiligo are very different disease states clinically. How is it that topical ruxolitinib cream shows efficacy in both of them? https://dermsquared.com/videos/dermbits/atopic-dermatitis-vitiligo-ruxolitinib-cream-efficacy-22 72 2022-04-28T00:14:34.000Z yes https://dermsquared.com/videos/dermbits/manage-diarrhea-associated-with-apremilast 2023-04-28T19:33:37.467Z https://image.mux.com/1M9WK01bBWfg4s67b2L2DHwUHVbMVImpukBooGSENgs4/thumbnail.jpg How do you manage the diarrhea associated with apremilast? How do you manage the diarrhea associated with apremilast? https://dermsquared.com/videos/dermbits/manage-diarrhea-associated-with-apremilast 126 2021-12-02T01:53:55.000Z yes https://dermsquared.com/videos/dermbits/hydrocolloidal-patches-acne-routine 2025-10-23T15:42:51.232Z https://image.mux.com/P1L3FcF1xBG5ayNGynQmJvmXndHHfHy6ADr02rcd54SE/thumbnail.jpg What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them? What role do hydrocolloidal patches play in an acne routine, and when do you typically recommend them? https://dermsquared.com/videos/dermbits/hydrocolloidal-patches-acne-routine 50 2025-10-22T21:23:41.076Z yes https://dermsquared.com/videos/dermbits/most-effective-strategies-preventing-actinic-keratosis-risk-populations 2025-10-20T22:31:44.153Z https://image.mux.com/VhkkAfvXZn02023yzEqObezsimhjJrLGYNH300sT701aqhI/thumbnail.jpg What are the most effective strategies for preventing actinic keratosis in at-risk populations? What are the most effective strategies for preventing actinic keratosis in at-risk populations? https://dermsquared.com/videos/dermbits/most-effective-strategies-preventing-actinic-keratosis-risk-populations 131 2025-02-12T16:21:49.874Z yes https://dermsquared.com/videos/dermbits/patients-recommended-spesolimab-and-exclusions 2023-08-31T20:44:29.647Z https://image.mux.com/HBW01mMi5frlYvVhLeJQ0125GOqYiM2DFoDhCL023T00Zlg/thumbnail.jpg Which patients are recommended for treatment with spesolimab, and are there any exclusions? Which patients are recommended for treatment with spesolimab, and are there any exclusions? https://dermsquared.com/videos/dermbits/patients-recommended-spesolimab-and-exclusions 96 2023-08-31T20:44:29.642Z yes https://dermsquared.com/videos/dermbits/benefit-of-ruxolitinib-over-topical-calcineurin-inhibitors 2023-10-31T21:18:39.118Z https://image.mux.com/VkXXOH1mYAynmqOQp01wGr024k7qAAtHAZmHzRz9j00EGU/thumbnail.jpg What is the benefit of ruxolitinib over topical calcineurin inhibitors? What is the benefit of ruxolitinib over topical calcineurin inhibitors? https://dermsquared.com/videos/dermbits/benefit-of-ruxolitinib-over-topical-calcineurin-inhibitors 36 2023-10-31T21:18:39.113Z yes https://dermsquared.com/videos/dermbits/longer-than-is-ideal 2026-05-07T17:29:20.827Z https://image.mux.com/mnYmzngimWO5tvpy4Ua8qzEJv200Wbn3CadTpLMt5x5I/thumbnail.jpg What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal? What keeps both clinicians and patients stuck in cycles of topical escalation longer than is ideal? https://dermsquared.com/videos/dermbits/longer-than-is-ideal 59 2026-05-07T17:29:20.819Z yes https://dermsquared.com/videos/dermbits/does-bimekizumab-have-a-boxed-warning 2024-01-01T16:05:04.099Z https://image.mux.com/CUtyDuK2fCY1007bLyti9XQrJ4MaTzEDzUTHycu0002cLw/thumbnail.jpg Does bimekizumab have a boxed warning? Does bimekizumab have a boxed warning? https://dermsquared.com/videos/dermbits/does-bimekizumab-have-a-boxed-warning 30 2024-01-01T16:05:04.093Z yes https://dermsquared.com/videos/dermbits/ideal-patient-ritlecitinib-and-notable-exclusions 2024-10-01T14:14:50.099Z https://image.mux.com/s233z5dNjZ6qV2bjZHaAIVbggPH55xjMIV8rxzJzxvo/thumbnail.jpg Who is the ideal patient for ritlecitinib, and are there any notable exclusions? Who is the ideal patient for ritlecitinib, and are there any notable exclusions? https://dermsquared.com/videos/dermbits/ideal-patient-ritlecitinib-and-notable-exclusions 39 2024-10-01T14:14:50.092Z yes https://dermsquared.com/videos/dermbits/compound-jak-inhibitors-into-creams 2023-04-28T19:26:27.348Z https://image.mux.com/EuiNuuJ6Vtuazf0015195pghfjaDksBrRbe76jWcnk7c/thumbnail.jpg Do you compound any currently available JAK inhibitors into creams for topical use by your patients? Do you compound any currently available JAK inhibitors into creams for topical use by your patients? https://dermsquared.com/videos/dermbits/compound-jak-inhibitors-into-creams 61 2021-10-29T00:11:47.000Z yes https://dermsquared.com/videos/dermbits/recommendations-pulse-dosing-vacations-hedgehog-inhibitors 2023-04-28T19:48:49.554Z https://image.mux.com/2q1g274eLmnm9PnpYzHSXrdHewvcpui7MXKI3BiBS8Q/thumbnail.jpg Are there any recommendations on pulse dosing or giving vacations for hedgehog inhibitors to improve compliance and tolerability? Are there any recommendations on pulse dosing or giving vacations for hedgehog inhibitors to improve compliance and tolerability? https://dermsquared.com/videos/dermbits/recommendations-pulse-dosing-vacations-hedgehog-inhibitors 50 2022-01-21T06:08:19.000Z yes https://dermsquared.com/videos/dermbits/ways-to-treat-vitiligo-surgically 2024-03-06T16:01:49.895Z https://image.mux.com/8diIrSNISUVqOEciyY93pN0001qy6YGTvbyfYOmLhssF8/thumbnail.jpg Are there ways to treat vitiligo surgically? Are there ways to treat vitiligo surgically? https://dermsquared.com/videos/dermbits/ways-to-treat-vitiligo-surgically 75 2024-03-06T16:01:49.885Z yes https://dermsquared.com/videos/dermbits/how-long-give-biologic-before-switch-agents 2023-04-28T20:23:03.847Z https://image.mux.com/JI9LySC01vUdiiO1PR1PooTGtKcwGkCqzNmUBFmYK01y00/thumbnail.jpg How long should you give any biologic before you decide to switch agents? How long should you give any biologic before you decide to switch agents? https://dermsquared.com/videos/dermbits/how-long-give-biologic-before-switch-agents 35 2022-08-05T19:00:39.000Z yes https://dermsquared.com/videos/dermbits/follow-up-monitoring-recommend-patients-on-ruxolitinib-for-vitiligo 2024-04-01T15:44:58.696Z https://image.mux.com/R3b9dPKmqOBZA8qCRP00U6PTeyG7AHTwaCnFwAr01vDHo/thumbnail.jpg What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo? What follow-up or monitoring do you recommend for patients on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/follow-up-monitoring-recommend-patients-on-ruxolitinib-for-vitiligo 30 2024-04-01T15:44:58.689Z yes https://dermsquared.com/videos/dermbits/dermatologist-vs-dermatopathologist-ordering-mypath 2025-07-15T03:05:47.787Z https://image.mux.com/LyYWupNfqrWLgo3pWcRtrEvw601Zm3ozC2POhJr2cRQM/thumbnail.jpg What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist? What are your thoughts on a dermatologist ordering MyPath vs a dermatopathologist? https://dermsquared.com/videos/dermbits/dermatologist-vs-dermatopathologist-ordering-mypath 154 2025-07-15T03:05:47.771Z yes https://dermsquared.com/videos/dermbits/nejm-article-melanoma-overdiagnosis-gep 2023-04-28T19:33:14.457Z https://image.mux.com/MIhkZILEqCdChn02wYhvJzhjUCJ02zxLbK4BXHqpUJ5oI/thumbnail.jpg Can you discuss your thoughts on the NEJM article on melanoma overdiagnosis and how GEP may fit into this? Can you discuss your thoughts on the NEJM article on melanoma overdiagnosis and how GEP may fit into this? https://dermsquared.com/videos/dermbits/nejm-article-melanoma-overdiagnosis-gep 101 2021-11-24T22:37:04.000Z yes https://dermsquared.com/videos/dermbits/dermbits-plaque-psoriasis-intertriginous-areas-how-do-you-approach-arcp22 2022-09-29T00:21:25.000Z https://image.mux.com/ibXlb7VGqacKFA01gUozqLteYMXq27PIf1cAKrvM3Wvw/thumbnail.jpg There has been increased emphasis placed on treatment of plaque psoriasis in intertriginous and/or genital areas. How do you approach management of disease in these areas? There has been increased emphasis placed on treatment of plaque psoriasis in intertriginous and/or genital areas. How do you approach management of disease in these areas? https://dermsquared.com/videos/dermbits/dermbits-plaque-psoriasis-intertriginous-areas-how-do-you-approach-arcp22 81 2022-09-29T00:21:25.000Z yes https://dermsquared.com/videos/dermbits/oral-jaks-insurance-alopecia-areata 2023-04-28T19:14:15.203Z https://image.mux.com/00iC8MXNsmEGlLmM01UrSEq6IUDjVuY37AGi5jI3ZH45U/thumbnail.jpg How do you get oral JAKs covered by insurance for alopecia areata? How do you get oral JAKs covered by insurance for alopecia areata? https://dermsquared.com/videos/dermbits/oral-jaks-insurance-alopecia-areata 44 2021-07-23T00:52:42.000Z yes https://dermsquared.com/videos/dermbits/how-quickly-does-bimekizumab-start-working 2023-10-24T16:35:06.924Z https://image.mux.com/010102zt2cCE5RMlaIzZPbef6TMrEpXnJLVJ5R00y2vHwB8/thumbnail.jpg How quickly does bimekizumab start working? How quickly does bimekizumab start working? https://dermsquared.com/videos/dermbits/how-quickly-does-bimekizumab-start-working 38 2023-10-24T16:35:06.912Z yes https://dermsquared.com/videos/dermbits/especially-appropriate 2026-05-07T17:30:07.923Z https://image.mux.com/vRq00A9MBe015AwfpvihJ9XVIy01fmMWA5MDo2i00RENT1g/thumbnail.jpg Are there particular comorbidity profiles where apremilast feels especially appropriate? Are there particular comorbidity profiles where apremilast feels especially appropriate? https://dermsquared.com/videos/dermbits/especially-appropriate 100 2026-05-07T17:30:07.913Z yes https://dermsquared.com/videos/dermbits/do-you-check-baseline-or-intermittent-labs-on-dupilumab-or-tralokinumab-for-ad 2023-07-27T19:59:50.641Z https://image.mux.com/5tYBca4j3GT3900i4Wge4iyu2hizXwBoxWCiGW02w3WDw/thumbnail.jpg Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD? Do you check baseline or intermittent labs on dupilumab or tralokinumab for AD? https://dermsquared.com/videos/dermbits/do-you-check-baseline-or-intermittent-labs-on-dupilumab-or-tralokinumab-for-ad 54 2023-07-27T19:59:50.636Z yes https://dermsquared.com/videos/dermbits/reservations-using-tirbanibulin-ointment-actinic-cheilitis 2024-01-23T19:41:29.085Z https://image.mux.com/UHU6AVpiHCZOzhBphLGr3XSpTATpWPMXhS9LFuIGaSI/thumbnail.jpg Any reservations about using tirbanibulin ointment for actinic cheilitis? Any reservations about using tirbanibulin ointment for actinic cheilitis? https://dermsquared.com/videos/dermbits/reservations-using-tirbanibulin-ointment-actinic-cheilitis 73 2022-02-10T17:27:53.000Z yes https://dermsquared.com/videos/dermbits/how-quickly-expect-itch-reduction-with-ruxolitinib-cream 2023-07-28T16:33:21.826Z https://image.mux.com/1M8qfCCHIejvHbnRhy019dOtJafRah00Eto101kHntqABE/thumbnail.jpg How quickly can patients expect to start feeling itch reduction with ruxolitinib cream? Summary According to Dr. Raj Chovatiya, ruxolitinib cream has shown impressive itch reduction results both in clinical studies and real-world applications. Patients using the cream can expect to experience significant itch relief within minutes to hours after application. Dr. Chovatiya's clinical experience aligns with the findings from phase two trial programs, where patients reported fast and noticeable improvements in their itch scores shortly after using the cream. Key Points Ruxolitinib cream provides rapid itch reduction. Both real-world experiences and clinical studies have demonstrated the fast resolution of itch with ruxolitinib cream. The cream has been praised for its quick and effective action in reducing itch, as acknowledged by patients and healthcare professionals alike. https://dermsquared.com/videos/dermbits/how-quickly-expect-itch-reduction-with-ruxolitinib-cream 44 2023-07-27T19:13:03.408Z yes https://dermsquared.com/videos/dermbits/duobrii-lotion-to-avoid-irritation 2023-04-28T19:44:39.756Z https://image.mux.com/dXEII1skUwLOY1fbAUU6THts6R38R9Pu6VSMIXl5KIQ/thumbnail.jpg How do you apply Duobrii lotion in order to avoid irritation? How do you apply Duobrii lotion in order to avoid irritation? https://dermsquared.com/videos/dermbits/duobrii-lotion-to-avoid-irritation 48 2021-12-30T00:25:51.000Z yes https://dermsquared.com/videos/dermbits/can-ixekizumab-used-combination-topical-treatments-recommended-approach 2024-09-24T18:20:50.979Z https://image.mux.com/htrpiQH5gLAfIsVsk5PBV025wydyGQXUET3XI00jBvlIY/thumbnail.jpg Can ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach? Can ixekizumab be used in combination with topical treatments, and if so, what is the recommended approach? https://dermsquared.com/videos/dermbits/can-ixekizumab-used-combination-topical-treatments-recommended-approach 132 2024-09-24T18:20:50.973Z yes https://dermsquared.com/videos/dermbits/clascoterone-acne-minoxidil-anti-androgens 2023-04-28T19:16:39.067Z https://image.mux.com/mTCxzy4lwNN02C023VB6FJ01YzN6pjBzUwqSd2h4wV5Wdw/thumbnail.jpg Why does clascoterone work for acne and not minoxidil since they are both anti-androgens? Why does clascoterone work for acne and not minoxidil since they are both anti-androgens? https://dermsquared.com/videos/dermbits/clascoterone-acne-minoxidil-anti-androgens 96 2021-08-12T23:25:57.000Z yes https://dermsquared.com/videos/dermbits/dermbits-do-you-feel-comfortable-using-topical-ruxolitinib-in-combination-with-dupilumab-adrc22 2022-10-28T22:12:52.000Z https://image.mux.com/duisrPQk00cbUWAB02PUbY6dYSDXMnbKwl3ZvMhywuKX00/thumbnail.jpg Do you feel comfortable using topical ruxolitinib in combination with dupilumab? Do you feel comfortable using topical ruxolitinib in combination with dupilumab? https://dermsquared.com/videos/dermbits/dermbits-do-you-feel-comfortable-using-topical-ruxolitinib-in-combination-with-dupilumab-adrc22 50 2022-10-28T22:12:52.000Z yes https://dermsquared.com/videos/dermbits/new-31-gep-reporting-what-it-means 2023-04-28T19:26:54.598Z https://image.mux.com/vqx2xO5zAkdVGzrF6nQteQcZxBhowTyExr4Y6byCf9U/thumbnail.jpg Can you explain how the new 31 GEP reporting has changed and what it means? Can you explain how the new 31 GEP reporting has changed and what it means? https://dermsquared.com/videos/dermbits/new-31-gep-reporting-what-it-means 62 2021-10-29T00:07:40.000Z yes https://dermsquared.com/videos/dermbits/role-ritlecitinib-maintenance-therapy-alopecia-areata-who-achieved-hair-regrowth 2024-11-07T16:11:03.534Z https://image.mux.com/GyGdjTOFCL7ejOxgyt7WPZMv76huuC5j02GN6EQI62Kk/thumbnail.jpg What is the role of ritlecitinib in maintenance therapy for patients with alopecia areata who have achieved hair regrowth? What is the role of ritlecitinib in maintenance therapy for patients with alopecia areata who have achieved hair regrowth? https://dermsquared.com/videos/dermbits/role-ritlecitinib-maintenance-therapy-alopecia-areata-who-achieved-hair-regrowth 22 2024-11-07T16:11:03.523Z yes https://dermsquared.com/videos/dermbits/how-early-intervention-impact-long-term-course-psoriasis 2024-11-01T13:48:26.678Z https://image.mux.com/uSdtJOyZDXOzZHa6eakBbwgdJHndvZFzTiTqa00PassI/thumbnail.jpg How can early intervention impact the long-term course of psoriasis? How can early intervention impact the long-term course of psoriasis? https://dermsquared.com/videos/dermbits/how-early-intervention-impact-long-term-course-psoriasis 31 2024-11-01T13:48:26.670Z yes https://dermsquared.com/videos/dermbits/safety-tirbanibulin-larger-surface-areas 2025-10-20T22:31:12.162Z https://image.mux.com/heHUpv02o018J3Ve81pghyPB7uu4vFL022ekrq2MHCEXic/thumbnail.jpg How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials? How does the safety of tirbanibulin ointment when treating larger surface areas compare to the safety observed in the original clinical trials? https://dermsquared.com/videos/dermbits/safety-tirbanibulin-larger-surface-areas 83 2025-02-12T16:22:49.589Z yes https://dermsquared.com/videos/dermbits/baricitinib-patients-with-substantial-eyebrow-eyelash-loss 2023-09-29T16:20:07.718Z https://image.mux.com/ycQ8OuOt2RYKpm8LFv47QDcE00c42x8pEg01XMrypwArg/thumbnail.jpg Is baricitinib effective for patients with substantial eyebrow and eyelash loss? Is baricitinib effective for patients with substantial eyebrow and eyelash loss? https://dermsquared.com/videos/dermbits/baricitinib-patients-with-substantial-eyebrow-eyelash-loss 68 2023-09-29T16:20:07.710Z yes https://dermsquared.com/videos/dermbits/clinician-and-patient-perspective 2025-11-14T15:23:48.686Z https://image.mux.com/tj2FL008HknzvvR9VZ2iLjJI1MTqqV8HAfK00QOqBz6VE/thumbnail.jpg What makes a sunscreen well formulated from both a clinician and patient perspective? What makes a sunscreen well formulated from both a clinician and patient perspective? https://dermsquared.com/videos/dermbits/clinician-and-patient-perspective 104 2025-11-14T15:23:48.677Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-risk-nmsc-ruxolitinib-vitiligo 2024-07-01T14:43:37.855Z https://image.mux.com/Bt02syl7z59nPQRb01as41pCBTPorAKtUtuayGPOQUnCQ/thumbnail.jpg How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo? How should you counsel patients about the risk of NMSC while using ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-counsel-patients-risk-nmsc-ruxolitinib-vitiligo 36 2024-07-01T14:43:37.849Z yes https://dermsquared.com/videos/dermbits/moving-to-systemic-therapy 2026-03-03T16:10:10.895Z https://image.mux.com/6L6mu1XhQFxKBQg6JuOwlSN00UffSy5sscKcueryMruo/thumbnail.jpg In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy? In your experience, what helps patients stay engaged during the early weeks after moving to systemic therapy? https://dermsquared.com/videos/dermbits/moving-to-systemic-therapy 51 2026-03-03T16:10:10.888Z yes https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-roflumilast 2023-08-31T20:43:10.607Z https://image.mux.com/gQDaz1odcaavj5Yl2pXY1PD02uB4qX02vow3ofxefvViA/thumbnail.jpg Who is the ideal patient for roflumilast? Who is the ideal patient for roflumilast? https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-roflumilast 109 2023-08-31T20:43:10.603Z yes https://dermsquared.com/videos/dermbits/dose-adjustments-needed-for-renal-or-hepatic-impairment-ixekizumab 2024-08-20T18:28:34.283Z https://image.mux.com/wiqj1600dspxQvter8yKqY1oACyRrj127qQG1z00HEQZk/thumbnail.jpg Are there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab? Are there any dose adjustments needed for patients with renal or hepatic impairment when using ixekizumab? https://dermsquared.com/videos/dermbits/dose-adjustments-needed-for-renal-or-hepatic-impairment-ixekizumab 35 2024-08-20T18:15:36.867Z yes https://dermsquared.com/videos/dermbits/patients-with-limited-bsa 2026-06-12T18:54:00.277Z https://image.mux.com/vrfAK3UllcKwkX5HSFlUCs96L7E01rY1bkSOtJ02IbZH4/thumbnail.jpg What helps secure approval for ruxolitinib in patients with limited BSA? What helps secure approval for ruxolitinib in patients with limited BSA? https://dermsquared.com/videos/dermbits/patients-with-limited-bsa 59 2026-06-02T14:11:46.719Z yes https://dermsquared.com/videos/dermbits/what-should-patients-do-if-they-miss-a-dose-of-ritlecitinib 2024-12-02T15:44:25.456Z https://image.mux.com/OevlL4KlxnsBzbuYroHcqkzfy0052I7UHLxODhFW7opQ/thumbnail.jpg What should patients do if they miss a dose of ritlecitinib? What should patients do if they miss a dose of ritlecitinib? https://dermsquared.com/videos/dermbits/what-should-patients-do-if-they-miss-a-dose-of-ritlecitinib 25 2024-12-02T15:44:25.449Z yes https://dermsquared.com/videos/dermbits/tapering-or-stopping-associated-with-gpp 2023-08-31T20:43:53.534Z https://image.mux.com/1XNZOjxGuCTIsmYB7K01mUoEVSkMxSNFdVznf3tSdVSM/thumbnail.jpg The use, tapering, or stopping of which medications can be associated with GPP? The use, tapering, or stopping of which medications can be associated with GPP? https://dermsquared.com/videos/dermbits/tapering-or-stopping-associated-with-gpp 112 2023-08-31T20:43:53.529Z yes https://dermsquared.com/videos/dermbits/does-patient-age-impact-effectiveness-safety-ritlecitinib 2024-09-17T19:07:25.405Z https://image.mux.com/hgoQaUjAANga82EWgTFaoHlPiV1eDLZqIZjmwrW01IDg/thumbnail.jpg Does patient age impact the effectiveness and safety of ritlecitinib? Does patient age impact the effectiveness and safety of ritlecitinib? https://dermsquared.com/videos/dermbits/does-patient-age-impact-effectiveness-safety-ritlecitinib 55 2024-09-17T19:07:25.400Z yes https://dermsquared.com/videos/dermbits/has-been-particularly-useful 2026-05-26T14:44:11.516Z https://image.mux.com/b00cL5cU9yXukamB00yHQXv6b004W9ZtHX4T102FxzwefgI/thumbnail.jpg Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful? Are there specific body areas or disease patterns in AD where tapinarof has been particularly useful? https://dermsquared.com/videos/dermbits/has-been-particularly-useful 50 2026-05-26T14:44:11.507Z yes https://dermsquared.com/videos/dermbits/approval-for-ruxolitinib-cream 2026-02-02T15:20:53.450Z https://image.mux.com/01hUn1ltNqrgnl6iESGp3YKFKHy9y2RNIM2w2mJXSpyQ/thumbnail.jpg What documentation details helps support approval for ruxolitinib cream? What documentation details helps support approval for ruxolitinib cream? https://dermsquared.com/videos/dermbits/approval-for-ruxolitinib-cream 60 2026-02-02T15:20:53.444Z yes https://dermsquared.com/videos/dermbits/use-of-itraconazole-in-vismodigib-resistant-bccs 2023-04-28T20:05:45.879Z https://image.mux.com/2edAVxkWNmK5oFWAjssknPJiYv9JOZ4ahr2mShQ4029s/thumbnail.jpg Can you elaborate on the use of itraconazole in vismodigib-resistant BCCs? Can you elaborate on the use of itraconazole in vismodigib-resistant BCCs? https://dermsquared.com/videos/dermbits/use-of-itraconazole-in-vismodigib-resistant-bccs 46 2022-03-14T19:59:01.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-roflumilast 2023-08-31T20:42:09.561Z https://image.mux.com/3ZhH7MJnH62NgNnzDvFN0001CCXIc2Zm2LzNqdonyeXF4/thumbnail.jpg What is the mechanism of action of roflumilast? What is the mechanism of action of roflumilast? https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-roflumilast 27 2023-08-31T20:42:09.556Z yes https://dermsquared.com/videos/dermbits/topical-ruxolitinib-first-line-therapy-sensitive-22 2023-04-28T20:20:17.816Z https://image.mux.com/dNJZinAKfECB567cApeRAqvaNsRpIAi2P01M0001S01fXSc/thumbnail.jpg Do you use topical ruxolitinib as a first line therapy for sensitive body areas? Do you use topical ruxolitinib as a first line therapy for sensitive body areas? https://dermsquared.com/videos/dermbits/topical-ruxolitinib-first-line-therapy-sensitive-22 45 2022-07-27T21:29:13.000Z yes https://dermsquared.com/videos/dermbits/can-vitiligo-spontaneously-resolve 2025-06-03T13:45:26.817Z https://image.mux.com/yrfquYbakZjgOJTsNlqssC01Nd5Isl7jbIwL9KT3DSN00/thumbnail.jpg Can vitiligo spontaneously resolve? Can vitiligo spontaneously resolve? https://dermsquared.com/videos/dermbits/can-vitiligo-spontaneously-resolve 41 2025-06-03T13:45:26.809Z yes https://dermsquared.com/videos/dermbits/what-is-the-best-treatment-for-lichen-planus-pigmentosus 2023-07-27T20:01:55.102Z https://image.mux.com/p1ebr8GCNJqzj00yB5Wscaouc00KQZQ3taL02AS8rZwCNg/thumbnail.jpg What is the best treatment for lichen planus pigmentosus? What is the best treatment for lichen planus pigmentosus? https://dermsquared.com/videos/dermbits/what-is-the-best-treatment-for-lichen-planus-pigmentosus 98 2023-07-27T19:58:49.538Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-used-intermittently-maintenance-reduce-flares-relapse 2023-10-31T21:18:27.899Z https://image.mux.com/itRHTeI1UUFad6yHYiU00rdrWW1800SrU01fUhAoUsGdjo/thumbnail.jpg Can ruxolitinib be used intermittently as maintenance to reduce flares and relapse? Can ruxolitinib be used intermittently as maintenance to reduce flares and relapse? https://dermsquared.com/videos/dermbits/ruxolitinib-used-intermittently-maintenance-reduce-flares-relapse 35 2023-10-31T21:18:27.891Z yes https://dermsquared.com/videos/dermbits/when-recommend-wet-wrap-therapy-with-atopic-dermatitis-flare 2023-07-28T16:23:43.120Z https://image.mux.com/NrD02OYhj9Xej129L4X6EEe9aYyuLQB9C1mAJX7W00Bis/thumbnail.jpg When do you recommend the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare? Summary In the video, Dr. Raj Chovatiya discusses the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare. He describes wet wrap therapy as an effective approach for achieving fast control of highly acute, severe atopic dermatitis. Wet wrap therapy involves wrapping the affected areas in wet bandages, which helps to cool down the skin and provide relief. Dr. Chovatiya mentions that wet wrap therapy is particularly useful for patients who require urgent control of their atopic dermatitis but may not be able to start systemic therapy immediately. It can be used in cases where a patient is a good candidate for systemic therapy but cannot receive it promptly. For example, patients who end up being hospitalized for a day or two due to the severity of their condition can benefit from wet wrap therapy during their hospital stay. While wet wrap therapy is an effective option, Dr. Chovatiya acknowledges that it can be cumbersome for patients to manage at home. Therefore, its use may be more practical and achievable in a hospital setting, where healthcare professionals can ensure appropriate application and changes of the wet wraps. Overall, wet wrap therapy is considered a valuable approach for rapidly managing acute, severe atopic dermatitis, especially when systemic therapy may not be immediately accessible. Key Points Wet wrap therapy is recommended for patients with atopic dermatitis experiencing a flare. It is particularly effective when fast control of highly acute, very severe atopic dermatitis is needed. Wet wrap therapy is not used for every patient because it can be cumbersome, especially at home. It can be beneficial for patients who may be good candidates for systemic therapy but cannot start it immediately. https://dermsquared.com/videos/dermbits/when-recommend-wet-wrap-therapy-with-atopic-dermatitis-flare 64 2023-07-27T19:18:48.020Z yes https://dermsquared.com/videos/dermbits/winlevi-replacing-aczone 2023-04-28T19:06:13.976Z https://image.mux.com/tv2H6twqngWdrrYP572rAllTDw8qLZtIU7Ll6A3imvo/thumbnail.jpg Do you see WINLEVI replacing ACZONE? Do you see WINLEVI replacing ACZONE? https://dermsquared.com/videos/dermbits/winlevi-replacing-aczone 81 2021-05-28T16:35:52.000Z yes https://dermsquared.com/videos/dermbits/how-better-educate-patients-minimizing-risk-developing-scc 2023-08-31T21:15:10.826Z https://image.mux.com/341iJuFKNZEZ0102MntKQwAlMv3GBqrRYYa99hq00xZNoc/thumbnail.jpg How can we better educate our patients on minimizing the risk of developing SCC? How can we better educate our patients on minimizing the risk of developing SCC? https://dermsquared.com/videos/dermbits/how-better-educate-patients-minimizing-risk-developing-scc 51 2023-08-31T20:51:24.772Z yes https://dermsquared.com/videos/dermbits/dermbits-how-important-is-the-delivery-vehicle-for-topical-treatment-of-psoriasis-arcp-22 2023-11-01T17:28:51.847Z https://image.mux.com/OREn8UTv8xpjdgA01XKQmckL5Qoa9IvlvecrZFYuG4j00/thumbnail.jpg How important is the delivery vehicle for topical treatment of psoriasis? How important is the delivery vehicle for topical treatment of psoriasis? https://dermsquared.com/videos/dermbits/dermbits-how-important-is-the-delivery-vehicle-for-topical-treatment-of-psoriasis-arcp-22 88 2022-09-29T00:19:19.000Z yes https://dermsquared.com/videos/dermbits/why-is-systemic-therapy-for-atopic-dermatitis-still-underutilized-despite-the-availability-of-newer-targeted-options 2025-10-01T22:30:02.123Z https://image.mux.com/9qylJKSwc32NlYlr014qnHEtAM43rpIBqyPnqpuEfKMc/thumbnail.jpg Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options? Why is systemic therapy for atopic dermatitis still underutilized, despite the availability of newer targeted options? https://dermsquared.com/videos/dermbits/why-is-systemic-therapy-for-atopic-dermatitis-still-underutilized-despite-the-availability-of-newer-targeted-options 104 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/why-arent-more-patients-moderate-ad-treated-advanced-systemic-therapies 2025-05-01T13:40:52.434Z https://image.mux.com/9Q36vB4xpFGmJ5mlIxIqhJSyUnz1qhipzviU02cW5awA/thumbnail.jpg Why aren’t more patients with moderate AD treated with advanced systemic therapies? Why aren’t more patients with moderate AD treated with advanced systemic therapies? https://dermsquared.com/videos/dermbits/why-arent-more-patients-moderate-ad-treated-advanced-systemic-therapies 61 2025-05-01T13:40:52.427Z yes https://dermsquared.com/videos/dermbits/live-vaccines-pediatric-ixekizumab 2023-04-28T19:17:15.587Z https://image.mux.com/4OBh7bIEvMFrXhH9Hn1B1p0000GN00SHirnmVcD35c977k/thumbnail.jpg How would you address live vaccines in pediatric patients on Ixekizumab? How would you address live vaccines in pediatric patients on Ixekizumab? https://dermsquared.com/videos/dermbits/live-vaccines-pediatric-ixekizumab 181 2021-08-13T00:01:56.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-ruxolitinib-for-vitiligo 2024-04-01T15:45:10.822Z https://image.mux.com/mVY2OSJLg5pTCVpICghfkMNohZosUCLlI5mJfGebq02w/thumbnail.jpg What is the safety profile of ruxolitinib for vitiligo? What is the safety profile of ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-ruxolitinib-for-vitiligo 73 2024-04-01T15:45:10.808Z yes https://dermsquared.com/videos/dermbits/common-laboratory-abnormalities-associated-with-gpp 2023-06-30T17:07:18.127Z https://image.mux.com/mshO500YGZhMElNpSnn1Bs6S1xhbNIaHtMOQLXlOmr5I/thumbnail.jpg What are some of the common laboratory abnormalities associated with GPP? What are some of the common laboratory abnormalities associated with GPP? https://dermsquared.com/videos/dermbits/common-laboratory-abnormalities-associated-with-gpp 60 2023-06-27T17:27:20.341Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-importance-of-adherence-when-prescribing-topical-treatment-psoriasis 2023-11-01T17:22:57.000Z https://image.mux.com/ZOvXnWSEHOTIR01y1AXrB89b6l01wXL01901kjcoN7x01YCc/thumbnail.jpg How do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis? How do you counsel patients on the importance of adherence when prescribing a topical treatment for psoriasis? https://dermsquared.com/videos/dermbits/how-counsel-patients-importance-of-adherence-when-prescribing-topical-treatment-psoriasis 24 2023-11-01T15:03:24.839Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-useful-moderate-disease 2023-04-28T18:50:44.333Z https://image.mux.com/ADKrQ1qBOg7dccvBy6qJnUNHvgGnxTirD53u013gpoO4/thumbnail.jpg Is topical ruxolitinib cream useful for patients with moderate disease? Is topical ruxolitinib cream useful for patients with moderate disease? https://dermsquared.com/videos/dermbits/ruxolitinib-useful-moderate-disease 89 2021-10-14T18:21:36.000Z yes https://dermsquared.com/videos/dermbits/how-dose-ivig-dermatomyositis-myopathy 2023-04-28T20:04:03.415Z https://image.mux.com/DiiZe00EcXY8sR00XIqN4qyNOUzpqzCl66iblTI7FSyL8/thumbnail.jpg How do you dose IVIG for dermatomyositis with and without myopathy? How do you dose IVIG for dermatomyositis with and without myopathy? https://dermsquared.com/videos/dermbits/how-dose-ivig-dermatomyositis-myopathy 48 2022-02-17T22:52:41.000Z yes https://dermsquared.com/videos/dermbits/strategies-dermatologists-improve-patient-adherence-ruxolitinib-vitiligo 2025-03-03T14:14:31.342Z https://image.mux.com/n2lVi7NvdUFhr4NZ9hjJBQpBo1zDsaGcBJ4O5zDWQ6c/thumbnail.jpg What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo? What strategies can dermatologists use to improve patient adherence to ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/strategies-dermatologists-improve-patient-adherence-ruxolitinib-vitiligo 50 2025-03-03T14:14:31.330Z yes https://dermsquared.com/videos/dermbits/can-vitiligo-be-treated-with-surgical-intervention 2025-05-01T13:45:11.212Z https://image.mux.com/sFLPrtVFBGzW1JhsAI0200mG568fP2mLE02g6SBdY3ID2o/thumbnail.jpg Can vitiligo be treated with surgical intervention? Can vitiligo be treated with surgical intervention? https://dermsquared.com/videos/dermbits/can-vitiligo-be-treated-with-surgical-intervention 78 2025-05-01T13:45:11.200Z yes https://dermsquared.com/videos/dermbits/suitable-treatment-option-psoriasis-patients-medicare 2023-04-28T20:07:30.005Z https://image.mux.com/vwcL9McmLR00iPh5eTZ01ouvG9Pmgsqw6rN9WHsK298UA/thumbnail.jpg What would be a suitable treatment option for psoriasis patients on Medicare? What would be a suitable treatment option for psoriasis patients on Medicare? https://dermsquared.com/videos/dermbits/suitable-treatment-option-psoriasis-patients-medicare 42 2022-04-21T19:31:49.000Z yes https://dermsquared.com/videos/dermbits/how-advise-patients-ruxolitinib-vitiligo-signs-of-repigmentation 2024-05-31T13:34:09.816Z https://image.mux.com/v700DHyAsETMbi7vBZViNU7CGgbZUsa8Kn9MlEVJ0201qg/thumbnail.jpg How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation? How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation? https://dermsquared.com/videos/dermbits/how-advise-patients-ruxolitinib-vitiligo-signs-of-repigmentation 26 2024-05-31T13:34:09.811Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-perioral-dermatitis-22 2023-04-28T19:56:26.879Z https://image.mux.com/uqzS4vLlYmCmWjzFHInrB1etjrkoJpTIG02GkreHBtas/thumbnail.jpg Does ruxolitinib work for perioral dermatitis? Does ruxolitinib work for perioral dermatitis? https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-perioral-dermatitis-22 39 2022-01-31T22:03:00.000Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-with-other-jak-inhibitors 2024-04-01T15:45:06.679Z https://image.mux.com/00TcY01mM9nWto4jmL2rvP02MOO2L7t8tCETQbuMYxBEsg/thumbnail.jpg Can ruxolitinib for vitiligo be used with other JAK inhibitors? Can ruxolitinib for vitiligo be used with other JAK inhibitors? https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-with-other-jak-inhibitors 16 2024-04-01T15:45:06.674Z yes https://dermsquared.com/videos/dermbits/cosmeceuticals-recommend-for-lightening 2023-04-28T19:16:18.386Z https://image.mux.com/ZbmliZiIhm13Yr5tXz7RgBOJf01lDpnwBYyFxIjOJi0000/thumbnail.jpg Which cosmeceuticals do you recommend for lightening? Which cosmeceuticals do you recommend for lightening? https://dermsquared.com/videos/dermbits/cosmeceuticals-recommend-for-lightening 24 2021-08-05T22:11:10.000Z yes https://dermsquared.com/videos/dermbits/systemic-like-apremilast 2026-03-03T16:08:04.363Z https://image.mux.com/4R9ztXoTIP5DH3tpaFCoGj5Yw4CvrdgJNam1d3pgouU/thumbnail.jpg What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast? What patient conversations tend to trigger that shift from topical-only management to a systemic like apremilast? https://dermsquared.com/videos/dermbits/systemic-like-apremilast 42 2026-03-03T16:08:04.349Z yes https://dermsquared.com/videos/dermbits/jak-inhibitors-effective-treatment-alopecia 2023-04-28T18:59:36.395Z https://image.mux.com/Hi79IJjkPdSLjP3fgCSEIJHpZlLQEqvgks00FT001IX9Q/thumbnail.jpg Are JAK inhibitors (specifically tofacitinib or ruxolitinib) an effective treatment option for alopecia areata? Are JAK inhibitors (specifically tofacitinib or ruxolitinib) an effective treatment option for alopecia areata? https://dermsquared.com/videos/dermbits/jak-inhibitors-effective-treatment-alopecia 44 2021-04-14T23:10:42.000Z yes https://dermsquared.com/videos/dermbits/your-clinical-experience 2026-05-26T14:43:39.890Z https://image.mux.com/bnTvpbQ49QzFeiZp01GQsBoaR4Yjq39jLlsTisiiPwIE/thumbnail.jpg Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience? Which efficacy outcomes with tapinarof for AD have proven most meaningful in your clinical experience? https://dermsquared.com/videos/dermbits/your-clinical-experience 116 2026-05-26T14:43:39.880Z yes https://dermsquared.com/videos/dermbits/why-important-to-address-actinic-keratosis-as-chronic-condition 2025-10-20T22:30:18.866Z https://image.mux.com/H3doNGtge01tC42sNbFjnQXue5td01NbEizA8Baryh5rM/thumbnail.jpg Why is it important to address actinic keratosis as a chronic condition rather than isolated lesions? Why is it important to address actinic keratosis as a chronic condition rather than isolated lesions? https://dermsquared.com/videos/dermbits/why-important-to-address-actinic-keratosis-as-chronic-condition 108 2025-02-12T16:21:56.883Z yes https://dermsquared.com/videos/dermbits/lab-monitoring-delgocitinib-cream 2025-08-08T19:56:39.618Z https://image.mux.com/PRG01M6eW5MPQw43EKlHeJKQpI015rGokUntGSqQosYEo/thumbnail.jpg Is routine lab monitoring required for patients on delgocitinib cream? Is routine lab monitoring required for patients on delgocitinib cream? https://dermsquared.com/videos/dermbits/lab-monitoring-delgocitinib-cream 67 2025-08-08T19:56:39.612Z yes https://dermsquared.com/videos/dermbits/dermbits-are-there-any-body-areas-that-you-do-not-recommend-ruxolitinib-cream-adrc22 2022-10-28T22:11:12.000Z https://image.mux.com/XSK4KnRSKfo6JIRjiJPpD1BvUi8xT6XXuOV7VNtbUZM/thumbnail.jpg Are there any body areas that you do not recommend ruxolitinib cream? Are there any body areas that you do not recommend ruxolitinib cream? https://dermsquared.com/videos/dermbits/dermbits-are-there-any-body-areas-that-you-do-not-recommend-ruxolitinib-cream-adrc22 25 2022-10-28T22:11:12.000Z yes https://dermsquared.com/videos/dermbits/what-kind-of-monitoring-is-suggested-for-patients-taking-baricitinib 2023-10-19T21:20:11.345Z https://image.mux.com/45cGpOEa02vIjiXDvQZcrYgth00Pj02vRLJcYScgXplXcY/thumbnail.jpg What kind of monitoring is suggested for patients taking baricitinib? What kind of monitoring is suggested for patients taking baricitinib? https://dermsquared.com/videos/dermbits/what-kind-of-monitoring-is-suggested-for-patients-taking-baricitinib 189 2023-09-29T16:20:57.935Z yes https://dermsquared.com/videos/dermbits/is-phototherapy-effective-in-all-types-of-vitiligo 2024-07-01T14:44:24.488Z https://image.mux.com/a6C6H69NP02WZdNySBtFNz2PU7sASA1LZTretYcJ02fC4/thumbnail.jpg Is phototherapy effective in all types of vitiligo? Is phototherapy effective in all types of vitiligo? https://dermsquared.com/videos/dermbits/is-phototherapy-effective-in-all-types-of-vitiligo 42 2024-07-01T14:44:24.482Z yes https://dermsquared.com/videos/dermbits/do-topical-calcineurin-inhibitors-have-role-adjunctive-therapy-ruxolitinib 2025-04-02T16:22:48.680Z https://image.mux.com/UGT7nkByyeEG015iku015UVqMq51Cp9EOmRu4JGAcnv6A/thumbnail.jpg Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely? Do topical calcineurin inhibitors and corticosteroids have a role as adjunctive therapy with ruxolitinib, or should they be replaced entirely? https://dermsquared.com/videos/dermbits/do-topical-calcineurin-inhibitors-have-role-adjunctive-therapy-ruxolitinib 41 2025-04-02T16:22:48.671Z yes https://dermsquared.com/videos/dermbits/most-common-side-effects-ixekizumab-long-term-use 2024-09-24T18:18:38.912Z https://image.mux.com/Doa6NAh01ZkWrcK3avb1uo022dmV7BWXA00XQZoyRMyTb8/thumbnail.jpg What are the most common side effects associated with ixekizumab in long-term use? What are the most common side effects associated with ixekizumab in long-term use? https://dermsquared.com/videos/dermbits/most-common-side-effects-ixekizumab-long-term-use 170 2024-09-24T18:18:38.904Z yes https://dermsquared.com/videos/dermbits/apremilast-reenter-consideration 2026-05-07T17:29:36.465Z https://image.mux.com/UueAdxZUelja538MaVZ8pYpGaboqtRebraBrLV91w9Q/thumbnail.jpg In patients who have failed or discontinued biologics, when does apremilast reenter consideration? In patients who have failed or discontinued biologics, when does apremilast reenter consideration? https://dermsquared.com/videos/dermbits/apremilast-reenter-consideration 72 2026-05-07T17:29:36.455Z yes https://dermsquared.com/videos/dermbits/limitations-current-conventional-clinical-measures-determine-psoriasis-severity 2024-01-01T16:08:45.800Z https://image.mux.com/TfHtmqBy7HRrukpQO5zzjUtaHZM58m2HLwU1jFvbO1E/thumbnail.jpg What are some of the limitations of the current conventional clinical measures used to determine psoriasis severity? What are some of the limitations of the current conventional clinical measures used to determine psoriasis severity? https://dermsquared.com/videos/dermbits/limitations-current-conventional-clinical-measures-determine-psoriasis-severity 103 2024-01-01T16:04:56.521Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-associated-with-cantharidin 2023-11-09T21:34:45.332Z https://image.mux.com/LprTPOKxJ0200lUh7MHSjG2SHLf2JrLl6UKmG401AZRXOc/thumbnail.jpg What are some of the most common adverse reactions associated with cantharidin? What are some of the most common adverse reactions associated with cantharidin? https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-associated-with-cantharidin 57 2023-11-09T21:34:45.325Z yes https://dermsquared.com/videos/dermbits/with-nonsteroidal-therapies 2026-05-26T14:44:46.660Z https://image.mux.com/tUC1ZdXAN01stmTVc3S01r5ZbYe00ajZXPbYEPHAmIitCQ/thumbnail.jpg How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies? How do you balance short-term AD control with steroids vs longer-term maintenance with nonsteroidal therapies? https://dermsquared.com/videos/dermbits/with-nonsteroidal-therapies 107 2026-05-26T14:44:46.646Z yes https://dermsquared.com/videos/dermbits/what-ingredients-topical-therapies-plaque-psoriasis-irritation-patients-affect-clinical-outcomes 2023-05-31T19:55:17.133Z https://image.mux.com/AmViKC3mH2Bj7DRAFN22YOLq61sXSUopXlScsIxRfDE/thumbnail.jpg What common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients? What common ingredients in topical therapies for plaque psoriasis may cause irritation for your patients? https://dermsquared.com/videos/dermbits/what-ingredients-topical-therapies-plaque-psoriasis-irritation-patients-affect-clinical-outcomes 116 2023-05-31T19:55:17.126Z yes https://dermsquared.com/videos/dermbits/dermbits-why-has-the-40-gep-test-been-validated-on-several-data-sets-WCM2300013-scc23 2023-05-17T20:08:19.595Z https://image.mux.com/eSboy1Fk8ZX3dWtDHAhiucZEGkOpdUu02TSO7op91ckM/thumbnail.jpg Why has the 40-GEP test been validated on several data sets? Why has the 40-GEP test been validated on several data sets? https://dermsquared.com/videos/dermbits/dermbits-why-has-the-40-gep-test-been-validated-on-several-data-sets-WCM2300013-scc23 32 2023-05-17T20:08:19.589Z yes https://dermsquared.com/videos/dermbits/oral-tranexamic-acid-splitting-650-mg-tablet 2023-04-28T19:12:50.530Z https://image.mux.com/9Tcb9GFdpXltIMU9N7p7uYFYOxcbpKlMYXMWcgGobhQ/thumbnail.jpg How do you have your patients take oral tranexamic acid? Is there any benefit to splitting the 650 mg tablet? How do you have your patients take oral tranexamic acid? Is there any benefit to splitting the 650 mg tablet? https://dermsquared.com/videos/dermbits/oral-tranexamic-acid-splitting-650-mg-tablet 42 2021-07-07T22:39:29.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-importance-of-early-intervention-in-preventing-disease-progression-in-atopic-dermatitis 2025-04-01T14:18:12.240Z https://image.mux.com/2Eo3U2oE1ISy3gXqPAlrDLNzrnm6LCaiKw9028A8c1wg/thumbnail.jpg What is the importance of early intervention in preventing disease progression in atopic dermatitis? What is the importance of early intervention in preventing disease progression in atopic dermatitis? https://dermsquared.com/videos/dermbits/what-is-the-importance-of-early-intervention-in-preventing-disease-progression-in-atopic-dermatitis 62 2025-04-01T14:18:12.233Z yes https://dermsquared.com/videos/dermbits/overturn-a-denial 2026-03-02T17:52:15.312Z https://image.mux.com/h5L4ialYSbOJxtxNtSJOdCSEX3LhRRtjZwXTxtDooMo/thumbnail.jpg What supporting materials help overturn a denial? What supporting materials help overturn a denial? https://dermsquared.com/videos/dermbits/overturn-a-denial 77 2026-03-02T17:52:15.294Z yes https://dermsquared.com/videos/dermbits/role-of-the-jak-stat-pathway-in-vitiligo 2024-04-01T15:44:49.084Z https://image.mux.com/VPP65tDsP2Kh01AoLdveK5IABeEEbqTGLDiBKsH28AeU/thumbnail.jpg What is the role of the JAK-STAT pathway in vitiligo? What is the role of the JAK-STAT pathway in vitiligo? https://dermsquared.com/videos/dermbits/role-of-the-jak-stat-pathway-in-vitiligo 62 2024-04-01T15:44:49.078Z yes https://dermsquared.com/videos/dermbits/moving-beyond-population-risk 2026-06-11T14:58:54.746Z https://image.mux.com/3K9YIUBytbw3mI9n0121r91lu9SfwJelzU602m76hASl4/thumbnail.jpg Understanding the i31-SLNB Score: Moving Beyond Population Risk Understanding the i31-SLNB Score: Moving Beyond Population Risk https://dermsquared.com/videos/dermbits/moving-beyond-population-risk 26 2025-07-01T14:15:03.412Z yes https://dermsquared.com/videos/dermbits/risk-rebound-worsening-vitiligo-after-discontinuing-ruxolitinib 2024-05-31T13:34:02.494Z https://image.mux.com/9UOlTggKuHdGgvPfRVgq00Lt61OWUaDbmFt1bCCXbhUA/thumbnail.jpg Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib? Is there any risk of rebound or worsening of vitiligo symptoms after discontinuing ruxolitinib? https://dermsquared.com/videos/dermbits/risk-rebound-worsening-vitiligo-after-discontinuing-ruxolitinib 32 2024-05-31T13:34:02.489Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-overall-safety-and-tolerability-profile-for-topical-roflumilast-arcp22 2023-05-11T14:53:25.355Z https://image.mux.com/38zbrnTUZ01Jr8M1DWjpZeyUN11JSqZdOoTs003OFjEMw/thumbnail.jpg What is the overall safety and tolerability profile for topical roflumilast? What is the overall safety and tolerability profile for topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-overall-safety-and-tolerability-profile-for-topical-roflumilast-arcp22 47 2022-10-28T22:59:05.000Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-effects-tapinarof-atopic-dermatitis 2025-02-03T19:11:02.140Z https://image.mux.com/RMn1kT5Wr3IrAcuKJAj3aMCJBRRYpaSnQhvlWqjV02sE/thumbnail.jpg What are the most common adverse effects observed with tapinarof for atopic dermatitis? What are the most common adverse effects observed with tapinarof for atopic dermatitis? https://dermsquared.com/videos/dermbits/most-common-adverse-effects-tapinarof-atopic-dermatitis 27 2025-02-03T19:11:02.133Z yes https://dermsquared.com/videos/dermbits/dermbits-what-are-the-advocacy-priorities-of-the-aad-WCM230005 2023-03-10T00:11:22.000Z https://image.mux.com/3sKhVKCLELUmENaRL01kZBk004sGGNfGfeYB9fbmyYtkc/thumbnail.jpg What are the advocacy priorities of the AAD? What are the advocacy priorities of the AAD? https://dermsquared.com/videos/dermbits/dermbits-what-are-the-advocacy-priorities-of-the-aad-WCM230005 26 2023-03-10T00:11:22.000Z yes https://dermsquared.com/videos/dermbits/threshold-in-select-patients 2026-03-06T16:28:20.285Z https://image.mux.com/pOt02h02U9zPmiCTn00JGXNynHOf02Stxfd3DYjtvJKPOjI/thumbnail.jpg Has the DecisionDx Melanoma test influenced your imaging threshold in select patients? Has the DecisionDx Melanoma test influenced your imaging threshold in select patients? https://dermsquared.com/videos/dermbits/threshold-in-select-patients 123 2026-03-06T16:28:20.280Z yes https://dermsquared.com/videos/dermbits/how-frequently-follow-up-patients-ruxolitinib-vitiligo 2025-03-03T14:14:44.165Z https://image.mux.com/DJ6vJLnGtmAH6AJU6r02AQqbiB7p01s02BMugd2IKw8QSU/thumbnail.jpg How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo? How frequently should dermatologists follow up with patients taking ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-frequently-follow-up-patients-ruxolitinib-vitiligo 42 2025-03-03T14:14:44.158Z yes https://dermsquared.com/videos/dermbits/benefit-to-extending-dosing-interval-ixekizumab-stable-psoriasis 2024-10-18T17:18:21.819Z https://image.mux.com/2STcnSKX7YY3qto00qrOpEE7RHlYvjjekmk6weLgd4w8/thumbnail.jpg Is there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis? Is there any benefit to extending the dosing interval of ixekizumab in patients with stable psoriasis? https://dermsquared.com/videos/dermbits/benefit-to-extending-dosing-interval-ixekizumab-stable-psoriasis 74 2024-10-18T17:18:21.812Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-you-stagger-poly-l-lactic-acid-treatments-with-hyaluronic-acid-and-botox 2023-01-11T20:42:49.000Z https://image.mux.com/3ajQf02stbYjyjv272NGly02R1H01xWHpwddzvfsWl2R4E/thumbnail.jpg How do you stagger Poly-L-lactic acid treatments with hyaluronic acid and botox? How do you stagger Poly-L-lactic acid treatments with hyaluronic acid and botox? https://dermsquared.com/videos/dermbits/dermbits-how-do-you-stagger-poly-l-lactic-acid-treatments-with-hyaluronic-acid-and-botox 52 2023-01-11T20:42:49.000Z yes https://dermsquared.com/videos/dermbits/lesser-known-factors-that-can-increase-risk-of-developing-scc 2023-08-31T21:15:02.767Z https://image.mux.com/2MEoT3xzEFVjVmuslNDTzXTBTB02qMpsenx021hZAHg3o/thumbnail.jpg What are some lesser-known factors that can increase the risk of developing SCC? What are some lesser-known factors that can increase the risk of developing SCC? https://dermsquared.com/videos/dermbits/lesser-known-factors-that-can-increase-risk-of-developing-scc 32 2023-08-31T20:51:29.068Z yes https://dermsquared.com/videos/dermbits/can-you-reuse-the-cantharidin-applicator 2023-11-30T19:19:06.745Z https://image.mux.com/meax1f2OPTd9LNo3wSO9gIKfaANRqkvrOTRe4k4oP54/thumbnail.jpg Can you reuse the cantharidin applicator? Can you reuse the cantharidin applicator? https://dermsquared.com/videos/dermbits/can-you-reuse-the-cantharidin-applicator 27 2023-11-30T19:19:06.731Z yes https://dermsquared.com/videos/dermbits/what-is-koebner-phenomenon-vitiligo 2025-05-01T13:44:25.115Z https://image.mux.com/IrYRoKHn01Pv2CQMrVZ8ROJWgjWBn02021Hprn1buYaOyg/thumbnail.jpg What is the Koebner phenomenon in vitiligo? What is the Koebner phenomenon in vitiligo? https://dermsquared.com/videos/dermbits/what-is-koebner-phenomenon-vitiligo 64 2025-05-01T13:44:25.108Z yes https://dermsquared.com/videos/dermbits/can-patients-treated-with-spesolimab-receive-live-vaccines 2023-08-31T20:47:22.452Z https://image.mux.com/6BHCzKNaNvbZRBSkYqoitP4bGc736zP6ZmpIk36Oolk/thumbnail.jpg Can patients treated with spesolimab receive live vaccines? Can patients treated with spesolimab receive live vaccines? https://dermsquared.com/videos/dermbits/can-patients-treated-with-spesolimab-receive-live-vaccines 73 2023-08-31T20:47:22.447Z yes https://dermsquared.com/videos/dermbits/how-quickly-results-with-topical-roflumilast-22 2023-04-28T20:26:52.997Z https://image.mux.com/AjRjlvd02bU02JTTcvpL12eoJMiMquurotl4WDO4ZDYDs/thumbnail.jpg How quickly do patients see results with topical roflumilast? How quickly do patients see results with topical roflumilast? https://dermsquared.com/videos/dermbits/how-quickly-results-with-topical-roflumilast-22 22 2022-08-30T23:11:38.000Z yes https://dermsquared.com/videos/dermbits/biologic-medication-best-moderate-severe-hs 2023-04-28T19:46:26.868Z https://image.mux.com/RREyp1fbeBRy00fKrEJUt00bwyccRaGPXcWte01lhGYchQ/thumbnail.jpg What biologic medication (other than Humira) has worked best in your experience for your moderate to severe HS? What biologic medication (other than Humira) has worked best in your experience for your moderate to severe HS? https://dermsquared.com/videos/dermbits/biologic-medication-best-moderate-severe-hs 61 2022-01-06T21:02:34.000Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-start-childhood 2023-04-28T19:31:05.168Z https://image.mux.com/7pcO00ENNufXFVDktIrZKUXmuFMxCTD15ZW3aWpDGa00A/thumbnail.jpg Does atopic dermatitis always start in childhood? Does atopic dermatitis always start in childhood? https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-start-childhood 78 2021-11-17T20:40:33.000Z yes https://dermsquared.com/videos/dermbits/why-organ-transplant-recipients-have-a-higher-risk-of-developing-scc 2023-08-31T21:15:27.849Z https://image.mux.com/yEf3UIzvmjJ6ukdNFIrpHOOcPQVJdXTnrjWf02nZH3X8/thumbnail.jpg Why do organ transplant recipients have a higher risk of developing SCC? Why do organ transplant recipients have a higher risk of developing SCC? https://dermsquared.com/videos/dermbits/why-organ-transplant-recipients-have-a-higher-risk-of-developing-scc 56 2023-08-31T20:51:15.757Z yes https://dermsquared.com/videos/dermbits/dermbits-how-durable-is-the-efficacy-of-topical-roflumilast-for-the-long-term-artr00033-arcp22 2022-11-29T21:59:39.000Z https://image.mux.com/Td1YaJxUbUvV02XQ4SJeVmfXA4s02iiDN343DKjv02BAO8/thumbnail.jpg How durable is the efficacy of topical roflumilast for the long-term? How durable is the efficacy of topical roflumilast for the long-term? https://dermsquared.com/videos/dermbits/dermbits-how-durable-is-the-efficacy-of-topical-roflumilast-for-the-long-term-artr00033-arcp22 19 2022-11-29T21:59:39.000Z yes https://dermsquared.com/videos/dermbits/oral-jak-inhibitors-pediatric-alopecia-areata 2023-04-28T19:19:35.948Z https://image.mux.com/z5ash1qQWb5nsg6u01OMfnYcGZJRA02iDZ9QEdx3oGaOw/thumbnail.jpg Do you prescribe oral JAK inhibitors for your pediatric patients with vitiligo or alopecia areata? Do you prescribe oral JAK inhibitors for your pediatric patients with vitiligo or alopecia areata? https://dermsquared.com/videos/dermbits/oral-jak-inhibitors-pediatric-alopecia-areata 61 2021-09-09T02:20:07.000Z yes https://dermsquared.com/videos/dermbits/managing-their-disease 2026-03-03T16:09:15.021Z https://image.mux.com/3Y01I5pmI1Tl01JOsTVnTUOl0001oe3oNk8GTiN010281US7g/thumbnail.jpg In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease? In what situations does apremilast still meaningfully improve a patient’s experience of managing their disease? https://dermsquared.com/videos/dermbits/managing-their-disease 42 2026-03-03T16:09:15.015Z yes https://dermsquared.com/videos/dermbits/approaching-long-term-monitoring-atypical-dysplastic-nevi 2025-07-15T03:05:20.877Z https://image.mux.com/2013ZOBJNreKXihaBSWLJuXxehnV2rPqo01HnFx3SxDPE/thumbnail.jpg How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi? How do you typically approach long-term monitoring for patients with a history of severely atypical nevi or dysplastic nevi? https://dermsquared.com/videos/dermbits/approaching-long-term-monitoring-atypical-dysplastic-nevi 95 2025-07-15T03:05:20.870Z yes https://dermsquared.com/videos/dermbits/how-soon-patients-on-ixekizumab-psoriasis-expect-results 2024-08-20T18:29:03.125Z https://image.mux.com/L3BG00wa94P02ztyKQEN5NTsi3UnDxVa1M16t8Wxl29XQ/thumbnail.jpg How soon can patients on ixekizumab for psoriasis expect to see results? How soon can patients on ixekizumab for psoriasis expect to see results? https://dermsquared.com/videos/dermbits/how-soon-patients-on-ixekizumab-psoriasis-expect-results 92 2024-08-20T18:14:39.090Z yes https://dermsquared.com/videos/dermbits/certain-patients-or-lesions 2026-05-22T13:20:03.395Z https://image.mux.com/n00a27UTc8k33ElFoEc8SOvRkL9HPu3FvHm02QidPtA00s/thumbnail.jpg In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions? In your experience, what are the common reasons traditional topical therapies fall short in certain patients or lesions? https://dermsquared.com/videos/dermbits/certain-patients-or-lesions 56 2026-05-22T13:20:03.382Z yes https://dermsquared.com/videos/dermbits/how-do-you-approach-long-term-management-of-plaque-psoriasis 2024-01-01T16:05:00.677Z https://image.mux.com/01QtXmMuzX8ayHAGDgZ02Ewf7ELNE2aMympcw91x9VFxo/thumbnail.jpg How do you approach long-term management of plaque psoriasis? How do you approach long-term management of plaque psoriasis? https://dermsquared.com/videos/dermbits/how-do-you-approach-long-term-management-of-plaque-psoriasis 165 2024-01-01T16:05:00.671Z yes https://dermsquared.com/videos/dermbits/oral-therapy-particularly-appealing 2026-05-07T17:29:09.576Z https://image.mux.com/ETMS12R3tNKWZNZuHo5AuQqiYY02B00Ry4a91AnH4LWBA/thumbnail.jpg What lifestyle or occupational factors make oral therapy particularly appealing? What lifestyle or occupational factors make oral therapy particularly appealing? https://dermsquared.com/videos/dermbits/oral-therapy-particularly-appealing 87 2026-05-07T17:29:09.565Z yes https://dermsquared.com/videos/dermbits/is-decision-dx-test-appropriate-all-patients-melanoma-or-specific-eligibility-criteria 2025-03-03T14:12:31.737Z https://image.mux.com/Etg02ZQpEr9Vsu82SFrfI4br5ikmOT2ixUrUFEbmUi38/thumbnail.jpg Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria? Is the DecisionDx test appropriate for all patients with melanoma, or are there specific eligibility criteria? https://dermsquared.com/videos/dermbits/is-decision-dx-test-appropriate-all-patients-melanoma-or-specific-eligibility-criteria 47 2025-03-03T14:12:31.730Z yes https://dermsquared.com/videos/dermbits/topical-therapies-for-vitiligo 2026-06-10T14:39:41.662Z https://image.mux.com/oOnidYkYO5bK6vq01T1I5QP8k64rpjN01EEC02HN1IoNc00/thumbnail.jpg How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo? How do you counsel patients on the timeline of repigmentation with topical therapies for vitiligo? https://dermsquared.com/videos/dermbits/topical-therapies-for-vitiligo 54 2026-06-10T14:39:41.651Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-tailor-treatment-plans-for-patients-with-frequent-infections-related-to-atopic-dermatitis 2025-04-01T14:18:31.872Z https://image.mux.com/FbIizf6tXXoU8MJypW75vBIoe3xr011paLOH20001ND66Y/thumbnail.jpg How can dermatologists tailor treatment plans for patients with frequent infections related to atopic dermatitis? How can dermatologists tailor treatment plans for patients with frequent infections related to atopic dermatitis? https://dermsquared.com/videos/dermbits/how-can-dermatologists-tailor-treatment-plans-for-patients-with-frequent-infections-related-to-atopic-dermatitis 79 2025-04-01T14:18:31.865Z yes https://dermsquared.com/videos/dermbits/which-parts-of-the-body-ruxolitinib-work-best 2024-05-01T13:33:29.105Z https://image.mux.com/LjSaZl7MB2ID99wRMdkGrbwDqMZpJVz9XMjJ291hzTU/thumbnail.jpg Which parts of the body does ruxolitinib work best on? Which parts of the body does ruxolitinib work best on? https://dermsquared.com/videos/dermbits/which-parts-of-the-body-ruxolitinib-work-best 40 2024-05-01T13:33:29.095Z yes https://dermsquared.com/videos/dermbits/monitoring-recommended-routine-patient-management-bimekizumab-liver-enzyme-levels 2024-01-03T17:12:46.878Z https://image.mux.com/gm01ihLHkpzkuGfT1wHIOHvUPbOGeBGshY1KVPLnJ02028/thumbnail.jpg What monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels? What monitoring is recommended for routine patient management with bimekizumab to assess liver enzyme levels? https://dermsquared.com/videos/dermbits/monitoring-recommended-routine-patient-management-bimekizumab-liver-enzyme-levels 45 2024-01-03T17:12:46.869Z yes https://dermsquared.com/videos/dermbits/dermbits-what-leads-to-burnout-and-what-can-we-do-to-help-deal-with-it-WCM2300010 2023-03-10T00:23:20.000Z https://image.mux.com/ofuFnG4Lh01H53isVfEkn8R017YqGyMe3x3Pkwo0001i4FA/thumbnail.jpg What leads to burnout, and what can we do to help deal with it? What leads to burnout, and what can we do to help deal with it? https://dermsquared.com/videos/dermbits/dermbits-what-leads-to-burnout-and-what-can-we-do-to-help-deal-with-it-WCM2300010 50 2023-03-10T00:23:20.000Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-ruxolitinib-for-vitiligo 2024-03-06T16:02:50.068Z https://image.mux.com/7aeD9m6wbbAtgkRCjOWn00Nvcd8iUTkSSRdfZp01KgWfw/thumbnail.jpg What is the recommended dosing regimen for ruxolitinib for vitiligo? What is the recommended dosing regimen for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-ruxolitinib-for-vitiligo 58 2024-03-06T16:02:50.063Z yes https://dermsquared.com/videos/dermbits/auth-to-formal-appeal 2026-03-02T17:52:51.501Z https://image.mux.com/CGr2Qd02P8Y7LWDR2102cglZc62NUQ7DsJHu3BnFq7oTw/thumbnail.jpg When do you escalate from prior auth to formal appeal? When do you escalate from prior auth to formal appeal? https://dermsquared.com/videos/dermbits/auth-to-formal-appeal 102 2026-03-02T17:52:51.480Z yes https://dermsquared.com/videos/dermbits/dermbits-what-are-high-risk-features-of-cscc-WCM2300020-scc23 2023-05-17T20:08:07.552Z https://image.mux.com/ZFebWUwEQnFs7ZyGpCL8WTGNJwRxhTKmjjau2Sr7ZzY/thumbnail.jpg What are high risk features of cSCC? What are high risk features of cSCC? https://dermsquared.com/videos/dermbits/dermbits-what-are-high-risk-features-of-cscc-WCM2300020-scc23 59 2023-05-17T20:08:07.547Z yes https://dermsquared.com/videos/dermbits/ideal-patient-tapinarof-and-any-notable-exclusions 2024-04-08T18:35:58.125Z https://image.mux.com/8SZ2vgxgbloWvr2ZNw00mEYqPV5rSDrYMfcjwoU17CME/thumbnail.jpg Who is the ideal patient for tapinarof, and are there any notable exclusions? Who is the ideal patient for tapinarof, and are there any notable exclusions? https://dermsquared.com/videos/dermbits/ideal-patient-tapinarof-and-any-notable-exclusions 41 2024-04-08T18:35:58.120Z yes https://dermsquared.com/videos/dermbits/gep-tests-supplement-traditional-pathology-melanoma 2025-07-15T03:04:53.477Z https://image.mux.com/rUDD8gQIS4M4Dw3Liw896we1etPaa3VEvYqQgz01g3rs/thumbnail.jpg Are GEP tests meant to replace or supplement traditional pathology for melanoma? Are GEP tests meant to replace or supplement traditional pathology for melanoma? https://dermsquared.com/videos/dermbits/gep-tests-supplement-traditional-pathology-melanoma 64 2025-07-15T03:04:53.457Z yes https://dermsquared.com/videos/dermbits/can-dupilumab-cause-ctcl 2023-04-28T19:14:50.309Z https://image.mux.com/hIvs7yUYEL02KBsIwxqKeAowWGSMdmqja2EL7a29400sk/thumbnail.jpg Can dupilumab cause cutaneous T-cell lymphoma (CTCL)? Can dupilumab cause cutaneous T-cell lymphoma (CTCL)? https://dermsquared.com/videos/dermbits/can-dupilumab-cause-ctcl 122 2021-07-23T01:07:53.000Z yes https://dermsquared.com/videos/dermbits/is-there-risk-systemic-absorption-ruxolitinib-vitiligo 2025-03-03T14:14:12.290Z https://image.mux.com/qmxghVpNlmtr01wh7F1AJ7Bq6fDjD3PJuJElqi512GDk/thumbnail.jpg Is there a risk of systemic absorption with ruxolitinib for vitiligo? Is there a risk of systemic absorption with ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/is-there-risk-systemic-absorption-ruxolitinib-vitiligo 38 2025-03-03T14:14:12.283Z yes https://dermsquared.com/videos/dermbits/managing-nonresponders-ritlecitinib-patients-alopecia-areata 2024-10-01T14:14:37.345Z https://image.mux.com/YXHWVulSvod7rswPyPbwYxZnKvVk7zgyPzjNwg01PiPM/thumbnail.jpg What is your approach for managing nonresponders or partial responders to ritlecitinib in patients with alopecia areata? What is your approach for managing nonresponders or partial responders to ritlecitinib in patients with alopecia areata? https://dermsquared.com/videos/dermbits/managing-nonresponders-ritlecitinib-patients-alopecia-areata 31 2024-10-01T14:14:37.337Z yes https://dermsquared.com/videos/dermbits/what-patient-disease-characteristics-consider-choosing-systemic-therapy-metastatic-scc 2023-11-17T16:51:55.459Z https://image.mux.com/gtm1AStpCCVCmf3IUtGbDumknA7cU283FIkIzifC7Eg/thumbnail.jpg What patient and disease characteristics do you consider when choosing a systemic therapy for patients with metastatic SCC? What patient and disease characteristics do you consider when choosing a systemic therapy for patients with metastatic SCC? https://dermsquared.com/videos/dermbits/what-patient-disease-characteristics-consider-choosing-systemic-therapy-metastatic-scc 65 2023-11-17T16:36:54.668Z yes https://dermsquared.com/videos/dermbits/how-common-atopic-dermatitis-psoriasis 2023-04-28T19:50:05.543Z https://image.mux.com/8bhil7PeIf9ELNMadCuF2BzgYzOgewmgb6hG4TBT01XE/thumbnail.jpg How common is atopic dermatitis compared to psoriasis? How common is atopic dermatitis compared to psoriasis? https://dermsquared.com/videos/dermbits/how-common-atopic-dermatitis-psoriasis 93 2022-01-28T01:13:02.000Z yes https://dermsquared.com/videos/dermbits/advantages-topical-therapy-as-monotherapy-over-systemic-therapy-plaque-psoriasis 2023-08-31T20:40:23.399Z https://image.mux.com/fGfqPWPxSe00d76Xv7lAiPqVMXHXHBNh00QiyIbLhpV3k/thumbnail.jpg What are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis?   What are the advantages of topical therapy as monotherapy over systemic therapy for plaque psoriasis?   https://dermsquared.com/videos/dermbits/advantages-topical-therapy-as-monotherapy-over-systemic-therapy-plaque-psoriasis 112 2023-08-31T20:40:23.394Z yes https://dermsquared.com/videos/dermbits/adherence-in-daily-life 2025-11-14T15:27:37.599Z https://image.mux.com/98o0238CrDEo3CKIu101f6rw501Z162ZVaOMuRrAJME1Dk/thumbnail.jpg What are your go-to strategies for improving sunscreen adherence in daily life? What are your go-to strategies for improving sunscreen adherence in daily life? https://dermsquared.com/videos/dermbits/adherence-in-daily-life 85 2025-11-14T15:27:37.593Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-cream-treatment-atopic-dermatitis 2023-04-28T19:37:58.170Z https://image.mux.com/02AmN8bz2MT00J4SVNlvI3SUYEeU8900lxgLIuQVR9kCmw/thumbnail.jpg How does ruxolitinib cream fit in your treatment algorithm for your atopic dermatitis patients? How does ruxolitinib cream fit in your treatment algorithm for your atopic dermatitis patients? https://dermsquared.com/videos/dermbits/ruxolitinib-cream-treatment-atopic-dermatitis 40 2021-12-15T01:38:41.000Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-of-ixekizumab 2024-07-17T16:13:22.279Z https://image.mux.com/g9DSUktJjmuz3DvgsC01vEQSA007i00zq3q7D18UXsKJuY/thumbnail.jpg What is the mechanism of action of ixekizumab? What is the mechanism of action of ixekizumab? https://dermsquared.com/videos/dermbits/mechanism-of-action-of-ixekizumab 40 2024-07-17T16:13:22.270Z yes https://dermsquared.com/videos/dermbits/answer-in-early-melanoma 2026-06-11T14:52:38.166Z https://image.mux.com/lbdqZmg01RlytYFPP01wEJzY66lU7yyIg9tbokSpqB5Ls/thumbnail.jpg The Questions We’re Really Trying to Answer in Early Melanoma The Questions We’re Really Trying to Answer in Early Melanoma https://dermsquared.com/videos/dermbits/answer-in-early-melanoma 47 2025-03-03T14:12:40.165Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ruxolitinib-for-vitiligo 2024-03-06T16:03:08.034Z https://image.mux.com/008LyNmsORtQpqSuWkgVMv9o64qZb601TVDRjai00sDG7g/thumbnail.jpg What are the most common adverse reactions seen with ruxolitinib for vitiligo? What are the most common adverse reactions seen with ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ruxolitinib-for-vitiligo 73 2024-03-06T16:03:08.029Z yes https://dermsquared.com/videos/dermbits/severity-seems-borderline 2026-04-02T16:21:53.919Z https://image.mux.com/RLotQDF01W02NrSlThsUp3d100atI5sLj71lwf5gVCc02Xs/thumbnail.jpg How do you document medical necessity when disease severity seems borderline? How do you document medical necessity when disease severity seems borderline? https://dermsquared.com/videos/dermbits/severity-seems-borderline 64 2026-04-02T14:31:50.614Z yes https://dermsquared.com/videos/dermbits/who-is-a-good-candidate-for-lebrikizumab 2024-12-02T16:28:13.493Z https://image.mux.com/KzbRkHbsRyxOfICUWoM02Kw1uuQf3Mu9lblS02w202nBZA/thumbnail.jpg Who is a good candidate for lebrikizumab? Who is a good candidate for lebrikizumab? https://dermsquared.com/videos/dermbits/who-is-a-good-candidate-for-lebrikizumab 32 2024-12-02T16:28:13.486Z yes https://dermsquared.com/videos/dermbits/dermbits-clinical-tips-identify-patients-intertriginous-psoriasis-avoided-artr00031-arcp22 2022-11-29T21:44:17.000Z https://image.mux.com/ERbyOX92TCvS13ehZAJeodwet1kyJqOWzMOeEmmq4ig/thumbnail.jpg What are some clinical tips to help identify and/or uncover whether patients have intertriginous psoriasis so that these areas are not overlooked or avoided? What are some clinical tips to help identify and/or uncover whether patients have intertriginous psoriasis so that these areas are not overlooked or avoided? https://dermsquared.com/videos/dermbits/dermbits-clinical-tips-identify-patients-intertriginous-psoriasis-avoided-artr00031-arcp22 21 2022-11-29T21:44:17.000Z yes https://dermsquared.com/videos/dermbits/how-integrate-multidisciplinary-approach-patient-care-to-address-diverse-aspects-vitiligo 2025-06-03T13:45:22.313Z https://image.mux.com/Srr13T5d00F00kWCGwVa4xiFNw02EH9mPoAkxGBWUAwFws/thumbnail.jpg How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo? How can dermatologists integrate a multidisciplinary approach in patient care to address the diverse aspects of vitiligo? https://dermsquared.com/videos/dermbits/how-integrate-multidisciplinary-approach-patient-care-to-address-diverse-aspects-vitiligo 48 2025-06-03T13:45:22.306Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-you-counsel-patients-on-their-skincare-regimen-WC220008 2022-12-23T02:18:48.000Z https://image.mux.com/NwsvZec6k1X02shAZIyThq2mfhyN26Fy5HP02rHzJ02cwE/thumbnail.jpg How do you counsel patients on their skincare regimen? How do you counsel patients on their skincare regimen? https://dermsquared.com/videos/dermbits/dermbits-how-do-you-counsel-patients-on-their-skincare-regimen-WC220008 58 2022-12-23T02:18:48.000Z yes https://dermsquared.com/videos/dermbits/how-do-you-navigate-it 2026-07-01T13:48:58.050Z https://image.mux.com/VN6Ig5DaFGdL1k01gFijfw005Bxbw89OLwsPrKLGxtPZQ/thumbnail.jpg When does combination therapy complicate access—and how do you navigate it? When does combination therapy complicate access—and how do you navigate it? https://dermsquared.com/videos/dermbits/how-do-you-navigate-it 81 2026-07-01T13:48:58.040Z yes https://dermsquared.com/videos/dermbits/how-does-sarecycline-fit-into-the-current-guidelines-for-acne-management-and-antibiotic-stewardship 2025-05-07T17:26:35.759Z https://image.mux.com/uO024B7jlFZPFCwMNZkGdWNAFDEg01BICHiJSYz3TsSps/thumbnail.jpg How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship? How does sarecycline fit into the current guidelines for acne management and antibiotic stewardship? https://dermsquared.com/videos/dermbits/how-does-sarecycline-fit-into-the-current-guidelines-for-acne-management-and-antibiotic-stewardship 168 2025-05-07T17:24:00.801Z yes https://dermsquared.com/videos/dermbits/protection-or-visible-light-defense 2025-11-14T15:25:38.566Z https://image.mux.com/WLoBPfO3GTnF01vAxF1jKBRf00uwcs61lYNn6xtccMf1M/thumbnail.jpg What makes a sunscreen particularly effective for pigment protection or visible-light defense? What makes a sunscreen particularly effective for pigment protection or visible-light defense? https://dermsquared.com/videos/dermbits/protection-or-visible-light-defense 60 2025-11-14T15:25:38.558Z yes https://dermsquared.com/videos/dermbits/any-environmental-factors-trigger-exacerbate-alopecia-areata 2024-11-07T16:10:54.975Z https://image.mux.com/6IDsWe01Yoqs01K6B6B4QnzSheZRMVc8cjRuuFQRsTOis/thumbnail.jpg Are there any environmental factors that can trigger or exacerbate alopecia areata? Are there any environmental factors that can trigger or exacerbate alopecia areata? https://dermsquared.com/videos/dermbits/any-environmental-factors-trigger-exacerbate-alopecia-areata 79 2024-11-07T16:10:54.963Z yes https://dermsquared.com/videos/dermbits/home-based-nb-uvb-device 2025-10-20T17:26:34.473Z https://image.mux.com/Ny8tdjsVOJZDn5004AaDR2sRrwhMogGdhwc3vNRoh6bY/thumbnail.jpg What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device? What practical steps can a dermatologist take to start prescribing a home-based NB-UVB device? https://dermsquared.com/videos/dermbits/home-based-nb-uvb-device 48 2025-10-13T20:13:16.212Z yes https://dermsquared.com/videos/dermbits/primary-endpoint-of-the-effasayil-trial 2023-08-31T20:44:13.387Z https://image.mux.com/Nr5lvnTTENpcQL01z5vaIutSvmlQLITNB00DtcXJlsfhs/thumbnail.jpg What was the primary endpoint of the Effasayil trial? What was the primary endpoint of the Effasayil trial? https://dermsquared.com/videos/dermbits/primary-endpoint-of-the-effasayil-trial 37 2023-08-31T20:44:13.381Z yes https://dermsquared.com/videos/dermbits/how-soon-should-treatment-be-initiated-after-diagnosing-vitiligo 2024-07-01T14:44:36.300Z https://image.mux.com/De2VAlID02NuQKj8kMAObcYMGIZlemRP7GGOs004yNAtM/thumbnail.jpg How soon should treatment be initiated after diagnosing vitiligo? How soon should treatment be initiated after diagnosing vitiligo? https://dermsquared.com/videos/dermbits/how-soon-should-treatment-be-initiated-after-diagnosing-vitiligo 32 2024-07-01T14:44:36.293Z yes https://dermsquared.com/videos/dermbits/navigate-concerns-from-parents-pediatric-patients-molluscum-contagiosum 2023-11-17T16:50:11.085Z https://image.mux.com/cda0200Bn3PM015y9EXPZ01eqdW9HipCX7Ybli01nlD3Laew/thumbnail.jpg How do you navigate concerns from parents of pediatric patients with molluscum contagiosum? How do you navigate concerns from parents of pediatric patients with molluscum contagiosum? https://dermsquared.com/videos/dermbits/navigate-concerns-from-parents-pediatric-patients-molluscum-contagiosum 143 2023-11-09T21:34:19.117Z yes https://dermsquared.com/videos/dermbits/some-of-the-systemic-associations-of-acute-gpp 2023-07-20T18:16:35.977Z https://image.mux.com/4lVVrguXI00qckykHUykzXcHFOcL2enPOBvyC7lFS00y8/thumbnail.jpg What are some of the systemic associations of acute GPP? What are some of the systemic associations of acute GPP? https://dermsquared.com/videos/dermbits/some-of-the-systemic-associations-of-acute-gpp 44 2023-06-27T17:27:42.823Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-camp-discovery-and-how-can-i-get-involved-WCM230006 2023-03-10T00:15:41.000Z https://image.mux.com/NyVk00LtT801x9eYrIKeeCVg31jlQ5SDZgVuEUsgrjUqo/thumbnail.jpg What is Camp Discovery, and how can I get involved? What is Camp Discovery, and how can I get involved? https://dermsquared.com/videos/dermbits/dermbits-what-is-camp-discovery-and-how-can-i-get-involved-WCM230006 41 2023-03-10T00:15:41.000Z yes https://dermsquared.com/videos/dermbits/effect-covid-19-on-rosacea 2023-04-28T19:50:55.510Z https://image.mux.com/CgcP8Q4Dbi65rrPTGvZfB1IWihUHM00ZlRY5T5D97LkU/thumbnail.jpg What effect does COVID-19 have on rosacea? What effect does COVID-19 have on rosacea? https://dermsquared.com/videos/dermbits/effect-covid-19-on-rosacea 54 2022-01-28T01:15:10.000Z yes https://dermsquared.com/videos/dermbits/unmet-needs-still-remaining-atopic-dermatitis-treatment-landscape 2023-10-31T21:18:14.597Z https://image.mux.com/Ht5QJbhQOeMiAEQb8j2R016xG6nQd02uEPELvJd5ilRqI/thumbnail.jpg What are some of the unmet needs still remaining in the atopic dermatitis treatment landscape? What are some of the unmet needs still remaining in the atopic dermatitis treatment landscape? https://dermsquared.com/videos/dermbits/unmet-needs-still-remaining-atopic-dermatitis-treatment-landscape 40 2023-10-31T21:18:14.589Z yes https://dermsquared.com/videos/dermbits/patients-with-vitiligo-other-autoimmune-diseases 2025-05-01T13:45:04.354Z https://image.mux.com/dZDW3CNUkTuwMK9Cc8SBRv4cAQAUzaftDhMlttCHy6g/thumbnail.jpg Is it common for patients with vitiligo to have other autoimmune diseases? Is it common for patients with vitiligo to have other autoimmune diseases? https://dermsquared.com/videos/dermbits/patients-with-vitiligo-other-autoimmune-diseases 66 2025-05-01T13:45:04.347Z yes https://dermsquared.com/videos/dermbits/what-is-the-likelihood-spontaneous-hair-regrowth-alopecia-areata 2024-10-01T14:14:23.217Z https://image.mux.com/ZSaDeti3DV00zLm3V5ZzBFMtuBwrxUMTJ3njzHmBeNHw/thumbnail.jpg What is the likelihood of spontaneous hair regrowth in patients with alopecia areata? What is the likelihood of spontaneous hair regrowth in patients with alopecia areata? https://dermsquared.com/videos/dermbits/what-is-the-likelihood-spontaneous-hair-regrowth-alopecia-areata 29 2024-10-01T14:14:23.194Z yes https://dermsquared.com/videos/dermbits/types-melanocytic-lesions-mypath-test-best-suited 2025-07-15T03:04:10.944Z https://image.mux.com/Xr00AaCryzK00502Bb02Wus4RbbqIc1lxlcUtgMiEl7PSpY/thumbnail.jpg What types of melanocytic lesions is the MyPath test best suited for? What types of melanocytic lesions is the MyPath test best suited for? https://dermsquared.com/videos/dermbits/types-melanocytic-lesions-mypath-test-best-suited 101 2025-07-15T03:04:10.904Z yes https://dermsquared.com/videos/dermbits/treatment-with-topical-therapies 2026-06-10T14:39:24.135Z https://image.mux.com/4A6iy4zzhsp02pdPQD02DmcJhrDvmy9CkkYk70189pph5M/thumbnail.jpg For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies? For patients with vitiligo, what do you focus on in the initial visit before patients even begin treatment with topical therapies? https://dermsquared.com/videos/dermbits/treatment-with-topical-therapies 101 2026-06-10T14:39:24.125Z yes https://dermsquared.com/videos/dermbits/topical-ruxolitinib-itch-atopic-dermatitis-22 2023-04-28T20:18:47.555Z https://image.mux.com/4sD02Zv2Z01iSjRVxAQ4GtqzkhcW1p8h6sZ7hutkC9Tls/thumbnail.jpg How effective is topical ruxolitinib with itch experienced by patients who suffer from atopic dermatitis? How effective is topical ruxolitinib with itch experienced by patients who suffer from atopic dermatitis? https://dermsquared.com/videos/dermbits/topical-ruxolitinib-itch-atopic-dermatitis-22 47 2022-07-27T21:51:45.000Z yes https://dermsquared.com/videos/dermbits/insurance-mid-treatment 2026-06-12T18:53:24.450Z https://image.mux.com/S1APysqJ25WL400PSwA4cellnRu829PkOToNMtOlUO7g/thumbnail.jpg How do you handle coverage for patients switching insurance mid-treatment? How do you handle coverage for patients switching insurance mid-treatment? https://dermsquared.com/videos/dermbits/insurance-mid-treatment 77 2026-06-02T14:10:55.757Z yes https://dermsquared.com/videos/dermbits/dupilumab-for-moderate-to-severe-failing 2023-04-28T19:11:44.763Z https://image.mux.com/9kee5BPPFQkS1uvqq00jrZ02KV9FFFqpYatORWpfhzR2I/thumbnail.jpg Do you support dupilumab for all of the AD spectrum conditions if moderate-to-severe and failing? Do you support dupilumab for all of the AD spectrum conditions if moderate-to-severe and failing? https://dermsquared.com/videos/dermbits/dupilumab-for-moderate-to-severe-failing 145 2021-07-07T22:33:38.000Z yes https://dermsquared.com/videos/dermbits/significance-of-immune-privilege-pathogenesis-alopecia-areata 2024-10-01T14:14:28.126Z https://image.mux.com/dcWseYIDb9xXJl02VD1dd7aVW9HakQ38PZ5jg5qdeIi4/thumbnail.jpg What is the significance of immune privilege in the pathogenesis of alopecia areata? What is the significance of immune privilege in the pathogenesis of alopecia areata? https://dermsquared.com/videos/dermbits/significance-of-immune-privilege-pathogenesis-alopecia-areata 33 2024-10-01T14:14:28.109Z yes https://dermsquared.com/videos/dermbits/how-pathophysiology-gpp-differ-from-plaque-type-psoriasis 2023-06-30T17:16:21.758Z https://image.mux.com/N02amAZ3dBYBT5XCG9PpCS7iYkYtFjcJ1IeTRhJAJ3bQ/thumbnail.jpg How does the pathophysiology in GPP differ from plaque type psoriasis? How does the pathophysiology in GPP differ from plaque type psoriasis? https://dermsquared.com/videos/dermbits/how-pathophysiology-gpp-differ-from-plaque-type-psoriasis 51 2023-06-27T17:27:27.929Z yes https://dermsquared.com/videos/dermbits/dermbits-can-topical-roflumilast-replace-topical-corticosteroids-or-are-they-meant-to-be-used-in-tandem-arcp22 2023-05-11T14:54:01.338Z https://image.mux.com/ulmzt2i01wPKfwoZaKlk8yz8G01qnzGdq8gNOwWu02sHTw/thumbnail.jpg Can topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem? Can topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem? https://dermsquared.com/videos/dermbits/dermbits-can-topical-roflumilast-replace-topical-corticosteroids-or-are-they-meant-to-be-used-in-tandem-arcp22 53 2022-10-28T22:57:45.000Z yes https://dermsquared.com/videos/dermbits/how-effective-tapinarof-reducing-itch-atopic-dermatitis 2025-02-03T19:11:18.429Z https://image.mux.com/8VsrzD32PM8iQSvReYaC01i5vR7dQsGHHjVkzZaX4Uc00/thumbnail.jpg How effective is tapinarof in reducing itch for patients with atopic dermatitis? How effective is tapinarof in reducing itch for patients with atopic dermatitis? https://dermsquared.com/videos/dermbits/how-effective-tapinarof-reducing-itch-atopic-dermatitis 21 2025-02-03T19:11:18.424Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-explain-decision-dx-melanoma-test 2025-03-03T14:12:04.586Z https://image.mux.com/zkZv1qaOHTQMBqzJG01QT01z801uKk1ZwqCl01t5hWlAcTQ/thumbnail.jpg How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients? How can dermatologists explain the DecisionDx Melanoma test and its significance to their patients? https://dermsquared.com/videos/dermbits/how-dermatologists-explain-decision-dx-melanoma-test 44 2025-03-03T14:12:04.549Z yes https://dermsquared.com/videos/dermbits/how-is-cantharidin-applied 2023-12-11T16:07:31.889Z https://image.mux.com/4MRtUKMo02zJkaOwg6FrkrDgD3HClYSJimCHKWRHducc/thumbnail.jpg How is cantharidin applied? How is cantharidin applied? https://dermsquared.com/videos/dermbits/how-is-cantharidin-applied 29 2023-12-11T16:07:31.883Z yes https://dermsquared.com/videos/dermbits/most-important-patient-education-points-when-initiating-treatment-with-lebrikizumab 2024-12-02T16:27:44.619Z https://image.mux.com/IPDSVcm513e85xPS4rJhVbtQWY5Ww9H8Qj9LFauak9o/thumbnail.jpg What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? https://dermsquared.com/videos/dermbits/most-important-patient-education-points-when-initiating-treatment-with-lebrikizumab 49 2024-12-02T16:27:44.610Z yes https://dermsquared.com/videos/dermbits/recommended-approach-managing-patients-not-respond-ruxolitinib-vitiligo 2024-07-01T14:43:28.901Z https://image.mux.com/QWqcX4fPuy4r5w01hfFfeBgOQO1l4HV01BUGN4qPg1O8I/thumbnail.jpg What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo? What is your recommended approach for managing patients who do not respond to ruxolitinib therapy for vitiligo? https://dermsquared.com/videos/dermbits/recommended-approach-managing-patients-not-respond-ruxolitinib-vitiligo 28 2024-07-01T14:43:28.895Z yes https://dermsquared.com/videos/dermbits/follow-up-reliability 2026-07-01T13:49:22.810Z https://image.mux.com/Av5Db9QD4MtlM1zbLe714OaPlExC1NW4c02FE4Q9V23U/thumbnail.jpg How do you manage access for patients with limited follow-up reliability? How do you manage access for patients with limited follow-up reliability? https://dermsquared.com/videos/dermbits/follow-up-reliability 102 2026-07-01T13:49:22.802Z yes https://dermsquared.com/videos/dermbits/why-denatonium-benzoate-included-in-ingredient-list-cantharidin 2023-11-30T19:19:01.191Z https://image.mux.com/Z00HBkO4k41JCGZVjFnvSI8Jyh3Wg3pBuq7ZORno77JI/thumbnail.jpg Why is denatonium benzoate included in the ingredient list for cantharidin? Why is denatonium benzoate included in the ingredient list for cantharidin? https://dermsquared.com/videos/dermbits/why-denatonium-benzoate-included-in-ingredient-list-cantharidin 25 2023-11-30T19:19:01.181Z yes https://dermsquared.com/videos/dermbits/improves-approvals 2026-03-02T17:53:20.464Z https://image.mux.com/Gel602Pk4qsj00eaDaIahHljfhMWpR6E6n01ced01WpNeXM/thumbnail.jpg What’s one documentation habit that consistently improves approvals? What’s one documentation habit that consistently improves approvals? https://dermsquared.com/videos/dermbits/improves-approvals 85 2026-03-02T17:53:20.455Z yes https://dermsquared.com/videos/dermbits/dermbits-is-scc-more-deadly-than-melanoma-WCM2300018-scc23 2023-05-17T20:07:59.197Z https://image.mux.com/zLOzxcStDdozgivuvVflrAqQstvne2VcKlT702CoUxJI/thumbnail.jpg Is SCC more deadly than melanoma? Is SCC more deadly than melanoma? https://dermsquared.com/videos/dermbits/dermbits-is-scc-more-deadly-than-melanoma-WCM2300018-scc23 32 2023-05-17T20:07:59.192Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-with-therapeutic-biologics 2025-04-02T16:22:41.409Z https://image.mux.com/K42UnnN0202tOPAhx01DLrLVG84Mao4DXeTK9zNTYvAEkI/thumbnail.jpg Can ruxolitinib for vitiligo be used with therapeutic biologics? Can ruxolitinib for vitiligo be used with therapeutic biologics? https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-with-therapeutic-biologics 37 2025-04-02T16:22:41.403Z yes https://dermsquared.com/videos/dermbits/how-approach-conversations-partial-vs-complete-repigmentation-ruxolitinib-vitiligo 2025-06-03T13:46:04.661Z https://image.mux.com/TeRoAd5QMOyVXyxPSG00ZfCrPnuXNeSRKu75B4m201Ilc/thumbnail.jpg How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo? How should dermatologists approach conversations about partial vs complete repigmentation for patients on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-approach-conversations-partial-vs-complete-repigmentation-ruxolitinib-vitiligo 60 2025-06-03T13:46:04.655Z yes https://dermsquared.com/videos/dermbits/should-lebrikizumab-be-used-as-monotherapy-or-can-it-be-combined-with-other-treatments 2025-04-01T14:21:25.983Z https://image.mux.com/tzYh1uTf7BM4ZM9QqFLezxT3ThVV02ARQIncOt00B7TkE/thumbnail.jpg Should lebrikizumab be used as monotherapy or can it be combined with other treatments? Should lebrikizumab be used as monotherapy or can it be combined with other treatments? https://dermsquared.com/videos/dermbits/should-lebrikizumab-be-used-as-monotherapy-or-can-it-be-combined-with-other-treatments 53 2025-04-01T14:17:55.306Z yes https://dermsquared.com/videos/dermbits/combine-ruxolitinib-with-calcineurin-inhibitors-22 2023-04-28T19:55:49.300Z https://image.mux.com/ZOTt02G7sIRtjCLsgr003AOFjJoTEBu8SSRLECtCr8SlQ/thumbnail.jpg Can you combine topical ruxolitinib with topical calcineurin inhibitors? Can you combine topical ruxolitinib with topical calcineurin inhibitors? https://dermsquared.com/videos/dermbits/combine-ruxolitinib-with-calcineurin-inhibitors-22 33 2022-01-31T22:04:17.000Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-decide-escalate-systemic-therapy-ad 2025-05-01T13:41:09.861Z https://image.mux.com/f2Jefd1xIrs6E9oYxd52EJDaH8v6l02iJ9ykisyntah4/thumbnail.jpg How can dermatologists decide when to escalate to a systemic therapy for a patient with AD? How can dermatologists decide when to escalate to a systemic therapy for a patient with AD? https://dermsquared.com/videos/dermbits/how-dermatologists-decide-escalate-systemic-therapy-ad 54 2025-05-01T13:41:09.850Z yes https://dermsquared.com/videos/dermbits/what-challenges-exist-in-assessing-ad-in-patients-with-skin-of-color-and-how-can-they-be-addressed 2025-10-01T20:41:32.025Z https://image.mux.com/x4RzSu8vyBZ5xDv01NYqyy52BZdmi79BSzKQghv9kGyw/thumbnail.jpg What challenges exist in assessing AD in patients with skin of color, and how can they be addressed? What challenges exist in assessing AD in patients with skin of color, and how can they be addressed? https://dermsquared.com/videos/dermbits/what-challenges-exist-in-assessing-ad-in-patients-with-skin-of-color-and-how-can-they-be-addressed 155 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/impact-ritlecitinib-s-dual-inhibition-jak-tec-pathways-alopecia-areata 2024-12-02T15:44:45.726Z https://image.mux.com/3wbJ5OZJsCph7ieUQPGrl2s4bXzYkNy01nbsgzo1Xp200/thumbnail.jpg What impact does ritlecitinib’s dual inhibition of JAK and TEC pathways have on the immune response in alopecia areata? What impact does ritlecitinib’s dual inhibition of JAK and TEC pathways have on the immune response in alopecia areata? https://dermsquared.com/videos/dermbits/impact-ritlecitinib-s-dual-inhibition-jak-tec-pathways-alopecia-areata 47 2024-12-02T15:44:45.719Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-address-challenges-and-disparities-in-access-vitiligo-care 2024-04-01T15:44:43.988Z https://image.mux.com/CScBJrHj56AxPvxeFk500azodTN00XaW8hrqU02z35TsD8/thumbnail.jpg How can dermatologists address challenges and disparities in access to vitiligo care? How can dermatologists address challenges and disparities in access to vitiligo care? https://dermsquared.com/videos/dermbits/how-can-dermatologists-address-challenges-and-disparities-in-access-vitiligo-care 57 2024-04-01T15:44:43.975Z yes https://dermsquared.com/videos/dermbits/new-and-exciting-treating-pediatric-patients-plaque-psoriasis 2023-11-01T21:22:29.078Z https://image.mux.com/vqCGVKHlQcxclhLX02INLOkdPeH00WrlkXN2JYXoZlKKQ/thumbnail.jpg What is new and exciting for treating pediatric patients with plaque psoriasis? What is new and exciting for treating pediatric patients with plaque psoriasis? https://dermsquared.com/videos/dermbits/new-and-exciting-treating-pediatric-patients-plaque-psoriasis 21 2023-11-01T21:22:29.072Z yes https://dermsquared.com/videos/dermbits/side-effects-with-apremilast 2026-04-13T19:10:15.860Z https://image.mux.com/VPAmLlBMC902CgIQiVvKt01K5hFnlwFwv7jOu88Lhorac/thumbnail.jpg What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast? What strategies have you found helpful for minimizing early discontinuation related to gastrointestinal side effects with apremilast? https://dermsquared.com/videos/dermbits/side-effects-with-apremilast 175 2026-04-13T19:10:15.853Z yes https://dermsquared.com/videos/dermbits/ongoing-monitoring-recommended-ritlecitinib 2024-12-02T15:44:18.511Z https://image.mux.com/vdDVbFFTQDB3ErvYHbHMKM9Wuz9XYjBMBwbQ5vMvZ1U/thumbnail.jpg What ongoing monitoring is recommended for patients taking ritlecitinib? What ongoing monitoring is recommended for patients taking ritlecitinib? https://dermsquared.com/videos/dermbits/ongoing-monitoring-recommended-ritlecitinib 40 2024-12-02T15:44:18.499Z yes https://dermsquared.com/videos/dermbits/dermbits-do-you-recommend-treating-cheeks-and-tear-trough-with-hyaluronic-acid-filler 2022-12-02T07:50:31.000Z https://image.mux.com/B94fb00N01rHPfiCiRgfk9AGRjGFD8g7OfZBy2fHPRsq8/thumbnail.jpg Do you recommend treating cheeks and tear trough with hyaluronic acid filler? Do you recommend treating cheeks and tear trough with hyaluronic acid filler? https://dermsquared.com/videos/dermbits/dermbits-do-you-recommend-treating-cheeks-and-tear-trough-with-hyaluronic-acid-filler 28 2022-12-02T07:50:31.000Z yes https://dermsquared.com/videos/dermbits/additional-procedure-needed-specimen-for-40-gep-test 2023-08-31T21:14:29.824Z https://image.mux.com/YFkJhWG96IEuQCM4dVZWy3NhGoE1D2vJ22HO02G1i1Hk/thumbnail.jpg Is an additional procedure needed to collect a specimen for the 40-GEP test? Is an additional procedure needed to collect a specimen for the 40-GEP test? https://dermsquared.com/videos/dermbits/additional-procedure-needed-specimen-for-40-gep-test 23 2023-08-31T20:51:56.010Z yes https://dermsquared.com/videos/dermbits/what-monitoring-is-essential-patients-long-term-systemic-psoriasis-therapies 2024-09-24T18:18:21.518Z https://image.mux.com/hmhz02adDKmXjK8YlJM44OHAt52D5vs4IUxpVDH94HNA/thumbnail.jpg What monitoring is essential for patients on long-term systemic psoriasis therapies? What monitoring is essential for patients on long-term systemic psoriasis therapies? https://dermsquared.com/videos/dermbits/what-monitoring-is-essential-patients-long-term-systemic-psoriasis-therapies 165 2024-09-24T18:18:21.512Z yes https://dermsquared.com/videos/dermbits/perform-skin-biopsy-on-patients-with-atopic-dermatitis-22 2023-04-28T20:08:37.277Z https://image.mux.com/vY2A3edxuhFRPRe02cpvqmzojRKp3wuak8V9yxSubum4/thumbnail.jpg Do you ever need to perform a skin biopsy on patients with atopic dermatitis? Do you ever need to perform a skin biopsy on patients with atopic dermatitis? https://dermsquared.com/videos/dermbits/perform-skin-biopsy-on-patients-with-atopic-dermatitis-22 83 2022-04-28T00:09:12.000Z yes https://dermsquared.com/videos/dermbits/salicylic-acid-ingredient-acne 2025-10-23T15:41:50.847Z https://image.mux.com/13Cy77EsF5RFl1CGzqkhvBR3cPeMla00vD9QAM4GuE8k/thumbnail.jpg Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery? Why is salicylic acid a useful ingredient in acne cleansers, and how can formulation approaches improve its delivery? https://dermsquared.com/videos/dermbits/salicylic-acid-ingredient-acne 46 2025-10-22T21:22:47.098Z yes https://dermsquared.com/videos/dermbits/what-factors-contribute-progression-mild-to-severe-psoriasis 2024-11-01T13:48:29.997Z https://image.mux.com/ZTXVFVF5fR1D886VnsSbXaBYuSt1hdhGraVZX02yw01KI/thumbnail.jpg What factors contribute to the progression from mild to severe psoriasis? What factors contribute to the progression from mild to severe psoriasis? https://dermsquared.com/videos/dermbits/what-factors-contribute-progression-mild-to-severe-psoriasis 32 2024-11-01T13:48:29.991Z yes https://dermsquared.com/videos/dermbits/how-lifestyle-factors-impact-approach-psoriasis-management 2024-04-08T18:35:25.650Z https://image.mux.com/dV2jgMJlgiVCxrXcxGmYDH1unrn4T4dujzB1aGt9E018/thumbnail.jpg How do lifestyle factors like diet and stress impact your approach to psoriasis management? How do lifestyle factors like diet and stress impact your approach to psoriasis management? https://dermsquared.com/videos/dermbits/how-lifestyle-factors-impact-approach-psoriasis-management 103 2024-04-08T18:35:25.645Z yes https://dermsquared.com/videos/dermbits/strategies-to-improve-adherence-with-ruxolitinib 2023-10-31T21:18:45.136Z https://image.mux.com/ksJbirN01rxV02G01evIls5N5wMkNGK7RZGVfPCavYd7wk/thumbnail.jpg What strategies can you use to improve adherence with ruxolitinib? What strategies can you use to improve adherence with ruxolitinib? https://dermsquared.com/videos/dermbits/strategies-to-improve-adherence-with-ruxolitinib 37 2023-10-31T21:18:45.130Z yes https://dermsquared.com/videos/dermbits/dermbits-how-long-ad-patients-improvement-pruritus-treatment-topical-ruxolitinib-cream-ADRC00072-adrc23 2023-01-30T22:26:38.000Z https://image.mux.com/TtKAY8QLL9FjteFMIDshvaxdv1GmooIruWXw1rn6MeE/thumbnail.jpg How long before AD patients experience improvement in pruritus after beginning treatment with topical ruxolitinib cream? How long before AD patients experience improvement in pruritus after beginning treatment with topical ruxolitinib cream? https://dermsquared.com/videos/dermbits/dermbits-how-long-ad-patients-improvement-pruritus-treatment-topical-ruxolitinib-cream-ADRC00072-adrc23 36 2023-01-30T22:26:38.000Z yes https://dermsquared.com/videos/dermbits/age-indications-upcoming-jaks 2023-04-28T19:34:23.953Z https://image.mux.com/a02kCx02bhnPuLjQbsCpQOfgWA006fEsDmAnYPD6Oem87w/thumbnail.jpg What are the age indications for upcoming JAKs? What are the age indications for upcoming JAKs? https://dermsquared.com/videos/dermbits/age-indications-upcoming-jaks 22 2021-12-15T01:44:16.000Z yes https://dermsquared.com/videos/dermbits/dermbits-does-topical-roflumilast-treat-pruritus-associated-with-psoriasis-arcp22 2022-09-29T00:15:37.000Z https://image.mux.com/WuxMuEJz3JX02ThyBaHOJP9VABCdLLuzUgsr02IR902WFQ/thumbnail.jpg Does topical roflumilast treat pruritus associated with psoriasis? Does topical roflumilast treat pruritus associated with psoriasis? https://dermsquared.com/videos/dermbits/dermbits-does-topical-roflumilast-treat-pruritus-associated-with-psoriasis-arcp22 45 2022-09-29T00:15:37.000Z yes https://dermsquared.com/videos/dermbits/how-often-alopecia-areata-present-conjunction-nail-changes-and-aid-diagnosis 2024-12-02T15:44:01.962Z https://image.mux.com/yvY01endwf4JFpR1yx8CcgFf7EdEqV3qtILxxKjlCtrQ/thumbnail.jpg How often does alopecia areata present in conjunction with nail changes, and how can this aid diagnosis? How often does alopecia areata present in conjunction with nail changes, and how can this aid diagnosis? https://dermsquared.com/videos/dermbits/how-often-alopecia-areata-present-conjunction-nail-changes-and-aid-diagnosis 45 2024-12-02T15:44:01.952Z yes https://dermsquared.com/videos/dermbits/can-ixekizumab-therapy-lead-sustained-remission-or-disease-modification-psoriasis 2024-11-01T13:48:44.493Z https://image.mux.com/xnH01ZCHQaRjbaoJCRTAWhVOfCVU1VsEiPeo163sMGZo/thumbnail.jpg Can ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis? Can ixekizumab therapy lead to sustained remission or disease modification in patients with psoriasis? https://dermsquared.com/videos/dermbits/can-ixekizumab-therapy-lead-sustained-remission-or-disease-modification-psoriasis 36 2024-11-01T13:48:44.460Z yes https://dermsquared.com/videos/dermbits/monitor-patients-on-oral-jak-inhibitors 2023-04-28T19:20:55.818Z https://image.mux.com/m00tWaYj8hh4RJTOFoOAUBZrlcGSo2PIXGYYYjlJkYbI/thumbnail.jpg What are the recommendations on how to monitor patients on oral JAK inhibitors? What are the recommendations on how to monitor patients on oral JAK inhibitors? https://dermsquared.com/videos/dermbits/monitor-patients-on-oral-jak-inhibitors 126 2021-09-16T15:50:52.000Z yes https://dermsquared.com/videos/dermbits/clinical-evidence-support-role-probiotics-prebiotics-atopic-dermatitis 2025-01-31T18:03:10.416Z https://image.mux.com/Sg6TuoUj2auM01bDp4HHJCOcPPsiTfw2KbKjpjzu6X2o/thumbnail.jpg Is there any clinical evidence to support the role of probiotics and prebiotics in managing atopic dermatitis? Is there any clinical evidence to support the role of probiotics and prebiotics in managing atopic dermatitis? https://dermsquared.com/videos/dermbits/clinical-evidence-support-role-probiotics-prebiotics-atopic-dermatitis 103 2025-01-31T18:03:10.409Z yes https://dermsquared.com/videos/dermbits/is-sarecycline-an-appropriate-option-for-pediatric-and-preteen-patients-with-acne 2025-05-07T17:25:51.786Z https://image.mux.com/VmEEZfc01fpDvMcwnLKqpMfQpcOyEq4RioZILfGM4jTI/thumbnail.jpg Is sarecycline an appropriate option for pediatric and preteen patients with acne? Is sarecycline an appropriate option for pediatric and preteen patients with acne? https://dermsquared.com/videos/dermbits/is-sarecycline-an-appropriate-option-for-pediatric-and-preteen-patients-with-acne 130 2025-05-07T17:23:30.255Z yes https://dermsquared.com/videos/dermbits/patients-alopecia-areata-more-likely-have-other-dermatologic-conditions 2023-07-27T19:24:36.883Z https://image.mux.com/p01szJFPykLlcraBQcLDP01Y02FWT1u02i1FFXznnYFwUJQ/thumbnail.jpg Are patients with alopecia areata more likely to have other dermatologic conditions? Summary In this video, Dr. Michael Cameron addresses the question of whether patients with alopecia areata are more likely to have other dermatologic conditions. He confirms that patients with alopecia areata indeed have a higher likelihood of experiencing other dermatologic conditions. One common comorbid condition seen with alopecia areata is atopic dermatitis. Dr. Cameron explains that autoimmune diseases, including alopecia areata, often run in families. Consequently, it's possible for family members to have different autoimmune conditions, such as thyroid disease or atopic dermatitis. Additionally, he mentions that the alopecia areata population frequently exhibits cases of eczema (atopic dermatitis). The video emphasizes the existence of these associations and suggests that understanding such connections may be helpful for clinicians in diagnosing and treating patients with alopecia areata. Key Points Patients with alopecia areata are more likely to have other dermatologic conditions. Comorbid conditions are common, with atopic dermatitis being a significant one. Autoimmune diseases often run in families, suggesting a genetic link. • There may be a pattern where certain family members have different autoimmune conditions, e.g., one family member having thyroid disease and another having atopic dermatitis. Among the AA (alopecia areata) population, eczema (atopic dermatitis) is frequently observed. https://dermsquared.com/videos/dermbits/patients-alopecia-areata-more-likely-have-other-dermatologic-conditions 26 2023-07-27T19:24:36.876Z yes https://dermsquared.com/videos/dermbits/how-long-for-report-to-be-delivered-40-gep-test 2023-11-17T16:51:33.439Z https://image.mux.com/PpSdkR6PTOmCnexWOkmVR7eK3OU02wcIiOLklozczSck/thumbnail.jpg How long does it take for a report to be delivered for the 40-GEP test? How long does it take for a report to be delivered for the 40-GEP test? https://dermsquared.com/videos/dermbits/how-long-for-report-to-be-delivered-40-gep-test 15 2023-11-17T16:37:15.743Z yes https://dermsquared.com/videos/dermbits/recommended-approach-tapering-or-discontinuing-baricitinib-alopecia-areata-remission 2024-10-01T14:54:51.609Z https://image.mux.com/piidcX6wCtw02eh8OrhXWbXqBGspddwkCFo1uCLsoy14/thumbnail.jpg What is the recommended approach for tapering or discontinuing baricitinib therapy in patients with alopecia areata who have achieved remission? What is the recommended approach for tapering or discontinuing baricitinib therapy in patients with alopecia areata who have achieved remission? https://dermsquared.com/videos/dermbits/recommended-approach-tapering-or-discontinuing-baricitinib-alopecia-areata-remission 42 2024-10-01T14:54:51.600Z yes https://dermsquared.com/videos/dermbits/technically-qualifies-for-either 2026-05-07T17:29:52.644Z https://image.mux.com/wavR6y3EOp02exH8T00V00BwamMcr5rke6ZDWkL009fK6M00/thumbnail.jpg How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either? How do you decide between apremilast and initiating a biologic in a patient who technically qualifies for either? https://dermsquared.com/videos/dermbits/technically-qualifies-for-either 88 2026-05-07T17:29:52.637Z yes https://dermsquared.com/videos/dermbits/covid-19-infection-stop-biologic 2023-04-28T19:46:51.021Z https://image.mux.com/AkWKBDCbXA01BFl3RQ5jdEyjC7DrzINXvVudvv900Vda8/thumbnail.jpg If a patient develops a COVID-19 infection, should I stop my biologic? If a patient develops a COVID-19 infection, should I stop my biologic? https://dermsquared.com/videos/dermbits/covid-19-infection-stop-biologic 30 2022-01-11T16:57:35.000Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ritlecitinib 2024-09-17T19:06:52.296Z https://image.mux.com/700YSo7P922KGUyMqMoqlR01XDk7NA3Map3W7xtyddniU/thumbnail.jpg What are the most common adverse reactions seen with ritlecitinib? What are the most common adverse reactions seen with ritlecitinib? https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ritlecitinib 41 2024-09-17T19:06:52.289Z yes https://dermsquared.com/videos/dermbits/rare-clinical-subtypes-of-vitiligo 2025-05-01T13:44:45.982Z https://image.mux.com/IzDSVIhoWppCgDVKPRL00vRi2lnKpvlRh702LluK02EBJ00/thumbnail.jpg What are some rare clinical subtypes of vitiligo? What are some rare clinical subtypes of vitiligo? https://dermsquared.com/videos/dermbits/rare-clinical-subtypes-of-vitiligo 69 2025-05-01T13:44:45.975Z yes https://dermsquared.com/videos/dermbits/role-of-phototherapy-treatment-alopecia-areata 2024-10-01T14:54:39.949Z https://image.mux.com/Tzo7ESBXJpMrgKY01bnRGsM7lOKJgj4iRNNpDTTzgBQU/thumbnail.jpg What is the role of phototherapy in the treatment of alopecia areata? What is the role of phototherapy in the treatment of alopecia areata? https://dermsquared.com/videos/dermbits/role-of-phototherapy-treatment-alopecia-areata 48 2024-10-01T14:54:39.940Z yes https://dermsquared.com/videos/dermbits/dermbits-was-the-folliculitis-reported-in-the-tapinarof-trials-problematic-01687-ptc22 2021-12-27T17:09:15.000Z https://image.mux.com/NgiPRaOK00EBY3rPuHZiDLXPkG4J4Ya1nNH9DqAZIzzM/thumbnail.jpg Was the folliculitis reported in the tapinarof trials problematic? Was the folliculitis reported in the tapinarof trials problematic? https://dermsquared.com/videos/dermbits/dermbits-was-the-folliculitis-reported-in-the-tapinarof-trials-problematic-01687-ptc22 44 2021-12-27T17:09:15.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-maintenance-therapy-vitiligo-once-repigmentation-has-been-achieved 2025-04-02T16:23:04.894Z https://image.mux.com/i97BXhtKRxyl12OZW01lwXaqsbM4S7B8QoastrYm0001Hw/thumbnail.jpg Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved? Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved? https://dermsquared.com/videos/dermbits/ruxolitinib-maintenance-therapy-vitiligo-once-repigmentation-has-been-achieved 51 2025-04-02T16:23:04.888Z yes https://dermsquared.com/videos/dermbits/what-is-generalized-pustular-psoriasis-gpp 2023-06-27T17:27:51.092Z https://image.mux.com/J8MDyxk7XpAfDdEc4ZYabvDgaTgrVy6fVKBu01WSpYZw/thumbnail.jpg What is Generalized Pustular Psoriasis (GPP)? What is Generalized Pustular Psoriasis (GPP)? https://dermsquared.com/videos/dermbits/what-is-generalized-pustular-psoriasis-gpp 39 2023-06-27T17:27:51.087Z yes https://dermsquared.com/videos/dermbits/long-term-treatment-necessary-observe-maximal-clinical-benefit-baricitinib 2023-09-29T16:20:51.119Z https://image.mux.com/A02vEJ9UMb2F3NfrMPzpFUkjfskediWC1NB9gLW9pj7o/thumbnail.jpg Is long-term treatment necessary to observe maximal clinical benefit from baricitinib? Is long-term treatment necessary to observe maximal clinical benefit from baricitinib? https://dermsquared.com/videos/dermbits/long-term-treatment-necessary-observe-maximal-clinical-benefit-baricitinib 110 2023-09-29T16:20:51.114Z yes https://dermsquared.com/videos/dermbits/who-is-at-risk-for-gpp 2023-07-20T17:21:10.100Z https://image.mux.com/bzgS00DUwhBd46aq68GJysPhnqDIEIJDYXqPPCJ02k79Y/thumbnail.jpg Who is at risk for GPP? Who is at risk for GPP? https://dermsquared.com/videos/dermbits/who-is-at-risk-for-gpp 37 2023-06-27T17:27:38.801Z yes https://dermsquared.com/videos/dermbits/how-important-are-vehicles-in-topical-plaque-psoriasis-therapy 2023-05-31T19:54:42.509Z https://image.mux.com/FxMtYl8D8CmdzbO3VUAg6BBkLKg9JJhw701FGobYc01u8/thumbnail.jpg How important are vehicles in topical Plaque Psoriasis therapy?  How important are vehicles in topical Plaque Psoriasis therapy?  https://dermsquared.com/videos/dermbits/how-important-are-vehicles-in-topical-plaque-psoriasis-therapy 86 2023-05-31T19:54:42.503Z yes https://dermsquared.com/videos/dermbits/dermbits-total-body-skin-exams-patients-screen-skin-cancer-topical-ruxolitinib-ADRC00081-adrc23 2023-02-15T23:47:43.000Z https://image.mux.com/IOzl5vowBOl2Glr0100NLImXLs7uKNp7c0001pwS00LgC015I/thumbnail.jpg Should you perform total body skin exams on patients to screen for skin cancer in patients using topical ruxolitinib? Should you perform total body skin exams on patients to screen for skin cancer in patients using topical ruxolitinib? https://dermsquared.com/videos/dermbits/dermbits-total-body-skin-exams-patients-screen-skin-cancer-topical-ruxolitinib-ADRC00081-adrc23 21 2023-02-15T23:47:43.000Z yes https://dermsquared.com/videos/dermbits/endpoints-extended-to-57-days 2025-10-20T22:26:10.975Z https://image.mux.com/NFlUKORovsFInQdJFphEY01p6JUmgBnkw2Z02JVrzLhYg/thumbnail.jpg How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days? How do you advise scheduling follow-up visits for patients on tirbanibulin, knowing pivotal trial endpoints extended to 57 days? https://dermsquared.com/videos/dermbits/endpoints-extended-to-57-days 132 2025-10-17T21:17:14.639Z yes https://dermsquared.com/videos/dermbits/dermbits-safety-issues-using-ruxolitinib-cream-patients-dupilumab-or-tralokinumab-ADRC00047-adrc22 2022-04-28T00:18:00.000Z https://image.mux.com/K01reIBdReMXxaFUyh2bLZ015qyk5NTLO6700gpEwp28Mw/thumbnail.jpg Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab? Are you concerned about additional safety issues with using topical ruxolitinib cream in patients treated with dupilumab or tralokinumab? https://dermsquared.com/videos/dermbits/dermbits-safety-issues-using-ruxolitinib-cream-patients-dupilumab-or-tralokinumab-ADRC00047-adrc22 75 2022-04-28T00:18:00.000Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-you-discuss-potential-stinging-and-burning-with-topical-ruxolitinib-use-adrc22 2022-10-28T22:07:22.000Z https://image.mux.com/ovbfhKN64B00RygAA02I5f9j3Bcx4w8sHnPA7HvMClZvg/thumbnail.jpg How do you discuss potential stinging and burning with topical ruxolitinib use? How do you discuss potential stinging and burning with topical ruxolitinib use? https://dermsquared.com/videos/dermbits/dermbits-how-do-you-discuss-potential-stinging-and-burning-with-topical-ruxolitinib-use-adrc22 30 2022-10-28T22:07:22.000Z yes https://dermsquared.com/videos/dermbits/primary-measure-efficacy-2-clinical-trials-conducted-baricitinib 2023-09-29T16:20:26.832Z https://image.mux.com/028TtIWdR7kB01cZZJTcVEftt02mzoVGB01YzrU0101r02i02iU/thumbnail.jpg What was the primary measure of efficacy in the 2 randomized double-blind clinical trials conducted on baricitinib? What was the primary measure of efficacy in the 2 randomized double-blind clinical trials conducted on baricitinib? https://dermsquared.com/videos/dermbits/primary-measure-efficacy-2-clinical-trials-conducted-baricitinib 113 2023-09-29T16:20:26.827Z yes https://dermsquared.com/videos/dermbits/combine-tapinarof-with-topical-steroids-22 2023-04-28T19:58:36.701Z https://image.mux.com/01VYn3S5WSRdvaCsqhZ5QrvkZw3bg02d02jHSQtmizdNlY/thumbnail.jpg Can you combine tapinarof with topical steroids? Can you combine tapinarof with topical steroids? https://dermsquared.com/videos/dermbits/combine-tapinarof-with-topical-steroids-22 59 2022-02-01T00:50:33.000Z yes https://dermsquared.com/videos/dermbits/some-of-the-biggest-challenges-treating-molluscum-contagiosum 2023-11-30T19:18:27.683Z https://image.mux.com/n9G02BMxDXfCx01G3HXPs6CkTW02Y601u02oCxeVfRkE8e2U/thumbnail.jpg What are some of the biggest challenges in treating molluscum contagiosum? What are some of the biggest challenges in treating molluscum contagiosum? https://dermsquared.com/videos/dermbits/some-of-the-biggest-challenges-treating-molluscum-contagiosum 45 2023-11-30T19:18:27.674Z yes https://dermsquared.com/videos/dermbits/patient-education-over-counter-products-support 2025-10-23T15:43:26.117Z https://image.mux.com/c4iTRiYO1t4JbP00AcXbxtHiFV8rk1Z5gyQzPWYChugI/thumbnail.jpg What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies? What role does patient education play in making sure over-the-counter products support rather than interfere with prescription therapies? https://dermsquared.com/videos/dermbits/patient-education-over-counter-products-support 42 2025-10-22T21:24:22.364Z yes https://dermsquared.com/videos/dermbits/how-safety-profile-ixekizumab-compare-other-il-17-inhibitors 2024-08-20T18:29:11.558Z https://image.mux.com/101YhgLYsg5Q301PWUneHi4djlN00qL2wyWMJMKS0201LZ01o/thumbnail.jpg How does the safety profile of ixekizumab compare to other IL-17 inhibitors? How does the safety profile of ixekizumab compare to other IL-17 inhibitors? https://dermsquared.com/videos/dermbits/how-safety-profile-ixekizumab-compare-other-il-17-inhibitors 96 2024-08-20T18:14:12.517Z yes https://dermsquared.com/videos/dermbits/amzeeq-combined-with-benzoyl-peroxide 2023-04-28T19:03:14.423Z https://image.mux.com/CGlRXw2wsiIwKjqi977Y2As4FZBK8FAzL1Iq02l864wU/thumbnail.jpg Can AMZEEQ be combined with benzoyl peroxide? Can AMZEEQ be combined with benzoyl peroxide? https://dermsquared.com/videos/dermbits/amzeeq-combined-with-benzoyl-peroxide 79 2021-05-13T23:42:39.000Z yes https://dermsquared.com/videos/dermbits/difference-between-mypath-melanoma-test-decisiondx-melanoma-test 2025-07-15T03:04:24.960Z https://image.mux.com/z67Uvf2oJxo3gMwBx2cwasUPIO82RoCV7uYrSv01imDM/thumbnail.jpg What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test? What is the difference between the MyPath Melanoma test and the DecisionDx-Melanoma test? https://dermsquared.com/videos/dermbits/difference-between-mypath-melanoma-test-decisiondx-melanoma-test 122 2025-07-15T03:04:24.859Z yes https://dermsquared.com/videos/dermbits/specific-patient-populations-higher-risk-adverse-effects-ixekizumab 2024-11-01T13:49:03.538Z https://image.mux.com/Zrn5yd00Pq3I00dJT6w7K02CoUibdvmtCRY57I00SP2ZF0000/thumbnail.jpg Are there specific patient populations who are at higher risk for adverse effects from ixekizumab? Are there specific patient populations who are at higher risk for adverse effects from ixekizumab? https://dermsquared.com/videos/dermbits/specific-patient-populations-higher-risk-adverse-effects-ixekizumab 36 2024-11-01T13:49:03.531Z yes https://dermsquared.com/videos/dermbits/treating-thicker-plaques-consider-zoryve-instead-of-steroids 2025-07-15T03:07:03.257Z https://image.mux.com/2zmmB6fKCKU2m2bWzHnqplNynIw1N1fs6V91cRb3Ld4/thumbnail.jpg When it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids? When it comes to treating thicker plaques on hands and feet, why should you consider Zoryve instead of steroids? https://dermsquared.com/videos/dermbits/treating-thicker-plaques-consider-zoryve-instead-of-steroids 105 2025-07-15T03:07:03.235Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-work-with-allergists-atopic-dermatitis 2025-07-01T13:40:44.456Z https://image.mux.com/HEJYbuAjR00MDxYyEiojcDvGUpNIRHyjrqsMKxDRWSMg/thumbnail.jpg How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies? How can dermatologists work with allergists to manage patients with atopic dermatitis and significant environmental or food allergies? https://dermsquared.com/videos/dermbits/how-can-dermatologists-work-with-allergists-atopic-dermatitis 138 2025-07-01T13:40:44.450Z yes https://dermsquared.com/videos/dermbits/most-important-factors-when-selecting-first-line-biologic-psoriasis 2024-08-20T18:28:02.345Z https://image.mux.com/ezcPVtcQhm7RHgpeqrHRVLDbpGl5kmYXvqHeI4qN94E/thumbnail.jpg What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis? What are the most important factors to consider when selecting a first-line biologic for patients with psoriasis? https://dermsquared.com/videos/dermbits/most-important-factors-when-selecting-first-line-biologic-psoriasis 154 2024-08-20T18:16:08.426Z yes https://dermsquared.com/videos/dermbits/how-quickly-patients-experience-clearance-with-topical-roflumilast 2023-06-29T16:16:42.608Z https://image.mux.com/gvTFRl00ZeTp1CdpISa8MIFI94EMF2D5vRJtUHGd00sCA/thumbnail.jpg How quickly do patients experience clearance results with topical roflumilast? How quickly do patients experience clearance results with topical roflumilast? https://dermsquared.com/videos/dermbits/how-quickly-patients-experience-clearance-with-topical-roflumilast 61 2023-06-29T16:16:42.604Z yes https://dermsquared.com/videos/dermbits/how-ethnicity-influence-presentation-management-vitiligo 2024-05-01T14:00:21.925Z https://image.mux.com/MpzYdqHShiC2Bwjqb3y5b3VQd5g023aezsXEVrV1uN024/thumbnail.jpg How does ethnicity influence the presentation and management of vitiligo? How does ethnicity influence the presentation and management of vitiligo? https://dermsquared.com/videos/dermbits/how-ethnicity-influence-presentation-management-vitiligo 41 2024-05-01T14:00:21.920Z yes https://dermsquared.com/videos/dermbits/relationship-between-itch-improvement-and-overall-ad-control 2025-05-01T13:39:59.309Z https://image.mux.com/1jS5d5FoIUofdZQga9EGz9kMkYh1aqH6ZLftzeVwMEk/thumbnail.jpg What is the relationship between itch improvement and overall AD control? What is the relationship between itch improvement and overall AD control? https://dermsquared.com/videos/dermbits/relationship-between-itch-improvement-and-overall-ad-control 49 2025-05-01T13:39:59.302Z yes https://dermsquared.com/videos/dermbits/patient-adherenceritlecitinib-and-how-encourage 2024-12-02T15:44:38.965Z https://image.mux.com/DltZw1IBjr2MOOJnJcuCb4foV9lDCmevHuwr00oPPXMg/thumbnail.jpg How important is patient adherence when using ritlecitinib, and how can dermatologists encourage it? How important is patient adherence when using ritlecitinib, and how can dermatologists encourage it? https://dermsquared.com/videos/dermbits/patient-adherenceritlecitinib-and-how-encourage 38 2024-12-02T15:44:38.953Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-vitiligo-dangers-unregulated-skin-lightening-bleaching-creams 2024-03-06T16:01:27.056Z https://image.mux.com/00kDaGFs9yvf1Vn8r02xeY675E003m7wI2xsnnZvVS7YtM/thumbnail.jpg How do you counsel patients with vitiligo on the dangers of unregulated skin lightening / bleaching creams? How do you counsel patients with vitiligo on the dangers of unregulated skin lightening / bleaching creams? https://dermsquared.com/videos/dermbits/how-counsel-patients-vitiligo-dangers-unregulated-skin-lightening-bleaching-creams 96 2024-03-06T16:01:27.052Z yes https://dermsquared.com/videos/dermbits/discuss-ruxolitinib-cream-safety-concerns 2023-04-28T19:39:13.023Z https://image.mux.com/MBX009sakIs6gFSbCQ021rphf9uuyC2bJy1sNHlx4UpxE/thumbnail.jpg How do you discuss ruxolitinib cream safety concerns with your patients? How do you discuss ruxolitinib cream safety concerns with your patients? https://dermsquared.com/videos/dermbits/discuss-ruxolitinib-cream-safety-concerns 38 2021-12-15T01:52:16.000Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-betamethasone-dipropionate-spray-05 2023-11-01T17:26:22.606Z https://image.mux.com/y6C00GKOx7FLhMn1w4l7blSsgBoEIonrWnjPi7cyAVUk/thumbnail.jpg What is the recommended dosing regimen for betamethasone dipropionate spray 0.05%? What is the recommended dosing regimen for betamethasone dipropionate spray 0.05%? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-betamethasone-dipropionate-spray-05 11 2023-11-01T15:05:18.725Z yes https://dermsquared.com/videos/dermbits/stress-importance-adherence-ruxolitinib-for-vitiligo 2025-06-03T13:46:10.294Z https://image.mux.com/LpsY7BbIGFjE2cYD43cTJtbKKMk7YQFDXDnlTXDwvhA/thumbnail.jpg How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo? How do you stress the importance of adherence to patients taking ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/stress-importance-adherence-ruxolitinib-for-vitiligo 48 2025-06-03T13:46:10.286Z yes https://dermsquared.com/videos/dermbits/other-topical-options 2026-07-01T13:50:07.949Z https://image.mux.com/C6vHFwpbWCoKGESJ01XAn5zyXoUTGbi9n901kc3VAP77I/thumbnail.jpg What clinical context supports ruxolitinib over other topical options? What clinical context supports ruxolitinib over other topical options? https://dermsquared.com/videos/dermbits/other-topical-options 74 2026-07-01T13:50:07.942Z yes https://dermsquared.com/videos/dermbits/explain-different-moisturizers-atopic-dermatitis 2023-04-28T19:35:25.585Z https://image.mux.com/e02BSPNp9x2HlLCX1JTQdAnk019Xkvxb2AIbArY4gJyAc/thumbnail.jpg Can you explain the different types of moisturizers for atopic dermatitis? Can you explain the different types of moisturizers for atopic dermatitis? https://dermsquared.com/videos/dermbits/explain-different-moisturizers-atopic-dermatitis 57 2021-12-15T01:42:48.000Z yes https://dermsquared.com/videos/dermbits/accuracy-metrics-40-gep-test-compare-with-ajcc-8-and-bwh 2023-11-17T16:51:10.038Z https://image.mux.com/wmKlMgd74pYEaIz6AQCreh7XlCVWya5BK7C1VtPMA4A/thumbnail.jpg How do accuracy metrics of the 40-GEP test compare with those of the AJCC8 and BWH? How do accuracy metrics of the 40-GEP test compare with those of the AJCC8 and BWH? https://dermsquared.com/videos/dermbits/accuracy-metrics-40-gep-test-compare-with-ajcc-8-and-bwh 58 2023-11-17T16:37:28.883Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis--long-term-efficacy-sustained-symptom-control-lebrikizumab 2024-11-06T15:54:51.358Z https://image.mux.com/IKa5RtKrwMvA6EAnlc2301VvSjozZp3CrcCC8DGcs6aY/thumbnail.jpg What can patients with atopic dermatitis expect in terms of long-term efficacy and sustained symptom control with lebrikizumab treatment? What can patients with atopic dermatitis expect in terms of long-term efficacy and sustained symptom control with lebrikizumab treatment? https://dermsquared.com/videos/dermbits/atopic-dermatitis--long-term-efficacy-sustained-symptom-control-lebrikizumab 37 2024-11-06T15:54:51.352Z yes https://dermsquared.com/videos/dermbits/dermbits-sensitizing-ingredients-irritants-topical-roflumilast-propylene-glycol-arcp22 2022-09-29T00:20:34.000Z https://image.mux.com/NIxNeQ01QILpLcLI6XZu6igdlUKG9DnAKvMYSXsRt2Os/thumbnail.jpg Are there any sensitizing ingredients or irritants in topical roflumilast and does it contain propylene glycol? Are there any sensitizing ingredients or irritants in topical roflumilast and does it contain propylene glycol? https://dermsquared.com/videos/dermbits/dermbits-sensitizing-ingredients-irritants-topical-roflumilast-propylene-glycol-arcp22 45 2022-09-29T00:20:34.000Z yes https://dermsquared.com/videos/dermbits/can-sarecycline-be-combined-with-topical-treatments-or-other-systemic-therapies 2025-05-07T17:26:22.875Z https://image.mux.com/nqZQ00Lgvf3nwxV4Vz2OOiOW35RhrHoiWS9QnX6IGrpo/thumbnail.jpg Can sarecycline be combined with topical treatments or other systemic therapies? Can sarecycline be combined with topical treatments or other systemic therapies? https://dermsquared.com/videos/dermbits/can-sarecycline-be-combined-with-topical-treatments-or-other-systemic-therapies 99 2025-05-07T17:23:49.494Z yes https://dermsquared.com/videos/dermbits/how-does-the-narrow-spectrum-activity-of-sarecycline-impact-its-efficacy-and-safety-in-acne 2025-05-07T17:25:24.434Z https://image.mux.com/M1YKmvD5ZZviCvYysMnCUpj101MxmvZigaVyhwrVojAs/thumbnail.jpg How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne? How does the narrow-spectrum activity of sarecycline impact its efficacy and safety in acne? https://dermsquared.com/videos/dermbits/how-does-the-narrow-spectrum-activity-of-sarecycline-impact-its-efficacy-and-safety-in-acne 120 2025-05-07T17:23:10.147Z yes https://dermsquared.com/videos/dermbits/limitations-of-the-older-biologics-for-psoriasis 2024-01-03T21:21:38.875Z https://image.mux.com/vauAfz4PrXXUDWl5GTE8py1JDEF1QuCPpiixKltshG8/thumbnail.jpg What are some limitations of the older biologics for psoriasis? What are some limitations of the older biologics for psoriasis? https://dermsquared.com/videos/dermbits/limitations-of-the-older-biologics-for-psoriasis 153 2024-01-01T16:04:52.223Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-delgocitinib 2025-08-08T19:57:43.115Z https://image.mux.com/tFqSWegC1WAGhrwLOK00bbS00NJAsSjTBHfn3TwLwuhp00/thumbnail.jpg What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology? What is the mechanism of action of delgocitinib cream, and how is it relevant to CHE pathophysiology? https://dermsquared.com/videos/dermbits/mechanism-of-action-delgocitinib 90 2025-08-08T19:57:43.080Z yes https://dermsquared.com/videos/dermbits/hair-recoverable-in-pattern-hair-loss 2023-04-28T19:23:54.414Z https://image.mux.com/rTdrpHPvp5LMymRU5ZVa01hlTZ1XyIcAHpw01vewDSPCw/thumbnail.jpg Is hair recoverable in pattern hair loss? Is hair recoverable in pattern hair loss? https://dermsquared.com/videos/dermbits/hair-recoverable-in-pattern-hair-loss 87 2021-10-13T23:37:40.000Z yes https://dermsquared.com/videos/dermbits/dermbits-if-a-patient-is-on-oral-spironolactone-and-is-trying-to-conceive-how-long-before-that-should-they-stop-the-spironolactone-WC220015 2023-01-27T16:41:10.000Z https://image.mux.com/zFoybpwS00p0000P9EfMzplz23E6w7pQpVJTNdpQu5B5ZY/thumbnail.jpg If a patient is on oral spironolactone and is trying to conceive, how long before that should they stop the spironolactone? If a patient is on oral spironolactone and is trying to conceive, how long before that should they stop the spironolactone? https://dermsquared.com/videos/dermbits/dermbits-if-a-patient-is-on-oral-spironolactone-and-is-trying-to-conceive-how-long-before-that-should-they-stop-the-spironolactone-WC220015 72 2023-01-27T16:41:10.000Z yes https://dermsquared.com/videos/dermbits/limitations-other-atopic-dermatitis-therapies-ruxolitinib-address 2023-07-28T18:43:40.146Z https://image.mux.com/7FSM01gT84j02AP3OsfFMAH2MVZ37cMbK017QaRwqU1iCw/thumbnail.jpg What limitations of other atopic dermatitis therapies does ruxolitinib cream address? Summary Dr. Raj Chovatiya discusses the limitations of other atopic dermatitis therapies and how ruxolitinib cream addresses these issues. Historically, topical therapies for atopic dermatitis have had some shortcomings. Topical corticosteroids, while effective, are considered a "blunt instrument" and may lead to various side effects, such as thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids. On the other hand, topical calcineurin inhibitors have modest potency and may cause adverse events like stinging and burning. There has also been concern about a potential risk of lymphomas, although this has not been supported in the long term. Therefore, there has been a need for a topical therapy that is safe, effective, and non-steroidal. Ruxolitinib cream appears to meet these requirements. It offers potency comparable to some of the stronger topical corticosteroids, and it has a favorable steroid-sparing effect. Furthermore, both clinical trial data and real-world evidence suggest that ruxolitinib cream is a safe option for managing atopic dermatitis. This addresses the limitations of previous therapies and provides a promising treatment alternative for those with the condition. Key Points Ruxolitinib cream addresses limitations of other atopic dermatitis therapies. Traditional topical therapies for atopic dermatitis have some gaps in their care and there is a general desire for a topical therapy that is safe, effective, and non-steroid-based. Topical corticosteroids are broadly acting but often associated with side effects like thinning of the skin, pigmentary issues, loss of subcutaneous fat, and potential systemic absorption of steroids. Topical calcineurin inhibitors have modest potency and can cause adverse events such as stinging and burning. Ruxolitinib cream offers potency comparable to strong topical corticosteroids and a steroid-sparing effect. Ruxolitinib cream's safety has been supported by both clinical trial data and real-world data. https://dermsquared.com/videos/dermbits/limitations-other-atopic-dermatitis-therapies-ruxolitinib-address 78 2023-07-27T19:12:44.862Z yes https://dermsquared.com/videos/dermbits/role-patient-preferences-play-selecting-psoriasis-treatment 2024-10-18T17:18:00.611Z https://image.mux.com/mziW7TqfgJ02WzJ7KZAcxwogJ2LMbVJwm018VJxpZSYWY/thumbnail.jpg What role do patient preferences play in selecting a psoriasis treatment regimen? What role do patient preferences play in selecting a psoriasis treatment regimen? https://dermsquared.com/videos/dermbits/role-patient-preferences-play-selecting-psoriasis-treatment 66 2024-10-18T17:18:00.604Z yes https://dermsquared.com/videos/dermbits/considerations-when-diagnosing-treating-atopic-dermatitis-skin-of-color 2023-10-31T21:18:18.768Z https://image.mux.com/301TVCDiUQSLiU02sKHp9F3YBS1m02yOpNtCJWvKGwUj4o/thumbnail.jpg What are some considerations when diagnosing and treating atopic dermatitis in patients with skin of color? What are some considerations when diagnosing and treating atopic dermatitis in patients with skin of color? https://dermsquared.com/videos/dermbits/considerations-when-diagnosing-treating-atopic-dermatitis-skin-of-color 35 2023-10-31T21:18:18.761Z yes https://dermsquared.com/videos/dermbits/can-topical-roflumilast-be-used-in-combination-with-systemic-therapies 2023-11-01T21:22:43.743Z https://image.mux.com/Ir6GPUQP00UAi02uuKv901dzcHzbSHjC01bqYsirAw017f8w/thumbnail.jpg Can topical roflumilast be used in combination with systemic therapies? Can topical roflumilast be used in combination with systemic therapies? https://dermsquared.com/videos/dermbits/can-topical-roflumilast-be-used-in-combination-with-systemic-therapies 20 2023-11-01T21:22:43.737Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-aron-regimen-adrc22 2022-10-28T22:17:12.000Z https://image.mux.com/802T6E4BrYq01kkJgIW3YOcJT1e00cpWFMI00vZ9EexXo6I/thumbnail.jpg What is the Aron Regimen? What is the Aron Regimen? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-aron-regimen-adrc22 31 2022-10-28T22:17:12.000Z yes https://dermsquared.com/videos/dermbits/the-benefit-of-ruxolitinib-over-topical-corticosteroids 2023-10-31T21:18:35.131Z https://image.mux.com/6SWVDdjxD1w8IQs801tG7NTl00DYsi6j6BemKCLCsl0201E/thumbnail.jpg What is the benefit of ruxolitinib over topical corticosteroids? What is the benefit of ruxolitinib over topical corticosteroids? https://dermsquared.com/videos/dermbits/the-benefit-of-ruxolitinib-over-topical-corticosteroids 36 2023-10-31T21:18:35.126Z yes https://dermsquared.com/videos/dermbits/why-ruxolitinib-uniquely-suited-vitiligo 2025-03-03T14:15:29.065Z https://image.mux.com/Z2SK1WsoIGloj7Mwu3JVKQckOe6nOVVwifpXG01R3z9o/thumbnail.jpg Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors? Why is ruxolitinib uniquely suited to treat vitiligo compared to other JAK inhibitors? https://dermsquared.com/videos/dermbits/why-ruxolitinib-uniquely-suited-vitiligo 35 2025-03-03T14:15:29.057Z yes https://dermsquared.com/videos/dermbits/how-quickly-can-patients-expect-results-ruxolitinib-vitiligo 2024-04-01T15:45:15.513Z https://image.mux.com/ex7o7EFL9o5b02Lr7S9Alx3qd7wGr6yf5btr00tyGHbbM/thumbnail.jpg How quickly can patients expect to see results with ruxolitinib for vitiligo? How quickly can patients expect to see results with ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-quickly-can-patients-expect-results-ruxolitinib-vitiligo 46 2024-04-01T15:45:15.507Z yes https://dermsquared.com/videos/dermbits/preferred-treatment-for-acute-guttate-psoriasis 2023-04-28T20:15:05.789Z https://image.mux.com/lihJ802JH8wKL1yD916RB9RozK5ilbLIk2iGZ1MtRmMk/thumbnail.jpg What is your preferred treatment for acute guttate psoriasis? What is your preferred treatment for acute guttate psoriasis? https://dermsquared.com/videos/dermbits/preferred-treatment-for-acute-guttate-psoriasis 43 2022-06-09T15:31:20.000Z yes https://dermsquared.com/videos/dermbits/how-formulation-of-roflumilast-differ-from-other-topicals 2023-08-31T20:42:21.474Z https://image.mux.com/G9eEXC4kA2N013kYasQCw2z02Gy1Zp6J8eRgZbpHYrwtg/thumbnail.jpg How does the formulation of roflumilast differ from other topicals? How does the formulation of roflumilast differ from other topicals? https://dermsquared.com/videos/dermbits/how-formulation-of-roflumilast-differ-from-other-topicals 68 2023-08-31T20:42:21.469Z yes https://dermsquared.com/videos/dermbits/connection-between-calcineurin-inhibitors-and-scc-development-and-progression 2023-08-31T21:15:19.390Z https://image.mux.com/7rdowOrsTUnDD02lcPJVuKXxThT7rm3sZUQ85d6GxW2w/thumbnail.jpg What is the connection between calcineurin inhibitors and SCC development and progression? What is the connection between calcineurin inhibitors and SCC development and progression? https://dermsquared.com/videos/dermbits/connection-between-calcineurin-inhibitors-and-scc-development-and-progression 50 2023-08-31T20:51:20.474Z yes https://dermsquared.com/videos/dermbits/what-laboratory-monitoring-if-any-is-recommended-for-patients-starting-and-continuing-on-lebrikizumab 2025-10-01T22:37:29.662Z https://image.mux.com/7ROM3x6hys4qoUVWdowT01OEgAvXj2krScSpg01HLU9t8/thumbnail.jpg What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab? What laboratory monitoring, if any, is recommended for patients starting and continuing on lebrikizumab? https://dermsquared.com/videos/dermbits/what-laboratory-monitoring-if-any-is-recommended-for-patients-starting-and-continuing-on-lebrikizumab 116 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/management-of-plaque-psoriasis-in-challenging-sensitive-areas 2023-06-29T16:12:11.716Z https://image.mux.com/MFUfgvSC7nuKBeREeI3nSSEPztq1JGFQkt4ZuWOf26g/thumbnail.jpg How do you approach management of plaque psoriasis in challenging sensitive areas? How do you approach management of plaque psoriasis in challenging sensitive areas? https://dermsquared.com/videos/dermbits/management-of-plaque-psoriasis-in-challenging-sensitive-areas 94 2023-06-29T16:12:11.711Z yes https://dermsquared.com/videos/dermbits/incorporate-mypath-results-histologic-discordance 2025-07-15T03:06:00.729Z https://image.mux.com/IazsVeG3eA42S3gPrf01m2wY9ITw900ngR02fb00FzYA00bI/thumbnail.jpg How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline? How do you incorporate MyPath results when there is histologic discordance or when pathology is borderline? https://dermsquared.com/videos/dermbits/incorporate-mypath-results-histologic-discordance 122 2025-07-15T03:06:00.721Z yes https://dermsquared.com/videos/dermbits/understand-differently-now 2026-04-13T19:10:56.015Z https://image.mux.com/qp8g4qtTlGZ01JLcwORWWf2B8VKzDXGlWPw8lgo8Nf6M/thumbnail.jpg When apremilast first launched, how was it positioned, and what do we understand differently now? When apremilast first launched, how was it positioned, and what do we understand differently now? https://dermsquared.com/videos/dermbits/understand-differently-now 115 2026-04-13T19:10:56.008Z yes https://dermsquared.com/videos/dermbits/what-are-the-latest-insights-into-the-impact-of-hormonal-fluctuations-on-acne-severity 2025-05-07T17:27:01.383Z https://image.mux.com/00dTRzjntqB6jP3FPVA01W00k01Pur02g2IyC9ZkkcIl9blE/thumbnail.jpg What are the latest insights into the impact of hormonal fluctuations on acne severity? What are the latest insights into the impact of hormonal fluctuations on acne severity? https://dermsquared.com/videos/dermbits/what-are-the-latest-insights-into-the-impact-of-hormonal-fluctuations-on-acne-severity 149 2025-05-07T17:24:19.355Z yes https://dermsquared.com/videos/dermbits/key-risk-factors-developing-actinic-keratosis 2025-10-20T22:29:55.924Z https://image.mux.com/003PoJ669z6exTPKwaRIS1gP7c5W94mUNPDah01yUCtWI/thumbnail.jpg What are the key risk factors for developing actinic keratosis, and how can dermatologists identify high-risk patients? What are the key risk factors for developing actinic keratosis, and how can dermatologists identify high-risk patients? https://dermsquared.com/videos/dermbits/key-risk-factors-developing-actinic-keratosis 166 2025-02-12T16:22:03.744Z yes https://dermsquared.com/videos/dermbits/access-to-newer-topicals 2026-02-02T15:21:41.083Z https://image.mux.com/mmuFQlWLbbNSnFpkRKR1IU00WqWqyd4PW00IKDE76Grwk/thumbnail.jpg What are common documentation mistakes that delay access to newer topicals? What are common documentation mistakes that delay access to newer topicals? https://dermsquared.com/videos/dermbits/access-to-newer-topicals 53 2026-02-02T15:21:41.076Z yes https://dermsquared.com/videos/dermbits/surgical-and-pathological-findings-scc-good-candidate-40-gep-test 2023-08-31T21:14:25.006Z https://image.mux.com/Ba2GGY02pXEllsZIyx9mS02yR2N4DJtfIlYXsK1rCMBiU/thumbnail.jpg What surgical and pathological findings would make a patient with SCC a good candidate for the 40-GEP test? What surgical and pathological findings would make a patient with SCC a good candidate for the 40-GEP test? https://dermsquared.com/videos/dermbits/surgical-and-pathological-findings-scc-good-candidate-40-gep-test 52 2023-08-31T20:52:02.307Z yes https://dermsquared.com/videos/dermbits/nb-uvb-phototherapy 2025-10-20T17:22:53.251Z https://image.mux.com/00eNHvwOMLxZVSzXXw9yb2j02RHFRIzV01nvPJsKVcUx5U/thumbnail.jpg What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy? What kind of clearance rates can be expected in psoriasis with NB-UVB phototherapy? https://dermsquared.com/videos/dermbits/nb-uvb-phototherapy 89 2025-10-13T20:16:16.967Z yes https://dermsquared.com/videos/dermbits/molecular-diagnostics-mypath-reduce-overtreatment 2025-07-15T03:05:33.662Z https://image.mux.com/ohRIXssKgavOeRvKWGhn18dUqsKO2X401UF6tsWX01pPw/thumbnail.jpg How can molecular diagnostics like MyPath reduce overtreatment in certain patients? How can molecular diagnostics like MyPath reduce overtreatment in certain patients? https://dermsquared.com/videos/dermbits/molecular-diagnostics-mypath-reduce-overtreatment 70 2025-07-15T03:05:33.646Z yes https://dermsquared.com/videos/dermbits/what-steps-ensure-broader-access-genomic-staging-tools 2025-07-01T14:14:01.677Z https://image.mux.com/02lW0202PhMmVMQ02GlAmbfcQClnfMqirN01VCU2fTc4tu1E/thumbnail.jpg What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB? What steps can be taken to ensure broader access to genomic staging tools like i31-SLNB? https://dermsquared.com/videos/dermbits/what-steps-ensure-broader-access-genomic-staging-tools 80 2025-07-01T14:14:01.668Z yes https://dermsquared.com/videos/dermbits/how-ritlecitinib-compare-topical-treatments-alopecia-areata 2024-11-07T16:10:59.121Z https://image.mux.com/301k8fmtAyxd3GLJ02WjYbvGSp7hxNcs6mpVVYTxU01H3w/thumbnail.jpg How does ritlecitinib compare to topical treatments for alopecia areata? How does ritlecitinib compare to topical treatments for alopecia areata? https://dermsquared.com/videos/dermbits/how-ritlecitinib-compare-topical-treatments-alopecia-areata 36 2024-11-07T16:10:59.110Z yes https://dermsquared.com/videos/dermbits/recommended-monitoring-patients-psoriasis-ixekizumab 2024-10-18T17:18:09.654Z https://image.mux.com/lVCTTNFqswuGTFnhdgFPiE91RvZxAguQ01YaGGVrwGLk/thumbnail.jpg What is the recommended monitoring for patients with psoriasis receiving ixekizumab? What is the recommended monitoring for patients with psoriasis receiving ixekizumab? https://dermsquared.com/videos/dermbits/recommended-monitoring-patients-psoriasis-ixekizumab 63 2024-10-18T17:18:09.647Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-maintenance-therapy-patients-vitiligo-repigmentation 2025-06-03T13:46:21.170Z https://image.mux.com/BX1KWS502ude743016IpCY8BB6pvrxi5QjXTH5aXBj9es/thumbnail.jpg Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved? Can ruxolitinib be used as a maintenance therapy in patients with vitiligo once repigmentation has been achieved? https://dermsquared.com/videos/dermbits/ruxolitinib-maintenance-therapy-patients-vitiligo-repigmentation 33 2025-06-03T13:46:21.155Z yes https://dermsquared.com/videos/dermbits/how-has-the-31-gep-test-report-evolved 2025-07-02T19:30:58.215Z https://image.mux.com/agyhiiiWVlbZCAWCoHUvHesCH01UF6kp9014Gi7xzx9G4/thumbnail.jpg How has the 31-GEP test report evolved? How has the 31-GEP test report evolved? https://dermsquared.com/videos/dermbits/how-has-the-31-gep-test-report-evolved 51 2025-07-01T14:14:26.063Z yes https://dermsquared.com/videos/dermbits/dermbits-transition-from-cyclosporine-to-dupilumab-atopic-dermatitis-01578 2021-07-15T21:53:40.000Z https://image.mux.com/02Ql00VWFrE001QW1uwLg01CBMyguq29rsG02NNSJMMDKMdo/thumbnail.jpg How do I transition from cyclosporine to dupilumab for patients with atopic dermatitis? How do I transition from cyclosporine to dupilumab for patients with atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-transition-from-cyclosporine-to-dupilumab-atopic-dermatitis-01578 60 2021-07-15T21:53:40.000Z yes https://dermsquared.com/videos/dermbits/dermbits-reduce-the-frequency-of-tralokinumab-in-patients-who-respond-to-the-medication-ADRC00088-adrc23 2023-02-16T00:02:00.000Z https://image.mux.com/twHDnj02pEt24IiXfO2duA68CuafaMM01n3bWwrlUO73M/thumbnail.jpg Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication? Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication? https://dermsquared.com/videos/dermbits/dermbits-reduce-the-frequency-of-tralokinumab-in-patients-who-respond-to-the-medication-ADRC00088-adrc23 24 2023-02-16T00:02:00.000Z yes https://dermsquared.com/videos/dermbits/notable-results-true-v1-and-true-v2-trials-ruxolitinib-vitiligo 2024-05-01T13:44:50.863Z https://image.mux.com/kaJCy6hp7AEGvjy9GeK3nFzYkmKDSS01UG9fWm8EYMR4/thumbnail.jpg What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo? What were the notable results of the TRuE-V1 and TRuE-V2 trials on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/notable-results-true-v1-and-true-v2-trials-ruxolitinib-vitiligo 23 2024-05-01T13:44:50.847Z yes https://dermsquared.com/videos/dermbits/how-tapinarof-differ-mechanistically-topical-treatments-atopic-dermatitis 2025-02-03T19:10:37.575Z https://image.mux.com/EVbJffN6c4YvA6nRaOqslXLIVk6p7TAggcKllPuitF8/thumbnail.jpg How does tapinarof differ mechanistically from other topical treatments for atopic dermatitis? How does tapinarof differ mechanistically from other topical treatments for atopic dermatitis? https://dermsquared.com/videos/dermbits/how-tapinarof-differ-mechanistically-topical-treatments-atopic-dermatitis 32 2025-02-03T19:10:37.569Z yes https://dermsquared.com/videos/dermbits/combine-tapinarof-and-biologics-22 2023-04-28T19:59:00.394Z https://image.mux.com/S0101iNEb8jkaiAGFe00KS4Ngxbba9szgdw401Ds8CI016uA/thumbnail.jpg Do you anticipate that you will be able to combine tapinarof and biologics? Do you anticipate that you will be able to combine tapinarof and biologics? https://dermsquared.com/videos/dermbits/combine-tapinarof-and-biologics-22 56 2022-02-01T00:51:48.000Z yes https://dermsquared.com/videos/dermbits/can-other-topical-products-be-used-after-cantharidin-application 2023-11-09T21:34:34.578Z https://image.mux.com/fbcm4ixEkgf02vebzn5L1fxBD9Bi4J9rn95V59Z3uPys/thumbnail.jpg Can other topical products be used after cantharidin application? Can other topical products be used after cantharidin application? https://dermsquared.com/videos/dermbits/can-other-topical-products-be-used-after-cantharidin-application 61 2023-11-09T21:34:34.572Z yes https://dermsquared.com/videos/dermbits/how-distribution-pattern-hair-loss-influence-treatment-decisions-alopecia-areata 2024-10-01T14:54:43.543Z https://image.mux.com/Uul4HZC14e4200WSbiHcQ2uGzIz4ddUWCM6O00lpDmsd00/thumbnail.jpg How does the distribution pattern of hair loss influence treatment decisions in alopecia areata? How does the distribution pattern of hair loss influence treatment decisions in alopecia areata? https://dermsquared.com/videos/dermbits/how-distribution-pattern-hair-loss-influence-treatment-decisions-alopecia-areata 27 2024-10-01T14:54:43.533Z yes https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-ixekizumab 2024-07-17T16:13:33.314Z https://image.mux.com/HIhoH8bKtukTVNlCrTna02cywdFA18W01hDFO3VNEOmmE/thumbnail.jpg What is the dosing regimen for ixekizumab? What is the dosing regimen for ixekizumab? https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-ixekizumab 42 2024-07-17T16:13:33.308Z yes https://dermsquared.com/videos/dermbits/what-ways-can-alopecia-areata-affect-quality-of-life 2023-07-27T19:25:24.793Z https://image.mux.com/Rv2PShGwK01HVodEyRLTefMSbcjZbQYsKIm0182JQiW200/thumbnail.jpg In what ways can alopecia areata affect quality of life? Summary In this video, Dr. Michael Cameron discusses the various ways in which alopecia areata can significantly impact the quality of life of patients. He highlights that alopecia areata can have a debilitating effect on a person's emotional well-being due to feelings of embarrassment and anxiety associated with hair loss. Additionally, patients often experience anticipation and stress related to the uncertainty of future hair loss, which can be particularly distressing during significant life events. Furthermore, Dr. Cameron emphasizes that the functional impairment caused by alopecia areata should not be overlooked. For instance, loss of eyebrows can result in sweat getting into the eyes, causing discomfort and inconvenience. Overall, the condition affects individuals in myriad ways, and its impact extends beyond just the physical aspect of hair loss, affecting both emotional and functional aspects of the patients' quality of life. Key Points Alopecia areata can cause a myriad of challenges and impairments to overall well-being and daily life activities. Hair loss from alopecia areata can lead to feelings of embarrassment and anxiety, affecting self-esteem and confidence. The anticipation of future hair loss can cause stress and uncertainty is also negatively impactful. Functional impairment is often overlooked, such as sweat getting into the eyes due to eyebrow loss. The emotional and psychological toll of alopecia areata can be profound and should not be underestimated. https://dermsquared.com/videos/dermbits/what-ways-can-alopecia-areata-affect-quality-of-life 40 2023-07-27T19:22:37.172Z yes https://dermsquared.com/videos/dermbits/when-refer-adjuvant-radiation-squamous-cells-small-caliber-nerves 2023-04-28T20:22:08.246Z https://image.mux.com/gy200vLR6c8WR501KavyFqSUXj2NkJDEezR00t6YXHdOVM/thumbnail.jpg When do you refer adjuvant radiation for squamous cells and small caliber nerves? When do you refer adjuvant radiation for squamous cells and small caliber nerves? https://dermsquared.com/videos/dermbits/when-refer-adjuvant-radiation-squamous-cells-small-caliber-nerves 56 2022-07-29T00:00:13.000Z yes https://dermsquared.com/videos/dermbits/ixekizumabs-mechanism-action-differ-other-biologics-psoriasis 2024-09-24T18:21:16.966Z https://image.mux.com/3YuC8KEF122TKVTR8jsvy1ijhWUK2NiIwaMlKMjYfdU/thumbnail.jpg How does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis? How does ixekizumab's mechanism of action differ from that of other biologics used for psoriasis? https://dermsquared.com/videos/dermbits/ixekizumabs-mechanism-action-differ-other-biologics-psoriasis 94 2024-09-24T18:21:16.960Z yes https://dermsquared.com/videos/dermbits/staff-spend-gaining-patient-access-to-medication-for-plaque-psoriasis 2023-05-31T19:56:08.072Z https://image.mux.com/nO9TNca4RcJ6Ru3cyNY0188WuK3jmwTNu0101HeTEBgvTk/thumbnail.jpg How much time does your staff have to spend gaining patient access to medication for plaque psoriasis?  How much time does your staff have to spend gaining patient access to medication for plaque psoriasis?  https://dermsquared.com/videos/dermbits/staff-spend-gaining-patient-access-to-medication-for-plaque-psoriasis 70 2023-05-31T19:56:08.067Z yes https://dermsquared.com/videos/dermbits/for-ak-field-therapy 2025-10-20T22:26:48.976Z https://image.mux.com/nqhTvjOO02mtYI3dhjTdBBq01HGVIrI5lURBeKrgQUA00I/thumbnail.jpg When might you choose tirbanibulin over 5-FU for AK field therapy? When might you choose tirbanibulin over 5-FU for AK field therapy? https://dermsquared.com/videos/dermbits/for-ak-field-therapy 138 2025-10-17T21:16:50.791Z yes https://dermsquared.com/videos/dermbits/report-doing-fine 2026-04-13T19:08:23.797Z https://image.mux.com/701SnxwJT6wqEoGXlDEXCLiF5ngtQSmptE021u9HSpLa4/thumbnail.jpg What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”? What subtle cues, behavioral or clinical, make you suspect a patient is not satisfied or is overwhelmed by topical regimens, even if they report “doing fine”? https://dermsquared.com/videos/dermbits/report-doing-fine 111 2026-04-13T19:08:23.791Z yes https://dermsquared.com/videos/dermbits/how-set-expectations-patients-before-starting-ruxolitinib-vitiligo 2024-04-01T15:45:25.557Z https://image.mux.com/019ow4GODXCjkH1B8Iw02PuueKcXGoF7KBiEpcrkgMyaA/thumbnail.jpg How do you set expectations with patients before starting them on ruxolitinib for vitiligo? How do you set expectations with patients before starting them on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-set-expectations-patients-before-starting-ruxolitinib-vitiligo 50 2024-04-01T15:45:25.551Z yes https://dermsquared.com/videos/dermbits/side-effects-absorica-ld-and-isotretinoin 2023-04-28T19:09:17.954Z https://image.mux.com/cSmZYIg004ElskJUL8gpD2UydSbpoOt9pGbp4z3OKfAc/thumbnail.jpg Are there any differences in the side effect profiles between ABSORICA LD and traditional isotretinoin? Are there any differences in the side effect profiles between ABSORICA LD and traditional isotretinoin? https://dermsquared.com/videos/dermbits/side-effects-absorica-ld-and-isotretinoin 75 2021-06-18T22:04:37.000Z yes https://dermsquared.com/videos/dermbits/bathing-children-with-atopic-dermatitis 2023-04-28T19:18:12.911Z https://image.mux.com/TAK3HNcyYaDQf00sZ4EH9jlA4t6CQAnckhQWFnxjKCCs/thumbnail.jpg How frequently do you recommend bathing children with atopic dermatitis? How frequently do you recommend bathing children with atopic dermatitis? https://dermsquared.com/videos/dermbits/bathing-children-with-atopic-dermatitis 59 2021-08-26T20:21:06.000Z yes https://dermsquared.com/videos/dermbits/benefit-of-ruxolitinib-over-topical-pde-4-inhibitors 2023-10-31T21:18:31.539Z https://image.mux.com/g4zdUfEU5sVpTYHFFehfFW1QScVWlvelvpa00OdKxJtI/thumbnail.jpg What is the benefit of ruxolitinib over topical PDE-4 inhibitors? What is the benefit of ruxolitinib over topical PDE-4 inhibitors? https://dermsquared.com/videos/dermbits/benefit-of-ruxolitinib-over-topical-pde-4-inhibitors 37 2023-10-31T21:18:31.533Z yes https://dermsquared.com/videos/dermbits/approach-when-counseling-patient-experienced-multiple-ad-treatment-failures 2025-02-03T19:10:25.793Z https://image.mux.com/I6sqs4OqZPtq7k4f36JfN5f2bZOXig19CfkaRaua00vA/thumbnail.jpg What is your approach when counseling a patient who has experienced multiple AD treatment failures? What is your approach when counseling a patient who has experienced multiple AD treatment failures? https://dermsquared.com/videos/dermbits/approach-when-counseling-patient-experienced-multiple-ad-treatment-failures 30 2025-02-03T19:10:25.663Z yes https://dermsquared.com/videos/dermbits/more-persuasive 2026-03-02T17:50:59.443Z https://image.mux.com/Ne7tc2zo9SxgewTDRj9Ina8cd9p8qyTHot8CudERDvw/thumbnail.jpg What clinical details make an appeal letter more persuasive? What clinical details make an appeal letter more persuasive? https://dermsquared.com/videos/dermbits/more-persuasive 106 2026-03-02T17:50:59.437Z yes https://dermsquared.com/videos/dermbits/dermbits-how-effective-is-topical-roflumilast-at-treating-sensitive-areas-face-genitalia-and-intertriginous-psoriasis-areas-arcp22 2023-05-11T14:56:39.025Z https://image.mux.com/qpXmO4hc4004G9y8LIVOGNTwnIMCXYHKmxfNkoqv300AU/thumbnail.jpg How effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas? How effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas? https://dermsquared.com/videos/dermbits/dermbits-how-effective-is-topical-roflumilast-at-treating-sensitive-areas-face-genitalia-and-intertriginous-psoriasis-areas-arcp22 48 2022-10-28T22:47:17.000Z yes https://dermsquared.com/videos/dermbits/major-subtypes-che-differentiated 2025-08-08T19:57:56.561Z https://image.mux.com/A1SVjGmcTil64AcWfeQHoHByiVxkKiwWdxohSyHjsZo/thumbnail.jpg What are the major subtypes of CHE, and how can they be differentiated in clinical practice? What are the major subtypes of CHE, and how can they be differentiated in clinical practice? https://dermsquared.com/videos/dermbits/major-subtypes-che-differentiated 67 2025-08-08T19:57:56.555Z yes https://dermsquared.com/videos/dermbits/limitations-topical-steroids-respect-to-management-plaque-psoriasis 2023-11-01T21:23:02.649Z https://image.mux.com/7uoqKs7KLnNCqMwENOy01iBMM02s99ML5oszoSnGy401Kc/thumbnail.jpg What are some of the limitations of topical steroids with respect to management of plaque psoriasis? What are some of the limitations of topical steroids with respect to management of plaque psoriasis? https://dermsquared.com/videos/dermbits/limitations-topical-steroids-respect-to-management-plaque-psoriasis 27 2023-11-01T21:23:02.644Z yes https://dermsquared.com/videos/dermbits/mild-to-moderate-clinically-but-have-significant-quality-of-life-impairment 2025-10-01T22:39:41.389Z https://image.mux.com/VlyekiBxbSdjPXDw02lHw34scVtsnM012fQ2fQ3sPHx7w/thumbnail.jpg How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment? How should dermatologists approach patients with AD who appear “mild to moderate” clinically but have significant quality-of-life impairment? https://dermsquared.com/videos/dermbits/mild-to-moderate-clinically-but-have-significant-quality-of-life-impairment 123 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/after-bathing-applying-moisturizer 2023-04-28T18:53:36.213Z https://image.mux.com/dSWOtxLVdAHAtPCd5uwfYZPMDNpgrVawcAzqW4r7m1o/thumbnail.jpg How long after bathing do you recommend applying moisturizer? How long after bathing do you recommend applying moisturizer? https://dermsquared.com/videos/dermbits/after-bathing-applying-moisturizer 70 2021-10-14T14:47:02.000Z yes https://dermsquared.com/videos/dermbits/topical-medications-novel-atopic-dermatitis 2023-04-28T19:28:38.584Z https://image.mux.com/2UbgOPEdhNTGd2krUzGaAqaOFN5fFSwXKH4TZlb02m014/thumbnail.jpg What other topical medications with novel mechanisms of action are in the pipeline for atopic dermatitis? What other topical medications with novel mechanisms of action are in the pipeline for atopic dermatitis? https://dermsquared.com/videos/dermbits/topical-medications-novel-atopic-dermatitis 100 2021-11-17T17:55:04.000Z yes https://dermsquared.com/videos/dermbits/off-label-use-of-il-17-il-1-2-and-il-23-inhibitors-for-hs 2023-04-28T20:03:00.207Z https://image.mux.com/02mWHo300bImUcm9IXYVsmVfWw2mZcs00LemR1mTpn7UO4/thumbnail.jpg Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS? Can you expand on the off-label use of IL-17, IL-12, and IL-23 inhibitors for HS? https://dermsquared.com/videos/dermbits/off-label-use-of-il-17-il-1-2-and-il-23-inhibitors-for-hs 79 2022-02-10T17:36:14.000Z yes https://dermsquared.com/videos/dermbits/future-management-approaches 2025-10-20T22:28:18.506Z https://image.mux.com/jJh5WLDghvE3ZYn00X02MBk8FsMR4EXqNOHOQf9A4ACyQ/thumbnail.jpg What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches? What advancements in the understanding of actinic keratosis pathophysiology or treatment are shaping future management approaches? https://dermsquared.com/videos/dermbits/future-management-approaches 120 2025-10-17T21:18:01.111Z yes https://dermsquared.com/videos/dermbits/what-differentiates-lebrikizumab-from-other-il-13-inhibitors-atopic-dermatitis 2024-10-01T16:26:49.446Z https://image.mux.com/Tx8WOrbh4w1LR2rlyL3w02QlTGZGOicKlQuCfHmqlnMo/thumbnail.jpg What differentiates lebrikizumab from other IL-13 inhibitors for atopic dermatitis? What differentiates lebrikizumab from other IL-13 inhibitors for atopic dermatitis? https://dermsquared.com/videos/dermbits/what-differentiates-lebrikizumab-from-other-il-13-inhibitors-atopic-dermatitis 44 2024-10-01T16:26:49.440Z yes https://dermsquared.com/videos/dermbits/benefits-of-spray-treatment-betamethasone-dipropionate-spray-05-plaque-psoriasis 2023-11-01T17:27:29.227Z https://image.mux.com/zAhQhsX4LUC00mOb7E4bPwNyu2Z3LncOdyGrLbYliw9M/thumbnail.jpg What are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis? What are some of the benefits of a spray treatment like betamethasone dipropionate spray 0.05% for plaque psoriasis? https://dermsquared.com/videos/dermbits/benefits-of-spray-treatment-betamethasone-dipropionate-spray-05-plaque-psoriasis 18 2023-11-01T15:04:14.618Z yes https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-baricitinib 2023-07-27T19:22:30.795Z https://image.mux.com/vD0202T7cXRSNGhw02A5g00yCBme402X4ru02m8Xoa26Z02DSI/thumbnail.jpg What is the recommended dosing regimen for baricitinib? Summary In the video, Dr. Michael Cameron discusses the recommended dosing regimen for baricitinib. He mentions that for most patients, the initial dosage should be two milligrams. However, if the patient has total or almost complete scalp hair loss or hair loss that involves the eyebrows or eyelashes, the label suggests starting with four milligrams. Once a response is achieved, it is advisable to consider reducing the dosage back to two milligrams. Key Points The majority of patients should start with two milligrams according to the label. If patients have total or almost complete scalp hair loss or eyebrow or eyelash involvement, they can start with four milligrams. After achieving a response, consider reducing the dosage back to two milligrams. https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-baricitinib 25 2023-07-27T19:22:30.790Z yes https://dermsquared.com/videos/dermbits/impact-your-treatment-recommendations 2025-12-19T16:23:35.045Z https://image.mux.com/qUFRrVVHEUpGd5d7uOM5j9D8yhXyAqvwz9c02S5J4rJ00/thumbnail.jpg How does a positive or negative MyPath Melanoma result impact your treatment recommendations? How does a positive or negative MyPath Melanoma result impact your treatment recommendations? https://dermsquared.com/videos/dermbits/impact-your-treatment-recommendations 87 2025-12-19T16:23:35.034Z yes https://dermsquared.com/videos/dermbits/lesion-count-affect-this-risk 2025-10-20T22:29:12.826Z https://image.mux.com/geS93VXrD7zSBcLwuWBxKzWPhHoLRYzOiBNl15lFq7A/thumbnail.jpg What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk? What is the estimated risk of progression from actinic keratosis to squamous cell carcinoma, and how does lesion count affect this risk? https://dermsquared.com/videos/dermbits/lesion-count-affect-this-risk 137 2025-10-17T21:17:35.829Z yes https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-treatment-flexibility 2025-10-20T22:31:52.417Z https://image.mux.com/1ADapZOSZ50161PPxmqrxZaBg3oLxyeXtNYrr81tJx54/thumbnail.jpg With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers? With tirbanibulin ointment now approved for treating a larger surface area up to 100 cm², how does this improve treatment flexibility for patients and providers? https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-treatment-flexibility 74 2025-02-12T16:23:08.533Z yes https://dermsquared.com/videos/dermbits/roflumilast-cream-with-topical-steroids 2023-04-28T19:43:08.089Z https://image.mux.com/7w1WDPpp46lS5O7Dr2dUNhhBX9vhufC3R6Ork0202Pt01c/thumbnail.jpg Can you use roflumilast cream with topical steroids? Can you use roflumilast cream with topical steroids? https://dermsquared.com/videos/dermbits/roflumilast-cream-with-topical-steroids 73 2021-12-27T17:16:41.000Z yes https://dermsquared.com/videos/dermbits/classification-from-40-gep-test-consider-sentinel-lymph-node-biopsy 2023-08-31T21:14:50.753Z https://image.mux.com/oSkAvRYzJr4STMrgMa6Z8IF1XuN2xfR9mT4BXkfai01o/thumbnail.jpg What classification from the 40-GEP test would make you consider sentinel lymph node biopsy? What classification from the 40-GEP test would make you consider sentinel lymph node biopsy? https://dermsquared.com/videos/dermbits/classification-from-40-gep-test-consider-sentinel-lymph-node-biopsy 51 2023-08-31T20:51:45.179Z yes https://dermsquared.com/videos/dermbits/should-dermatologists-adjust-lebrikizumab-dosing-in-patients-who-experience-flares-during-maintenance-therapy 2025-10-01T22:34:36.612Z https://image.mux.com/dzVY6ZGhlFVwdpygVheP1uW98ybf7lbFa00C8kk02PTS8/thumbnail.jpg Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy? Should dermatologists adjust lebrikizumab dosing in patients who experience flares during maintenance therapy? https://dermsquared.com/videos/dermbits/should-dermatologists-adjust-lebrikizumab-dosing-in-patients-who-experience-flares-during-maintenance-therapy 133 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/safety-biologics-patients-history-melanoma 2023-04-28T19:45:30.710Z https://image.mux.com/RiDqatvZeTZ1v6Q2R7kPhNJzrnf4u1A002y59D7jkurU/thumbnail.jpg Are there safety concerns with using biologics in patients with a history of melanoma? Are there safety concerns with using biologics in patients with a history of melanoma? https://dermsquared.com/videos/dermbits/safety-biologics-patients-history-melanoma 89 2021-12-30T00:44:01.000Z yes https://dermsquared.com/videos/dermbits/use-of-advance-ad-tx 2026-03-06T16:26:51.418Z https://image.mux.com/AzILO01nb9EYSiT7imRppEgCzTnQkfdyEr96ueNKtiis/thumbnail.jpg What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx? What type of patient with atopic dermatitis makes you consider the use of AdvanceAD-Tx? https://dermsquared.com/videos/dermbits/use-of-advance-ad-tx 79 2026-03-06T16:26:51.412Z yes https://dermsquared.com/videos/dermbits/overall-tolerability-topical-roflumilast-most-common-side-effects-22 2023-04-28T20:26:06.564Z https://image.mux.com/f3nDtmN1602sTPYlyU6ctHSqxWw3jeuXN02MeTmAiQP4Y/thumbnail.jpg What is the overall tolerability of topical roflumilast and what are the most common side effects? What is the overall tolerability of topical roflumilast and what are the most common side effects? https://dermsquared.com/videos/dermbits/overall-tolerability-topical-roflumilast-most-common-side-effects-22 54 2022-08-30T23:12:52.000Z yes https://dermsquared.com/videos/dermbits/how-ritlecitinib-perform-patients-severe-alopecia-areata 2024-09-17T19:07:00.506Z https://image.mux.com/lC8Cfa2on2S015HdF01iCSjyjUIPG006sd7IK68SK2bwX4/thumbnail.jpg How does ritlecitinib perform in patients with severe alopecia areata? How does ritlecitinib perform in patients with severe alopecia areata? https://dermsquared.com/videos/dermbits/how-ritlecitinib-perform-patients-severe-alopecia-areata 100 2024-09-17T19:07:00.499Z yes https://dermsquared.com/videos/dermbits/monitoring-parameters-follow-treatment-lebrikizumab 2024-11-06T15:54:59.565Z https://image.mux.com/xidu6A5ZgIPtQeFdSkXzRbXN9jZXldMdAYjoveDh8Zg/thumbnail.jpg Are there any specific monitoring parameters that dermatologists should follow during treatment with lebrikizumab? Are there any specific monitoring parameters that dermatologists should follow during treatment with lebrikizumab? https://dermsquared.com/videos/dermbits/monitoring-parameters-follow-treatment-lebrikizumab 21 2024-11-06T15:54:59.551Z yes https://dermsquared.com/videos/dermbits/restart-retinoids-after-chemical-peel 2023-04-28T18:59:04.379Z https://image.mux.com/pvTXnFUewfLDT00EZOsGRiyL9UZGmD7FlRCXehe4f674/thumbnail.jpg When do you restart retinoids and azelaic acid after a chemical peel? When do you restart retinoids and azelaic acid after a chemical peel? https://dermsquared.com/videos/dermbits/restart-retinoids-after-chemical-peel 39 2021-03-31T20:30:05.000Z yes https://dermsquared.com/videos/dermbits/long-term-vision-gep-guided-melanoma-staging 2025-07-01T14:14:06.088Z https://image.mux.com/v3Rn38CdgYf623S00Hi3vnEct94EZfsYwv6OavRFhJiw/thumbnail.jpg What is the long-term vision for GEP-guided melanoma staging? What is the long-term vision for GEP-guided melanoma staging? https://dermsquared.com/videos/dermbits/long-term-vision-gep-guided-melanoma-staging 48 2025-07-01T14:14:06.082Z yes https://dermsquared.com/videos/dermbits/fda-approved-therapies 2026-06-12T18:53:10.167Z https://image.mux.com/rZloCL5U4Y5URgwUKC01tpn8UH9etpD02g5zjRVSUImjo/thumbnail.jpg How do you handle denials for FDA-approved therapies? How do you handle denials for FDA-approved therapies? https://dermsquared.com/videos/dermbits/fda-approved-therapies 66 2026-06-02T14:10:34.552Z yes https://dermsquared.com/videos/dermbits/dermbits-are-there-any-natural-options-to-treat-atopic-dermatitis-ADRC00079-adrc23 2023-01-30T22:51:24.000Z https://image.mux.com/h7te4d2t9vE7uYVCAd5DogicXDRbFI02cEejqv1GypLA/thumbnail.jpg Are there any natural options to treat atopic dermatitis? Are there any natural options to treat atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-are-there-any-natural-options-to-treat-atopic-dermatitis-ADRC00079-adrc23 83 2023-01-30T22:51:24.000Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-improve-diagnostic-accuracy-for-ad-in-skin-of-color 2025-10-22T22:39:03.112Z https://image.mux.com/HxO02vJyeI8c6z8YFAOzVSjjWyNb6xVTy8VJG8q02sVDE/thumbnail.jpg How can dermatologists improve diagnostic accuracy for AD in skin of color? How can dermatologists improve diagnostic accuracy for AD in skin of color? https://dermsquared.com/videos/dermbits/how-can-dermatologists-improve-diagnostic-accuracy-for-ad-in-skin-of-color 140 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/patient-education-convey-starting-ixekizumab 2024-08-20T18:28:19.989Z https://image.mux.com/UeViqCfuX3HdTRTIBT62D01TyWia812NGgSGDbVab3Jw/thumbnail.jpg What patient education points are important to convey to patients starting ixekizumab? What patient education points are important to convey to patients starting ixekizumab? https://dermsquared.com/videos/dermbits/patient-education-convey-starting-ixekizumab 130 2024-08-20T18:15:26.022Z yes https://dermsquared.com/videos/dermbits/limitations-other-topical-therapies-roflumilast-address-for-plaque-psoriasis 2023-11-01T21:22:54.712Z https://image.mux.com/JDWcJN00GyPFiaq4VaRQvG8gRZEHQ4FUmEcpYt9EoUfo/thumbnail.jpg What limitations of other topical therapies does roflumilast address for patients with plaque psoriasis? What limitations of other topical therapies does roflumilast address for patients with plaque psoriasis? https://dermsquared.com/videos/dermbits/limitations-other-topical-therapies-roflumilast-address-for-plaque-psoriasis 32 2023-11-01T21:22:54.708Z yes https://dermsquared.com/videos/dermbits/considerations--ixekizumab-patients-history-infections 2024-11-01T13:48:58.809Z https://image.mux.com/LzjchVKo01A5B00oKkiWuHVRPDoWjCNUKoks9q00HjwJSs/thumbnail.jpg What are the considerations for using ixekizumab in patients with a history of serious infections? What are the considerations for using ixekizumab in patients with a history of serious infections? https://dermsquared.com/videos/dermbits/considerations--ixekizumab-patients-history-infections 39 2024-11-01T13:48:58.803Z yes https://dermsquared.com/videos/dermbits/ixekizumab-patients-comorbidities-like-hepatitis-b-tuberculosis 2024-08-20T18:28:52.549Z https://image.mux.com/GJN21YDdBV5ZkVixn02qKtl5GYysNwzWDbjvvhW00RY8g/thumbnail.jpg Can ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis? Can ixekizumab be safely used in patients with comorbidities like hepatitis B or tuberculosis? https://dermsquared.com/videos/dermbits/ixekizumab-patients-comorbidities-like-hepatitis-b-tuberculosis 187 2024-08-20T18:15:05.614Z yes https://dermsquared.com/videos/dermbits/therapeutic-algorithm-treating-patients-hair-loss-22 2023-04-28T20:15:31.549Z https://image.mux.com/YaQ2oH01aQIsuGWUJcqkLLKosFhdTJbJZQLrKqnxqiy00/thumbnail.jpg What is your therapeutic algorithm for treating patients with hair loss? What is your therapeutic algorithm for treating patients with hair loss? https://dermsquared.com/videos/dermbits/therapeutic-algorithm-treating-patients-hair-loss-22 83 2022-06-16T18:00:20.000Z yes https://dermsquared.com/videos/dermbits/approach-treatment-patients-primary-cicatricial-alopecia 2024-10-01T14:54:35.161Z https://image.mux.com/tP602SjiZ17a00ppJpLJuo7v022pHwKC5u9GLvaNABDV1Q/thumbnail.jpg How do you approach treatment in patients with primary cicatricial alopecia? How do you approach treatment in patients with primary cicatricial alopecia? https://dermsquared.com/videos/dermbits/approach-treatment-patients-primary-cicatricial-alopecia 50 2024-10-01T14:54:35.155Z yes https://dermsquared.com/videos/dermbits/dermatoses-topical-jak-inhibitors-investigated 2023-04-28T19:38:38.569Z https://image.mux.com/bMil2WZxFfSRok79a8lLhHi66h3OAr9zGTr8KK01Af4E/thumbnail.jpg What dermatoses are topical JAK inhibitors being investigated for? What dermatoses are topical JAK inhibitors being investigated for? https://dermsquared.com/videos/dermbits/dermatoses-topical-jak-inhibitors-investigated 34 2021-12-15T01:39:41.000Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-clobetasol-propionate-cream-0-025 2023-11-01T17:20:20.690Z https://image.mux.com/OFiubZrVTvz5YUnp3VfLgzhVHfSPObZocnrJjoaFvnI/thumbnail.jpg What is the recommended dosing regimen for clobetasol propionate cream 0.025%? What is the recommended dosing regimen for clobetasol propionate cream 0.025%? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-clobetasol-propionate-cream-0-025 13 2023-11-01T16:26:25.851Z yes https://dermsquared.com/videos/dermbits/dermbits-is-there-any-evidence-that-patients-can-build-tolerance-to-topical-roflumilast-artr00032-arcp22 2022-11-29T21:51:11.000Z https://image.mux.com/73AD5n6Q63SPgfxQBHNnSa54R1SqFP6004Xe9uL00Do00A/thumbnail.jpg Is there any evidence that patients can build tolerance to topical roflumilast? Is there any evidence that patients can build tolerance to topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-is-there-any-evidence-that-patients-can-build-tolerance-to-topical-roflumilast-artr00032-arcp22 16 2022-11-29T21:51:11.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-outlook-on-microneedling-for-vitiligo 2025-04-02T16:22:05.641Z https://image.mux.com/Ivm02JcadBOjy2rqRiMmYl7q9Ene8oaE5iwtintZvWSE/thumbnail.jpg What is the outlook on microneedling for vitiligo? What is the outlook on microneedling for vitiligo? https://dermsquared.com/videos/dermbits/what-is-the-outlook-on-microneedling-for-vitiligo 48 2025-04-02T16:22:05.635Z yes https://dermsquared.com/videos/dermbits/dermbits-differences-atopic-dermatitis-molecular-cellular-markers-skin-of-color-patients-ADRC00077-adrc23 2023-01-30T22:15:00.000Z https://image.mux.com/KLDoBDSUdSGnNzAACeJU41Wp02j01R4366pRvsb41A01V00/thumbnail.jpg Are there differences in atopic dermatitis molecular and cellular markers in Skin of Color patients? Are there differences in atopic dermatitis molecular and cellular markers in Skin of Color patients? https://dermsquared.com/videos/dermbits/dermbits-differences-atopic-dermatitis-molecular-cellular-markers-skin-of-color-patients-ADRC00077-adrc23 27 2023-01-30T22:15:00.000Z yes https://dermsquared.com/videos/dermbits/lab-monitoring-with-tapinarof-22 2023-04-28T19:59:18.306Z https://image.mux.com/Wz5NWAybM5iBrCgG41N01sgW00U5NfJrckaAIW96Glvk4/thumbnail.jpg Do you foresee any lab monitoring with tapinarof? Do you foresee any lab monitoring with tapinarof? https://dermsquared.com/videos/dermbits/lab-monitoring-with-tapinarof-22 30 2022-02-01T00:52:54.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-40-gep-test 2023-07-27T19:28:26.240Z https://image.mux.com/b2wudfYw5kdFNKZqeWUnuQtxs9F1JH9UacZ4mXxKjpg/thumbnail.jpg What is the 40-GEP test? Summary In the video, Dr. Darrell Rigel explains that the 40-GEP test is a new approach to assess prognosis with squamous cell carcinoma. The test utilizes gene expression profiles (genomics) to provide additional information beyond traditional clinical and histologic factors. By incorporating genomics, the 40-GEP test offers an extra dimension to better evaluate the prognosis of patients with squamous cell carcinoma, potentially leading to more accurate and personalized treatment decisions. Key Points The 40-GEP test is a test that utilizes gene expression profiles to assess prognosis in cases of squamous cell carcinoma. It represents a new approach in contrast to the traditional method of using clinical and histologic factors to determine prognosis. The test offers an advantage by introducing genomics as an additional dimension to improve the accuracy of prognosis assessment. The term "40-GEP" refers to the specific gene expression profile that is analyzed in the test. By incorporating genomic information, the 40-GEP test aims to provide a more comprehensive and precise evaluation of the prognosis for squamous cell carcinoma patients. https://dermsquared.com/videos/dermbits/what-is-the-40-gep-test 30 2023-07-27T19:28:26.233Z yes https://dermsquared.com/videos/dermbits/response-to-prior-therapy 2026-06-12T18:54:18.290Z https://image.mux.com/HU00YMxnJSKLLLRbX1SpIxxJimBGcMHQiXTTikR74bF00/thumbnail.jpg How do you position ruxolitinib after partial response to prior therapy? How do you position ruxolitinib after partial response to prior therapy? https://dermsquared.com/videos/dermbits/response-to-prior-therapy 47 2026-06-02T14:12:10.469Z yes https://dermsquared.com/videos/dermbits/dermbits-differences-burden-of-atopic-dermatitis-by-race-ADRC00076-adrc23 2023-01-30T22:09:06.000Z https://image.mux.com/Tdo2pEcUQiRPHa5h9JiuD7uU4IxYuFtNdlTfbFWJgao/thumbnail.jpg Are there differences in the burden of atopic dermatitis by race? Are there differences in the burden of atopic dermatitis by race? https://dermsquared.com/videos/dermbits/dermbits-differences-burden-of-atopic-dermatitis-by-race-ADRC00076-adrc23 25 2023-01-30T22:09:06.000Z yes https://dermsquared.com/videos/dermbits/can-delgocitinib-che-used-continuous-basis 2025-08-08T19:56:36.027Z https://image.mux.com/2ruPVXm402SQ6PiCZ48m5omw7raf4JptrxUe547XbS6c/thumbnail.jpg Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns? Can delgocitinib cream for CHE be used on a continuous or as-needed basis depending on flare patterns? https://dermsquared.com/videos/dermbits/can-delgocitinib-che-used-continuous-basis 102 2025-08-08T19:56:36.020Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-identify-and-manage-treatment-resistance-in-patients-with-ad 2025-10-01T20:39:39.963Z https://image.mux.com/KhjrRxRG5vDxIdtzMwtO00fHTBkX6gBxy201dEnQRGbYo/thumbnail.jpg How can dermatologists identify and manage treatment resistance in patients with AD? How can dermatologists identify and manage treatment resistance in patients with AD? https://dermsquared.com/videos/dermbits/how-can-dermatologists-identify-and-manage-treatment-resistance-in-patients-with-ad 176 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/approach-treating-acne-sensitive-skin 2025-10-23T15:41:34.865Z https://image.mux.com/00MBNZgBnXL01nKvwhYG9ei02ngoQB9ZKalG00HKIPKQCiE/thumbnail.jpg How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin? How do you approach treating acne without compromising the skin barrier, especially in patients with sensitive skin? https://dermsquared.com/videos/dermbits/approach-treating-acne-sensitive-skin 60 2025-10-22T21:22:33.971Z yes https://dermsquared.com/videos/dermbits/what-properties-roflumilast-allow-once-daily-dosing-regimen 2023-08-31T20:40:36.326Z https://image.mux.com/yVUN100LV4Otyan8QuySrQQmk01hdelCilsHg1U4PZlV8/thumbnail.jpg What properties of roflumilast allow it to follow a once-daily dosing regimen? What properties of roflumilast allow it to follow a once-daily dosing regimen? https://dermsquared.com/videos/dermbits/what-properties-roflumilast-allow-once-daily-dosing-regimen 51 2023-08-31T20:40:36.321Z yes https://dermsquared.com/videos/dermbits/skin-reactions-tirbanibulin-ointment 2025-10-20T22:31:02.970Z https://image.mux.com/YLikSHyT1SjdmeqPKLgGFOm4HpwXoKTgbjcVA2g6lLY/thumbnail.jpg Are skin reactions common with tirbanibulin ointment, and when do they typically peak? Are skin reactions common with tirbanibulin ointment, and when do they typically peak? https://dermsquared.com/videos/dermbits/skin-reactions-tirbanibulin-ointment 67 2025-02-12T16:22:40.079Z yes https://dermsquared.com/videos/dermbits/how-do-you-utilize-product-samples-in-plaque-psoriasis 2023-05-31T19:56:24.520Z https://image.mux.com/jY013YKWZtYzsnYuKoxTCv1abUAo45ugBDnK02oo7i3bE/thumbnail.jpg How do you utilize product samples in plaque psoriasis?  How do you utilize product samples in plaque psoriasis?  https://dermsquared.com/videos/dermbits/how-do-you-utilize-product-samples-in-plaque-psoriasis 61 2023-05-31T19:56:24.508Z yes https://dermsquared.com/videos/dermbits/dermbits-contact-dermatitis-use-topical-jak-inhibitors-atopic-dermatitis-01654-adrc21 2021-11-17T17:58:18.000Z https://image.mux.com/x174tqCGWwPrPCkw01qtT2oc00dCl6rgXYjooQph8N00Fg/thumbnail.jpg Is there any data on contact dermatitis with use of topical JAK inhibitors for atopic dermatitis? Is there any data on contact dermatitis with use of topical JAK inhibitors for atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-contact-dermatitis-use-topical-jak-inhibitors-atopic-dermatitis-01654-adrc21 56 2021-11-17T17:58:18.000Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-i-order-the-40-gep-test-WCM2300017-scc23 2023-05-17T20:07:41.451Z https://image.mux.com/CXfZ3YtHbx5cb71f301C8UbsWdERoVSQjWS00ODALNOSE/thumbnail.jpg How do I order the 40-GEP test? How do I order the 40-GEP test? https://dermsquared.com/videos/dermbits/dermbits-how-do-i-order-the-40-gep-test-WCM2300017-scc23 33 2023-05-17T20:07:41.446Z yes https://dermsquared.com/videos/dermbits/molecular-data-is-necessary 2026-03-06T16:30:03.188Z https://image.mux.com/Yl8ZlFeMmjDWDmnCQWTKN53H00r58Z4TTDERzKKL01DuM/thumbnail.jpg In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary? In the evaluation of melanocytic lesions suspicious for melanoma, how do you decide when diagnostic ambiguity is acceptable versus when additional molecular data is necessary? https://dermsquared.com/videos/dermbits/molecular-data-is-necessary 67 2026-03-06T16:30:03.181Z yes https://dermsquared.com/videos/dermbits/what-areas-of-body-betamethasone-dipropionate-spray-05-work-best 2023-11-01T17:23:46.391Z https://image.mux.com/cIFSb3mBmEKuOI6YkF4011OQSUZeK34itfBXdjKhtAWY/thumbnail.jpg What areas of the body does betamethasone dipropionate spray 0.05% work best on? What areas of the body does betamethasone dipropionate spray 0.05% work best on? https://dermsquared.com/videos/dermbits/what-areas-of-body-betamethasone-dipropionate-spray-05-work-best 20 2023-11-01T16:25:07.216Z yes https://dermsquared.com/videos/dermbits/change-management 2026-03-06T16:29:32.732Z https://image.mux.com/I3Ya02UjFZy702LuQXs14JhJ3UkwntP0101wcXwq72iIRIg/thumbnail.jpg Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management? Have there been cases where DecisionDx-SCC reclassified a tumor you initially considered low or intermediate risk? How did that change management? https://dermsquared.com/videos/dermbits/change-management 122 2026-03-06T16:29:32.722Z yes https://dermsquared.com/videos/dermbits/how-can-patients-vitiligo-get-involved-support-groups 2025-05-01T13:44:14.772Z https://image.mux.com/5JQ8LQK4NabtjQms6XXfhiJczX02013iL4i2bLd02dC01Kw/thumbnail.jpg How can patients with vitiligo get involved in support groups? How can patients with vitiligo get involved in support groups? https://dermsquared.com/videos/dermbits/how-can-patients-vitiligo-get-involved-support-groups 52 2025-05-01T13:44:14.764Z yes https://dermsquared.com/videos/dermbits/side-effects-finasteride-after-discontinuation 2023-04-28T19:05:14.650Z https://image.mux.com/YgCPAS01sG89IQS5G4xhg6u7r7V6a02sVl40201Bt97EQhQ/thumbnail.jpg Can you address potential long term side effects from finasteride after discontinuation? Can you address potential long term side effects from finasteride after discontinuation? https://dermsquared.com/videos/dermbits/side-effects-finasteride-after-discontinuation 43 2021-05-21T18:27:32.000Z yes https://dermsquared.com/videos/dermbits/combine-ruxolitinib-with-corticosteroids-22 2023-04-28T19:56:05.323Z https://image.mux.com/ipOqRjeyGDDJEJs500qZrJx57KrhpjwITTylMoOtOwoc/thumbnail.jpg Can you combine topical ruxolitinib with topical corticosteroids? Can you combine topical ruxolitinib with topical corticosteroids? https://dermsquared.com/videos/dermbits/combine-ruxolitinib-with-corticosteroids-22 45 2022-01-31T22:00:27.000Z yes https://dermsquared.com/videos/dermbits/initial-treatment-choice 2026-03-06T16:28:05.283Z https://image.mux.com/nE6AzC8oBbvvfmfnyjepaoE9pU5n3ygIAKaQW8NuQQI/thumbnail.jpg Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice? Has testing with AdvanceAD-TX ever shifted you away from your initial treatment choice? https://dermsquared.com/videos/dermbits/initial-treatment-choice 72 2026-03-06T16:28:05.278Z yes https://dermsquared.com/videos/dermbits/mild-to-moderate-disease 2026-05-04T20:18:40.795Z https://image.mux.com/TyDFTcU7ZKrrLPMu7TappNt8ZnI4v2b01UmHVac71rNw/thumbnail.jpg How do you document medical necessity for ruxolitinib in mild-to-moderate disease? How do you document medical necessity for ruxolitinib in mild-to-moderate disease? https://dermsquared.com/videos/dermbits/mild-to-moderate-disease 74 2026-05-04T20:18:40.789Z yes https://dermsquared.com/videos/dermbits/is-bimekizumab-effective-patients-who-failed-il-17-blocker 2024-01-01T16:07:58.314Z https://image.mux.com/Y8kJvtlCnS6i4RioMo7kEJQ3uk4t3F7cL007wbSM755A/thumbnail.jpg Is bimekizumab effective for patients who have failed an IL-17 blocker? Is bimekizumab effective for patients who have failed an IL-17 blocker? https://dermsquared.com/videos/dermbits/is-bimekizumab-effective-patients-who-failed-il-17-blocker 85 2024-01-01T16:05:20.183Z yes https://dermsquared.com/videos/dermbits/dermbits-which-psoriasis-symptoms-most-burdensome-for-patients-artr00038-arcp22 2022-11-29T23:34:45.000Z https://image.mux.com/beIqkbBqh00rGC01c5NEtv4YKVFur7b2z3jlp00Av84XQc/thumbnail.jpg Which psoriasis symptoms are most burdensome for patients? Which psoriasis symptoms are most burdensome for patients? https://dermsquared.com/videos/dermbits/dermbits-which-psoriasis-symptoms-most-burdensome-for-patients-artr00038-arcp22 17 2022-11-29T23:34:45.000Z yes https://dermsquared.com/videos/dermbits/what-are-the-traditional-scc-prognostic-paradigms 2023-07-27T19:20:58.229Z https://image.mux.com/UPDbHKSiTToQV00lDX801Z8hYpXK97awEAJ5ZJQ4jNb8A/thumbnail.jpg What are the traditional SCC prognostic paradigms? Summary In the video, Dr. Darrell Rigel discusses the traditional prognostic paradigms for squamous cell carcinoma (SCC). Currently, the two commonly used criteria are the AJCC (American Joint Committee on Cancer) criteria and the Boston Women and Brigham's criteria. These criteria rely on assessing clinical and histopathologic factors such as the diameter of the lesion and the presence of perineural invasion, among other factors. However, Dr. Rigel points out that these traditional paradigms do not take into account genomic information. This is where the 40-GEP test comes into play. The 40-GEP test provides additional genomic information, which can be integrated into the prognosis assessment to improve accuracy. By incorporating genomic data, clinicians can gain valuable insights into the underlying genetic characteristics of SCC, leading to a more comprehensive and refined prognosis for patients. This advancement in prognostic evaluation may ultimately aid in better treatment decision-making and patient outcomes. Key Points Traditional SCC prognostic paradigms: AJCC criteria, Boston Women, and Brigham’s criteria. Assessment of prognosis for squamous cell carcinoma based on clinical and histopathologic factors. Factors used in traditional criteria include diameter of the lesion and perineural invasion involvement. Traditional methods lack consideration of genomics in prognosis assessment. The 40-GEP test provides additional genomic information for better and more accurate prognosis integration. https://dermsquared.com/videos/dermbits/what-are-the-traditional-scc-prognostic-paradigms 43 2023-07-27T19:20:58.224Z yes https://dermsquared.com/videos/dermbits/how-discuss-40-gep-test-results-with-patients 2023-07-27T19:21:09.206Z https://image.mux.com/dvxmFU2qiONefXdkNkv00EYyEgAhkCWLTW2KVkQmbIXU/thumbnail.jpg How do you discuss 40-GEP test results with patients? Summary Dr. Darrell Rigel discusses how he approaches the discussion of 40-GEP (Genomic Expression Profile) test results with his patients. He emphasizes the importance of having a frank conversation with the patients about their test results. The 40-GEP test results are relatively easy for patients to understand because they are categorized into three levels of risk: low risk, mid-risk, and high risk. Depending on which risk category the patient falls into, Dr. Rigel tailors his discussion accordingly. For patients with low-risk results, Dr. Rigel can confidently inform them that there is no need for advanced treatments or additional therapies beyond close monitoring. However, for patients in the mid-risk or high-risk category, he may discuss the possibility of additional therapies such as adjuvant radiation or the use of specific medications like cemiplimab, PD1 inhibitors, or other more advanced treatments. The primary goal of discussing these test results with patients is to provide them with a clear understanding of their risk level and prognosis. This information allows for informed decision-making regarding the necessity and potential benefits of further treatment options, ensuring the best possible care for each individual patient. Key Points 40-GEP test results are easy for patients to understand as they are categorized into three levels of risk: low, mid risk, and high risk. The degree of risk and prognosis are used to determine whether additional therapy is necessary, and the doctor should tailor their discussion with the patient accordingly. Treatment options discussed with mid to high-risk patients may include adjuvant radiation, cemiplimab, PD1 inhibitors, or more advanced treatments. For low-risk patients, the need for advanced treatments is deemed unnecessary, and close patient monitoring may suffice. https://dermsquared.com/videos/dermbits/how-discuss-40-gep-test-results-with-patients 55 2023-07-27T19:21:09.200Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-effective-treating-itch 2023-04-28T18:48:31.280Z https://image.mux.com/F9fkig2sO3RKlUjm02M82EQUQk9JOJYSVrUsqRVeD28g/thumbnail.jpg Is ruxolitinib cream effective in treating itch associated with atopic dermatitis? Is ruxolitinib cream effective in treating itch associated with atopic dermatitis? https://dermsquared.com/videos/dermbits/ruxolitinib-effective-treating-itch 57 2021-10-14T18:43:45.000Z yes https://dermsquared.com/videos/dermbits/selection-in-ambiguous-cases 2026-03-06T16:27:50.499Z https://image.mux.com/019c51K2DnPj01u02enrdW817WgGMc7mnriztdiXbht02KY/thumbnail.jpg How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases? How can the AdvanceAD-TX test help dermatologists narrow biologic or JAK inhibitor selection in ambiguous cases? https://dermsquared.com/videos/dermbits/selection-in-ambiguous-cases 55 2026-03-06T16:27:50.494Z yes https://dermsquared.com/videos/dermbits/what-is-epidemiology-of-vitiligo 2025-05-01T13:43:51.520Z https://image.mux.com/ao14wvGbAm9rBP00J016Uy4MQaKs01No94lF4bcZqqwlDo/thumbnail.jpg What is the epidemiology of vitiligo? What is the epidemiology of vitiligo? https://dermsquared.com/videos/dermbits/what-is-epidemiology-of-vitiligo 58 2025-05-01T13:43:51.513Z yes https://dermsquared.com/videos/dermbits/test-for-a-suspicious-lesion 2025-12-19T16:22:27.856Z https://image.mux.com/FxG39DCcjgEibhqNhK200FNnrA17Ob6iAknrr2DWxwaY/thumbnail.jpg When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion? When should dermatologists consider the use of MyPath Melanoma test for a suspicious lesion? https://dermsquared.com/videos/dermbits/test-for-a-suspicious-lesion 80 2025-12-19T16:22:27.850Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-best-sunscreen-to-prevent-skin-cancer-WCM2300019-scc23 2023-05-17T20:08:11.952Z https://image.mux.com/wz1MnoxXaJ3tzevlN9f7ZE00YQqjaImXBel00N9utQGqs/thumbnail.jpg What is the best sunscreen to prevent skin cancer? What is the best sunscreen to prevent skin cancer? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-best-sunscreen-to-prevent-skin-cancer-WCM2300019-scc23 62 2023-05-17T20:08:11.947Z yes https://dermsquared.com/videos/dermbits/what-distinguishes-moa-ritlecitinib-other-jak-inhibitors 2024-09-17T19:07:19.311Z https://image.mux.com/upSxD4j3mSReV1vwqwaEmxGGaXXR00byTcmHaVjpohiQ/thumbnail.jpg What distinguishes the MOA of ritlecitinib from other JAK inhibitors? What distinguishes the MOA of ritlecitinib from other JAK inhibitors? https://dermsquared.com/videos/dermbits/what-distinguishes-moa-ritlecitinib-other-jak-inhibitors 23 2024-09-17T19:07:19.293Z yes https://dermsquared.com/videos/dermbits/dermbits-is-topical-ruxolitinib-safe-for-use-on-the-face-armpit-or-groin-ADRC00083-adrc23 2023-02-15T23:52:58.000Z https://image.mux.com/1k00yQTh200MLCWPNxc00701WP2O01VjXpqVQEGX2liDFMEQ/thumbnail.jpg Is topical ruxolitinib safe for use on the face, armpit or groin? Is topical ruxolitinib safe for use on the face, armpit or groin? https://dermsquared.com/videos/dermbits/dermbits-is-topical-ruxolitinib-safe-for-use-on-the-face-armpit-or-groin-ADRC00083-adrc23 18 2023-02-15T23:52:58.000Z yes https://dermsquared.com/videos/dermbits/how-mechanism-of-action-baricitinib-differ-from-topical-jak-inhibitors 2023-07-27T19:23:17.536Z https://image.mux.com/V7jtQXN7UALVaIkbfrwXMnvPzZIiZBe5IK9iaQEmMl4/thumbnail.jpg How does the mechanism of action of baricitinib differ from topical JAK inhibitors? Summary In this video, Dr. Michael Cameron explains the difference between the mechanism of action (MOA) of baricitinib and topical JAK (Janus kinase) inhibitors. He mentions that the MOA of both baricitinib and topical JAK inhibitors is essentially the same. However, the critical difference lies in their delivery methods. According to Dr. Cameron, he has personally tried using topical JAK inhibitors off-label for mild alopecia areata, but without success. The challenge with topical JAK inhibitors is developing a formulation that can consistently and effectively deliver the JAK inhibitor to the hair follicles where the disease occurs. On the other hand, the advantage of Olumiant (baricitinib) is that it is administered orally, allowing the JAK inhibitor to be delivered systemically. This enables it to reach the hair follicles where the disease is happening, potentially making it a more effective treatment for conditions like alopecia areata. In summary, the key difference between baricitinib and topical JAK inhibitors lies in their delivery methods, with baricitinib being an oral treatment that can reach the affected hair follicles more effectively. Key Points The mechanism of action (MOA) of baricitinib and topical JAK inhibitors is the same, but the critical difference lies in the delivery method. Baricitinib is advantageous because it is delivered orally, allowing the JAK inhibitor to reach the hair follicles where the disease is occurring. Developing a topical formulation that effectively delivers the JAK inhibitor to the hair follicle has been challenging, thus an advantage of baricitinib is that it is administered orally. https://dermsquared.com/videos/dermbits/how-mechanism-of-action-baricitinib-differ-from-topical-jak-inhibitors 41 2023-07-27T19:23:17.531Z yes https://dermsquared.com/videos/dermbits/how-does-repigmentation-progress-over-time-with-ruxolitinib-treatment 2025-04-02T16:22:18.129Z https://image.mux.com/cWPTcEZSD44ni3ohWIWDUTyfko901X00V3rLZYz5qqBb4/thumbnail.jpg How does repigmentation progress over time with ruxolitinib treatment? How does repigmentation progress over time with ruxolitinib treatment? https://dermsquared.com/videos/dermbits/how-does-repigmentation-progress-over-time-with-ruxolitinib-treatment 45 2025-04-02T16:22:18.117Z yes https://dermsquared.com/videos/dermbits/dupilumab-to-patients-history-malignancy 2023-04-28T19:35:54.704Z https://image.mux.com/GOh02LQRXcMBX5nXu00Ix3ENhBl856aqsx2bFngdF8fzc/thumbnail.jpg Can you prescribe dupilumab to patients with a history of malignancy? Can you prescribe dupilumab to patients with a history of malignancy? https://dermsquared.com/videos/dermbits/dupilumab-to-patients-history-malignancy 35 2021-12-15T01:42:00.000Z yes https://dermsquared.com/videos/dermbits/ideal-patient-ixekizumab-any-notable-exclusions 2024-08-20T18:28:46.528Z https://image.mux.com/3oUWMeXPh5FV8GFGa8z1FHm00zDmOhRQMKCS6mKEDfsg/thumbnail.jpg Who is the ideal patient for ixekizumab, and are there any notable exclusions? Who is the ideal patient for ixekizumab, and are there any notable exclusions? https://dermsquared.com/videos/dermbits/ideal-patient-ixekizumab-any-notable-exclusions 52 2024-08-20T18:15:16.665Z yes https://dermsquared.com/videos/dermbits/-how-much-ns-reconstitute-dysport 2023-04-28T20:12:07.065Z https://image.mux.com/OMskQI800TS9ghkPzjxsNpPPDheWrEKGZ01NH021t1192s/thumbnail.jpg With how much NS do you reconstitute your Dysport? With how much NS do you reconstitute your Dysport? https://dermsquared.com/videos/dermbits/-how-much-ns-reconstitute-dysport 75 2022-04-28T16:23:25.000Z yes https://dermsquared.com/videos/dermbits/is-tapinarof-well-tolerated-on-sensitive-skin-areas 2024-04-08T18:35:37.947Z https://image.mux.com/TKCjS5A02xEUpbuOxk00c9OHI00DfbGP8bIWM00yiqWFECs/thumbnail.jpg Is tapinarof well tolerated on sensitive skin areas? Is tapinarof well tolerated on sensitive skin areas? https://dermsquared.com/videos/dermbits/is-tapinarof-well-tolerated-on-sensitive-skin-areas 45 2024-04-08T18:35:37.941Z yes https://dermsquared.com/videos/dermbits/therapies-currently-in-pipeline-treatment-of-vitiligo 2025-03-03T14:14:01.957Z https://image.mux.com/9E02tn7x9mhWU7mSzw8m6Lp2SzBdd7iOiXqXTb6oqZnQ/thumbnail.jpg What are some therapies that are currently in the pipeline for the treatment of vitiligo? What are some therapies that are currently in the pipeline for the treatment of vitiligo? https://dermsquared.com/videos/dermbits/therapies-currently-in-pipeline-treatment-of-vitiligo 63 2025-03-03T14:14:01.949Z yes https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-combination-with-other-biologics-jak-inhibitors-or-immunosuppressants 2023-07-27T19:23:23.456Z https://image.mux.com/PmK6ZlTnNUady4015nK4hEJNfQ00fGQlTToy1EKVgNTRU/thumbnail.jpg Can baricitinib be used in combination with other biologics, JAK inhibitors, or immunosuppressants? Summary In the video, Dr. Michael Cameron addresses the question of whether baricitinib can be used in combination with other biologics, JAK inhibitors, or immunosuppressants for the treatment of alopecia areata. According to Dr. Cameron, it is not recommended to use other immunosuppressants alongside baricitinib for alopecia areata. The label and data for baricitinib indicate that it should be used as a standalone treatment and should not be combined with other immunosuppressant medications. Key Points Baricitinib should not be used in combination with other immunosuppressants for alopecia areata. The label and data clearly indicate that using baricitinib alongside other immunosuppressants is not recommended. The video emphasizes the importance of avoiding the simultaneous use of other immunosuppressants with baricitinib for this condition. https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-combination-with-other-biologics-jak-inhibitors-or-immunosuppressants 18 2023-07-27T19:23:23.449Z yes https://dermsquared.com/videos/dermbits/how-should-patients-educated-potential-long-term-outcomes-ritlecitinib 2024-09-17T19:07:14.900Z https://image.mux.com/qMb02xQN5CbJxSdZ81LQn51s98BRx4j8hA02pd01G2jn74/thumbnail.jpg How should patients be educated about the potential long-term outcomes of ritlecitinib therapy? How should patients be educated about the potential long-term outcomes of ritlecitinib therapy? https://dermsquared.com/videos/dermbits/how-should-patients-educated-potential-long-term-outcomes-ritlecitinib 63 2024-09-17T19:07:14.889Z yes https://dermsquared.com/videos/dermbits/efficacy-ruxolitinib-vitiligo-vary-across-fitzpatrick-skin-types 2025-03-03T14:15:10.342Z https://image.mux.com/otiJxm4jPGwaIWJmt029rRGSmlYJ01O6apWvd1OtAUFkI/thumbnail.jpg Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types? Does the efficacy of ruxolitinib for vitiligo vary across Fitzpatrick skin types? https://dermsquared.com/videos/dermbits/efficacy-ruxolitinib-vitiligo-vary-across-fitzpatrick-skin-types 35 2025-03-03T14:15:10.334Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-intermittently 2024-05-31T13:34:13.697Z https://image.mux.com/Be8rmIPGW502gkCNmFKflsveU3VO5PHrDNlDWyACs3JE/thumbnail.jpg Can ruxolitinib for vitiligo be used intermittently? Can ruxolitinib for vitiligo be used intermittently? https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-be-used-intermittently 20 2024-05-31T13:34:13.691Z yes https://dermsquared.com/videos/dermbits/efficacy-of-baricitinib-compare-to-topical-and-corticosteroid-treatments 2023-09-29T16:20:22.035Z https://image.mux.com/tgXbvuhYF00GJ01iQMy00hYhDAfQLdQ9EJ3xErKem1n02WE/thumbnail.jpg How does the efficacy of baricitinib compare to topical and corticosteroid treatments? How does the efficacy of baricitinib compare to topical and corticosteroid treatments? https://dermsquared.com/videos/dermbits/efficacy-of-baricitinib-compare-to-topical-and-corticosteroid-treatments 92 2023-09-29T16:20:22.026Z yes https://dermsquared.com/videos/dermbits/dissatisfaction-or-nonadherence 2026-04-13T19:07:58.413Z https://image.mux.com/LBFL9500Mu2FaMYRUQly8yCqQ1CtgAy7aNBY1wuVptPQ/thumbnail.jpg What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence? What does topical treatment fatigue look like in your patients, and how often do you see it drive dissatisfaction or nonadherence? https://dermsquared.com/videos/dermbits/dissatisfaction-or-nonadherence 85 2026-04-13T19:07:58.404Z yes https://dermsquared.com/videos/dermbits/extensive-skin-disease-dermatomyositis-immunosuppressants-ivig 2023-04-28T19:49:21.225Z https://image.mux.com/TdeUCuX9YIh5jS6yHdgVU0202v019JN02E6ym02jWi7KfwaY/thumbnail.jpg For patients with extensive skin disease from dermatomyositis, are you still trying traditional immunosuppressants prior to moving to IVIG? For patients with extensive skin disease from dermatomyositis, are you still trying traditional immunosuppressants prior to moving to IVIG? https://dermsquared.com/videos/dermbits/extensive-skin-disease-dermatomyositis-immunosuppressants-ivig 52 2022-01-21T06:17:03.000Z yes https://dermsquared.com/videos/dermbits/transition-psoriasis-methotrexate-to-biologic 2023-04-28T19:08:15.567Z https://image.mux.com/VM501DaM1dhs028tdcPlOXeYX5i1OiDeeD5Sj1LN003JwQ/thumbnail.jpg How do you transition a psoriasis patient from methotrexate to a biologic? Can you use them concurrently? How do you transition a psoriasis patient from methotrexate to a biologic? Can you use them concurrently? https://dermsquared.com/videos/dermbits/transition-psoriasis-methotrexate-to-biologic 103 2021-06-11T16:03:58.000Z yes https://dermsquared.com/videos/dermbits/dermbits-patients-on-dupilumab-develop-psoriasis-phenotype-biopsy-indicative-psoriasis-ADRC00068-ad0123 2022-12-22T21:29:59.000Z https://image.mux.com/2WO002fOO2liq35VPxQNhS02IJ9egVMcTsQR7jwUF6cWw/thumbnail.jpg What do you do for patients on dupilumab who develop a psoriasis phenotype and biopsy indicative of psoriasis? What do you do for patients on dupilumab who develop a psoriasis phenotype and biopsy indicative of psoriasis? https://dermsquared.com/videos/dermbits/dermbits-patients-on-dupilumab-develop-psoriasis-phenotype-biopsy-indicative-psoriasis-ADRC00068-ad0123 84 2022-12-22T21:29:59.000Z yes https://dermsquared.com/videos/dermbits/interesting-facets-of-pathophysiology-molluscum-contagiosum 2023-11-09T21:34:23.525Z https://image.mux.com/tm01gWWgP5NR01DVEGqAQxHaf8Mb9TWei7p6bCp1Tlr6s/thumbnail.jpg What are some interesting facets of the pathophysiology of molluscum contagiosum? What are some interesting facets of the pathophysiology of molluscum contagiosum? https://dermsquared.com/videos/dermbits/interesting-facets-of-pathophysiology-molluscum-contagiosum 43 2023-11-09T21:34:23.517Z yes https://dermsquared.com/videos/dermbits/dermbits-which-patients-may-benefit-the-most-from-topical-roflumilast-arcp22 2023-05-11T14:56:05.426Z https://image.mux.com/pzi00udiAJ8fVCQA2c3dydhMSN5012acAwjJjoXXqDYrY/thumbnail.jpg Which patients may benefit the most from topical roflumilast? Which patients may benefit the most from topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-which-patients-may-benefit-the-most-from-topical-roflumilast-arcp22 37 2022-10-28T22:48:49.000Z yes https://dermsquared.com/videos/dermbits/role-patient-education-play-improving-adherence-psoriasis-treatment-regimens 2024-07-17T16:13:07.524Z https://image.mux.com/00m01cL5BnLkTwAd01C02UrJ0053Ox5udYkQeAJM7NmcDZ7I/thumbnail.jpg What role does patient education play in improving adherence to psoriasis treatment regimens? What role does patient education play in improving adherence to psoriasis treatment regimens? https://dermsquared.com/videos/dermbits/role-patient-education-play-improving-adherence-psoriasis-treatment-regimens 57 2024-07-17T16:13:07.510Z yes https://dermsquared.com/videos/dermbits/how-address-concerns-injection-site-reactions-ixekizumab 2024-09-24T18:17:45.158Z https://image.mux.com/A3zC7xyRBNgI6Fb1WKFdoSXPP12yG2ZYmBli02snsl8s/thumbnail.jpg How should dermatologists address concerns about injection-site reactions in patients starting ixekizumab? How should dermatologists address concerns about injection-site reactions in patients starting ixekizumab? https://dermsquared.com/videos/dermbits/how-address-concerns-injection-site-reactions-ixekizumab 145 2024-09-24T18:17:45.151Z yes https://dermsquared.com/videos/dermbits/may-not-appear-immediately 2025-10-20T22:27:06.043Z https://image.mux.com/8pW00yU6pnvwaVjq7vkjAJisr5cb1XS601B55kPB64V5Y/thumbnail.jpg How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately? How do you counsel patients and colleagues about the timeline of response, given that visible skin reaction may not appear immediately? https://dermsquared.com/videos/dermbits/may-not-appear-immediately 120 2025-10-17T21:16:39.153Z yes https://dermsquared.com/videos/dermbits/turnaround-time-mypath-results-reported 2025-07-15T03:04:37.992Z https://image.mux.com/4Hrl0000wPJylwGXlsd9rrTMtKsYGiCh01WVvL003aRaD8o/thumbnail.jpg What is the turnaround time for results from the MyPath Melanoma test, and how are results reported? What is the turnaround time for results from the MyPath Melanoma test, and how are results reported? https://dermsquared.com/videos/dermbits/turnaround-time-mypath-results-reported 45 2025-07-15T03:04:37.980Z yes https://dermsquared.com/videos/dermbits/shared-decision-making-improving-ad-outcomes 2025-07-01T13:40:55.443Z https://image.mux.com/hVBwtPrJ6KSGSm0202SC701WfDrrwBqIaGLuyTHuRKzNm00/thumbnail.jpg What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice? What role does shared decision-making play in improving AD outcomes, and how can it be implemented in practice? https://dermsquared.com/videos/dermbits/shared-decision-making-improving-ad-outcomes 89 2025-07-01T13:40:55.429Z yes https://dermsquared.com/videos/dermbits/home-phototherapyuv-for-vitiligo 2023-04-28T19:02:49.672Z https://image.mux.com/qanTDd2tTi00Rxbfs7LM0151WOGdPwWjBpHJB4N02ITMhM/thumbnail.jpg How effective are home phototherapy/UV units for Vitiligo? How effective are home phototherapy/UV units for Vitiligo? https://dermsquared.com/videos/dermbits/home-phototherapyuv-for-vitiligo 37 2021-05-07T00:10:17.000Z yes https://dermsquared.com/videos/dermbits/what-makes-some-melanocytic-lesions-difficult-to-diagnose-based-on-histopathology-alone 2025-12-19T16:24:09.782Z https://image.mux.com/aVyyPfiu9RrEDoEKLb01FDIWYtwRPoXqvMxZU6SgoxTI/thumbnail.jpg What makes some melanocytic lesions difficult to diagnose based on histopathology alone? What makes some melanocytic lesions difficult to diagnose based on histopathology alone? https://dermsquared.com/videos/dermbits/what-makes-some-melanocytic-lesions-difficult-to-diagnose-based-on-histopathology-alone 56 2025-12-19T16:24:09.776Z yes https://dermsquared.com/videos/dermbits/limited-bsa-disease 2026-04-13T19:08:57.676Z https://image.mux.com/GGrvqB8Nr00kL4wnWKn902R3zKL00ExAXfgDJt02OCZIxSU/thumbnail.jpg Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease? Are dermatologists sometimes too cautious about systemic therapy in limited BSA disease? https://dermsquared.com/videos/dermbits/limited-bsa-disease 125 2026-04-13T19:08:57.670Z yes https://dermsquared.com/videos/dermbits/how-quickly-see-clearance-after-spesolimab-infusion 2023-08-31T20:44:04.627Z https://image.mux.com/mrE00sqbD7Pof22vi2gGkmcTZ0211zipSKv2inid8hNPA/thumbnail.jpg How quickly can patients see the onset of pustular clearance after a spesolimab infusion?  How quickly can patients see the onset of pustular clearance after a spesolimab infusion?  https://dermsquared.com/videos/dermbits/how-quickly-see-clearance-after-spesolimab-infusion 67 2023-08-31T20:44:04.622Z yes https://dermsquared.com/videos/dermbits/long-term-safety-and-durability-profile-roflumilast 2023-08-31T20:40:07.748Z https://image.mux.com/2HaMFK00lpNADTip4oEy302Yn7wxZosO8UlZyHsNPvbG4/thumbnail.jpg What does the long-term safety and durability profile look like for roflumilast? What does the long-term safety and durability profile look like for roflumilast? https://dermsquared.com/videos/dermbits/long-term-safety-and-durability-profile-roflumilast 58 2023-08-31T20:39:45.658Z yes https://dermsquared.com/videos/dermbits/can-40-gep-test-be-performed-on-superficial-biopsies 2023-11-17T16:51:40.906Z https://image.mux.com/oaY00TkKzSfdklyF52fmdZbtYG294utLp6kk9Eg6udQs/thumbnail.jpg Can the 40-GEP test be performed on superficial biopsies? Can the 40-GEP test be performed on superficial biopsies? https://dermsquared.com/videos/dermbits/can-40-gep-test-be-performed-on-superficial-biopsies 37 2023-11-17T16:37:08.818Z yes https://dermsquared.com/videos/dermbits/limitations-gep-testing-melanoma-diagnosis 2025-07-15T03:05:09.229Z https://image.mux.com/Q6JKGwJvHtZWYv8o7kiP02pyyzoslbF01U5Se5RXkgWNo/thumbnail.jpg What are the limitations of GEP testing in melanoma diagnosis? What are the limitations of GEP testing in melanoma diagnosis? https://dermsquared.com/videos/dermbits/limitations-gep-testing-melanoma-diagnosis 48 2025-07-15T03:05:09.223Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-support-patients-managing-psychological-impacts-vitiligo 2025-03-03T14:13:42.016Z https://image.mux.com/jDvVSAbmzf00aEdD00Yu6skYB65un4atZpX3KE5eOP8VA/thumbnail.jpg How can dermatologists support patients in managing the psychological impacts of living with vitiligo? How can dermatologists support patients in managing the psychological impacts of living with vitiligo? https://dermsquared.com/videos/dermbits/how-dermatologists-support-patients-managing-psychological-impacts-vitiligo 49 2025-03-03T14:13:42.007Z yes https://dermsquared.com/videos/dermbits/are-there-ongoing-studies-or-emerging-insights-into-additional-indications-for-sarecycline-beyond-acne 2025-05-09T13:49:54.548Z https://image.mux.com/01Ccd74dtyOodZNok00X4v1pLIjLuTC2asYYentxwcpD8/thumbnail.jpg Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne? Are there ongoing studies or emerging insights into additional indications for sarecycline beyond acne? https://dermsquared.com/videos/dermbits/are-there-ongoing-studies-or-emerging-insights-into-additional-indications-for-sarecycline-beyond-acne 107 2025-05-07T17:24:09.510Z yes https://dermsquared.com/videos/dermbits/over-the-next-5-to-10-years 2025-12-19T16:23:57.676Z https://image.mux.com/vzH601d2orYhvO2ZeuphAtvrfWyOQD8l5SdUSs01yyHfc/thumbnail.jpg What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years? What role do you see molecular diagnostics playing in the early detection and management of melanoma over the next 5 to 10 years? https://dermsquared.com/videos/dermbits/over-the-next-5-to-10-years 63 2025-12-19T16:23:57.670Z yes https://dermsquared.com/videos/dermbits/what-lab-assessments-recommended-prior-initiating-ritlecitinib 2024-09-17T19:06:56.894Z https://image.mux.com/NZC8VdGQTTZiCCEV9FDttlgXUWqMBd01reAV2hLjZ4PQ/thumbnail.jpg What lab assessments are recommended prior to initiating ritlecitinib? What lab assessments are recommended prior to initiating ritlecitinib? https://dermsquared.com/videos/dermbits/what-lab-assessments-recommended-prior-initiating-ritlecitinib 23 2024-09-17T19:06:56.888Z yes https://dermsquared.com/videos/dermbits/is-lebrikizumab-appropriate-for-patients-who-have-failed-other-biologics 2025-04-01T14:17:24.880Z https://image.mux.com/H8hxjRe02bRmufkhftjnoG2V02FrPrD34DLh01f00L009BEk/thumbnail.jpg Is lebrikizumab appropriate for patients who have failed other biologics? Is lebrikizumab appropriate for patients who have failed other biologics? https://dermsquared.com/videos/dermbits/is-lebrikizumab-appropriate-for-patients-who-have-failed-other-biologics 52 2025-04-01T14:17:24.870Z yes https://dermsquared.com/videos/dermbits/basis-delayed-nodules-voluma-group 2023-04-28T19:32:52.561Z https://image.mux.com/yOabW9cjj9nw58zrzYM014nYn4yux01ya61RMnh61MdJI/thumbnail.jpg Is there any basis to the concern about delayed nodules with the Voluma group of products? Is there any basis to the concern about delayed nodules with the Voluma group of products? https://dermsquared.com/videos/dermbits/basis-delayed-nodules-voluma-group 59 2021-11-18T23:52:05.000Z yes https://dermsquared.com/videos/dermbits/vitiligo-or-atopic-dermatitis 2026-05-04T20:17:47.955Z https://image.mux.com/poy3HOvx02oAf1Q5cacdKgFOtNZAaVv4QMEl00Gmhac9U/thumbnail.jpg How do you document quality-of-life impact in vitiligo or atopic dermatitis? How do you document quality-of-life impact in vitiligo or atopic dermatitis? https://dermsquared.com/videos/dermbits/vitiligo-or-atopic-dermatitis 113 2026-05-04T20:17:47.948Z yes https://dermsquared.com/videos/dermbits/boxed-warnings-package-topical-ruxolitinib-cream-22 2023-04-28T20:09:08.333Z https://image.mux.com/skuwXexA8C00npRPIezmDKsBcrXTExG01FEBjtKoPxwkU/thumbnail.jpg How clinically relevant are the boxed warnings that are in the package insert with topical ruxolitinib cream? How clinically relevant are the boxed warnings that are in the package insert with topical ruxolitinib cream? https://dermsquared.com/videos/dermbits/boxed-warnings-package-topical-ruxolitinib-cream-22 87 2022-04-28T00:11:11.000Z yes https://dermsquared.com/videos/dermbits/does-roflumilast-continue-to-be-effective-over-a-long-period-of-time 2023-08-31T20:39:55.997Z https://image.mux.com/01YaIM59A7CnLj019vT7Qm5r6jQ6nnIwMOSfMA02z45D3A/thumbnail.jpg Does roflumilast continue to be effective over a long period of time? Does roflumilast continue to be effective over a long period of time? https://dermsquared.com/videos/dermbits/does-roflumilast-continue-to-be-effective-over-a-long-period-of-time 65 2023-08-31T20:39:55.992Z yes https://dermsquared.com/videos/dermbits/how-delgocitinib-differ-mechanistically-other-topical-che 2025-08-08T19:57:35.756Z https://image.mux.com/WATP02rm5qvkIa8QZSc029nJiKTIww00fPZ25t00cVkQIV00/thumbnail.jpg How does delgocitinib differ mechanistically from other topical therapies used for CHE? How does delgocitinib differ mechanistically from other topical therapies used for CHE? https://dermsquared.com/videos/dermbits/how-delgocitinib-differ-mechanistically-other-topical-che 165 2025-08-08T19:57:35.750Z yes https://dermsquared.com/videos/dermbits/efficacy-bimekizumab-compared-to-other-psoriasis-medications 2024-01-03T21:21:16.577Z https://image.mux.com/JCYId5uGx1XN7XGOmRO00uq5ecWWw5aLazY02EdzOX02mY/thumbnail.jpg Has the efficacy of bimekizumab been compared to other psoriasis medications? Has the efficacy of bimekizumab been compared to other psoriasis medications? https://dermsquared.com/videos/dermbits/efficacy-bimekizumab-compared-to-other-psoriasis-medications 51 2024-01-01T16:05:16.038Z yes https://dermsquared.com/videos/dermbits/current-recommendations-lebrikizumab-pediatric-atopic-dermatitis-patients 2024-10-01T16:26:45.882Z https://image.mux.com/tIYUJ6NxgBoNIVNPM5qoi2uihOwjctODoKC3e4cZkCc/thumbnail.jpg What are the current recommendations for the use of lebrikizumab in pediatric atopic dermatitis patients? What are the current recommendations for the use of lebrikizumab in pediatric atopic dermatitis patients? https://dermsquared.com/videos/dermbits/current-recommendations-lebrikizumab-pediatric-atopic-dermatitis-patients 55 2024-10-01T16:26:45.876Z yes https://dermsquared.com/videos/dermbits/how-manage-expectations-patients-beginning-treatment-baricitinib 2024-10-01T14:55:01.196Z https://image.mux.com/Ru873tsiziZ00dgH5cBLjcVHxzGRYF3p5K01tGepT1jHM/thumbnail.jpg How do you manage expectations for patients beginning treatment with baricitinib? How do you manage expectations for patients beginning treatment with baricitinib? https://dermsquared.com/videos/dermbits/how-manage-expectations-patients-beginning-treatment-baricitinib 42 2024-10-01T14:55:01.163Z yes https://dermsquared.com/videos/dermbits/treat-folliculitis-reported-with-tapinarof-22 2023-04-28T20:00:56.268Z https://image.mux.com/8Ciq1xxbnNI9KaSF9Tzo9lBBBb01am00S02gSpSQfqrCpo/thumbnail.jpg How do you treat the folliculitis reported with tapinarof? How do you treat the folliculitis reported with tapinarof? https://dermsquared.com/videos/dermbits/treat-folliculitis-reported-with-tapinarof-22 62 2022-02-01T01:16:17.000Z yes https://dermsquared.com/videos/dermbits/coverage-lags-behind-innovation 2026-07-01T13:48:26.501Z https://image.mux.com/xAZOISYT8ObhZZ6BaS02Gb8yagWLPR3Sar7jyXQu8800g/thumbnail.jpg What do you do when coverage lags behind innovation? What do you do when coverage lags behind innovation? https://dermsquared.com/videos/dermbits/coverage-lags-behind-innovation 90 2026-07-01T13:48:26.491Z yes https://dermsquared.com/videos/dermbits/oncology-or-radiation-oncology 2026-03-06T16:29:05.130Z https://image.mux.com/TW6EBqAl37UC72M4f8DDh01dZZKHrB1OYquPVcfzGQ00Y/thumbnail.jpg How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology? How does the DecisionDx-SCC test influence referrals to surgical oncology or radiation oncology? https://dermsquared.com/videos/dermbits/oncology-or-radiation-oncology 78 2026-03-06T16:29:05.123Z yes https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-tapinarof 2024-04-08T18:35:49.957Z https://image.mux.com/gUg7vdeTSI2ltYkaqRseZ6m5kWIm6zHA02EneRMbdT02g/thumbnail.jpg What is the mechanism of action of tapinarof? What is the mechanism of action of tapinarof? https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-tapinarof 51 2024-04-08T18:35:49.953Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-ixekizumab-compare-biologics-psoriasis 2024-09-24T18:21:04.152Z https://image.mux.com/jXtkv00huB00K02l8rrMWl4H1cpNqt5f2z4pu16L4024fW8/thumbnail.jpg How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis? How does the recommended dosing regimen for ixekizumab compare to those of other biologics for psoriasis? https://dermsquared.com/videos/dermbits/recommended-dosing-ixekizumab-compare-biologics-psoriasis 126 2024-09-24T18:21:04.146Z yes https://dermsquared.com/videos/dermbits/how-important-is-continuity-of-care-for-topical-plaque-psoriasis-therapy 2023-05-31T19:55:51.010Z https://image.mux.com/xYnslU4dTFoLtO01EIDEMahNMWtKQSyqEMSGmq4fiGyM/thumbnail.jpg How important is continuity of care for topical plaque psoriasis therapy?  How important is continuity of care for topical plaque psoriasis therapy?  https://dermsquared.com/videos/dermbits/how-important-is-continuity-of-care-for-topical-plaque-psoriasis-therapy 53 2023-05-31T19:55:51.004Z yes https://dermsquared.com/videos/dermbits/long-term-outcomes-ixekizumab-durability-response-maintenance 2024-10-18T17:18:30.199Z https://image.mux.com/VfjXvx00ydx3YiqE00CJmVfAwzSxFZtV801IwaPlgOW02CM/thumbnail.jpg What are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance? What are the long-term outcomes of ixekizumab therapy in terms of durability of response and maintenance of skin clearance? https://dermsquared.com/videos/dermbits/long-term-outcomes-ixekizumab-durability-response-maintenance 36 2024-10-18T17:18:30.192Z yes https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-tapinarof 2024-04-08T18:36:05.149Z https://image.mux.com/hGNztQToK00Pr9dlVIer02tPQS2C5osN7QN6wdZGcKAco/thumbnail.jpg What is the recommended dosing regimen for tapinarof? What is the recommended dosing regimen for tapinarof? https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-tapinarof 14 2024-04-08T18:36:05.144Z yes https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-indicated-patients-12-years-older-significance-topical-treatment-options-patients-arcp22 2022-09-29T00:18:39.000Z https://image.mux.com/XMSEwK71M2J00QkkjiEQF6VD6c7kGdeb44ItMGXj8AJc/thumbnail.jpg Topical roflumilast is indicated for patients 12 years and older. What is the significance of this as you think about topical treatment options for patients? Topical roflumilast is indicated for patients 12 years and older. What is the significance of this as you think about topical treatment options for patients? https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-indicated-patients-12-years-older-significance-topical-treatment-options-patients-arcp22 62 2022-09-29T00:18:39.000Z yes https://dermsquared.com/videos/dermbits/dermbits-efficacy-outcomes-topical-roflumilast-phase-3-clinical-trials-arcp22 2022-08-30T23:08:31.000Z https://image.mux.com/hGQYG2N01CrlhM6f01DnBQeoQHJc9Dr4xNlQK01OnX8mmo/thumbnail.jpg What were the efficacy outcomes for topical roflumilast in Phase 3 clinical trials? What were the efficacy outcomes for topical roflumilast in Phase 3 clinical trials? https://dermsquared.com/videos/dermbits/dermbits-efficacy-outcomes-topical-roflumilast-phase-3-clinical-trials-arcp22 33 2022-08-30T23:08:31.000Z yes https://dermsquared.com/videos/dermbits/patient-populations-careful-prescribing-ruxolitinib 2023-04-28T19:37:21.039Z https://image.mux.com/Zs801zeIY2Bev6Ui01osAtZXtSK9D9J00P9SB3ESAZlao4/thumbnail.jpg In which patient populations should we be careful in prescribing ruxolitinib cream? In which patient populations should we be careful in prescribing ruxolitinib cream? https://dermsquared.com/videos/dermbits/patient-populations-careful-prescribing-ruxolitinib 40 2021-12-15T01:37:28.000Z yes https://dermsquared.com/videos/dermbits/when-focusing-on-newer-therapies 2026-06-01T14:56:41.716Z https://image.mux.com/d3xX00fUVWsVfgcWkSY3WKeSIDcPb4qllqVzUelupJa4/thumbnail.jpg What do dermatologists sometimes overlook about apremilast when focusing on newer therapies? What do dermatologists sometimes overlook about apremilast when focusing on newer therapies? https://dermsquared.com/videos/dermbits/when-focusing-on-newer-therapies 133 2026-06-01T14:56:41.704Z yes https://dermsquared.com/videos/dermbits/moving-beyond-topicals 2026-06-01T14:57:13.619Z https://image.mux.com/7zBPSSS008FASyMOQHY8tUaeUiKkscJvzmc00RpgE2OtQ/thumbnail.jpg How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals? How do functionally sensitive areas like hands, feet, or scalp change your threshold for moving beyond topicals? https://dermsquared.com/videos/dermbits/moving-beyond-topicals 96 2026-06-01T14:57:13.612Z yes https://dermsquared.com/videos/dermbits/dermbits-srt-vs-electronic-brachytherapy-01124 2022-03-09T17:48:29.000Z https://image.mux.com/mOOMLtqJicu3OGg2cTRWgPL3iIk66Q7bd8OpXJq5SPU/thumbnail.jpg SRT vs electronic brachytherapy? SRT vs electronic brachytherapy? https://dermsquared.com/videos/dermbits/dermbits-srt-vs-electronic-brachytherapy-01124 88 2022-03-09T17:48:29.000Z yes https://dermsquared.com/videos/dermbits/dermbits-differences-genetic-risk-factors-atopic-dermatitis-skin-of-color-patients-ADRC00078-adrc23 2023-01-30T22:18:41.000Z https://image.mux.com/E01S4niyPkh2tKArbZkHslTh3oCuAt01eEJ3AQSvMopww/thumbnail.jpg Are there differences in the genetic risk factors for atopic dermatitis in Skin of Color patients? Are there differences in the genetic risk factors for atopic dermatitis in Skin of Color patients? https://dermsquared.com/videos/dermbits/dermbits-differences-genetic-risk-factors-atopic-dermatitis-skin-of-color-patients-ADRC00078-adrc23 32 2023-01-30T22:18:41.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-vitiligo-be-used-with-therapeutic-biologics 2025-06-03T13:46:14.877Z https://image.mux.com/QlbqGq9T3kafExuJhATJD1swbWH5VZumrBf7T2jd02JE/thumbnail.jpg Can ruxolitinib for vitiligo be used with therapeutic biologics? Can ruxolitinib for vitiligo be used with therapeutic biologics? https://dermsquared.com/videos/dermbits/ruxolitinib-vitiligo-be-used-with-therapeutic-biologics 33 2025-06-03T13:46:14.871Z yes https://dermsquared.com/videos/dermbits/with-new-treatments-psoriasis-approved-recent-years-still-unmet-need 2023-10-24T16:35:23.645Z https://image.mux.com/c2zV81e00oCjswOPqOSPkxeQK3Yu02X00s2bIb01ibxKXDM/thumbnail.jpg With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need? With all of the new treatments for psoriasis that have been approved in recent years, is there still an unmet need? https://dermsquared.com/videos/dermbits/with-new-treatments-psoriasis-approved-recent-years-still-unmet-need 65 2023-10-24T16:35:23.638Z yes https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-efficacy-compare-with-other 2025-10-20T22:30:45.412Z https://image.mux.com/Dx7BURn2AYslPgTntRFo02mnxg4c5Fv3O5EvCZ77T968/thumbnail.jpg How does tirbanibulin ointment's efficacy compare with other field-directed therapies for actinic keratosis? How does tirbanibulin ointment's efficacy compare with other field-directed therapies for actinic keratosis? https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-efficacy-compare-with-other 109 2025-02-12T16:22:21.985Z yes https://dermsquared.com/videos/dermbits/dermbits-what-advice-would-you-give-a-young-dermatologist-who-wants-to-get-involved-in-leadership-in-our-specialty-WCM230008 2023-03-10T00:20:26.000Z https://image.mux.com/SexmUEGKapOy02erhfdAt23fd2SDVrkYraG7TU1hmeJ00/thumbnail.jpg What advice would you give a young dermatologist who wants to get involved in leadership in our specialty? What advice would you give a young dermatologist who wants to get involved in leadership in our specialty? https://dermsquared.com/videos/dermbits/dermbits-what-advice-would-you-give-a-young-dermatologist-who-wants-to-get-involved-in-leadership-in-our-specialty-WCM230008 39 2023-03-10T00:20:26.000Z yes https://dermsquared.com/videos/dermbits/combination-therapy-hard-to-treat-atopic-dermatitis-22 2023-04-28T20:18:17.506Z https://image.mux.com/Bybz2pnWJESo01YsO5z101jT4VyxyvAsANwE01zk5vMHZE/thumbnail.jpg Have you ever used combination therapy for hard-to-treat atopic dermatitis patients? Have you ever used combination therapy for hard-to-treat atopic dermatitis patients? https://dermsquared.com/videos/dermbits/combination-therapy-hard-to-treat-atopic-dermatitis-22 65 2022-07-27T21:53:54.000Z yes https://dermsquared.com/videos/dermbits/how-effective-is-sarecycline-for-managing-truncal-acne 2025-05-07T17:25:37.415Z https://image.mux.com/aFDITpOEzpeTFhGdsACsKDMzxTuIPnDYDks3qzwJZZ00/thumbnail.jpg How effective is sarecycline for managing truncal acne? How effective is sarecycline for managing truncal acne? https://dermsquared.com/videos/dermbits/how-effective-is-sarecycline-for-managing-truncal-acne 101 2025-05-07T17:23:20.396Z yes https://dermsquared.com/videos/dermbits/lifestyle-modifications-recommended-patients-ixekizumab 2024-10-18T17:18:13.194Z https://image.mux.com/Z01rmOREPmft800PwIq321MVjmQc4e8Rxhb8WaCUr007BQ/thumbnail.jpg What lifestyle modifications should be recommended to patients receiving ixekizumab? What lifestyle modifications should be recommended to patients receiving ixekizumab? https://dermsquared.com/videos/dermbits/lifestyle-modifications-recommended-patients-ixekizumab 48 2024-10-18T17:18:13.182Z yes https://dermsquared.com/videos/dermbits/factors-should-be-considered-treatment-pediatric-vitiligo 2024-07-01T14:44:43.390Z https://image.mux.com/1Ij16auHbA8yhyIUouWViqJFW9EzUSmp3ST8MLwA3Yw/thumbnail.jpg What factors should be considered when selecting treatment for pediatric patients with vitiligo? What factors should be considered when selecting treatment for pediatric patients with vitiligo? https://dermsquared.com/videos/dermbits/factors-should-be-considered-treatment-pediatric-vitiligo 45 2024-07-01T14:44:43.384Z yes https://dermsquared.com/videos/dermbits/are-there-any-limitations-on-duration-of-use-with-roflumilast 2023-08-31T20:42:58.283Z https://image.mux.com/00WBJVQXJUnqG006wDYJldjKsVRlxmbhJUHJ00nXvszwe00/thumbnail.jpg Are there any limitations on duration of use with roflumilast? Are there any limitations on duration of use with roflumilast? https://dermsquared.com/videos/dermbits/are-there-any-limitations-on-duration-of-use-with-roflumilast 58 2023-08-31T20:42:58.278Z yes https://dermsquared.com/videos/dermbits/how-skin-barrier-dysfunction-contribute-pathogenesis-atopic-dermatitis 2025-02-03T19:10:15.699Z https://image.mux.com/ZxEKn1PuSR01bQEx49ma19aWpeUQ01xfqOGZgsQvHqJ004/thumbnail.jpg How does skin barrier dysfunction contribute to the pathogenesis of atopic dermatitis? How does skin barrier dysfunction contribute to the pathogenesis of atopic dermatitis? https://dermsquared.com/videos/dermbits/how-skin-barrier-dysfunction-contribute-pathogenesis-atopic-dermatitis 27 2025-02-03T19:10:15.688Z yes https://dermsquared.com/videos/dermbits/options-for-treating-scars-22 2023-04-28T20:22:32.426Z https://image.mux.com/zzeIRmSASQc7LqD5Q501hVylp00cD3WjKy9PeGlClWnjI/thumbnail.jpg What are your options for treating scars in your practice? What are your options for treating scars in your practice? https://dermsquared.com/videos/dermbits/options-for-treating-scars-22 72 2022-08-05T16:49:50.000Z yes https://dermsquared.com/videos/dermbits/hold-dupilumab-prior-live-vaccine 2023-04-28T19:03:47.401Z https://image.mux.com/PmccaTju02b7JH7O8016HzdUZDYC3u01gvH5xxrd00S004QI/thumbnail.jpg How long should you hold dupilumab prior to live vaccine injection? How long should you hold dupilumab prior to live vaccine injection? https://dermsquared.com/videos/dermbits/hold-dupilumab-prior-live-vaccine 120 2021-05-13T23:52:09.000Z yes https://dermsquared.com/videos/dermbits/how-microbiome-differ-patients-atopic-dermatitis 2025-01-31T18:07:17.183Z https://image.mux.com/1K6wDBowME25MgyYat1CFciXonV00uevFM6YzVdSVB8E/thumbnail.jpg How does the skin microbiome differ in patients with atopic dermatitis compared to healthy controls? How does the skin microbiome differ in patients with atopic dermatitis compared to healthy controls? https://dermsquared.com/videos/dermbits/how-microbiome-differ-patients-atopic-dermatitis 28 2025-01-31T18:03:20.139Z yes https://dermsquared.com/videos/dermbits/clearly-benign-or-malignant 2025-12-19T16:22:45.576Z https://image.mux.com/PvgwV82sM02xK01iAHvGBlvzcR49IVZ02L5R3BfF01zGsO4/thumbnail.jpg How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant? How should MyPath Melanoma test results be interpreted, especially when the result is not clearly benign or malignant? https://dermsquared.com/videos/dermbits/clearly-benign-or-malignant 57 2025-12-19T16:22:45.487Z yes https://dermsquared.com/videos/dermbits/complications-and-long-term-effects-associated-with-molluscum-contagiosum 2023-11-30T19:18:34.842Z https://image.mux.com/qhagJHVru025RwDpWKQtXPvhGbWRaPWxPbNNmNfdAAZk/thumbnail.jpg What are some complications and long-term effects associated with molluscum contagiosum? What are some complications and long-term effects associated with molluscum contagiosum? https://dermsquared.com/videos/dermbits/complications-and-long-term-effects-associated-with-molluscum-contagiosum 25 2023-11-30T19:18:34.832Z yes https://dermsquared.com/videos/dermbits/should-baricitinib-be-considered-first-line-therapy-alopecia-areata 2024-10-01T14:55:15.031Z https://image.mux.com/5OWArSOqxB4wJsFu102Clho1rEuZdcBmgfalNqBqp9mQ/thumbnail.jpg Should baricitinib be considered as a first-line therapy for alopecia areata? Should baricitinib be considered as a first-line therapy for alopecia areata? https://dermsquared.com/videos/dermbits/should-baricitinib-be-considered-first-line-therapy-alopecia-areata 34 2024-10-01T14:55:15.025Z yes https://dermsquared.com/videos/dermbits/considerations-ixekizumab-patients-comorbidities-diabetes-or-cardiovascular-disease 2024-09-24T18:19:26.597Z https://image.mux.com/C9VAz2QQZDR00rD02w8T8YBixqiTzCoFHPMQFwvZZp2No/thumbnail.jpg What are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease? What are the considerations for using ixekizumab in patients with comorbidities such as diabetes or cardiovascular disease? https://dermsquared.com/videos/dermbits/considerations-ixekizumab-patients-comorbidities-diabetes-or-cardiovascular-disease 139 2024-09-24T18:19:26.589Z yes https://dermsquared.com/videos/dermbits/recommended-duration-treatment-ritlecitinib-alopecia-areata 2024-11-07T16:11:12.561Z https://image.mux.com/qZ7v2yj2Ht00Y9mvmQ00IsEXBGLPWWyyMhycaA01WyIEAs/thumbnail.jpg What is the recommended duration of treatment with ritlecitinib for alopecia areata? What is the recommended duration of treatment with ritlecitinib for alopecia areata? https://dermsquared.com/videos/dermbits/recommended-duration-treatment-ritlecitinib-alopecia-areata 43 2024-11-07T16:11:12.554Z yes https://dermsquared.com/videos/dermbits/jak-therapy-vs-monoclonal-antibody-therapy 2023-04-28T19:29:18.235Z https://image.mux.com/6sEJ2BCGkjbnq4v165g5EWlMQh72wuzYpm7GPh00f02IY/thumbnail.jpg What are the advantages of JAK therapy vs. monoclonal antibody therapy for atopic dermatitis? What are the advantages of JAK therapy vs. monoclonal antibody therapy for atopic dermatitis? https://dermsquared.com/videos/dermbits/jak-therapy-vs-monoclonal-antibody-therapy 69 2021-11-17T17:56:48.000Z yes https://dermsquared.com/videos/dermbits/dermbits-options-available-using-topical-ruxolitinib-cream-atopic-dermatitis-ADRC00048-adrc22 2022-04-28T00:19:34.000Z https://image.mux.com/u1QKMOo0002CZWN2cHQiNnpC8Jb2dzBIBCjh00vyA94J01w/thumbnail.jpg Considering all the options that are available, when do you consider using topical ruxolitinib cream for treatment of atopic dermatitis? Considering all the options that are available, when do you consider using topical ruxolitinib cream for treatment of atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-options-available-using-topical-ruxolitinib-cream-atopic-dermatitis-ADRC00048-adrc22 94 2022-04-28T00:19:34.000Z yes https://dermsquared.com/videos/dermbits/should-patients-with-moderate-ad-by-treated-with-systemic-therapies-earlier-in-disease-progression 2025-10-01T20:38:38.210Z https://image.mux.com/HbmZxT009AgbONpXckdP01c2Vb01kvYTGwG5hbR7pc3nN00/thumbnail.jpg Should patients with moderate AD by treated with systemic therapies earlier in disease progression? Should patients with moderate AD by treated with systemic therapies earlier in disease progression? https://dermsquared.com/videos/dermbits/should-patients-with-moderate-ad-by-treated-with-systemic-therapies-earlier-in-disease-progression 131 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/hypochlorous-acid-staphylococcus-decolonization-scalp 2023-04-28T19:19:11.575Z https://image.mux.com/a4aTPB01BAyvclZ00SfSyI8Fdzq3OfM00Ylgv4DiNgRswQ/thumbnail.jpg Can hypochlorous acid products be useful for staphylococcus aureus decolonization and can they be sprayed on the scalp? Can hypochlorous acid products be useful for staphylococcus aureus decolonization and can they be sprayed on the scalp? https://dermsquared.com/videos/dermbits/hypochlorous-acid-staphylococcus-decolonization-scalp 69 2021-09-01T20:15:33.000Z yes https://dermsquared.com/videos/dermbits/is-there-drug-monitoring-required-for-bimekizumab 2023-11-09T16:52:44.767Z https://image.mux.com/CGAq1PgNhT5QL71ghlHQW6VGdBCW02zv8ZSo402YdWzJc/thumbnail.jpg Is there drug monitoring required for bimekizumab? Is there drug monitoring required for bimekizumab? https://dermsquared.com/videos/dermbits/is-there-drug-monitoring-required-for-bimekizumab 48 2023-11-09T16:52:44.761Z yes https://dermsquared.com/videos/dermbits/what-is-i31-slnb-algorithm-enhance-slnb-guidance-melanoma-management 2025-03-03T14:13:01.743Z https://image.mux.com/95b66WyJ9buus4as7ShSHDUFE1nF02WL5jsbK4Tybbow/thumbnail.jpg What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management? What is the i31-SLNB algorithm, and how can it enhance SLNB guidance in melanoma management? https://dermsquared.com/videos/dermbits/what-is-i31-slnb-algorithm-enhance-slnb-guidance-melanoma-management 63 2025-03-03T14:13:01.729Z yes https://dermsquared.com/videos/dermbits/how-should-acne-treatments-be-adjusted-for-patients-with-sensitive-or-atopic-skin 2025-05-07T17:27:25.830Z https://image.mux.com/EfzZ7unk24E01teYQrDKhGREtl7u1wxF9szuMOp02jyfQ/thumbnail.jpg How should acne treatments be adjusted for patients with sensitive or atopic skin? How should acne treatments be adjusted for patients with sensitive or atopic skin? https://dermsquared.com/videos/dermbits/how-should-acne-treatments-be-adjusted-for-patients-with-sensitive-or-atopic-skin 97 2025-05-07T17:24:37.957Z yes https://dermsquared.com/videos/dermbits/il-17-to-an-il-23-wait-before-initiating-new-drug 2023-04-28T20:16:58.699Z https://image.mux.com/CTc7rhZAXZrnxBBZwh9Hz5eacK2fIig9ExxAahtaras/thumbnail.jpg When changing from an IL-17 to an IL-23 or vice versa, how long do you typically wait before initiating a new drug? When changing from an IL-17 to an IL-23 or vice versa, how long do you typically wait before initiating a new drug? https://dermsquared.com/videos/dermbits/il-17-to-an-il-23-wait-before-initiating-new-drug 38 2022-07-12T19:44:13.000Z yes https://dermsquared.com/videos/dermbits/would-you-pair-dupixent-with-otezla-atopic-dermatitis 2023-04-28T20:05:06.708Z https://image.mux.com/kHt202WbSNpcyWU00UTwT6jiUop2tkARSEEKVNKbETCZc/thumbnail.jpg Would you ever pair Dupixent with Otezla for atopic dermatitis? Would you ever pair Dupixent with Otezla for atopic dermatitis? https://dermsquared.com/videos/dermbits/would-you-pair-dupixent-with-otezla-atopic-dermatitis 60 2022-03-03T01:04:05.000Z yes https://dermsquared.com/videos/dermbits/ordering-my-path-melanoma 2025-12-19T16:22:55.130Z https://image.mux.com/A2NOZFHb3ISnW1cqnoAxmfy3F6EL3C81VSQ00oAbtFkk/thumbnail.jpg What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma? What logistical considerations should dermatologists keep in mind when ordering MyPath Melanoma? https://dermsquared.com/videos/dermbits/ordering-my-path-melanoma 61 2025-12-19T16:22:55.123Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-encourage-holistic-approach-psoriasis 2024-11-01T13:48:22.565Z https://image.mux.com/IHpGmjdXiuAvoCoMjeJSQRSmMCh6NjasMF201M2hL9Bc/thumbnail.jpg How can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support? How can dermatologists encourage a holistic approach to psoriasis treatment, including lifestyle modifications and mental health support? https://dermsquared.com/videos/dermbits/how-dermatologists-encourage-holistic-approach-psoriasis 37 2024-11-01T13:48:22.556Z yes https://dermsquared.com/videos/dermbits/efficacy-bimekizumab-from-three-pivotal-head-to-head-trials 2023-10-24T16:35:46.776Z https://image.mux.com/XRHgnm6F4BZxQmJRhs4002s3DENNmPGft8SlLLRY4fUk/thumbnail.jpg Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials? Can you speak to the efficacy of bimekizumab from the three pivotal head-to-head trials? https://dermsquared.com/videos/dermbits/efficacy-bimekizumab-from-three-pivotal-head-to-head-trials 58 2023-10-24T16:35:46.771Z yes https://dermsquared.com/videos/dermbits/tapinarof-steroid-tacrolimus-pimecrolimus-crisaborole 2023-04-28T19:42:28.578Z https://image.mux.com/T6G600Hym4xouSgG899EPCWR2M4bvrlGJ009hRVb5BSzs/thumbnail.jpg Do you see tapinarof cream functioning more as a steroid-sparing topical the way tacrolimus, pimecrolimus and crisaborole do? Do you see tapinarof cream functioning more as a steroid-sparing topical the way tacrolimus, pimecrolimus and crisaborole do? https://dermsquared.com/videos/dermbits/tapinarof-steroid-tacrolimus-pimecrolimus-crisaborole 69 2021-12-27T17:12:53.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-cream-is-indicated-for-short-term-use-when-should-patients-discontinue-use 2023-07-28T16:15:27.654Z https://image.mux.com/cRl5T6shM2P4tcT6sIaNTJg6YIUuvDMAFMcqUzQG5QE/thumbnail.jpg Ruxolitinib cream is indicated for short-term use; when should patients discontinue use? Summary In the video, Dr. Raj Chovatiya discusses the appropriate use and discontinuation of ruxolitinib cream, considering patients' responses to the therapy. According to the prescribing information, ruxolitinib cream is meant for short-term use. For patients who are good candidates for this treatment, the recommended usage is twice daily for eight weeks. After the initial eight-week period, patients and healthcare providers should assess the response to the treatment. If significant improvement is observed, patients should continue using the cream. However, if the desired results are not achieved at that point, it is essential to reevaluate whether ruxolitinib cream is the right treatment option. The indication statement for ruxolitinib cream also mentions "non-continuous chronic use." This refers to the trial program's design, where some patients used the cream on an as-needed basis in the long run. The decision to continue or discontinue the treatment should be based on the individual's response and the discussion between the patient and their healthcare provider in real-world scenarios. Key Points The duration of use depends on the patient's response to the treatment. The prescribing information recommends using it twice daily for eight weeks and assessing the results. If there is improvement, patients should continue using it. If there isn't significant improvement after the initial eight weeks, it's essential to reassess whether this treatment is right for the patient. The indication statement also mentions the possibility of non-continuous chronic use, as seen in the trial program design. In the real world, healthcare professionals will have discussions with their patients about using the cream on an as-needed basis in the long run. https://dermsquared.com/videos/dermbits/ruxolitinib-cream-is-indicated-for-short-term-use-when-should-patients-discontinue-use 60 2023-07-27T19:13:22.708Z yes https://dermsquared.com/videos/dermbits/notable-results-of-the-true-ad-clinical-trials-topical-ruxolitinib 2023-10-31T21:18:23.010Z https://image.mux.com/E02eQpsUHk1n7QEidnXE6wM9yKnm1Mp810201hK201i01fZU/thumbnail.jpg What were the notable results of the TRuE-AD clinical trials for topical ruxolitinib? What were the notable results of the TRuE-AD clinical trials for topical ruxolitinib? https://dermsquared.com/videos/dermbits/notable-results-of-the-true-ad-clinical-trials-topical-ruxolitinib 44 2023-10-31T21:18:23.004Z yes https://dermsquared.com/videos/dermbits/that-are-not-clearly-malignant 2025-12-19T16:23:24.091Z https://image.mux.com/ja00nttSj5XnFPDyDkuR2e7nQx4R8CZqqZ3GLcGy2XdY/thumbnail.jpg Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant? Can you describe how MyPath Melanoma adds clinical value when evaluating melanocytic lesions that are not clearly malignant? https://dermsquared.com/videos/dermbits/that-are-not-clearly-malignant 87 2025-12-19T16:23:24.085Z yes https://dermsquared.com/videos/dermbits/how-address-patient-concerns-long-term-use-biologics 2024-10-18T17:17:55.194Z https://image.mux.com/gkfKJfhbaHvG02exvTN8XRljDI016zEQbpYT2FVsjrQdA/thumbnail.jpg How do you address patient concerns about the long-term use of biologics? How do you address patient concerns about the long-term use of biologics? https://dermsquared.com/videos/dermbits/how-address-patient-concerns-long-term-use-biologics 61 2024-10-18T17:17:55.187Z yes https://dermsquared.com/videos/dermbits/common-reasons-undertreatment-patients-psoriasis-and-address-this 2024-07-17T16:13:14.900Z https://image.mux.com/2LuOMVTtiVTFqu6TDK75fQIhMp02nr003uKcTFWujOs2U/thumbnail.jpg What are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this? What are some common reasons for undertreatment of patients with psoriasis and how can dermatologists address this? https://dermsquared.com/videos/dermbits/common-reasons-undertreatment-patients-psoriasis-and-address-this 62 2024-07-17T16:13:14.893Z yes https://dermsquared.com/videos/dermbits/manage-candidiasis-on-il-17-inhibitors 2023-04-28T19:01:04.658Z https://image.mux.com/6BLlmpdXbROy34wcC9J02Yp1uDMF57RQKvByYiofKvWA/thumbnail.jpg How do you manage patients who develop candidiasis while on IL-17 inhibitors? How do you manage patients who develop candidiasis while on IL-17 inhibitors? https://dermsquared.com/videos/dermbits/manage-candidiasis-on-il-17-inhibitors 104 2021-04-22T23:17:08.000Z yes https://dermsquared.com/videos/dermbits/should-ruxolitinib-be-used-monotherapy-or-combined-vitiligo 2024-05-01T13:33:46.051Z https://image.mux.com/Bj02T6ekkqISDKZ0121AoI88LPwykgHCG6OJPerZo402LQ/thumbnail.jpg Should ruxolitinib be used as a monotherapy or can it be combined with other treatments for vitiligo? Should ruxolitinib be used as a monotherapy or can it be combined with other treatments for vitiligo? https://dermsquared.com/videos/dermbits/should-ruxolitinib-be-used-monotherapy-or-combined-vitiligo 39 2024-05-01T13:33:46.037Z yes https://dermsquared.com/videos/dermbits/how-manage-patients-psoriasis-concurrent-inflammatory-bowel-disease 2024-08-20T18:27:53.391Z https://image.mux.com/A8SK3Epj3QJZLYYRRszVzOjnqHjgUGm2ymIcBFcAVbY/thumbnail.jpg How do you manage patients with psoriasis with concurrent inflammatory bowel disease? How do you manage patients with psoriasis with concurrent inflammatory bowel disease? https://dermsquared.com/videos/dermbits/how-manage-patients-psoriasis-concurrent-inflammatory-bowel-disease 85 2024-08-20T18:16:18.555Z yes https://dermsquared.com/videos/dermbits/mypath-melanoma-test-lesion-previously-biopsied 2025-07-15T03:06:43.110Z https://image.mux.com/3fnfJOkHE4NDE52ucud01WLjj02XywTxxRoVzuYSURKJQ/thumbnail.jpg Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance? Can I order the MyPath Melanoma test on a lesion that has been previously biopsied, or does it need to be planned in advance? https://dermsquared.com/videos/dermbits/mypath-melanoma-test-lesion-previously-biopsied 34 2025-07-15T03:06:43.103Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-used-with-phototherapy 2024-07-01T14:43:24.433Z https://image.mux.com/7jE7KPzHuhPTJOEt200SZr8mYLC5HRYF602tPsQK1SRsI/thumbnail.jpg Can ruxolitinib be used with phototherapy Can ruxolitinib be used with phototherapy https://dermsquared.com/videos/dermbits/can-ruxolitinib-used-with-phototherapy 19 2024-07-01T14:43:24.426Z yes https://dermsquared.com/videos/dermbits/did-any-patients-in-clinical-trials-for-lebrikizumab-achieve-easi-90 2025-04-01T14:17:37.282Z https://image.mux.com/lFjTVCBa6dbKNt3dnjbuYoq58013E9un01xLTb9JAsINY/thumbnail.jpg Did any patients in clinical trials for lebrikizumab achieve EASI90? Did any patients in clinical trials for lebrikizumab achieve EASI90? https://dermsquared.com/videos/dermbits/did-any-patients-in-clinical-trials-for-lebrikizumab-achieve-easi-90 44 2025-04-01T14:17:36.985Z yes https://dermsquared.com/videos/dermbits/dermbits-how-was-the-40-gep-test-developed-WCM2300012-scc23 2023-05-17T20:07:51.028Z https://image.mux.com/qQioBuJNxLX01oNT6atvoiJBNyaQFPqJLtUc394gHdOk/thumbnail.jpg How was the 40-GEP test developed? How was the 40-GEP test developed? https://dermsquared.com/videos/dermbits/dermbits-how-was-the-40-gep-test-developed-WCM2300012-scc23 35 2023-05-17T20:07:51.024Z yes https://dermsquared.com/videos/dermbits/limitation-regarding-body-surface-area-topical-ruxolitinib-22 2023-04-28T20:21:08.000Z https://image.mux.com/p62dpJMQkf2JkZJpfr4slsNRBH4Npi8opQ4BmO12eP00/thumbnail.jpg Is there a limitation regarding body surface area with topical ruxolitinib? Is there a limitation regarding body surface area with topical ruxolitinib? https://dermsquared.com/videos/dermbits/limitation-regarding-body-surface-area-topical-ruxolitinib-22 80 2022-07-27T21:50:01.000Z yes https://dermsquared.com/videos/dermbits/emerging-therapies-or-treatment-modalities-being-investigated-vitiligo 2025-03-03T14:13:51.600Z https://image.mux.com/YiiFoWwwfnXWIiHIHIiSK00XgXA2eaEQQbDXp1SvIn6c/thumbnail.jpg What are the emerging therapies or treatment modalities being investigated for vitiligo? What are the emerging therapies or treatment modalities being investigated for vitiligo? https://dermsquared.com/videos/dermbits/emerging-therapies-or-treatment-modalities-being-investigated-vitiligo 36 2025-03-03T14:13:51.593Z yes https://dermsquared.com/videos/dermbits/dermbits-how-are-pbms-and-health-insurance-companies-related-to-one-another-WCM230004 2023-03-10T00:09:41.000Z https://image.mux.com/QPypbYygFUTRILST3iGPLwKrDrL601bVZBcZFT00ICGYw/thumbnail.jpg How are PBMs and Health insurance companies related to one another? How are PBMs and Health insurance companies related to one another? https://dermsquared.com/videos/dermbits/dermbits-how-are-pbms-and-health-insurance-companies-related-to-one-another-WCM230004 28 2023-03-10T00:09:41.000Z yes https://dermsquared.com/videos/dermbits/personalize-patients-skincare-routine-22 2023-04-28T20:17:41.871Z https://image.mux.com/CQxE1pJvwBn3oIgoROsVSgimdJo02sEnXJzjlwdcfrwU/thumbnail.jpg How do you personalize a patient's skincare routine? How do you personalize a patient's skincare routine? https://dermsquared.com/videos/dermbits/personalize-patients-skincare-routine-22 67 2022-07-20T04:49:14.000Z yes https://dermsquared.com/videos/dermbits/expected-timelines-clinical-improvement-initiating-systemic-therapies-ad 2025-05-01T13:41:31.748Z https://image.mux.com/zb3evm68eTxs01jxZLyl7gX8c46q02V3Ljs2dLkpYb5Qw/thumbnail.jpg What are the expected timelines for clinical improvement when initiating systemic therapies for AD? What are the expected timelines for clinical improvement when initiating systemic therapies for AD? https://dermsquared.com/videos/dermbits/expected-timelines-clinical-improvement-initiating-systemic-therapies-ad 67 2025-05-01T13:41:31.741Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-you-determine-patient-better-candidate-for-topical-treatment-vs-an-oral-or-biologic-arcp22 2023-05-11T14:55:38.882Z https://image.mux.com/W2CgE02OFohagY1x6lTGosKZDnbdDJgx17Nwo02FlGgo8/thumbnail.jpg How do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic? How do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic? https://dermsquared.com/videos/dermbits/dermbits-how-do-you-determine-patient-better-candidate-for-topical-treatment-vs-an-oral-or-biologic-arcp22 44 2022-10-28T22:51:03.000Z yes https://dermsquared.com/videos/dermbits/triple-therapy-post-inflammatory-hyperpigmentation 2023-04-28T19:04:31.973Z https://image.mux.com/lQaCU02301ppYSKb6ES2rpSsWUNMC4wbUITb6W700mArzQ/thumbnail.jpg Do you ever use triple therapy cream for Post-Inflammatory Hyperpigmentation? Do you ever use triple therapy cream for Post-Inflammatory Hyperpigmentation? https://dermsquared.com/videos/dermbits/triple-therapy-post-inflammatory-hyperpigmentation 42 2021-05-21T18:17:48.000Z yes https://dermsquared.com/videos/dermbits/should-lebrikizumab-monotherapy-or-combined-other-treatments 2024-12-02T16:27:52.122Z https://image.mux.com/Ta5bix02yufuvOWIp2BwTH00klXd8w4E4jH5oY4bIE9OU/thumbnail.jpg Should lebrikizumab be used as monotherapy, or can it be combined with other treatments? Should lebrikizumab be used as monotherapy, or can it be combined with other treatments? https://dermsquared.com/videos/dermbits/should-lebrikizumab-monotherapy-or-combined-other-treatments 32 2024-12-02T16:27:51.424Z yes https://dermsquared.com/videos/dermbits/can-tapinarof-be-used-in-pregnant-patients-with-psoriasis 2023-07-27T19:57:56.491Z https://image.mux.com/pF3eGK101eeO025mqoIau4M2sV02tACXG2G00TQUS1u7nYI/thumbnail.jpg Can tapinarof be used in pregnant patients with psoriasis? Can tapinarof be used in pregnant patients with psoriasis? https://dermsquared.com/videos/dermbits/can-tapinarof-be-used-in-pregnant-patients-with-psoriasis 29 2023-07-27T19:57:56.484Z yes https://dermsquared.com/videos/dermbits/how-test-inform-clinical-management-patients-high-risk-scc 2023-11-17T16:52:11.439Z https://image.mux.com/DuLg9SaVhgyAvx5xZAX01aA6iDxaQBE5jvVqedUznxCc/thumbnail.jpg How does the test inform the clinical management of patients with high-risk SCC? How does the test inform the clinical management of patients with high-risk SCC? https://dermsquared.com/videos/dermbits/how-test-inform-clinical-management-patients-high-risk-scc 73 2023-11-17T16:36:46.639Z yes https://dermsquared.com/videos/dermbits/why-patients-atopic-dermatitis-more-at-risk-contracting-molluscum-contagiosum 2023-11-30T19:18:41.831Z https://image.mux.com/zcGppgmbUbL022lrz4djTkr9LMvrIEGJcN29tFvWPZbA/thumbnail.jpg Why are patients with atopic dermatitis more at risk of contracting molluscum contagiosum? Why are patients with atopic dermatitis more at risk of contracting molluscum contagiosum? https://dermsquared.com/videos/dermbits/why-patients-atopic-dermatitis-more-at-risk-contracting-molluscum-contagiosum 28 2023-11-30T19:18:41.824Z yes https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-safely-full-face 2025-10-20T22:32:00.224Z https://image.mux.com/J3ccejxDp5ySlUEiIHqjhWffO5bc6nlW4D2N7vkW01t8/thumbnail.jpg Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face? Can tirbanibulin ointment be safely and effectively used for actinic keratosis on the full face? https://dermsquared.com/videos/dermbits/tirbanibulin-ointment-safely-full-face 53 2025-02-12T16:22:58.204Z yes https://dermsquared.com/videos/dermbits/jak-first-line-vs-monoclonal-antibody 2023-04-28T19:20:32.538Z https://image.mux.com/p9BWQt02D4017bxPU01EnaTeLa4BGrL7VM01PKQfgkrPoTk/thumbnail.jpg How do you decide whether to use a JAK first line vs monoclonal antibody? How do you decide whether to use a JAK first line vs monoclonal antibody? https://dermsquared.com/videos/dermbits/jak-first-line-vs-monoclonal-antibody 192 2021-09-16T15:40:51.000Z yes https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-the-40-gep-test 2023-07-27T19:21:27.788Z https://image.mux.com/TF1ntTac5ZSJHLQTL1811deillWMN5xi4xWuSQmdc4c/thumbnail.jpg Who is the ideal patient for the 40-GEP test? Summary Dr. Darrell Rigel explains in the video that the ideal patient for the 40-GEP test is someone who has a more advanced tumor. The main objective of this test is to identify individuals at the highest risk for metastatic disease. A class 2B result from the test indicates the highest risk, with a likelihood of 50 to 60% for metastatic disease. Therefore, the test is most appropriate for patients who already have an advanced tumor and have other risk factors associated with it. The test was not specifically designed for individuals with early-stage squamous cell carcinoma or squamous cell in situ, as the data was not collected for such cases. In summary, the 40-GEP test is recommended for patients with more advanced disease and additional risk factors for metastatic progression. Key Points The 40-GEP test is designed for patients with a more advanced tumor. The purpose of the test is to identify those at the highest risk for metastatic disease. A class 2B result from the 40-GEP test indicates the highest risk, with a 50 to 60% chance of metastatic disease. The ideal patient for the test is someone who already has an advanced tumor to some extent and has other risk factors for metastasis. The test is not suitable for individuals with squamous cell in situ or very early squamous cell cancer, as the data for the test was not collected for such cases. The focus of the 40-GEP test is on patients with more advanced disease to provide meaningful results. https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-the-40-gep-test 47 2023-07-27T19:21:27.783Z yes https://dermsquared.com/videos/dermbits/what-should-patients-expect-when-stop-treatment-tapinarof 2024-04-08T18:35:46.004Z https://image.mux.com/VNdy00pCLDOT2DVzdGqCahUJLIvyE52vpYuqiBPNVP02A/thumbnail.jpg What should patients expect when they stop treatment with tapinarof? What should patients expect when they stop treatment with tapinarof? https://dermsquared.com/videos/dermbits/what-should-patients-expect-when-stop-treatment-tapinarof 56 2024-04-08T18:35:45.996Z yes https://dermsquared.com/videos/dermbits/important-considerations-treating-plaque-psoriasis-sensitive-areas 2023-11-01T21:22:58.502Z https://image.mux.com/R004eBzWSOlEPyA98iROzU6nPJYmmydrBxuGlABtouWc/thumbnail.jpg What are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals? What are important considerations when treating plaque psoriasis in sensitive areas such as the face, folds, and genitals? https://dermsquared.com/videos/dermbits/important-considerations-treating-plaque-psoriasis-sensitive-areas 42 2023-11-01T21:22:58.496Z yes https://dermsquared.com/videos/dermbits/dermbits-which-toxin-is-best-00155 2023-05-17T19:19:20.167Z https://image.mux.com/xCtmHpul5ZTnUeOVqqhbS02ESD0101ZjrAbMZxLHZ5Q01tI/thumbnail.jpg Which toxin is best? Which toxin is best? https://dermsquared.com/videos/dermbits/dermbits-which-toxin-is-best-00155 63 2021-05-07T00:06:07.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-coverage-decisions 2026-04-02T16:22:34.012Z https://image.mux.com/mD2SqsV1pMuoGWJkG00xP1ICPUzGH2bapuWYeQQ9k6XM/thumbnail.jpg How do you document body surface area or lesion burden for ruxolitinib coverage decisions? How do you document body surface area or lesion burden for ruxolitinib coverage decisions? https://dermsquared.com/videos/dermbits/ruxolitinib-coverage-decisions 65 2026-04-02T14:33:18.493Z yes https://dermsquared.com/videos/dermbits/are-il-23-blockers-as-effective-as-tnf-and-il-17-blockers-at-preventing-the-progression-of-psa 2023-07-27T19:38:59.386Z https://image.mux.com/MHvF01Apk5YxHOzPXa8WvnzWcMvexaAueK7CqfZRuo1A/thumbnail.jpg Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA? Are IL-23 blockers as effective as TNF and IL-17 blockers at preventing the progression of PsA? https://dermsquared.com/videos/dermbits/are-il-23-blockers-as-effective-as-tnf-and-il-17-blockers-at-preventing-the-progression-of-psa 66 2023-07-27T19:38:59.377Z yes https://dermsquared.com/videos/dermbits/strategies-improve-adherence-psoriasis-treatment 2024-09-24T18:18:57.017Z https://image.mux.com/hp009fQU8bzblWUgZBXhiJKD02gm58JfdOruJcaSRcrBM/thumbnail.jpg What strategies can be used to improve patient adherence in psoriasis treatment regimens? What strategies can be used to improve patient adherence in psoriasis treatment regimens? https://dermsquared.com/videos/dermbits/strategies-improve-adherence-psoriasis-treatment 490 2024-09-24T18:18:57.011Z yes https://dermsquared.com/videos/dermbits/considerations-when-transitioning-another-biologic-to-lebrikizumab 2025-02-18T17:43:38.058Z https://image.mux.com/yzxoTyJFTHbEEGwDImm3TYLhFuKpToog5XEOYWUR83U/thumbnail.jpg What considerations should be taken when transitioning a patient from another biologic to lebrikizumab? What considerations should be taken when transitioning a patient from another biologic to lebrikizumab? https://dermsquared.com/videos/dermbits/considerations-when-transitioning-another-biologic-to-lebrikizumab 51 2025-02-18T17:43:38.050Z yes https://dermsquared.com/videos/dermbits/how-should-dermatologists-determine-when-to-escalate-from-topical-to-systemic-acne-treatments 2025-05-07T17:27:12.910Z https://image.mux.com/i0101aauF1fWemn2qcz9dh2pNMU4r33PCzYGki2URFHmA/thumbnail.jpg How should dermatologists determine when to escalate from topical to systemic acne treatments? How should dermatologists determine when to escalate from topical to systemic acne treatments? https://dermsquared.com/videos/dermbits/how-should-dermatologists-determine-when-to-escalate-from-topical-to-systemic-acne-treatments 116 2025-05-07T17:24:28.101Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-symptom-fluctuation-reinforce-importance-treatment-adherence 2025-05-01T13:42:10.693Z https://image.mux.com/2Lt00ZQHl01A1U01B2de9kXUOLgvsjp5sQ6uOux900ub8Oo/thumbnail.jpg How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence? How do you counsel patients on symptom fluctuation and reinforce the importance of treatment adherence? https://dermsquared.com/videos/dermbits/how-counsel-patients-symptom-fluctuation-reinforce-importance-treatment-adherence 67 2025-05-01T13:42:10.682Z yes https://dermsquared.com/videos/dermbits/after-steroid-failure 2026-05-04T20:18:13.211Z https://image.mux.com/1EXF01Ui9RsF4LUxuDjUNlNuLGI9rGCxVr2QhkaEScSI/thumbnail.jpg How do you justify nonsteroidal therapy after steroid failure? How do you justify nonsteroidal therapy after steroid failure? https://dermsquared.com/videos/dermbits/after-steroid-failure 73 2026-05-04T20:18:13.205Z yes https://dermsquared.com/videos/dermbits/how-identify-patients-who-would-benefit-from-ruxolitinib-cream 2023-08-04T21:01:37.644Z https://image.mux.com/4MbzstH023D9ycxwgvQnFM00Wi8LeixKMIK02VSKPw00E74/thumbnail.jpg How can I identify patients who would benefit from ruxolitinib cream? Summary Dr Raj Chovatiya addresses the question of how to identify a patient who would benefit from ruxolitinib cream. He explains that the right patients for this treatment are those with mild to moderate symptoms and a body surface area of involvement between 3% and 20%. These criteria are based on the FDA indication and clinical trial design.In real-world scenarios, patients seeking ruxolitinib cream often have already tried topical corticosteroids or topical calcineurin inhibitors, and a key factor to consider is if patients have not experienced adequate control of their symptoms with these other therapies. The ideal candidate for ruxolitinib cream is someone who desires not only lesional control but also itch control. Overall, identifying patients who would benefit from ruxolitinib cream involves assessing the severity of their condition, the affected body surface area, and the inadequacy of previous treatments in controlling their symptoms. Key Points The key question is: "Who is the right patient for ruxolitinib cream?" The ideal patient profile includes those with mild to moderate symptomsPatients typically have a body surface area of involvement between 3% and 20% Patient candidates have often already tried topical corticosteroids or topical calcineurin inhibitors The target patient is someone who hasn't achieved sufficient control with other therapiesThe desired outcome is not only lesional control, but also itch relief https://dermsquared.com/videos/dermbits/how-identify-patients-who-would-benefit-from-ruxolitinib-cream 51 2023-07-27T19:28:09.504Z yes https://dermsquared.com/videos/dermbits/results-2-year-open-label-extension-ruxolitinib-vitiligo 2024-05-01T13:33:55.244Z https://image.mux.com/ILWGvE00jSXQIvLJv6VOLhJfZwldDOmydBmuMkYwjEfk/thumbnail.jpg What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo? What results were seen in the 2-year open-label extension for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/results-2-year-open-label-extension-ruxolitinib-vitiligo 39 2024-05-01T13:33:55.237Z yes https://dermsquared.com/videos/dermbits/dermatologists-approach-ixekizumab-therapy-patients-planning-conceive 2024-09-24T18:20:24.435Z https://image.mux.com/uiBSDapTdlZLTujX4JUrlWh7OFWQkzCaeYN1eSwtH2Y/thumbnail.jpg How should dermatologists approach ixekizumab therapy in patients planning to conceive? How should dermatologists approach ixekizumab therapy in patients planning to conceive? https://dermsquared.com/videos/dermbits/dermatologists-approach-ixekizumab-therapy-patients-planning-conceive 177 2024-09-24T18:20:24.419Z yes https://dermsquared.com/videos/dermbits/dermbits-do-you-augment-oral-andor-biologic-therapy-with-a-topical-arcp22 2023-05-11T14:55:14.480Z https://image.mux.com/ik4AcXTCdO0202mDI011FH301pgIyfrfcwDMdMXeUmqgKQk/thumbnail.jpg Do you augment oral and/or biologic therapy with a topical? Do you augment oral and/or biologic therapy with a topical? https://dermsquared.com/videos/dermbits/dermbits-do-you-augment-oral-andor-biologic-therapy-with-a-topical-arcp22 44 2022-10-28T22:52:41.000Z yes https://dermsquared.com/videos/dermbits/theyve-been-overlooked 2026-05-22T13:20:20.285Z https://image.mux.com/2sxlE5xhd51pRMF4AAZczu7whcGRxBSrX2Lt2iqbADo/thumbnail.jpg Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked? Are there any older dermatologic therapies or approaches that you feel are underutilized today, and why do you think they’ve been overlooked? https://dermsquared.com/videos/dermbits/theyve-been-overlooked 78 2026-05-22T13:20:20.273Z yes https://dermsquared.com/videos/dermbits/any-concern-using-topical-jak-inhibitors-in-patients-on-dupilumab 2023-07-27T19:55:53.519Z https://image.mux.com/2n98pzvv026hDWtOVF8Iq01NkZlJpbf02X02008etGQKTqRY/thumbnail.jpg Any concern using topical JAK inhibitors in patients on dupilumab? Any concern using topical JAK inhibitors in patients on dupilumab? https://dermsquared.com/videos/dermbits/any-concern-using-topical-jak-inhibitors-in-patients-on-dupilumab 69 2023-07-27T19:55:53.507Z yes https://dermsquared.com/videos/dermbits/how-far-laterally-inject-frontalis 2023-04-28T19:23:35.153Z https://image.mux.com/g1vm6wQzh102GinbPUbOJUB9XBIaD89ETynO3wvXJitQ/thumbnail.jpg How far laterally will you inject the frontalis? How far laterally will you inject the frontalis? https://dermsquared.com/videos/dermbits/how-far-laterally-inject-frontalis 50 2021-10-07T22:41:43.000Z yes https://dermsquared.com/videos/dermbits/dermbits-does-topical-ruxolitinib-work-for-pruritus-or-pruritic-disorders-ADRC00084-adrc23 2023-02-15T23:55:38.000Z https://image.mux.com/QS1G6012gDFB0200NH00nnx01KQQ9SeLhCyI33ZfsTZWrLbs/thumbnail.jpg Does topical ruxolitinib work for pruritus or pruritic disorders? Does topical ruxolitinib work for pruritus or pruritic disorders? https://dermsquared.com/videos/dermbits/dermbits-does-topical-ruxolitinib-work-for-pruritus-or-pruritic-disorders-ADRC00084-adrc23 17 2023-02-15T23:55:38.000Z yes https://dermsquared.com/videos/dermbits/lab-monitoring-in-patients-prescribed-topical-ruxolitinib-22 2023-04-28T20:19:55.434Z https://image.mux.com/FVHrgY3Hgj018ILH3ATQX4Q1j37iXj00ARFN27NOHpM8s/thumbnail.jpg Do you do any lab monitoring in patients prescribed topical ruxolitinib? Do you do any lab monitoring in patients prescribed topical ruxolitinib? https://dermsquared.com/videos/dermbits/lab-monitoring-in-patients-prescribed-topical-ruxolitinib-22 32 2022-07-27T21:45:57.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-pathophysiology-of-gpp 2023-06-30T17:20:19.699Z https://image.mux.com/5SbgZcbPYcl502C0002HL2D02MJz16Ns9801Cv1YjmvS7U3U/thumbnail.jpg What is the pathophysiology of GPP? What is the pathophysiology of GPP? https://dermsquared.com/videos/dermbits/what-is-the-pathophysiology-of-gpp 49 2023-06-27T17:27:31.512Z yes https://dermsquared.com/videos/dermbits/how-would-you-describe-tolerability-of-topical-roflumilast 2023-06-29T16:12:51.598Z https://image.mux.com/X2S3YCNlEmSY00fUeNaQG5YMyVck7uyx36zG23nVfU2g/thumbnail.jpg How would you describe the overall tolerability of topical roflumilast? How would you describe the overall tolerability of topical roflumilast? https://dermsquared.com/videos/dermbits/how-would-you-describe-tolerability-of-topical-roflumilast 56 2023-06-29T16:12:51.593Z yes https://dermsquared.com/videos/dermbits/rate-facial-repigmentation-clinical-trials-ruxolitinib-vitiligo 2025-03-03T14:14:57.669Z https://image.mux.com/SsTt6z02SZ7HI7F1KUjaH7qFHvkCp4SNvBRe9jxXg8zA/thumbnail.jpg What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo? What rate of facial repigmentation was seen in clinical trials for ruxolitinib in patients with vitiligo? https://dermsquared.com/videos/dermbits/rate-facial-repigmentation-clinical-trials-ruxolitinib-vitiligo 51 2025-03-03T14:14:57.661Z yes https://dermsquared.com/videos/dermbits/hydrophobically-modified-polymers-role 2025-10-23T15:42:37.144Z https://image.mux.com/i2x3Q02CvGwi78gbWJExLmMsmKebHhf9WXJo6cZ4PXlc/thumbnail.jpg What are hydrophobically modified polymers, and what role do they play in cleanser tolerability? What are hydrophobically modified polymers, and what role do they play in cleanser tolerability? https://dermsquared.com/videos/dermbits/hydrophobically-modified-polymers-role 45 2025-10-22T21:23:27.210Z yes https://dermsquared.com/videos/dermbits/widespread-conditions 2025-10-20T17:27:08.951Z https://image.mux.com/naus6GwPqMhLdU2XXqhbktgFKJM02minc02XJmlszI1Gk/thumbnail.jpg Is home-based NB-UVB better suited for localized disease or widespread conditions? Is home-based NB-UVB better suited for localized disease or widespread conditions? https://dermsquared.com/videos/dermbits/widespread-conditions 61 2025-10-13T20:14:08.212Z yes https://dermsquared.com/videos/dermbits/how-does-the-cantharidin-applicator-work 2023-11-09T21:34:38.250Z https://image.mux.com/kEzDpJ91aX02pYL01Ozet02jmVt00u02ch0201SY00PDzzrfVWc/thumbnail.jpg How does the cantharidin applicator work? How does the cantharidin applicator work? https://dermsquared.com/videos/dermbits/how-does-the-cantharidin-applicator-work 67 2023-11-09T21:34:38.243Z yes https://dermsquared.com/videos/dermbits/oral-surveillance-study-and-how-relate-labeling-language-olumiant 2023-07-27T19:22:59.918Z https://image.mux.com/yWy3eQSse901ydAv5BxR73eAB1PbVv5JxYb01Kj3BoiYU/thumbnail.jpg What was the ORAL Surveillance study, and how does it relate to the labeling language of Olumiant? Summary In this video, Dr. Michael Cameron discusses the ORAL Surveillance study and its relevance to the labeling language of the drug Olumiant (baricitinib), particularly in dermatology practice. The ORAL Surveillance study was conducted to evaluate the safety of the JAK inhibitor tofacitinib in the rheumatoid arthritis (RA) population. The study specifically targeted high-risk patients, who were over the age of 50 and had at least one cardiovascular risk factor. All the RA patients in the study were also on methotrexate, with a median dose of 17 milligrams, and 60% of them were on chronic prednisone. This means the patients in this study were at a significantly higher risk compared to younger, healthier patients typically seen in dermatology, such as those with alopecia areata. Dr. Cameron emphasizes the importance of understanding the context and differences in patient populations when considering the safety of JAK inhibitors in dermatology. While the ORAL Surveillance study provided crucial safety data for tofacitinib in RA patients, the risks and safety profile may differ in dermatology patients who do not share the same high-risk characteristics. Despite this difference in patient populations, the labeling language of Olumiant, which is based on the ORAL Surveillance study, includes a boxed warning. Dr. Cameron points out that dermatology providers should be aware of the ORAL Surveillance study's context and the higher-risk profile of the RA patients involved. By understanding these distinctions, healthcare professionals can confidently and safely use JAK inhibitors in dermatology patients, even if the boxed warning is still present in the drug's labeling language. Key Points The ORAL Surveillance study focused on the JAK inhibitor tofacitinib in the rheumatoid arthritis (RA) population. The study included high-risk patients who were over 50 years old and had at least one cardiovascular risk factor. All RA patients in the study were on methotrexate with a median dose of 17 milligrams, and 60% were on chronic prednisone. The patient population in the study was markedly different from younger and healthier patients with conditions like alopecia areata. The safety profile of JAK inhibitors in dermatology is different from that observed in the RA population in the ORAL Surveillance study. Despite the differences in safety, the boxed warning language from the ORAL Surveillance study still applies to JAK inhibitors. Contextual understanding is necessary to ensure the safe use of JAK inhibitors in dermatology. https://dermsquared.com/videos/dermbits/oral-surveillance-study-and-how-relate-labeling-language-olumiant 77 2023-07-27T19:22:59.913Z yes https://dermsquared.com/videos/dermbits/dermbits-head-to-head-studies-efficacy-topical-ruxolitinib-compared-topical-steroid-ADRC00070-adrc23 2023-01-30T22:21:23.000Z https://image.mux.com/MmeOfMaV02gFerPA02301JmYKDBTr02enwO5cKLSCaCA4rs/thumbnail.jpg Are there any head-to-head studies that look at the efficacy of topical ruxolitinib cream compared to a topical steroid? Are there any head-to-head studies that look at the efficacy of topical ruxolitinib cream compared to a topical steroid? https://dermsquared.com/videos/dermbits/dermbits-head-to-head-studies-efficacy-topical-ruxolitinib-compared-topical-steroid-ADRC00070-adrc23 47 2023-01-30T22:21:23.000Z yes https://dermsquared.com/videos/dermbits/action-of-apremilast 2026-06-01T14:56:14.410Z https://image.mux.com/Rl9SxTI5fan0183jYg1NPvvhaFvHUy01CPlFAZiFfQD6k/thumbnail.jpg What is the mechanism of action of apremilast? What is the mechanism of action of apremilast? https://dermsquared.com/videos/dermbits/action-of-apremilast 107 2026-06-01T14:56:14.400Z yes https://dermsquared.com/videos/dermbits/impact-teledermatology-will-it-persist 2023-04-28T19:18:50.913Z https://image.mux.com/eLiGuutEkfpHZQ02rRsRiedETnNrWJYeVvLKnnFrIx01I/thumbnail.jpg What level of impact is teledermatology having on dermatology and will it persist? What level of impact is teledermatology having on dermatology and will it persist? https://dermsquared.com/videos/dermbits/impact-teledermatology-will-it-persist 59 2021-09-01T19:05:02.000Z yes https://dermsquared.com/videos/dermbits/role-of-biopsy-confirming-diagnosis-psoriasis 2024-10-18T17:18:04.839Z https://image.mux.com/KWE7sfM9T02U5kuj602byXCT3n7XUAjKmkTSBwNI8oVI00/thumbnail.jpg What is the role of biopsy in confirming a diagnosis of psoriasis? What is the role of biopsy in confirming a diagnosis of psoriasis? https://dermsquared.com/videos/dermbits/role-of-biopsy-confirming-diagnosis-psoriasis 58 2024-10-18T17:18:04.831Z yes https://dermsquared.com/videos/dermbits/difference-between-wynzora-and-enstilar 2023-04-28T19:47:47.598Z https://image.mux.com/wypC3Fb3JM436XKJHHviWDXCN85ZfetdDxGU4A6NiZ4/thumbnail.jpg What is the difference between Wynzora and Enstilar? What is the difference between Wynzora and Enstilar? https://dermsquared.com/videos/dermbits/difference-between-wynzora-and-enstilar 22 2022-01-12T17:38:51.000Z yes https://dermsquared.com/videos/dermbits/vitamin-supplementation-in-treating-vitiligo 2023-04-28T19:08:41.353Z https://image.mux.com/aSbzk5ULxF3vmn00JdmIlrkuCMf5TlXC01duwl00mxd6go/thumbnail.jpg Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients? Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients? https://dermsquared.com/videos/dermbits/vitamin-supplementation-in-treating-vitiligo 41 2021-06-11T16:13:37.000Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-used-combination-with-therapeutic-biologics-jak-inhibitors-immunosuppressants 2023-07-28T16:03:21.887Z https://image.mux.com/s77qZViZJSRNHFZeNx3qROeBWbzaNuMnt9Bd6VrY2HY/thumbnail.jpg Can ruxolitinib cream be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants? Summary In the video, Dr. Raj Chovatiya addresses the question of whether ruxolitinib cream can be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. According to the FDA approved prescribing information, ruxolitinib cream was studied and approved as a monotherapy. Therefore, the label indicates that it should not be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. However, despite this indication on the label, real-world data from various sources, including Dr. Chovatiya's group, suggest that some individuals are combining ruxolitinib cream with other therapies successfully. This practice deviates from the approved label usage. Nevertheless, ongoing studies are being conducted to evaluate the efficacy and safety of using ruxolitinib cream in combination with other therapies. These studies aim to provide valuable insights into the potential benefits and risks of such combinations, ensuring informed and evidence-based treatment decisions for patients. Key Points Ruxolitinib cream was studied and approved as a monotherapy. The FDA-approved prescribing information for ruxolitinib cream indicates that it should not be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants. Despite the label indication, real-world data shows that some people are combining ruxolitinib cream with other therapies successfully, deviating from the approved usage. There are ongoing studies to determine the efficacy and safety of using ruxolitinib cream in combination with other therapies. These studies aim to provide more insights into the potential benefits and risks for individuals who use the cream in combination with other treatments. https://dermsquared.com/videos/dermbits/can-ruxolitinib-used-combination-with-therapeutic-biologics-jak-inhibitors-immunosuppressants 50 2023-07-27T19:12:55.126Z yes https://dermsquared.com/videos/dermbits/approach-counseling-patient-experienced-multiple-treatment-failures 2024-07-17T16:13:11.139Z https://image.mux.com/Zmn2zr4zZObdDt01fTUJvQio1w9wTeyBgFEyqbgnXYzU/thumbnail.jpg What is your approach when counseling a patient who has experienced multiple treatment failures? What is your approach when counseling a patient who has experienced multiple treatment failures? https://dermsquared.com/videos/dermbits/approach-counseling-patient-experienced-multiple-treatment-failures 68 2024-07-17T16:13:11.129Z yes https://dermsquared.com/videos/dermbits/do-patients-using-roflumilast-experience-stinging-and-burning 2023-08-31T20:42:39.756Z https://image.mux.com/CTLZ1p00zId1o4sn7SNRpxPanc00qgZXVnzxzoH6pLLzc/thumbnail.jpg Do patients using roflumilast experience stinging and burning? Do patients using roflumilast experience stinging and burning? https://dermsquared.com/videos/dermbits/do-patients-using-roflumilast-experience-stinging-and-burning 46 2023-08-31T20:42:39.749Z yes https://dermsquared.com/videos/dermbits/patients-switching-to-lebrikizumab-after-dupilumab-treatment 2025-10-01T22:40:40.844Z https://image.mux.com/teyPjPvu4lzCwBJbGEc023oOMuhRn5bamVk5kgKF2PCw/thumbnail.jpg What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment? What were the key findings of the ADapt trial, which studied patients switching to lebrikizumab after dupilumab treatment? https://dermsquared.com/videos/dermbits/patients-switching-to-lebrikizumab-after-dupilumab-treatment 183 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/patient-history-of-ms-treat-tnf-blocker 2023-04-28T20:06:14.742Z https://image.mux.com/uMub00NF6Zf6L01U5eThoQaGE5QvutT4jPZrUm7Fb7tZg/thumbnail.jpg If a patient has a family history of MS, would you treat the patient with a TNF Blocker or switch to something else? If a patient has a family history of MS, would you treat the patient with a TNF Blocker or switch to something else? https://dermsquared.com/videos/dermbits/patient-history-of-ms-treat-tnf-blocker 22 2022-04-15T00:07:35.000Z yes https://dermsquared.com/videos/dermbits/topical-treatments-in-vitiligo 2026-06-10T14:40:30.608Z https://image.mux.com/02mff4kOqQUVnkPJ48I2B86RsEbBy7gTIEoR9UdInaE00/thumbnail.jpg What are the most common adherence challenges you see with topical treatments in vitiligo? What are the most common adherence challenges you see with topical treatments in vitiligo? https://dermsquared.com/videos/dermbits/topical-treatments-in-vitiligo 79 2026-06-10T14:40:30.600Z yes https://dermsquared.com/videos/dermbits/why-consider-treating-chin-fillers-lip-augmentation 2023-05-10T21:29:37.531Z https://image.mux.com/LX44YwKCNaHQ5TUlV7uLJUyvdBz901rOptsqanjOXNXc/thumbnail.jpg Why should you consider treating the chin with fillers when considering lip augmentation? Why should you consider treating the chin with fillers when considering lip augmentation? https://dermsquared.com/videos/dermbits/why-consider-treating-chin-fillers-lip-augmentation 41 2023-05-10T20:29:50.471Z yes https://dermsquared.com/videos/dermbits/special-considerations-transitioning-patients-psoriasis-ixekizumab 2024-11-01T13:48:35.175Z https://image.mux.com/Dvv1otpJY8TMeIFY55mmdXOdHH90200ESCw2JL5jDdQ800/thumbnail.jpg Are there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab? Are there any special considerations for transitioning patients with psoriasis from other biologic agents to ixekizumab? https://dermsquared.com/videos/dermbits/special-considerations-transitioning-patients-psoriasis-ixekizumab 53 2024-11-01T13:48:35.168Z yes https://dermsquared.com/videos/dermbits/coverage-for-ruxolitinib 2026-04-02T16:20:52.118Z https://image.mux.com/5KncImWMyHpn9n2l026l5nXkW01b7SzSwUKWrv01Hh8wpM/thumbnail.jpg How do you frame quality-of-life impact when requesting coverage for ruxolitinib? How do you frame quality-of-life impact when requesting coverage for ruxolitinib? https://dermsquared.com/videos/dermbits/coverage-for-ruxolitinib 50 2026-04-02T14:28:43.138Z yes https://dermsquared.com/videos/dermbits/tips-for-successful-prior-authorization-ruxolitinib-for-vitiligo 2025-06-03T13:45:52.122Z https://image.mux.com/kYUiKZNKhNTh3oz5bC900P3DWelkjyku2TCxKSvpoba8/thumbnail.jpg What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo? What are some tips for successful prior authorization for patients recommended for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/tips-for-successful-prior-authorization-ruxolitinib-for-vitiligo 40 2025-06-03T13:45:52.115Z yes https://dermsquared.com/videos/dermbits/should-ixekizumab--monotherapy-or-concomitantly-other-therapies 2024-11-01T13:48:39.826Z https://image.mux.com/xoxgeC1IOeUyoIdX3qr1qBp7tQFjfNmKgqMHGuR00pWQ/thumbnail.jpg Should ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies? Should ixekizumab be used as a monotherapy, or can it be used concomitantly with other therapies? https://dermsquared.com/videos/dermbits/should-ixekizumab--monotherapy-or-concomitantly-other-therapies 26 2024-11-01T13:48:39.819Z yes https://dermsquared.com/videos/dermbits/classification-40-gep-test-consider-baseline-radiologic-imaging 2023-08-31T21:14:35.762Z https://image.mux.com/zqOY5nyrP00kVqtN6xu4iHmpkvqYbUUtkiRKXrq3sfEo/thumbnail.jpg What classification from the 40-GEP test would make you consider baseline radiologic imaging? What classification from the 40-GEP test would make you consider baseline radiologic imaging? https://dermsquared.com/videos/dermbits/classification-40-gep-test-consider-baseline-radiologic-imaging 42 2023-08-31T20:51:50.875Z yes https://dermsquared.com/videos/dermbits/diagnoses-confused-with-atopic-dermatitis-22 2023-04-28T20:07:56.071Z https://image.mux.com/00THRIhm3S29dkr00SqfmL02xpvwLWQkXNnMgaMuEEFPtE/thumbnail.jpg What other diagnoses can be confused with atopic dermatitis? What other diagnoses can be confused with atopic dermatitis? https://dermsquared.com/videos/dermbits/diagnoses-confused-with-atopic-dermatitis-22 81 2022-04-28T00:04:28.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-compare-topical-corticosteroids-calcineurin-vitiligo 2025-03-03T14:15:18.022Z https://image.mux.com/Z52Q5vYm55qhV12Qimj6gQwonvY1DC33Pfy5HKpgrtU/thumbnail.jpg How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo? How does ruxolitinib compare to topical corticosteroids and topical calcineurin inhibitors for vitiligo? https://dermsquared.com/videos/dermbits/ruxolitinib-compare-topical-corticosteroids-calcineurin-vitiligo 50 2025-03-03T14:15:18.013Z yes https://dermsquared.com/videos/dermbits/can-dietary-changes-lifestyle-modifications-supplements-influence-alopecia-areata 2024-09-17T19:02:30.682Z https://image.mux.com/T1VTZi2TEUsTBsRJx00xZzzWz3gnxSmSxs71yCTLzJf8/thumbnail.jpg Can dietary changes, lifestyle modifications, or supplements influence the course of alopecia areata? Can dietary changes, lifestyle modifications, or supplements influence the course of alopecia areata? https://dermsquared.com/videos/dermbits/can-dietary-changes-lifestyle-modifications-supplements-influence-alopecia-areata 101 2024-09-17T19:02:30.675Z yes https://dermsquared.com/videos/dermbits/do-new-topicals-address-underlying-systemic-inflammation 2023-07-27T19:56:36.269Z https://image.mux.com/fIemdGIxPFbcLITpJFbqqv4L4zr3uXLTir00BnldRNmc/thumbnail.jpg Do new topicals address underlying systemic inflammation? Do new topicals address underlying systemic inflammation? https://dermsquared.com/videos/dermbits/do-new-topicals-address-underlying-systemic-inflammation 89 2023-07-27T19:56:36.264Z yes https://dermsquared.com/videos/dermbits/dermbits-does-topical-roflumilast-data-supports-safety-efficacy-long-term-use-arcp22 2022-09-29T00:13:42.000Z https://image.mux.com/01ubBylSoLt7Vd00JaTxa29QRZqp008La02uOOh4CTdvWIs/thumbnail.jpg Does topical roflumilast have data that supports its safety and efficacy for long-term use? Does topical roflumilast have data that supports its safety and efficacy for long-term use? https://dermsquared.com/videos/dermbits/dermbits-does-topical-roflumilast-data-supports-safety-efficacy-long-term-use-arcp22 45 2022-09-29T00:13:42.000Z yes https://dermsquared.com/videos/dermbits/do-you-recommend-getting-the-zoster-vaccine-before-starting-a-jak-inhibitor 2023-07-27T19:57:30.037Z https://image.mux.com/XYpX01ZQh02Mil4RDP2O3x7vetKRa01Ac02tJno6soD1rro/thumbnail.jpg Do you recommend getting the zoster vaccine before starting a JAK inhibitor? Do you recommend getting the zoster vaccine before starting a JAK inhibitor? https://dermsquared.com/videos/dermbits/do-you-recommend-getting-the-zoster-vaccine-before-starting-a-jak-inhibitor 75 2023-07-27T19:57:30.032Z yes https://dermsquared.com/videos/dermbits/dermbits-can-topical-ruxolitinib-be-used-in-pediatric-patients-adrc22 2022-10-28T22:15:43.000Z https://image.mux.com/02kmysPZV8jR4hed1ZR00RDVmE8PDy9102U2D7S02301Xbew/thumbnail.jpg Can topical ruxolitinib be used in pediatric patients? Can topical ruxolitinib be used in pediatric patients? https://dermsquared.com/videos/dermbits/dermbits-can-topical-ruxolitinib-be-used-in-pediatric-patients-adrc22 18 2022-10-28T22:15:43.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-tapinarof 2024-04-08T18:35:53.836Z https://image.mux.com/O7YgyBGPzSYxBMgJvo17ea2deKLkSIjcoQ5Dm39eqeE/thumbnail.jpg What is the safety profile of tapinarof? What is the safety profile of tapinarof? https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-tapinarof 70 2024-04-08T18:35:53.825Z yes https://dermsquared.com/videos/dermbits/how-manage-patients-reporting-skin-sensitivity-ruxolitinib-vitiligo 2025-06-03T13:45:58.311Z https://image.mux.com/9R7vYYNFh00bznUTMkOIdW5Yz00Q00OwyvJNo02kYU202wUo/thumbnail.jpg How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo? How should dermatologists manage patients reporting skin sensitivity while on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-manage-patients-reporting-skin-sensitivity-ruxolitinib-vitiligo 48 2025-06-03T13:45:58.305Z yes https://dermsquared.com/videos/dermbits/oral-candidiasis-how-managed-and-has-it-required-discontinuation-medication 2023-10-24T16:35:12.846Z https://image.mux.com/jzFL2Ja1PRmfmye026gb7m8fz00FsHqrIpK8uPjVnyYZA/thumbnail.jpg Regarding oral candidiasis, how has this been managed and has it required discontinuation of the medication? Regarding oral candidiasis, how has this been managed and has it required discontinuation of the medication? https://dermsquared.com/videos/dermbits/oral-candidiasis-how-managed-and-has-it-required-discontinuation-medication 103 2023-10-24T16:35:12.840Z yes https://dermsquared.com/videos/dermbits/prp-hair-loss-patients 2023-04-28T19:18:28.667Z https://image.mux.com/013M011T2QP4uzHthfZJJ01yJU2w3Xm400slecsu00n4dWWY/thumbnail.jpg How do you discuss PRP for hair loss with your patients? How do you discuss PRP for hair loss with your patients? https://dermsquared.com/videos/dermbits/prp-hair-loss-patients 90 2021-08-26T20:36:54.000Z yes https://dermsquared.com/videos/dermbits/dermbits-vitamin-supplementation-important-in-treating-vitiligo-00899 2021-06-11T16:13:37.000Z https://image.mux.com/aSbzk5ULxF3vmn00JdmIlrkuCMf5TlXC01duwl00mxd6go/thumbnail.jpg Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients? Is vitamin supplementation important in treating vitiligo? Are there supplements that you recommend for your vitiligo patients? https://dermsquared.com/videos/dermbits/dermbits-vitamin-supplementation-important-in-treating-vitiligo-00899 41 2021-06-11T16:13:37.000Z yes https://dermsquared.com/videos/dermbits/bsa-ruxolitinib-vitiligo 2025-06-03T13:46:26.574Z https://image.mux.com/R7G49SMDxtzBnNJpY76L02LroETT6fQaPYsRDiklXki8/thumbnail.jpg Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo? Is there a limit on body surface area that ruxolitinib can be applied to for vitiligo? https://dermsquared.com/videos/dermbits/bsa-ruxolitinib-vitiligo 30 2025-06-03T13:46:26.568Z yes https://dermsquared.com/videos/dermbits/has-emergence-new-topical-options-affected-course-of-treatment-select 2023-08-31T20:40:15.884Z https://image.mux.com/k0219o2kqe3znhaUwX8ikcZ5HY02gJmBxK9DtX011APuXg/thumbnail.jpg Has the emergence of new topical options affected the course of treatment you select for your patients? Has the emergence of new topical options affected the course of treatment you select for your patients? https://dermsquared.com/videos/dermbits/has-emergence-new-topical-options-affected-course-of-treatment-select 85 2023-08-31T20:40:15.878Z yes https://dermsquared.com/videos/dermbits/what-are-the-trends-in-us-incidence-of-scc 2023-07-27T19:20:53.442Z https://image.mux.com/s01Paa9iugokwZYzWpE1GNMbkUDK02jlcBgSk7T367lNk/thumbnail.jpg What are the trends in US incidence of SCC? Summary Dr. Darrell Rigel discusses the trends in the incidence of cutaneous squamous cell carcinoma (SCC) in the United States. He states that the incidence of SCC is consistently increasing, particularly in the southern half of the country. This rising trend highlights the need to improve the identification of patients who are at the highest risk of developing metastatic disease and facing death due to SCC. By identifying these high-risk patients, healthcare providers can administer more aggressive therapies to appropriately treat the condition and improve patient outcomes. Key Points Cutaneous squamous cell carcinoma (SCC) incidence is on the rise in the United States. The increase in SCC incidence is particularly notable in the southern half of the country. Identifying patients at the highest risk for metastatic disease and death is becoming increasingly important. The goal is to treat high-risk patients with more aggressive therapy to improve outcomes. The rising trend in SCC calls for improved methods of identifying and diagnosing high-risk patients. Early detection and appropriate treatment are crucial in managing SCC cases effectively. https://dermsquared.com/videos/dermbits/what-are-the-trends-in-us-incidence-of-scc 27 2023-07-27T19:20:53.436Z yes https://dermsquared.com/videos/dermbits/what-role-lebrikizumab-play-steroid-sparing-strategies-atopic-dermatitis 2024-10-01T16:26:41.804Z https://image.mux.com/ww5eCy4l3eCMPOL01xB01bEAg02lFBXzS02RuLev1R6LKdY/thumbnail.jpg What role can lebrikizumab play in steroid-sparing strategies for patients with atopic dermatitis? What role can lebrikizumab play in steroid-sparing strategies for patients with atopic dermatitis? https://dermsquared.com/videos/dermbits/what-role-lebrikizumab-play-steroid-sparing-strategies-atopic-dermatitis 78 2024-10-01T16:26:41.799Z yes https://dermsquared.com/videos/dermbits/vitiligo-when-using-topical-therapies 2026-06-10T14:39:57.911Z https://image.mux.com/tZlAica2l02u2SgwoI00uc2tYAMjbVuhfEq2O00q01fk02yo/thumbnail.jpg How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies? How do you explain differences in response between facial and nonfacial vitiligo when using topical therapies? https://dermsquared.com/videos/dermbits/vitiligo-when-using-topical-therapies 64 2026-06-10T14:39:57.904Z yes https://dermsquared.com/videos/dermbits/specific-counseling-points-patients-starting-baricitinib-alopecia-areata 2024-10-01T14:54:56.498Z https://image.mux.com/6hRcn3VDWYKL7TmfRjfc9ieyp021MYkmuuobHdFpfWPM/thumbnail.jpg Are there any specific counseling points that dermatologists should discuss with patients before starting baricitinib therapy for alopecia areata? Are there any specific counseling points that dermatologists should discuss with patients before starting baricitinib therapy for alopecia areata? https://dermsquared.com/videos/dermbits/specific-counseling-points-patients-starting-baricitinib-alopecia-areata 51 2024-10-01T14:54:56.491Z yes https://dermsquared.com/videos/dermbits/conflict-with-clinical-guidelines 2026-06-12T18:53:38.704Z https://image.mux.com/LtvuFLiofTXfPazBsmjOmtSJns1I502EoZMOZFYopPYk/thumbnail.jpg What’s your approach when payer criteria conflict with clinical guidelines? What’s your approach when payer criteria conflict with clinical guidelines? https://dermsquared.com/videos/dermbits/conflict-with-clinical-guidelines 75 2026-06-02T14:11:12.815Z yes https://dermsquared.com/videos/dermbits/thoughts-on-topical-roflumilast-becoming-standard 2023-06-29T16:12:17.927Z https://image.mux.com/UgM2VgDzh61ZCYrVIyRViokmnXqi3rYJb58sjBwrJP4/thumbnail.jpg What are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids? What are your thoughts on topical roflumilast as becoming standard of care and gradual shifting away from topical corticosteroids? https://dermsquared.com/videos/dermbits/thoughts-on-topical-roflumilast-becoming-standard 175 2023-06-29T16:12:17.922Z yes https://dermsquared.com/videos/dermbits/prior-authorization-review 2026-04-02T16:22:14.728Z https://image.mux.com/Ouic4XSU00C8fGaraPRK00J00CSWGbswbGdM4qH9A7p5500/thumbnail.jpg What clinical language resonates most with payers during prior authorization review? What clinical language resonates most with payers during prior authorization review? https://dermsquared.com/videos/dermbits/prior-authorization-review 68 2026-04-02T14:32:36.907Z yes https://dermsquared.com/videos/dermbits/treating-atopic-dermatitis-elderly 2023-04-28T18:53:12.485Z https://image.mux.com/PZWMu5q4MwfL6Qu1YTxfi0000zrxXWxQSOOVvZtPacavE/thumbnail.jpg How does treating atopic dermatitis in elderly patients differ from younger patient populations? How does treating atopic dermatitis in elderly patients differ from younger patient populations? https://dermsquared.com/videos/dermbits/treating-atopic-dermatitis-elderly 105 2021-10-14T14:49:06.000Z yes https://dermsquared.com/videos/dermbits/what-sccs-are-appropriate-for-the-40-gep-test 2023-07-27T19:21:12.965Z https://image.mux.com/9wtkYPiDdzsn7ZDTdkycZEKqN2DzBf62LERXCJiTndc/thumbnail.jpg What SCCs are appropriate for the 40-GEP test? Summary In this video, Dr. Darrell Rigel addresses the question of which squamous cell carcinomas (SCCs) are suitable for the 40-GEP test. He emphasizes that not all SCCs are appropriate for this particular test. The data used to develop the test was gathered from cases of advanced squamous cell carcinomas, specifically those that have at least one of the high-risk factors such as large diameter, significant depth, and other risk factors associated with advanced disease. The 40-GEP test is not intended for use with squamous cell carcinoma in situ or early-stage squamous cell carcinomas. Instead, it is specifically designed and validated for cases where there are indicators of advanced disease. Key Points SCCs (Squamous Cell Carcinomas) that are appropriate for the 40-GEP (Gene Expression Profiling) test are specific types of cases. The test's data was collected on advanced squamous cell carcinomas, which means it is not suitable for squamous cell carcinoma in situ (early stage) cases. It is specifically designed for squamous cell carcinomas that have at least one of the high-risk factors associated with advanced disease. The high-risk factors include diameter, depth, and other risk factors that indicate the likelihood of the carcinoma being in an advanced stage. https://dermsquared.com/videos/dermbits/what-sccs-are-appropriate-for-the-40-gep-test 32 2023-07-27T19:21:12.959Z yes https://dermsquared.com/videos/dermbits/il-17-inhibitors-work-more-il-23-inhibitors 2023-04-28T19:21:42.868Z https://image.mux.com/75wfitKJ900pCPIQHEL1iHr1ziEU8w5pd79S1wAH822k/thumbnail.jpg Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what does that mean for my patients? Do IL-17 inhibitors work more quickly than IL-23 inhibitors and what does that mean for my patients? https://dermsquared.com/videos/dermbits/il-17-inhibitors-work-more-il-23-inhibitors 115 2021-09-23T23:25:00.000Z yes https://dermsquared.com/videos/dermbits/durability-response-delgocitinib-che-after-discontinuation 2025-08-08T19:56:49.596Z https://image.mux.com/byJzuDDXuyJcBPWGOOL1TlFUPgNu1HwVoSV9cbPndVY/thumbnail.jpg What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation? What is known about the durability of response of delgocitinib cream for CHE after treatment discontinuation? https://dermsquared.com/videos/dermbits/durability-response-delgocitinib-che-after-discontinuation 116 2025-08-08T19:56:49.590Z yes https://dermsquared.com/videos/dermbits/dose-spironolactone-in-acne-patients-22 2023-04-28T20:13:59.758Z https://image.mux.com/XEmAtWrGeLbrXtQvgdmnpFijCR5hQa6xu51ZhvrDqiQ/thumbnail.jpg What dose of spironolactone do you typically use in your acne patients? What dose of spironolactone do you typically use in your acne patients? https://dermsquared.com/videos/dermbits/dose-spironolactone-in-acne-patients-22 73 2022-05-18T06:05:53.000Z yes https://dermsquared.com/videos/dermbits/key-points-educating-patients-alopecia-areata-management 2024-12-02T15:43:55.203Z https://image.mux.com/zzvuj00P5uTyNN82lag98B1yOP02SY4Ood00Mtk5o02z8uU/thumbnail.jpg What are the key points for educating patients about alopecia areata and its management? What are the key points for educating patients about alopecia areata and its management? https://dermsquared.com/videos/dermbits/key-points-educating-patients-alopecia-areata-management 65 2024-12-02T15:43:55.196Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-cream-with-a-biologic-agent-22 2023-04-28T20:13:24.000Z https://image.mux.com/e9n4b7YC0023i2Hjmv302avUAjDsh9pRE01Y3FjS00O02ucI/thumbnail.jpg Can you use ruxolitinib cream with a biologic agent? Can you use ruxolitinib cream with a biologic agent? https://dermsquared.com/videos/dermbits/ruxolitinib-cream-with-a-biologic-agent-22 51 2022-05-11T22:22:53.000Z yes https://dermsquared.com/videos/dermbits/how-does-severity-alopecia-areata-influence-treatment-decisions 2024-11-07T16:10:47.005Z https://image.mux.com/6H901ZfWginljHgLN01Px014PW15d3PoEk3VdBFmzGESZ4/thumbnail.jpg How does the severity of alopecia areata influence treatment decisions? How does the severity of alopecia areata influence treatment decisions? https://dermsquared.com/videos/dermbits/how-does-severity-alopecia-areata-influence-treatment-decisions 91 2024-11-07T16:10:46.996Z yes https://dermsquared.com/videos/dermbits/flexibility-dosing-schedule-lebrikizumab 2025-07-01T13:41:36.081Z https://image.mux.com/vtjp3TcOKEPcbeQa4wHmi6zKZoerkvQ3q8MBuZVUKgE/thumbnail.jpg Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs? Is there flexibility in the dosing schedule for lebrikizumab to accommodate individual patient needs? https://dermsquared.com/videos/dermbits/flexibility-dosing-schedule-lebrikizumab 68 2025-07-01T13:41:36.074Z yes https://dermsquared.com/videos/dermbits/topical-jak-inhibitors-tofacitinib-ruxolitinib 2023-04-28T19:22:23.903Z https://image.mux.com/H6nNOC02jUbZxobzjqImNcNi6YtXur1JJKiwMBT6PJww/thumbnail.jpg How do you compound your topical JAK inhibitors like tofacitinib or ruxolitinib? How do you compound your topical JAK inhibitors like tofacitinib or ruxolitinib? https://dermsquared.com/videos/dermbits/topical-jak-inhibitors-tofacitinib-ruxolitinib 37 2021-09-29T15:00:45.000Z yes https://dermsquared.com/videos/dermbits/how-important-is-delivery-vehicle-when-selecting-topical-treatment-psoriasis 2023-11-01T15:03:45.616Z https://image.mux.com/hOy1JO9z9X3eFwAW2FDwtRS3XlAt25SgAfmSJ8zii5o/thumbnail.jpg How important is the delivery vehicle when selecting a topical treatment for psoriasis? How important is the delivery vehicle when selecting a topical treatment for psoriasis? https://dermsquared.com/videos/dermbits/how-important-is-delivery-vehicle-when-selecting-topical-treatment-psoriasis 16 2023-11-01T15:03:45.610Z yes https://dermsquared.com/videos/dermbits/primary-endpoint-allegro-2b-3-trial-ritlecitinib 2024-11-05T15:23:40.517Z https://image.mux.com/011Rx00b022TPEhfRC02qY02livyxBJR9l01J4U73Vcn7bgH8/thumbnail.jpg What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib? What was the primary endpoint of the ALLEGRO-2b/3 trial for ritlecitinib? https://dermsquared.com/videos/dermbits/primary-endpoint-allegro-2b-3-trial-ritlecitinib 32 2024-10-01T14:14:45.918Z yes https://dermsquared.com/videos/dermbits/routinely-atopic-dermatitis-antimicrobial-or-antibiotic-therapy-22 2023-04-28T20:08:16.183Z https://image.mux.com/8DlxeQF9agvaDUxOoSTXJPm8025LSFwE00FGlYe600OScI/thumbnail.jpg Is it necessary to routinely treat atopic dermatitis with antimicrobial or antibiotic therapy to get patients to improve? Is it necessary to routinely treat atopic dermatitis with antimicrobial or antibiotic therapy to get patients to improve? https://dermsquared.com/videos/dermbits/routinely-atopic-dermatitis-antimicrobial-or-antibiotic-therapy-22 63 2022-04-28T00:07:27.000Z yes https://dermsquared.com/videos/dermbits/what-role-does-proactive-vs-reactive-therapy-play-in-maintaining-long-term-disease-control-in-ad 2025-10-01T20:35:23.457Z https://image.mux.com/3xipC2jGwNDMdkTqTQNcw00EP1xPgXj3RP2g254k2nL4/thumbnail.jpg What role does proactive vs reactive therapy play in maintaining long-term disease control in AD? What role does proactive vs reactive therapy play in maintaining long-term disease control in AD? https://dermsquared.com/videos/dermbits/what-role-does-proactive-vs-reactive-therapy-play-in-maintaining-long-term-disease-control-in-ad 95 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/systemic-safety-treating-plaque-psoriasis-with-topical-therapies 2023-05-31T19:55:36.232Z https://image.mux.com/5i1FU00FVofstLa3C8BanAcGLveEOCCWJ8Opx7ZZ01qKM/thumbnail.jpg Should we really care about systemic safety when treating Plaque Psoriasis with topical therapies?  Should we really care about systemic safety when treating Plaque Psoriasis with topical therapies?  https://dermsquared.com/videos/dermbits/systemic-safety-treating-plaque-psoriasis-with-topical-therapies 56 2023-05-31T19:55:36.225Z yes https://dermsquared.com/videos/dermbits/how-long-keep-patients-topical-ruxolitinib-atopic-dermatitis-22 2023-04-28T20:19:31.299Z https://image.mux.com/kSA3bI66ZVkdnUt7XDS2uP28KsLIuo02AsrMr4zhhPcw/thumbnail.jpg How long do you keep patients on topical ruxolitinib who suffer from atopic dermatitis? How long do you keep patients on topical ruxolitinib who suffer from atopic dermatitis? https://dermsquared.com/videos/dermbits/how-long-keep-patients-topical-ruxolitinib-atopic-dermatitis-22 42 2022-07-27T21:48:13.000Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-vitiligo-about-sun-protection 2024-05-01T13:32:51.974Z https://image.mux.com/HOvje1KjU1AbgK5wzQUkA1szp7O025kUcsQ4Q52aBcgE/thumbnail.jpg How do you counsel patients with vitiligo about the need for sun protection? How do you counsel patients with vitiligo about the need for sun protection? https://dermsquared.com/videos/dermbits/how-counsel-patients-vitiligo-about-sun-protection 45 2024-05-01T13:32:51.968Z yes https://dermsquared.com/videos/dermbits/are-most-patients-beginning-lebrikizumab-already-previously-treated-with-another-biologic-or-are-some-biologic-naive 2025-10-01T22:32:46.770Z https://image.mux.com/Bh00HwbtETgdrvrfnUFBbqmXPSr8UNtykLn02M5KHbtog/thumbnail.jpg Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve? Are most patients beginning lebrikizumab already previously treated with another biologic, or are some biologic-naïve? https://dermsquared.com/videos/dermbits/are-most-patients-beginning-lebrikizumab-already-previously-treated-with-another-biologic-or-are-some-biologic-naive 58 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/nail-scalp-psoriasis-greater-risk-developing-psoriatic-arthritis 2024-08-21T20:02:47.550Z https://image.mux.com/HkAaIoHEmF4naEOl302CirmFzM01SsCEAGWk4wnzaFmyI/thumbnail.jpg Do patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis? Do patients with nail and scalp psoriasis have a greater risk of developing psoriatic arthritis? https://dermsquared.com/videos/dermbits/nail-scalp-psoriasis-greater-risk-developing-psoriatic-arthritis 83 2024-08-20T18:15:57.535Z yes https://dermsquared.com/videos/dermbits/wait-between-injections-when-switching-biologics-22 2023-04-28T19:59:41.257Z https://image.mux.com/biCF6lFBXPVwdLuCrTSWimR0196iIEMLXfDGBuz75ZsA/thumbnail.jpg Do you have patients wait a specified period of time between injections when switching biologics? Do you have patients wait a specified period of time between injections when switching biologics? https://dermsquared.com/videos/dermbits/wait-between-injections-when-switching-biologics-22 67 2022-02-01T00:54:05.000Z yes https://dermsquared.com/videos/dermbits/home-phototherapy-unit 2025-10-20T17:28:27.320Z https://image.mux.com/PUfMOlsSrBd4VZUe6a02Iy9iDEyWV51QO02qH02HilRDz4/thumbnail.jpg What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit? What practical considerations should dermatologists keep in mind when setting up a patient with an at-home phototherapy unit? https://dermsquared.com/videos/dermbits/home-phototherapy-unit 97 2025-10-13T20:15:52.683Z yes https://dermsquared.com/videos/dermbits/long-term-safety-and-efficacy-data-of-topical-roflumilast 2023-06-29T16:12:45.206Z https://image.mux.com/VMvJvjbDh00NqPlgiFF014VZKPrnvAHXeUA1WVHYGcKBI/thumbnail.jpg What is the long-term safety and efficacy data of topical roflumilast?  What is the long-term safety and efficacy data of topical roflumilast?  https://dermsquared.com/videos/dermbits/long-term-safety-and-efficacy-data-of-topical-roflumilast 138 2023-06-29T16:12:45.201Z yes https://dermsquared.com/videos/dermbits/how-manage-expectations-beginning-treatment-ritlecitinib 2024-11-07T16:11:25.871Z https://image.mux.com/6clQIp31K6AhQnHSS00x00OZW6mNkwicd028JlN02Tk4zdA/thumbnail.jpg How do you manage expectations for patients beginning treatment with ritlecitinib? How do you manage expectations for patients beginning treatment with ritlecitinib? https://dermsquared.com/videos/dermbits/how-manage-expectations-beginning-treatment-ritlecitinib 101 2024-11-07T16:11:25.864Z yes https://dermsquared.com/videos/dermbits/strategies-manage-common-side-effects-tirbanibulin-ointment 2025-10-20T22:30:53.820Z https://image.mux.com/IB9nLu1j1WcXsYqLydA6k58cv00Y7LLJzpxaNq1jVq54/thumbnail.jpg What strategies can dermatologists use to manage common side effects associated with tirbanibulin ointment? What strategies can dermatologists use to manage common side effects associated with tirbanibulin ointment? https://dermsquared.com/videos/dermbits/strategies-manage-common-side-effects-tirbanibulin-ointment 98 2025-02-12T16:22:31.282Z yes https://dermsquared.com/videos/dermbits/at-home-phototherapy 2025-10-20T17:27:56.488Z https://image.mux.com/OK7JgCtP8TVuMzzUzQZoKPvdDzNZxBxr4e8AYGZ3bOU/thumbnail.jpg How straightforward is the prescribing and enrollment process for at-home phototherapy? How straightforward is the prescribing and enrollment process for at-home phototherapy? https://dermsquared.com/videos/dermbits/at-home-phototherapy 25 2025-10-13T20:15:11.967Z yes https://dermsquared.com/videos/dermbits/j-lo-olive-oil-non-botox 2023-04-28T19:07:25.795Z https://image.mux.com/pNtp4lYWV1mz6Q9007FY2SsIybY1PPFStD46bivw8ZG4/thumbnail.jpg Can you comment on hot topic of J Lo and her olive oil and non use of BOTOX? Can you comment on hot topic of J Lo and her olive oil and non use of BOTOX? https://dermsquared.com/videos/dermbits/j-lo-olive-oil-non-botox 47 2021-06-04T20:05:27.000Z yes https://dermsquared.com/videos/dermbits/how-has-topical-roflumilast-simplified-consult-patients-plaque-psoriasis 2023-06-29T16:12:38.168Z https://image.mux.com/ywt8M6aAp02N2YkyyEkr8oeJk7VgRbwG00Zl02PEU2ifpc/thumbnail.jpg How has topical roflumilast simplified the way you consult patients with plaque psoriasis? How has topical roflumilast simplified the way you consult patients with plaque psoriasis? https://dermsquared.com/videos/dermbits/how-has-topical-roflumilast-simplified-consult-patients-plaque-psoriasis 127 2023-06-29T16:12:38.125Z yes https://dermsquared.com/videos/dermbits/but-not-complete-repigmentation 2026-06-10T14:40:16.605Z https://image.mux.com/ffpwtROESU8CeE5mEm3x76pR3YuvmNx8ivzcO02pg90200/thumbnail.jpg How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation? How do you counsel patients with vitiligo who are seeing partial improvement but not complete repigmentation? https://dermsquared.com/videos/dermbits/but-not-complete-repigmentation 75 2026-06-10T14:40:16.593Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-help-patients-manage-the-psychosocial-impact-atopic-dermatitis-including-anxiety-depression 2024-10-01T16:26:17.110Z https://image.mux.com/XO6Qs02svcopmDwWbAHxr3zol77uBlSsVkqXy9GWQsKM/thumbnail.jpg How can dermatologists help patients manage the psychosocial impact of atopic dermatitis, including anxiety and depression? How can dermatologists help patients manage the psychosocial impact of atopic dermatitis, including anxiety and depression? https://dermsquared.com/videos/dermbits/how-dermatologists-help-patients-manage-the-psychosocial-impact-atopic-dermatitis-including-anxiety-depression 117 2024-10-01T16:26:17.103Z yes https://dermsquared.com/videos/dermbits/how-ruxolitinib-compare-treatment-options-vitiligo 2024-05-31T13:34:06.280Z https://image.mux.com/TyKrUOTQGWbZoplpVoIUqmfNY02kogpG79YaYJyHTWb00/thumbnail.jpg How does ruxolitinib compare to other treatment options for vitiligo? How does ruxolitinib compare to other treatment options for vitiligo? https://dermsquared.com/videos/dermbits/how-ruxolitinib-compare-treatment-options-vitiligo 33 2024-05-31T13:34:06.275Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-of-spesolimab 2023-08-31T20:47:49.754Z https://image.mux.com/wIBgFQlO6v02O5JzWUXciL8W3xWdup00plyDBuxO9KXL8/thumbnail.jpg What is the mechanism of action of spesolimab? What is the mechanism of action of spesolimab? https://dermsquared.com/videos/dermbits/mechanism-of-action-of-spesolimab 58 2023-08-31T20:47:49.750Z yes https://dermsquared.com/videos/dermbits/dermbits-do-you-worry-about-systemic-absorption-with-topical-ruxolitinib-adrc22 2022-10-28T22:14:10.000Z https://image.mux.com/1QRnCtwwaxY8DYudGd7n2M16fzV2K4Dq5twbGY159N4/thumbnail.jpg Do you worry about systemic absorption with topical ruxolitinib? Do you worry about systemic absorption with topical ruxolitinib? https://dermsquared.com/videos/dermbits/dermbits-do-you-worry-about-systemic-absorption-with-topical-ruxolitinib-adrc22 38 2022-10-28T22:14:10.000Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-on-quality-of-life-impacts-psoriasis 2024-04-08T18:35:21.962Z https://image.mux.com/3Xuklv89Aq9D4t01kvNcbuN1B024WoKmnjs02aK01J3mWus/thumbnail.jpg How do you counsel patients on quality of life impacts from psoriasis? How do you counsel patients on quality of life impacts from psoriasis? https://dermsquared.com/videos/dermbits/how-counsel-patients-on-quality-of-life-impacts-psoriasis 51 2024-04-08T18:35:21.951Z yes https://dermsquared.com/videos/dermbits/lebrikizumab-compare-jak-inhibitors-safety-efficacy 2025-07-01T13:41:20.936Z https://image.mux.com/VAp2xsfK00hfedNYXUqfbLl2zLBUNlvU3ZIPjiPMEgPk/thumbnail.jpg How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis? How does lebrikizumab compare to JAK inhibitors in terms of safety and efficacy for patients with atopic dermatitis? https://dermsquared.com/videos/dermbits/lebrikizumab-compare-jak-inhibitors-safety-efficacy 127 2025-07-01T13:41:20.930Z yes https://dermsquared.com/videos/dermbits/how-much-normal-saline-to-reconstitute-dysport 2023-04-28T20:04:30.425Z https://image.mux.com/61ptA00JOI5rMuu9nAKU3h5WL801WYppd3401WX3HlrIhA/thumbnail.jpg How much normal saline do you use to reconstitute Dysport? How much normal saline do you use to reconstitute Dysport? https://dermsquared.com/videos/dermbits/how-much-normal-saline-to-reconstitute-dysport 75 2022-02-18T18:51:12.000Z yes https://dermsquared.com/videos/dermbits/how-do-you-identify-and-manage-itch-dominant-ad-patients 2025-10-01T20:32:15.861Z https://image.mux.com/5IMMq4lVbN028RUXKwi02HDdnJWeJILpWeJUj9fB02sIjs/thumbnail.jpg How do you identify and manage itch-dominant AD patients? How do you identify and manage itch-dominant AD patients? https://dermsquared.com/videos/dermbits/how-do-you-identify-and-manage-itch-dominant-ad-patients 117 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/evaluate-lebrikizumab-dupilumab 2025-07-01T13:41:51.292Z https://image.mux.com/l7t7GsIGfgJb5L01YPV4GI2ES61Vcv01mvQNSumGEtBrU/thumbnail.jpg How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient? How should dermatologists evaluate whether lebrikizumab is a better option than dupilumab for a given patient? https://dermsquared.com/videos/dermbits/evaluate-lebrikizumab-dupilumab 212 2025-07-01T13:41:51.286Z yes https://dermsquared.com/videos/dermbits/what-primary-endpoints--psoaring-1-and-psoaring-2-trials-tapinarof 2024-04-08T18:35:42.197Z https://image.mux.com/CUGLOoyheMdkEGtlK8nIz8bV3U3LesPxvODtDdhCdxA/thumbnail.jpg What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof? What were the primary endpoints of the PSOARING 1 and PSOARING 2 trials for tapinarof? https://dermsquared.com/videos/dermbits/what-primary-endpoints--psoaring-1-and-psoaring-2-trials-tapinarof 37 2024-04-08T18:35:42.190Z yes https://dermsquared.com/videos/dermbits/ways-dermatologists-customize-treatment-plans-lebrikizumab 2025-02-18T17:52:05.446Z https://image.mux.com/RjJBDLdl6yWv00CwqzoGnzkYxE9Xt37y3rURNgW3aTAU/thumbnail.jpg In what ways can dermatologists customize treatment plans when prescribing lebrikizumab? In what ways can dermatologists customize treatment plans when prescribing lebrikizumab? https://dermsquared.com/videos/dermbits/ways-dermatologists-customize-treatment-plans-lebrikizumab 23 2025-02-18T17:52:05.436Z yes https://dermsquared.com/videos/dermbits/rate-of-blindness-fat-injections 2023-04-28T19:25:48.375Z https://image.mux.com/WnD8dO4BtsChN6RdmfZRGZiaSFBHB01jF9bp55iRVamM/thumbnail.jpg Can you make a comment on rate of blindness in fat injections? Can you make a comment on rate of blindness in fat injections? https://dermsquared.com/videos/dermbits/rate-of-blindness-fat-injections 77 2021-11-03T03:53:26.000Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-spesolimab 2023-08-31T20:47:32.468Z https://image.mux.com/FLis3V5AwY4NBM9X1DXIsKK02h9TBPHZ02PmdgEddxeKM/thumbnail.jpg What is the recommended dosing regimen for spesolimab? What is the recommended dosing regimen for spesolimab? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-spesolimab 77 2023-08-31T20:47:32.462Z yes https://dermsquared.com/videos/dermbits/stop-their-biologic-if-positive-covid-22 2023-04-28T20:00:11.025Z https://image.mux.com/5kKPF2029LuA2Ascw8FjLFJduBOeRNagvWbibGlgPlzw/thumbnail.jpg Do you tell your patients to stop their biologic if they test positive for COVID? Do you tell your patients to stop their biologic if they test positive for COVID? https://dermsquared.com/videos/dermbits/stop-their-biologic-if-positive-covid-22 70 2022-02-01T01:13:50.000Z yes https://dermsquared.com/videos/dermbits/how-ixekizumab-impact-cardiovascular-risk-factors-patients-with-psoriasis 2024-10-18T17:18:33.989Z https://image.mux.com/23gZySklJX5E024027B5t9vBsWw6wNnia2c3VV00laNlQE/thumbnail.jpg How does ixekizumab impact cardiovascular risk factors in patients with psoriasis? How does ixekizumab impact cardiovascular risk factors in patients with psoriasis? https://dermsquared.com/videos/dermbits/how-ixekizumab-impact-cardiovascular-risk-factors-patients-with-psoriasis 48 2024-10-18T17:18:33.977Z yes https://dermsquared.com/videos/dermbits/moisturizers-enhance-photoprotection 2025-11-14T15:24:54.455Z https://image.mux.com/76m3jxYSos7aN1o02GkYH4KVA01BrtarezvD01qLeDmqmc/thumbnail.jpg How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection? How do ingredients beyond UV filters, like antioxidants or moisturizers, enhance photoprotection? https://dermsquared.com/videos/dermbits/moisturizers-enhance-photoprotection 48 2025-11-14T15:24:54.448Z yes https://dermsquared.com/videos/dermbits/dermbits-patients-concerned-about-systemic-absorption-of-topical-medications-ADRC00074-adrc23 2023-01-30T22:46:00.000Z https://image.mux.com/JYHgAH6iEi3YSe6fea8BGhXp9Jo7573IKT6qcb3zAQE/thumbnail.jpg What should l tell patients concerned about systemic absorption of topical medications? What should l tell patients concerned about systemic absorption of topical medications? https://dermsquared.com/videos/dermbits/dermbits-patients-concerned-about-systemic-absorption-of-topical-medications-ADRC00074-adrc23 33 2023-01-30T22:46:00.000Z yes https://dermsquared.com/videos/dermbits/dermbits-can-topical-roflumilast-be-used-for-younger-patients-arcp22 2023-05-11T14:54:24.585Z https://image.mux.com/6tyPH00LYw01FmRim02caccTYDZDYGg02VpkIPHohtuRIzI/thumbnail.jpg Can topical roflumilast be used for younger patients? Can topical roflumilast be used for younger patients? https://dermsquared.com/videos/dermbits/dermbits-can-topical-roflumilast-be-used-for-younger-patients-arcp22 29 2022-10-28T22:56:26.000Z yes https://dermsquared.com/videos/dermbits/dermbits-in-your-opinion-what-is-the-most-worrisome-trend-in-healthcare-WCM230007 2023-03-10T00:17:55.000Z https://image.mux.com/24PlsC9Zti97SEuq00SqpzH015nfK1Eu6MsWCyKCrktdU/thumbnail.jpg In your opinion, what is the most worrisome trend in Healthcare? In your opinion, what is the most worrisome trend in Healthcare? https://dermsquared.com/videos/dermbits/dermbits-in-your-opinion-what-is-the-most-worrisome-trend-in-healthcare-WCM230007 41 2023-03-10T00:17:55.000Z yes https://dermsquared.com/videos/dermbits/triggers-that-may-exacerbate-vitiligo 2024-05-31T13:33:37.546Z https://image.mux.com/n6m44d4Q00jNdX7bO87vtLFy902Z4Hi01bkgfwa5KKAj7I/thumbnail.jpg What are some triggers that may exacerbate vitiligo? What are some triggers that may exacerbate vitiligo? https://dermsquared.com/videos/dermbits/triggers-that-may-exacerbate-vitiligo 27 2024-05-31T13:33:37.540Z yes https://dermsquared.com/videos/dermbits/when-evaluating-patient-with-suspected-gpp-what-entities-to-exclude 2023-06-30T17:12:03.823Z https://image.mux.com/W702NHhqXsM20249pZYFIpom9uy76tA8TBCdRcDhnZ9FU/thumbnail.jpg When evaluating a patient with suspected GPP, what other entities does one need to exclude? When evaluating a patient with suspected GPP, what other entities does one need to exclude? https://dermsquared.com/videos/dermbits/when-evaluating-patient-with-suspected-gpp-what-entities-to-exclude 48 2023-06-27T17:27:24.383Z yes https://dermsquared.com/videos/dermbits/data-pla-positivity-dysplastic-nevi 2023-04-28T19:24:18.298Z https://image.mux.com/SfLykCF88h6MNjc6uMZtwy5VdwA6LCZBtocyAT4yYd8/thumbnail.jpg What is the data on PLA positivity for dysplastic nevi? What is the data on PLA positivity for dysplastic nevi? https://dermsquared.com/videos/dermbits/data-pla-positivity-dysplastic-nevi 70 2021-10-13T23:50:08.000Z yes https://dermsquared.com/videos/dermbits/conversation-patients-safety-of-topical-ruxolitinib-22 2023-04-28T20:21:32.304Z https://image.mux.com/DjwhrSa02GXbDTy6e7zcpp8Mb01xQAHwLzHe5iWTdUxZ4/thumbnail.jpg What conversation do you have with your patients with regard to the safety of topical ruxolitinib? What conversation do you have with your patients with regard to the safety of topical ruxolitinib? https://dermsquared.com/videos/dermbits/conversation-patients-safety-of-topical-ruxolitinib-22 67 2022-07-27T21:14:05.000Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-for-cantharidin 2023-11-30T19:19:11.546Z https://image.mux.com/cCNs3RQ5a02Z2GnjSSy4WdEJ4HqWv402gecXu40283UQaQ/thumbnail.jpg What is the mechanism of action for cantharidin? What is the mechanism of action for cantharidin? https://dermsquared.com/videos/dermbits/mechanism-of-action-for-cantharidin 34 2023-11-30T19:19:11.539Z yes https://dermsquared.com/videos/dermbits/is-topical-roflumilast-safe-and-effective-for-long-term-use 2023-11-01T21:22:40.311Z https://image.mux.com/s4W5AaPiiQyMAmxoAheK2DNMaAnbQtjkkHWWvCl02xPc/thumbnail.jpg Is topical roflumilast safe and effective for long-term use? Is topical roflumilast safe and effective for long-term use? https://dermsquared.com/videos/dermbits/is-topical-roflumilast-safe-and-effective-for-long-term-use 26 2023-11-01T21:22:40.301Z yes https://dermsquared.com/videos/dermbits/alone-does-not 2026-03-06T16:27:25.492Z https://image.mux.com/UnTZ3MBqoTFFyT1V00Ax313eCMkh4Fm3r8MXhBl3O33A/thumbnail.jpg What can AdvanceAD-TX tell you that clinical phenotype alone does not? What can AdvanceAD-TX tell you that clinical phenotype alone does not? https://dermsquared.com/videos/dermbits/alone-does-not 97 2026-03-06T16:27:25.482Z yes https://dermsquared.com/videos/dermbits/impact-biologics-covid-vaccine-efficacy 2023-04-28T19:25:25.954Z https://image.mux.com/1gPv1hlxeaKe3RU8wudZB8j00b7Qv5HEcxVkgeszeTew/thumbnail.jpg Can you comment on the impact of biologics on COVID vaccine efficacy? Can you comment on the impact of biologics on COVID vaccine efficacy? https://dermsquared.com/videos/dermbits/impact-biologics-covid-vaccine-efficacy 117 2021-11-03T04:03:09.000Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-uremic-pruritus-22 2023-04-28T19:57:58.732Z https://image.mux.com/N02hCg2aAmJrAA5nrfReZZodE9Jb9e02P00WV1TDPnSzfA/thumbnail.jpg Does ruxolitinib work for uremic pruritus? Does ruxolitinib work for uremic pruritus? https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-uremic-pruritus-22 22 2022-01-31T21:55:32.000Z yes https://dermsquared.com/videos/dermbits/any-head-to-head-studies-comparing-ixekizumab-to-other-biologics 2024-08-20T18:28:10.548Z https://image.mux.com/nB5yJw1Sa02PcYgXeEfC3htLwH8QG6DPHS7eexKOyZvo/thumbnail.jpg Are there any head-to-head studies comparing ixekizumab to other biologics? Are there any head-to-head studies comparing ixekizumab to other biologics? https://dermsquared.com/videos/dermbits/any-head-to-head-studies-comparing-ixekizumab-to-other-biologics 114 2024-08-20T18:15:47.029Z yes https://dermsquared.com/videos/dermbits/dermbits-what-do-we-need-to-know-about-telederm-WCM230009 2023-03-10T00:22:02.000Z https://image.mux.com/4mFG1WWOVfonrAu02Bv427AS9IDJbbqWbbNx6EWk00lqA/thumbnail.jpg What do we need to know about telederm? What do we need to know about telederm? https://dermsquared.com/videos/dermbits/dermbits-what-do-we-need-to-know-about-telederm-WCM230009 41 2023-03-10T00:22:02.000Z yes https://dermsquared.com/videos/dermbits/evidence-to-suggest-ixekizumab-more-effective-certain-psoriasis-phenotypes-patient-subgroups 2024-10-18T17:18:17.427Z https://image.mux.com/TdYXEbj4GJe02WgjRtE7rZNjGHOHzfZQG6gMYPoTIYLA/thumbnail.jpg Is there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups? Is there any evidence to suggest ixekizumab is more effective in certain psoriasis phenotypes or patient subgroups? https://dermsquared.com/videos/dermbits/evidence-to-suggest-ixekizumab-more-effective-certain-psoriasis-phenotypes-patient-subgroups 53 2024-10-18T17:18:17.420Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-success-rate-of-tralokinumab-in-patients-who-have-failed-dupilumab-ADRC00086-adrc23 2023-06-29T16:33:46.414Z https://image.mux.com/W01uFy21N5N8oQfD6Xvhwb46yeLX009OgODBteO6IGVE8/thumbnail.jpg What is the success rate of tralokinumab in patients who have failed dupilumab? What is the success rate of tralokinumab in patients who have failed dupilumab? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-success-rate-of-tralokinumab-in-patients-who-have-failed-dupilumab-ADRC00086-adrc23 19 2023-06-29T16:33:46.404Z yes https://dermsquared.com/videos/dermbits/what-outcomes-have-been-observed-with-monthly-maintenance-dosing-of-lebrikizumab 2025-10-01T22:38:36.484Z https://image.mux.com/Nht01u3D4HbC7P01g9EzlAo6s9LhdO1gP8cXT9weneoFA/thumbnail.jpg What outcomes have been observed with monthly maintenance dosing of lebrikizumab? What outcomes have been observed with monthly maintenance dosing of lebrikizumab? https://dermsquared.com/videos/dermbits/what-outcomes-have-been-observed-with-monthly-maintenance-dosing-of-lebrikizumab 179 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/what-results-were-seen-in-the-clinical-trials-for-lebrikizumab-regarding-itch-reduction 2025-10-01T22:36:24.868Z https://image.mux.com/Rf7fKbJHJd004R5rWcRDFP4KMlIxBQO51xE1ptcHuIXA/thumbnail.jpg What results were seen in the clinical trials for lebrikizumab regarding itch reduction? What results were seen in the clinical trials for lebrikizumab regarding itch reduction? https://dermsquared.com/videos/dermbits/what-results-were-seen-in-the-clinical-trials-for-lebrikizumab-regarding-itch-reduction 115 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-mechanism-of-action-of-topical-roflumilast-and-how-is-it-different-than-other-pde4-inhibitors-arcp22 2023-05-11T14:56:56.677Z https://image.mux.com/CX1JAwR02VpYII1MnMXOZkv4Ugk02DQ00N7kjwSFdwxsJU/thumbnail.jpg What is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors? What is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-mechanism-of-action-of-topical-roflumilast-and-how-is-it-different-than-other-pde4-inhibitors-arcp22 40 2022-10-28T22:45:33.000Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-sequestration-when-can-we-expect-it-to-end-WCM230003 2023-03-10T00:07:07.000Z https://image.mux.com/uMohY6OqPY9WGjdhl1n2oqZjnyfO9z027jnu3tA8DrYc/thumbnail.jpg What is Sequestration, when can we expect it to end? What is Sequestration, when can we expect it to end? https://dermsquared.com/videos/dermbits/dermbits-what-is-sequestration-when-can-we-expect-it-to-end-WCM230003 47 2023-03-10T00:07:07.000Z yes https://dermsquared.com/videos/dermbits/is-the-40-gep-test-covered-by-medicare 2023-07-27T19:21:05.457Z https://image.mux.com/tvp1UZiBgJh00009EGUcOnJta958qM9ZO8AgEMLl4oqYk/thumbnail.jpg Is the 40-GEP test covered by Medicare? Summary In the video, Dr. Darrell Rigel addresses the question of whether the 40-GEP test is covered by Medicare. He explains that currently, there is insurance coverage available for some cases, but the specific coverage rules may vary depending on the Medicare coverage carrier. He mentions that over time, the coverage for the 40-GEP test is expected to become more clear and standardized. Dr. Rigel also mentions that the company offering the 40-GEP test accepts insurance as a form of payment. This approach is designed to make it easier for patients to access the test results without facing financial burdens. Key Points The 40-GEP test may be covered by Medicare, but the coverage is not consistent across all cases. Different Medicare coverage carriers have varying rules regarding the 40-GEP test's insurance coverage. The insurance coverage situation is expected to become more clear and standardized at some point in the future. The company conducting the 40-GEP test accepts insurance as a form of payment from patients. https://dermsquared.com/videos/dermbits/is-the-40-gep-test-covered-by-medicare 33 2023-07-27T19:21:05.452Z yes https://dermsquared.com/videos/dermbits/can-patients-treated-with-lebrikizumab-receive-live-vaccines 2024-10-01T16:26:37.438Z https://image.mux.com/aTpfoL7gkldsiZYnhChrfajFbccYbK00LklHoDYsdKWQ/thumbnail.jpg Can patients treated with lebrikizumab receive live vaccines? Can patients treated with lebrikizumab receive live vaccines? https://dermsquared.com/videos/dermbits/can-patients-treated-with-lebrikizumab-receive-live-vaccines 64 2024-10-01T16:26:37.431Z yes https://dermsquared.com/videos/dermbits/than-as-monotherapy 2026-06-01T14:56:30.180Z https://image.mux.com/wxsOIQq9iK6VSqQvymB00cs3PnwFjMCR4v01RpKNkZxZE/thumbnail.jpg In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy? In what scenarios do you find apremilast works best alongside other therapies rather than as monotherapy? https://dermsquared.com/videos/dermbits/than-as-monotherapy 108 2026-06-01T14:56:30.172Z yes https://dermsquared.com/videos/dermbits/data-calcipotriene-cream-vs-ointment-with-5-fu 2023-04-28T20:06:38.271Z https://image.mux.com/VuuESGbpf5l023M381l4AIwduYYmvrJD1RQilDmlQXs4/thumbnail.jpg Is there data on using calcipotriene cream vs ointment in combination with 5-FU and does the order of application matter? Is there data on using calcipotriene cream vs ointment in combination with 5-FU and does the order of application matter? https://dermsquared.com/videos/dermbits/data-calcipotriene-cream-vs-ointment-with-5-fu 74 2022-04-15T00:43:02.000Z yes https://dermsquared.com/videos/dermbits/how-soon-can-patients-start-seeing-results-on-baricitinib 2023-07-27T19:23:08.665Z https://image.mux.com/ZyL6BJGVmaDhOtzrtVcUsHBGd201lJtXsX7ioLhw81ys/thumbnail.jpg How soon can patients start seeing results on baricitinib? Summary In the video, Dr. Michael Cameron discusses the response patterns of patients with alopecia areata to the medication baricitinib. He points out that alopecia areata is composed of multiple diseases or different endotypes, leading to various response curves. Based on his experience with patients on baricitinib, he has observed a few different response patterns. According to Dr. Cameron, some patients may experience regrowth of hair as early as four weeks after starting treatment with baricitinib. However, he also notes that other patients may take up to nine months to see noticeable results. Therefore, he advises healthcare professionals to counsel their patients that it is possible to see a response within four weeks, but it could also take as long as nine months for the medication to show its effects on hair regrowth in cases of alopecia areata. Key Points Alopecia areata is a condition with multiple diseases or different endotypes, leading to varying response patterns in patients. Patients on baricitinib may experience different response curves. Some patients may start seeing regrowth as early as four weeks after starting treatment, where others may take as long as nine months to see results. Healthcare professionals should counsel patients that the time to see a response can vary. https://dermsquared.com/videos/dermbits/how-soon-can-patients-start-seeing-results-on-baricitinib 33 2023-07-27T19:23:08.659Z yes https://dermsquared.com/videos/dermbits/dosage-finasteride-androgenetic-alopecia-post-menopausal 2023-04-28T19:13:48.874Z https://image.mux.com/eNfa6w7thAfmolcRy4EMhTaeifAhGaFXdRQw3PK72Qk/thumbnail.jpg What are your thoughts and dosage of finasteride for androgenetic alopecia in post-menopausal women? What are your thoughts and dosage of finasteride for androgenetic alopecia in post-menopausal women? https://dermsquared.com/videos/dermbits/dosage-finasteride-androgenetic-alopecia-post-menopausal 37 2021-07-15T21:35:40.000Z yes https://dermsquared.com/videos/dermbits/dermbits-how-is-roflumilast-different-than-other-pde4-inhibitors-arcp22 2022-09-29T00:11:15.000Z https://image.mux.com/k00hVeCGvzAnhHfGSn7gCfRqToDssRP4qHnOL1mGi4oQ/thumbnail.jpg How is roflumilast different than other PDE4 inhibitors? How is roflumilast different than other PDE4 inhibitors? https://dermsquared.com/videos/dermbits/dermbits-how-is-roflumilast-different-than-other-pde4-inhibitors-arcp22 56 2022-09-29T00:11:15.000Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-budget-neutrality-and-how-does-it-affect-our-reimbursement-WCM230002 2023-03-10T00:04:24.000Z https://image.mux.com/Y2RMFffjQ00p4QOxY01zkAetOhgYjO01IIsFNC56p2rmp8/thumbnail.jpg What is Budget neutrality, and how does it affect our reimbursement? What is Budget neutrality, and how does it affect our reimbursement? https://dermsquared.com/videos/dermbits/dermbits-what-is-budget-neutrality-and-how-does-it-affect-our-reimbursement-WCM230002 44 2023-03-10T00:04:24.000Z yes https://dermsquared.com/videos/dermbits/emerging-technologies-diagnostic-tools-enhance-the-early-detection-of-vitiligo 2025-04-02T16:22:11.219Z https://image.mux.com/lGnOIA7HFhMsi16esxDRtkGcjzuQEwkIOs6csT5nfE8/thumbnail.jpg Are there any emerging technologies or diagnostic tools that can enhance the early detection of vitiligo? Are there any emerging technologies or diagnostic tools that can enhance the early detection of vitiligo? https://dermsquared.com/videos/dermbits/emerging-technologies-diagnostic-tools-enhance-the-early-detection-of-vitiligo 69 2025-04-02T16:22:11.214Z yes https://dermsquared.com/videos/dermbits/patient-on-long-term-prednisone-from-pcp-also-start--jak 2023-07-27T19:54:45.569Z https://image.mux.com/pIejBUU00FFcWa3cUAvQtnoKflVchm3QmFv3wX7fCUDA/thumbnail.jpg If a patient is on long term prednisone from PCP for refractory AD can that patient also start a JAK? If a patient is on long term prednisone from PCP for refractory AD can that patient also start a JAK? https://dermsquared.com/videos/dermbits/patient-on-long-term-prednisone-from-pcp-also-start--jak 29 2023-07-27T19:54:45.563Z yes https://dermsquared.com/videos/dermbits/address-compliance-patients-topical-treatment-of-plaque-psoriasis 2023-06-12T14:55:40.883Z https://image.mux.com/FqdgcIDpdCo6qT2icGpNUubE800B5yr013P4aBAwUvAdI/thumbnail.jpg How do you address compliance with your patients in topical treatment of plaque psoriasis? How do you address compliance with your patients in topical treatment of plaque psoriasis? https://dermsquared.com/videos/dermbits/address-compliance-patients-topical-treatment-of-plaque-psoriasis 31 2023-05-31T20:03:12.252Z yes https://dermsquared.com/videos/dermbits/dermbits-does-tralokinumab-have-a-higher-rate-of-conjunctivitis-versus-dupilumab-ADRC00087-adrc23 2023-07-31T18:30:16.232Z https://image.mux.com/JaC00CQXc5uxEBpUgoM002gPFiCTHYACTAT8N2u77ZXDs/thumbnail.jpg Does tralokinumab have a higher rate of conjunctivitis versus dupilumab? Does tralokinumab have a higher rate of conjunctivitis versus dupilumab? https://dermsquared.com/videos/dermbits/dermbits-does-tralokinumab-have-a-higher-rate-of-conjunctivitis-versus-dupilumab-ADRC00087-adrc23 22 2023-02-16T00:00:00.000Z yes https://dermsquared.com/videos/dermbits/prescribing-ruxolitinib-cream 2026-03-02T17:53:51.958Z https://image.mux.com/T6r02ysd7C01H6ceZut02SWzGkKl8pzI00zRUmnudmbkvaQ/thumbnail.jpg How do you document steroid failure before prescribing ruxolitinib cream? How do you document steroid failure before prescribing ruxolitinib cream? https://dermsquared.com/videos/dermbits/prescribing-ruxolitinib-cream 100 2026-03-02T17:53:51.952Z yes https://dermsquared.com/videos/dermbits/chronic-hand-eczema-differ-from-atopic-dermatitis 2025-08-08T19:58:05.651Z https://image.mux.com/IwpJvOC003S0000JGRpC5HU1oX28uM9bRPLart6XpJ6PjM/thumbnail.jpg How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis? How is chronic hand eczema defined clinically, and how does it differ from atopic dermatitis? https://dermsquared.com/videos/dermbits/chronic-hand-eczema-differ-from-atopic-dermatitis 79 2025-08-08T19:58:05.645Z yes https://dermsquared.com/videos/dermbits/disappointment-or-discontinuation 2026-03-03T16:08:54.127Z https://image.mux.com/KbPYqmMa7wRa1Y9hAD00201Ld432rIc8AtTi5zk02zMnqk/thumbnail.jpg When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation? When patients move from years of topical management to apremilast, what expectation resets are most important to prevent early disappointment or discontinuation? https://dermsquared.com/videos/dermbits/disappointment-or-discontinuation 36 2026-03-03T16:08:54.118Z yes https://dermsquared.com/videos/dermbits/therapy-and-biologics 2026-05-07T17:30:20.457Z https://image.mux.com/Nsn5OIBMm5ZxZiWRB00PVTJH022sh5PCUw7OWIo6yCXpw/thumbnail.jpg Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics? Are there specific patient profiles where apremilast helps bridge the gap between topical therapy and biologics? https://dermsquared.com/videos/dermbits/therapy-and-biologics 38 2026-05-07T17:30:20.449Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-effectively-recognize-manage-mental-health-comorbidities-ad 2025-05-01T13:42:26.676Z https://image.mux.com/Y015YWkDkrVcx3p7RymhtqkBSLKOkxJFBOUP002rgyKns/thumbnail.jpg How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD? How can dermatologists effectively recognize and manage mental health comorbidities in patients with AD? https://dermsquared.com/videos/dermbits/how-dermatologists-effectively-recognize-manage-mental-health-comorbidities-ad 70 2025-05-01T13:42:26.669Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-on-sensitive-skin-areas 2024-03-06T16:02:39.354Z https://image.mux.com/202XFMBoVp00286BBzyVCDm00EjCO2xklZDRFuRxmCyUwU/thumbnail.jpg Can ruxolitinib for vitiligo be used on sensitive skin areas? Can ruxolitinib for vitiligo be used on sensitive skin areas? https://dermsquared.com/videos/dermbits/can-ruxolitinib-for-vitiligo-on-sensitive-skin-areas 50 2024-03-06T16:02:39.350Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-alopecia-areata-22 2023-04-28T19:53:00.449Z https://image.mux.com/47ZzIcEAW02MDr2dihgxiG00n9f022ZPX400dXleeVmSoow/thumbnail.jpg Does ruxolitinib work for alopecia areata? Does ruxolitinib work for alopecia areata? https://dermsquared.com/videos/dermbits/ruxolitinib-work-for-alopecia-areata-22 26 2022-01-31T22:17:30.000Z yes https://dermsquared.com/videos/dermbits/suicides-reported-psoriasis-treatments-liability 2023-04-28T19:45:56.747Z https://image.mux.com/oTslAi8JkPhGfTUO01DAvAXGghQfYWkcejVQjeM01Ei02Y/thumbnail.jpg I understand the suicides reported with psoriasis treatments were likely unrelated, but I am concerned about liability using it? I understand the suicides reported with psoriasis treatments were likely unrelated, but I am concerned about liability using it? https://dermsquared.com/videos/dermbits/suicides-reported-psoriasis-treatments-liability 99 2021-12-27T17:20:16.000Z yes https://dermsquared.com/videos/dermbits/tirbanibulin-over-the-250-mg 2025-10-20T22:24:02.713Z https://image.mux.com/T82ORti9SwHNBPxj9DNMGrqfbcXzH01300gnv01Vuk01gO4/thumbnail.jpg What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg? What are the practical advantages of prescribing the 350 mg packet of tirbanibulin over the 250 mg? https://dermsquared.com/videos/dermbits/tirbanibulin-over-the-250-mg 87 2025-10-17T21:24:16.094Z yes https://dermsquared.com/videos/dermbits/which-patients-eligible-cantharidin-and-any-notable-exclusions 2023-11-09T21:34:50.161Z https://image.mux.com/go7CaHoAwuzDCLqOpykjslFhc7Asu3wGJbhsDPusYc4/thumbnail.jpg Which patients are eligible for treatment with cantharidin, and are there any notable exclusions? Which patients are eligible for treatment with cantharidin, and are there any notable exclusions? https://dermsquared.com/videos/dermbits/which-patients-eligible-cantharidin-and-any-notable-exclusions 39 2023-11-09T21:34:50.155Z yes https://dermsquared.com/videos/dermbits/what-is-the-psychosocial-impact-of-vitiligo 2024-03-06T16:01:19.348Z https://image.mux.com/3hnpMJuWhvIMFInIzBWaV7pPcPIZa00u7KG3l4MJIYjc/thumbnail.jpg What is the psychosocial impact of vitiligo? What is the psychosocial impact of vitiligo? https://dermsquared.com/videos/dermbits/what-is-the-psychosocial-impact-of-vitiligo 94 2024-03-06T16:01:19.341Z yes https://dermsquared.com/videos/dermbits/standard-topical-steroids 2026-05-22T13:18:38.869Z https://image.mux.com/lkip6Wg3smi5Kw62In263Xq7Zu7j1OdQHaBvouoSdWI/thumbnail.jpg Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids? Can you walk through how you use the occlusive nature of Cordran Tape in practice, and how it changes your approach compared to standard topical steroids? https://dermsquared.com/videos/dermbits/standard-topical-steroids 103 2026-05-22T13:18:38.860Z yes https://dermsquared.com/videos/dermbits/decision-dx-melanoma-test-and-how-does-it-work 2025-03-03T14:12:48.819Z https://image.mux.com/TDD6qg0202y3CmI4phrzhD8v4xM023K35iZk45WmRZyiMg/thumbnail.jpg What is the DecisionDx Melanoma test, and how does it work? What is the DecisionDx Melanoma test, and how does it work? https://dermsquared.com/videos/dermbits/decision-dx-melanoma-test-and-how-does-it-work 45 2025-03-03T14:12:48.812Z yes https://dermsquared.com/videos/dermbits/ways-you-set-expectations-patients-before-starting-ruxolitinib-for-vitiligo 2024-03-06T16:02:17.868Z https://image.mux.com/01seKcRb00eza8OeB2BfeOWgmgA8th7zKviISHi46rOTg/thumbnail.jpg What are some ways you set expectations with patients before starting them on ruxolitinib for vitiligo? What are some ways you set expectations with patients before starting them on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/ways-you-set-expectations-patients-before-starting-ruxolitinib-for-vitiligo 79 2024-03-06T16:02:17.864Z yes https://dermsquared.com/videos/dermbits/for-ambiguous-lesions 2026-03-06T16:29:49.332Z https://image.mux.com/3sZEvwvdqknIYjQDOVZXk7nb2QmkSMNLekiwXSJLEK4/thumbnail.jpg Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions? Has MyPath meaningfully reduced the number of wide excisions you perform for ambiguous lesions? https://dermsquared.com/videos/dermbits/for-ambiguous-lesions 111 2026-03-06T16:29:49.326Z yes https://dermsquared.com/videos/dermbits/ritlecitinib-combination-topical-treatments-alopecia-areata 2024-10-01T14:15:22.606Z https://image.mux.com/NTbk8gwfA02xQxkMmcrxohvkiVwW00NU1CndSEOUdTlWk/thumbnail.jpg Can ritlecitinib be used in combination with topical treatments for alopecia areata? Can ritlecitinib be used in combination with topical treatments for alopecia areata? https://dermsquared.com/videos/dermbits/ritlecitinib-combination-topical-treatments-alopecia-areata 44 2024-10-01T14:15:22.598Z yes https://dermsquared.com/videos/dermbits/how-do-foresee-the-40-gep-test-contributing-standard-of-care-scc 2023-09-18T16:03:00.357Z https://image.mux.com/VgUw8RY9cgkqueTBaWsH01HcjYT5TcHszEoB00XWMUAXc/thumbnail.jpg How do you foresee the 40-GEP test contributing to standard of care for SCC? How do you foresee the 40-GEP test contributing to standard of care for SCC? https://dermsquared.com/videos/dermbits/how-do-foresee-the-40-gep-test-contributing-standard-of-care-scc 73 2023-08-31T20:52:16.072Z yes https://dermsquared.com/videos/dermbits/how-long-should-ruxolitinib-treatment-be-continued-for-optimal-results 2024-05-01T13:33:34.176Z https://image.mux.com/X1bJHxcrp01czjt13ytCtVqe01402L7OGAsGPeXtc61ezM/thumbnail.jpg How long should ruxolitinib treatment be continued for optimal results? How long should ruxolitinib treatment be continued for optimal results? https://dermsquared.com/videos/dermbits/how-long-should-ruxolitinib-treatment-be-continued-for-optimal-results 36 2024-05-01T13:33:34.170Z yes https://dermsquared.com/videos/dermbits/ideal-treatment-plans 2026-06-12T18:52:53.706Z https://image.mux.com/PppNhPrYgga5bkRU8LEn4sIWfsth6A7TScKfkV3Ibic/thumbnail.jpg How do you balance access realities with ideal treatment plans? How do you balance access realities with ideal treatment plans? https://dermsquared.com/videos/dermbits/ideal-treatment-plans 80 2026-06-02T14:10:15.327Z yes https://dermsquared.com/videos/dermbits/ingredients-technologies-balance-acne-treatment 2025-10-23T15:42:18.876Z https://image.mux.com/NcmFVz0042lqm6zDD6uXcl00yOwA2vyHOycYwA02NH00ano/thumbnail.jpg Are there specific ingredients or technologies that help balance acne treatment with barrier preservation? Are there specific ingredients or technologies that help balance acne treatment with barrier preservation? https://dermsquared.com/videos/dermbits/ingredients-technologies-balance-acne-treatment 53 2025-10-22T21:23:14.315Z yes https://dermsquared.com/videos/dermbits/drug-interactions-to-consider-ruxolitinib-vitiligo 2024-05-01T13:33:24.701Z https://image.mux.com/wacMA65nAw1YnBvw6C01IvoWAy6gcbax5YVh3uB76hT00/thumbnail.jpg Are there any drug interactions to consider when prescribing ruxolitinib for vitiligo? Are there any drug interactions to consider when prescribing ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/drug-interactions-to-consider-ruxolitinib-vitiligo 26 2024-05-01T13:33:24.692Z yes https://dermsquared.com/videos/dermbits/recent-data-supports-utility-i31-slnb-score-guiding-slnb-decisions 2025-07-01T14:14:17.951Z https://image.mux.com/RpLNv0102V7uQBZke6mUxT7OvX1s00CaSmc4FFeSkgKGyo/thumbnail.jpg What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions? What recent data supports the utility of the i31-SLNB score in guiding SLNB decisions? https://dermsquared.com/videos/dermbits/recent-data-supports-utility-i31-slnb-score-guiding-slnb-decisions 102 2025-07-01T14:14:17.946Z yes https://dermsquared.com/videos/dermbits/is-there-a-need-for-loading-doses-when-initiating-ixekizumab-therapy 2024-09-24T18:20:37.237Z https://image.mux.com/g8Rcl46EaoSYhoh8PtdsPiCW76xXvdsCfZFxVqUIwRs/thumbnail.jpg Is there a need for loading doses when initiating ixekizumab therapy? Is there a need for loading doses when initiating ixekizumab therapy? https://dermsquared.com/videos/dermbits/is-there-a-need-for-loading-doses-when-initiating-ixekizumab-therapy 64 2024-09-24T18:20:37.231Z yes https://dermsquared.com/videos/dermbits/consider-jak-inhibitors-immunosuppressive-than-biologics 2023-04-28T19:10:15.613Z https://image.mux.com/xwmDMjs3zinHUGuaptgtXFlJPdRrf6d26WrmJaum007E/thumbnail.jpg Should we consider the JAK inhibitors more broadly immunosuppressive than the biologics? Should we consider the JAK inhibitors more broadly immunosuppressive than the biologics? https://dermsquared.com/videos/dermbits/consider-jak-inhibitors-immunosuppressive-than-biologics 105 2021-06-24T19:00:45.000Z yes https://dermsquared.com/videos/dermbits/what-clinical-features-define-an-ideal-patient-profile-for-starting-lebrikizumab 2025-10-01T22:31:55.986Z https://image.mux.com/AYWVytU5ZLKJc1P5aTQ2aMBpo51Q00TBJ5VyjaVrjwLA/thumbnail.jpg What clinical features define an ideal patient profile for starting lebrikizumab? What clinical features define an ideal patient profile for starting lebrikizumab? https://dermsquared.com/videos/dermbits/what-clinical-features-define-an-ideal-patient-profile-for-starting-lebrikizumab 114 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/how-do-comorbidities-affect-the-decision-to-prescribe-ruxolitinib-for-vitiligo 2025-04-02T16:22:33.441Z https://image.mux.com/PIIU7MtK2H7tTLGrjkr7ORrSSTrRPXWyBltK75NNutM/thumbnail.jpg How do comorbidities affect the decision to prescribe ruxolitinib for vitiligo? How do comorbidities affect the decision to prescribe ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/how-do-comorbidities-affect-the-decision-to-prescribe-ruxolitinib-for-vitiligo 41 2025-04-02T16:22:33.435Z yes https://dermsquared.com/videos/dermbits/taltz-compare-head-to-head-humira-psoriatic-arthritis 2023-04-28T20:07:07.956Z https://image.mux.com/s52J901006LgJqyp1Ze2tW9W01J011ksECpPzE3axjU024UY/thumbnail.jpg How does Taltz compare head to head with Humira for psoriatic arthritis? How does Taltz compare head to head with Humira for psoriatic arthritis? https://dermsquared.com/videos/dermbits/taltz-compare-head-to-head-humira-psoriatic-arthritis 16 2022-04-21T16:15:07.000Z yes https://dermsquared.com/videos/dermbits/dermbits-alternative-therapies-which-have-data-showing-efficacy-in-the-treatment-of-ad-ADRC00089-adrc23 2023-02-16T00:03:42.000Z https://image.mux.com/5MON83oxl01IyJjlR7Ll016DUE3lvDtKTHmrvlYVuEkNk/thumbnail.jpg Are there any complementary and alternative therapies which have data showing efficacy in the treatment of AD? Are there any complementary and alternative therapies which have data showing efficacy in the treatment of AD? https://dermsquared.com/videos/dermbits/dermbits-alternative-therapies-which-have-data-showing-efficacy-in-the-treatment-of-ad-ADRC00089-adrc23 29 2023-02-16T00:03:42.000Z yes https://dermsquared.com/videos/dermbits/how-safety-profile-baricitinib-compare-systemic-corticosteroids-alopecia-areata 2024-10-01T14:55:11.185Z https://image.mux.com/EeUBxLSDKKGP2UAQseFpAKGawXPx2pksOo79dG3yyY00/thumbnail.jpg How does the safety profile of baricitinib compare to systemic corticosteroids in the treatment of alopecia areata? How does the safety profile of baricitinib compare to systemic corticosteroids in the treatment of alopecia areata? https://dermsquared.com/videos/dermbits/how-safety-profile-baricitinib-compare-systemic-corticosteroids-alopecia-areata 73 2024-10-01T14:55:11.178Z yes https://dermsquared.com/videos/dermbits/lebrikizumab-perform-treating-difficult-areas-atopic-dermatitis 2024-12-02T16:28:19.001Z https://image.mux.com/025r0100JLdCfrfeEik02kTaFXcRIoaiD3xsGftnrMyGdp4/thumbnail.jpg How does lebrikizumab perform in treating difficult-to-manage areas like the face and hands in atopic dermatitis? How does lebrikizumab perform in treating difficult-to-manage areas like the face and hands in atopic dermatitis? https://dermsquared.com/videos/dermbits/lebrikizumab-perform-treating-difficult-areas-atopic-dermatitis 46 2024-12-02T16:28:18.993Z yes https://dermsquared.com/videos/dermbits/what-are-the-practical-considerations-for-incorporating-lebrikizumab-into-long-term-treatment-plans 2025-04-01T14:18:03.817Z https://image.mux.com/xXhgaZF6MkW87997Tv1r5XwPLMc3NpZz9g39zlEkqn8/thumbnail.jpg What are the practical considerations for incorporating lebrikizumab into long-term treatment plans? What are the practical considerations for incorporating lebrikizumab into long-term treatment plans? https://dermsquared.com/videos/dermbits/what-are-the-practical-considerations-for-incorporating-lebrikizumab-into-long-term-treatment-plans 67 2025-04-01T14:18:03.810Z yes https://dermsquared.com/videos/dermbits/how-should-this-shape-your-counseling 2025-11-14T15:28:22.101Z https://image.mux.com/ARChrglX00CenTiIntljdH5GtrQe3FcqSvtrb7qtrjFw/thumbnail.jpg Which common medications increase photosensitivity, and how should this shape your counseling? Which common medications increase photosensitivity, and how should this shape your counseling? https://dermsquared.com/videos/dermbits/how-should-this-shape-your-counseling 107 2025-11-14T15:28:22.094Z yes https://dermsquared.com/videos/dermbits/new-therapies-like-ruxolitinib 2026-02-02T15:21:20.789Z https://image.mux.com/P7ygAe913GdjDmee01I1o01rVd1WzVaZa0294Ybx00JVXHA/thumbnail.jpg Can EHR templates improve access for new therapies like ruxolitinib? Can EHR templates improve access for new therapies like ruxolitinib? https://dermsquared.com/videos/dermbits/new-therapies-like-ruxolitinib 43 2026-02-02T15:21:20.782Z yes https://dermsquared.com/videos/dermbits/how-undertake-multidisciplinary-approach-scc-management 2023-11-17T16:50:27.918Z https://image.mux.com/bjeowG279a1nlBFXAP00xXj9g8W00BKYtzrKn00LPD1CSI/thumbnail.jpg How do you undertake a multidisciplinary approach to SCC management? How do you undertake a multidisciplinary approach to SCC management? https://dermsquared.com/videos/dermbits/how-undertake-multidisciplinary-approach-scc-management 61 2023-11-17T16:37:46.542Z yes https://dermsquared.com/videos/dermbits/stability-and-uv-coverage 2025-11-14T15:26:06.210Z https://image.mux.com/BEBaEg9PCFvh1TzEQoPOtoYtrmBSjc15Y9i9Jyqa02Vk/thumbnail.jpg What is Helioplex technology, and how does it improve stability and UV coverage? What is Helioplex technology, and how does it improve stability and UV coverage? https://dermsquared.com/videos/dermbits/stability-and-uv-coverage 53 2025-11-14T15:26:06.204Z yes https://dermsquared.com/videos/dermbits/key-results-adoring-1-adoring-2-trials-tapinarof-efficacy 2025-02-03T19:11:26.452Z https://image.mux.com/01rVCcipO3Ylsf6OoD8ebZ6zXJhjOEzfG01ba5bYJape4/thumbnail.jpg What were the key results from the ADORING 1 and ADORING 2 pivotal trials for tapinarof in terms of efficacy? What were the key results from the ADORING 1 and ADORING 2 pivotal trials for tapinarof in terms of efficacy? https://dermsquared.com/videos/dermbits/key-results-adoring-1-adoring-2-trials-tapinarof-efficacy 38 2025-02-03T19:11:26.446Z yes https://dermsquared.com/videos/dermbits/noncompete-agreements-in-dermatology-practices 2023-04-28T19:34:01.815Z https://image.mux.com/O2eRAOfD2ea2FO8Dx026HnT2nIpynUyTQwl01akEQOFfU/thumbnail.jpg How are noncompete agreements handled in dermatology practices? How are noncompete agreements handled in dermatology practices? https://dermsquared.com/videos/dermbits/noncompete-agreements-in-dermatology-practices 75 2021-12-10T00:43:42.000Z yes https://dermsquared.com/videos/dermbits/how-cdecision-dx-melanoma-test-contribute-improved-survival-outcomes 2025-03-03T14:12:22.019Z https://image.mux.com/ymcI2uLIlFq4Jq7CC4Z65vlWCLSwwT2uY7OEDC8IaOI/thumbnail.jpg How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients? How can the DecisionDx Melanoma test contribute to improved survival outcomes for patients? https://dermsquared.com/videos/dermbits/how-cdecision-dx-melanoma-test-contribute-improved-survival-outcomes 41 2025-03-03T14:12:22.013Z yes https://dermsquared.com/videos/dermbits/recommendations-for-tapering-ruxolitinib-for-vitiligo-minimize-rebound-depigmentation 2025-04-02T16:22:56.928Z https://image.mux.com/lM3a01peexqIwC9Kn01LEAjXXQlQMY7ddD9EignR9wCzs/thumbnail.jpg Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation? Are there any recommendations for tapering ruxolitinib for vitiligo to minimize rebound depigmentation? https://dermsquared.com/videos/dermbits/recommendations-for-tapering-ruxolitinib-for-vitiligo-minimize-rebound-depigmentation 31 2025-04-02T16:22:56.922Z yes https://dermsquared.com/videos/dermbits/when-treating-actinic-keratosis 2025-10-20T22:28:05.376Z https://image.mux.com/fOQpiw5f008265XAQSDYCKuc1x02tfsfN7mpua3q3Q006g/thumbnail.jpg How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis? How can dermatologists decide between lesion-directed and field-directed therapies when treating actinic keratosis? https://dermsquared.com/videos/dermbits/when-treating-actinic-keratosis 157 2025-10-17T21:17:49.182Z yes https://dermsquared.com/videos/dermbits/how-long-remain-lebrikizumab-optimal-long-term-control 2025-04-01T14:17:17.400Z https://image.mux.com/OiIXaAwHq7WhtoY00RnW4ww6qLHtBKpzciZ8wK7Cl00pk/thumbnail.jpg How long should patients remain on lebrikizumab to achieve optimal long-term control of their atopic dermatitis symptoms? How long should patients remain on lebrikizumab to achieve optimal long-term control of their atopic dermatitis symptoms? https://dermsquared.com/videos/dermbits/how-long-remain-lebrikizumab-optimal-long-term-control 58 2025-04-01T14:17:17.391Z yes https://dermsquared.com/videos/dermbits/inadequate-response-to-topical-therapies-before-initiating-lebrikizumab 2025-10-01T22:29:03.558Z https://image.mux.com/700yzEZab4HrC00vRvBPekGeA5srvjwUrvPYNp7iUjpUM/thumbnail.jpg Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab? Do patients need to demonstrate inadequate response to topical therapies before initiating lebrikizumab? https://dermsquared.com/videos/dermbits/inadequate-response-to-topical-therapies-before-initiating-lebrikizumab 69 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/paltrow-xeomin-natural-botox-use 2023-04-28T19:27:57.234Z https://image.mux.com/oa6krls1AF801Dq7fE8ZtlLYwoVc6EbUYoaeSvILywd4/thumbnail.jpg Gwyneth Paltrow is promoting Xeomin as a 'natural' Botox. In my 13 years, we mostly use Xeomin for people that are resistant to Botox or Dysport. Thoughts? Gwyneth Paltrow is promoting Xeomin as a 'natural' Botox. In my 13 years, we mostly use Xeomin for people that are resistant to Botox or Dysport. Thoughts? https://dermsquared.com/videos/dermbits/paltrow-xeomin-natural-botox-use 129 2021-10-19T16:36:25.000Z yes https://dermsquared.com/videos/dermbits/impact-on-patient-quality-of-life 2025-10-20T22:27:38.607Z https://image.mux.com/o7wkySoiDEw4kR3ksAZUp9jCdq0028kDmuMN1n8v501Fo/thumbnail.jpg What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life? What were the key findings of the PROAK study, and how did its results inform our understanding of tirbanibulin’s impact on patient quality of life? https://dermsquared.com/videos/dermbits/impact-on-patient-quality-of-life 113 2025-10-17T21:17:26.004Z yes https://dermsquared.com/videos/dermbits/therapies-like-5-fu 2025-10-20T22:27:25.192Z https://image.mux.com/kvRQZ9pHvrLbFTGngX2ZVgRfqvFQVOt8f55mRfybAuc/thumbnail.jpg In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU? In terms of a clearance timeline, what expectations should clinicians set with themselves and with patients starting tirbanibulin, especially when comparing it with therapies like 5-FU? https://dermsquared.com/videos/dermbits/therapies-like-5-fu 104 2025-10-17T21:16:27.271Z yes https://dermsquared.com/videos/dermbits/treat-patients-not-seen-success-dupilumab-22 2023-04-28T20:18:00.107Z https://image.mux.com/r007TXzoFp01ycPnljfqYuTBg1OYLc9IkHcxJMj2tjyCI/thumbnail.jpg How do you treat patients who have not seen success with dupilumab? How do you treat patients who have not seen success with dupilumab? https://dermsquared.com/videos/dermbits/treat-patients-not-seen-success-dupilumab-22 69 2022-07-27T21:55:21.000Z yes https://dermsquared.com/videos/dermbits/treat-patients-with-both-psoriasis-eczema-or-eczema-inflammatory-arthritis-22 2023-04-28T20:20:48.154Z https://image.mux.com/tx019jsZY48RLB4YhzGKsslOhvDeR2iu6omrt00Q3Rq2I/thumbnail.jpg How do you treat patients with both psoriasis and eczema, or eczema and inflammatory arthritis? How do you treat patients with both psoriasis and eczema, or eczema and inflammatory arthritis? https://dermsquared.com/videos/dermbits/treat-patients-with-both-psoriasis-eczema-or-eczema-inflammatory-arthritis-22 92 2022-07-27T21:57:23.000Z yes https://dermsquared.com/videos/dermbits/clearer-after-genomic-testing 2026-03-23T19:05:19.888Z https://image.mux.com/W3SfMWGsZ027HTVeurmT6Wl4c8AeKdj02QdPGT01IpmuwE/thumbnail.jpg What is the single most meaningful management decision that becomes clearer after genomic testing? What is the single most meaningful management decision that becomes clearer after genomic testing? https://dermsquared.com/videos/dermbits/clearer-after-genomic-testing 46 2026-03-06T16:25:53.382Z yes https://dermsquared.com/videos/dermbits/how-decision-dx-melanoma-test-compare-other-gep-tests 2025-03-03T14:12:13.570Z https://image.mux.com/JizJa00DS6iy01QtX5CUqXwZale4qU00e9Ek5odfMGrU1s/thumbnail.jpg How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility? How does the DecisionDx Melanoma test compare to other GEP tests, such as the CP-GEP test, in clinical accuracy and utility? https://dermsquared.com/videos/dermbits/how-decision-dx-melanoma-test-compare-other-gep-tests 91 2025-03-03T14:12:13.499Z yes https://dermsquared.com/videos/dermbits/patient-access-programs-available-for-the-40-gep-test 2023-08-31T21:14:40.681Z https://image.mux.com/MZJ4P2pxYlvOGthzwxPvaIbENasg1avU01zJtnkI9egU/thumbnail.jpg Are there any patient access programs available for the 40-GEP test? Are there any patient access programs available for the 40-GEP test? https://dermsquared.com/videos/dermbits/patient-access-programs-available-for-the-40-gep-test 26 2023-08-31T20:51:38.673Z yes https://dermsquared.com/videos/dermbits/when-is-baricitinib-recommended-for-atopic-dermatitis 2023-09-29T16:20:36.089Z https://image.mux.com/6wsdId4PY025FyQ8HJzmaCEwV01e1j02novIdiZYihVu9A/thumbnail.jpg When is baricitinib recommended for atopic dermatitis? When is baricitinib recommended for atopic dermatitis? https://dermsquared.com/videos/dermbits/when-is-baricitinib-recommended-for-atopic-dermatitis 112 2023-09-29T16:20:36.083Z yes https://dermsquared.com/videos/dermbits/baseline-salt-score-patients-included-in-brave-aa-1-and-brave-aa-2-trials 2023-09-29T16:20:31.299Z https://image.mux.com/00HyqYenp5SUtbHFu02200TOJ7nFitt0000028UypWcQcAu00E/thumbnail.jpg What was the baseline SALT score for patients included in the BRAVE-AA1 and BRAVE-AA2 trials? What was the baseline SALT score for patients included in the BRAVE-AA1 and BRAVE-AA2 trials? https://dermsquared.com/videos/dermbits/baseline-salt-score-patients-included-in-brave-aa-1-and-brave-aa-2-trials 58 2023-09-29T16:20:31.294Z yes https://dermsquared.com/videos/dermbits/how-manage-atopic-dermatitis-pregnancy-breastfeeding 2024-11-06T15:54:36.608Z https://image.mux.com/01OzHqU4q7cL5uvzmWMmsR8MNWyZwaevkWBpr9JRxm7w/thumbnail.jpg How should dermatologists manage atopic dermatitis during pregnancy and breastfeeding? How should dermatologists manage atopic dermatitis during pregnancy and breastfeeding? https://dermsquared.com/videos/dermbits/how-manage-atopic-dermatitis-pregnancy-breastfeeding 95 2024-11-06T15:54:36.602Z yes https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-combination-with-topical-treatments 2023-09-29T16:20:17.244Z https://image.mux.com/Y00njNgkF4hzA3VuUUq7b5sm83lk5QooltZuXn02zhZYg/thumbnail.jpg Can baricitinib be used in combination with topical treatments? Can baricitinib be used in combination with topical treatments? https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-combination-with-topical-treatments 131 2023-09-29T16:20:17.229Z yes https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-impact-quality-of-life-patients-with-psoriasis-artr00037-arcp22 2022-11-29T23:32:35.000Z https://image.mux.com/5X1UwsP3uNmfambbAa2JmXcBBowZvuQQtCi7Z202TfkI/thumbnail.jpg How can topical roflumilast impact quality of life in patients with psoriasis? How can topical roflumilast impact quality of life in patients with psoriasis? https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-impact-quality-of-life-patients-with-psoriasis-artr00037-arcp22 27 2022-11-29T23:32:35.000Z yes https://dermsquared.com/videos/dermbits/long-term-safety-and-efficacy-topical-roflumilast-22 2023-04-28T20:25:39.366Z https://image.mux.com/uuefxbdtHPnSuI01oni5u1YpFvl3UpR2wmZey23Z3SjM/thumbnail.jpg What is the long-term safety and efficacy data of topical roflumilast? What is the long-term safety and efficacy data of topical roflumilast? https://dermsquared.com/videos/dermbits/long-term-safety-and-efficacy-topical-roflumilast-22 18 2022-08-30T23:13:59.000Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-co-morbidities 2023-04-28T19:32:09.961Z https://image.mux.com/wPr7bMUU1R0000MjS01dUcedFDWKNh2M4D2JmIHIbZGNKk/thumbnail.jpg Do people with atopic dermatitis always have atopic co-morbidities? Do people with atopic dermatitis always have atopic co-morbidities? https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-co-morbidities 74 2021-11-17T20:50:42.000Z yes https://dermsquared.com/videos/dermbits/role-il-13-pathway-ad-pathogenesis-and-treatment 2025-05-01T13:39:44.725Z https://image.mux.com/2Ku01w4PxfdOk4uPiqKZ4hiRjJYo15kMk9OcZvgvx01U8/thumbnail.jpg What is the role of the IL-13 pathway in AD pathogenesis and treatment? What is the role of the IL-13 pathway in AD pathogenesis and treatment? https://dermsquared.com/videos/dermbits/role-il-13-pathway-ad-pathogenesis-and-treatment 45 2025-05-01T13:39:44.717Z yes https://dermsquared.com/videos/dermbits/hydroquinone-melasma-drug-holidays 2023-04-28T18:47:42.161Z https://image.mux.com/HRLf6hk3Ul01mCCqMb5DkHAjQraCWfKlBjTw02ZWkhHnE/thumbnail.jpg How long do you allow patients to use hydroquinone 4% since melasma is a chronic disease that can last for years? Do you use "drug holidays"? How long do you allow patients to use hydroquinone 4% since melasma is a chronic disease that can last for years? Do you use "drug holidays"? https://dermsquared.com/videos/dermbits/hydroquinone-melasma-drug-holidays 40 2021-07-29T20:02:38.000Z yes https://dermsquared.com/videos/dermbits/dermbits-consider-ruxolitinib-instead-tcs-patient-dupilumab-breakthrough-flares-ADRC00069-ad0123 2022-12-22T21:19:36.000Z https://image.mux.com/nOgrD94NkfQOfc02HhfA01UVyn00MAkKQFRO4CYT02JDy01Y/thumbnail.jpg Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares? Would you consider using ruxolitinib instead of TCS with a patient on dupilumab for breakthrough flares? https://dermsquared.com/videos/dermbits/dermbits-consider-ruxolitinib-instead-tcs-patient-dupilumab-breakthrough-flares-ADRC00069-ad0123 156 2022-12-22T21:19:36.000Z yes https://dermsquared.com/videos/dermbits/what-classification-40-gep-test-would-consider-referral-radiation-oncologist-radiation-therapy 2023-11-17T16:51:47.701Z https://image.mux.com/BqHzv8rDPHxuhsv5HE4pgZIXCuwrfMSUHP1w02V026OfY/thumbnail.jpg What classification from the 40-GEP test would make you consider referral to a radiation oncologist and adjuvant radiation therapy? What classification from the 40-GEP test would make you consider referral to a radiation oncologist and adjuvant radiation therapy? https://dermsquared.com/videos/dermbits/what-classification-40-gep-test-would-consider-referral-radiation-oncologist-radiation-therapy 47 2023-11-17T16:37:03.431Z yes https://dermsquared.com/videos/dermbits/more-options-treat-psoriasis-how-choose-when-to-use-roflumilast 2023-11-01T21:22:33.226Z https://image.mux.com/YVZpyzLy501HFGCZQVxn345OANVRUitq73twdoAEZGNQ/thumbnail.jpg Now that there are more options to treat psoriasis, how do you choose when to use roflumilast? Now that there are more options to treat psoriasis, how do you choose when to use roflumilast? https://dermsquared.com/videos/dermbits/more-options-treat-psoriasis-how-choose-when-to-use-roflumilast 25 2023-11-01T21:22:33.222Z yes https://dermsquared.com/videos/dermbits/prefer-cosentyx-and-tremfya-joint-indication 2023-04-28T20:11:40.739Z https://image.mux.com/faV502W5fiikyLN6gdUTMZiHUwwc7gdB7z4VefPV4f4s/thumbnail.jpg I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes? I tend to prefer Cosentyx and Tremfya since they have the joint indication. Do you think these are coming for the other drugs in these classes? https://dermsquared.com/videos/dermbits/prefer-cosentyx-and-tremfya-joint-indication 58 2022-04-28T15:47:02.000Z yes https://dermsquared.com/videos/dermbits/safety-profile-of-lebrikizumab 2025-07-02T16:55:27.010Z https://image.mux.com/j1vJMGHzbdO7PgfMy5tn3ESzOG5Hje5dRa2SvRKAOyo/thumbnail.jpg What is lebrikizumab's safety profile? What is lebrikizumab's safety profile? https://dermsquared.com/videos/dermbits/safety-profile-of-lebrikizumab 69 2025-07-01T13:41:29.075Z yes https://dermsquared.com/videos/dermbits/what-are-the-limitations-of-ruxolitinib-for-vitiligo 2024-04-01T15:45:02.776Z https://image.mux.com/MYZGPu7DHJyPmI7EaqEgHzg01JnQqVVn5QOmmmay86sc/thumbnail.jpg What are the limitations of use for ruxolitinib for vitiligo? What are the limitations of use for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/what-are-the-limitations-of-ruxolitinib-for-vitiligo 33 2024-04-01T15:45:02.769Z yes https://dermsquared.com/videos/dermbits/limitations-of-traditional-scoring-scaling-systems-assessing-ad-severity 2025-07-01T13:40:49.251Z https://image.mux.com/O3302LbgY62FRjtSlTel4i8E7aFO02vPnQYbeGuksusNk/thumbnail.jpg What are some limitations of traditional scoring/scaling systems in assessing AD severity? What are some limitations of traditional scoring/scaling systems in assessing AD severity? https://dermsquared.com/videos/dermbits/limitations-of-traditional-scoring-scaling-systems-assessing-ad-severity 167 2025-07-01T13:40:49.241Z yes https://dermsquared.com/videos/dermbits/what-makes-formulation-of-clobetasol-propionate-cream-025-unique 2023-11-01T17:25:33.648Z https://image.mux.com/02iXKw8fNOeOHyI01C4xSc02zJ8qJlMDTc3dSff2its6iI/thumbnail.jpg What makes the formulation of clobetasol propionate cream 0.025% unique? What makes the formulation of clobetasol propionate cream 0.025% unique? https://dermsquared.com/videos/dermbits/what-makes-formulation-of-clobetasol-propionate-cream-025-unique 19 2023-11-01T16:28:31.996Z yes https://dermsquared.com/videos/dermbits/risk-factors-history-physical-examination-scc-good-candidate-for-the-40-gep-test 2023-08-31T21:10:29.282Z https://image.mux.com/3sF01IL6NPiI3Vi1v1i9hd32PDPBSwvveUSxE00g76M01c/thumbnail.jpg What risk factors relating to history and physical examination would make a patient with SCC a good candidate for the 40-GEP test? What risk factors relating to history and physical examination would make a patient with SCC a good candidate for the 40-GEP test? https://dermsquared.com/videos/dermbits/risk-factors-history-physical-examination-scc-good-candidate-for-the-40-gep-test 44 2023-08-31T20:52:12.000Z yes https://dermsquared.com/videos/dermbits/important-comorbidities-associated-with-vitiligo 2024-05-01T13:33:19.918Z https://image.mux.com/q99KHfOSMBWOC1EpsCP9ojOsa102CXt02uwux57zIunoU/thumbnail.jpg What are some important comorbidities associated with vitiligo? What are some important comorbidities associated with vitiligo? https://dermsquared.com/videos/dermbits/important-comorbidities-associated-with-vitiligo 20 2024-05-01T13:33:19.911Z yes https://dermsquared.com/videos/dermbits/read-the-i31-slnb-score 2026-06-11T15:06:18.834Z https://image.mux.com/C006HztqTNGnZC015fqi101vfSlYBFaaFlAMDh8GfV71M4/thumbnail.jpg Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score Risk Thresholds That Change Decisions: How to Read the i31-SLNB Score https://dermsquared.com/videos/dermbits/read-the-i31-slnb-score 62 2025-07-01T14:14:45.564Z yes https://dermsquared.com/videos/dermbits/dermbits-if-you-treat-a-rosacea-patient-with-a-laser-do-you-stop-other-concomitant-rosacea-treatments-WC220014 2023-04-27T17:02:52.571Z https://image.mux.com/geRGA025yT02j00b251Yoy39q59nIqdszDlw1afGrBv13c/thumbnail.jpg If you treat a rosacea patient with a laser do you stop other concomitant rosacea treatments? If you treat a rosacea patient with a laser do you stop other concomitant rosacea treatments? https://dermsquared.com/videos/dermbits/dermbits-if-you-treat-a-rosacea-patient-with-a-laser-do-you-stop-other-concomitant-rosacea-treatments-WC220014 104 2022-12-23T01:55:36.000Z yes https://dermsquared.com/videos/dermbits/lesser-known-risk-factors-of-gpp 2023-08-31T20:40:48.980Z https://image.mux.com/uIvHjBt02F00ubEa9ajwTqi2xoYfL6ZZ2Gq02FJu00gH2Yc/thumbnail.jpg What are some lesser-known risk factors of GPP? What are some lesser-known risk factors of GPP? https://dermsquared.com/videos/dermbits/lesser-known-risk-factors-of-gpp 74 2023-08-31T20:40:48.975Z yes https://dermsquared.com/videos/dermbits/how-effectively-position-lebrikizumab-option-patients-atopic-dermatitis-considering-variety-other-therapies 2024-11-06T15:54:41.223Z https://image.mux.com/5LaQ2XdDIBpPto00otN48bEX4t4WFs602yi9xfefU3Xms/thumbnail.jpg How can dermatologists effectively position lebrikizumab as a treatment option to patients with atopic dermatitis, considering the variety of other available therapies? How can dermatologists effectively position lebrikizumab as a treatment option to patients with atopic dermatitis, considering the variety of other available therapies? https://dermsquared.com/videos/dermbits/how-effectively-position-lebrikizumab-option-patients-atopic-dermatitis-considering-variety-other-therapies 33 2024-11-06T15:54:41.217Z yes https://dermsquared.com/videos/dermbits/role-tapinarof-restoring-skin-barrier-function-atopic-dermatitis 2025-02-03T19:10:45.789Z https://image.mux.com/bOwVACV9BHj9ajtkSJ2OQlEFu02CCa02iZHIUM86b302WU/thumbnail.jpg What role does tapinarof play in restoring skin barrier function in atopic dermatitis? What role does tapinarof play in restoring skin barrier function in atopic dermatitis? https://dermsquared.com/videos/dermbits/role-tapinarof-restoring-skin-barrier-function-atopic-dermatitis 24 2025-02-03T19:10:45.779Z yes https://dermsquared.com/videos/dermbits/what-is-the-retinol-sandwich-method-managing-acne 2025-10-23T15:43:38.529Z https://image.mux.com/yFJFhm4M585fTiS701v00yx02YiOYeBkepqITwMe7NMmM8/thumbnail.jpg What is the "retinol sandwich" method for managing acne? What is the "retinol sandwich" method for managing acne? https://dermsquared.com/videos/dermbits/what-is-the-retinol-sandwich-method-managing-acne 115 2025-10-22T21:24:32.479Z yes https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-baricitinib 2023-07-27T19:23:12.968Z https://image.mux.com/mQxQKW8NMI7cpE02Z3rHUY1YMrWoysyKOQmLa15Q3O500/thumbnail.jpg What is the mechanism of action of baricitinib? What is the mechanism of action of baricitinib? https://dermsquared.com/videos/dermbits/what-is-the-mechanism-of-action-of-baricitinib 45 2023-07-27T19:23:12.961Z yes https://dermsquared.com/videos/dermbits/tapinarof-work-for-vitiligo-22 2023-04-28T20:00:30.570Z https://image.mux.com/XkZVDJ8xTrJx7t004mxUv64hWwDbiHpJdyn1UAi1IOIE/thumbnail.jpg Does tapinarof work for vitiligo? Does tapinarof work for vitiligo? https://dermsquared.com/videos/dermbits/tapinarof-work-for-vitiligo-22 61 2022-02-01T01:14:55.000Z yes https://dermsquared.com/videos/dermbits/dermbits-which-patients-should-be-considered-for-the-40-gep-test-WCM2300015-scc23 2023-05-17T20:08:15.586Z https://image.mux.com/01mvxKmYwaiFPDM3nw4uhS02CUdXPU9g8OqFhDdI1K01wc/thumbnail.jpg Which patients should be considered for the 40-GEP test? Which patients should be considered for the 40-GEP test? https://dermsquared.com/videos/dermbits/dermbits-which-patients-should-be-considered-for-the-40-gep-test-WCM2300015-scc23 43 2023-05-17T20:08:15.581Z yes https://dermsquared.com/videos/dermbits/what-factors-can-help-dermatologists-determine-which-cytokine-pathway-to-target-when-selecting-a-therapy-for-ad 2025-10-01T20:36:21.860Z https://image.mux.com/a2nssMrFNwDR021s2012b8OoS68gD88KilG01gyEAUIWrI/thumbnail.jpg What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD? What factors can help dermatologists determine which cytokine pathway to target when selecting a therapy for AD? https://dermsquared.com/videos/dermbits/what-factors-can-help-dermatologists-determine-which-cytokine-pathway-to-target-when-selecting-a-therapy-for-ad 178 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/support-programs-to-help-patients-access-bimekizumab 2023-10-24T16:35:19.193Z https://image.mux.com/HAWZNKYmYJORjMnawvdPSF01ewsauaEIpK2PwUyRuLdc/thumbnail.jpg Are there any support programs to help patients access bimekizumab? Are there any support programs to help patients access bimekizumab? https://dermsquared.com/videos/dermbits/support-programs-to-help-patients-access-bimekizumab 29 2023-10-24T16:35:19.188Z yes https://dermsquared.com/videos/dermbits/protection-beyond-spf-ratings 2025-11-14T15:25:13.598Z https://image.mux.com/8z7eMxCIalrCQ2nHX1f3akFNfKgIWA7OD1wI1SL8n8Y/thumbnail.jpg How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings? How do you identify sunscreens that offer reliable broad-spectrum protection beyond SPF ratings? https://dermsquared.com/videos/dermbits/protection-beyond-spf-ratings 68 2025-11-14T15:25:13.591Z yes https://dermsquared.com/videos/dermbits/jak-inhibitors-efficacious-21 2023-04-28T18:55:49.408Z https://image.mux.com/HSflElYJZqQXd8o6pyYH00eJ1rynjDxsbDdNSYzzF99E/thumbnail.jpg Are topical JAK inhibitors, on the whole, more efficacious than superpotent topical steroids for atopic dermatitis? Are topical JAK inhibitors, on the whole, more efficacious than superpotent topical steroids for atopic dermatitis? https://dermsquared.com/videos/dermbits/jak-inhibitors-efficacious-21 71 2021-10-14T14:39:13.000Z yes https://dermsquared.com/videos/dermbits/when-consider-biologic-first-line-treatment-psoriasis 2024-07-17T16:13:18.389Z https://image.mux.com/E3T02w02aO802jV6aRHuSBMMqVc01I3phE4Ynx4Le8hrroE/thumbnail.jpg When do you consider a biologic as a first-line treatment for psoriasis? When do you consider a biologic as a first-line treatment for psoriasis? https://dermsquared.com/videos/dermbits/when-consider-biologic-first-line-treatment-psoriasis 45 2024-07-17T16:13:18.382Z yes https://dermsquared.com/videos/dermbits/why-is-there-a-boxed-warning-for-ruxolitinib-for-vitiligo 2024-03-06T16:03:15.539Z https://image.mux.com/T2ZUVAgqTsSEs02cRKJQ9I00B1xnFT6wxauV9xXspqocQ/thumbnail.jpg Why is there a boxed warning for ruxolitinib for vitiligo? Why is there a boxed warning for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/why-is-there-a-boxed-warning-for-ruxolitinib-for-vitiligo 89 2024-03-06T16:03:15.534Z yes https://dermsquared.com/videos/dermbits/product-profile-topical-roflumilast-to-hcp-colleagues-who-are-reluctant 2023-06-29T16:12:31.123Z https://image.mux.com/IndtZ2XOongWPTF7Afs01Cvd640100ji0114P9gbqpZ9H8o/thumbnail.jpg How would you present the product profile of topical roflumilast to HCP colleagues who are reluctant due to poor prior experience with other PDE4 inhibitors? How would you present the product profile of topical roflumilast to HCP colleagues who are reluctant due to poor prior experience with other PDE4 inhibitors? https://dermsquared.com/videos/dermbits/product-profile-topical-roflumilast-to-hcp-colleagues-who-are-reluctant 136 2023-06-29T16:12:31.118Z yes https://dermsquared.com/videos/dermbits/counsel-patients-with-hair-loss-on-results-22 2023-04-28T20:12:58.941Z https://image.mux.com/8qEOzoIH5IzIZJO00y7MGOKHkrCZxjjuAOfAVSwZ9JFc/thumbnail.jpg How do you counsel patients with hair loss on their results? How do you counsel patients with hair loss on their results? https://dermsquared.com/videos/dermbits/counsel-patients-with-hair-loss-on-results-22 68 2022-05-05T21:32:06.000Z yes https://dermsquared.com/videos/dermbits/customize-treatment-plans-when-prescribing-lebrikizumab 2024-11-06T15:54:45.969Z https://image.mux.com/LW7drpZqMpm9ztKOLwX1l3hYjXJ98GROu7wmz00IBRj00/thumbnail.jpg In what ways can dermatologists customize treatment plans when prescribing lebrikizumab? In what ways can dermatologists customize treatment plans when prescribing lebrikizumab? https://dermsquared.com/videos/dermbits/customize-treatment-plans-when-prescribing-lebrikizumab 37 2024-11-06T15:54:45.962Z yes https://dermsquared.com/videos/dermbits/risk-thrombosis-warning-ruxolitinib-cream 2023-04-28T19:30:07.130Z https://image.mux.com/2BOApMTf2NHrc8sFdpDPAuotUarXBA5BmHNi5T78ydg/thumbnail.jpg How concerned are you about the risk of thrombosis mentioned in the boxed warning for ruxolitinib cream? How concerned are you about the risk of thrombosis mentioned in the boxed warning for ruxolitinib cream? https://dermsquared.com/videos/dermbits/risk-thrombosis-warning-ruxolitinib-cream 45 2021-11-17T20:34:47.000Z yes https://dermsquared.com/videos/dermbits/factors-considered-determining-patient-eligible-ruxolitinib-vitiligo 2024-05-31T13:33:54.714Z https://image.mux.com/jESTfOsE53IR01hJshim9Nh01iaxQ2YTReE5Acf2ejwsA/thumbnail.jpg What factors should be considered when determining if a patient is eligible for ruxolitinib for vitiligo? What factors should be considered when determining if a patient is eligible for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/factors-considered-determining-patient-eligible-ruxolitinib-vitiligo 23 2024-05-31T13:33:54.708Z yes https://dermsquared.com/videos/dermbits/role-of-aryl-hydrocarbon-receptor-psoriasis-and-psoriasis-management 2024-04-08T18:35:33.453Z https://image.mux.com/io02d6H9n4PRQdzM73b2grpYcLHTfqXa00ArRilnJ9ZJo/thumbnail.jpg What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management? What is the role of the Aryl hydrocarbon receptor in psoriasis and psoriasis management? https://dermsquared.com/videos/dermbits/role-of-aryl-hydrocarbon-receptor-psoriasis-and-psoriasis-management 60 2024-04-08T18:35:33.441Z yes https://dermsquared.com/videos/dermbits/perception-formulation-cream-topical-roflumilast-and-why-22 2023-04-28T20:23:51.652Z https://image.mux.com/bFuPzyXwW3L02HYOqn4WAW9PlNg5WZUuGvNsMUcJjLwk/thumbnail.jpg What’s your perception of the formulation/cream of topical roflumilast and why does this matter for patients? What’s your perception of the formulation/cream of topical roflumilast and why does this matter for patients? https://dermsquared.com/videos/dermbits/perception-formulation-cream-topical-roflumilast-and-why-22 29 2022-08-30T23:15:19.000Z yes https://dermsquared.com/videos/dermbits/how-can-dermatologists-differentiate-atopic-dermatitis-from-other-eczematous-conditions 2024-10-01T16:26:25.269Z https://image.mux.com/SDKvjVwoGInKWfMG8DML008kw8Nk2MX4xeQIVM7gTty00/thumbnail.jpg How can dermatologists differentiate atopic dermatitis from other eczematous conditions? How can dermatologists differentiate atopic dermatitis from other eczematous conditions? https://dermsquared.com/videos/dermbits/how-can-dermatologists-differentiate-atopic-dermatitis-from-other-eczematous-conditions 190 2024-10-01T16:26:25.261Z yes https://dermsquared.com/videos/dermbits/how-counsel-patients-atopic-dermatitis-reducing-risk-skin-infection 2025-02-03T19:10:19.700Z https://image.mux.com/VxDbezhdlEOF391byb299KtulWWNogr96MNzQj65SWs/thumbnail.jpg How do you counsel patients with atopic dermatitis on reducing the risk of skin infection? How do you counsel patients with atopic dermatitis on reducing the risk of skin infection? https://dermsquared.com/videos/dermbits/how-counsel-patients-atopic-dermatitis-reducing-risk-skin-infection 34 2025-02-03T19:10:19.693Z yes https://dermsquared.com/videos/dermbits/notable-drug-interactions-ritlecitinib 2024-10-01T14:15:17.720Z https://image.mux.com/nPQh600DbrrY00ntxMy1Yio9CHqCrBWaEDpBO2RJC5nJg/thumbnail.jpg Are there any notable drug interactions seen with ritlecitinib? Are there any notable drug interactions seen with ritlecitinib? https://dermsquared.com/videos/dermbits/notable-drug-interactions-ritlecitinib 36 2024-10-01T14:15:17.713Z yes https://dermsquared.com/videos/dermbits/side-effects-ruxolitinib-21 2023-04-28T18:54:54.397Z https://image.mux.com/o6tD02WdFBNYXnKIyv1idOMCM4h4UxvYbLhg2Sn7wdTc/thumbnail.jpg What are the most common side effects of ruxolitinib cream? What are the most common side effects of ruxolitinib cream? https://dermsquared.com/videos/dermbits/side-effects-ruxolitinib-21 50 2021-10-14T14:40:46.000Z yes https://dermsquared.com/videos/dermbits/which-class-is-best-predictor-metastasis-40-gep-test 2023-08-31T21:14:56.746Z https://image.mux.com/Dd001i02qCcJvJ01vFpClxw4Xadlz3U8dDXGvtK6r3C94U/thumbnail.jpg Which class is the best predictor of metastasis with regard to the 40-GEP test? Which class is the best predictor of metastasis with regard to the 40-GEP test? https://dermsquared.com/videos/dermbits/which-class-is-best-predictor-metastasis-40-gep-test 40 2023-08-31T20:51:33.109Z yes https://dermsquared.com/videos/dermbits/is-there-any-long-term-safety-data-available-for-lebrikizumab 2025-04-01T14:17:11.424Z https://image.mux.com/yKpAsWHVuGGWF7f01M1DtTngEjaTiI81ut3E1mPD00j8o/thumbnail.jpg Is there any long-term safety data available for lebrikizumab? Is there any long-term safety data available for lebrikizumab? https://dermsquared.com/videos/dermbits/is-there-any-long-term-safety-data-available-for-lebrikizumab 36 2025-04-01T14:17:11.417Z yes https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-first-line-agent-disease-severities-artr00035-arcp22 2022-11-29T23:18:17.000Z https://image.mux.com/kZGp8gpPUT81iPSd3NOskTVQHbMq023QjralCdHn015FE/thumbnail.jpg Can topical roflumilast be used as a first-line agent? Are all disease severities appropriate for topical roflumilast? Can topical roflumilast be used as a first-line agent? Are all disease severities appropriate for topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-first-line-agent-disease-severities-artr00035-arcp22 17 2022-11-29T23:18:17.000Z yes https://dermsquared.com/videos/dermbits/tapinarof-work-for-atopic-dermatitis-22 2023-04-28T20:01:52.429Z https://image.mux.com/2nXMN2HV4ZVFiwUGv5lgSQCGfa6F7uFneQTQXeGHnyQ/thumbnail.jpg Will tapinarof work for atopic dermatitis? Will tapinarof work for atopic dermatitis? https://dermsquared.com/videos/dermbits/tapinarof-work-for-atopic-dermatitis-22 44 2022-02-01T01:18:58.000Z yes https://dermsquared.com/videos/dermbits/how-soon-can-patients-alopecia-areata-see-results-ritlecitinib 2024-09-17T19:07:09.783Z https://image.mux.com/02JII02Mf02OL6TVx2tA402jKYcOHVJWA2Ybk86RmofqYyc/thumbnail.jpg How soon can patients with alopecia areata begin to see results on ritlecitinib? How soon can patients with alopecia areata begin to see results on ritlecitinib? https://dermsquared.com/videos/dermbits/how-soon-can-patients-alopecia-areata-see-results-ritlecitinib 35 2024-09-17T19:07:09.777Z yes https://dermsquared.com/videos/dermbits/ajcc-staging-dont-align 2026-03-06T16:28:34.653Z https://image.mux.com/EfMNTRYeA37SwSpQvZE01Rw023g6PWx7dA5uAIRryaqlg/thumbnail.jpg How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align? How do you approach situations where genomic risk classification from DecisionDx Melanoma and AJCC staging don’t align? https://dermsquared.com/videos/dermbits/ajcc-staging-dont-align 210 2026-03-06T16:28:34.647Z yes https://dermsquared.com/videos/dermbits/maintenance-therapy-atopic-dermatitis-recommend-to-patients 2023-10-31T21:18:09.557Z https://image.mux.com/pyw0230202gweVh1ea7qJAc7PBy6p00gAaKDYX302umwyLCM/thumbnail.jpg What maintenance therapy for atopic dermatitis do you recommend to patients? What maintenance therapy for atopic dermatitis do you recommend to patients? https://dermsquared.com/videos/dermbits/maintenance-therapy-atopic-dermatitis-recommend-to-patients 40 2023-10-31T21:18:09.536Z yes https://dermsquared.com/videos/dermbits/monitor-laboratory-testing-topical-jak 2023-04-28T19:17:38.803Z https://image.mux.com/4qrtTLwTRB5hF00IuDjbh5nG00xR9q028KnU5Nmy4qV300Q/thumbnail.jpg Do you need to monitor any laboratory testing with topical JAK inhibitors? Do you need to monitor any laboratory testing with topical JAK inhibitors? https://dermsquared.com/videos/dermbits/monitor-laboratory-testing-topical-jak 69 2021-08-18T14:11:58.000Z yes https://dermsquared.com/videos/dermbits/prevent-muscle-cramps-patients-vismodegib 2023-04-28T20:17:19.567Z https://image.mux.com/HUsrjW3rnAy01t02kGqsoj8TIWhboXmftpu9qz6J01w5TY/thumbnail.jpg What can you do to prevent muscle cramps in patients on vismodegib? What can you do to prevent muscle cramps in patients on vismodegib? https://dermsquared.com/videos/dermbits/prevent-muscle-cramps-patients-vismodegib 51 2022-07-12T19:47:42.000Z yes https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-different-subtypes-of-alopecia-areata 2024-10-01T14:54:47.591Z https://image.mux.com/e3kaYwtKVLE01NQZLCtMy8d6vMCQHDPvqvf47VChkzbM/thumbnail.jpg Can baricitinib be used in different subtypes of alopecia areata? Can baricitinib be used in different subtypes of alopecia areata? https://dermsquared.com/videos/dermbits/can-baricitinib-be-used-in-different-subtypes-of-alopecia-areata 31 2024-10-01T14:54:47.584Z yes https://dermsquared.com/videos/dermbits/what-place-topicals-have-psoriasis-treatment-now-therapeutic-options-expanded 2023-11-01T17:20:59.276Z https://image.mux.com/SPG3EgowXAAAnbTRXy5gYag00YHsUoH00F802nDFRlKi2I/thumbnail.jpg What place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically? What place do topicals have in the psoriasis treatment landscape now that the range of therapeutic options has expanded dramatically? https://dermsquared.com/videos/dermbits/what-place-topicals-have-psoriasis-treatment-now-therapeutic-options-expanded 34 2023-11-01T15:02:52.903Z yes https://dermsquared.com/videos/dermbits/challenges-in-diagnosing-melanoma-skin-of-color 2025-03-03T14:11:55.716Z https://image.mux.com/yZyJ3f51pNp2MU6PwuwBrpstW01A902oKbWx02ZdqxKuGU/thumbnail.jpg What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed? What are the challenges in diagnosing melanoma in patients with skin of color, and how can they be addressed? https://dermsquared.com/videos/dermbits/challenges-in-diagnosing-melanoma-skin-of-color 67 2025-03-03T14:11:55.703Z yes https://dermsquared.com/videos/dermbits/dermbits-combined-dupilumab-other-systemic-anti-inflammatories-partial-responders-dupilumab-ADRC00067-ad0123 2022-12-22T21:33:09.000Z https://image.mux.com/VL6sCvOaW9ir24o4lhjEz3ArwnTppx00vonxoBuka02Lc/thumbnail.jpg Have you combined dupilumab with any other systemic anti-inflammatories for partial responders to dupilumab? Have you combined dupilumab with any other systemic anti-inflammatories for partial responders to dupilumab? https://dermsquared.com/videos/dermbits/dermbits-combined-dupilumab-other-systemic-anti-inflammatories-partial-responders-dupilumab-ADRC00067-ad0123 76 2022-12-22T21:33:09.000Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-vitiligo-be-used-sensitive-skin-areas-dr 2024-05-01T14:04:02.474Z https://image.mux.com/XYpMFbelQQ4ZOdmWkgNT7EUBTQY754w702qv3ZnfD005w/thumbnail.jpg Can ruxolitinib for vitiligo be used on sensitive skin areas (David Rosmarin, MA, MD)? Can ruxolitinib for vitiligo be used on sensitive skin areas (David Rosmarin, MA, MD)? https://dermsquared.com/videos/dermbits/can-ruxolitinib-vitiligo-be-used-sensitive-skin-areas-dr 20 2024-05-01T14:04:02.459Z yes https://dermsquared.com/videos/dermbits/how-newer-biologic-agents-compare-to-traditional-biologics-psoriasis 2024-07-17T16:13:03.952Z https://image.mux.com/DRBBIx8RdmRFk6F8P01iq8Vt011WWEnxpxJ302qblxvHKg/thumbnail.jpg How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment? How do newer biologic agents like IL-17 inhibitors compare to traditional biologics in psoriasis treatment? https://dermsquared.com/videos/dermbits/how-newer-biologic-agents-compare-to-traditional-biologics-psoriasis 69 2024-07-17T16:13:03.941Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-granulomatous-diseases-annulare-cutaneous-sarcoid-22 2023-04-28T19:57:31.355Z https://image.mux.com/1AnyXN48QXLjaA8OT0100R02688GDAUHcjas6hMBM0001dWs/thumbnail.jpg Does ruxolitinib work for other granulomatous diseases like granuloma annulare or cutaneous sarcoid? Does ruxolitinib work for other granulomatous diseases like granuloma annulare or cutaneous sarcoid? https://dermsquared.com/videos/dermbits/ruxolitinib-granulomatous-diseases-annulare-cutaneous-sarcoid-22 32 2022-01-31T21:58:46.000Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-the-incidence-of-metastatic-scc-deaths-compared-to-melanoma-01342 2022-09-22T21:35:02.000Z https://image.mux.com/Y1WeV6Z01aZxvFWI88Z1UqfFGmPI01qHNrDgS9TjiiUFg/thumbnail.jpg What is the incidence of metastatic SCC deaths compared to melanoma? What is the incidence of metastatic SCC deaths compared to melanoma? https://dermsquared.com/videos/dermbits/dermbits-what-is-the-incidence-of-metastatic-scc-deaths-compared-to-melanoma-01342 40 2022-09-22T21:35:02.000Z yes https://dermsquared.com/videos/dermbits/tips-topicals-burning-application 2023-04-28T18:52:12.631Z https://image.mux.com/BwRQB202gWL3K7Hshc52wpZeHFgy5h2HMFKfKHL301wsI/thumbnail.jpg Any tips for when patients won’t use their topicals due to burning with application? Any tips for when patients won’t use their topicals due to burning with application? https://dermsquared.com/videos/dermbits/tips-topicals-burning-application 86 2021-10-14T14:50:51.000Z yes https://dermsquared.com/videos/dermbits/psychological-support-resources-patients-alopecia-areata 2024-12-02T15:43:50.734Z https://image.mux.com/Tgqv01nMNsrN8Sg7mKvkZGhmj7g3JOdQvgpnxM00r3WqY/thumbnail.jpg What psychological support or resources can be provided to patients with alopecia areata? What psychological support or resources can be provided to patients with alopecia areata? https://dermsquared.com/videos/dermbits/psychological-support-resources-patients-alopecia-areata 33 2024-12-02T15:43:50.728Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-effects-lebrikizumab 2024-11-06T15:55:04.268Z https://image.mux.com/Pj8Z3vlGb1kVV9K4p01iengz6n01SKzCjRglwgs51JD2s/thumbnail.jpg What are the most common adverse effects observed with lebrikizumab? What are the most common adverse effects observed with lebrikizumab? https://dermsquared.com/videos/dermbits/most-common-adverse-effects-lebrikizumab 26 2024-11-06T15:55:04.256Z yes https://dermsquared.com/videos/dermbits/their-disease-as-severe 2026-03-03T16:09:41.886Z https://image.mux.com/oUNSE1SeW4OkERaP4h3VSkZ7bXlIVKdFTglDCCofWjU/thumbnail.jpg How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”? How do you introduce the idea of systemic therapy to patients who don’t view their disease as “severe”? https://dermsquared.com/videos/dermbits/their-disease-as-severe 65 2026-03-03T16:09:41.881Z yes https://dermsquared.com/videos/dermbits/of-ruxolitinib-over-time 2026-07-01T13:49:54.463Z https://image.mux.com/5pfDvuQ9aLIyk02frNT6lIB4F01ZFCJhBw2Z5tMQKh6BQ/thumbnail.jpg What documentation supports continued use of ruxolitinib over time? What documentation supports continued use of ruxolitinib over time? https://dermsquared.com/videos/dermbits/of-ruxolitinib-over-time 86 2026-07-01T13:49:54.456Z yes https://dermsquared.com/videos/dermbits/dermbits-can-you-integrate-hormonal-therapy-with-sarecycline-WC220010 2022-05-05T21:29:41.000Z https://image.mux.com/LwwATRF4ayMK8Hr6a9gIfULHT2GIyz14Lzjv501lpDZo/thumbnail.jpg Can you integrate hormonal therapy with sarecycline? Can you integrate hormonal therapy with sarecycline? https://dermsquared.com/videos/dermbits/dermbits-can-you-integrate-hormonal-therapy-with-sarecycline-WC220010 62 2022-05-05T21:29:41.000Z yes https://dermsquared.com/videos/dermbits/home-based-nb-uvb-devices 2025-10-20T17:26:52.765Z https://image.mux.com/lDOi4lf5adfIim3ikA01lHVIbvhl5EtpawJl85rkm1B00/thumbnail.jpg What are the key benefits of home-based NB-UVB devices? What are the key benefits of home-based NB-UVB devices? https://dermsquared.com/videos/dermbits/home-based-nb-uvb-devices 78 2025-10-13T20:13:37.727Z yes https://dermsquared.com/videos/dermbits/issues-delay-treatment 2026-02-02T15:22:18.131Z https://image.mux.com/Ua4V9RIwJnuwGhey6pmwe64rX4JoHahuNhHhYt1Ohxo/thumbnail.jpg How do you talk to patients when access issues delay treatment? How do you talk to patients when access issues delay treatment? https://dermsquared.com/videos/dermbits/issues-delay-treatment 79 2026-02-02T15:22:18.125Z yes https://dermsquared.com/videos/dermbits/stronger-retinoids-post-inflammatory-hyperpigmentation 2023-04-28T19:24:58.947Z https://image.mux.com/N5KqgnNEdBm2Y3epsB402F02By2GXGaJJUMlTtEw9K0044/thumbnail.jpg Are stronger retinoids more effective for Post-Inflammatory Hyperpigmentation compared to weaker retinoids? Are stronger retinoids more effective for Post-Inflammatory Hyperpigmentation compared to weaker retinoids? https://dermsquared.com/videos/dermbits/stronger-retinoids-post-inflammatory-hyperpigmentation 44 2021-11-11T18:27:51.000Z yes https://dermsquared.com/videos/dermbits/why-doesnt-scc-get-the-respect-it-should 2023-07-27T19:21:01.993Z https://image.mux.com/yM4rWWz00lBQ3j0202FTRpxAfR02tbjbhzqqIT99ICZn602E/thumbnail.jpg Why doesn't SCC get the respect it should? Summary In the video "Why doesn't SCC get the respect it should?" Dr. Darrell Rigel discusses the lack of recognition that cutaneous squamous cell carcinoma (SCC) receives in comparison to other types of skin cancer. He likens SCC to the "Rodney Dangerfield" of skin cancer, meaning it doesn't receive the respect it deserves. The reason for this lack of recognition is that SCC falls in the middle between basal cell carcinoma (which has lower risk) and melanoma (which has a much higher risk). However, Dr. Rigel points out that the data shows almost as many people die from cutaneous squamous cell carcinoma in the United States as from melanoma. Although the percentage of SCC-related deaths may be lower due to the higher prevalence of SCC cases, the actual number of deaths is significant. This underscores the importance of better assessing the prognosis of cutaneous squamous cell carcinoma to raise awareness about its severity and address its impact on public health effectively. Key Points SCC (Squamous Cell Carcinoma) is often overlooked and does not receive the respect it deserves. One of the reasons for SCC's lack of attention is because it falls in the middle when comparing it to other skin cancers. Basal cell carcinoma is considered less risky, while melanoma is regarded as a higher-risk skin cancer. However, Dr. Rigel emphasizes the importance of recognizing that SCC is still a significant concern. In the United States, the number of deaths from cutaneous squamous cell carcinoma is almost as high as that of melanoma. The lower percentage of SCC-related deaths compared to melanoma can be attributed to the higher number of SCC cases overall (more contagious squamous cells). Dr. Rigel stresses the need to improve the assessment of prognosis for SCC to better understand and address its impact on public health. https://dermsquared.com/videos/dermbits/why-doesnt-scc-get-the-respect-it-should 42 2023-07-27T19:21:01.988Z yes https://dermsquared.com/videos/dermbits/maximum-dosage-per-week-recommended-for-ruxolitinib-cream 2023-07-28T16:21:10.371Z https://image.mux.com/TFi6Bj5Z7nclNxeQP84R3e34m3ezy8W02nZtEJavDIRU/thumbnail.jpg What is the maximum dosage per week recommended for ruxolitinib cream? Summary In the video, Dr. Raj Chovatiya explains the recommended maximum dosage per week for ruxolitinib cream, considering individual variations in atopic dermatitis severity and body surface area. Generally, the prescribing information suggests twice daily use of the cream, not exceeding one 60-gram tube per week. So, over the course of four weeks (approximately a month), the maximum usage should not exceed four 60-gram tubes. However, the actual amount used may differ based on the individual's body surface area. For example, if someone has less than 10% body surface area affected by atopic dermatitis, one tube might last a long time, while someone with a body surface area in the 10 to 20% range may use the cream more frequently. It's essential for patients to follow their doctor's specific instructions and not exceed the recommended dosage. Key Points Maximum dosage per week recommended for ruxolitinib cream depends on body surface area and the severity of atopic dermatitis. Individual usage may vary based on the person's body surface area. If someone has less than 10% body surface area (BSA), one tube may last longer compared to someone with 10 to 20% BSA. The prescribing information suggests twice daily use and up to one 60-gram tube per week. Over the course of four weeks, the maximum usage should not exceed four 60-gram tubes. https://dermsquared.com/videos/dermbits/maximum-dosage-per-week-recommended-for-ruxolitinib-cream 42 2023-07-27T19:14:54.234Z yes https://dermsquared.com/videos/dermbits/how-i31-slnb-score-impact-decision-refer-patient-sentinel-lymph-node-biopsy 2025-07-01T14:14:36.436Z https://image.mux.com/01kCR01vQ01jO2NPn7TYl2YE02nFGf9Z7YLyRD00ORPcgPy8/thumbnail.jpg How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy? How does the i31-SLNB score impact the decision to refer a patient for sentinel lymph node biopsy? https://dermsquared.com/videos/dermbits/how-i31-slnb-score-impact-decision-refer-patient-sentinel-lymph-node-biopsy 40 2025-07-01T14:14:36.429Z yes https://dermsquared.com/videos/dermbits/standard-histopathologic-evaluation 2025-12-19T16:22:14.861Z https://image.mux.com/f1ZdI5RQJ9qICbrajKfeC8W6CLbyZ79CZWI4aDptsTU/thumbnail.jpg How does the MyPath Melanoma test differ from standard histopathologic evaluation? How does the MyPath Melanoma test differ from standard histopathologic evaluation? https://dermsquared.com/videos/dermbits/standard-histopathologic-evaluation 73 2025-12-19T16:22:14.854Z yes https://dermsquared.com/videos/dermbits/dermbits-who-is-topical-roflumilast-approved-for-arcp22 2022-08-30T23:04:38.000Z https://image.mux.com/JUcMXVKeNJtpD2xHVUTjtnW02027UvIrUBYD3acx1Nj4w/thumbnail.jpg Who is topical roflumilast approved for? Who is topical roflumilast approved for? https://dermsquared.com/videos/dermbits/dermbits-who-is-topical-roflumilast-approved-for-arcp22 16 2022-08-30T23:04:38.000Z yes https://dermsquared.com/videos/dermbits/criteria-assessing-severity-atopic-dermatitis-and-treatment-decisions 2024-12-02T16:27:39.067Z https://image.mux.com/EGGequll31sQkuYTKhQhv026P5f2FSlb01HLyU02Uqfo4c/thumbnail.jpg What are the criteria for assessing the severity of atopic dermatitis, and how does this influence treatment decisions? What are the criteria for assessing the severity of atopic dermatitis, and how does this influence treatment decisions? https://dermsquared.com/videos/dermbits/criteria-assessing-severity-atopic-dermatitis-and-treatment-decisions 76 2024-12-02T16:27:39.050Z yes https://dermsquared.com/videos/dermbits/ritlecitinib-combination-other-jak-inhibitors-biologic-immunomodulators-cyclosporine-immunosuppressants 2024-10-01T14:14:58.957Z https://image.mux.com/DOgx2R6hoWZq4RNr28TLQKMhjnq9AIwuXQNoqWUUZFU/thumbnail.jpg Can ritlecitinib be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants? Can ritlecitinib be used in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants? https://dermsquared.com/videos/dermbits/ritlecitinib-combination-other-jak-inhibitors-biologic-immunomodulators-cyclosporine-immunosuppressants 29 2024-10-01T14:14:58.951Z yes https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-bimekizumab 2023-11-09T16:52:40.846Z https://image.mux.com/XN00bmiRF01DOZspWaG2IjUYhVhBBQ9mvZywSsgKY1WP4/thumbnail.jpg What is the dosing regimen for bimekizumab? What is the dosing regimen for bimekizumab? https://dermsquared.com/videos/dermbits/what-is-the-dosing-regimen-for-bimekizumab 33 2023-11-09T16:52:40.839Z yes https://dermsquared.com/videos/dermbits/clinical-salicylic-acid-with-polymeric-cleansing 2025-10-23T15:43:02.912Z https://image.mux.com/G01LEJ02Yd88hyoxMqajpW1m9200Z9yDjOjHxLYORbRIcQ/thumbnail.jpg What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology? What’s the clinical significance of using 2% salicylic acid in combination with polymeric cleansing technology? https://dermsquared.com/videos/dermbits/clinical-salicylic-acid-with-polymeric-cleansing 52 2025-10-22T21:23:51.488Z yes https://dermsquared.com/videos/dermbits/why-has-phototherapy-declined-in-use-and-are-the-main-barriers-clinical-or-logistical 2025-10-20T17:28:12.580Z https://image.mux.com/KAmLfwpU6CNltnAiWeD7005e8QHxj6n6zjarOmQvjlqE/thumbnail.jpg Why has phototherapy declined in use, and are the main barriers clinical or logistical? Why has phototherapy declined in use, and are the main barriers clinical or logistical? https://dermsquared.com/videos/dermbits/why-has-phototherapy-declined-in-use-and-are-the-main-barriers-clinical-or-logistical 126 2025-10-13T20:15:32.131Z yes https://dermsquared.com/videos/dermbits/significance-roflumilast-indication-inclusive-intertriginous-areas-plaque-psoriasis 2025-07-15T03:07:22.783Z https://image.mux.com/izRPGDy56HJBOd9JsJe6AhfX1x7fLTNhbI9R37EcMhk/thumbnail.jpg Can you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis? Can you explain the significance of roflumilast’s indication being inclusive of intertriginous areas with plaque psoriasis? https://dermsquared.com/videos/dermbits/significance-roflumilast-indication-inclusive-intertriginous-areas-plaque-psoriasis 36 2025-07-15T03:07:22.776Z yes https://dermsquared.com/videos/dermbits/strategies-taper-ixekizumab-patients-sustained-remission 2024-11-01T13:48:49.014Z https://image.mux.com/PVI01uSYhQO4jgk0036qwWaszQYtY02ZZvmp5SoEnTSIDo/thumbnail.jpg What strategies can be used to taper ixekizumab in patients with sustained remission? What strategies can be used to taper ixekizumab in patients with sustained remission? https://dermsquared.com/videos/dermbits/strategies-taper-ixekizumab-patients-sustained-remission 37 2024-11-01T13:48:49.002Z yes https://dermsquared.com/videos/dermbits/safety-efficacy-clobetasol-propionate-cream-025-compare-with-05-cream 2023-11-01T15:05:03.041Z https://image.mux.com/hHviZQjiRQ1Mcw01nclKIjOpaSFMpBlKty34riS3Jxpg/thumbnail.jpg How does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream? How does the safety and efficacy of clobetasol propionate cream 0.025% compare with the 0.05% cream? https://dermsquared.com/videos/dermbits/safety-efficacy-clobetasol-propionate-cream-025-compare-with-05-cream 18 2023-11-01T15:05:03.034Z yes https://dermsquared.com/videos/dermbits/best-strategies-treating-atopic-dermatitis-sensitive-areas 2024-12-02T16:27:32.997Z https://image.mux.com/wy6FOBWci7NqT029VL8cf8JzQ8IzkYA9gqwQumbD5SVk/thumbnail.jpg What are the best strategies for treating atopic dermatitis in sensitive areas, such as the face or eyelids? What are the best strategies for treating atopic dermatitis in sensitive areas, such as the face or eyelids? https://dermsquared.com/videos/dermbits/best-strategies-treating-atopic-dermatitis-sensitive-areas 75 2024-12-02T16:27:32.990Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-be-used-first-line-treatment-vitiligo 2024-07-01T14:43:18.124Z https://image.mux.com/e3Wfmf7dfYkh2ZJDgipul6TFfFb3qhrVmR02Sx92g102s/thumbnail.jpg Can ruxolitinib be used as a first-line treatment for vitiligo? Can ruxolitinib be used as a first-line treatment for vitiligo? https://dermsquared.com/videos/dermbits/can-ruxolitinib-be-used-first-line-treatment-vitiligo 23 2024-07-01T14:43:18.115Z yes https://dermsquared.com/videos/dermbits/shampooing-seborrheic-dermatitis 2023-04-28T19:21:16.389Z https://image.mux.com/zvcA6GpWh1CvM02A2mIHSGhSp1KcZVymBAL02PByUM5008/thumbnail.jpg How often do you recommend shampooing with seborrheic dermatitis? How often do you recommend shampooing with seborrheic dermatitis? https://dermsquared.com/videos/dermbits/shampooing-seborrheic-dermatitis 100 2021-09-23T23:19:10.000Z yes https://dermsquared.com/videos/dermbits/manage-conjunctivitis-on-dupilumab 2023-04-28T19:00:05.637Z https://image.mux.com/7uUa9CclE00yqcGIEoj8WIe7WDtDSGmFP61UCK3c01KP8/thumbnail.jpg How do you manage conjunctivitis that occurs while on dupilumab? How do you manage conjunctivitis that occurs while on dupilumab? https://dermsquared.com/videos/dermbits/manage-conjunctivitis-on-dupilumab 167 2021-04-16T22:03:46.000Z yes https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ixekizumab 2024-07-17T16:13:37.005Z https://image.mux.com/MbWnEvOu7vLOTCgCzCTpUj01M2iRDlwpFkmmYQHx5pik/thumbnail.jpg What are the most common adverse reactions seen with ixekizumab? What are the most common adverse reactions seen with ixekizumab? https://dermsquared.com/videos/dermbits/most-common-adverse-reactions-ixekizumab 31 2024-07-17T16:13:36.999Z yes https://dermsquared.com/videos/dermbits/treatment-success-beyond-traditional-scaling-scoring-tools 2025-10-01T20:33:59.645Z https://image.mux.com/rJUBIY02n4GIeGrl8gWcxnqJAOh014BJXvFHfIqWY01Vyw/thumbnail.jpg How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools? How can dermatologists more effectively measure and monitor treatment success beyond traditional scaling/scoring tools? https://dermsquared.com/videos/dermbits/treatment-success-beyond-traditional-scaling-scoring-tools 136 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/what-is-the-role-of-il-13-in-driving-itch-in-ad 2025-05-01T13:40:15.052Z https://image.mux.com/TIE3oQo00fusfQ3L91nhrHjoqQcjaK1HYQwG0102021tuWY/thumbnail.jpg What is the role of IL-13 in driving itch in AD? What is the role of IL-13 in driving itch in AD? https://dermsquared.com/videos/dermbits/what-is-the-role-of-il-13-in-driving-itch-in-ad 51 2025-05-01T13:40:15.007Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-gep-tests-work-WCM2300011-scc23 2023-05-17T20:07:35.126Z https://image.mux.com/kyyBmDihdIi61t025MOe55nvgLPqMz4KNLf7bcxLpYtA/thumbnail.jpg How do GEP tests work? How do GEP tests work? https://dermsquared.com/videos/dermbits/dermbits-how-do-gep-tests-work-WCM2300011-scc23 37 2023-05-17T20:07:35.121Z yes https://dermsquared.com/videos/dermbits/moa-tapinarof-psoriasis-atopic-dermatitis 2023-04-28T19:39:49.812Z https://image.mux.com/5E02omgV26100N202GdEx0086Hjqo0201TuyZiBoTMIGQLsTA/thumbnail.jpg Is the MOA of tapinarof better suited for psoriasis or atopic dermatitis? Is the MOA of tapinarof better suited for psoriasis or atopic dermatitis? https://dermsquared.com/videos/dermbits/moa-tapinarof-psoriasis-atopic-dermatitis 56 2021-12-27T16:48:30.000Z yes https://dermsquared.com/videos/dermbits/can-ritlecitinib-be-used-in-all-subtypes-alopecia-areata 2024-11-07T16:11:16.760Z https://image.mux.com/bcAwxoD00hbUd89C6Kxk24lcykUNzIAoytwNAuaSpP400/thumbnail.jpg Can ritlecitinib be used in all subtypes of alopecia areata? Can ritlecitinib be used in all subtypes of alopecia areata? https://dermsquared.com/videos/dermbits/can-ritlecitinib-be-used-in-all-subtypes-alopecia-areata 51 2024-11-07T16:11:16.754Z yes https://dermsquared.com/videos/dermbits/the-treatment-pathway 2026-04-02T16:22:54.224Z https://image.mux.com/HVyvKhUQcYGzsZWA9U26AXPT9PkUm8WKsBHCGJJ01T02c/thumbnail.jpg When might ruxolitinib cream be appropriate earlier in the treatment pathway? When might ruxolitinib cream be appropriate earlier in the treatment pathway? https://dermsquared.com/videos/dermbits/the-treatment-pathway 65 2026-04-02T14:33:59.198Z yes https://dermsquared.com/videos/dermbits/contact-dermatitis-atopic-dermatitis-co-exist 2023-04-28T20:16:31.732Z https://image.mux.com/qndW3eBWw5ZKi7Yj1H7FPqucuWP2DB8YjpSoCUtc6O4/thumbnail.jpg Do contact dermatitis and atopic dermatitis commonly co-exist? Do contact dermatitis and atopic dermatitis commonly co-exist? https://dermsquared.com/videos/dermbits/contact-dermatitis-atopic-dermatitis-co-exist 66 2022-06-28T00:52:21.000Z yes https://dermsquared.com/videos/dermbits/what-are-the-most-effective-ways-to-communicate-realistic-treatment-expectations-to-patients-with-ad 2025-10-01T20:40:34.134Z https://image.mux.com/6nVws02hZ00LDmlwikhiAk00cEIlbW8zfCExZ011OluLt014/thumbnail.jpg What are the most effective ways to communicate realistic treatment expectations to patients with AD? What are the most effective ways to communicate realistic treatment expectations to patients with AD? https://dermsquared.com/videos/dermbits/what-are-the-most-effective-ways-to-communicate-realistic-treatment-expectations-to-patients-with-ad 138 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-ruxolitinib-topical-cream 2023-10-31T21:18:51.232Z https://image.mux.com/UfUENm5ol39CrmR02iA02OKDs6yN67wvVmeTewf0202UqBg/thumbnail.jpg What is the mechanism of action for ruxolitinib topical cream? What is the mechanism of action for ruxolitinib topical cream? https://dermsquared.com/videos/dermbits/mechanism-of-action-ruxolitinib-topical-cream 22 2023-10-31T21:18:51.227Z yes https://dermsquared.com/videos/dermbits/level-efficacy-adolescent-patients-vs-overall-population-ritlecitinib 2024-12-17T15:31:35.479Z https://image.mux.com/yKAIBq9JT7Q1Chr01jOWnslW011FRMflSSdR9Ik3ry00sU/thumbnail.jpg What level of efficacy is seen in adolescent patients vs the overall population of patients on ritlecitinib? What level of efficacy is seen in adolescent patients vs the overall population of patients on ritlecitinib? https://dermsquared.com/videos/dermbits/level-efficacy-adolescent-patients-vs-overall-population-ritlecitinib 22 2024-12-02T15:44:32.297Z yes https://dermsquared.com/videos/dermbits/biologics-when-undergo-orthopedic-surgery 2023-04-28T19:05:48.147Z https://image.mux.com/u26kgVVwUk7fyzyKW2zAHjvapIsiS5hgkhpi1uVMtiM/thumbnail.jpg How do you manage patients on biologics when they undergo orthopedic surgery? Do we need to hold the biologic? How do you manage patients on biologics when they undergo orthopedic surgery? Do we need to hold the biologic? https://dermsquared.com/videos/dermbits/biologics-when-undergo-orthopedic-surgery 57 2021-05-28T16:28:00.000Z yes https://dermsquared.com/videos/dermbits/how-does-the-40-gep-test-work 2023-07-27T19:21:16.628Z https://image.mux.com/S9lgd02oabnPpMucWpU25ZqnOJYl01phOVNg7xaD16kL8/thumbnail.jpg How does the 40-GEP test work? Summary In the video, Dr. Darrell Rigel explains how the 40-GEP test functions. The test involves the analysis of 40 specific genes to evaluate their expression levels. These genes are used in combination with a proprietary formula to determine a patient's prognosis. Based on the results, patients are categorized into low-risk, medium-risk, or high-risk groups. This classification helps medical professionals make more accurate assessments and tailor the appropriate treatment plan accordingly. Key Points The 40-GEP test utilizes 40 specific genes. Its primary purpose is to assess prognosis in medical cases. The test evaluates the degree of gene expression in combination with a proprietary formula. The evaluation helps categorize patients into different risk groups: low risk, medium risk, or high risk. The results of the test allow healthcare professionals to tailor treatment plans based on the risk group the patient falls into. By understanding the patient's risk level, the therapy can be adjusted accordingly to optimize treatment outcomes. https://dermsquared.com/videos/dermbits/how-does-the-40-gep-test-work 32 2023-07-27T19:21:16.624Z yes https://dermsquared.com/videos/dermbits/can-lebrikizumab-mild-atopic-dermatitis-or-moderate-to-severe-cases 2025-07-01T13:41:44.803Z https://image.mux.com/Z02AzOslSH8IFVAUHmu001orNnRzI9dxITpeogxuI7FFw/thumbnail.jpg Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases? Can lebrikizumab be considered for patients with mild atopic dermatitis, or is it primarily for moderate-to-severe cases? https://dermsquared.com/videos/dermbits/can-lebrikizumab-mild-atopic-dermatitis-or-moderate-to-severe-cases 124 2025-07-01T13:41:44.794Z yes https://dermsquared.com/videos/dermbits/risk-of-suicidal-ideation-behavior-patients-bimekizumab 2024-01-01T16:05:08.019Z https://image.mux.com/JByYT7QCl00NtG01I5oRcfMygXlPGFbAaXm2h1Mx4A029Q/thumbnail.jpg What is the risk of suicidal ideation or behavior in patients taking bimekizumab? What is the risk of suicidal ideation or behavior in patients taking bimekizumab? https://dermsquared.com/videos/dermbits/risk-of-suicidal-ideation-behavior-patients-bimekizumab 138 2024-01-01T16:05:08.014Z yes https://dermsquared.com/videos/dermbits/what-role-does-skin-microbiome-play-development-management-atopic-dermatitis 2024-10-01T16:26:21.514Z https://image.mux.com/giowIRQOR3Ct7TGRrHq2XBbB7GiDw2J1VnKfwHnw6pk/thumbnail.jpg What role does the skin microbiome play in the development and management of atopic dermatitis? What role does the skin microbiome play in the development and management of atopic dermatitis? https://dermsquared.com/videos/dermbits/what-role-does-skin-microbiome-play-development-management-atopic-dermatitis 116 2024-10-01T16:26:21.506Z yes https://dermsquared.com/videos/dermbits/patient-weight-impact-dosing-efficacy-ixekizumab 2024-11-01T13:48:53.682Z https://image.mux.com/uCaN4ZWnLjl00JYzhgiMwKkW38EV01TFYT4CpUmYdJ01Ow/thumbnail.jpg Does patient weight impact the dosing and efficacy of ixekizumab? Does patient weight impact the dosing and efficacy of ixekizumab? https://dermsquared.com/videos/dermbits/patient-weight-impact-dosing-efficacy-ixekizumab 20 2024-11-01T13:48:53.672Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-ritlecitinib 2024-10-01T14:14:41.468Z https://image.mux.com/B324IPnXSrfZo7sxg9iyG2KiFegxJGjxRyfxhcZccbU/thumbnail.jpg What is the recommended dosing regimen for ritlecitinib? What is the recommended dosing regimen for ritlecitinib? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-for-ritlecitinib 22 2024-10-01T14:14:41.460Z yes https://dermsquared.com/videos/dermbits/systemic-absorption-ruxolitinib-cream-clinicians-information-22 2023-04-28T20:09:29.343Z https://image.mux.com/7700TjAbZSs6NdnkJAeYu5026fCiyQm41tx3T5skt8uoI/thumbnail.jpg How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information? How were the studies completed that looked at the systemic absorption of topical ruxolitinib cream and what can clinicians glean from this information? https://dermsquared.com/videos/dermbits/systemic-absorption-ruxolitinib-cream-clinicians-information-22 86 2022-04-28T00:12:53.000Z yes https://dermsquared.com/videos/dermbits/can-ruxolitinib-be-used-with-phototherapy 2024-05-31T13:33:51.027Z https://image.mux.com/01Y2hoekxXQslLomz8t6O8W2KwXmYMOK016l4qXfO2Xws/thumbnail.jpg Can ruxolitinib be used with phototherapy? Can ruxolitinib be used with phototherapy? https://dermsquared.com/videos/dermbits/can-ruxolitinib-be-used-with-phototherapy 29 2024-05-31T13:33:51.022Z yes https://dermsquared.com/videos/dermbits/which-hypochlorous-acid-spray-do-you-use 2023-04-28T20:02:13.639Z https://image.mux.com/oJJHIJ7dXE70225uTJhoctXPP1TsY4u14zVGLnaKKp2s/thumbnail.jpg Which hypochlorous acid spray do you use? Which hypochlorous acid spray do you use? https://dermsquared.com/videos/dermbits/which-hypochlorous-acid-spray-do-you-use 64 2022-02-02T22:10:23.000Z yes https://dermsquared.com/videos/dermbits/differ-from-topical-treatments 2026-04-13T19:09:36.111Z https://image.mux.com/Fw601rncn4KKjEKYDTWdjQJeyZuh01sqab4nxQcYTI30000/thumbnail.jpg What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments? What do you emphasize early on so patients understand how improvement with apremilast may differ from topical treatments? https://dermsquared.com/videos/dermbits/differ-from-topical-treatments 155 2026-04-13T19:09:36.101Z yes https://dermsquared.com/videos/dermbits/dermbits-what-is-topical-roflumilast-arcp22 2022-08-30T23:02:28.000Z https://image.mux.com/02vJ7GMcdG3vd9Kk7g9ornn2C2T9uyUjiEDFN2TfD01i8/thumbnail.jpg What is topical roflumilast? What is topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-what-is-topical-roflumilast-arcp22 61 2022-08-30T23:02:28.000Z yes https://dermsquared.com/videos/dermbits/for-a-melanocytic-lesion 2025-12-19T16:23:08.279Z https://image.mux.com/MAFvb00EfGXlevLGLgkzEVXG1Uyonb6GlaRnff2uRnoE/thumbnail.jpg In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion? In what clinical scenarios might a dermatologist consider ordering MyPath Melanoma for a melanocytic lesion? https://dermsquared.com/videos/dermbits/for-a-melanocytic-lesion 83 2025-12-19T16:23:08.273Z yes https://dermsquared.com/videos/dermbits/failure-or-intolerance-clearly 2026-02-02T15:22:04.149Z https://image.mux.com/mAjmlaClDNMKWj0000xbtKIQBJAGsT02gqybhLrm01Fpl800/thumbnail.jpg What’s key to documenting steroid failure or intolerance clearly? What’s key to documenting steroid failure or intolerance clearly? https://dermsquared.com/videos/dermbits/failure-or-intolerance-clearly 71 2026-02-02T15:22:04.143Z yes https://dermsquared.com/videos/dermbits/do-issues-accessibility-affect-approach-when-considering-treatment-options-plaque-psoriasis 2023-11-01T17:21:24.651Z https://image.mux.com/gTll7vSGtAH00q1UsrdyLP2bcDp3oJuhlBwo01lK2WkHY/thumbnail.jpg Do issues of accessibility affect your approach when considering treatment options for plaque psoriasis? Do issues of accessibility affect your approach when considering treatment options for plaque psoriasis? https://dermsquared.com/videos/dermbits/do-issues-accessibility-affect-approach-when-considering-treatment-options-plaque-psoriasis 17 2023-11-01T15:03:08.544Z yes https://dermsquared.com/videos/dermbits/before-ruxolitinib-cream 2026-05-04T20:18:54.236Z https://image.mux.com/G2m79nPcldepd5k5fh3CcwcF1o9QBwzYUV9lsaJVCWA/thumbnail.jpg When is step therapy inappropriate before ruxolitinib cream? When is step therapy inappropriate before ruxolitinib cream? https://dermsquared.com/videos/dermbits/before-ruxolitinib-cream 71 2026-05-04T20:18:54.229Z yes https://dermsquared.com/videos/dermbits/what-are-the-long-term-impacts-of-early-onset-ad-on-child-development-and-overall-health 2025-10-01T20:37:23.336Z https://image.mux.com/01dAZbaGYT6ZubMSxo602MFP015Xf62BfVNSq4GlSWgHC8/thumbnail.jpg What are the long-term impacts of early-onset AD on child development and overall health? What are the long-term impacts of early-onset AD on child development and overall health? https://dermsquared.com/videos/dermbits/what-are-the-long-term-impacts-of-early-onset-ad-on-child-development-and-overall-health 98 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/potential-in-clinical-practice 2026-05-26T14:44:32.885Z https://image.mux.com/Z010001m2pI6nvLp5UWopEiq7oEHlO2laHq271fFCWE6ns/thumbnail.jpg Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice? Do you feel newer nonsteroidal topicals are being used to their full potential in clinical practice? https://dermsquared.com/videos/dermbits/potential-in-clinical-practice 74 2026-05-26T14:44:32.878Z yes https://dermsquared.com/videos/dermbits/can-lebrikizumab-used-topical-corticosteroids-or-topical-calcineurin-inhibitors 2024-10-01T16:26:29.734Z https://image.mux.com/HZRm00ztb0246apCpqAqtQeclOwW5Jvor9nFdz25Rk6vw/thumbnail.jpg Can lebrikizumab be used with topical corticosteroids or topical calcineurin inhibitors? Can lebrikizumab be used with topical corticosteroids or topical calcineurin inhibitors? https://dermsquared.com/videos/dermbits/can-lebrikizumab-used-topical-corticosteroids-or-topical-calcineurin-inhibitors 45 2024-10-01T16:26:29.728Z yes https://dermsquared.com/videos/dermbits/challenges-atypical-melanocytic-lesions-ambiguous-histology 2025-07-15T03:03:24.469Z https://image.mux.com/bJX01zPewXVF2t8YgguXQD7LEaj9hf2OFqNMN9K5FvrU/thumbnail.jpg What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? https://dermsquared.com/videos/dermbits/challenges-atypical-melanocytic-lesions-ambiguous-histology 103 2025-07-15T03:03:24.458Z yes https://dermsquared.com/videos/dermbits/tapinarof-rivaling-topical-steroids-psoriasis 2023-04-28T19:41:29.313Z https://image.mux.com/eGf00O5q8O1Uxv4mcdnx21UllEcWafkkAOJKDdzLrbos/thumbnail.jpg Do you see tapinarof cream rivaling topical steroids for topical monotherapy in psoriasis and/or atopic dermatitis? Do you see tapinarof cream rivaling topical steroids for topical monotherapy in psoriasis and/or atopic dermatitis? https://dermsquared.com/videos/dermbits/tapinarof-rivaling-topical-steroids-psoriasis 63 2021-12-27T17:10:49.000Z yes https://dermsquared.com/videos/dermbits/who-is-eligible-bimekizumab-notable-exclusion-criteria 2023-11-07T15:47:17.719Z https://image.mux.com/POdtqZ02X02KcFrZt16Jpea2QJNF9U5SvF004XVhSZJhLs/thumbnail.jpg Who is eligible for treatment with bimekizumab? Are there any notable exclusion criteria? Who is eligible for treatment with bimekizumab? Are there any notable exclusion criteria? https://dermsquared.com/videos/dermbits/who-is-eligible-bimekizumab-notable-exclusion-criteria 80 2023-11-07T15:44:07.574Z yes https://dermsquared.com/videos/dermbits/dermbits-did-the-ad-pivotal-trials-enroll-adequate-numbers-of-diverse-patients-ADRC00075-adrc23 2023-01-30T22:49:29.000Z https://image.mux.com/Tz48FYFaR00VQ1ZITDYQ8fe4IQCn02yMU7fwGDiarqZDo/thumbnail.jpg Did the AD pivotal trials enroll adequate numbers of diverse patients? Did the AD pivotal trials enroll adequate numbers of diverse patients? https://dermsquared.com/videos/dermbits/dermbits-did-the-ad-pivotal-trials-enroll-adequate-numbers-of-diverse-patients-ADRC00075-adrc23 29 2023-01-30T22:49:29.000Z yes https://dermsquared.com/videos/dermbits/fit-into-that-strategy 2025-10-20T22:26:35.906Z https://image.mux.com/NUQGtrAvYy3Ejeygt62SUqSi5plGBnSlPKuFzBGB8uI/thumbnail.jpg How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy? How do you approach field therapy in actinic keratosis, and where does tirbanibulin fit into that strategy? https://dermsquared.com/videos/dermbits/fit-into-that-strategy 126 2025-10-17T21:17:03.607Z yes https://dermsquared.com/videos/dermbits/dermbits-how-does-topical-ruxolitinib-address-pruritus-so-quickly-ADRC00073-adrc23 2023-01-30T22:43:56.000Z https://image.mux.com/802fYdqKZHnWizp01l5w00a01HoeQYGmRh1p1TgCYbu01VBc/thumbnail.jpg How does topical ruxolitinib address pruritus so quickly? How does topical ruxolitinib address pruritus so quickly? https://dermsquared.com/videos/dermbits/dermbits-how-does-topical-ruxolitinib-address-pruritus-so-quickly-ADRC00073-adrc23 22 2023-01-30T22:43:56.000Z yes https://dermsquared.com/videos/dermbits/srt-vs-electronic-brachytherapy 2023-04-28T20:05:28.316Z https://image.mux.com/mOOMLtqJicu3OGg2cTRWgPL3iIk66Q7bd8OpXJq5SPU/thumbnail.jpg SRT vs electronic brachytherapy? SRT vs electronic brachytherapy? https://dermsquared.com/videos/dermbits/srt-vs-electronic-brachytherapy 88 2022-03-09T17:48:29.000Z yes https://dermsquared.com/videos/dermbits/wsafety-profile-of-tapinarof-atopic-dermatitis 2025-02-03T19:11:10.383Z https://image.mux.com/FJT4P02Nvz3gyzcmzCwcS4rkmPMTu7kOc8Y9FXo1FfdY/thumbnail.jpg What is the safety profile of tapinarof for atopic dermatitis? What is the safety profile of tapinarof for atopic dermatitis? https://dermsquared.com/videos/dermbits/wsafety-profile-of-tapinarof-atopic-dermatitis 22 2025-02-03T19:11:10.377Z yes https://dermsquared.com/videos/dermbits/how-emergence-nonsteroidal-topical-options-impacted-your-practice 2023-08-31T20:40:29.177Z https://image.mux.com/gMjtKZ2UmNfwyLs54R01n9EmiPKvwm9Zn80001KkOOgwPA/thumbnail.jpg How have the emergence of nonsteroidal topical options in recent years impacted your practice? How have the emergence of nonsteroidal topical options in recent years impacted your practice? https://dermsquared.com/videos/dermbits/how-emergence-nonsteroidal-topical-options-impacted-your-practice 54 2023-08-31T20:40:29.172Z yes https://dermsquared.com/videos/dermbits/inclusion-of-younger-ages-adolescent-pediatric-indication-for-plaque-psoriasis-treatments 2023-06-29T16:12:03.478Z https://image.mux.com/u01sHhvRz900o1Cel3C6L6C100wT00ttpc003fYsAHzp1EwI/thumbnail.jpg How important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments? How important is inclusion of younger ages - adolescent or pediatric – when it comes to indication for plaque psoriasis treatments? https://dermsquared.com/videos/dermbits/inclusion-of-younger-ages-adolescent-pediatric-indication-for-plaque-psoriasis-treatments 135 2023-06-29T16:12:03.473Z yes https://dermsquared.com/videos/dermbits/slnb-in-clinical-practice 2026-06-11T15:06:47.693Z https://image.mux.com/ktI9D01THF8mrMY3791VOxChQRUFgZsZIwRjtkdJFLWk/thumbnail.jpg Where This Matters Most: Applying i31-SLNB in Clinical Practice Where This Matters Most: Applying i31-SLNB in Clinical Practice https://dermsquared.com/videos/dermbits/slnb-in-clinical-practice 84 2025-07-01T14:14:40.265Z yes https://dermsquared.com/videos/dermbits/patients-fit-profile-combination-therapy-biologics-topical-treatment-plaque-psoriasis 2023-05-31T19:56:56.793Z https://image.mux.com/rqgLRjEpeSHtgM7URynACGUFqtE02tPPAxaVrI9EY5s4/thumbnail.jpg Which patients fit the profile for combination therapy of Biologics and topical treatment in Plaque Psoriasis? Which patients fit the profile for combination therapy of Biologics and topical treatment in Plaque Psoriasis? https://dermsquared.com/videos/dermbits/patients-fit-profile-combination-therapy-biologics-topical-treatment-plaque-psoriasis 48 2023-05-31T19:56:56.787Z yes https://dermsquared.com/videos/dermbits/what-are-the-most-common-causes-of-drug-induced-vitiligo 2025-06-03T13:45:30.938Z https://image.mux.com/AZMWbTC3GkdJDfYM2hhFNMlsZN2GsZTbusi2EoJReMs/thumbnail.jpg What are the most common causes of drug-induced vitiligo? What are the most common causes of drug-induced vitiligo? https://dermsquared.com/videos/dermbits/what-are-the-most-common-causes-of-drug-induced-vitiligo 59 2025-06-03T13:45:30.931Z yes https://dermsquared.com/videos/dermbits/are-results-maintained-after-lowering-dosage-or-stoppage-baricitinib 2023-09-29T16:20:46.574Z https://image.mux.com/uVzo2BFKH1N02V02MmrhGHbMBFTmfIJLhhcfQR1Wmf009Q/thumbnail.jpg Are results maintained after lowering the dosage or stoppage of baricitinib? Are results maintained after lowering the dosage or stoppage of baricitinib? https://dermsquared.com/videos/dermbits/are-results-maintained-after-lowering-dosage-or-stoppage-baricitinib 131 2023-09-29T16:20:46.569Z yes https://dermsquared.com/videos/dermbits/resources-for-new-to-cosmetic-procedures 2023-04-28T19:01:34.756Z https://image.mux.com/te2B4R42xkVVStkMDO1kB4YtLd33QJ8joWB8zSOQF00I/thumbnail.jpg What resources exist for those new to cosmetic procedures? What resources exist for those new to cosmetic procedures? https://dermsquared.com/videos/dermbits/resources-for-new-to-cosmetic-procedures 79 2021-04-29T22:42:06.000Z yes https://dermsquared.com/videos/dermbits/what-considerations-made-elderly-patients-starting-ixekizumab 2024-09-24T18:20:07.036Z https://image.mux.com/5Zqt9kb501zyZmTUxTAUDFXFNP9X02C7CazbJzoLo5erk/thumbnail.jpg What considerations should be made for elderly patients starting ixekizumab? What considerations should be made for elderly patients starting ixekizumab? https://dermsquared.com/videos/dermbits/what-considerations-made-elderly-patients-starting-ixekizumab 223 2024-09-24T18:20:07.030Z yes https://dermsquared.com/videos/dermbits/dermatologic-syndromes-present-with-vitiligo 2025-05-01T13:44:35.201Z https://image.mux.com/o6jLrb7AqwH00Lf1ACIIZVWQmBRVrn7w6j3Q4hLR9pHo/thumbnail.jpg What are some dermatologic syndromes that present with vitiligo? What are some dermatologic syndromes that present with vitiligo? https://dermsquared.com/videos/dermbits/dermatologic-syndromes-present-with-vitiligo 60 2025-05-01T13:44:35.192Z yes https://dermsquared.com/videos/dermbits/what-is-the-my-path-melanoma-test-and-how-does-it-work 2025-07-15T03:03:56.662Z https://image.mux.com/m9m00Ertvmy00f6wEaeiwvPen5QhIlkpz5HWdLaLXu6ek/thumbnail.jpg What is the MyPath Melanoma test, and how does it work? What is the MyPath Melanoma test, and how does it work? https://dermsquared.com/videos/dermbits/what-is-the-my-path-melanoma-test-and-how-does-it-work 52 2025-07-15T03:03:56.607Z yes https://dermsquared.com/videos/dermbits/dermbits-see-persistent-facial-dermatitis-ad-patients-responded-to-dupilumab-ADRC00065-ad0123 2022-12-22T21:38:53.000Z https://image.mux.com/kb1QgByxz0200GAbYROarECzU01G6xsl02XqyFoci5SJs2o/thumbnail.jpg Do you see persistent facial dermatitis in AD patients who have responded to dupilumab? Do you see persistent facial dermatitis in AD patients who have responded to dupilumab? https://dermsquared.com/videos/dermbits/dermbits-see-persistent-facial-dermatitis-ad-patients-responded-to-dupilumab-ADRC00065-ad0123 96 2022-12-22T21:38:53.000Z yes https://dermsquared.com/videos/dermbits/how-ixekizumab-influence-risk-infections-psoriasis 2024-10-18T17:18:26.102Z https://image.mux.com/hYouuDWx9yIu8YbrEEx9oDynljZHP1cUEZT9Cdf02E5Q/thumbnail.jpg How does ixekizumab influence the risk of infections in patients with psoriasis? How does ixekizumab influence the risk of infections in patients with psoriasis? https://dermsquared.com/videos/dermbits/how-ixekizumab-influence-risk-infections-psoriasis 100 2024-10-18T17:18:26.095Z yes https://dermsquared.com/videos/dermbits/should-baricitinib-dosage-be-reduced-when-adequate-response-is-achieved 2023-09-29T16:20:41.697Z https://image.mux.com/Gt005El1KQxOzC9f00QFE3W4YbMDOKm3LMBqgYW3VElFE/thumbnail.jpg Should baricitinib dosage be reduced when adequate response is achieved? Should baricitinib dosage be reduced when adequate response is achieved? https://dermsquared.com/videos/dermbits/should-baricitinib-dosage-be-reduced-when-adequate-response-is-achieved 117 2023-09-29T16:20:41.691Z yes https://dermsquared.com/videos/dermbits/antioxidants-in-photoprotection 2025-11-14T15:26:56.229Z https://image.mux.com/6Yp00Nft02K1jz02I7wceisFzpXe6gFO2eqpCe4kHPE5kE/thumbnail.jpg What is your take on the role of antioxidants in photoprotection? What is your take on the role of antioxidants in photoprotection? https://dermsquared.com/videos/dermbits/antioxidants-in-photoprotection 46 2025-11-14T15:26:56.221Z yes https://dermsquared.com/videos/dermbits/dermbits-advantages-topical-roflumilast-other-topical-treatments-psoriasis-artr00036-arcp22 2022-11-29T23:29:27.000Z https://image.mux.com/wWWf8QKFMTshWbq28YEX2RVU324VF8TXrl7unaoMUuM/thumbnail.jpg What advantages does topical roflumilast have over other topical treatments for psoriasis? What advantages does topical roflumilast have over other topical treatments for psoriasis? https://dermsquared.com/videos/dermbits/dermbits-advantages-topical-roflumilast-other-topical-treatments-psoriasis-artr00036-arcp22 33 2022-11-29T23:29:27.000Z yes https://dermsquared.com/videos/dermbits/how-40-gep-test-influence-decision-to-use-radiologic-imaging-metastasis 2023-11-17T16:51:01.315Z https://image.mux.com/dq1n02Ky6DhxtIrLfi3mHwQ2eroD78yTLDIXr02PiRCz00/thumbnail.jpg How does the 40-GEP test influence your decision to use radiologic imaging to check regional lymph nodes and distant organs for metastasis? How does the 40-GEP test influence your decision to use radiologic imaging to check regional lymph nodes and distant organs for metastasis? https://dermsquared.com/videos/dermbits/how-40-gep-test-influence-decision-to-use-radiologic-imaging-metastasis 60 2023-11-17T16:37:35.384Z yes https://dermsquared.com/videos/dermbits/are-there-any-benefits-to-using-ruxolitinib-in-combination-with-narrowband-uvb-for-vitiligo 2025-04-02T16:22:26.344Z https://image.mux.com/kRTSXta02ZZbjKIKWezWUplm01uZ1EpTtcmqv2i6ea2hE/thumbnail.jpg Are there any benefits to using ruxolitinib in combination with narrowband UVB for vitiligo? Are there any benefits to using ruxolitinib in combination with narrowband UVB for vitiligo? https://dermsquared.com/videos/dermbits/are-there-any-benefits-to-using-ruxolitinib-in-combination-with-narrowband-uvb-for-vitiligo 37 2025-04-02T16:22:26.338Z yes https://dermsquared.com/videos/dermbits/is-there-any-long-term-safety-data-available-for-baricitinib 2023-07-27T19:23:32.527Z https://image.mux.com/xzsvo9CVMCmHPovUCUQ8SG6fsSb02rJ3NL7rn2HmIJnc/thumbnail.jpg Is there any long-term safety data available for baricitinib? Summary Dr. Michael Cameron discusses the long-term safety data available for baricitinib, a drug used in the treatment of rheumatoid arthritis and alopecia areata. The drug has been in use for many years for rheumatoid arthritis, and now several years of data are available for its use in alopecia areata. Comparing the safety data with that of another drug, tofacitinib, used in rheumatoid arthritis, there are no significant safety signals seen for baricitinib. The safety signals observed with tofacitinib in a study for rheumatoid arthritis included issues like malignancy, clustering of organ systems for malignancy (lymphoma or lung cancers), cardiac events, blood clots, and an increased risk of serious infections, including shingles. However, in the case of baricitinib used for alopecia areata, there are no such signals. The safety profile for baricitinib in alopecia areata is described as "really, really clean" by Dr. Cameron. Overall, the data indicates that baricitinib appears to be safe for long-term use in treating alopecia areata, with no significant safety concerns observed in the studied period. Key Points Baricitinib has been used for many years in rheumatoid arthritis. There is now data available for baricitinib use in alopecia areata. The safety signals observed with tofacitinib use in rheumatoid arthritis are not seen with baricitinib in alopecia areata. No signal for malignancy or clustering of organ systems for malignancy (e.g., lymphoma or lung cancers) is observed. There are no significant cardiac events or blood clot risks associated with baricitinib use. There is no increased risk for serious infections, including shingles, with baricitinib use. The rate of adverse events with baricitinib is almost numerically equivalent to placebo, with only a slight increase observed. Baricitinib shows a very clean safety profile in alopecia areata. https://dermsquared.com/videos/dermbits/is-there-any-long-term-safety-data-available-for-baricitinib 49 2023-07-27T19:23:32.522Z yes https://dermsquared.com/videos/dermbits/when-consider-patch-testing-che 2025-08-08T19:57:49.493Z https://image.mux.com/pZmskUtw3YodPZ3lieDwEJAPJqFrxlnGdZg7D54Ml1c/thumbnail.jpg When should dermatologists consider patch testing in patients with chronic hand eczema? When should dermatologists consider patch testing in patients with chronic hand eczema? https://dermsquared.com/videos/dermbits/when-consider-patch-testing-che 101 2025-08-08T19:57:49.487Z yes https://dermsquared.com/videos/dermbits/how-address-emotional-impact-alopecia-areata-particularly-younger 2024-11-07T16:10:50.892Z https://image.mux.com/JHrmq1CAhHuolo00ZxR028Qdl900g02WYelxzvL3U02iEGto/thumbnail.jpg How do you address the emotional impact of alopecia areata on patients, particularly younger individuals? How do you address the emotional impact of alopecia areata on patients, particularly younger individuals? https://dermsquared.com/videos/dermbits/how-address-emotional-impact-alopecia-areata-particularly-younger 90 2024-11-07T16:10:50.879Z yes https://dermsquared.com/videos/dermbits/enstilar-duobrii-localized-persistent-biologics 2023-04-28T19:43:44.082Z https://image.mux.com/vqIuy2aYLcrhGf1NlJEE00VIH4sFHuL6Q9PDPDbEWmmM/thumbnail.jpg Do you often add Enstilar or Duobrii to localized persistent areas while on biologics? Do you often add Enstilar or Duobrii to localized persistent areas while on biologics? https://dermsquared.com/videos/dermbits/enstilar-duobrii-localized-persistent-biologics 47 2021-12-27T17:17:53.000Z yes https://dermsquared.com/videos/dermbits/genomic-test-results 2026-03-06T16:26:33.042Z https://image.mux.com/m5eRYjGTH7am83fSPNYkJnwCIS2tub577013TiF54bfM/thumbnail.jpg Where do you think clinicians are most likely to misinterpret or overextend genomic test results? Where do you think clinicians are most likely to misinterpret or overextend genomic test results? https://dermsquared.com/videos/dermbits/genomic-test-results 81 2026-03-06T16:26:33.036Z yes https://dermsquared.com/videos/dermbits/is-ixekizumab-safe-for-use-in-pediatric-populations 2024-07-17T16:13:25.943Z https://image.mux.com/Ag6dKkKaPN302um9YS6l2uuW7KXkr7x4FAabi01NXLohc/thumbnail.jpg Is ixekizumab safe for use in pediatric populations? Is ixekizumab safe for use in pediatric populations? https://dermsquared.com/videos/dermbits/is-ixekizumab-safe-for-use-in-pediatric-populations 51 2024-07-17T16:13:25.936Z yes https://dermsquared.com/videos/dermbits/role-of-nutrition-in-dermatology-22 2023-04-28T20:14:18.152Z https://image.mux.com/daVQmWZRtjiGDl016RbB5uat3t1wgqCGMppmxhfWB4hk/thumbnail.jpg What is the role of nutrition in dermatology? What is the role of nutrition in dermatology? https://dermsquared.com/videos/dermbits/role-of-nutrition-in-dermatology-22 49 2022-06-03T02:55:55.000Z yes https://dermsquared.com/videos/dermbits/clinically-meaningful-in-ad 2026-05-26T14:42:39.624Z https://image.mux.com/ef5W8CsgyOp2cX8801Idsv00pxSl2N100NRr36WWmLNJ3k/thumbnail.jpg What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD? What aspects of tapinarof’s AhR-driven mechanism are most clinically meaningful in AD? https://dermsquared.com/videos/dermbits/clinically-meaningful-in-ad 76 2026-05-26T14:42:39.615Z yes https://dermsquared.com/videos/dermbits/what-insights-did-the-a-dhere-study-provide-about-combining-lebrikizumab-with-topical-corticosteroids 2025-10-01T22:35:23.704Z https://image.mux.com/iuPOA1VDy6R1Hw4X78wV1xsfVk02XKOrAIWlgXAmwfIs/thumbnail.jpg What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids? What insights did the ADhere study provide about combining lebrikizumab with topical corticosteroids? https://dermsquared.com/videos/dermbits/what-insights-did-the-a-dhere-study-provide-about-combining-lebrikizumab-with-topical-corticosteroids 131 2025-10-01T22:55:07.751Z yes https://dermsquared.com/videos/dermbits/dermbits-what-are-some-common-triggers-for-worsening-of-atopic-dermatitis-ADRC00061-ad0123 2022-12-22T21:49:28.000Z https://image.mux.com/5zQTFqS6gMsW02uGkcj9y4uaQQycDe1lg8jwEJOoHJyU/thumbnail.jpg What are some common triggers for worsening of atopic dermatitis? What are some common triggers for worsening of atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-what-are-some-common-triggers-for-worsening-of-atopic-dermatitis-ADRC00061-ad0123 91 2022-12-22T21:49:28.000Z yes https://dermsquared.com/videos/dermbits/roflumilast-vs-tapinarof-which-is-more-efficacious 2023-07-27T19:58:22.859Z https://image.mux.com/202ptFBFRJan9Jksy2Ln00xgtCu3JcOSQUb8aMqx5OFns/thumbnail.jpg Roflumilast vs tapinarof - which is more efficacious? Roflumilast vs tapinarof - which is more efficacious? https://dermsquared.com/videos/dermbits/roflumilast-vs-tapinarof-which-is-more-efficacious 67 2023-07-27T19:58:22.854Z yes https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-for-spesolimab 2023-06-30T16:52:13.804Z https://image.mux.com/0168V6Fg5KKozwvc8F7Y01tGgcxSEUk027NLTjRHymKHCg/thumbnail.jpg What is the safety profile for spesolimab? What is the safety profile for spesolimab? https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-for-spesolimab 51 2023-06-27T17:27:06.809Z yes https://dermsquared.com/videos/dermbits/dermbits-discuss-safety-concerns-warnings-with-patients-prescribed-ruxolitinib-cream-adrc22 2023-07-17T20:44:44.526Z https://image.mux.com/34t7q45xMGlk94k3C9VDHeLU401RtOorsiujftvL7xiY/thumbnail.jpg How do you discuss any safety concerns or warnings with patients prescribed ruxolitinib cream? How do you discuss any safety concerns or warnings with patients prescribed ruxolitinib cream? https://dermsquared.com/videos/dermbits/dermbits-discuss-safety-concerns-warnings-with-patients-prescribed-ruxolitinib-cream-adrc22 38 2022-10-28T22:04:20.000Z yes https://dermsquared.com/videos/dermbits/ritlecitinib--monotherapy-or-combined-other-therapies-optimal-results 2024-11-07T16:11:08.294Z https://image.mux.com/Qzxzqx2011qdiVtw01WBt1vSq02mwGsuxWsxwXEENG1rdI/thumbnail.jpg Can ritlecitinib be used as monotherapy, or can it be combined with other therapies for optimal results? Can ritlecitinib be used as monotherapy, or can it be combined with other therapies for optimal results? https://dermsquared.com/videos/dermbits/ritlecitinib--monotherapy-or-combined-other-therapies-optimal-results 58 2024-11-07T16:11:08.279Z yes https://dermsquared.com/videos/dermbits/how-lebrikizumab-impact-quality-life-atopic-dermatitis 2024-12-02T16:27:57.903Z https://image.mux.com/pjMyP5lO00STaSzEFcVu1cgPDS7VCU00IGe00upT4atpTU/thumbnail.jpg How does lebrikizumab impact the quality of life in patients with moderate to severe atopic dermatitis? How does lebrikizumab impact the quality of life in patients with moderate to severe atopic dermatitis? https://dermsquared.com/videos/dermbits/how-lebrikizumab-impact-quality-life-atopic-dermatitis 49 2024-12-02T16:27:57.896Z yes https://dermsquared.com/videos/dermbits/clinical-factors-guide-selecting-lebrikizumab-over-dupilumab-or-tralokinumab 2025-07-01T13:41:15.257Z https://image.mux.com/cCBzb8FggBDN6LqMkIh2pCfMKMYoPD02fSk6002WbRwNU/thumbnail.jpg What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab? What clinical factors should guide dermatologists in selecting lebrikizumab over dupilumab or tralokinumab? https://dermsquared.com/videos/dermbits/clinical-factors-guide-selecting-lebrikizumab-over-dupilumab-or-tralokinumab 121 2025-07-01T13:41:15.251Z yes https://dermsquared.com/videos/dermbits/early-signs-symptoms-associated-alopecia-areata 2024-09-17T19:02:34.641Z https://image.mux.com/VosXMc2xLXa4K87OGKuUICN01JqUjj3q1kDRL2jXw2700/thumbnail.jpg What are some early signs and symptoms associated with alopecia areata? What are some early signs and symptoms associated with alopecia areata? https://dermsquared.com/videos/dermbits/early-signs-symptoms-associated-alopecia-areata 56 2024-09-17T19:02:34.635Z yes https://dermsquared.com/videos/dermbits/mechanism-of-action-bimekizumab-how-differ-from-other-systemic-psoriasis-treatments 2023-11-07T15:45:16.610Z https://image.mux.com/DDphqinYhLgVBbnpK8fJ1wMJJEAwX57kd9eW8CEcFxI/thumbnail.jpg What is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments? What is the mechanism of action of bimekizumab and how does it differ from other systemic psoriasis treatments? https://dermsquared.com/videos/dermbits/mechanism-of-action-bimekizumab-how-differ-from-other-systemic-psoriasis-treatments 79 2023-11-07T15:44:19.534Z yes https://dermsquared.com/videos/dermbits/tolerability-tapinarof-cream-for-trials 2023-04-28T19:40:35.715Z https://image.mux.com/XdAbviwkq7GUBxbsm01JplrTThnC55Zgq023WjJ02W3XoE/thumbnail.jpg Was the tolerability of tapinarof cream better for the trials? Was the tolerability of tapinarof cream better for the trials? https://dermsquared.com/videos/dermbits/tolerability-tapinarof-cream-for-trials 55 2021-12-27T17:07:50.000Z yes https://dermsquared.com/videos/dermbits/step-therapy-plans 2026-03-02T17:54:14.468Z https://image.mux.com/ZFysXSbXe00I02w1HiGdcHJLqq74LU01X8Atzt41v00MOcY/thumbnail.jpg What helps secure coverage for ruxolitinib in step therapy plans? What helps secure coverage for ruxolitinib in step therapy plans? https://dermsquared.com/videos/dermbits/step-therapy-plans 93 2026-03-02T17:54:14.457Z yes https://dermsquared.com/videos/dermbits/how-does-lebrikizumab-fit-into-proactive-vs-reactive-ad-treatment-approaches 2025-04-01T14:17:46.615Z https://image.mux.com/UpgxJBqKAD005rP98kVsI8HO4pFH6X101AAcQf3wqRYhA/thumbnail.jpg How does lebrikizumab fit into proactive vs reactive AD treatment approaches? How does lebrikizumab fit into proactive vs reactive AD treatment approaches? https://dermsquared.com/videos/dermbits/how-does-lebrikizumab-fit-into-proactive-vs-reactive-ad-treatment-approaches 54 2025-04-01T14:17:46.608Z yes https://dermsquared.com/videos/dermbits/seen-in-terms-of-outcomes 2026-05-22T13:19:29.283Z https://image.mux.com/ChnUQ8g3nSKL3AvYi8riPDlna9e7JweW4f4pKR02VH02g/thumbnail.jpg Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes? Can you walk through a few of the highest-yield clinical scenarios where Cordran Tape really stands out, and what you’ve seen in terms of outcomes? https://dermsquared.com/videos/dermbits/seen-in-terms-of-outcomes 61 2026-05-22T13:19:29.275Z yes https://dermsquared.com/videos/dermbits/clinical-and-pathological-features-most-significantly-impact-melanoma-prognosis 2025-03-03T14:11:33.201Z https://image.mux.com/HePsWQAeg177AFyRPCxH8m00F9NNHXFbYycPQh00eR9B00/thumbnail.jpg What clinical and pathological features most significantly impact melanoma prognosis? What clinical and pathological features most significantly impact melanoma prognosis? https://dermsquared.com/videos/dermbits/clinical-and-pathological-features-most-significantly-impact-melanoma-prognosis 59 2025-03-03T14:11:33.191Z yes https://dermsquared.com/videos/dermbits/differences-topical-ruxolitinib-cream-non-steroidal-topical-therapies-22 2023-04-28T20:10:51.412Z https://image.mux.com/rfjVS9P4VD2rj2dEtXJd7FOk02L02pHrrJnApySkDOvxc/thumbnail.jpg What differences do you see clinically between topical ruxolitinib cream and other non-steroidal topical therapies used to treat atopic dermatitis? What differences do you see clinically between topical ruxolitinib cream and other non-steroidal topical therapies used to treat atopic dermatitis? https://dermsquared.com/videos/dermbits/differences-topical-ruxolitinib-cream-non-steroidal-topical-therapies-22 95 2022-04-28T00:16:20.000Z yes https://dermsquared.com/videos/dermbits/patients-pair-prescription-acne-medications 2025-10-23T15:43:14.275Z https://image.mux.com/2u8cG6004hp4gzyZRWcVKo7XTjpNEFXDfB8jRIySPqUE/thumbnail.jpg How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier? How can dermatologists help patients pair prescription acne medications with over-the-counter products that protect the skin barrier? https://dermsquared.com/videos/dermbits/patients-pair-prescription-acne-medications 56 2025-10-22T21:24:05.405Z yes https://dermsquared.com/videos/dermbits/what-are-treatment-options-for-gpp 2023-06-30T16:59:38.849Z https://image.mux.com/jKCAQpaqcIi02n2el1ByJQ1Ea3XV16zZYD7KuRZQeZDE/thumbnail.jpg What are treatment options for GPP? What are treatment options for GPP? https://dermsquared.com/videos/dermbits/what-are-treatment-options-for-gpp 65 2023-06-27T17:27:11.197Z yes https://dermsquared.com/videos/dermbits/how-tapinarofs-unique-mechanism-action-impact-disease-course 2025-02-03T19:10:53.875Z https://image.mux.com/4vrvpDInSYhf9SnBb43ML1kNexDOhNC00KAy8M01DnMH00/thumbnail.jpg How does tapinarof’s unique mechanism of action impact the disease course of atopic dermatitis? How does tapinarof’s unique mechanism of action impact the disease course of atopic dermatitis? https://dermsquared.com/videos/dermbits/how-tapinarofs-unique-mechanism-action-impact-disease-course 27 2025-02-03T19:10:53.865Z yes https://dermsquared.com/videos/dermbits/compare-information-31-gep-vs-slnb 2023-04-28T19:22:55.857Z https://image.mux.com/adMpxkfNTHuYSIO6Os9Ss01Uu02NX6BwiLn2PUOAm1oYI/thumbnail.jpg How would you compare and contrast the utility of the information from 31-GEP vs. SLNB? How would you compare and contrast the utility of the information from 31-GEP vs. SLNB? https://dermsquared.com/videos/dermbits/compare-information-31-gep-vs-slnb 78 2021-10-07T21:24:11.000Z yes https://dermsquared.com/videos/dermbits/biggest-challenge-topical-therapy-psoriasis-22 2023-04-28T20:01:24.715Z https://image.mux.com/626v02lxkloNBL39WHSTNhaXziHfn4xw4NBvlph2uhu00/thumbnail.jpg What do you see as the biggest challenge to topical therapy use in psoriasis? What do you see as the biggest challenge to topical therapy use in psoriasis? https://dermsquared.com/videos/dermbits/biggest-challenge-topical-therapy-psoriasis-22 60 2022-02-01T01:17:31.000Z yes https://dermsquared.com/videos/dermbits/how-advise-patients-ruxolitinib-vitiligo-looking-for-repigmentation 2024-07-01T14:43:33.309Z https://image.mux.com/t2bV2rop96WwVhfisViqaN5PO1AK9CuRGgs9DYLYHw4/thumbnail.jpg How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation How can you advise patients taking ruxolitinib for vitiligo on looking for signs of repigmentation https://dermsquared.com/videos/dermbits/how-advise-patients-ruxolitinib-vitiligo-looking-for-repigmentation 29 2024-07-01T14:43:33.292Z yes https://dermsquared.com/videos/dermbits/patients-maintained-on-prp-therapy 2023-04-28T19:10:51.990Z https://image.mux.com/u02JPdFnUR02iongLaAoROgWNy5EBFx62Kv7vgKxLfXh00/thumbnail.jpg Do patients need to be maintained on PRP therapy? If so, how often? Do patients need to be maintained on PRP therapy? If so, how often? https://dermsquared.com/videos/dermbits/patients-maintained-on-prp-therapy 18 2021-06-24T22:31:09.000Z yes https://dermsquared.com/videos/dermbits/factors-considered-treatment-duration-ixekizumab-psoriasis 2024-07-17T16:13:29.745Z https://image.mux.com/M8kYeWf53DP81q02O3y34ERsmsrhKwZexsOIouK9bA2k/thumbnail.jpg What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis? What factors should be considered when determining optimal treatment duration for ixekizumab in patients with psoriasis? https://dermsquared.com/videos/dermbits/factors-considered-treatment-duration-ixekizumab-psoriasis 57 2024-07-17T16:13:29.739Z yes https://dermsquared.com/videos/dermbits/dermbits-advantages-once-daily-steroid-free-topical-arcp22 2022-08-30T23:06:54.000Z https://image.mux.com/N9urIXJRryAY7S4waL9DOFiAmlznuZ29vRV76a6zbeg/thumbnail.jpg What are the advantages of a once-daily, steroid-free topical? What are the advantages of a once-daily, steroid-free topical? https://dermsquared.com/videos/dermbits/dermbits-advantages-once-daily-steroid-free-topical-arcp22 30 2022-08-30T23:06:54.000Z yes https://dermsquared.com/videos/dermbits/mypath-typically-covered-insurance 2025-07-15T03:06:13.343Z https://image.mux.com/r611MvMU600w2APH2Nzeod3W3iy2nQ5AP8xC6S6ePbGY/thumbnail.jpg Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs? Is the MyPath Melanoma test typically covered by insurance, and what should I tell patients about potential out-of-pocket costs? https://dermsquared.com/videos/dermbits/mypath-typically-covered-insurance 32 2025-07-15T03:06:13.337Z yes https://dermsquared.com/videos/dermbits/cantharidin-benefits-over-other-treatments-molluscum-contagiosum 2023-11-09T21:34:41.729Z https://image.mux.com/YVKhNmSVv6Co72VeGE5sKAp01jTgEIUriYBR017qNrCC8/thumbnail.jpg Does cantharidin provide any benefits over other treatments for molluscum contagiosum? Does cantharidin provide any benefits over other treatments for molluscum contagiosum? https://dermsquared.com/videos/dermbits/cantharidin-benefits-over-other-treatments-molluscum-contagiosum 68 2023-11-09T21:34:41.723Z yes https://dermsquared.com/videos/dermbits/ruxolitinib-cream-work-for-psoriasis-22 2023-04-28T19:55:02.826Z https://image.mux.com/N8jmvsurVS8zFF2lAGtwYaR78ygf200z5TB6SlLlhByM/thumbnail.jpg Does ruxolitinib cream work for psoriasis? Does ruxolitinib cream work for psoriasis? https://dermsquared.com/videos/dermbits/ruxolitinib-cream-work-for-psoriasis-22 19 2022-01-31T22:06:19.000Z yes https://dermsquared.com/videos/dermbits/lesions-with-ambiguous-histology 2025-12-19T16:23:46.042Z https://image.mux.com/jMGwP34Uig5prPCLMYDevOXxQYD9Ell9oCuxD2jHxF8/thumbnail.jpg What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody What are the biggest challenges in managing atypical melanocytic lesions with ambiguous histology? With Dr. Moody https://dermsquared.com/videos/dermbits/lesions-with-ambiguous-histology 73 2025-12-19T16:23:46.035Z yes https://dermsquared.com/videos/dermbits/latest-updates-role-il-4-and-il-13-pathogenesis-atopic-dermatitis 2025-01-31T18:07:31.718Z https://image.mux.com/QulaU76A2wf3esETfkaNcv2MM9OGkPxzoKfoHD3qPtU/thumbnail.jpg What are the latest updates on the role of IL-4 and IL-13 in the pathogenesis of atopic dermatitis? What are the latest updates on the role of IL-4 and IL-13 in the pathogenesis of atopic dermatitis? https://dermsquared.com/videos/dermbits/latest-updates-role-il-4-and-il-13-pathogenesis-atopic-dermatitis 93 2025-01-31T18:03:02.415Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-you-combine-thread-lifts-with-hyaluronic-acid-fillers 2022-12-14T19:39:41.000Z https://image.mux.com/EIqm00c8xiKCDPGGmjtsj9pTYmNGRQ3501dfyxo02pIyZA/thumbnail.jpg How do you combine thread lifts with hyaluronic acid fillers? How do you combine thread lifts with hyaluronic acid fillers? https://dermsquared.com/videos/dermbits/dermbits-how-do-you-combine-thread-lifts-with-hyaluronic-acid-fillers 36 2022-12-14T19:39:41.000Z yes https://dermsquared.com/videos/dermbits/dermbits-can-emollients-be-used-in-conjunction-with-topical-ruxolitinib-cream-ADRC00071 2023-01-30T22:23:53.000Z https://image.mux.com/X59Qp5nQ7TFCNAXRiw26gmsrag00ElaG1VgRJKUYiz02c/thumbnail.jpg Can emollients be used in conjunction with topical ruxolitinib cream? Can emollients be used in conjunction with topical ruxolitinib cream? https://dermsquared.com/videos/dermbits/dermbits-can-emollients-be-used-in-conjunction-with-topical-ruxolitinib-cream-ADRC00071 41 2023-01-30T22:23:53.000Z yes https://dermsquared.com/videos/dermbits/what-differentiates-il-13-from-il-4-in-the-progression-of-ad 2025-10-01T20:30:27.077Z https://image.mux.com/sLeFVmVlufBMibQG601HVw1IILUwXuK7m5t3uBJX6R1I/thumbnail.jpg What differentiates IL-13 from IL-4 in the progression of AD? What differentiates IL-13 from IL-4 in the progression of AD? https://dermsquared.com/videos/dermbits/what-differentiates-il-13-from-il-4-in-the-progression-of-ad 82 2025-10-01T20:52:17.553Z yes https://dermsquared.com/videos/dermbits/dermbits-what-excites-you-most-about-the-approval-of-topical-roflumilast-arcp22 2023-05-11T14:57:15.488Z https://image.mux.com/jIoiL3CTesLyc00wazbCcubcaYRuYskc01gLwwJ1HICE4/thumbnail.jpg What excites you most about the approval of topical roflumilast? What excites you most about the approval of topical roflumilast? https://dermsquared.com/videos/dermbits/dermbits-what-excites-you-most-about-the-approval-of-topical-roflumilast-arcp22 26 2022-10-28T22:41:29.000Z yes https://dermsquared.com/videos/dermbits/how-should-dermatologists-sequence-topical-and-systemic-treatments-in-patients-with-refractory-atopic-dermatitis 2025-04-01T14:18:21.614Z https://image.mux.com/FKbItay4S01OuL01dgtLd2WWko9qQQetE29xmTzvdARM00/thumbnail.jpg How should dermatologists sequence topical and systemic treatments in patients with refractory atopic dermatitis? How should dermatologists sequence topical and systemic treatments in patients with refractory atopic dermatitis? https://dermsquared.com/videos/dermbits/how-should-dermatologists-sequence-topical-and-systemic-treatments-in-patients-with-refractory-atopic-dermatitis 77 2025-04-01T14:18:21.590Z yes https://dermsquared.com/videos/dermbits/checking-potassium-drospirenone-concurrent-spironolactone-22 2023-04-28T20:14:50.676Z https://image.mux.com/01h0137sKCFX01WB0093ritlwtPfHARDzyJcszuWnn9ZLMc/thumbnail.jpg Do you suggest checking potassium on patients on drospirenone containing OCP with concurrent use of spironolactone on healthy patients? Do you suggest checking potassium on patients on drospirenone containing OCP with concurrent use of spironolactone on healthy patients? https://dermsquared.com/videos/dermbits/checking-potassium-drospirenone-concurrent-spironolactone-22 81 2022-06-09T15:27:52.000Z yes https://dermsquared.com/videos/dermbits/clinicopathologic-factors-significant-prognostic-value 2023-11-17T16:50:48.715Z https://image.mux.com/gUbwexJMqB00tqj2P7kf00FD8Ktp2Su02xcqwve017qb3dg/thumbnail.jpg What clinicopathologic factors have significant prognostic value? What clinicopathologic factors have significant prognostic value? https://dermsquared.com/videos/dermbits/clinicopathologic-factors-significant-prognostic-value 45 2023-11-17T16:37:40.792Z yes https://dermsquared.com/videos/dermbits/dermbits-botox-for-the-neck-where-do-you-start-and-how-many-units-do-you-recommend 2023-05-17T19:16:35.319Z https://image.mux.com/WVCObcWuYWnwqR6C7X7HDuRWTr01eTkbwcjskD7YtMYE/thumbnail.jpg Botox for the neck: where do you start and how many units do you recommend? Botox for the neck: where do you start and how many units do you recommend? https://dermsquared.com/videos/dermbits/dermbits-botox-for-the-neck-where-do-you-start-and-how-many-units-do-you-recommend 41 2023-04-28T22:30:57.000Z yes https://dermsquared.com/videos/dermbits/primary-endpoints-of-camp-1-and-camp-2-trials 2023-11-09T21:34:27.007Z https://image.mux.com/Zhe4tuwQN3hDbgzSpFLRvgCeAa9Sbn2lZjCDTIRpakQ/thumbnail.jpg What were the primary endpoints of the CAMP-1 and CAMP-2 trials? What were the primary endpoints of the CAMP-1 and CAMP-2 trials? https://dermsquared.com/videos/dermbits/primary-endpoints-of-camp-1-and-camp-2-trials 148 2023-11-09T21:34:26.999Z yes https://dermsquared.com/videos/dermbits/advantages-sensus-radiation-therapy-devices 2023-04-28T19:20:00.581Z https://image.mux.com/9ZI7u8Ah29kgqwhlloh4OZC00IdnPBlxtUswq9NaLmew/thumbnail.jpg What are the advantages of the Sensus device over older radiation therapy devices? What are the advantages of the Sensus device over older radiation therapy devices? https://dermsquared.com/videos/dermbits/advantages-sensus-radiation-therapy-devices 100 2021-09-09T02:34:23.000Z yes https://dermsquared.com/videos/dermbits/important-instructions-you-should-give-patients-treated-cantharidin 2023-11-30T19:18:51.801Z https://image.mux.com/2PqmqN1zf7DcuQ01UETXvP4SG3zLzNnXWfLrN5e1g4Cw/thumbnail.jpg What are some important instructions you should give to give patients being treated with cantharidin? What are some important instructions you should give to give patients being treated with cantharidin? https://dermsquared.com/videos/dermbits/important-instructions-you-should-give-patients-treated-cantharidin 31 2023-11-30T19:18:51.794Z yes https://dermsquared.com/videos/dermbits/patients-eligible-for-treatment-with-baricitinib-any-notable-exclusion-criteria 2023-07-27T19:23:04.173Z https://image.mux.com/ftpHMTdTwmoXpcSqjRR3UcDiyQcvYch3tsIPSlFyl01c/thumbnail.jpg Which patients are eligible for treatment with baricitinib and are there any notable exclusion criteria? Summary In the video, Dr. Michael Cameron discusses the eligibility criteria for treatment with baricitinib and highlights some notable exclusion criteria. According to the label for baricitinib, it is defined as a treatment option for severe alopecia areata. However, there are no specific requirements regarding body surface area involvement. The decision of what constitutes severe alopecia areata and necessitates treatment with baricitinib is left to the provider and the patient to determine. In terms of exclusion criteria, it is not recommended to use baricitinib in combination with other systemic immunosuppressants such as methotrexate, prednisone, and azathioprine. This indicates that patients who are already taking these medications should not be considered for baricitinib treatment due to potential adverse effects or interactions. In summary, patients eligible for baricitinib treatment are those with severe alopecia areata, as determined by the provider and the patient, and who are not already taking an immunosuppressant. Key Points There are no specific body surface area involvement requirements for eligibility. The decision on whether a case of alopecia areata is considered severe and requires baricitinib treatment is made jointly by the healthcare provider and the patient. Baricitinib should not be used in combination with other systemic immunosuppressants such as methotrexate, prednisone, and azathioprine. Contraindications include concurrent use of baricitinib with certain medications that have immunosuppressive properties. https://dermsquared.com/videos/dermbits/patients-eligible-for-treatment-with-baricitinib-any-notable-exclusion-criteria 34 2023-07-27T19:23:04.168Z yes https://dermsquared.com/videos/dermbits/recommended-monitoring-patients-ruxolitinib-vitiligo 2024-07-01T14:44:12.540Z https://image.mux.com/h00hEhUR543Y5nFQOkQvh0000Dc01amGr02ob00rDt0072l4jI/thumbnail.jpg Is there any recommended monitoring for patients on ruxolitinib for vitiligo? Is there any recommended monitoring for patients on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/recommended-monitoring-patients-ruxolitinib-vitiligo 22 2024-07-01T14:44:12.529Z yes https://dermsquared.com/videos/dermbits/clinical-sense-for-patients 2026-04-02T16:21:12.003Z https://image.mux.com/01WYkLq3zXcGhFfOHwkRd3JUE9bEzTtQrBbJljulaung/thumbnail.jpg When do bridge programs make the most clinical sense for patients? When do bridge programs make the most clinical sense for patients? https://dermsquared.com/videos/dermbits/clinical-sense-for-patients 36 2026-04-02T14:29:49.287Z yes https://dermsquared.com/videos/dermbits/what-areas-of-body-can-cantharidin-be-applied 2023-12-11T16:07:42.383Z https://image.mux.com/X591MWrQWdidUwOjJPMqjiW2PJLyJBVp00poIxl00KDF4/thumbnail.jpg On what areas of the body can cantharidin be applied? On what areas of the body can cantharidin be applied? https://dermsquared.com/videos/dermbits/what-areas-of-body-can-cantharidin-be-applied 37 2023-12-11T16:07:42.377Z yes https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-lebrikizumab 2024-12-02T16:28:03.369Z https://image.mux.com/uxxEMwo9bxF02LaOdEiVWLAv02WGc02q9zYuU11MtT0002y4/thumbnail.jpg What is the safety profile of lebrikizumab? What is the safety profile of lebrikizumab? https://dermsquared.com/videos/dermbits/what-is-the-safety-profile-of-lebrikizumab 30 2024-12-02T16:28:03.362Z yes https://dermsquared.com/videos/dermbits/how-quickly-improvement-ad-symptoms-lebrikizumab 2024-11-06T15:54:55.363Z https://image.mux.com/58qfFyoc6i5SgZlGSnrSMr029028z2eHIq7lkayS8wKR8/thumbnail.jpg How quickly can patients expect to see improvement in their AD symptoms with lebrikizumab? How quickly can patients expect to see improvement in their AD symptoms with lebrikizumab? https://dermsquared.com/videos/dermbits/how-quickly-improvement-ad-symptoms-lebrikizumab 21 2024-11-06T15:54:55.357Z yes https://dermsquared.com/videos/dermbits/common-patient-questions-or-concerns-genomic-testing 2025-07-01T14:14:31.580Z https://image.mux.com/BHU3LO2AM01ILVNufui02OqSPAReRBPwtp1DqT01w7gvLQ/thumbnail.jpg What are common patient questions or concerns about this type of genomic testing? What are common patient questions or concerns about this type of genomic testing? https://dermsquared.com/videos/dermbits/common-patient-questions-or-concerns-genomic-testing 86 2025-07-01T14:14:31.573Z yes https://dermsquared.com/videos/dermbits/weight-with-payers 2026-05-04T20:18:00.365Z https://image.mux.com/ehVZ327ok7r2MtHVPVuOSkKquM02aVKt02IAXNbfgdYSo/thumbnail.jpg Which clinical metrics carry the most weight with payers? Which clinical metrics carry the most weight with payers? https://dermsquared.com/videos/dermbits/weight-with-payers 72 2026-05-04T20:18:00.359Z yes https://dermsquared.com/videos/dermbits/difficult-access-topical-ruxolitinib-cream-insurance-plans-22 2023-04-28T20:11:14.291Z https://image.mux.com/DVTzIo52mgcPOgUXYf61Z2a7yEFoDIw02GwXwOS02gQXY/thumbnail.jpg Is it difficult to get access to topical ruxolitinib cream for patients through their insurance plans? Is it difficult to get access to topical ruxolitinib cream for patients through their insurance plans? https://dermsquared.com/videos/dermbits/difficult-access-topical-ruxolitinib-cream-insurance-plans-22 85 2022-04-28T00:20:50.000Z yes https://dermsquared.com/videos/dermbits/how-do-access-tolerability-and-efficacy-improve-compliance 2023-05-31T19:56:39.139Z https://image.mux.com/Uk7f1JIiwIwBhfVLEQHHeQSsae8hsgBMRwAVu5v00ruA/thumbnail.jpg How do access, tolerability and efficacy improve compliance?  How do access, tolerability and efficacy improve compliance?  https://dermsquared.com/videos/dermbits/how-do-access-tolerability-and-efficacy-improve-compliance 70 2023-05-31T19:56:39.134Z yes https://dermsquared.com/videos/dermbits/ideal-time-to-apply-emollients 2023-04-28T19:34:50.792Z https://image.mux.com/OgUDrhvy7yEuD9zndFS4bl4AuKETNMUlzGWI5YVdKoY/thumbnail.jpg Is there an ideal time to apply emollients? Is there an ideal time to apply emollients? https://dermsquared.com/videos/dermbits/ideal-time-to-apply-emollients 32 2021-12-15T01:43:30.000Z yes https://dermsquared.com/videos/dermbits/treatment-approach-for-ad 2026-05-26T14:43:58.653Z https://image.mux.com/l7HnZRw22Ykj5wziaqea9L6lDMcDOPmU94XVvthc0102o/thumbnail.jpg Where does tapinarof fit in your current treatment approach for AD? Where does tapinarof fit in your current treatment approach for AD? https://dermsquared.com/videos/dermbits/treatment-approach-for-ad 68 2026-05-26T14:43:58.643Z yes https://dermsquared.com/videos/dermbits/dermbits-do-you-patch-test-patients-while-on-dupilumab-ADRC00064-ad0123 2022-12-22T21:40:54.000Z https://image.mux.com/xaQWTlzDlBOiZxz9rzpuZHF5pS9sy6RrQJ8Tc6d5mGo/thumbnail.jpg Do you patch test patients while on dupilumab? Do you patch test patients while on dupilumab? https://dermsquared.com/videos/dermbits/dermbits-do-you-patch-test-patients-while-on-dupilumab-ADRC00064-ad0123 107 2022-12-22T21:40:54.000Z yes https://dermsquared.com/videos/dermbits/what-conditions-considered-clinical-differential-diagnosis-vitiligo 2025-05-01T13:43:38.080Z https://image.mux.com/wgJZ00wNMaLrtz00iJ02LytvQAclqFX5ob97QDrm3gn3N4/thumbnail.jpg What conditions should be considered in the clinical differential diagnosis of vitiligo? What conditions should be considered in the clinical differential diagnosis of vitiligo? https://dermsquared.com/videos/dermbits/what-conditions-considered-clinical-differential-diagnosis-vitiligo 80 2025-05-01T13:43:38.071Z yes https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-tirbanibulin-ointment 2025-10-20T22:30:37.028Z https://image.mux.com/004y5iu00k01sb01TAWCFFLNqtno5NLVzs1AQAiagfSRGo00/thumbnail.jpg What is the recommended dosing regimen for tirbanibulin ointment, and how does it differ from other field therapies? What is the recommended dosing regimen for tirbanibulin ointment, and how does it differ from other field therapies? https://dermsquared.com/videos/dermbits/recommended-dosing-regimen-tirbanibulin-ointment 69 2025-02-12T16:22:13.178Z yes https://dermsquared.com/videos/dermbits/patients-with-long-standing-vitiligo 2026-06-10T14:40:47.015Z https://image.mux.com/Uu701OgJxpb3017bk5mP01xA9p3Wgyuu3ZiJ3pwTGADtMQ/thumbnail.jpg What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo? What should clinicians keep in mind when considering treatment for patients with long-standing vitiligo? https://dermsquared.com/videos/dermbits/patients-with-long-standing-vitiligo 91 2026-06-10T14:40:47.005Z yes https://dermsquared.com/videos/dermbits/folic-acid-with-methotrexate 2023-04-28T19:02:04.372Z https://image.mux.com/KvmwTjyW48pMA2NBh01a1kP004idyJ7MacL1OA2RMg47o/thumbnail.jpg How do you give folic acid with methotrexate? How do you give folic acid with methotrexate? https://dermsquared.com/videos/dermbits/folic-acid-with-methotrexate 54 2021-04-30T17:55:17.000Z yes https://dermsquared.com/videos/dermbits/ritlecitinib-vaccines-schedules-patients 2024-12-02T15:44:57.204Z https://image.mux.com/6PI5bDGKxYMOg1ui56uscMuLREgzb1a0000fj8Qja6xCw/thumbnail.jpg Does ritlecitinib interact with vaccines, and should vaccination schedules be adjusted for patients on ritlecitinib? Does ritlecitinib interact with vaccines, and should vaccination schedules be adjusted for patients on ritlecitinib? https://dermsquared.com/videos/dermbits/ritlecitinib-vaccines-schedules-patients 39 2024-12-02T15:44:57.191Z yes https://dermsquared.com/videos/dermbits/favorite-biologic-treated-latent-tb 2023-04-28T19:15:20.433Z https://image.mux.com/hr53u02gEaNrZMEcKJdLYKrPTDVQxPOTPJTLvZ02LebnM/thumbnail.jpg What is your favorite biologic in those with treated latent TB? What is your favorite biologic in those with treated latent TB? https://dermsquared.com/videos/dermbits/favorite-biologic-treated-latent-tb 49 2021-07-29T20:15:11.000Z yes https://dermsquared.com/videos/dermbits/support-programs-available-patients-prescribed-baricitinib 2023-09-29T16:20:12.176Z https://image.mux.com/wxU83026AeVqyD146mQlDaiZXKpwfVlpfI1W2JXp2kVA/thumbnail.jpg Are there any support programs available for patients who are prescribed baricitinib? Are there any support programs available for patients who are prescribed baricitinib? https://dermsquared.com/videos/dermbits/support-programs-available-patients-prescribed-baricitinib 68 2023-09-29T16:20:12.171Z yes https://dermsquared.com/videos/dermbits/skin-barrier-acne-pathophysiology 2025-10-23T15:42:03.338Z https://image.mux.com/nZ87IceCoEXTuewTZH022MhQxrOnfsqxB02027MyyMx7x00/thumbnail.jpg What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection? What role does the skin barrier play in acne pathophysiology, and how should it influence treatment selection? https://dermsquared.com/videos/dermbits/skin-barrier-acne-pathophysiology 66 2025-10-22T21:23:00.333Z yes https://dermsquared.com/videos/dermbits/latest-advancements-in-understanding-pathogenesis-of-psoriasis 2024-04-08T18:35:29.376Z https://image.mux.com/aasqiu5QDJXzukjKyRz8VfDjLSwLG8TBFPZxiLuTZ2U/thumbnail.jpg What are the latest advancements in understanding the pathogenesis of psoriasis? What are the latest advancements in understanding the pathogenesis of psoriasis? https://dermsquared.com/videos/dermbits/latest-advancements-in-understanding-pathogenesis-of-psoriasis 53 2024-04-08T18:35:29.369Z yes https://dermsquared.com/videos/dermbits/dermbits-is-topical-roflumilast-safe-for-long-term-use-arcp22 2023-05-11T14:54:48.612Z https://image.mux.com/dVg0241Ufep300kAxz4GZx1ZsUu1DHNxJvoYHFp3ckRY4/thumbnail.jpg Is topical roflumilast safe for long-term use? Is topical roflumilast safe for long-term use? https://dermsquared.com/videos/dermbits/dermbits-is-topical-roflumilast-safe-for-long-term-use-arcp22 32 2022-10-28T22:54:59.000Z yes https://dermsquared.com/videos/dermbits/dermbits-approach-to-treatment-with-topical-roflumilast-differ-from-treatment-topical-steroids-arcp22 2022-08-30T23:16:38.000Z https://image.mux.com/4IZNRHX4XvLnfQBgAAJnwFRl98vZCTCtJuwJNTQebLM/thumbnail.jpg How does your approach to treatment with topical roflumilast differ from treatment with topical steroids? How does your approach to treatment with topical roflumilast differ from treatment with topical steroids? https://dermsquared.com/videos/dermbits/dermbits-approach-to-treatment-with-topical-roflumilast-differ-from-treatment-topical-steroids-arcp22 50 2022-08-30T23:16:38.000Z yes https://dermsquared.com/videos/dermbits/when-see-patients-back-from-lab-work 2023-04-28T19:44:10.478Z https://image.mux.com/cgWAhCjg5lnYGBZ6LvzeCJDvYAZGfW024VFncqSv8Zjw/thumbnail.jpg When do you see patients back from lab work? When do you see patients back from lab work? https://dermsquared.com/videos/dermbits/when-see-patients-back-from-lab-work 46 2021-12-27T17:19:08.000Z yes https://dermsquared.com/videos/dermbits/dermbits-is-topical-ruxolitinib-still-effective-once-a-day-for-atopic-dermatitis-ADRC00082-adrc23 2023-02-15T23:50:57.000Z https://image.mux.com/8BNmEApjOlR9a7gfCMutTQZXbpGVfjM01oZU7K22bokk/thumbnail.jpg Is topical ruxolitinib still effective if only used once a day for atopic dermatitis? Is topical ruxolitinib still effective if only used once a day for atopic dermatitis? https://dermsquared.com/videos/dermbits/dermbits-is-topical-ruxolitinib-still-effective-once-a-day-for-atopic-dermatitis-ADRC00082-adrc23 17 2023-02-15T23:50:57.000Z yes https://dermsquared.com/videos/dermbits/favorite-biologic-geriatric-patients 2023-04-28T19:13:16.696Z https://image.mux.com/fjvIa007sLy4uLKlaKXVNW8QL02pYFcoFAc01ql3ZgO71g/thumbnail.jpg What is your favorite biologic in geriatric patients? What is your favorite biologic in geriatric patients? https://dermsquared.com/videos/dermbits/favorite-biologic-geriatric-patients 83 2021-07-15T21:28:27.000Z yes https://dermsquared.com/videos/dermbits/contraindications-to-ruxolitinib-cream 2023-04-28T19:36:53.224Z https://image.mux.com/mI2f02iTKX3GfcLsgYu5Abaq47mYYqS301j9fYIzKktuA/thumbnail.jpg What are the contraindications to ruxolitinib cream? What are the contraindications to ruxolitinib cream? https://dermsquared.com/videos/dermbits/contraindications-to-ruxolitinib-cream 26 2021-12-15T01:36:18.000Z yes https://dermsquared.com/videos/dermbits/what-are-the-benefits-of-sarecycline-s-once-daily-dosing-compared-to-other-antibiotics 2025-05-07T17:26:09.149Z https://image.mux.com/00KLacBEH41F28lC1Ik3yFsG52kjVbV2wBLkbR401GK8k/thumbnail.jpg What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics? What are the benefits of sarecycline’s once-daily dosing compared to other antibiotics? https://dermsquared.com/videos/dermbits/what-are-the-benefits-of-sarecycline-s-once-daily-dosing-compared-to-other-antibiotics 98 2025-05-07T17:23:39.405Z yes https://dermsquared.com/videos/dermbits/clinical-findings-strike-most-choosing-topical-roflumilast-plaque-psoriasis 2023-11-01T21:22:50.473Z https://image.mux.com/JQU9oFFQYK8jf01rHqEl4DzIBjkWsHqP92sdBxm02jNMU/thumbnail.jpg What clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis? What clinical findings strike you most when choosing topical roflumilast for patients with plaque psoriasis? https://dermsquared.com/videos/dermbits/clinical-findings-strike-most-choosing-topical-roflumilast-plaque-psoriasis 25 2023-11-01T21:22:50.467Z yes https://dermsquared.com/videos/dermbits/most-common-lab-abnormalities-patients-ritlecitinib 2024-12-02T15:44:11.834Z https://image.mux.com/lwLEoNC5qHZpZ7Atr7pol01RMwIfsMnwd76s02DPNAKEo/thumbnail.jpg What are the most common lab abnormalities observed in patients with ritlecitinib? What are the most common lab abnormalities observed in patients with ritlecitinib? https://dermsquared.com/videos/dermbits/most-common-lab-abnormalities-patients-ritlecitinib 26 2024-12-02T15:44:11.827Z yes https://dermsquared.com/videos/dermbits/how-comorbidities-influence-management-alopecia-areata 2024-09-17T19:02:26.541Z https://image.mux.com/QUrAjzNKd7yQOUjwJteA2m01kVDr1tOGT00BUuQg4rXr8/thumbnail.jpg How does the presence of comorbidities influence the management of alopecia areata? How does the presence of comorbidities influence the management of alopecia areata? https://dermsquared.com/videos/dermbits/how-comorbidities-influence-management-alopecia-areata 65 2024-09-17T19:02:26.534Z yes https://dermsquared.com/videos/dermbits/when-should-oral-antibiotics-be-used-in-the-treatment-of-atopic-dermatitis 2023-07-28T16:26:26.599Z https://image.mux.com/00AOOlazF02eOvi6JmzHOeqRKa7lgstNVcy72TxCe1tLQ/thumbnail.jpg When should oral antibiotics be used in the treatment of atopic dermatitis? Summary In the video, Dr. Raj Chovatiya discusses the use of oral antibiotics in the treatment of atopic dermatitis. He points out that there is a historical misconception that oral antibiotics can be a helpful standalone treatment for atopic dermatitis. While infections, both on the skin and throughout the body, can be significant comorbidities in patients with atopic dermatitis, oral antibiotics should be considered in specific situations. The appropriate scenario to use oral antibiotics is when dealing with a patient, usually with severe atopic dermatitis, who has a lot of open and oozing areas with golden crusting, also known as impetiginization. In such cases, bacterial colonies are present in those open areas, and oral antibiotics may be useful in managing the infection. However, beyond this specific context, oral antibiotics should not be considered a long-term treatment strategy for atopic dermatitis. Instead, more targeted treatment approaches that address the immunopathogenic roots of atopic dermatitis should be considered for managing the condition. Key Points Oral antibiotics are not a recommended monotherapy for atopic dermatitis. Oral antibiotics can be useful in cases where the patient has severe atopic dermatitis with oozing, weeping, and golden crusting (impetiginization) in open areas, but not as a long-term treatment strategy for atopic dermatitis. Instead, targeted treatment approaches should be considered to address the underlying immunopathogenic factors of atopic dermatitis. https://dermsquared.com/videos/dermbits/when-should-oral-antibiotics-be-used-in-the-treatment-of-atopic-dermatitis 58 2023-07-27T19:15:33.688Z yes https://dermsquared.com/videos/dermbits/most-important-patient-education-lebrikizumab 2025-07-01T13:41:03.189Z https://image.mux.com/UCa1kLUmwFYrKTsufQj4wR6hvvvQ4PUUfg2OpGXNwKc/thumbnail.jpg What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong What are the most important patient education points you should counsel your patients on when initiating treatment with lebrikizumab? With Dr. Kwong https://dermsquared.com/videos/dermbits/most-important-patient-education-lebrikizumab 78 2025-07-01T13:41:03.180Z yes https://dermsquared.com/videos/dermbits/tips-reduce-risk-ring-warts 2023-04-28T19:09:45.390Z https://image.mux.com/00oag015S3I6qBADEodK8x11G42m2MQ96H0101C00OLQkwV4/thumbnail.jpg Any tips on how to reduce the risk of ring warts? Any tips on how to reduce the risk of ring warts? https://dermsquared.com/videos/dermbits/tips-reduce-risk-ring-warts 56 2021-06-18T22:11:33.000Z yes https://dermsquared.com/videos/dermbits/dermbits-should-i-consider-the-40-gep-test-in-lower-risk-patients-WCM2300016-scc23 2023-05-17T20:08:03.407Z https://image.mux.com/fWsYrCP3DyqAPzbM3MvERKgot4IKYAxmxZyqTCxhqcM/thumbnail.jpg Should I consider the 40-GEP test in lower risk patients? Should I consider the 40-GEP test in lower risk patients? https://dermsquared.com/videos/dermbits/dermbits-should-i-consider-the-40-gep-test-in-lower-risk-patients-WCM2300016-scc23 74 2023-05-17T20:08:03.401Z yes https://dermsquared.com/videos/dermbits/latent-tb-ruxolitinib-21 2023-04-28T18:54:26.724Z https://image.mux.com/S5DtuHyX8moEsAk8vy6FExaTNN01Qs5IpnYzTBmV8WV8/thumbnail.jpg Does a patient with latent TB need treatment before using ruxolitinib cream? Does a patient with latent TB need treatment before using ruxolitinib cream? https://dermsquared.com/videos/dermbits/latent-tb-ruxolitinib-21 68 2021-10-14T14:42:26.000Z yes https://dermsquared.com/videos/dermbits/evidence-oral-systemic-glutathione 2023-04-28T19:17:56.064Z https://image.mux.com/O00z02YJD2qb0002GcHxAyX02AWbgS6zksMF2aFjaoy02UazU/thumbnail.jpg Is there any evidence for the use of oral or systemic glutathione? Is there any evidence for the use of oral or systemic glutathione? https://dermsquared.com/videos/dermbits/evidence-oral-systemic-glutathione 37 2021-08-18T15:29:14.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-clinical-presentation-of-gpp 2023-07-27T19:28:56.533Z https://image.mux.com/SfZh01tTwlZdUp5vwl02lTLEN4Wf3irhXxOwVAa2ilHxM/thumbnail.jpg What is the clinical presentation of GPP? What is the clinical presentation of GPP? https://dermsquared.com/videos/dermbits/what-is-the-clinical-presentation-of-gpp 36 2023-06-29T16:38:26.168Z yes https://dermsquared.com/videos/dermbits/how-availability-nonsteroidal-topical-options-contributing-to-standard-care-plaque-psoriasis 2023-11-01T21:23:08.543Z https://image.mux.com/Lv1VPfOyryyYvnTxLih92n4m8IgVGUXroRk8ZnQN01ZU/thumbnail.jpg How do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis? How do you foresee the availability of nonsteroidal topical options contributing to the standard of care for plaque psoriasis? https://dermsquared.com/videos/dermbits/how-availability-nonsteroidal-topical-options-contributing-to-standard-care-plaque-psoriasis 36 2023-11-01T21:23:08.533Z yes https://dermsquared.com/videos/dermbits/check-bloodwork-patients-topical-ruxolitinib 2023-04-28T19:52:10.836Z https://image.mux.com/7Nk00q01xBNfv00OP1RplZ8KKshJg28aVK00E1FcOCnmUUQ/thumbnail.jpg Do you check bloodwork in patients on topical ruxolitinib? Do you check bloodwork in patients on topical ruxolitinib? https://dermsquared.com/videos/dermbits/check-bloodwork-patients-topical-ruxolitinib 28 2022-01-31T22:19:15.000Z yes https://dermsquared.com/videos/dermbits/risk-death-warning-ruxolitinib-cream 2023-04-28T19:30:34.033Z https://image.mux.com/3lN3e3aTCcT700hOghq1MW7iT8EF902CAmQVe7RmyGg1s/thumbnail.jpg How concerned are you about the risk of death mentioned in the boxed warning for ruxolitinib cream? How concerned are you about the risk of death mentioned in the boxed warning for ruxolitinib cream? https://dermsquared.com/videos/dermbits/risk-death-warning-ruxolitinib-cream 102 2021-11-17T20:38:10.000Z yes https://dermsquared.com/videos/dermbits/spesolimab-hypersensitivity-reactions-should-patients-be-monitored-for 2023-08-31T20:47:04.160Z https://image.mux.com/UMdpE4oWjy02nvQ8aLPwrfP02rEZvJCku00xsYeaOzuJxM/thumbnail.jpg What spesolimab-associated hypersensitivity reactions should patients be monitored for? What spesolimab-associated hypersensitivity reactions should patients be monitored for? https://dermsquared.com/videos/dermbits/spesolimab-hypersensitivity-reactions-should-patients-be-monitored-for 143 2023-08-31T20:47:04.155Z yes https://dermsquared.com/videos/dermbits/oral-jak-adverse-events-21 2023-04-28T18:56:49.480Z https://image.mux.com/Y5GYdTYTzgPi02WCcsSaYfdoiTI8SVGDZKK2dScfM4OM/thumbnail.jpg Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events? Do topical JAK inhibitors and oral JAK inhibitors have similar rates of systemic adverse events? https://dermsquared.com/videos/dermbits/oral-jak-adverse-events-21 68 2021-10-14T14:37:14.000Z yes https://dermsquared.com/videos/dermbits/what-is-the-long-term-safety-data-for-bimekizumab 2024-01-01T16:05:11.853Z https://image.mux.com/h9S1NyfwJMlXbxVB8TpG01rVVsQHHSF17zy8MeQKxwVo/thumbnail.jpg What is the long-term safety data for bimekizumab? What is the long-term safety data for bimekizumab? https://dermsquared.com/videos/dermbits/what-is-the-long-term-safety-data-for-bimekizumab 83 2024-01-01T16:05:11.847Z yes https://dermsquared.com/videos/dermbits/dermbits-recommend-cbc-topical-ruxolitinib-in-patients-history-thrombocytopenia-anemia-neutropenia-ADRC00080-adrc23 2023-02-20T00:15:38.000Z https://image.mux.com/Cx00TAHtWP02EMWesGzdvACwvSg42I2KCqPmi4cOdnbrY/thumbnail.jpg Do you recommend getting a CBC before using topical ruxolitinib in patients with a history of thrombocytopenia, anemia or neutropenia? Do you recommend getting a CBC before using topical ruxolitinib in patients with a history of thrombocytopenia, anemia or neutropenia? https://dermsquared.com/videos/dermbits/dermbits-recommend-cbc-topical-ruxolitinib-in-patients-history-thrombocytopenia-anemia-neutropenia-ADRC00080-adrc23 23 2023-02-20T00:15:38.000Z yes https://dermsquared.com/videos/dermbits/how-treatment-approach-differ-in-treating-segmental-vs-nonsegmental-vitiligo 2024-04-01T15:44:53.716Z https://image.mux.com/00tuoroEu65J022t7bqKoLNj5yu3yu00IbZByK5rw02qw0200/thumbnail.jpg How does your treatment approach differ in treating segmental vs nonsegmental vitiligo? How does your treatment approach differ in treating segmental vs nonsegmental vitiligo? https://dermsquared.com/videos/dermbits/how-treatment-approach-differ-in-treating-segmental-vs-nonsegmental-vitiligo 24 2024-04-01T15:44:53.704Z yes https://dermsquared.com/videos/dermbits/the-risks-of-photodamage 2025-11-14T15:28:05.060Z https://image.mux.com/7YPgQNT2iyZVECQT3BJ1E02xD1tEnW901RvF9LbK92n900/thumbnail.jpg Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage? Are there any patient groups you feel are undercounseled when it comes to the risks of photodamage? https://dermsquared.com/videos/dermbits/the-risks-of-photodamage 98 2025-11-14T15:28:05.053Z yes https://dermsquared.com/videos/dermbits/how-educate-patients-chronic-nature-ad-to-improve-adherence 2025-05-01T13:41:45.134Z https://image.mux.com/YYHK4iTeW87Fn23qsJs00yB6kPf7o81Tkg5xhDlH0201DI/thumbnail.jpg How do you educate patients about the chronic nature of AD to improve adherence? How do you educate patients about the chronic nature of AD to improve adherence? https://dermsquared.com/videos/dermbits/how-educate-patients-chronic-nature-ad-to-improve-adherence 51 2025-05-01T13:41:45.126Z yes https://dermsquared.com/videos/dermbits/how-quickly-che-improvement-delgocitinib 2025-08-08T19:57:28.881Z https://image.mux.com/pj77jEDF00V351tQInQX02437GAmUWqExv7kmpwxVJrWo/thumbnail.jpg How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream? How quickly can patients with CHE expect to see improvement in skin clearance with delgocitinib cream? https://dermsquared.com/videos/dermbits/how-quickly-che-improvement-delgocitinib 145 2025-08-08T19:57:28.875Z yes https://dermsquared.com/videos/dermbits/patients-lived-experience 2026-06-01T14:57:24.644Z https://image.mux.com/wgLez51txbjs8EwKb3IB01oiqDJQMA9dQHXoqBHne01T8/thumbnail.jpg Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience? Are we sometimes optimizing for BSA instead of optimizing for the patient’s lived experience? https://dermsquared.com/videos/dermbits/patients-lived-experience 163 2026-06-01T14:57:24.637Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-involve-flexural 2023-04-28T19:31:36.899Z https://image.mux.com/dNainuN9yHWykGhEFReKbpWCKAHg5Tgoi5DFj9zCXM00/thumbnail.jpg Does atopic dermatitis always involve the flexural areas? Does atopic dermatitis always involve the flexural areas? https://dermsquared.com/videos/dermbits/atopic-dermatitis-always-involve-flexural 56 2021-11-17T20:48:17.000Z yes https://dermsquared.com/videos/dermbits/contraindications-precautions-before-beginning-patient-ruxolitinib-vitiligo 2024-07-01T14:44:04.149Z https://image.mux.com/Kr9hJ8AVw9vohL00w6YTM1b86zsIwegL6ulSwnicw01RE/thumbnail.jpg Are there any contraindications or precautions dermatologists should consider before beginning a patient on ruxolitinib for vitiligo? Are there any contraindications or precautions dermatologists should consider before beginning a patient on ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/contraindications-precautions-before-beginning-patient-ruxolitinib-vitiligo 29 2024-07-01T14:44:04.143Z yes https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-data-shows-reduction-of-itch-artr00039-arcp22 2022-11-29T23:36:52.000Z https://image.mux.com/TXQHniV8KzhEELWu01WD1SKQnjOIBbdLtcOs702vmvynM/thumbnail.jpg Does topical roflumilast have data that shows reduction of itch? Does topical roflumilast have data that shows reduction of itch? https://dermsquared.com/videos/dermbits/dermbits-topical-roflumilast-data-shows-reduction-of-itch-artr00039-arcp22 24 2022-11-29T23:36:52.000Z yes https://dermsquared.com/videos/dermbits/itch-management-patients-severe-pruritus-atopic-dermatitis 2024-11-06T15:54:32.035Z https://image.mux.com/Kb8uMO01BJJraCW8ZW00kPT01HgdqC37sAPX01V8whA02fp8/thumbnail.jpg How should dermatologists approach itch management in patients with severe pruritus due to atopic dermatitis? How should dermatologists approach itch management in patients with severe pruritus due to atopic dermatitis? https://dermsquared.com/videos/dermbits/itch-management-patients-severe-pruritus-atopic-dermatitis 61 2024-11-06T15:54:32.029Z yes https://dermsquared.com/videos/dermbits/how-should-psoriasis-managed-patients-history-liver-disease 2024-09-24T18:17:57.056Z https://image.mux.com/2sih7WAr6YoF602Ek3bIJNlZBevpS02y00pnq7Xa5b1XTE/thumbnail.jpg How should psoriasis be managed in patients with a history of liver disease? How should psoriasis be managed in patients with a history of liver disease? https://dermsquared.com/videos/dermbits/how-should-psoriasis-managed-patients-history-liver-disease 128 2024-09-24T18:17:57.048Z yes https://dermsquared.com/videos/dermbits/specific-patient-populations-benefit-ritlecitinib-treatment 2024-11-07T16:11:21.180Z https://image.mux.com/QnuJ00EniD02r9hm8kqIiYdFw7G3FQu92GRVpE02NOC02K8/thumbnail.jpg What specific patient populations benefit the most from ritlecitinib treatment? What specific patient populations benefit the most from ritlecitinib treatment? https://dermsquared.com/videos/dermbits/specific-patient-populations-benefit-ritlecitinib-treatment 87 2024-11-07T16:11:21.168Z yes https://dermsquared.com/videos/dermbits/should-therapy-be-stopped-in-patients-who-experience-infectious-events-baricitinib 2024-10-01T14:55:06.643Z https://image.mux.com/5qMT7hl36nXB9X13H6xJsEc7h02T8kHkuip8f2hIaFiw/thumbnail.jpg Should therapy be stopped in patients who experience infectious events while on baricitinib? Should therapy be stopped in patients who experience infectious events while on baricitinib? https://dermsquared.com/videos/dermbits/should-therapy-be-stopped-in-patients-who-experience-infectious-events-baricitinib 27 2024-10-01T14:55:06.632Z yes https://dermsquared.com/videos/dermbits/which-areas-can-and-cant-ruxolitinib 2023-04-28T19:36:30.664Z https://image.mux.com/wrX83vuH7d8501sJUGocS802LdN6Z00WaXXSAYXaiXNPZk/thumbnail.jpg Which areas of the body can you and can’t you apply ruxolitinib cream to? Which areas of the body can you and can’t you apply ruxolitinib cream to? https://dermsquared.com/videos/dermbits/which-areas-can-and-cant-ruxolitinib 40 2021-12-15T01:41:07.000Z yes https://dermsquared.com/videos/dermbits/lesser-known-comorbidities-of-vitiligo 2024-05-31T13:33:45.311Z https://image.mux.com/oo022iVyd6lBUuK5fNSIr8pnDFUjU6lxM5wmMMO02uZfw/thumbnail.jpg What are some lesser-known comorbidities of vitiligo? What are some lesser-known comorbidities of vitiligo? https://dermsquared.com/videos/dermbits/lesser-known-comorbidities-of-vitiligo 26 2024-05-31T13:33:45.306Z yes https://dermsquared.com/videos/dermbits/pros-and-cons-of-different-topical-azelaic-acid-formulations-22 2023-04-28T20:15:53.257Z https://image.mux.com/bjxtJYP01lebEM01bpV26alpk2dhOadAokNZfcPkpFQ34/thumbnail.jpg What are the pros and cons of the different topical azelaic acid formulations? What are the pros and cons of the different topical azelaic acid formulations? https://dermsquared.com/videos/dermbits/pros-and-cons-of-different-topical-azelaic-acid-formulations-22 64 2022-06-28T00:45:49.000Z yes https://dermsquared.com/videos/dermbits/safety-profile-bimekizumab-and-most-common-adverse-effects 2023-11-07T15:47:36.609Z https://image.mux.com/bGdPaV7lGucUIFAoXW702yPkJPEB00XNTY36d5sgaWwzs/thumbnail.jpg What is the safety profile of bimekizumab and what are the most common adverse effects seen so far? What is the safety profile of bimekizumab and what are the most common adverse effects seen so far? https://dermsquared.com/videos/dermbits/safety-profile-bimekizumab-and-most-common-adverse-effects 146 2023-11-07T15:44:15.595Z yes https://dermsquared.com/videos/dermbits/augmenting-oral-and-or-biologic-therapy-with-a-topical-considerations 2023-06-29T16:11:54.255Z https://image.mux.com/iylQZ9TfJFQV2W00lHOWchIR6ZM1DexcVlo00jt83s8X8/thumbnail.jpg When augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through? When augmenting oral and/or biologic therapy with a topical, what are some of the considerations you think through? https://dermsquared.com/videos/dermbits/augmenting-oral-and-or-biologic-therapy-with-a-topical-considerations 76 2023-06-29T16:11:54.250Z yes https://dermsquared.com/videos/dermbits/i-iga-success-endpoint-and-why-is-it-important-22 2023-04-28T20:27:19.214Z https://image.mux.com/LFEevvsQbQdGnGlQ35EynxUV00vn9DKga96TFheZDk01I/thumbnail.jpg What is the I-IGA Success endpoint, and why is it important? What is the I-IGA Success endpoint, and why is it important? https://dermsquared.com/videos/dermbits/i-iga-success-endpoint-and-why-is-it-important-22 70 2022-08-30T23:10:51.000Z yes https://dermsquared.com/videos/dermbits/why-do-we-need-to-better-assess-scc-prognosis 2023-07-27T19:21:20.774Z https://image.mux.com/01BHoiRvVaudRWFS4VH3JSc007I5lUaU1Wnfle00tCiZbQ/thumbnail.jpg Why do we need to better assess SCC prognosis? Summary In the video, Dr. Darrell Rigel discusses the significance of better assessing the prognosis of squamous cell carcinoma (SCC), including cutaneous SCC. He emphasizes that SCC is a serious disease and can lead to fatalities. Therefore, it is crucial to have an accurate prognosis assessment to determine which patients require further therapy. Understanding the prognosis allows healthcare professionals to provide appropriate and timely treatment for those affected by SCC. Key Points Squamous cell carcinoma (SCC) is a serious disease, including cutaneous squamous cell carcinoma, and it can lead to fatalities. Accurate assessment of SCC prognosis is essential to determine the appropriate course of action for patients, including the need for further therapy. Prognosis assessment helps in identifying high-risk patients who may require more intensive treatments and monitoring. Early identification of patients with poor prognosis can potentially improve outcomes and increase survival rates. Tailoring treatment plans based on prognosis can help avoid over-treatment in low-risk cases and provide more aggressive approaches for high-risk cases. Monitoring prognosis allows healthcare professionals to make informed decisions and adjustments in treatment strategies as the disease progresses. Improved prognosis assessment contributes to a more personalized and effective approach to managing SCC patients. Research and advancements in prognosis assessment may lead to better understanding of SCC's behavior and potential new treatment options. Overall, accurate prognosis assessment is crucial for enhancing the management and outcomes of individuals with SCC. https://dermsquared.com/videos/dermbits/why-do-we-need-to-better-assess-scc-prognosis 25 2023-07-27T19:21:20.770Z yes https://dermsquared.com/videos/dermbits/dermbits-are-there-any-natural-options-for-ad-that-you-recommend-adrc22 2022-10-28T22:19:37.000Z https://image.mux.com/hBZsArOmwXlN6Nanpok300D62m675NBdr502szLcTyGWo/thumbnail.jpg Are there any natural options for AD that you recommend? Are there any natural options for AD that you recommend? https://dermsquared.com/videos/dermbits/dermbits-are-there-any-natural-options-for-ad-that-you-recommend-adrc22 83 2022-10-28T22:19:37.000Z yes https://dermsquared.com/videos/dermbits/can-alopecia-areata-present-with-atypical-or-unusual-clinical-features 2024-10-01T14:14:32.576Z https://image.mux.com/LUk00y7vH3YuH800UtH2MLJ9000201OugDIyV9WxRs9MadgM/thumbnail.jpg Can alopecia areata present with atypical or unusual clinical features? Can alopecia areata present with atypical or unusual clinical features? https://dermsquared.com/videos/dermbits/can-alopecia-areata-present-with-atypical-or-unusual-clinical-features 32 2024-10-01T14:14:32.565Z yes https://dermsquared.com/videos/dermbits/how-dermatologists-define-patient-moderate-ad-what-clinical-markers-guide-classification 2025-05-01T13:40:37.845Z https://image.mux.com/6D9PiLzPFE01NEqhjCH00Ouu58JLY2RVUQNqPIsbp801go/thumbnail.jpg How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification? How can dermatologists define a patient with moderate AD, and what clinical markers guide this classification? https://dermsquared.com/videos/dermbits/how-dermatologists-define-patient-moderate-ad-what-clinical-markers-guide-classification 74 2025-05-01T13:40:37.838Z yes https://dermsquared.com/videos/dermbits/few-weeks-on-apremilast 2026-06-01T14:56:56.120Z https://image.mux.com/BLeU5G43MaA6Z62Efw6FmTtULMHi6epibmeveIDcbnE/thumbnail.jpg What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast? What counseling strategies have made the biggest difference in helping patients get through the first few weeks on apremilast? https://dermsquared.com/videos/dermbits/few-weeks-on-apremilast 122 2026-06-01T14:56:56.112Z yes https://dermsquared.com/videos/dermbits/what-are-some-of-the-biggest-challenges-in-treating-gpp 2023-08-31T20:43:42.931Z https://image.mux.com/8tPSkrRoe02jMajE316uVjYnbraOM72yk02d5h0157zeGU/thumbnail.jpg What are some of the biggest challenges in treating GPP? What are some of the biggest challenges in treating GPP? https://dermsquared.com/videos/dermbits/what-are-some-of-the-biggest-challenges-in-treating-gpp 90 2023-08-31T20:43:42.925Z yes https://dermsquared.com/videos/dermbits/how-lebrikizumab-maintain-remission 2025-02-18T17:51:07.916Z https://image.mux.com/HeyOULsV39RWlqbFmznM012hGlE53TLL01m5800MT00XpfY/thumbnail.jpg How well does lebrikizumab maintain remission in patients who have achieved clear or almost clear skin? How well does lebrikizumab maintain remission in patients who have achieved clear or almost clear skin? https://dermsquared.com/videos/dermbits/how-lebrikizumab-maintain-remission 18 2025-02-18T17:51:07.907Z yes https://dermsquared.com/videos/dermbits/what-recommend-patients-atopic-dermatitis-who-require-long-term-treatment 2023-07-28T16:30:53.781Z https://image.mux.com/lxl6Wb01CVwZOkYvm3miVQ27ml3lzq1SXWpTbS7YM9vE/thumbnail.jpg What do you recommend for patients with atopic dermatitis who require long-term treatment? Summary In the video, Dr. Raj Chovatiya discusses the long-term treatment options for patients with atopic dermatitis, emphasizing that atopic dermatitis is a chronic disease. He stresses the importance of understanding this fact, as many patients may be seeking quick fixes for their condition. Once patients comprehend the chronic nature of the disease, they can explore more effective long-term treatment options. Dr. Chovatiya mentions several long-term treatment options available for atopic dermatitis. These include:Biologic therapies: These are advanced treatments that target specific molecules in the immune system to control inflammation and symptoms. Oral JAK (Janus kinase) inhibitors: These are medications taken orally that also work to suppress the immune system and reduce inflammation. Phototherapy: This treatment involves controlled exposure to ultraviolet light to improve symptoms. Oral immunosuppressants: Old-school medications that can be considered based on the patient's type and condition.Dr. Chovatiya acknowledges that all of these options will be part of his discussion with patients. However, he primarily focuses on framing the idea of atopic dermatitis as a chronic disease. This understanding will help patients realize that long-term, chronic approaches are often necessary to achieve proper control over the condition. Key Points Atopic dermatitis is a chronic disease that requires long-term treatment. Biologic therapies are available as a long-term treatment option for atopic dermatitis. Oral JAK inhibitors are also an option for long-term treatment of atopic dermatitis. Phototherapy can be considered as a potential long-term treatment approach. Old school oral immunosuppressants may be prescribed based on the patient's type and condition. The focus should be on educating patients about the chronic nature of the disease. Emphasizing the chronic aspect helps unlock possibilities for effective long-term treatments. The goal is to provide long-term control of atopic dermatitis using chronic approaches. https://dermsquared.com/videos/dermbits/what-recommend-patients-atopic-dermatitis-who-require-long-term-treatment 64 2023-07-27T19:15:48.071Z yes https://dermsquared.com/videos/dermbits/long-term-management-strategies-for-patients-with-vitiligo 2024-03-06T16:01:39.772Z https://image.mux.com/rECInQRUAxJR7eBIzOZ3Ii49fMySnukpGb01CLqeWR3k/thumbnail.jpg What long-term management strategies do you recommend for patients with vitiligo? What long-term management strategies do you recommend for patients with vitiligo? https://dermsquared.com/videos/dermbits/long-term-management-strategies-for-patients-with-vitiligo 69 2024-03-06T16:01:39.767Z yes https://dermsquared.com/videos/dermbits/dermbits-what-are-the-current-recommendations-for-elimination-diets-for-kids-with-ad-adrc22 2022-10-28T22:18:22.000Z https://image.mux.com/2qlMTHKIKtr3V9se01tm00DT00hHDee11QOl26mpaRXres/thumbnail.jpg What are the current recommendations for elimination diets for kids with AD? What are the current recommendations for elimination diets for kids with AD? https://dermsquared.com/videos/dermbits/dermbits-what-are-the-current-recommendations-for-elimination-diets-for-kids-with-ad-adrc22 48 2022-10-28T22:18:22.000Z yes https://dermsquared.com/videos/dermbits/dermbits-how-do-i-get-involved-with-the-aad-WCM230001 2023-03-09T23:55:45.000Z https://image.mux.com/hToXycYIVVCx1HK4hcyV02fYPDtzb9702Ix8Y2nJDlMKA/thumbnail.jpg How do I get involved with the AAD? How do I get involved with the AAD? https://dermsquared.com/videos/dermbits/dermbits-how-do-i-get-involved-with-the-aad-WCM230001 44 2023-03-09T23:55:45.000Z yes https://dermsquared.com/videos/dermbits/undertreated-with-topicals-alone 2026-03-03T16:08:29.137Z https://image.mux.com/443mYMJGLFukACYHNSbvHAvPd4hI1X01gkh7ZLylvMsg/thumbnail.jpg How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone? How do you position apremilast for patients who are not ready for injections but are clearly undertreated with topicals alone? https://dermsquared.com/videos/dermbits/undertreated-with-topicals-alone 45 2026-03-03T16:08:25.738Z yes https://dermsquared.com/videos/dermbits/patients-and-dermatologists 2025-10-20T17:27:43.785Z https://image.mux.com/X01o01iuZJxuJelfwVADNejZ4kJP8oKGW5UIaCUkhFOzs/thumbnail.jpg How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists? How does guided dosing mode on newer devices improve safety and reduce uncertainty for both patients and dermatologists? https://dermsquared.com/videos/dermbits/patients-and-dermatologists 49 2025-10-13T20:14:52.704Z yes https://dermsquared.com/videos/dermbits/how-manage-missed-doses-lebrikizumab 2024-11-06T15:55:08.892Z https://image.mux.com/u98IpfBtDAhxVBPYiIKGpymNht019n8Ze02lgvvImWtME/thumbnail.jpg How should dermatologists manage missed doses of lebrikizumab with patients? How should dermatologists manage missed doses of lebrikizumab with patients? https://dermsquared.com/videos/dermbits/how-manage-missed-doses-lebrikizumab 15 2024-11-06T15:55:08.886Z yes https://dermsquared.com/videos/dermbits/to-prescribe-for-clinicians 2025-10-20T17:28:58.495Z https://image.mux.com/jXQtnUmcxlg26JhV46wnzXpBnJ0102r3mOz901DjSfZUV00/thumbnail.jpg Is home-based NB-UVB a challenge to prescribe for clinicians? Is home-based NB-UVB a challenge to prescribe for clinicians? https://dermsquared.com/videos/dermbits/to-prescribe-for-clinicians 27 2025-10-13T20:12:47.384Z yes https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-ruxolitinib-cream 2023-07-28T16:18:03.985Z https://image.mux.com/L3t8gTpWb6x2Pb3NE1imtjzjPJH3Ivj91kqJKdahP2I/thumbnail.jpg What is the recommended dosing regimen for ruxolitinib cream? Summary In the video, Dr. Raj Chovatiya explains the recommended dosing regimen for ruxolitinib cream. The cream should be used twice daily and applied to all areas of active atopic dermatitis from head to toe. In clinical trial programs, it has been found effective for various areas of the body, including the head and neck, where traditional treatments might be limited. The cream can be safely used across the skin surface area twice daily, and it is advised not to exceed the usage of one 60-gram tube per week. Key Points Recommended dosing regimen for ruxolitinib cream: Twice daily application Application area: Apply to all areas of active atopic dermatitis from head to toe Common involvement areas in trial programs: Head and neck (limited to approximately 40% of people) • Maximum weekly usage: Not to exceed more than one 60-gram tube per week https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-ruxolitinib-cream 33 2023-07-27T19:15:12.493Z yes https://dermsquared.com/videos/dermbits/outlook-on-regenerative-therapies-vitiligo 2024-05-31T13:33:41.680Z https://image.mux.com/e13URaT01CiWYXefbrq37nUQD9Q5fYWJEmZXFpaMcCqI/thumbnail.jpg What is the outlook on regenerative therapies for vitiligo? What is the outlook on regenerative therapies for vitiligo? https://dermsquared.com/videos/dermbits/outlook-on-regenerative-therapies-vitiligo 25 2024-05-31T13:33:41.665Z yes https://dermsquared.com/videos/dermbits/key-considerations-systemic-corticosteroids-severe-atopic-dermatitis 2024-12-02T16:27:27.753Z https://image.mux.com/qJVfP2OGRWSzwQcZmnQNlT63n81D01er01PS56aoL1hZU/thumbnail.jpg What are the key considerations for using systemic corticosteroids in severe cases of atopic dermatitis? What are the key considerations for using systemic corticosteroids in severe cases of atopic dermatitis? https://dermsquared.com/videos/dermbits/key-considerations-systemic-corticosteroids-severe-atopic-dermatitis 56 2024-12-02T16:27:27.747Z yes https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-ruxolitinib-for-vitiligo 2024-04-01T15:45:30.415Z https://image.mux.com/u3C1QRafadQHNcRyyftGgg9018N9fTUrEaWqGw7Km5ik/thumbnail.jpg Who is the ideal patient for ruxolitinib for vitiligo? Who is the ideal patient for ruxolitinib for vitiligo? https://dermsquared.com/videos/dermbits/who-is-the-ideal-patient-for-ruxolitinib-for-vitiligo 45 2024-04-01T15:45:30.407Z yes https://dermsquared.com/videos/dermbits/atopic-dermatitis-quality-of-life 2023-04-28T18:51:33.403Z https://image.mux.com/026vt5Nt6A9e3upCD700i4tnRrTQm8Q85uTDgtfSkWe7c/thumbnail.jpg How much does atopic dermatitis affect a patient’s quality of life? How much does atopic dermatitis affect a patient’s quality of life? https://dermsquared.com/videos/dermbits/atopic-dermatitis-quality-of-life 131 2021-10-14T14:52:05.000Z yes